[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLjuoVMZ0cgUhmbprUimi_wej58CwIiSn5glwNEvOF60":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":83,"rows":90},"Eli Lilly and Company",[4],2058,false,228,547,1125783,197,18,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Healthy",286,{"name":18,"count":19},"Diabetes Mellitus, Type 2",124,{"name":21,"count":22},"Healthy Volunteers",85,{"name":24,"count":25},"Obesity",84,{"name":27,"count":28},"Overweight",62,{"name":30,"count":31},"Type 2 Diabetes",54,{"name":33,"count":34},"Diabetes Mellitus, Type 1",45,{"name":36,"count":37},"Breast Cancer",44,[39,44,49,53,57,62,66,70,74,78],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT01594723","A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","2015-03-20","120 mg LY2784544",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02246621","A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","2017-01-31","Abemaciclib",{"nctId":50,"briefTitle":51,"date":52,"intervention":48},"NCT02107703","A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","2017-02-14",{"nctId":54,"briefTitle":55,"date":56,"intervention":48},"NCT02152631","A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","2017-09-15",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT02711553","A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","2018-02-16","Ramucirumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":48},"NCT02747004","A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","2018-06-15",{"nctId":67,"briefTitle":68,"date":69,"intervention":61},"NCT02411448","A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","2019-01-23",{"nctId":71,"briefTitle":72,"date":73,"intervention":48},"NCT02763566","A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","2019-03-29",{"nctId":75,"briefTitle":76,"date":77,"intervention":48},"NCT02779751","A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer","2020-02-03",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT02937272","A Study of LY3200882 in Participants With Solid Tumors","2020-02-27","LY3200882",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,834,1069,1235,1414,1432,1450,2042,2320,2482,2719,3434,3843,3935,4082,4649,4736,4822,4876,4943,5405,5451,5514,5552,6140,6189,6329,6367,6739,6916,7189,7444,7619,7661,7743,7818,7889,7936,7983,8017,8048,8070,8092,8125,8147,8175,8247,8303,8352,8386,8425,8464,8490,8512,8534,8552,8570,8588,8606,8630,8648,8666,8684,8702,8720,8744,8831,8896,9098,9150,9188,9224,9303,9341,9386,9425,9465,9503,9525,9547,9574,9596,9757,9902,9940,9985,10021,10064,10097,10127,10169,10191,10213,10244,10276,10300,10318,10336,10354,10372,10392,10410,10428,10446,10464,10482,10500,10527,10545,10563,10581,10603,10626,10644,10670,10707,10781,10819,10857,10887,10987,11033,11084,11110,11132,11154,11186,11212,11341,11387,11440,11475,11501,11527,11571,11611,11655,11689,11725,11757,11779,11810,11831,11853,11874,11892,11910,11928,11946,11967,11985,12007,12025,12043,12061,12079,12104,12122,12146,12164,12187,12210,12232,12250,12273,12291,12313,12337,12355,12381,12399,12417,12439,12457,12475,12497,12515,12537,12564,12582,12600,12618,12636,12654,12675,12701,12719,12737,12758,12776,12799,12817,12842,13275,13347,13377,13395,13420,13771,13943,14040,14141,14219,14271,14319,14365,14426,14479,14531,14567,14604,14651,14701,14746,14792,14831,14866,14896,14927,14956,14984,15008,15038,15060,15091,15116,15138,15169,15191,15218,15240,15274,15304,15326,15348,15366,15389,15407,15425,15448,15466,15488,15510,15528,15546,15564,15585,15610,15628,15650,15671,15693,15711,15729,15747,15765,15786,15804,15822,15840,15858,15876,15898,15916,15934,15956,15974,15992,16010,16028,16050,16068,16090,16112,16130,16148,16166,16184,16202,16223,16241,16263,16281,16304,16322,16340,16363,16381,16399,16421,16439,16457,16475,16493,16516,16726,16864,17045,17256,17406,17553,17672,17766,17892,17968,18036,18127,18211,18295,18380,18453,18502,18553,18617,18679,18728,18789,18831,18880,18918,18952,18986,19028,19073,19122,19160,19190,19220,19246,19272,19311,19340,19366,19396,19429,19461,19496,19522,19555,19584,19615,19641,19678,19713,19739,19775,19797,19819,19857,19891,19913,19949,19973,19995,20019,20045,20067,20089,20111,20133,20155,20183,20205,20227,20256,20278,20308,20330,20348,20370,20388,20410,20428,20449,20467,20488,20512,20534,20552,20570,20588,20606,20624,20642,20664,20686,20704,20725,20748,20766,20784,20802,20828,20846,20864,20886,20904,20926,20944,20962,20980,20998,21016,21034,21057,21075,21093,21111,21133,21151,21169,21193,21211,21229,21252,21270,21293,21311,21329,21347,21369,21387,21405,21427,21445,21463,21481,21507,21525,21543,21564,21582,21600,21623,21646,21664,21682,21700,21718,21736,21758,21776,21794,21812,21830,21852,21870,21888,21906,21929,21952,21970,21995,22018,22040,22058,22076,22094,22115,22133,22156,22174,22301,22396,22486,22584,22656,22710,22784,22843,22902,22962,23026,23086,23133,23190,23232,23282,23329,23380,23437,23475,23517,23571,23616,23671,23719,23757,23802,23848,23890,23920,23952,23990,24027,24057,24103,24143,24182,24208,24239,24274,24303,24333,24362,24396,24425,24462,24497,24529,24566,24592,24618,24648,24686,24718,24740,24764,24786,24813,24843,24865,24887,24909,24934,24964,24988,25015,25037,25059,25083,25112,25140,25164,25186,25212,25240,25267,25301,25323,25350,25375,25400,25422,25452,25474,25512,25544,25566,25591,25613,25641,25674,25695,25713,25731,25749,25773,25791,25809,25827,25849,25867,25888,25910,25928,25946,25964,25986,26004,26025,26047,26065,26083,26105,26126,26144,26166,26184,26202,26224,26242,26260,26278,26296,26314,26332,26350,26368,26386,26408,26426,26444,26468,26486,26504,26522,26546,26564,26582,26600,26622,26646,26664,26682,26700,26724,26742,26760,26778,26796,26818,26836,26857,26880,26898,26916,26934,26952,26970,26991,27009,27030,27048,27069,27092,27110,27128,27146,27164,27185,27203,27221,27239,27257,27279,27297,27318,27342,27360,27378,27396,27414,27435,27453,27474,27492,27510,27532,27550,27573,27594,27615,27633,27651,27753,27806,27852,27894,27950,27995,28034,28074,28104,28134,28160,28186,28216,28254,28280,28306,28332,28358,28388,28410,28440,28462,28489,28517,28539,28561,28583,28605,28633,28655,28681,28703,28727,28758,28780,28811,28833,28859,28885,28907,28931,28968,28996,29020,29046,29072,29094,29121,29148,29170,29194,29216,29238,29268,29297,29319,29341,29369,29391,29421,29443,29464,29486,29504,29527,29545,29569,29587,29609,29632,29650,29673,29691,29709,29734,29752,29770,29788,29806,29828,29850,29871,29889,29911,29933,29957,29975,29993,30011,30033,30051,30074,30092,30110,30128,30146,30164,30186,30204,30222,30240,30263,30285,30303,30321,30339,30357,30378,30401,30419,30437,30455,30477,30499,30517,30535,30553,30574,30592,30610,30628,30649,30671,30694,30712,30730,30751,30769,30791,30809,30832,30853,30875,30898,30916,30938,30956,30980,30998,31019,31037,31059,31077,31100,31118,31136,31154,31172,31190,31208,31226,31247,31269,31292,31310,31328,31346,31364,31387,31405,31423,31441,31462,31480,31502,31520,31538,31559,31577,31600,31618,31636,31654,31672,31690,31708,31726,31744,31762,31780,31802,31820,31838,31856,31876,31899,31917,31935,31957,31975,31993,32015,32033,32054,32075,32097,32115,32133,32151,32172,32194,32212,32233,32251,32272,32290,32314,32332,32350,32371,32393,32414,32432,32450,32468,32489,32512,32534,32552,32570,32593,32611,32633,32656,32677,32698,32716,32737,32755,32773,32791,32814,32832,32850,32868,32890,32908,32926,32949,32971,32989,33010,33028,33046,33064,33082,33100,33126,33144,33162,33180,33201,33224,33246,33264,33282,33306,33324,33342,33360,33381,33399,33417,33435,33453,33476,33494,33517,33539,33557,33579,33597,33615,33637,33658,33679,33700,33722,33740,33758,33776,33799,33817,33835,33859,33877,33895,33913,33931,33952,33973,33991,34009,34027,34049,34067,34088,34110,34128,34146,34168,34186,34204,34222,34240,34258,34276,34294,34316,34334,34356,34374,34396,34414,34435,34456,34479,34497,34515,34533,34551,34569,34592,34610,34628,34646,34667,34690,35094,35376,35573,35747,35953,36126,36213,36300,36335,36372,36394,36416,36438,36460,36481,36504,36522,36540,36558,36576,36598,36619,36641,36663,36685,36703],{"intervention":92,"totalTrials":93,"cells":94},"Tirzepatide",73,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":315,"PHASE3":426,"PHASE4":758,"NA":832},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":314,"soonestReadout":259},[100,111,122,131,141,150,159,168,179,189,199,208,218,227,237,245,254,263,274,284,293,304],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT06345066","A Study of LY3841136 in Overweight and Obese Participants","COMPLETED",[85],"2025-09-29","2024-04-03",96,[24,27],[92,110],"LY3841136",{"nctId":112,"briefTitle":113,"status":103,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NCT03322631","A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes",[85],"2018-05-29","2018-11-28","2017-11-15",48,[120],"Type 2 Diabetes Mellitus",[92],{"nctId":123,"briefTitle":124,"status":103,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT04004988","A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants",[85],"2019-12-16","2019-08-19",47,[15],[92],{"nctId":132,"briefTitle":133,"status":103,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT04050553","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus",[85],"2022-01-25","2020-02-24",42,[18,139],"Hypoglycemia",[92],{"nctId":142,"briefTitle":143,"status":103,"phases":144,"primaryCompletion":127,"completion":127,"start":145,"enrollment":34,"conditions":146,"interventions":149},"NCT03482024","A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function",[85],"2018-03-30",[147,148],"Renal Insufficiency","End Stage Renal Disease",[92],{"nctId":151,"briefTitle":152,"status":103,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT05810597","A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices",[85],"2023-07-17","2023-04-03",65,[15],[92],{"nctId":160,"briefTitle":161,"status":103,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT05696847","A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity",[85],"2025-01-16","2023-02-07",28,[24],[92],{"nctId":169,"briefTitle":170,"status":103,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT06890611","A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants",[85],"2025-09-26","2025-03-25",125,[15],[177,92,178],"Bimagrumab","Bimagrumab + Tirzepatide Coformulation",{"nctId":180,"briefTitle":181,"status":103,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT04311411","A Study of Tirzepatide in Overweight and Very Overweight Participants",[85],"2022-12-16","2020-08-24",114,[24,27],[92,188],"Liraglutide",{"nctId":190,"briefTitle":191,"status":103,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT03951753","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)",[85],"2021-04-08","2019-06-28",117,[18],[92,198],"Semaglutide",{"nctId":200,"briefTitle":201,"status":103,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT05978713","A Study of Tirzepatide (LY3298176) in Healthy Lactating Females",[85],"2024-03-12","2023-07-31",11,[15],[92],{"nctId":209,"briefTitle":210,"status":103,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":216},"NCT04407234","A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide",[85],"2021-01-07","2020-09-15",36,[27,24,18],[92,217],"Acetaminophen",{"nctId":219,"briefTitle":220,"status":103,"phases":221,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT04081337","A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide",[85],"2022-05-26","2020-07-09",55,[24],[92],{"nctId":228,"briefTitle":229,"status":103,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT04172987","A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants",[85],"2021-02-09","2020-02-26",40,[15],[92,236],"EE\u002FNGM",{"nctId":238,"briefTitle":239,"status":103,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":31,"conditions":243,"interventions":244},"NCT04050670","A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes",[85],"2020-04-03","2019-09-13",[15],[92],{"nctId":246,"briefTitle":247,"status":103,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT03375463","A Study of Tirzepatide (LY3298176) in Healthy Participants",[85],"2018-12-27","2017-12-19",52,[15],[92,92,92],{"nctId":255,"briefTitle":256,"status":257,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":233,"conditions":261,"interventions":262},"NCT07299084","A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus","ACTIVE_NOT_RECRUITING",[85],"2026-11","2026-01-14",[18,27,24],[92],{"nctId":264,"briefTitle":265,"status":103,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT06297616","A Study of LY3841136 in Japanese Participants With Obesity or Overweight",[85],"2025-11-21","2024-04-15",128,[24,27],[110,272,92,273],"LY3841136-Placebo","Tirzepatide-Placebo",{"nctId":275,"briefTitle":276,"status":103,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT05582096","A Study of LY3457263 in Obese Participants",[85],"2023-06-08","2022-11-11",38,[27,24],[283,92],"LY3457263",{"nctId":285,"briefTitle":286,"status":103,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT04235959","A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus",[85],"2021-08-17","2020-10-21",24,[18],[92],{"nctId":294,"briefTitle":295,"status":103,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT02759107","A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)",[85],"2017-06-26","2016-05-11",142,[15,301],"Type 2 Diabetes Mellitus (T2DM)",[92,303],"Dulaglutide",{"nctId":305,"briefTitle":306,"status":103,"phases":307,"primaryCompletion":308,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":313},"NCT03940742","A Study of Tirzepatide in Participants With Impaired Liver Function",[85],"2020-09-22","2019-07-22",32,[312],"Hepatic Insufficiency",[92],1,{"trials":316,"activeCount":425,"soonestReadout":354},[317,329,338,350,360,370,381,390,404,415],{"nctId":318,"briefTitle":319,"status":257,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":326},"NCT06643728","A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight",[86],"2026-01-16","2027-01","2024-10-21",252,[24,27],[177,92,327,328],"Bimagrumab Placebo","Tirzepatide Placebo",{"nctId":330,"briefTitle":331,"status":103,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":337},"NCT03311724","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes",[86],"2018-04-24","2017-10-19",111,[30],[92],{"nctId":339,"briefTitle":340,"status":103,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT06373146","A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity",[86],"2025-12-15","2026-04-02","2024-04-24",392,[24],[92,348,273,349],"Mibavademab","Mibavademab-Placebo",{"nctId":351,"briefTitle":352,"status":257,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT06037252","A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity",[86],"2026-01-08","2026-10","2023-09-21",414,[30,24],[92],{"nctId":361,"briefTitle":362,"status":103,"phases":363,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":368},"NCT03131687","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus",[86],"2018-08-01","2017-05-24",318,[120],[369,303],"tirzepatide",{"nctId":371,"briefTitle":372,"status":103,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":380},"NCT04166773","A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)",[86],"2023-12-11","2024-01-10","2019-11-19",190,[379],"Nonalcoholic Steatohepatitis",[92],{"nctId":382,"briefTitle":383,"status":384,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":97,"conditions":388,"interventions":389},"NCT06901349","A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes","WITHDRAWN",[86],"2025-06-10","2025-05-23",[24,27],[177,92,327,328],{"nctId":391,"briefTitle":392,"status":393,"phases":394,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":400},"NCT06143956","A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight","RECRUITING",[86],"2027-09","2028-02","2023-11-17",1481,[24,27],[401,110,92,402,403],"LY3305677","LY3549492","LY3532226",{"nctId":405,"briefTitle":406,"status":257,"phases":407,"primaryCompletion":408,"completion":355,"start":409,"enrollment":410,"conditions":411,"interventions":414},"NCT05536804","A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes",[86],"2026-09","2023-02-08",140,[27,24,412,30,413],"Chronic Kidney Disease","T2D",[92],{"nctId":416,"briefTitle":417,"status":257,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT06603571","A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes",[86],"2026-06","2026-08","2024-09-20",350,[24,27],[110,92],5,{"trials":427,"activeCount":757,"soonestReadout":354},[428,439,450,458,468,478,487,496,507,517,526,536,546,557,567,577,589,599,611,625,635,644,652,661,671,681,690,701,711,720,729,737,746],{"nctId":429,"briefTitle":430,"status":103,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":437},"NCT04537923","A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin",[87],"2022-10-11","2022-11-01","2020-10-19",1428,[30],[92,438],"Insulin Lispro",{"nctId":440,"briefTitle":441,"status":257,"phases":442,"primaryCompletion":354,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT06588283","Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight",[87],"2026-05","2024-09-30",250,[447,24],"Psoriasis",[449,92],"Ixekizumab",{"nctId":451,"briefTitle":452,"status":257,"phases":453,"primaryCompletion":454,"completion":454,"start":432,"enrollment":455,"conditions":456,"interventions":457},"NCT05556512","A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity",[87],"2027-10",15374,[24,27],[92],{"nctId":459,"briefTitle":460,"status":257,"phases":461,"primaryCompletion":259,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT06914895","A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight",[87],"2026-12","2025-04-25",905,[466,24,27],"Type 1 Diabetes",[92],{"nctId":469,"briefTitle":470,"status":103,"phases":471,"primaryCompletion":203,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":477},"NCT05412004","Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea",[87],"2024-03-29","2022-06-21",469,[476,24],"Obstructive Sleep Apnea",[92],{"nctId":479,"briefTitle":480,"status":103,"phases":481,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":486},"NCT04255433","A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes",[87],"2025-06-12","2020-05-29",13299,[120],[92,303],{"nctId":488,"briefTitle":489,"status":103,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":495},"NCT06047548","A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",[87],"2026-01-20","2023-09-20",441,[27,24],[92],{"nctId":497,"briefTitle":498,"status":103,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":505},"NCT03730662","A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk",[87],"2021-01-22","2021-04-22","2018-11-20",2002,[120],[92,506],"Insulin Glargine",{"nctId":508,"briefTitle":509,"status":103,"phases":510,"primaryCompletion":511,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT03954834","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone",[87],"2020-10-05","2020-10-28","2019-06-03",478,[120],[92],{"nctId":518,"briefTitle":519,"status":103,"phases":520,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":525},"NCT05963022","A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)",[87],"2024-10-09","2023-08-21",206,[30],[92],{"nctId":527,"briefTitle":528,"status":103,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT04847557","A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial",[87],"2024-07-02","2021-04-20",731,[24,534],"Heart Failure With Preserved Ejection Fraction (HFpEF)",[92],{"nctId":537,"briefTitle":538,"status":393,"phases":539,"primaryCompletion":454,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT06439277","A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)",[87],"2030-12","2024-06-03",300,[24,544],"Weight Gain",[92],{"nctId":547,"briefTitle":548,"status":103,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":556},"NCT06588296","Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight",[87],"2025-11-18","2026-04-23","2024-09-24",279,[555,24],"Psoriatic Arthritis",[449,92],{"nctId":558,"briefTitle":559,"status":103,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT04039503","A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin",[87],"2020-12-22","2021-01-13","2019-08-30",475,[30],[92],{"nctId":568,"briefTitle":569,"status":103,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":576},"NCT04657016","A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program",[87],"2023-04-20","2023-05-12","2021-03-29",579,[24,27],[92],{"nctId":578,"briefTitle":579,"status":393,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":587},"NCT06937099","Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight",[87],"2028-05","2025-06-26",290,[585,586],"Crohn's Disease","Obesity or Overweight",[588,588,92],"Mirikizumab",{"nctId":590,"briefTitle":591,"status":103,"phases":592,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":598},"NCT04093752","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)",[87],"2021-11-01","2021-11-24","2019-12-09",917,[30],[92,506],{"nctId":600,"briefTitle":601,"status":393,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":609},"NCT07165028","A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)",[87],"2030-08","2032-08","2025-10-15",4500,[608],"Metabolic Dysfunction-Associated Steatotic Liver Disease",[92,610],"Retatrutide",{"nctId":612,"briefTitle":613,"status":103,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":624},"NCT05691712","A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes",[87],"2024-07-01","2023-02-05",257,[619,620,621,622,623],"Diabetes Type 2","Diabetes Mellitus","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases",[92],{"nctId":626,"briefTitle":627,"status":103,"phases":628,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT05024032","A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)",[87],"2022-12-27","2021-09-01",210,[24,27,633],"Metabolism and Nutrition Disorder",[92],{"nctId":636,"briefTitle":637,"status":103,"phases":638,"primaryCompletion":639,"completion":640,"start":573,"enrollment":641,"conditions":642,"interventions":643},"NCT04657003","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight",[87],"2023-03-16","2023-04-10",938,[30,27,24],[92],{"nctId":645,"briefTitle":646,"status":257,"phases":647,"primaryCompletion":462,"completion":462,"start":648,"enrollment":649,"conditions":650,"interventions":651},"NCT06662383","A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity",[87],"2024-11-01",800,[24],[610,92],{"nctId":653,"briefTitle":654,"status":257,"phases":655,"primaryCompletion":443,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":660},"NCT06075667","A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",[87],"2029-07","2023-10-16",150,[24,27],[92],{"nctId":662,"briefTitle":663,"status":103,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":670},"NCT03861052","A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes",[87],"2021-03-10","2021-03-31","2019-05-07",636,[30],[92,303],{"nctId":672,"briefTitle":673,"status":103,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":680},"NCT03987919","A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes",[87],"2021-01-28","2021-02-15","2019-07-30",1879,[30],[92,198],{"nctId":682,"briefTitle":683,"status":103,"phases":684,"primaryCompletion":685,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":689},"NCT04844918","A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease",[87],"2023-06-24","2021-05-10",267,[24],[92],{"nctId":691,"briefTitle":692,"status":103,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT03882970","A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes",[87],"2020-12-11","2021-01-04","2019-04-01",1444,[120],[92,700],"Insulin Degludec",{"nctId":702,"briefTitle":703,"status":103,"phases":704,"primaryCompletion":705,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":710},"NCT04184622","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight",[87],"2022-04-01","2024-07-06","2019-12-04",2539,[27,24],[92],{"nctId":712,"briefTitle":713,"status":257,"phases":714,"primaryCompletion":259,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":719},"NCT06962280","A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight",[87],"2027-07","2025-05-12",465,[466,24,27],[92],{"nctId":721,"briefTitle":722,"status":103,"phases":723,"primaryCompletion":724,"completion":725,"start":573,"enrollment":726,"conditions":727,"interventions":728},"NCT04660643","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss",[87],"2023-04-25","2023-05-18",783,[24,27],[92],{"nctId":730,"briefTitle":731,"status":393,"phases":732,"primaryCompletion":733,"completion":733,"start":582,"enrollment":422,"conditions":734,"interventions":736},"NCT06937086","Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study",[87],"2028-04",[735,586],"Ulcerative Colitis",[588,588,92],{"nctId":738,"briefTitle":739,"status":103,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT05822830","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities",[87],"2024-11-13","2023-04-21",751,[24,27],[92,198],{"nctId":747,"briefTitle":748,"status":103,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":755},"NCT03861039","A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes",[87],"2021-01-26","2021-02-16","2019-03-30",443,[120],[92,756],"Oral antihyperglycemic medication",10,{"trials":759,"activeCount":425,"soonestReadout":764},[760,771,780,787,796,805,813,823],{"nctId":761,"briefTitle":762,"status":257,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":769},"NCT05433584","A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes",[88],"2025-10-21","2027-11","2022-08-01",780,[30],[92,770],"Antihyperglycemic medication",{"nctId":772,"briefTitle":773,"status":393,"phases":774,"primaryCompletion":581,"completion":581,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT06857942","A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)",[88],"2025-03-19",200,[447,778],"Overweight or Obesity",[92],{"nctId":781,"briefTitle":782,"status":393,"phases":783,"primaryCompletion":765,"completion":765,"start":784,"enrollment":776,"conditions":785,"interventions":786},"NCT06864026","A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)",[88],"2025-03-06",[555,778],[92],{"nctId":788,"briefTitle":789,"status":393,"phases":790,"primaryCompletion":656,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":795},"NCT07247084","A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)",[88],"2032-07","2025-11-24",3000,[24],[92],{"nctId":797,"briefTitle":798,"status":103,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT06635057","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan",[88],"2026-04-15","2024-10-11",166,[30],[92],{"nctId":806,"briefTitle":807,"status":393,"phases":808,"primaryCompletion":454,"completion":454,"start":809,"enrollment":810,"conditions":811,"interventions":812},"NCT07438444","A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity",[88],"2026-02-27",344,[18,24,27],[92],{"nctId":814,"briefTitle":815,"status":103,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT05564039","A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)",[88],"2024-07-15","2024-08-12","2022-11-30",282,[30],[92,303],{"nctId":824,"briefTitle":825,"status":103,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":831},"NCT05706506","A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)",[88],"2023-10-31","2023-03-08",152,[30,18],[92],{"trials":833,"activeCount":97},[],{"intervention":588,"totalTrials":290,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":885,"PHASE3":948,"PHASE4":1055,"NA":1067},{"trials":837,"activeCount":97},[],{"trials":839,"activeCount":314,"soonestReadout":853},[840,849,858,868,877],{"nctId":841,"briefTitle":842,"status":103,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":848},"NCT05515601","A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants",[85],"2023-02-20","2022-08-31",396,[15],[588],{"nctId":850,"briefTitle":851,"status":393,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":857},"NCT07446101","A Study of Mirikizumab Solution (LY3074828) in Healthy Participants",[85],"2027-02","2026-03-24",450,[15],[588],{"nctId":859,"briefTitle":860,"status":103,"phases":861,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":866},"NCT03718884","A Study of Mirikizumab in Participants With Plaque Psoriasis",[85],"2019-10-28","2018-10-23",29,[447],[867,588],"Drug Cocktail",{"nctId":869,"briefTitle":870,"status":103,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT04548219","A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants",[85],"2021-01-11","2020-09-11",60,[15],[588],{"nctId":878,"briefTitle":879,"status":103,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":855,"conditions":883,"interventions":884},"NCT05644353","A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants",[85],"2023-05-25","2022-12-05",[15],[588],{"trials":886,"activeCount":947,"soonestReadout":940},[887,896,906,917,928,936],{"nctId":888,"briefTitle":889,"status":103,"phases":890,"primaryCompletion":891,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":895},"NCT04004611","A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)",[86],"2023-03-15","2020-05-18",26,[735],[588],{"nctId":897,"briefTitle":898,"status":103,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":905},"NCT02891226","A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease",[86],"2018-12-11","2021-02-05","2016-12-14",191,[585],[588],{"nctId":907,"briefTitle":908,"status":393,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":410,"conditions":913,"interventions":915},"NCT06598943","A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis",[86],"2027-12","2028-09","2024-10-10",[735,914],"Ulcerative Colitis Chronic",[916,588],"Eltrekibart",{"nctId":918,"briefTitle":919,"status":103,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT02899988","A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis",[86],"2017-06-19","2019-05-08","2016-09-14",205,[926],"Plaque Psoriasis",[588],{"nctId":929,"briefTitle":930,"status":103,"phases":931,"primaryCompletion":250,"completion":667,"start":932,"enrollment":933,"conditions":934,"interventions":935},"NCT02589665","A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis",[86],"2015-12-09",249,[735],[588],{"nctId":937,"briefTitle":938,"status":393,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":324,"conditions":943,"interventions":944},"NCT07186101","LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:",[86],"2027-05","2029-03","2025-11-10",[735],[945,588,946],"LY4268989","LY4268989 Placebo",2,{"trials":949,"activeCount":1054,"soonestReadout":979},[950,958,966,975,985,996,1006,1016,1025,1029,1039,1050],{"nctId":951,"briefTitle":952,"status":393,"phases":953,"primaryCompletion":540,"completion":540,"start":954,"enrollment":658,"conditions":955,"interventions":957},"NCT04844606","A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)",[87],"2021-05-26",[735,914,956,585],"Inflammatory Bowel Diseases",[588,588],{"nctId":959,"briefTitle":960,"status":393,"phases":961,"primaryCompletion":910,"completion":733,"start":962,"enrollment":963,"conditions":964,"interventions":965},"NCT05509777","A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease",[87],"2024-03-13",90,[585],[588],{"nctId":967,"briefTitle":968,"status":103,"phases":969,"primaryCompletion":970,"completion":971,"start":333,"enrollment":972,"conditions":973,"interventions":974},"NCT03482011","A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis",[87],"2019-03-21","2020-01-16",530,[447],[588],{"nctId":976,"briefTitle":977,"status":257,"phases":978,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":984},"NCT05767021","A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis",[87],"2024-08-09","2026-04","2023-05-17",172,[735,914],[588,588],{"nctId":986,"briefTitle":987,"status":103,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":994},"NCT03535194","A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)",[87],"2020-03-05","2020-06-03","2018-06-26",1484,[447],[588,995],"Secukinumab",{"nctId":997,"briefTitle":998,"status":999,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1005},"NCT03556202","A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)","TERMINATED",[87],"2022-02-07","2018-09-03",1936,[447],[588],{"nctId":1007,"briefTitle":1008,"status":257,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT04232553","A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease",[87],"2024-11-28","2027-04","2020-06-22",996,[585],[588],{"nctId":1017,"briefTitle":1018,"status":257,"phases":1019,"primaryCompletion":1020,"completion":910,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT03519945","A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)",[87],"2026-03-04","2018-07-18",1058,[735],[588],{"nctId":578,"briefTitle":579,"status":393,"phases":1026,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":1027,"interventions":1028},[87],[585,586],[588,588,92],{"nctId":1030,"briefTitle":1031,"status":103,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1038},"NCT03518086","An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)",[87],"2021-01-21","2024-05-15","2018-06-18",1281,[735],[588],{"nctId":1040,"briefTitle":1041,"status":103,"phases":1042,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1048},"NCT03926130","A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease",[87],"2023-08-23","2023-10-02","2019-07-23",1158,[585],[588,588,1049,1049],"Ustekinumab",{"nctId":730,"briefTitle":731,"status":393,"phases":1051,"primaryCompletion":733,"completion":733,"start":582,"enrollment":422,"conditions":1052,"interventions":1053},[87],[735,586],[588,588,92],7,{"trials":1056,"activeCount":314,"soonestReadout":911},[1057],{"nctId":1058,"briefTitle":1059,"status":1060,"phases":1061,"primaryCompletion":911,"completion":911,"start":419,"enrollment":1062,"conditions":1063,"interventions":1066},"NCT07612267","A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication","NOT_YET_RECRUITING",[88],14,[1064,1065],"Lactation","Inflammatory Bowel Disease",[588],{"trials":1068,"activeCount":97},[],{"intervention":1070,"totalTrials":1071,"cells":1072},"Pirtobrutinib",16,{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1182,"PHASE3":1202,"PHASE4":1204,"NA":1233},{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":314,"soonestReadout":1107},[1077,1085,1094,1103,1120,1128,1136,1144,1152,1163,1173],{"nctId":1078,"briefTitle":1079,"status":103,"phases":1080,"primaryCompletion":1081,"completion":1081,"start":695,"enrollment":1082,"conditions":1083,"interventions":1084},"NCT06180980","A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants",[85],"2021-03-08",20,[15],[1070],{"nctId":1086,"briefTitle":1087,"status":103,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1071,"conditions":1091,"interventions":1092},"NCT06194214","A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants",[85],"2021-06-09","2021-03-11",[15],[1070,1093],"Digoxin",{"nctId":1095,"briefTitle":1096,"status":103,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1071,"conditions":1100,"interventions":1101},"NCT06165146","A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants",[85],"2020-12-30","2020-11-10",[15],[1102,1070],"Repaglinide",{"nctId":1104,"briefTitle":1105,"status":257,"phases":1106,"primaryCompletion":1107,"completion":419,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1118},"NCT05024045","Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",[85],"2023-06-14","2021-09-30",316,[1111,1112,1113,1114,1115,1116,1117],"Leukemia, Lymphocytic, Chronic, B-Cell","Lymphoma, B-cell Marginal Zone","Lymphoma, Non-Hodgkin","Multiple Myeloma","B-cell Lymphoma","Waldenstrom Macroglobulinemia","Lymphoma, Mantle-Cell",[1119,1070],"LOXO-338",{"nctId":1121,"briefTitle":1122,"status":103,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":165,"conditions":1126,"interventions":1127},"NCT06258174","A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants",[85],"2021-12-22","2021-09-28",[15],[1070],{"nctId":1129,"briefTitle":1130,"status":103,"phases":1131,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1071,"conditions":1134,"interventions":1135},"NCT06190678","Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants",[85],"2021-06-04","2021-02-01",[15,147],[1070],{"nctId":1137,"briefTitle":1138,"status":103,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":214,"conditions":1142,"interventions":1143},"NCT06190691","Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants",[85],"2021-12-30","2020-12-18",[15,312],[1070],{"nctId":1145,"briefTitle":1146,"status":103,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":290,"conditions":1150,"interventions":1151},"NCT06181006","A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants",[85],"2020-12-01","2020-08-14",[15],[1070],{"nctId":1153,"briefTitle":1154,"status":103,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1160},"NCT06180967","A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants",[85],"2020-10-20","2020-09-03",15,[15],[1161,1162,1070],"Midazolam Syrup","Midazolam Solution",{"nctId":1164,"briefTitle":1165,"status":103,"phases":1166,"primaryCompletion":1167,"completion":1167,"start":872,"enrollment":1071,"conditions":1168,"interventions":1169},"NCT06215430","A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants",[85],"2021-04-15",[15],[1170,1171,1172,1070],"Caffeine","Omeprazole","Warfarin",{"nctId":1174,"briefTitle":1175,"status":103,"phases":1176,"primaryCompletion":666,"completion":666,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1180},"NCT06215521","A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants",[85],"2020-12-15",31,[15],[1070,1181],"Moxifloxacin",{"trials":1183,"activeCount":947,"soonestReadout":462},[1184,1193],{"nctId":1185,"briefTitle":1186,"status":393,"phases":1187,"primaryCompletion":462,"completion":853,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT06721013","A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia",[85,86],"2025-07-30",58,[1191],"Immune Thrombocytopenia (ITP)",[1070],{"nctId":1194,"briefTitle":1195,"status":257,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT07162181","Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers",[86],"2030-05","2025-08-07",13,[1113,1111,1115],[1070],{"trials":1203,"activeCount":97},[],{"trials":1205,"activeCount":1232,"soonestReadout":1197},[1206,1217,1225],{"nctId":1207,"briefTitle":1208,"status":393,"phases":1209,"primaryCompletion":1197,"completion":1210,"start":1211,"enrollment":658,"conditions":1212,"interventions":1215},"NCT07218341","A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[88],"2032-12","2026-03-09",[1213,1214],"Chronic Lymphocytic Leukemia","Lymphoma, Small Lymphocytic",[1070,1216],"Idelalisib",{"nctId":1218,"briefTitle":1219,"status":393,"phases":1220,"primaryCompletion":1197,"completion":1210,"start":1221,"enrollment":553,"conditions":1222,"interventions":1224},"NCT06876662","A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma or Non-Hodgkin Lymphoma",[88],"2025-05-20",[1213,1223],"Non-Hodgkin Lymphoma",[1070],{"nctId":1226,"briefTitle":1227,"status":393,"phases":1228,"primaryCompletion":1197,"completion":1210,"start":1221,"enrollment":1229,"conditions":1230,"interventions":1231},"NCT06876649","A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib",[88],787,[1213,1223],[1070],3,{"trials":1234,"activeCount":97},[],{"intervention":1236,"totalTrials":1237,"cells":1238},"Lebrikizumab",17,{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1260,"PHASE3":1273,"PHASE4":1401,"NA":1412},{"trials":1240,"activeCount":97},[],{"trials":1242,"activeCount":97},[1243,1252],{"nctId":1244,"briefTitle":1245,"status":103,"phases":1246,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1251},"NCT04840901","A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants",[85],"2022-02-11","2021-06-02",242,[15],[1236],{"nctId":1253,"briefTitle":1254,"status":103,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":290,"conditions":1258,"interventions":1259},"NCT06243198","A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants",[85],"2024-09-03","2024-03-28",[15],[1236],{"trials":1261,"activeCount":97},[1262],{"nctId":1263,"briefTitle":1264,"status":103,"phases":1265,"primaryCompletion":1266,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1272},"NCT03443024","A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis",[86],"2019-02-07","2019-05-23","2018-01-30",280,[1271],"Atopic Dermatitis",[1236],{"trials":1274,"activeCount":1400,"soonestReadout":1318},[1275,1286,1295,1305,1314,1323,1331,1341,1351,1361,1373,1383,1392],{"nctId":1276,"briefTitle":1277,"status":1278,"phases":1279,"primaryCompletion":910,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1285},"NCT05735483","A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to \u003C18 Years of Age With Moderate-to-Severe Atopic Dermatitis","ENROLLING_BY_INVITATION",[87],"2029-04","2023-03-09",310,[1271,1284],"Eczema",[1236],{"nctId":1287,"briefTitle":1288,"status":103,"phases":1289,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":523,"conditions":1293,"interventions":1294},"NCT04250350","Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis",[87],"2022-04-20","2022-06-22","2020-02-11",[1271],[1236],{"nctId":1296,"briefTitle":1297,"status":103,"phases":1298,"primaryCompletion":1299,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1304},"NCT05369403","A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab",[87],"2024-01-11","2025-02-05","2022-12-19",86,[1271],[1236],{"nctId":1306,"briefTitle":1307,"status":257,"phases":1308,"primaryCompletion":443,"completion":1309,"start":1310,"enrollment":523,"conditions":1311,"interventions":1313},"NCT06921759","A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis",[87],"2026-07","2025-04-21",[1312],"Atopic Hand and Foot Dermatitis",[1236],{"nctId":1315,"briefTitle":1316,"status":257,"phases":1317,"primaryCompletion":1318,"completion":420,"start":344,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT06280716","A Study of Lebrikizumab (LY3650150) With\u002FWithout Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis",[87],"2025-09-25",301,[1271],[1236,1322],"Topical Corticosteroid",{"nctId":1324,"briefTitle":1325,"status":257,"phases":1326,"primaryCompletion":260,"completion":462,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1330},"NCT05559359","A Study of Lebrikizumab (LY3650150) in Participants 6 Months to \u003C18 Years of Age With Moderate-to-Severe Atopic Dermatitis",[87],"2022-10-18",367,[1271,1284],[1236,1322],{"nctId":1332,"briefTitle":1333,"status":103,"phases":1334,"primaryCompletion":1335,"completion":1336,"start":1337,"enrollment":1338,"conditions":1339,"interventions":1340},"NCT04626297","A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)",[87],"2022-08-03","2022-09-30","2020-11-17",254,[1271],[1236],{"nctId":1342,"briefTitle":1343,"status":103,"phases":1344,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":1348,"conditions":1349,"interventions":1350},"NCT04178967","Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis",[87],"2021-07-12","2022-04-28","2019-10-29",445,[1271],[1236],{"nctId":1352,"briefTitle":1353,"status":103,"phases":1354,"primaryCompletion":1355,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1360},"NCT04146363","Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)",[87],"2021-06-21","2022-05-03","2019-09-24",424,[1271],[1236],{"nctId":1362,"briefTitle":1363,"status":103,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":665,"enrollment":16,"conditions":1367,"interventions":1372},"NCT04760314","A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis",[87],"2022-07-31","2023-02-01",[1368,1369,1284,1370,1371],"Dermatitis, Atopic","Dermatitis","Skin Diseases","Skin Diseases, Genetic",[1236,1322],{"nctId":1374,"briefTitle":1375,"status":103,"phases":1376,"primaryCompletion":1377,"completion":1378,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1382},"NCT04392154","Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)",[87],"2024-07-19","2025-04-22","2020-06-15",1153,[1271],[1236],{"nctId":1384,"briefTitle":1385,"status":103,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":963,"conditions":1390,"interventions":1391},"NCT05372419","A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color",[87],"2024-05-03","2025-02-17","2023-01-12",[1271],[1236],{"nctId":1393,"briefTitle":1394,"status":103,"phases":1395,"primaryCompletion":1396,"completion":1397,"start":77,"enrollment":8,"conditions":1398,"interventions":1399},"NCT04250337","Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.",[87],"2021-08-11","2021-09-16",[1271],[1236],4,{"trials":1402,"activeCount":314,"soonestReadout":1407},[1403],{"nctId":1404,"briefTitle":1405,"status":257,"phases":1406,"primaryCompletion":1407,"completion":408,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1411},"NCT07006792","A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden",[88],"2026-05-14","2025-06-16",233,[1271],[1236],{"trials":1413,"activeCount":97},[],{"intervention":770,"totalTrials":314,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1424,"NA":1430},{"trials":1417,"activeCount":97},[],{"trials":1419,"activeCount":97},[],{"trials":1421,"activeCount":97},[],{"trials":1423,"activeCount":97},[],{"trials":1425,"activeCount":314,"soonestReadout":764},[1426],{"nctId":761,"briefTitle":762,"status":257,"phases":1427,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":1428,"interventions":1429},[88],[30],[92,770],{"trials":1431,"activeCount":97},[],{"intervention":1216,"totalTrials":314,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1442,"NA":1448},{"trials":1435,"activeCount":97},[],{"trials":1437,"activeCount":97},[],{"trials":1439,"activeCount":97},[],{"trials":1441,"activeCount":97},[],{"trials":1443,"activeCount":314,"soonestReadout":1197},[1444],{"nctId":1207,"briefTitle":1208,"status":393,"phases":1445,"primaryCompletion":1197,"completion":1210,"start":1211,"enrollment":658,"conditions":1446,"interventions":1447},[88],[1213,1214],[1070,1216],{"trials":1449,"activeCount":97},[],{"intervention":48,"totalTrials":1451,"cells":1452},53,{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1708,"PHASE3":1886,"PHASE4":1998,"NA":2027},{"trials":1454,"activeCount":97},[],{"trials":1456,"activeCount":1232,"soonestReadout":77},[1457,1469,1481,1494,1514,1526,1542,1552,1562,1580,1592,1599,1614,1623,1633,1642,1658,1670,1682,1689,1698],{"nctId":1458,"briefTitle":1459,"status":103,"phases":1460,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1467},"NCT01394016","A Phase 1 Study of LY2835219 In Participants With Advanced Cancer",[85],"2014-05-29","2022-04-12","2009-12-07",225,[1466],"Advanced Cancer",[48,1468],"Fulvestrant",{"nctId":1470,"briefTitle":1471,"status":103,"phases":1472,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":893,"conditions":1476,"interventions":1479},"NCT02117648","A Study of LY2835219 in Participants With Cancer",[85],"2015-02","2015-08","2014-04",[1477,1478],"Neoplasm","Neoplasm Metastasis",[48,1480],"Clarithromycin",{"nctId":1482,"briefTitle":1483,"status":103,"phases":1484,"primaryCompletion":1485,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1492},"NCT02745769","A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents",[85],"2018-11-05","2019-01-22","2016-10-21",23,[1466,1490,1491],"Colorectal Cancer","Mantle Cell Lymphoma",[61,1493,48],"Merestinib",{"nctId":1495,"briefTitle":1496,"status":999,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1507},"NCT02784795","A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors",[85],"2018-08-09","2020-02-13","2016-11-04",94,[1503,36,1504,1505,1506],"Solid Tumor","Colon Cancer","Cholangiocarcinoma","Soft Tissue Sarcoma",[1508,1509,48,1510,1511,1512,1513],"LY3039478","Taladegib","Cisplatin","Gemcitabine","Carboplatin","LY3023414",{"nctId":1515,"briefTitle":1516,"status":103,"phases":1517,"primaryCompletion":1518,"completion":1519,"start":1520,"enrollment":757,"conditions":1521,"interventions":1523},"NCT05999968","Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment",[85],"2024-02-23","2026-01-21","2024-01-12",[1522],"Prostatic Neoplasms",[48,1524,1525],"Darolutamide","LHRH agonist\u002Fantagonist",{"nctId":1527,"briefTitle":1528,"status":103,"phases":1529,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":1533,"interventions":1536},"NCT02857270","A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced\u002FMetastatic Cancer",[85],"2021-02-10","2022-10-24","2016-09-29",[1466,1534,1535,1490],"Metastatic Melanoma","Metastatic Non-small Cell Lung Cancer",[1537,1538,48,1539,1511,1540,1541],"LY3214996","Midazolam","Nab-paclitaxel","Encorafenib","Cetuximab",{"nctId":1543,"briefTitle":1544,"status":103,"phases":1545,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1550},"NCT02677844","A Study of Abemaciclib in Healthy Participants",[85],"2016-07","2016-02",35,[15],[48,1551],"Loperamide",{"nctId":1553,"briefTitle":1554,"status":103,"phases":1555,"primaryCompletion":1556,"completion":1557,"start":1558,"enrollment":893,"conditions":1559,"interventions":1561},"NCT02919696","A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and\u002For Metastatic Cancers",[85],"2018-11-23","2019-09-03","2017-08-07",[1466,1560],"Metastatic Cancer",[48],{"nctId":1563,"briefTitle":1564,"status":257,"phases":1565,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":1569,"interventions":1573},"NCT04188548","A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer",[85],"2020-06-29","2019-12-10",500,[36,1570,1571,1572],"Advanced Breast Cancer","Metastatic Breast Cancer","Endometrial Cancer",[1574,48,1575,1576,1577,1578,1579],"LY3484356","Everolimus","Alpelisib","Trastuzumab","Aromatase Inhibitor","Pertuzumab",{"nctId":1581,"briefTitle":1582,"status":103,"phases":1583,"primaryCompletion":1584,"completion":1585,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1590},"NCT02411591","A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)",[85],"2017-06-23","2019-05-28","2015-06-04",66,[1589,1478],"Carcinoma, Non-Small-Cell Lung",[1591,48],"Necitumumab",{"nctId":1593,"briefTitle":1594,"status":103,"phases":1595,"primaryCompletion":1474,"completion":1474,"start":1596,"enrollment":1548,"conditions":1597,"interventions":1598},"NCT02387814","A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment",[85],"2015-03",[312],[48],{"nctId":1600,"briefTitle":1601,"status":103,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1611},"NCT01655225","A Study of LY3023414 in Participants With Advanced Cancer",[85],"2019-04-04","2022-02-02","2012-07-31",156,[1466,1560,1608,1571,1609,1610],"Non-Hodgkin's Lymphoma","Malignant Mesothelioma","Non-small Cell Lung Cancer",[1513,1538,1468,1612,1510,48,1613],"Pemetrexed","Letrozole",{"nctId":1615,"briefTitle":1616,"status":103,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1622},"NCT02482935","A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food",[85],"2015-09","2015-06",30,[15],[48],{"nctId":1624,"briefTitle":1625,"status":103,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":233,"conditions":1629,"interventions":1630},"NCT02884089","A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants",[85],"2016-12","2016-08",[15],[48,1631,1632],"Metformin","Iohexol",{"nctId":1634,"briefTitle":1635,"status":103,"phases":1636,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":118,"conditions":1640,"interventions":1641},"NCT02688088","A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body",[85],"2018-02-04","2021-01-06","2016-03-08",[1478],[867,48],{"nctId":1643,"briefTitle":1644,"status":103,"phases":1645,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":1649,"conditions":1650,"interventions":1655},"NCT02791334","A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors",[85],"2020-05-22","2024-06-27","2016-06-29",164,[1503,1651,1652,1653,1654],"Microsatellite Instability-High (MSI-H) Solid Tumors","Cutaneous Melanoma","Pancreatic Cancer","Breast Cancer (HR+HER2-)",[1656,61,48,1493,1657],"LY3300054","LY3321367",{"nctId":1659,"briefTitle":1660,"status":257,"phases":1661,"primaryCompletion":462,"completion":462,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1665},"NCT05307705","A Study of LOXO-783 in Patients With Breast Cancer\u002FOther Solid Tumors",[85],"2022-05-11",193,[36],[1666,1468,1667,48,1668,1669],"LOXO-783","Imlunestrant","Anastrozole, Exemestane, or Letrozole","Paclitaxel",{"nctId":1671,"briefTitle":1672,"status":103,"phases":1673,"primaryCompletion":1674,"completion":1675,"start":1676,"enrollment":1677,"conditions":1678,"interventions":1679},"NCT04071262","A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer",[85],"2021-02-12","2021-08-30","2019-12-20",6,[1466],[48,1680,1681],"Abiraterone Acetate","Prednisolone",{"nctId":1683,"briefTitle":1544,"status":103,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1547,"enrollment":1686,"conditions":1687,"interventions":1688},"NCT02672423",[85],"2016-10",127,[15],[48,48],{"nctId":75,"briefTitle":76,"status":257,"phases":1690,"primaryCompletion":77,"completion":462,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1695},[85],"2016-11-14",100,[1694,36],"Non Small Cell Lung Cancer",[48,1696,1697],"Pembrolizumab","Anastrozole",{"nctId":1699,"briefTitle":1700,"status":103,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":299,"conditions":1705,"interventions":1707},"NCT02079636","A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)",[85],"2018-05-02","2019-08-29","2014-03-28",[1706],"Carcinoma, Non-small Cell Lung",[48,1612,1511,61,1513,1696],{"trials":1709,"activeCount":425,"soonestReadout":65},[1710,1723,1735,1747,1762,1770,1783,1796,1806,1812,1821,1832,1844,1852,1863,1876],{"nctId":1711,"briefTitle":1712,"status":999,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":425,"conditions":1716,"interventions":1719},"NCT04165031","A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation",[85,86],"2020-10-30","2019-11-28",[1717,1718,1490],"Advanced Solid Tumor","Non-Small Cell Lung Cancer",[1720,48,1541,1721,1722],"LY3499446","Erlotinib","Docetaxel",{"nctId":1724,"briefTitle":1725,"status":103,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":1730,"conditions":1731,"interventions":1734},"NCT02308020","A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",[86],"2018-11-08","2019-11-08","2015-04-20",162,[36,1610,1732,1733],"Melanoma","Brain Metastases",[48],{"nctId":1736,"briefTitle":1737,"status":257,"phases":1738,"primaryCompletion":1739,"completion":462,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1744},"NCT05440786","CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma",[86],"2025-01-15","2022-09-20",46,[1743,1478],"Sarcoma, Ewing",[48,1745,1746],"Irinotecan","Temozolomide",{"nctId":1748,"briefTitle":1749,"status":393,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":1754,"interventions":1756},"NCT05768139","First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",[85,86],"2030-07","2023-04-17",880,[36,1755],"Solid Tumors, Adult",[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],"STX-478","Ribociclib","Palbociclib","Exemestane","Tamoxifen",{"nctId":1763,"briefTitle":1764,"status":103,"phases":1765,"primaryCompletion":1766,"completion":1281,"start":116,"enrollment":1767,"conditions":1768,"interventions":1769},"NCT03703466","A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer",[86],"2019-07-29",72,[1571],[48],{"nctId":1771,"briefTitle":1772,"status":103,"phases":1773,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":128,"conditions":1777,"interventions":1780},"NCT04238819","A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma",[85,86],"2024-03-15","2025-08-19","2020-11-09",[1778,1779],"Relapsed Solid Tumor","Refractory Solid Tumor",[48,1745,1746,1781,1782],"Dinutuximab","GM-CSF",{"nctId":1784,"briefTitle":1785,"status":103,"phases":1786,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1794},"NCT02675231","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",[86],"2019-04-08","2023-11-09","2016-05-23",237,[1792,1793],"Hormone Receptor Positive Breast Cancer","HER-2 Positive Breast Cancer",[48,1577,1468,1795],"Standard of Care Single Agent Chemotherapy",{"nctId":1797,"briefTitle":1798,"status":103,"phases":1799,"primaryCompletion":1800,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1805},"NCT02102490","A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread",[86],"2016-04-30","2018-10-22","2014-06-10",132,[1571],[48],{"nctId":63,"briefTitle":64,"status":257,"phases":1807,"primaryCompletion":65,"completion":462,"start":923,"enrollment":1808,"conditions":1809,"interventions":1810},[86],234,[1571],[48,1761,1811],"Prophylactic Loperamide",{"nctId":1813,"briefTitle":1814,"status":103,"phases":1815,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":165,"conditions":1819,"interventions":1820},"NCT01739309","Study of LY2835219 for Mantle Cell Lymphoma",[86],"2015-09-28","2022-09-05","2013-03-20",[1491],[48],{"nctId":1822,"briefTitle":1823,"status":103,"phases":1824,"primaryCompletion":1825,"completion":1826,"start":1474,"enrollment":1827,"conditions":1828,"interventions":1831},"NCT02441946","A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",[86],"2016-08-16","2018-02-12",224,[36,1829,1830],"Hormone Receptor Positive Tumor","Early-Stage Breast Carcinoma",[48,1551,1697],{"nctId":1833,"briefTitle":1834,"status":103,"phases":1835,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":1839,"conditions":1840,"interventions":1842},"NCT02981342","A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma",[86],"2018-04-20","2018-11-09","2017-01-12",106,[1841],"Pancreatic Ductal Adenocarcinoma",[48,1513,1511,1843],"Capecitabine",{"nctId":1845,"briefTitle":1846,"status":257,"phases":1847,"primaryCompletion":765,"completion":396,"start":1848,"enrollment":34,"conditions":1849,"interventions":1851},"NCT06413706","A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy",[86],"2024-10-25",[1850],"Glioma",[48,1746],{"nctId":1853,"briefTitle":1854,"status":103,"phases":1855,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":1859,"conditions":1860,"interventions":1862},"NCT02450539","A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer",[86],"2017-03-31","2020-07-29","2015-08-06",159,[1861],"Non-Small Cell Lung Cancer Stage IV",[48,1722],{"nctId":1864,"briefTitle":1865,"status":393,"phases":1866,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":1869,"interventions":1873},"NCT05999994","A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer",[86],"2020-01-22",105,[1870,1871,1872],"Neoplasms","Child","Adolescent",[61,1874,1875,1511,1722,48,1745,1746],"Cyclophosphamide","Vinorelbine",{"nctId":1877,"briefTitle":1878,"status":103,"phases":1879,"primaryCompletion":1880,"completion":1881,"start":1882,"enrollment":37,"conditions":1883,"interventions":1885},"NCT04408924","Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer",[86],"2022-04-27","2023-06-02","2021-01-20",[1884],"Metastatic Castration-Resistant Prostate Cancer",[48],{"trials":1887,"activeCount":757,"soonestReadout":47},[1888,1895,1907,1918,1928,1951,1957,1965,1975,1981,1991],{"nctId":50,"briefTitle":51,"status":257,"phases":1889,"primaryCompletion":52,"completion":910,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1894},[87],"2014-07-22",669,[1893],"Breast Neoplasms",[48,1468],{"nctId":1896,"briefTitle":1897,"status":257,"phases":1898,"primaryCompletion":1899,"completion":419,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},"NCT03706365","A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer",[86,87],"2024-01-02","2018-11-26",393,[1903],"Prostate Cancer",[48,1905,1906],"Abiraterone acetate","Prednisone",{"nctId":1908,"briefTitle":1909,"status":393,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1916},"NCT07174336","A Study of Tersolisib (LY4064809\u002FSTX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",[87],"2029-05","2033-05","2025-12-22",920,[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],"LY4064809",{"nctId":1919,"briefTitle":1920,"status":257,"phases":1921,"primaryCompletion":1922,"completion":910,"start":1923,"enrollment":1924,"conditions":1925,"interventions":1927},"NCT05169567","Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer",[87],"2024-02-08","2022-03-11",368,[1926,1478],"Breast Neoplasm",[48,1468],{"nctId":1929,"briefTitle":1930,"status":257,"phases":1931,"primaryCompletion":1932,"completion":454,"start":1933,"enrollment":1934,"conditions":1935,"interventions":1948},"NCT05288166","A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)",[87],"2024-02-15","2022-04-14",925,[1522,1478,1936,1937,1938,1939,1940,1941,1942,1680,1943,1944,1945,1906,1681,1946,1947],"Urogenital Neoplasms","Physiological Effects of Drugs","Antineoplastic Agents","Antineoplastic Agents, Hormonal","Androgens","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Steroid Synthesis Inhibitors","Cytochrome P-450","Enzyme Inhibitors","Cyclin-Dependent Kinase 4","Cyclin-Dependent Kinase 6",[48,1949,1950],"Abiraterone","Prednisone or Prednisolone",{"nctId":54,"briefTitle":55,"status":257,"phases":1952,"primaryCompletion":56,"completion":462,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1956},[87],"2014-10-03",453,[1694],[48,1721],{"nctId":1958,"briefTitle":1959,"status":999,"phases":1960,"primaryCompletion":1961,"completion":1961,"start":686,"enrollment":335,"conditions":1962,"interventions":1963},"NCT04752332","A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer",[87],"2024-06-26",[1893],[48,1964],"Standard Adjuvant ET",{"nctId":1966,"briefTitle":1967,"status":257,"phases":1968,"primaryCompletion":1969,"completion":1911,"start":1970,"enrollment":1971,"conditions":1972,"interventions":1973},"NCT03155997","Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer",[87],"2020-03-16","2017-07-12",5637,[36],[48,1974],"Standard Adjuvant Endocrine Therapy",{"nctId":45,"briefTitle":46,"status":257,"phases":1976,"primaryCompletion":47,"completion":462,"start":1977,"enrollment":1978,"conditions":1979,"interventions":1980},[87],"2014-11-06",493,[36],[48,1697,1613],{"nctId":1982,"briefTitle":1983,"status":257,"phases":1984,"primaryCompletion":1985,"completion":1986,"start":1987,"enrollment":1988,"conditions":1989,"interventions":1990},"NCT04975308","A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",[87],"2024-06-24","2027-08","2021-10-04",874,[1893,1478],[1667,1760,1468,48],{"nctId":71,"briefTitle":72,"status":257,"phases":1992,"primaryCompletion":73,"completion":1993,"start":1994,"enrollment":1995,"conditions":1996,"interventions":1997},[87],"2028-03","2016-12-05",463,[36],[48,1697,1613,1468],{"trials":1999,"activeCount":97},[2000,2009,2019],{"nctId":2001,"briefTitle":2002,"status":999,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":1400,"conditions":2006,"interventions":2007},"NCT04031885","A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",[88],"2020-08-11","2019-08-14",[1571],[48,1468,2008],"Standard Chemotherapy",{"nctId":2010,"briefTitle":2011,"status":384,"phases":2012,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":97,"conditions":2016,"interventions":2017},"NCT03988114","A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",[88],"2022-03-23","2023-03-23","2019-09-16",[1571],[48,2018],"Nonsteroidal Aromatase Inhibitor",{"nctId":2020,"briefTitle":2021,"status":103,"phases":2022,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":776,"conditions":2025,"interventions":2026},"NCT04707196","A Study of Abemaciclib in Indian Women With Advanced Breast Cancer",[88],"2023-01-09","2021-02-22",[1893,1478],[48,2018,1468],{"trials":2028,"activeCount":97},[2029,2036],{"nctId":2030,"briefTitle":2031,"status":2032,"phases":2033,"conditions":2034,"interventions":2035},"NCT02792725","Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer","APPROVED_FOR_MARKETING",[],[1571],[48],{"nctId":2037,"briefTitle":2038,"status":2032,"phases":2039,"conditions":2040,"interventions":2041},"NCT03763604","Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer",[],[1571],[48],{"intervention":2043,"totalTrials":1620,"cells":2044},"Orforglipron",{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2103,"PHASE3":2105,"PHASE4":2316,"NA":2318},{"trials":2046,"activeCount":97},[],{"trials":2048,"activeCount":97},[2049,2057,2066,2075,2083,2095],{"nctId":2050,"briefTitle":2051,"status":103,"phases":2052,"primaryCompletion":2053,"completion":2053,"start":2054,"enrollment":1302,"conditions":2055,"interventions":2056},"NCT06692348","A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants",[85],"2025-06-09","2024-12-13",[15],[2043],{"nctId":2058,"briefTitle":2059,"status":103,"phases":2060,"primaryCompletion":2061,"completion":2061,"start":2062,"enrollment":1620,"conditions":2063,"interventions":2064},"NCT06370728","A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants",[85],"2024-07-23","2024-05-06",[15],[2043,2065],"Carbamazepine",{"nctId":2067,"briefTitle":2068,"status":103,"phases":2069,"primaryCompletion":1300,"completion":1300,"start":2070,"enrollment":2071,"conditions":2072,"interventions":2073},"NCT06704763","A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants",[85],"2024-12-06",27,[15],[2043,1538,2074],"Quinidine",{"nctId":2076,"briefTitle":2077,"status":103,"phases":2078,"primaryCompletion":2079,"completion":2079,"start":1388,"enrollment":2080,"conditions":2081,"interventions":2082},"NCT06824051","A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight",[85],"2026-01-26",120,[24,27],[2043],{"nctId":2084,"briefTitle":2085,"status":103,"phases":2086,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":2089,"interventions":2091},"NCT06186622","A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants",[85],"2024-07-10",50,[15,2090,27],"Obese",[2043,2092,1093,2093,217,1538,2094],"Simvastatin","Rosuvastatin","Sodium Bicarbonate",{"nctId":2096,"briefTitle":2097,"status":103,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":1985,"enrollment":2100,"conditions":2101,"interventions":2102},"NCT06440980","A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight",[85],"2025-06-02",533,[15,2090,27,24],[2043],{"trials":2104,"activeCount":97},[],{"trials":2106,"activeCount":1158,"soonestReadout":2180},[2107,2117,2126,2134,2142,2149,2158,2166,2176,2185,2193,2202,2222,2230,2239,2246,2255,2263,2270,2279,2286,2292,2300,2309],{"nctId":2108,"briefTitle":2109,"status":393,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":2113,"conditions":2114,"interventions":2116},"NCT07223593","Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease",[87],"2028-06","2025-10-31",1205,[2115],"Peripheral Arterial Disease",[2043],{"nctId":2118,"briefTitle":2119,"status":257,"phases":2120,"primaryCompletion":259,"completion":322,"start":2121,"enrollment":2122,"conditions":2123,"interventions":2125},"NCT06649045","A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight",[87],"2024-10-22",600,[2124,778],"OSA",[2043],{"nctId":2127,"briefTitle":2128,"status":393,"phases":2129,"primaryCompletion":910,"completion":2130,"start":2131,"enrollment":658,"conditions":2132,"interventions":2133},"NCT06672939","A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities",[87],"2031-01","2024-11-18",[24,27],[2043],{"nctId":2135,"briefTitle":2136,"status":103,"phases":2137,"primaryCompletion":2138,"completion":2138,"start":204,"enrollment":2139,"conditions":2140,"interventions":2141},"NCT05931380","A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease",[87],"2025-06-19",238,[24],[2043],{"nctId":2143,"briefTitle":2144,"status":257,"phases":2145,"primaryCompletion":1986,"completion":1986,"start":2146,"enrollment":2122,"conditions":2147,"interventions":2148},"NCT06972459","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity",[87],"2025-05-15",[24,27],[2043],{"nctId":2150,"briefTitle":2151,"status":257,"phases":2152,"primaryCompletion":395,"completion":395,"start":2153,"enrollment":2154,"conditions":2155,"interventions":2157},"NCT06948435","A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1",[87],"2025-04-30",487,[2156,778],"Hypertension",[2043],{"nctId":2159,"briefTitle":2160,"status":103,"phases":2161,"primaryCompletion":172,"completion":172,"start":375,"enrollment":2162,"conditions":2163,"interventions":2164},"NCT06192108","A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin",[87],962,[30],[2043,2165],"Dapagliflozin",{"nctId":2167,"briefTitle":2168,"status":393,"phases":2169,"primaryCompletion":2170,"completion":2170,"start":2171,"enrollment":2172,"conditions":2173,"interventions":2175},"NCT07241390","A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and\u002For Chronic Kidney Disease (ATTAIN-Outcomes)",[87],"2031-08","2025-12-01",7140,[2174,412],"Atherosclerosis Cardiovascular Disease",[2043],{"nctId":2177,"briefTitle":2178,"status":257,"phases":2179,"primaryCompletion":2180,"completion":454,"start":2181,"enrollment":2182,"conditions":2183,"interventions":2184},"NCT05869903","A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities",[87],"2025-07-25","2023-06-05",3127,[24,27,778],[2043],{"nctId":2186,"briefTitle":2187,"status":393,"phases":2188,"primaryCompletion":733,"completion":581,"start":2189,"enrollment":649,"conditions":2190,"interventions":2192},"NCT07153471","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee",[87],"2025-09-15",[2191],"Osteoarthritis",[2043],{"nctId":2194,"briefTitle":2195,"status":103,"phases":2196,"primaryCompletion":2197,"completion":2197,"start":2198,"enrollment":2199,"conditions":2200,"interventions":2201},"NCT05971940","A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone",[87],"2025-04-03","2023-08-09",559,[30],[2043],{"nctId":2203,"briefTitle":2204,"status":1060,"phases":2205,"primaryCompletion":940,"completion":940,"start":443,"enrollment":2206,"conditions":2207,"interventions":2221},"NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting",[87],130,[18,2208,621,2209,2210,623,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220],"Diabetes Melletus","Metabolic Disorders","Nutritional and Metabolic Diseases","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[2043],{"nctId":2223,"briefTitle":2224,"status":103,"phases":2225,"primaryCompletion":2189,"completion":2189,"start":2226,"enrollment":2227,"conditions":2228,"interventions":2229},"NCT06109311","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and\u002For SGLT-2 Inhibitor",[87],"2023-11-10",546,[30],[2043],{"nctId":2231,"briefTitle":2232,"status":103,"phases":2233,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2238},"NCT06010004","A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes",[87],"2025-06-05","2023-09-28",466,[30],[2043],{"nctId":2240,"briefTitle":2241,"status":257,"phases":2242,"primaryCompletion":1986,"completion":1986,"start":2146,"enrollment":2243,"conditions":2244,"interventions":2245},"NCT06993792","A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes",[87],1200,[24,27,30],[2043],{"nctId":2247,"briefTitle":2248,"status":103,"phases":2249,"primaryCompletion":2250,"completion":2250,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2254},"NCT06045221","A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin",[87],"2025-08-22","2023-09-22",1698,[30],[2043,198],{"nctId":2256,"briefTitle":2257,"status":103,"phases":2258,"primaryCompletion":2259,"completion":2259,"start":2181,"enrollment":2260,"conditions":2261,"interventions":2262},"NCT05872620","A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes",[87],"2025-08-08",1613,[24,27,30],[2043],{"nctId":2264,"briefTitle":2265,"status":257,"phases":2266,"primaryCompletion":1986,"completion":1986,"start":2267,"enrollment":2122,"conditions":2268,"interventions":2269},"NCT06972472","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes",[87],"2025-05-19",[24,27,30],[2043],{"nctId":2271,"briefTitle":2272,"status":393,"phases":2273,"primaryCompletion":1993,"completion":1993,"start":2274,"enrollment":2275,"conditions":2276,"interventions":2278},"NCT07202884","A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight",[87],"2025-09-30",1000,[2277],"Urinary Incontinence,Stress",[2043],{"nctId":2280,"briefTitle":2281,"status":393,"phases":2282,"primaryCompletion":853,"completion":2283,"start":2131,"enrollment":174,"conditions":2284,"interventions":2285},"NCT06672549","A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)",[87],"2027-03",[24,27],[2043],{"nctId":2287,"briefTitle":2288,"status":257,"phases":2289,"primaryCompletion":395,"completion":395,"start":2153,"enrollment":2154,"conditions":2290,"interventions":2291},"NCT06952530","A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2",[87],[2156],[2043],{"nctId":2293,"briefTitle":2294,"status":103,"phases":2295,"primaryCompletion":267,"completion":267,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2299},"NCT06584916","A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)",[87],"2024-09-13",376,[24,27],[2043],{"nctId":2301,"briefTitle":2302,"status":103,"phases":2303,"primaryCompletion":2304,"completion":2304,"start":155,"enrollment":2305,"conditions":2306,"interventions":2308},"NCT05803421","A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk",[87],"2026-03-16",2749,[30,24,778,27,2307,412],"Cardiovascular Diseases",[2043,506],{"nctId":2310,"briefTitle":2311,"status":257,"phases":2312,"primaryCompletion":395,"completion":395,"start":2153,"enrollment":2313,"conditions":2314,"interventions":2315},"NCT06948422","A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)",[87],974,[2156],[2043],{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[],{"intervention":610,"totalTrials":12,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2351,"PHASE3":2363,"PHASE4":2478,"NA":2480},{"trials":2323,"activeCount":97},[],{"trials":2325,"activeCount":947,"soonestReadout":443},[2326,2335,2343],{"nctId":2327,"briefTitle":2328,"status":103,"phases":2329,"primaryCompletion":2330,"completion":2330,"start":2331,"enrollment":1620,"conditions":2332,"interventions":2333},"NCT06808802","To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants",[85],"2025-04-15","2025-02-03",[15],[610,2334],"Metoprolol",{"nctId":2336,"briefTitle":2337,"status":257,"phases":2338,"primaryCompletion":443,"completion":443,"start":2339,"enrollment":2340,"conditions":2341,"interventions":2342},"NCT06982846","A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia",[85],"2025-06-06",78,[120],[610],{"nctId":2344,"briefTitle":2345,"status":393,"phases":2346,"primaryCompletion":259,"completion":259,"start":2099,"enrollment":2347,"conditions":2348,"interventions":2350},"NCT06982859","A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus",[85],95,[620,2349],"Insulin Sensitivity",[610,198],{"trials":2352,"activeCount":97},[2353],{"nctId":2354,"briefTitle":2355,"status":103,"phases":2356,"primaryCompletion":2357,"completion":764,"start":2358,"enrollment":2359,"conditions":2360,"interventions":2362},"NCT05936151","A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes",[86],"2025-10-01","2023-07-20",146,[778,2361,30],"CKD",[610],{"trials":2364,"activeCount":2477,"soonestReadout":2420},[2365,2376,2386,2393,2401,2409,2416,2426,2433,2442,2451,2455,2459,2468],{"nctId":2366,"briefTitle":2367,"status":257,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2375},"NCT06383390","The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",[87],"2029-02","2024-04-30",10000,[2373,2374],"Atherosclerotic Cardiovascular Disease (ASCVD)","Chronic Kidney Disease (CKD)",[610],{"nctId":2377,"briefTitle":2378,"status":103,"phases":2379,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":2383,"conditions":2384,"interventions":2385},"NCT06354660","Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)",[87],"2026-01-22","2026-02-20","2024-04-10",537,[619],[610],{"nctId":2387,"briefTitle":2388,"status":257,"phases":2389,"primaryCompletion":443,"completion":443,"start":2390,"enrollment":2275,"conditions":2391,"interventions":2392},"NCT05929079","A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight",[87],"2023-07-11",[30,24,27,476],[610],{"nctId":2394,"briefTitle":2395,"status":257,"phases":2396,"primaryCompletion":420,"completion":322,"start":2397,"enrollment":2398,"conditions":2399,"interventions":2400},"NCT06260722","Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)",[87],"2024-02-21",1250,[18],[610,198],{"nctId":2402,"briefTitle":2403,"status":257,"phases":2404,"primaryCompletion":733,"completion":733,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2408},"NCT06859268","A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity",[87],"2025-03-05",643,[24],[610],{"nctId":2410,"briefTitle":2411,"status":257,"phases":2412,"primaryCompletion":355,"completion":259,"start":1774,"enrollment":2413,"conditions":2414,"interventions":2415},"NCT06297603","Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and\u002For SGLT2 Inhibitor (TRANSCEND-T2D-3)",[87],320,[30],[610],{"nctId":2417,"briefTitle":2418,"status":257,"phases":2419,"primaryCompletion":2420,"completion":443,"start":2421,"enrollment":2422,"conditions":2423,"interventions":2425},"NCT05929066","A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight",[87],"2026-04-06","2023-07-10",2335,[24,27,2424,476],"Osteoarthritis, Knee",[610],{"nctId":2427,"briefTitle":2428,"status":257,"phases":2429,"primaryCompletion":715,"completion":715,"start":2430,"enrollment":445,"conditions":2431,"interventions":2432},"NCT07232719","A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight",[87],"2025-11-17",[24,27],[610],{"nctId":2434,"briefTitle":2435,"status":103,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":1348,"conditions":2439,"interventions":2441},"NCT05931367","A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee",[87],"2025-11-14","2023-08-01",[24,27,2440],"Osteo Arthritis Knee",[610],{"nctId":2443,"briefTitle":2444,"status":393,"phases":2445,"primaryCompletion":2446,"completion":2447,"start":2448,"enrollment":2122,"conditions":2449,"interventions":2450},"NCT07357415","A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight",[87],"2028-10","2028-11","2026-01-24",[24,27],[610],{"nctId":600,"briefTitle":601,"status":393,"phases":2452,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":2453,"interventions":2454},[87],[608],[92,610],{"nctId":645,"briefTitle":646,"status":257,"phases":2456,"primaryCompletion":462,"completion":462,"start":648,"enrollment":649,"conditions":2457,"interventions":2458},[87],[24],[610,92],{"nctId":2460,"briefTitle":2461,"status":393,"phases":2462,"primaryCompletion":395,"completion":395,"start":2463,"enrollment":2464,"conditions":2465,"interventions":2467},"NCT07035093","A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain",[87],"2025-05-29",586,[24,27,2466],"Chronic Low Back Pain (CLBP)",[610],{"nctId":2469,"briefTitle":2470,"status":257,"phases":2471,"primaryCompletion":2472,"completion":443,"start":2473,"enrollment":2474,"conditions":2475,"interventions":2476},"NCT05882045","A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease",[87],"2026-04-16","2023-05-30",1946,[24,2307],[610],12,{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"intervention":1696,"totalTrials":1082,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2643,"PHASE3":2673,"PHASE4":2715,"NA":2717},{"trials":2485,"activeCount":97},[],{"trials":2487,"activeCount":1677,"soonestReadout":77},[2488,2497,2509,2523,2535,2546,2564,2575,2598,2613,2625,2635,2639],{"nctId":2489,"briefTitle":2490,"status":103,"phases":2491,"primaryCompletion":2492,"completion":2493,"start":971,"enrollment":251,"conditions":2494,"interventions":2495},"NCT04148937","A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",[85],"2021-05-12","2022-06-20",[1466],[2496,1696],"LY3475070",{"nctId":2498,"briefTitle":2499,"status":393,"phases":2500,"primaryCompletion":1751,"completion":1751,"start":2501,"enrollment":2502,"conditions":2503,"interventions":2507},"NCT07046923","A Study of LY4175408 in Participants With Advanced Cancer",[85],"2025-07-28",240,[1589,2504,2505,1478,2506],"Small Cell Lung Carcinoma","Endometrial Neoplasms","Triple Negative Breast Cancer",[2508,1696,1512,1510],"LY4175408",{"nctId":2510,"briefTitle":2511,"status":257,"phases":2512,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":2515,"interventions":2517},"NCT06607185","A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",[85],"2030-01",750,[1841,1610,1490,1717,2516],"Metastatic Solid Tumor",[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],"LY4066434.","Nab paclitaxel","Oxaliplatin","Leucovorin","5Fluorouracil",{"nctId":2524,"briefTitle":2525,"status":393,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":1389,"enrollment":2528,"conditions":2529,"interventions":2532},"NCT05614739","FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3",[85],"2027-06",535,[2530,1478,2531],"Urinary Bladder Neoplasms","Ureteral Neoplasms",[2533,1696,2534],"LOXO-435","enfortumab vedotin",{"nctId":2536,"briefTitle":2537,"status":103,"phases":2538,"primaryCompletion":2539,"completion":2540,"start":2541,"enrollment":2542,"conditions":2543,"interventions":2544},"NCT03126591","A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma",[85],"2021-05-06","2023-02-21","2017-07-03",41,[1506],[2545,1696],"Olaratumab",{"nctId":2547,"briefTitle":2548,"status":393,"phases":2549,"primaryCompletion":853,"completion":1011,"start":2550,"enrollment":2551,"conditions":2552,"interventions":2558},"NCT06400472","A Study of LY4170156 in Participants With Selected Advanced Solid Tumors",[85],"2024-05-20",495,[2553,2505,2554,1589,2555,2556,2557],"Ovarian Neoplasms","Uterine Cervical Neoplasms","Triple Negative Breast Neoplasms","Pancreatic Neoplasm","Colorectal Neoplasms",[2559,2560,2561,2562,2563],"LY4170156","bevacizumab","carboplatin","Itraconazole","pembrolizumab",{"nctId":2565,"briefTitle":2566,"status":103,"phases":2567,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":2571,"conditions":2572,"interventions":2574},"NCT02451930","A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC",[85],"2017-01-26","2019-09-17","2015-09-04",71,[2573],"Stage IV Non-Small Cell Lung Cancer",[1591,1696],{"nctId":2576,"briefTitle":2577,"status":103,"phases":2578,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":2583,"interventions":2590},"NCT02009449","A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",[85],"2019-02-19","2023-07-22","2013-11-15",353,[1732,1903,2584,2585,2586,2587,2588,2589,36],"Ovarian Cancer","Renal Cell Carcinoma","Colorectal Carcinoma","Pancreatic Carcinoma","Non-small Cell Lung Carcinoma","Solid Tumors",[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],"Pegilodecakin","Paclitaxel or Docetaxel and Carboplatin or Cisplatin","FOLFOX","gemcitabine\u002Fnab-paclitaxel","Pazopanib","nivolumab","Gemcitabine\u002Fcarboplatin",{"nctId":2599,"briefTitle":2600,"status":999,"phases":2601,"primaryCompletion":989,"completion":989,"start":862,"enrollment":947,"conditions":2602,"interventions":2611},"NCT04099277","A Study of LY3435151 in Participants With Solid Tumors",[85],[1503,2603,2604,2605,2606,2607,2608,2609,2610],"Triple-negative Breast Cancer","Gastric Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Cervical Carcinoma","High Grade Serous Ovarian Carcinoma","Hepatocellular Carcinoma","Undifferentiated Pleomorphic Sarcoma","Leiomyosarcoma",[2612,1696],"LY3435151",{"nctId":2614,"briefTitle":2615,"status":103,"phases":2616,"primaryCompletion":2617,"completion":1462,"start":2618,"enrollment":2619,"conditions":2620,"interventions":2624},"NCT02443324","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",[85],"2018-08-31","2015-07-29",175,[2604,2621,1610,2622,2623],"Adenocarcinoma of the Gastroesophageal Junction","Carcinoma, Transitional Cell","Biliary Tract Cancer",[61,1696],{"nctId":2626,"briefTitle":2627,"status":393,"phases":2628,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2633},"NCT06561685","A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors",[85],"2024-09-19",340,[2516,1717,1610,2632],"SMARCA4-Deficient Tumor",[2634,1696,1510,1512,1612,1669,2519],"LY4050784",{"nctId":75,"briefTitle":76,"status":257,"phases":2636,"primaryCompletion":77,"completion":462,"start":1691,"enrollment":1692,"conditions":2637,"interventions":2638},[85],[1694,36],[48,1696,1697],{"nctId":1699,"briefTitle":1700,"status":103,"phases":2640,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":299,"conditions":2641,"interventions":2642},[85],[1706],[48,1612,1511,61,1513,1696],{"trials":2644,"activeCount":314,"soonestReadout":1011},[2645,2656,2664],{"nctId":2646,"briefTitle":2647,"status":257,"phases":2648,"primaryCompletion":1011,"completion":1011,"start":2649,"enrollment":2650,"conditions":2651,"interventions":2654},"NCT04956640","Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",[85,86],"2021-07-19",540,[1589,2557,2505,2553,2652,2653],"Pancreatic Neoplasms","Biliary Tract Neoplasms",[2655,1696,1541,1612,1510,1512],"LY3537982",{"nctId":2657,"briefTitle":2658,"status":384,"phases":2659,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":97,"conditions":2662,"interventions":2663},"NCT04158700","A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer",[85,86],"2023-05-11","2019-12-05",[1466],[82,1696],{"nctId":2665,"briefTitle":2666,"status":999,"phases":2667,"primaryCompletion":2668,"completion":989,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2672},"NCT03382899","Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer",[86],"2019-12-06","2018-03-19",101,[1694],[2591,1696],{"trials":2674,"activeCount":1400,"soonestReadout":2679},[2675,2686,2697,2707],{"nctId":2676,"briefTitle":2677,"status":257,"phases":2678,"primaryCompletion":2679,"completion":2680,"start":2681,"enrollment":2682,"conditions":2683,"interventions":2684},"NCT04194944","A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer",[87],"2023-05-01","2030-06","2020-02-17",261,[1718],[2685,1512,1510,1612,1696],"Selpercatinib",{"nctId":2687,"briefTitle":2688,"status":393,"phases":2689,"primaryCompletion":1911,"completion":2690,"start":2691,"enrollment":2692,"conditions":2693,"interventions":2694},"NCT06890598","Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer",[87],"2032-02","2025-03-27",700,[1589],[2695,1696,2696],"Olomorasib","Durvalumab",{"nctId":2698,"briefTitle":2699,"status":393,"phases":2700,"primaryCompletion":2701,"completion":1912,"start":2702,"enrollment":855,"conditions":2703,"interventions":2704},"NCT07218380","A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract",[87],"2029-10","2025-12-12",[2622,2530,1478],[2705,2706,1696],"Vepugratinib","EV",{"nctId":2708,"briefTitle":2709,"status":393,"phases":2710,"primaryCompletion":765,"completion":2130,"start":2711,"enrollment":2712,"conditions":2713,"interventions":2714},"NCT06119581","A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer",[87],"2023-12-21",1264,[1589,1478],[2655,1696,1510,1512,1612],{"trials":2716,"activeCount":97},[],{"trials":2718,"activeCount":97},[],{"intervention":1510,"totalTrials":2720,"cells":2721},82,{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2827,"PHASE3":3312,"PHASE4":3423,"NA":3425},{"trials":2723,"activeCount":97},[],{"trials":2725,"activeCount":425,"soonestReadout":81},[2726,2738,2742,2746,2750,2759,2769,2773,2784,2794,2805,2809,2816],{"nctId":2727,"briefTitle":2728,"status":103,"phases":2729,"primaryCompletion":2730,"completion":2731,"start":2732,"enrollment":2733,"conditions":2734,"interventions":2737},"NCT03027284","A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer",[85],"2019-06-20","2020-03-17","2017-02-03",19,[1466,1560,2735,1505,2736,1503,1608],"Biliary Tract Carcinoma","Gall Bladder Carcinoma",[1493,1510,1511],{"nctId":1495,"briefTitle":1496,"status":999,"phases":2739,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":2740,"interventions":2741},[85],[1503,36,1504,1505,1506],[1508,1509,48,1510,1511,1512,1513],{"nctId":2498,"briefTitle":2499,"status":393,"phases":2743,"primaryCompletion":1751,"completion":1751,"start":2501,"enrollment":2502,"conditions":2744,"interventions":2745},[85],[1589,2504,2505,1478,2506],[2508,1696,1512,1510],{"nctId":2510,"briefTitle":2511,"status":257,"phases":2747,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":2748,"interventions":2749},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":2751,"briefTitle":2752,"status":103,"phases":2753,"primaryCompletion":1546,"completion":2754,"start":1473,"enrollment":12,"conditions":2755,"interventions":2757},"NCT02359058","A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer",[85],"2016-11",[2756],"Stomach Neoplasms",[61,1843,1510,2758,2520],"S-1",{"nctId":2760,"briefTitle":2761,"status":257,"phases":2762,"primaryCompletion":154,"completion":443,"start":2763,"enrollment":776,"conditions":2764,"interventions":2767},"NCT04521686","Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations",[85],"2020-10-01",[1505,2765,1850,2766],"Chondrosarcoma","Any Solid Tumor",[2768,1511,1510,2696],"LY3410738",{"nctId":1600,"briefTitle":1601,"status":103,"phases":2770,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":2771,"interventions":2772},[85],[1466,1560,1608,1571,1609,1610],[1513,1538,1468,1612,1510,48,1613],{"nctId":2774,"briefTitle":2775,"status":103,"phases":2776,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2780},"NCT02124148","A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer",[85],"2014-06-18",167,[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],"Prexasertib","G-CSF","Fluorouracil",{"nctId":2785,"briefTitle":2786,"status":103,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":2790,"conditions":2791,"interventions":2793},"NCT02555644","A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer",[85],"2019-01-14","2016-02-24",70,[2792],"Head and Neck Neoplasms",[2781,1510,1541],{"nctId":2795,"briefTitle":2796,"status":999,"phases":2797,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":1808,"conditions":2801,"interventions":2803},"NCT01284335","A Safety Study in Participants With Advanced Solid Tumors",[85],"2012-10","2016-05","2008-07",[2802],"Advanced Solid Tumors",[1511,1722,1746,1510,1721,2804],"LY573636",{"nctId":2626,"briefTitle":2627,"status":393,"phases":2806,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":2807,"interventions":2808},[85],[2516,1717,1610,2632],[2634,1696,1510,1512,1612,1669,2519],{"nctId":79,"briefTitle":80,"status":257,"phases":2810,"primaryCompletion":81,"completion":1986,"start":2811,"enrollment":2812,"conditions":2813,"interventions":2814},[85],"2016-11-21",223,[1503],[82,1656,1511,2815,1510],"nab-Paclitaxel",{"nctId":2817,"briefTitle":2818,"status":103,"phases":2819,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":377,"conditions":2823,"interventions":2825},"NCT01285037","A Study of LY2801653 in Advanced Cancer",[85],"2017-07-21","2017-09-11","2009-09-09",[2824],"Cancer",[2826,1541,1510,1511,61],"LY2801653",{"trials":2828,"activeCount":947,"soonestReadout":60},[2829,2840,2851,2860,2871,2880,2886,2894,2905,2913,2924,2934,2943,2951,2960,2970,2980,2991,3000,3008,3016,3023,3035,3044,3055,3064,3073,3082,3090,3099,3108,3118,3128,3136,3144,3148,3156,3164,3172,3181,3190,3199,3205,3212,3223,3231,3239,3246,3255,3262,3270,3278,3288,3298,3304],{"nctId":2830,"briefTitle":2831,"status":103,"phases":2832,"completion":2833,"start":2834,"enrollment":2088,"conditions":2835,"interventions":2837},"NCT00190801","Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma",[86],"2005-09","2003-09",[2836],"Gastrointestinal Neoplasms",[2838,2839],"pemetrexed","cisplatin",{"nctId":2841,"briefTitle":2842,"status":103,"phases":2843,"primaryCompletion":2844,"completion":2845,"start":2846,"enrollment":2847,"conditions":2848,"interventions":2850},"NCT00867009","A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer",[86],"2011-05","2014-09","2009-04",113,[2849],"Non-Small-Cell Lung Cancer",[1612,1510,1541],{"nctId":2852,"briefTitle":2853,"status":103,"phases":2854,"completion":2855,"start":2856,"enrollment":2477,"conditions":2857,"interventions":2859},"NCT00251550","Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma",[85,86],"2006-08","2005-10",[2858],"Malignant Pleural Mesotherioma",[1612,1510],{"nctId":2861,"briefTitle":2862,"status":103,"phases":2863,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":2868,"interventions":2869},"NCT00870870","A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before",[86],"2012-04","2012-05","2009-03",64,[1718],[1511,1510,2870,1541,2870,1541,1512],"IMC-A12",{"nctId":2872,"briefTitle":2873,"status":103,"phases":2874,"completion":2875,"start":2876,"enrollment":1082,"conditions":2877,"interventions":2879},"NCT00386815","Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma",[86],"2007-02","2006-10",[2878],"Malignant Pleural Mesothelioma",[2838,2839],{"nctId":58,"briefTitle":59,"status":257,"phases":2881,"primaryCompletion":60,"completion":462,"start":2882,"enrollment":2883,"conditions":2884,"interventions":2885},[86],"2016-05-19",309,[2623,1560,1466],[61,1493,1510,1511],{"nctId":2887,"briefTitle":2888,"status":103,"phases":2889,"conditions":2890,"interventions":2892},"NCT00051506","ALIMTA(Pemetrexed)\u002FCisplatin and ALIMTA(Pemetrexed)\u002FCarboplatin in Extensive Stage Small Cell Lung Cancer.",[86],[2891],"Lung Neoplasms",[2893,2561,2839],"ALIMTA",{"nctId":2895,"briefTitle":2896,"status":103,"phases":2897,"primaryCompletion":2898,"completion":2898,"start":2899,"enrollment":1767,"conditions":2900,"interventions":2904},"NCT01109524","Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer",[86],"2012-09","2010-07",[2891,2901,2902,2903],"Carcinoma","Cancer of the Lung","Non-Small-Cell Lung Carcinoma",[1541,1510,1875],{"nctId":2906,"briefTitle":2907,"status":103,"phases":2908,"completion":2909,"start":2834,"enrollment":1199,"conditions":2910,"interventions":2911},"NCT00490659","Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes",[86],"2004-12",[1718],[2912,2839],"gemcitabine",{"nctId":2914,"briefTitle":2915,"status":103,"phases":2916,"primaryCompletion":2917,"completion":1618,"start":2918,"enrollment":2919,"conditions":2920,"interventions":2922},"NCT01081041","A Study in Head and Neck Cancer",[86],"2013-08","2010-06",187,[2921],"Head and Neck Cancer",[1541,1510,1512,2923],"5-Fluorouracil",{"nctId":2925,"briefTitle":2926,"status":103,"phases":2927,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":2931,"conditions":2932,"interventions":2933},"NCT00402051","Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)",[86],"2008-12","2009-05","2006-11",133,[2849],[1612,1510,1512],{"nctId":2935,"briefTitle":2936,"status":103,"phases":2937,"primaryCompletion":2800,"completion":2800,"start":2938,"enrollment":2939,"conditions":2940,"interventions":2942},"NCT00320515","Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer",[85,86],"2004-03",89,[2941],"Neoplasm, Gastric",[2838,2839],{"nctId":2944,"briefTitle":2945,"status":103,"phases":2946,"completion":2947,"start":2948,"enrollment":1692,"conditions":2949,"interventions":2950},"NCT00192101","Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and\u002For Taxanes",[86],"2005-07","2004-10",[1571],[2912,2839],{"nctId":2952,"briefTitle":2953,"status":103,"phases":2954,"primaryCompletion":2955,"completion":2956,"start":2875,"enrollment":2790,"conditions":2957,"interventions":2958},"NCT00409006","Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers",[86],"2009-08","2010-05",[1610],[1612,1510,2959],"Gefitinib",{"nctId":2961,"briefTitle":2962,"status":103,"phases":2963,"primaryCompletion":2964,"completion":2965,"start":2966,"enrollment":1548,"conditions":2967,"interventions":2969},"NCT01606748","A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin",[86],"2013-06","2016-06","2012-08",[2968],"Malignant Solid Tumor",[1591,1511,1510],{"nctId":2971,"briefTitle":2972,"status":999,"phases":2973,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":1548,"conditions":2976,"interventions":2978},"NCT00538681","Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo",[86],"2008-11","2007-09",[2977],"Lung Cancer",[2979,2838,2839],"enzastaurin",{"nctId":2981,"briefTitle":2982,"status":103,"phases":2983,"primaryCompletion":2984,"completion":2985,"start":2986,"enrollment":2987,"conditions":2988,"interventions":2990},"NCT01763788","A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",[85,86],"2017-06-28","2018-10-17","2013-05-07",192,[2989],"Squamous Non-small Cell Lung Cancer",[1591,1511,1510],{"nctId":2992,"briefTitle":2993,"status":103,"phases":2994,"primaryCompletion":2995,"completion":2995,"start":2855,"enrollment":2996,"conditions":2997,"interventions":2999},"NCT00374868","Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)",[85,86],"2008-04",59,[2998],"Urologic Neoplasms",[2838,2839],{"nctId":3001,"briefTitle":3002,"status":103,"phases":3003,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":2080,"conditions":3006,"interventions":3007},"NCT00482014","A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer",[85,86],"2011-10","2007-05",[2849],[2838,2839,2561],{"nctId":3009,"briefTitle":3010,"status":103,"phases":3011,"primaryCompletion":2917,"completion":2917,"start":3012,"enrollment":3013,"conditions":3014,"interventions":3015},"NCT01087970","A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer",[86],"2010-08",69,[2792],[1612,1541,1512,1510],{"nctId":3017,"briefTitle":3018,"status":103,"phases":3019,"primaryCompletion":2899,"completion":3020,"start":2846,"enrollment":2790,"conditions":3021,"interventions":3022},"NCT00887549","A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer",[86],"2011-06",[1718],[2838,2839],{"nctId":3024,"briefTitle":3025,"status":103,"phases":3026,"primaryCompletion":3027,"completion":3028,"start":3029,"enrollment":2733,"conditions":3030,"interventions":3031},"NCT01165021","A Study of Pemetrexed\u002FCisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer",[86],"2013-07","2016-04","2010-11",[1694],[1612,1510,3032,3033,3034],"Folic Acid","Vitamin B12","Dexamethasone",{"nctId":3036,"briefTitle":3037,"status":103,"phases":3038,"completion":3039,"start":3040,"enrollment":3041,"conditions":3042,"interventions":3043},"NCT00490399","Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas",[86],"2004-09","2003-03",39,[2735],[2912,2839],{"nctId":3045,"briefTitle":3046,"status":103,"phases":3047,"primaryCompletion":3048,"completion":3049,"start":3050,"enrollment":3051,"conditions":3052,"interventions":3053},"NCT01004250","A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer",[86],"2012-11","2013-12","2009-10",109,[1718],[1612,1510,3054],"Bevacizumab",{"nctId":3056,"briefTitle":3057,"status":103,"phases":3058,"primaryCompletion":3059,"completion":3059,"start":3060,"enrollment":1451,"conditions":3061,"interventions":3063},"NCT00415168","Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer",[86],"2009-07","2006-12",[3062],"Gastric Cancer",[2838,2839],{"nctId":3065,"briefTitle":3066,"status":103,"phases":3067,"primaryCompletion":3068,"completion":2965,"start":3069,"enrollment":982,"conditions":3070,"interventions":3071},"NCT01232452","A Study in Non-Small Cell Lung Cancer",[86],"2013-01","2011-04",[2903],[1612,1510,3072],"Cixutumumab",{"nctId":3074,"briefTitle":3075,"status":103,"phases":3076,"completion":3077,"start":3078,"enrollment":947,"conditions":3079,"interventions":3081},"NCT00490880","Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer",[86],"2004-08","2003-11",[3080],"Bladder Cancer",[2912,2839],{"nctId":3083,"briefTitle":3084,"status":103,"phases":3085,"primaryCompletion":3086,"completion":2798,"start":3087,"enrollment":1587,"conditions":3088,"interventions":3089},"NCT01057589","A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer",[86],"2012-02","2010-02",[2792],[1612,1541,1510],{"nctId":3091,"briefTitle":3092,"status":103,"phases":3093,"primaryCompletion":3094,"completion":3094,"start":2834,"enrollment":3095,"conditions":3096,"interventions":3098},"NCT00087698","Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma",[86],"2008-02",77,[3097],"Pleural Neoplasms",[2838,2839],{"nctId":3100,"briefTitle":3101,"status":103,"phases":3102,"primaryCompletion":2974,"completion":3103,"start":3040,"enrollment":2867,"conditions":3104,"interventions":3105},"NCT00191139","Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)",[86],"2009-02",[1610],[2912,3106,2839,3107],"docetaxel","etoposide",{"nctId":3109,"briefTitle":3110,"status":103,"phases":3111,"primaryCompletion":3112,"completion":3113,"start":3114,"enrollment":1269,"conditions":3115,"interventions":3116},"NCT01160744","A Study of Pemetrexed and Carboplatin\u002FCisplatin or Gemcitabine and Carboplatin\u002FCisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)",[86],"2014-01","2018-04","2010-09",[1589],[3117,1612,1512,1510,1511,1512],"IMC-1121B",{"nctId":3119,"briefTitle":3120,"status":103,"phases":3121,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":3126,"interventions":3127},"NCT01788566","A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer",[86],"2014-08","2015-12","2013-03",61,[1610],[1591,1511,1510],{"nctId":3129,"briefTitle":3130,"status":103,"phases":3131,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":25,"conditions":3134,"interventions":3135},"NCT00380588","Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer",[86],"2008-10","2006-09",[2623],[2912,2839],{"nctId":3137,"briefTitle":3138,"status":103,"phases":3139,"primaryCompletion":2846,"completion":2846,"start":3140,"enrollment":156,"conditions":3141,"interventions":3142},"NCT00191789","Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer",[86],"2003-02",[36],[2912,3143,2839],"doxorubicin",{"nctId":2646,"briefTitle":2647,"status":257,"phases":3145,"primaryCompletion":1011,"completion":1011,"start":2649,"enrollment":2650,"conditions":3146,"interventions":3147},[85,86],[1589,2557,2505,2553,2652,2653],[2655,1696,1541,1612,1510,1512],{"nctId":3149,"briefTitle":3150,"status":103,"phases":3151,"primaryCompletion":2800,"completion":3152,"start":3153,"enrollment":1620,"conditions":3154,"interventions":3155},"NCT00191308","Molecular Profiling in Lung Cancer Patients",[86],"2010-12","2005-05",[1718,2901],[2838,2839],{"nctId":3157,"briefTitle":3158,"status":103,"phases":3159,"completion":3160,"start":3161,"enrollment":2088,"conditions":3162,"interventions":3163},"NCT00191841","Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy",[86],"2006-02","2002-12",[1589],[2912,1510],{"nctId":3165,"briefTitle":3166,"status":103,"phases":3167,"completion":3168,"start":3169,"enrollment":1692,"conditions":3170,"interventions":3171},"NCT00489996","Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer",[86],"2005-06","2003-01",[1718],[2912,2839],{"nctId":3173,"briefTitle":3174,"status":103,"phases":3175,"completion":3176,"start":2834,"enrollment":3177,"conditions":3178,"interventions":3179},"NCT00069875","A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer",[86],"2005-12",195,[1589],[1511,3180,2839],"LY293111",{"nctId":3182,"briefTitle":3183,"status":103,"phases":3184,"completion":3185,"start":3186,"enrollment":2790,"conditions":3187,"interventions":3189},"NCT00191230","Gemcitabine\u002FPlatinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer",[86],"2006-07","2001-09",[3188],"Carcinoma, Non Small Cell Lung",[2912,2561,2839],{"nctId":3191,"briefTitle":3192,"status":103,"phases":3193,"completion":3194,"start":3195,"enrollment":757,"conditions":3196,"interventions":3197},"NCT00491127","Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma",[86],"2004-06","2003-04",[1608],[2912,2839,3198],"dexamethasone",{"nctId":3200,"briefTitle":3201,"status":103,"phases":3202,"primaryCompletion":3068,"completion":3027,"start":3050,"enrollment":963,"conditions":3203,"interventions":3204},"NCT01000480","A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer",[86],[1694],[1612,1510],{"nctId":3206,"briefTitle":3207,"status":103,"phases":3208,"completion":3153,"start":3209,"enrollment":1730,"conditions":3210,"interventions":3211},"NCT00191490","A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer",[86],"2002-07",[1589],[1511,3106,2839],{"nctId":3213,"briefTitle":3214,"status":103,"phases":3215,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":3220,"interventions":3221},"NCT00191854","Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line",[86],"2008-08","2009-11","2005-03",147,[36],[2912,3222,2561,2839],"paclitaxel",{"nctId":3224,"briefTitle":3225,"status":999,"phases":3226,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":757,"conditions":3229,"interventions":3230},"NCT00259285","Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer",[86],"2007-12","2005-11",[2849],[2838,2839],{"nctId":3232,"briefTitle":3233,"status":103,"phases":3234,"completion":3235,"start":3236,"enrollment":2790,"conditions":3237,"interventions":3238},"NCT00191815","Combination Chemotherapy for Metastatic Breast Cancer",[86],"2007-10","2002-10",[36],[1511,2839],{"nctId":3240,"briefTitle":3241,"status":999,"phases":3242,"primaryCompletion":2995,"completion":2995,"start":3235,"enrollment":425,"conditions":3243,"interventions":3245},"NCT00475657","Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer",[86],[3244],"Small Cell Lung Cancer",[2838,2839],{"nctId":3247,"briefTitle":3248,"status":103,"phases":3249,"primaryCompletion":3250,"completion":2799,"start":3251,"enrollment":128,"conditions":3252,"interventions":3253},"NCT01099358","Study in Advanced Solid Tumors",[86],"2015-10","2010-04",[1503],[1541,1510,3254],"5 - Fluorouracil",{"nctId":3256,"briefTitle":3257,"status":103,"phases":3258,"completion":3259,"start":2938,"enrollment":2867,"conditions":3260,"interventions":3261},"NCT00191620","Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.",[86],"2006-05",[2903],[1511,2839],{"nctId":3263,"briefTitle":3264,"status":103,"phases":3265,"primaryCompletion":3266,"completion":3027,"start":3176,"enrollment":3267,"conditions":3268,"interventions":3269},"NCT00269152","Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer",[86],"2007-11",122,[1718],[2838,2839,2561],{"nctId":3271,"briefTitle":3272,"status":103,"phases":3273,"completion":3176,"start":3274,"enrollment":251,"conditions":3275,"interventions":3277},"NCT00191763","Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer",[86],"2002-11",[3276],"Carcinoma, Non-Small-Cell-Lung Cancer",[1511,2839],{"nctId":3279,"briefTitle":3280,"status":103,"phases":3281,"primaryCompletion":3282,"completion":3122,"start":3283,"enrollment":3284,"conditions":3285,"interventions":3286},"NCT01139775","A Study in Non Small Cell Lung Cancer",[85,86],"2013-05","2011-02",76,[1694],[1612,1510,3287],"LY2603618",{"nctId":3289,"briefTitle":3290,"status":999,"phases":3291,"primaryCompletion":3292,"completion":3292,"start":2875,"enrollment":3293,"conditions":3294,"interventions":3297},"NCT00447421","A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy",[85,86],"2008-05",9,[3244,3295,3296],"Carcinoma, Small Cell","SCLC",[2838,2839],{"nctId":3299,"briefTitle":3300,"status":103,"phases":3301,"primaryCompletion":3227,"completion":3227,"start":2909,"enrollment":2088,"conditions":3302,"interventions":3303},"NCT00191334","Gemcitabine in Ovarian Cancer",[86],[2584],[2912,2839],{"nctId":3305,"briefTitle":3306,"status":103,"phases":3307,"primaryCompletion":3308,"completion":3217,"start":3077,"enrollment":3309,"conditions":3310,"interventions":3311},"NCT00192036","Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer",[86],"2008-01",49,[1694],[2912,2839],{"trials":3313,"activeCount":947,"soonestReadout":2679},[3314,3325,3333,3344,3352,3361,3368,3376,3386,3390,3401,3411,3415],{"nctId":3315,"briefTitle":3316,"status":103,"phases":3317,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":3321,"conditions":3322,"interventions":3323},"NCT00686959","Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer",[87],"2014-10","2014-11","2008-09",598,[1694],[1612,1510,3324,1875,1669,1512],"Etoposide",{"nctId":3326,"briefTitle":3327,"status":103,"phases":3328,"primaryCompletion":2918,"completion":3329,"start":2974,"enrollment":3330,"conditions":3331,"interventions":3332},"NCT00789373","A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer",[87],"2017-11",939,[1718],[1612,1510,1612],{"nctId":3334,"briefTitle":3335,"status":103,"phases":3336,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":3341,"interventions":3343},"NCT00087711","A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",[87],"2007-01","2008-03","2004-07",1713,[3342],"Non Small Cell Lung Carcinoma",[2838,2912,2839],{"nctId":3345,"briefTitle":3346,"status":103,"phases":3347,"primaryCompletion":3348,"completion":3318,"start":3217,"enrollment":3349,"conditions":3350,"interventions":3351},"NCT01017874","A Study of Alimta\u002FCisplatin\u002FGefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer",[87],"2013-04",236,[1694],[1612,1510,2959,2959],{"nctId":3353,"briefTitle":3354,"status":103,"phases":3355,"primaryCompletion":2995,"completion":2995,"start":3356,"enrollment":3357,"conditions":3358,"interventions":3360},"NCT00191100","Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix",[87],"2002-05",515,[3359],"Cancer of Cervix",[1511,1510],{"nctId":3362,"briefTitle":3363,"status":103,"phases":3364,"primaryCompletion":3048,"completion":3048,"start":3217,"enrollment":3365,"conditions":3366,"interventions":3367},"NCT01005680","A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer",[87],256,[1694],[1612,1511,1510],{"nctId":3369,"briefTitle":3370,"status":103,"phases":3371,"primaryCompletion":2975,"completion":2975,"start":3372,"enrollment":3373,"conditions":3374,"interventions":3375},"NCT00191126","Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC",[87],"2000-09",263,[1718],[2912,1510],{"nctId":3377,"briefTitle":3378,"status":103,"phases":3379,"primaryCompletion":3380,"completion":3381,"start":3382,"enrollment":3383,"conditions":3384,"interventions":3385},"NCT00981058","First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin",[87],"2013-06-17","2024-05-30","2010-01-07",1093,[1694],[1591,1511,1510],{"nctId":2676,"briefTitle":2677,"status":257,"phases":3387,"primaryCompletion":2679,"completion":2680,"start":2681,"enrollment":2682,"conditions":3388,"interventions":3389},[87],[1718],[2685,1512,1510,1612,1696],{"nctId":3391,"briefTitle":3392,"status":103,"phases":3393,"primaryCompletion":3394,"completion":1149,"start":3395,"enrollment":3396,"conditions":3397,"interventions":3400},"NCT02314117","A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer",[87],"2017-01-17","2015-01-20",645,[3398,3399],"Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[61,1843,1510,2783],{"nctId":3402,"briefTitle":3403,"status":103,"phases":3404,"primaryCompletion":3405,"completion":3406,"start":3407,"enrollment":3408,"conditions":3409,"interventions":3410},"NCT00982111","First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin",[87],"2012-11-14","2020-12-23","2009-11-02",633,[1694],[1612,1510,1591],{"nctId":2708,"briefTitle":2709,"status":393,"phases":3412,"primaryCompletion":765,"completion":2130,"start":2711,"enrollment":2712,"conditions":3413,"interventions":3414},[87],[1589,1478],[2655,1696,1510,1512,1612],{"nctId":3416,"briefTitle":3417,"status":103,"phases":3418,"primaryCompletion":3419,"completion":3419,"start":3060,"enrollment":3420,"conditions":3421,"interventions":3422},"NCT00415194","A Study for Patients With Head and Neck Cancer",[87],"2010-03",795,[2792],[2838,2839],{"trials":3424,"activeCount":97},[],{"trials":3426,"activeCount":97},[3427],{"nctId":3428,"briefTitle":3429,"status":2032,"phases":3430,"conditions":3431,"interventions":3433},"NCT00040625","ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.",[],[3432],"Mesothelioma",[1612,1510],{"intervention":1512,"totalTrials":1189,"cells":3435},{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3475,"PHASE3":3750,"PHASE4":3831,"NA":3841},{"trials":3437,"activeCount":97},[],{"trials":3439,"activeCount":1400,"soonestReadout":853},[3440,3448,3452,3456,3460,3464,3471],{"nctId":3441,"briefTitle":3442,"status":103,"phases":3443,"primaryCompletion":3027,"completion":3027,"start":3337,"enrollment":1189,"conditions":3444,"interventions":3446},"NCT01445119","A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas",[85],[3445],"Recurrent Gliomas",[3447,1512],"Enzastaurin",{"nctId":1495,"briefTitle":1496,"status":999,"phases":3449,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":3450,"interventions":3451},[85],[1503,36,1504,1505,1506],[1508,1509,48,1510,1511,1512,1513],{"nctId":2498,"briefTitle":2499,"status":393,"phases":3453,"primaryCompletion":1751,"completion":1751,"start":2501,"enrollment":2502,"conditions":3454,"interventions":3455},[85],[1589,2504,2505,1478,2506],[2508,1696,1512,1510],{"nctId":2510,"briefTitle":2511,"status":257,"phases":3457,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":3458,"interventions":3459},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":2547,"briefTitle":2548,"status":393,"phases":3461,"primaryCompletion":853,"completion":1011,"start":2550,"enrollment":2551,"conditions":3462,"interventions":3463},[85],[2553,2505,2554,1589,2555,2556,2557],[2559,2560,2561,2562,2563],{"nctId":3465,"briefTitle":3466,"status":103,"phases":3467,"primaryCompletion":3069,"completion":3069,"start":3266,"enrollment":2542,"conditions":3468,"interventions":3469},"NCT01287520","A Study of LY2090314 in Patients With Advanced or Metastatic Cancer",[85],[1466],[3470,2838,1512],"LY2090314",{"nctId":2626,"briefTitle":2627,"status":393,"phases":3472,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":3473,"interventions":3474},[85],[2516,1717,1610,2632],[2634,1696,1510,1512,1612,1669,2519],{"trials":3476,"activeCount":314,"soonestReadout":1011},[3477,3483,3490,3499,3505,3509,3520,3528,3532,3541,3551,3555,3562,3571,3578,3584,3588,3596,3604,3608,3612,3624,3631,3641,3650,3657,3665,3669,3673,3680,3689,3693,3702,3706,3713,3722,3728,3732,3742],{"nctId":3478,"briefTitle":3479,"status":384,"phases":3480,"primaryCompletion":3132,"completion":3132,"start":3132,"enrollment":97,"conditions":3481,"interventions":3482},"NCT00768131","A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel",[86],[2891,1589],[1541,1669,1512],{"nctId":3484,"briefTitle":3485,"status":103,"phases":3486,"primaryCompletion":2956,"completion":3152,"start":3060,"enrollment":3487,"conditions":3488,"interventions":3489},"NCT00343291","A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb\u002FIV NSCLC",[86],121,[1718],[1541,3054,1669,1512],{"nctId":3491,"briefTitle":3492,"status":103,"phases":3493,"primaryCompletion":3112,"completion":1628,"start":3494,"enrollment":963,"conditions":3495,"interventions":3497},"NCT01439568","A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma",[86],"2011-09",[3496],"Extensive Stage Small Cell Lung Carcinoma",[3498,1512,3324],"LY2510924",{"nctId":3500,"briefTitle":3501,"status":999,"phases":3502,"primaryCompletion":3132,"completion":3132,"start":2975,"enrollment":1400,"conditions":3503,"interventions":3504},"NCT00494026","Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)",[86],[3244],[2838,2561],{"nctId":2861,"briefTitle":2862,"status":103,"phases":3506,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":3507,"interventions":3508},[86],[1718],[1511,1510,2870,1541,2870,1541,1512],{"nctId":3510,"briefTitle":3511,"status":103,"phases":3512,"primaryCompletion":3513,"completion":3514,"start":3515,"enrollment":31,"conditions":3516,"interventions":3518},"NCT02392507","A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC",[86],"2018-01-29","2019-11-06","2015-10-12",[3517],"Carcinoma, Non-Small Cell Lung Cancer (NSCLC)",[1591,3519,1512],"Nab-Paclitaxel",{"nctId":3521,"briefTitle":3522,"status":103,"phases":3523,"primaryCompletion":3251,"completion":3012,"start":3524,"enrollment":3525,"conditions":3526,"interventions":3527},"NCT00325234","Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer",[86],"2006-06",135,[36],[1612,1512,1511,1875],{"nctId":2887,"briefTitle":2888,"status":103,"phases":3529,"conditions":3530,"interventions":3531},[86],[2891],[2893,2561,2839],{"nctId":3533,"briefTitle":3534,"status":103,"phases":3535,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":310,"conditions":3538,"interventions":3539},"NCT00034541","Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer",[85,86],"2003-05","2000-12",[1589],[3540,3222,2561],"cetuximab",{"nctId":3542,"briefTitle":3543,"status":103,"phases":3544,"primaryCompletion":3251,"completion":3545,"start":2930,"enrollment":3546,"conditions":3547,"interventions":3550},"NCT00391118","Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (\"Sugar Pill\")",[86],"2012-07",153,[2584,3548,3549],"Fallopian Tube Neoplasms","Peritoneal Neoplasm",[2979,2561,3222],{"nctId":2914,"briefTitle":2915,"status":103,"phases":3552,"primaryCompletion":2917,"completion":1618,"start":2918,"enrollment":2919,"conditions":3553,"interventions":3554},[86],[2921],[1541,1510,1512,2923],{"nctId":3556,"briefTitle":3557,"status":999,"phases":3558,"primaryCompletion":1473,"completion":1473,"start":3068,"enrollment":893,"conditions":3559,"interventions":3560},"NCT01722292","A Study of LY2940680 in Small Cell Lung Cancer",[85,86],[2504],[3561,1512,3324],"LY2940680",{"nctId":3563,"briefTitle":3564,"status":103,"phases":3565,"completion":3566,"start":3567,"enrollment":1054,"conditions":3568,"interventions":3570},"NCT00490711","Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer",[86],"2005-04","2003-07",[3569],"Epithelial Ovarian Cancer",[2912,2561,3222],{"nctId":3572,"briefTitle":3573,"status":999,"phases":3574,"primaryCompletion":3575,"completion":2846,"start":3133,"enrollment":2542,"conditions":3576,"interventions":3577},"NCT00356525","Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor",[86],"2008-06",[2891],[2838,2912,2561,1612],{"nctId":3579,"briefTitle":3580,"status":103,"phases":3581,"primaryCompletion":3103,"completion":3103,"start":3235,"enrollment":233,"conditions":3582,"interventions":3583},"NCT00533429","Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy",[86],[1610],[2979,2838,2561,2560],{"nctId":2925,"briefTitle":2926,"status":103,"phases":3585,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":2931,"conditions":3586,"interventions":3587},[86],[2849],[1612,1510,1512],{"nctId":3589,"briefTitle":3590,"status":103,"phases":3591,"primaryCompletion":3059,"completion":3059,"start":3592,"enrollment":3593,"conditions":3594,"interventions":3595},"NCT00308750","First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)",[86],"2006-03",218,[1718],[2979,2838,3106,2561],{"nctId":3597,"briefTitle":3598,"status":103,"phases":3599,"primaryCompletion":3524,"completion":3524,"start":2834,"enrollment":3041,"conditions":3600,"interventions":3602},"NCT00063401","Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[86],[2584,3601,3548],"Peritoneal Neoplasms",[3603,1669,1512],"Cetuximab:",{"nctId":3001,"briefTitle":3002,"status":103,"phases":3605,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":2080,"conditions":3606,"interventions":3607},[85,86],[2849],[2838,2839,2561],{"nctId":3009,"briefTitle":3010,"status":103,"phases":3609,"primaryCompletion":2917,"completion":2917,"start":3012,"enrollment":3013,"conditions":3610,"interventions":3611},[86],[2792],[1612,1541,1512,1510],{"nctId":3613,"briefTitle":3614,"status":103,"phases":3615,"primaryCompletion":3616,"completion":3617,"start":3545,"enrollment":3618,"conditions":3619,"interventions":3622},"NCT01663857","A Study LY2228820 for Recurrent Ovarian Cancer",[85,86],"2017-05-25","2018-05-11",118,[3569,3620,3621],"Fallopian Tube Cancer","Primary Peritoneal Cancer",[3623,1512,1511],"LY2228820",{"nctId":3625,"briefTitle":3626,"status":103,"phases":3627,"completion":3185,"start":3628,"enrollment":3095,"conditions":3629,"interventions":3630},"NCT00191256","Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer",[86],"2001-06",[3188],[1511,1512,1669],{"nctId":3632,"briefTitle":3633,"status":103,"phases":3634,"start":3635,"conditions":3636,"interventions":3639},"NCT00042679","A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.",[86],"2002-06",[1589,3637,3638],"Pulmonary Neoplasms","Neoplasms, Lung",[1511,1512,3640],"LY900003",{"nctId":3642,"briefTitle":3643,"status":103,"phases":3644,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":3647,"conditions":3648,"interventions":3649},"NCT00097227","Trial of Carboplatin\u002FPaclitaxel\u002FCetuximab in Stage IIIB\u002FIV Non-Small Cell Lung Cancer (NSCLC)",[86],"2007-04","2004-11",165,[1610],[1541,1512,1669],{"nctId":3651,"briefTitle":3652,"status":103,"phases":3653,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":3654,"conditions":3655,"interventions":3656},"NCT00097214","Carboplatin Plus Cetuximab for Treatment of Stage IIIB\u002FIV Non-Small Cell Lung Cancer (NSCLC)",[86],57,[1610],[1512,1541],{"nctId":3658,"briefTitle":3659,"status":103,"phases":3660,"primaryCompletion":3004,"completion":3661,"start":3662,"enrollment":2542,"conditions":3663,"interventions":3664},"NCT00735696","A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer",[86],"2012-01","2009-01",[1694],[61,1669,1512],{"nctId":3109,"briefTitle":3110,"status":103,"phases":3666,"primaryCompletion":3112,"completion":3113,"start":3114,"enrollment":1269,"conditions":3667,"interventions":3668},[86],[1589],[3117,1612,1512,1510,1511,1512],{"nctId":2646,"briefTitle":2647,"status":257,"phases":3670,"primaryCompletion":1011,"completion":1011,"start":2649,"enrollment":2650,"conditions":3671,"interventions":3672},[85,86],[1589,2557,2505,2553,2652,2653],[2655,1696,1541,1612,1510,1512],{"nctId":3674,"briefTitle":3675,"status":103,"phases":3676,"completion":3161,"start":3677,"enrollment":2088,"conditions":3678,"interventions":3679},"NCT00051493","ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.",[86],"2002-04",[1589],[2893,1512],{"nctId":3681,"briefTitle":3682,"status":103,"phases":3683,"primaryCompletion":2917,"completion":3684,"start":3685,"enrollment":3686,"conditions":3687,"interventions":3688},"NCT00918203","A Study of Paclitaxel\u002FCarboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[86],"2017-11-17","2010-01",137,[1718],[2545,1669,1512],{"nctId":3182,"briefTitle":3183,"status":103,"phases":3690,"completion":3185,"start":3186,"enrollment":2790,"conditions":3691,"interventions":3692},[86],[3188],[2912,2561,2839],{"nctId":3694,"briefTitle":3695,"status":103,"phases":3696,"primaryCompletion":3697,"completion":3698,"start":3068,"enrollment":2778,"conditions":3699,"interventions":3701},"NCT01769391","A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer",[86],"2015-04","2017-07",[3700],"Squamous Non Small Cell Lung Cancer",[1591,1669,1512],{"nctId":3213,"briefTitle":3214,"status":103,"phases":3703,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":3704,"interventions":3705},[86],[36],[2912,3222,2561,2839],{"nctId":3707,"briefTitle":3708,"status":103,"phases":3709,"completion":2833,"start":3710,"enrollment":2088,"conditions":3711,"interventions":3712},"NCT00072865","Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer",[86],"2003-06",[36,1478],[1612,1512],{"nctId":3714,"briefTitle":3715,"status":103,"phases":3716,"primaryCompletion":3717,"completion":3250,"start":2918,"enrollment":3718,"conditions":3719,"interventions":3720},"NCT01063075","A Study in Advanced Solid Tumors",[86],"2015-05",34,[1503],[1541,1512,3721],"5 - FU",{"nctId":3723,"briefTitle":3724,"status":103,"phases":3725,"primaryCompletion":2974,"completion":3217,"start":2855,"enrollment":28,"conditions":3726,"interventions":3727},"NCT00350792","Pemetrexed\u002FCarboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients",[86],[1694],[2838,2561],{"nctId":3263,"briefTitle":3264,"status":103,"phases":3729,"primaryCompletion":3266,"completion":3027,"start":3176,"enrollment":3267,"conditions":3730,"interventions":3731},[86],[1718],[2838,2839,2561],{"nctId":3733,"briefTitle":3734,"status":384,"phases":3735,"primaryCompletion":3736,"completion":3737,"start":2754,"enrollment":97,"conditions":3738,"interventions":3741},"NCT02941601","A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)",[86],"2017-12","2019-02",[3739,3740],"Locally Advanced Squamous Non-Small Cell Lung Cancer","Metastatic Squamous Non-Small Cell Lung Cancer",[1591,1511,1512],{"nctId":3743,"briefTitle":3744,"status":103,"phases":3745,"primaryCompletion":3132,"completion":3132,"start":3746,"enrollment":658,"conditions":3747,"interventions":3748},"NCT00191451","A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer",[86],"2004-04",[36],[1511,1512,3749],"Herceptin",{"trials":3751,"activeCount":1232,"soonestReadout":2679},[3752,3756,3765,3772,3779,3786,3793,3805,3809,3816,3827],{"nctId":3315,"briefTitle":3316,"status":103,"phases":3753,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":3321,"conditions":3754,"interventions":3755},[87],[1694],[1612,1510,3324,1875,1669,1512],{"nctId":3757,"briefTitle":3758,"status":103,"phases":3759,"primaryCompletion":2955,"completion":2955,"start":3236,"enrollment":3760,"conditions":3761,"interventions":3764},"NCT00191646","An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy",[87],919,[3762,3548,2553,3763,3601],"Genital Neoplasms, Female","Pelvic Neoplasms",[1511,1669,1512],{"nctId":3766,"briefTitle":3767,"status":103,"phases":3768,"primaryCompletion":2899,"completion":2899,"start":3235,"enrollment":3769,"conditions":3770,"interventions":3771},"NCT00520676","Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer",[87],260,[1718],[2838,3106,2561],{"nctId":3773,"briefTitle":3774,"status":103,"phases":3775,"primaryCompletion":2864,"completion":3776,"start":2928,"enrollment":3330,"conditions":3777,"interventions":3778},"NCT00762034","A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",[87],"2014-12",[1610],[1612,1612,1669,1512,3054,3054],{"nctId":3780,"briefTitle":3781,"status":103,"phases":3782,"primaryCompletion":3575,"completion":3575,"start":2855,"enrollment":3783,"conditions":3784,"interventions":3785},"NCT00363415","Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer",[87],908,[3244],[2838,3107,2561],{"nctId":3787,"briefTitle":3788,"status":103,"phases":3789,"primaryCompletion":3645,"completion":3216,"start":2909,"enrollment":3790,"conditions":3791,"interventions":3792},"NCT00112294","Study of Taxane\u002FCarboplatin +\u002F- Cetuximab as First-Line Treatment for Patients With Advanced\u002FMetastatic Non-Small Cell Lung Cancer",[87],755,[2903],[1669,1722,1512,1541],{"nctId":3794,"briefTitle":3795,"status":393,"phases":3796,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":3799,"interventions":3800},"NCT07213804","A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer",[87],"2025-10-22",1080,[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],"Sofetabart Mipitecan","Topotecan","Pegylated liposomal doxorubicin","MIRV",{"nctId":2676,"briefTitle":2677,"status":257,"phases":3806,"primaryCompletion":2679,"completion":2680,"start":2681,"enrollment":2682,"conditions":3807,"interventions":3808},[87],[1718],[2685,1512,1510,1612,1696],{"nctId":3810,"briefTitle":3811,"status":103,"phases":3812,"completion":3813,"start":2938,"enrollment":1249,"conditions":3814,"interventions":3815},"NCT00190710","A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer",[87],"2007-08",[1718],[1511,1512],{"nctId":3817,"briefTitle":3818,"status":103,"phases":3819,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":3824,"interventions":3826},"NCT00948675","Study of Participants With Advanced Non-Small Cell Lung Cancer",[87],"2013-01-31","2020-11-06","2009-09-01",361,[3825],"Advanced Non-Small Cell Lung Cancer",[1612,1512,1669,3054],{"nctId":2708,"briefTitle":2709,"status":393,"phases":3828,"primaryCompletion":765,"completion":2130,"start":2711,"enrollment":2712,"conditions":3829,"interventions":3830},[87],[1589,1478],[2655,1696,1510,1512,1612],{"trials":3832,"activeCount":97},[3833],{"nctId":3834,"briefTitle":3835,"status":103,"phases":3836,"primaryCompletion":3837,"completion":3838,"start":3217,"enrollment":3051,"conditions":3839,"interventions":3840},"NCT01020786","A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients",[88],"2011-03","2012-06",[1694],[1612,1512],{"trials":3842,"activeCount":97},[],{"intervention":1468,"totalTrials":1158,"cells":3844},{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3872,"PHASE3":3901,"PHASE4":3923,"NA":3933},{"trials":3846,"activeCount":97},[],{"trials":3848,"activeCount":947,"soonestReadout":3865},[3849,3853,3857,3861],{"nctId":1458,"briefTitle":1459,"status":103,"phases":3850,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":1464,"conditions":3851,"interventions":3852},[85],[1466],[48,1468],{"nctId":1600,"briefTitle":1601,"status":103,"phases":3854,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":3855,"interventions":3856},[85],[1466,1560,1608,1571,1609,1610],[1513,1538,1468,1612,1510,48,1613],{"nctId":1659,"briefTitle":1660,"status":257,"phases":3858,"primaryCompletion":462,"completion":462,"start":1662,"enrollment":1663,"conditions":3859,"interventions":3860},[85],[36],[1666,1468,1667,48,1668,1669],{"nctId":3862,"briefTitle":3863,"status":257,"phases":3864,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":3868,"interventions":3869},"NCT02057133","A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread",[85],"2021-03-15","2014-03-10",198,[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],"LY2835219","Endocrine therapy",{"trials":3873,"activeCount":314,"soonestReadout":1751},[3874,3878,3882,3891],{"nctId":1748,"briefTitle":1749,"status":393,"phases":3875,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":3876,"interventions":3877},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":1784,"briefTitle":1785,"status":103,"phases":3879,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":3880,"interventions":3881},[86],[1792,1793],[48,1577,1468,1795],{"nctId":3883,"briefTitle":3884,"status":103,"phases":3885,"primaryCompletion":3886,"completion":1473,"start":3216,"enrollment":3887,"conditions":3888,"interventions":3889},"NCT00728949","A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer",[86],"2012-03",93,[1571],[2870,3890,1697,1613,1760,1468],"tamoxifen",{"nctId":3892,"briefTitle":3893,"status":103,"phases":3894,"primaryCompletion":3895,"completion":3896,"start":3897,"enrollment":1606,"conditions":3898,"interventions":3899},"NCT00451555","Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer",[86],"2010-12-28","2018-10-18","2007-04-11",[36],[2979,3900],"fulvestrant",{"trials":3902,"activeCount":425,"soonestReadout":52},[3903,3907,3911,3915,3919],{"nctId":50,"briefTitle":51,"status":257,"phases":3904,"primaryCompletion":52,"completion":910,"start":1890,"enrollment":1891,"conditions":3905,"interventions":3906},[87],[1893],[48,1468],{"nctId":1908,"briefTitle":1909,"status":393,"phases":3908,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":3909,"interventions":3910},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"nctId":1919,"briefTitle":1920,"status":257,"phases":3912,"primaryCompletion":1922,"completion":910,"start":1923,"enrollment":1924,"conditions":3913,"interventions":3914},[87],[1926,1478],[48,1468],{"nctId":1982,"briefTitle":1983,"status":257,"phases":3916,"primaryCompletion":1985,"completion":1986,"start":1987,"enrollment":1988,"conditions":3917,"interventions":3918},[87],[1893,1478],[1667,1760,1468,48],{"nctId":71,"briefTitle":72,"status":257,"phases":3920,"primaryCompletion":73,"completion":1993,"start":1994,"enrollment":1995,"conditions":3921,"interventions":3922},[87],[36],[48,1697,1613,1468],{"trials":3924,"activeCount":97},[3925,3929],{"nctId":2001,"briefTitle":2002,"status":999,"phases":3926,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":1400,"conditions":3927,"interventions":3928},[88],[1571],[48,1468,2008],{"nctId":2020,"briefTitle":2021,"status":103,"phases":3930,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":776,"conditions":3931,"interventions":3932},[88],[1893,1478],[48,2018,1468],{"trials":3934,"activeCount":97},[],{"intervention":3936,"totalTrials":1199,"cells":3937},"Donanemab",{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3958,"PHASE3":3996,"PHASE4":4068,"NA":4070},{"trials":3939,"activeCount":97},[],{"trials":3941,"activeCount":97},[3942,3950],{"nctId":3943,"briefTitle":3944,"status":103,"phases":3945,"primaryCompletion":3946,"completion":3946,"start":3947,"enrollment":137,"conditions":3948,"interventions":3949},"NCT05567159","A Study of Donanemab (LY3002813) in Healthy Participants",[85],"2023-07-14","2022-10-04",[15],[3936],{"nctId":3951,"briefTitle":3952,"status":103,"phases":3953,"primaryCompletion":3954,"completion":3954,"start":3955,"enrollment":214,"conditions":3956,"interventions":3957},"NCT05533411","A Study of Donanemab (LY3002813) in Healthy Chinese Participants",[85],"2023-01-05","2022-09-14",[15],[3936],{"trials":3959,"activeCount":314,"soonestReadout":3964},[3960,3971,3983],{"nctId":3961,"briefTitle":3962,"status":1060,"phases":3963,"primaryCompletion":3964,"completion":3964,"start":443,"enrollment":422,"conditions":3965,"interventions":3970},"NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)",[86],"2028-08",[3966,3967,3968,3969],"Cognitive Dysfunction","Lewy Body Disease","Synucleinopathies","Amyloid",[3936],{"nctId":3972,"briefTitle":3973,"status":103,"phases":3974,"primaryCompletion":3975,"completion":3976,"start":3977,"enrollment":3978,"conditions":3979,"interventions":3981},"NCT03367403","A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)",[86],"2020-12-04","2021-09-21","2017-12-18",272,[3980],"Alzheimer Disease",[3936,3982],"LY3202626",{"nctId":3984,"briefTitle":3985,"status":103,"phases":3986,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":2347,"conditions":3989,"interventions":3994},"NCT04640077","A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)",[86],"2024-02-27","2020-11-23",[3980,3990,3991,3992,3993],"Dementia","Brain Diseases","Central Nervous System Diseases","Cognitive Impairment",[3995],"donanemab",{"trials":3997,"activeCount":1677,"soonestReadout":4053},[3998,4010,4024,4032,4042,4049,4058],{"nctId":3999,"briefTitle":4000,"status":103,"phases":4001,"primaryCompletion":4002,"completion":4003,"start":4004,"enrollment":4005,"conditions":4006,"interventions":4008},"NCT05108922","A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)",[87],"2022-09-09","2023-09-19","2021-11-16",148,[4007,3980],"Mild Cognitive Impairment (MCI)",[3936,4009],"Aducanumab",{"nctId":4011,"briefTitle":4012,"status":257,"phases":4013,"primaryCompletion":581,"completion":4014,"start":4015,"enrollment":4016,"conditions":4017,"interventions":4023},"NCT05508789","A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)",[87],"2028-07","2022-10-10",1500,[3980,3990,3991,3992,4018,4019,4020,4021,4022],"Nervous System Diseases","Tauopathies","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorders",[3936],{"nctId":4025,"briefTitle":4026,"status":257,"phases":4027,"primaryCompletion":765,"completion":765,"start":4028,"enrollment":4029,"conditions":4030,"interventions":4031},"NCT05026866","A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)",[87],"2021-08-27",2996,[3980],[3936],{"nctId":4033,"briefTitle":4034,"status":257,"phases":4035,"primaryCompletion":4036,"completion":940,"start":4037,"enrollment":4038,"conditions":4039,"interventions":4041},"NCT05738486","A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)",[87],"2024-05-16","2023-02-28",1175,[4040,3990,3991,3992,4018,4020,4021,4022],"Alzheimer's Disease",[3936,3034],{"nctId":4043,"briefTitle":4044,"status":1060,"phases":4045,"primaryCompletion":4046,"completion":4046,"start":980,"enrollment":410,"conditions":4047,"interventions":4048},"NCT07571161","Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease",[87],"2030-04",[3980],[3936],{"nctId":4050,"briefTitle":4051,"status":257,"phases":4052,"primaryCompletion":4053,"completion":2447,"start":4054,"enrollment":4055,"conditions":4056,"interventions":4057},"NCT04437511","A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)",[87],"2023-04-14","2020-06-19",1736,[3980],[3936],{"nctId":4059,"briefTitle":4060,"status":1060,"phases":4061,"primaryCompletion":4062,"completion":4063,"start":443,"enrollment":4064,"conditions":4065,"interventions":4067},"NCT07602582","A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).",[87],"2029-09","2029-12",550,[3980,3990,4066],"Plaque, Amyloid",[3936],{"trials":4069,"activeCount":97},[],{"trials":4071,"activeCount":314,"soonestReadout":4076},[4072],{"nctId":4073,"briefTitle":4074,"status":393,"phases":4075,"primaryCompletion":4076,"completion":4076,"start":4077,"enrollment":4078,"conditions":4079,"interventions":4080},"NCT06566170","A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease",[],"2033-02","2024-10-07",6250,[3980],[3936,4081],"Usual Care",{"intervention":1511,"totalTrials":4083,"cells":4084},99,{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4167,"PHASE3":4574,"PHASE4":4645,"NA":4647},{"trials":4086,"activeCount":97},[],{"trials":4088,"activeCount":1400,"soonestReadout":81},[4089,4093,4102,4106,4110,4114,4118,4126,4138,4142,4148,4152,4156,4163],{"nctId":2727,"briefTitle":2728,"status":103,"phases":4090,"primaryCompletion":2730,"completion":2731,"start":2732,"enrollment":2733,"conditions":4091,"interventions":4092},[85],[1466,1560,2735,1505,2736,1503,1608],[1493,1510,1511],{"nctId":4094,"briefTitle":4095,"status":103,"phases":4096,"primaryCompletion":2845,"completion":4097,"start":4098,"enrollment":1677,"conditions":4099,"interventions":4100},"NCT02154646","A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body",[85],"2015-07","2014-05",[2652],[4101,1511],"LY2157299",{"nctId":1495,"briefTitle":1496,"status":999,"phases":4103,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":4104,"interventions":4105},[85],[1503,36,1504,1505,1506],[1508,1509,48,1510,1511,1512,1513],{"nctId":2510,"briefTitle":2511,"status":257,"phases":4107,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":4108,"interventions":4109},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":1527,"briefTitle":1528,"status":103,"phases":4111,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":4112,"interventions":4113},[85],[1466,1534,1535,1490],[1537,1538,48,1539,1511,1540,1541],{"nctId":2760,"briefTitle":2761,"status":257,"phases":4115,"primaryCompletion":154,"completion":443,"start":2763,"enrollment":776,"conditions":4116,"interventions":4117},[85],[1505,2765,1850,2766],[2768,1511,1510,2696],{"nctId":4119,"briefTitle":4120,"status":103,"phases":4121,"primaryCompletion":2864,"completion":4122,"start":3020,"enrollment":1082,"conditions":4123,"interventions":4124},"NCT01358968","A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine",[85],"2012-12",[2824],[3287,4125,1612,1511],"Desipramine",{"nctId":4127,"briefTitle":4128,"status":393,"phases":4129,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":4132,"interventions":4133},"NCT06586515","MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",[85],"2024-09-12",630,[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],"LY3962673","nab-paclitaxel","leucovorin","5-fluorouracil",{"nctId":2795,"briefTitle":2796,"status":999,"phases":4139,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":1808,"conditions":4140,"interventions":4141},[85],[2802],[1511,1722,1746,1510,1721,2804],{"nctId":4143,"briefTitle":4144,"status":103,"phases":4145,"primaryCompletion":2964,"completion":1546,"start":2844,"enrollment":1237,"conditions":4146,"interventions":4147},"NCT01341457","A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors",[85],[2589],[3287,1511],{"nctId":79,"briefTitle":80,"status":257,"phases":4149,"primaryCompletion":81,"completion":1986,"start":2811,"enrollment":2812,"conditions":4150,"interventions":4151},[85],[1503],[82,1656,1511,2815,1510],{"nctId":2817,"briefTitle":2818,"status":103,"phases":4153,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":377,"conditions":4154,"interventions":4155},[85],[2824],[2826,1541,1510,1511,61],{"nctId":4157,"briefTitle":4158,"status":103,"phases":4159,"primaryCompletion":4160,"completion":3086,"start":3283,"enrollment":1232,"conditions":4161,"interventions":4162},"NCT01296568","C14 Study in Oncology Patients With Advanced and\u002For Metastatic Solid Tumors",[85],"2011-12",[1466],[3287,1612,1511],{"nctId":1699,"briefTitle":1700,"status":103,"phases":4164,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":299,"conditions":4165,"interventions":4166},[85],[1706],[48,1612,1511,61,1513,1696],{"trials":4168,"activeCount":947,"soonestReadout":60},[4169,4173,4182,4186,4192,4196,4200,4207,4213,4217,4226,4230,4236,4240,4244,4248,4254,4262,4269,4275,4282,4286,4290,4294,4298,4304,4308,4319,4327,4331,4337,4341,4345,4349,4358,4362,4369,4375,4379,4388,4397,4403,4412,4416,4424,4430,4434,4438,4444,4451,4455,4462,4466,4470,4479,4483,4490,4494,4500,4506,4512,4518,4522,4526,4530,4534,4542,4546,4552,4558,4562,4570],{"nctId":2861,"briefTitle":2862,"status":103,"phases":4170,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":4171,"interventions":4172},[86],[1718],[1511,1510,2870,1541,2870,1541,1512],{"nctId":4174,"briefTitle":4175,"status":103,"phases":4176,"completion":3266,"start":3710,"enrollment":25,"conditions":4177,"interventions":4178},"NCT00192075","A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)\u002FFolinic Acid Versus Avastin + Oxaliplatin + 5FU\u002FFolinic Acid in Metastatic Colorectal Cancer",[86],[1490],[1511,4179,4180,4181],"avastin","5FU\u002Ffolinic acid","oxaliplatin",{"nctId":58,"briefTitle":59,"status":257,"phases":4183,"primaryCompletion":60,"completion":462,"start":2882,"enrollment":2883,"conditions":4184,"interventions":4185},[86],[2623,1560,1466],[61,1493,1510,1511],{"nctId":4187,"briefTitle":4188,"status":103,"phases":4189,"primaryCompletion":3094,"completion":3419,"start":3524,"enrollment":28,"conditions":4190,"interventions":4191},"NCT00334802","Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer",[86],[1571],[2912,3222],{"nctId":3521,"briefTitle":3522,"status":103,"phases":4193,"primaryCompletion":3251,"completion":3012,"start":3524,"enrollment":3525,"conditions":4194,"interventions":4195},[86],[36],[1612,1512,1511,1875],{"nctId":2906,"briefTitle":2907,"status":103,"phases":4197,"completion":2909,"start":2834,"enrollment":1199,"conditions":4198,"interventions":4199},[86],[1718],[2912,2839],{"nctId":4201,"briefTitle":4202,"status":103,"phases":4203,"completion":3185,"start":2909,"enrollment":3125,"conditions":4204,"interventions":4205},"NCT00101842","Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer",[85,86],[2622],[1612,1511,4206],"Platinol",{"nctId":4208,"briefTitle":4209,"status":103,"phases":4210,"conditions":4211,"interventions":4212},"NCT00034489","A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.",[86],[1893],[2838,2912],{"nctId":3563,"briefTitle":3564,"status":103,"phases":4214,"completion":3566,"start":3567,"enrollment":1054,"conditions":4215,"interventions":4216},[86],[3569],[2912,2561,3222],{"nctId":4218,"briefTitle":4219,"status":103,"phases":4220,"completion":2856,"start":4221,"enrollment":4222,"conditions":4223,"interventions":4225},"NCT00191711","Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.",[86],"2004-02",43,[4224],"Superficial Bladder Cancer",[1511],{"nctId":3572,"briefTitle":3573,"status":999,"phases":4227,"primaryCompletion":3575,"completion":2846,"start":3133,"enrollment":2542,"conditions":4228,"interventions":4229},[86],[2891],[2838,2912,2561,1612],{"nctId":4231,"briefTitle":4232,"status":999,"phases":4233,"primaryCompletion":1619,"completion":1619,"start":3124,"enrollment":1199,"conditions":4234,"interventions":4235},"NCT01632306","A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer",[85,86],[1653],[3470,2593,1511,1539],{"nctId":2944,"briefTitle":2945,"status":103,"phases":4237,"completion":2947,"start":2948,"enrollment":1692,"conditions":4238,"interventions":4239},[86],[1571],[2912,2839],{"nctId":2961,"briefTitle":2962,"status":103,"phases":4241,"primaryCompletion":2964,"completion":2965,"start":2966,"enrollment":1548,"conditions":4242,"interventions":4243},[86],[2968],[1591,1511,1510],{"nctId":2981,"briefTitle":2982,"status":103,"phases":4245,"primaryCompletion":2984,"completion":2985,"start":2986,"enrollment":2987,"conditions":4246,"interventions":4247},[85,86],[2989],[1591,1511,1510],{"nctId":4249,"briefTitle":4250,"status":103,"phases":4251,"completion":3228,"start":2948,"enrollment":1620,"conditions":4252,"interventions":4253},"NCT00191347","A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer",[86],[36],[2838,2912],{"nctId":4255,"briefTitle":4256,"status":103,"phases":4257,"primaryCompletion":4258,"completion":4258,"start":3338,"enrollment":251,"conditions":4259,"interventions":4261},"NCT00623233","Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer",[86],"2011-01",[1571,4260],"Locally Advanced Breast Cancer",[1511,3054],{"nctId":4263,"briefTitle":4264,"status":103,"phases":4265,"primaryCompletion":2995,"completion":2995,"start":4266,"enrollment":874,"conditions":4267,"interventions":4268},"NCT00316199","Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer",[86],"2006-04",[1571],[2912,3222],{"nctId":4270,"briefTitle":4271,"status":999,"phases":4272,"primaryCompletion":3308,"completion":3308,"start":2875,"enrollment":2733,"conditions":4273,"interventions":4274},"NCT00383331","Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer",[86],[2849],[1612,1511],{"nctId":4276,"briefTitle":4277,"status":103,"phases":4278,"completion":3218,"start":3567,"enrollment":4279,"conditions":4280,"interventions":4281},"NCT00489983","Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy",[86],91,[1718],[2838,2912],{"nctId":3613,"briefTitle":3614,"status":103,"phases":4283,"primaryCompletion":3616,"completion":3617,"start":3545,"enrollment":3618,"conditions":4284,"interventions":4285},[85,86],[3569,3620,3621],[3623,1512,1511],{"nctId":3625,"briefTitle":3626,"status":103,"phases":4287,"completion":3185,"start":3628,"enrollment":3095,"conditions":4288,"interventions":4289},[86],[3188],[1511,1512,1669],{"nctId":3632,"briefTitle":3633,"status":103,"phases":4291,"start":3635,"conditions":4292,"interventions":4293},[86],[1589,3637,3638],[1511,1512,3640],{"nctId":3036,"briefTitle":3037,"status":103,"phases":4295,"completion":3039,"start":3040,"enrollment":3041,"conditions":4296,"interventions":4297},[86],[2735],[2912,2839],{"nctId":4299,"briefTitle":4300,"status":103,"phases":4301,"primaryCompletion":3292,"completion":3292,"start":3176,"enrollment":2206,"conditions":4302,"interventions":4303},"NCT00267020","Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer",[86],[2556],[2979,2912],{"nctId":3074,"briefTitle":3075,"status":103,"phases":4305,"completion":3077,"start":3078,"enrollment":947,"conditions":4306,"interventions":4307},[86],[3080],[2912,2839],{"nctId":4309,"briefTitle":4310,"status":103,"phases":4311,"primaryCompletion":4312,"completion":4313,"start":4314,"enrollment":4315,"conditions":4316,"interventions":4318},"NCT03086369","A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer",[85,86],"2021-01-05","2021-06-17","2017-06-22",184,[4317],"Metastatic Pancreatic Cancer",[2545,1539,1511],{"nctId":4320,"briefTitle":4321,"status":103,"phases":4322,"completion":3077,"start":3567,"enrollment":4323,"conditions":4324,"interventions":4326},"NCT00491114","Intravesical Chemotherapy Treatment of Superficial Bladder Cancer",[86],8,[4325],"Bladder Neoplasms",[1511],{"nctId":3100,"briefTitle":3101,"status":103,"phases":4328,"primaryCompletion":2974,"completion":3103,"start":3040,"enrollment":2867,"conditions":4329,"interventions":4330},[86],[1610],[2912,3106,2839,3107],{"nctId":4332,"briefTitle":4333,"status":103,"phases":4334,"completion":3133,"start":3161,"enrollment":118,"conditions":4335,"interventions":4336},"NCT00061477","Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma",[86],[3432],[1612,1511],{"nctId":3109,"briefTitle":3110,"status":103,"phases":4338,"primaryCompletion":3112,"completion":3113,"start":3114,"enrollment":1269,"conditions":4339,"interventions":4340},[86],[1589],[3117,1612,1512,1510,1511,1512],{"nctId":3119,"briefTitle":3120,"status":103,"phases":4342,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":4343,"interventions":4344},[86],[1610],[1591,1511,1510],{"nctId":3129,"briefTitle":3130,"status":103,"phases":4346,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":25,"conditions":4347,"interventions":4348},[86],[2623],[2912,2839],{"nctId":4350,"briefTitle":4351,"status":103,"phases":4352,"primaryCompletion":3217,"completion":3048,"start":2875,"enrollment":4353,"conditions":4354,"interventions":4356},"NCT00436280","Chemotherapy for Participants With Lymphoma",[86],68,[4355],"Lymphoma, Large Cell, Diffuse",[2979,2912,4357,4181],"rituximab",{"nctId":3137,"briefTitle":3138,"status":103,"phases":4359,"primaryCompletion":2846,"completion":2846,"start":3140,"enrollment":156,"conditions":4360,"interventions":4361},[86],[36],[2912,3143,2839],{"nctId":4363,"briefTitle":4364,"status":103,"phases":4365,"primaryCompletion":3813,"completion":2846,"start":4366,"enrollment":1790,"conditions":4367,"interventions":4368},"NCT00191243","Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer",[86],"2002-03",[36],[1511,3106],{"nctId":4370,"briefTitle":4371,"status":103,"phases":4372,"completion":3005,"start":3236,"enrollment":34,"conditions":4373,"interventions":4374},"NCT00191568","Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer",[86],[2652],[1511,2520],{"nctId":3157,"briefTitle":3158,"status":103,"phases":4376,"completion":3160,"start":3161,"enrollment":2088,"conditions":4377,"interventions":4378},[86],[1589],[2912,1510],{"nctId":4380,"briefTitle":4381,"status":103,"phases":4382,"primaryCompletion":4383,"completion":1627,"start":3020,"enrollment":4384,"conditions":4385,"interventions":4386},"NCT01373164","A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer",[85,86],"2015-11",170,[1870,1478,1653],[4387,1511],"Galunisertib",{"nctId":4389,"briefTitle":4390,"status":103,"phases":4391,"primaryCompletion":4392,"completion":4393,"start":4394,"enrollment":1282,"conditions":4395,"interventions":4396},"NCT02659020","A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma",[85,86],"2020-07-28","2021-04-27","2016-03-01",[1506],[2545,1511,1722],{"nctId":4398,"briefTitle":4399,"status":103,"phases":4400,"completion":3133,"start":3161,"enrollment":118,"conditions":4401,"interventions":4402},"NCT00061451","Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial",[86],[1589],[1612,1511],{"nctId":4404,"briefTitle":4405,"status":999,"phases":4406,"primaryCompletion":4407,"completion":4407,"start":4408,"enrollment":1488,"conditions":4409,"interventions":4411},"NCT04145700","CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma",[85,86],"2023-02-23","2020-03-04",[4410],"Synovial Sarcoma",[61,1511,1722],{"nctId":3165,"briefTitle":3166,"status":103,"phases":4413,"completion":3168,"start":3169,"enrollment":1692,"conditions":4414,"interventions":4415},[86],[1718],[2912,2839],{"nctId":4417,"briefTitle":4418,"status":103,"phases":4419,"primaryCompletion":4420,"completion":3049,"start":3103,"enrollment":4421,"conditions":4422,"interventions":4423},"NCT00839332","A Study for Participants With Pancreatic Cancer",[85,86],"2013-02",157,[2652],[3287,1511],{"nctId":4425,"briefTitle":4426,"status":103,"phases":4427,"conditions":4428,"interventions":4429},"NCT00034593","A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium",[86],[2998],[2893,2912],{"nctId":3173,"briefTitle":3174,"status":103,"phases":4431,"completion":3176,"start":2834,"enrollment":3177,"conditions":4432,"interventions":4433},[86],[1589],[1511,3180,2839],{"nctId":3182,"briefTitle":3183,"status":103,"phases":4435,"completion":3185,"start":3186,"enrollment":2790,"conditions":4436,"interventions":4437},[86],[3188],[2912,2561,2839],{"nctId":4439,"briefTitle":4440,"status":103,"phases":4441,"primaryCompletion":2846,"completion":2966,"start":3259,"enrollment":2919,"conditions":4442,"interventions":4443},"NCT00320541","A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer",[86],[36],[2912,3222,2560],{"nctId":4445,"briefTitle":4446,"status":103,"phases":4447,"completion":3133,"start":4448,"enrollment":233,"conditions":4449,"interventions":4450},"NCT00191971","2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen",[86],"2004-01",[2998,2622],[1511],{"nctId":3191,"briefTitle":3192,"status":103,"phases":4452,"completion":3194,"start":3195,"enrollment":757,"conditions":4453,"interventions":4454},[86],[1608],[2912,2839,3198],{"nctId":4456,"briefTitle":4457,"status":103,"phases":4458,"completion":2930,"start":4459,"enrollment":2080,"conditions":4460,"interventions":4461},"NCT00191672","A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer",[86],"2003-12",[1893],[1511,1669,1722],{"nctId":3206,"briefTitle":3207,"status":103,"phases":4463,"completion":3153,"start":3209,"enrollment":1730,"conditions":4464,"interventions":4465},[86],[1589],[1511,3106,2839],{"nctId":3213,"briefTitle":3214,"status":103,"phases":4467,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":4468,"interventions":4469},[86],[36],[2912,3222,2561,2839],{"nctId":4471,"briefTitle":4472,"status":103,"phases":4473,"completion":4474,"start":3339,"enrollment":4475,"conditions":4476,"interventions":4477},"NCT00192062","A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer",[86],"2007-06",80,[36],[2912,4478],"vinorelbine",{"nctId":1833,"briefTitle":1834,"status":103,"phases":4480,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":1839,"conditions":4481,"interventions":4482},[86],[1841],[48,1513,1511,1843],{"nctId":4484,"briefTitle":4485,"status":103,"phases":4486,"completion":3645,"start":4459,"enrollment":963,"conditions":4487,"interventions":4488},"NCT00192049","A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer",[86],[4224],[1511,4489],"mitomycin C",{"nctId":3232,"briefTitle":3233,"status":103,"phases":4491,"completion":3235,"start":3236,"enrollment":2790,"conditions":4492,"interventions":4493},[86],[36],[1511,2839],{"nctId":4495,"briefTitle":4496,"status":103,"phases":4497,"completion":3160,"start":3140,"enrollment":118,"conditions":4498,"interventions":4499},"NCT00061464","Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.",[86],[1589],[2838,2912],{"nctId":4501,"briefTitle":4502,"status":999,"phases":4503,"primaryCompletion":3132,"completion":2928,"start":3259,"enrollment":3125,"conditions":4504,"interventions":4505},"NCT00326911","Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer",[86],[4317],[3540,2560,2912,3540],{"nctId":4507,"briefTitle":4508,"status":103,"phases":4509,"completion":2856,"start":3169,"enrollment":2206,"conditions":4510,"interventions":4511},"NCT00055250","A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer",[86],[1653],[1511,3180],{"nctId":4513,"briefTitle":4514,"status":103,"phases":4515,"primaryCompletion":3308,"completion":3308,"start":3567,"enrollment":93,"conditions":4516,"interventions":4517},"NCT00063570","Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy",[86],[36,1893],[1612,1511,1511,1612],{"nctId":3256,"briefTitle":3257,"status":103,"phases":4519,"completion":3259,"start":2938,"enrollment":2867,"conditions":4520,"interventions":4521},[86],[2903],[1511,2839],{"nctId":3271,"briefTitle":3272,"status":103,"phases":4523,"completion":3176,"start":3274,"enrollment":251,"conditions":4524,"interventions":4525},[86],[3276],[1511,2839],{"nctId":3733,"briefTitle":3734,"status":384,"phases":4527,"primaryCompletion":3736,"completion":3737,"start":2754,"enrollment":97,"conditions":4528,"interventions":4529},[86],[3739,3740],[1591,1511,1512],{"nctId":1864,"briefTitle":1865,"status":393,"phases":4531,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":4532,"interventions":4533},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"nctId":4535,"briefTitle":4536,"status":103,"phases":4537,"completion":3228,"start":4538,"enrollment":1620,"conditions":4539,"interventions":4541},"NCT00191503","Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma",[86],"2005-01",[4540],"Adenocarcinoma",[1612,1511],{"nctId":3299,"briefTitle":3300,"status":103,"phases":4543,"primaryCompletion":3227,"completion":3227,"start":2909,"enrollment":2088,"conditions":4544,"interventions":4545},[86],[2584],[2912,2839],{"nctId":4547,"briefTitle":4548,"status":103,"phases":4549,"completion":2855,"start":4459,"enrollment":118,"conditions":4550,"interventions":4551},"NCT00071136","Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",[85,86],[2891],[2838,2912],{"nctId":4553,"briefTitle":4554,"status":103,"phases":4555,"primaryCompletion":3338,"completion":3419,"start":3168,"enrollment":4353,"conditions":4556,"interventions":4557},"NCT00191269","Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen",[86],[1571],[2912,2912],{"nctId":3305,"briefTitle":3306,"status":103,"phases":4559,"primaryCompletion":3308,"completion":3217,"start":3077,"enrollment":3309,"conditions":4560,"interventions":4561},[86],[1694],[2912,2839],{"nctId":4563,"briefTitle":4564,"status":103,"phases":4565,"completion":4566,"start":4366,"enrollment":1587,"conditions":4567,"interventions":4569},"NCT00191373","A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease",[86],"2007-07",[1893,4568,36],"Cancer of the Breast",[1511,1577],{"nctId":3743,"briefTitle":3744,"status":103,"phases":4571,"primaryCompletion":3132,"completion":3132,"start":3746,"enrollment":658,"conditions":4572,"interventions":4573},[86],[36],[1511,1512,3749],{"trials":4575,"activeCount":314,"soonestReadout":733},[4576,4580,4584,4588,4592,4596,4604,4611,4615,4619,4623,4630,4638],{"nctId":3334,"briefTitle":3335,"status":103,"phases":4577,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":4578,"interventions":4579},[87],[3342],[2838,2912,2839],{"nctId":3757,"briefTitle":3758,"status":103,"phases":4581,"primaryCompletion":2955,"completion":2955,"start":3236,"enrollment":3760,"conditions":4582,"interventions":4583},[87],[3762,3548,2553,3763,3601],[1511,1669,1512],{"nctId":3353,"briefTitle":3354,"status":103,"phases":4585,"primaryCompletion":2995,"completion":2995,"start":3356,"enrollment":3357,"conditions":4586,"interventions":4587},[87],[3359],[1511,1510],{"nctId":3362,"briefTitle":3363,"status":103,"phases":4589,"primaryCompletion":3048,"completion":3048,"start":3217,"enrollment":3365,"conditions":4590,"interventions":4591},[87],[1694],[1612,1511,1510],{"nctId":3369,"briefTitle":3370,"status":103,"phases":4593,"primaryCompletion":2975,"completion":2975,"start":3372,"enrollment":3373,"conditions":4594,"interventions":4595},[87],[1718],[2912,1510],{"nctId":4597,"briefTitle":4598,"status":103,"phases":4599,"primaryCompletion":3012,"completion":3012,"start":2833,"enrollment":4600,"conditions":4601,"interventions":4603},"NCT00236899","Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC",[87],241,[4602],"Metastatic Breast Cancer (MBC)",[1511,1722,1669],{"nctId":4605,"briefTitle":4606,"status":103,"phases":4607,"completion":3228,"start":3209,"enrollment":1730,"conditions":4608,"interventions":4609},"NCT00191607","A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.",[87],[3762,3548,2553,3763,3601],[1511,4610],"liposomal doxorubicin",{"nctId":3377,"briefTitle":3378,"status":103,"phases":4612,"primaryCompletion":3380,"completion":3381,"start":3382,"enrollment":3383,"conditions":4613,"interventions":4614},[87],[1694],[1591,1511,1510],{"nctId":3794,"briefTitle":3795,"status":393,"phases":4616,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":4617,"interventions":4618},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"nctId":3810,"briefTitle":3811,"status":103,"phases":4620,"completion":3813,"start":2938,"enrollment":1249,"conditions":4621,"interventions":4622},[87],[1718],[1511,1512],{"nctId":4624,"briefTitle":4625,"status":999,"phases":4626,"primaryCompletion":3338,"completion":3575,"start":4448,"enrollment":4627,"conditions":4628,"interventions":4629},"NCT00191477","Instillation of Gemcitabine in Patients With Superficial Bladder Cancer",[87],355,[4325],[1511],{"nctId":4631,"briefTitle":4632,"status":103,"phases":4633,"primaryCompletion":2974,"completion":2974,"start":4634,"enrollment":564,"conditions":4635,"interventions":4636},"NCT00191152","A Phase III Trial For Patients With Metastatic Breast Cancer",[87],"2002-02",[36,1893,4568],[2912,3106,4637],"capecitabine",{"nctId":4639,"briefTitle":4640,"status":103,"phases":4641,"completion":4642,"start":3236,"enrollment":542,"conditions":4643,"interventions":4644},"NCT00191438","Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents",[87],"2007-03",[1893],[2912,4637,3106],{"trials":4646,"activeCount":97},[],{"trials":4648,"activeCount":97},[],{"intervention":4650,"totalTrials":3293,"cells":4651},"LY3537031",{"EARLY_PHASE1":4652,"PHASE1":4654,"PHASE2":4694,"PHASE3":4715,"PHASE4":4732,"NA":4734},{"trials":4653,"activeCount":97},[],{"trials":4655,"activeCount":1232,"soonestReadout":1309},[4656,4663,4670,4678,4685],{"nctId":4657,"briefTitle":4658,"status":393,"phases":4659,"primaryCompletion":420,"completion":420,"start":4660,"enrollment":310,"conditions":4661,"interventions":4662},"NCT07165002","A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment",[85],"2025-10-20",[15,312],[4650],{"nctId":4664,"briefTitle":4665,"status":103,"phases":4666,"primaryCompletion":1132,"completion":1132,"start":4667,"enrollment":233,"conditions":4668,"interventions":4669},"NCT04648865","A Study of LY3537031 in Healthy Participants",[85],"2020-12-09",[15],[4650],{"nctId":4671,"briefTitle":4672,"status":257,"phases":4673,"primaryCompletion":1309,"completion":1309,"start":4674,"enrollment":4675,"conditions":4676,"interventions":4677},"NCT06606106","A Study of LY3537031 in Overweight, Obese, and Healthy Participants",[85],"2024-09-05",302,[27,24],[4650],{"nctId":4679,"briefTitle":4680,"status":257,"phases":4681,"primaryCompletion":408,"completion":408,"start":4682,"enrollment":1741,"conditions":4683,"interventions":4684},"NCT07202871","A Study of How the Body Absorbs LY3537031",[85],"2025-11-03",[15],[4650,4650],{"nctId":4686,"briefTitle":4687,"status":103,"phases":4688,"primaryCompletion":2472,"completion":2472,"start":4689,"enrollment":1178,"conditions":4690,"interventions":4693},"NCT07165015","A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment",[85],"2025-09-18",[4691,15,147,4692],"Renal Impairment","End Stage Renal Disease (ESRD)",[4650],{"trials":4695,"activeCount":947,"soonestReadout":715},[4696,4706],{"nctId":4697,"briefTitle":4698,"status":393,"phases":4699,"primaryCompletion":395,"completion":765,"start":4700,"enrollment":4701,"conditions":4702,"interventions":4705},"NCT07545759","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)",[86],"2026-05-06",531,[4703,4704],"Irritable Bowel Syndrome","Diarrhea",[4650],{"nctId":4707,"briefTitle":4708,"status":393,"phases":4709,"primaryCompletion":715,"completion":395,"start":4710,"enrollment":4711,"conditions":4712,"interventions":4714},"NCT07545772","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)",[86],"2026-04-29",342,[4703,4713],"Constipation",[4650],{"trials":4716,"activeCount":947,"soonestReadout":733},[4717,4726],{"nctId":4718,"briefTitle":4719,"status":393,"phases":4720,"primaryCompletion":733,"completion":733,"start":4721,"enrollment":4722,"conditions":4723,"interventions":4725},"NCT07219953","A Study of Brenipatide in Participants With Alcohol Use Disorder",[87],"2025-10-16",1100,[4724],"Alcohol Use Disorder",[4650],{"nctId":4727,"briefTitle":4728,"status":393,"phases":4729,"primaryCompletion":733,"completion":733,"start":605,"enrollment":4722,"conditions":4730,"interventions":4731},"NCT07219966","A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder",[87],[4724],[4650],{"trials":4733,"activeCount":97},[],{"trials":4735,"activeCount":97},[],{"intervention":4737,"totalTrials":3293,"cells":4738},"Eloralintide",{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4760,"PHASE3":4778,"PHASE4":4818,"NA":4820},{"trials":4740,"activeCount":97},[],{"trials":4742,"activeCount":97},[4743,4753],{"nctId":4744,"briefTitle":4745,"status":103,"phases":4746,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":4749,"conditions":4750,"interventions":4751},"NCT06916065","A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity",[85],"2026-01-19","2025-04-09",188,[27,24],[4752,4737],"Eloralintide and Tirzepatide",{"nctId":4754,"briefTitle":4755,"status":103,"phases":4756,"primaryCompletion":4757,"completion":4757,"start":1310,"enrollment":1620,"conditions":4758,"interventions":4759},"NCT06916091","A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight",[85],"2025-09-09",[24,27],[4737],{"trials":4761,"activeCount":947,"soonestReadout":2283},[4762,4771],{"nctId":4763,"briefTitle":4764,"status":393,"phases":4765,"primaryCompletion":2283,"completion":940,"start":4721,"enrollment":776,"conditions":4766,"interventions":4767},"NCT07215559","A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes",[86],[24,27,18],[4768,4737,4769,4770],"Macupatide","Macupatide Placebo","Eloralintide Placebo",{"nctId":4772,"briefTitle":4773,"status":1060,"phases":4774,"primaryCompletion":395,"completion":396,"start":419,"enrollment":4775,"conditions":4776,"interventions":4777},"NCT07589608","A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight",[86],400,[27,24],[4768,4737],{"trials":4779,"activeCount":425,"soonestReadout":4800},[4780,4788,4796,4804,4811],{"nctId":4781,"briefTitle":4782,"status":393,"phases":4783,"primaryCompletion":1993,"completion":1751,"start":4784,"enrollment":4785,"conditions":4786,"interventions":4787},"NCT07321886","A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes",[87],"2026-02-06",1980,[24,27],[4737],{"nctId":4789,"briefTitle":4790,"status":393,"phases":4791,"primaryCompletion":1993,"completion":733,"start":4792,"enrollment":649,"conditions":4793,"interventions":4795},"NCT07369011","A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight",[87],"2026-02-10",[4794,24,27],"Sleep Apnea, Obstructive",[4737],{"nctId":4797,"briefTitle":4798,"status":393,"phases":4799,"primaryCompletion":4800,"completion":396,"start":342,"enrollment":4801,"conditions":4802,"interventions":4803},"NCT07282600","A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes",[87],"2028-01",1035,[27,24],[4737],{"nctId":4805,"briefTitle":4806,"status":393,"phases":4807,"primaryCompletion":2111,"completion":4014,"start":4792,"enrollment":4808,"conditions":4809,"interventions":4810},"NCT07392190","A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin",[87],900,[27,24],[4737],{"nctId":4812,"briefTitle":4813,"status":393,"phases":4814,"primaryCompletion":1993,"completion":581,"start":4815,"enrollment":4808,"conditions":4816,"interventions":4817},"NCT07353931","Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight",[87],"2026-02-09",[2191,778],[4737],{"trials":4819,"activeCount":97},[],{"trials":4821,"activeCount":97},[],{"intervention":1697,"totalTrials":3293,"cells":4823},{"EARLY_PHASE1":4824,"PHASE1":4826,"PHASE2":4836,"PHASE3":4850,"PHASE4":4872,"NA":4874},{"trials":4825,"activeCount":97},[],{"trials":4827,"activeCount":947,"soonestReadout":77},[4828,4832],{"nctId":3862,"briefTitle":3863,"status":257,"phases":4829,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":4830,"interventions":4831},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"nctId":75,"briefTitle":76,"status":257,"phases":4833,"primaryCompletion":77,"completion":462,"start":1691,"enrollment":1692,"conditions":4834,"interventions":4835},[85],[1694,36],[48,1696,1697],{"trials":4837,"activeCount":314,"soonestReadout":1751},[4838,4842,4846],{"nctId":1748,"briefTitle":1749,"status":393,"phases":4839,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":4840,"interventions":4841},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":1822,"briefTitle":1823,"status":103,"phases":4843,"primaryCompletion":1825,"completion":1826,"start":1474,"enrollment":1827,"conditions":4844,"interventions":4845},[86],[36,1829,1830],[48,1551,1697],{"nctId":3883,"briefTitle":3884,"status":103,"phases":4847,"primaryCompletion":3886,"completion":1473,"start":3216,"enrollment":3887,"conditions":4848,"interventions":4849},[86],[1571],[2870,3890,1697,1613,1760,1468],{"trials":4851,"activeCount":1400,"soonestReadout":47},[4852,4856,4860,4868],{"nctId":1908,"briefTitle":1909,"status":393,"phases":4853,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":4854,"interventions":4855},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"nctId":45,"briefTitle":46,"status":257,"phases":4857,"primaryCompletion":47,"completion":462,"start":1977,"enrollment":1978,"conditions":4858,"interventions":4859},[87],[36],[48,1697,1613],{"nctId":4861,"briefTitle":4862,"status":257,"phases":4863,"primaryCompletion":454,"completion":4864,"start":3947,"enrollment":4865,"conditions":4866,"interventions":4867},"NCT05514054","A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer",[87],"2032-03",8000,[1893],[1667,1761,1697,1613,1760],{"nctId":71,"briefTitle":72,"status":257,"phases":4869,"primaryCompletion":73,"completion":1993,"start":1994,"enrollment":1995,"conditions":4870,"interventions":4871},[87],[36],[48,1697,1613,1468],{"trials":4873,"activeCount":97},[],{"trials":4875,"activeCount":97},[],{"intervention":4877,"totalTrials":1054,"cells":4878},"Brenipatide",{"EARLY_PHASE1":4879,"PHASE1":4881,"PHASE2":4890,"PHASE3":4930,"PHASE4":4939,"NA":4941},{"trials":4880,"activeCount":97},[],{"trials":4882,"activeCount":314,"soonestReadout":853},[4883],{"nctId":4884,"briefTitle":4885,"status":393,"phases":4886,"primaryCompletion":853,"completion":853,"start":4887,"enrollment":658,"conditions":4888,"interventions":4889},"NCT07476118","A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity",[85],"2026-03-18",[24,27],[4877],{"trials":4891,"activeCount":425,"soonestReadout":853},[4892,4899,4906,4914,4921],{"nctId":4893,"briefTitle":4894,"status":393,"phases":4895,"primaryCompletion":765,"completion":765,"start":4792,"enrollment":855,"conditions":4896,"interventions":4898},"NCT07410507","A Study of Brenipatide in Adult Participants With Schizophrenia",[86],[4897],"Schizophrenia",[4877],{"nctId":4900,"briefTitle":4901,"status":393,"phases":4902,"primaryCompletion":733,"completion":2111,"start":3797,"enrollment":4701,"conditions":4903,"interventions":4905},"NCT07219173","A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma",[86],[4904],"Asthma",[4877,4877],{"nctId":4907,"briefTitle":4908,"status":393,"phases":4909,"primaryCompletion":853,"completion":853,"start":4682,"enrollment":4910,"conditions":4911,"interventions":4913},"NCT07223840","A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse",[86],222,[4912],"Smoking",[4877],{"nctId":4915,"briefTitle":4916,"status":393,"phases":4917,"primaryCompletion":765,"completion":765,"start":792,"enrollment":4775,"conditions":4918,"interventions":4920},"NCT07286175","A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)",[86],[4919],"Bipolar Disorder",[4877],{"nctId":4922,"briefTitle":4923,"status":393,"phases":4924,"primaryCompletion":1993,"completion":1993,"start":4925,"enrollment":717,"conditions":4926,"interventions":4928},"NCT07420283","A Study of Brenipatide in Participants With Opioid Use Disorder",[86],"2026-02-13",[4927],"Opioid Use Disorder",[4877,4929],"Buprenorphine",{"trials":4931,"activeCount":314,"soonestReadout":396},[4932],{"nctId":4933,"briefTitle":4934,"status":393,"phases":4935,"primaryCompletion":396,"completion":396,"start":4815,"enrollment":2275,"conditions":4936,"interventions":4938},"NCT07412756","A Study of Brenipatide in Adult Participants With Major Depressive Disorder",[87],[4937],"Depressive Disorder, Major",[4877],{"trials":4940,"activeCount":97},[],{"trials":4942,"activeCount":97},[],{"intervention":4944,"totalTrials":4945,"cells":4946},"Baricitinib",51,{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":5047,"PHASE3":5103,"PHASE4":5373,"NA":5393},{"trials":4948,"activeCount":97},[],{"trials":4950,"activeCount":97},[4951,4959,4969,4976,4985,4992,4999,5005,5011,5018,5026,5034,5040],{"nctId":4952,"briefTitle":4953,"status":103,"phases":4954,"primaryCompletion":4955,"completion":4955,"start":2917,"enrollment":12,"conditions":4956,"interventions":4957},"NCT01910311","A Study of Baricitinib and Rifampicin in Healthy Participants",[85],"2013-10",[21],[4944,4958],"Rifampicin",{"nctId":4960,"briefTitle":4961,"status":103,"phases":4962,"primaryCompletion":4963,"completion":4964,"start":4965,"enrollment":137,"conditions":4966,"interventions":4967},"NCT03212638","A Study of Baricitinib in Healthy Participants",[85],"2017-07-31","2017-11-01","2017-06-27",[15],[4968,4944],"Baricitinib suspension",{"nctId":4970,"briefTitle":4971,"status":103,"phases":4972,"primaryCompletion":3027,"completion":3027,"start":2964,"enrollment":1071,"conditions":4973,"interventions":4975},"NCT01870388","A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease",[85],[4974,312],"Liver Diseases",[4944],{"nctId":4977,"briefTitle":4978,"status":103,"phases":4979,"primaryCompletion":4980,"completion":4980,"start":2917,"enrollment":214,"conditions":4981,"interventions":4982},"NCT01924299","A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants",[85],"2013-11",[21],[4944,4983,4984],"Ketoconazole","Fluconazole",{"nctId":4986,"briefTitle":4987,"status":103,"phases":4988,"primaryCompletion":3049,"completion":3049,"start":4955,"enrollment":12,"conditions":4989,"interventions":4990},"NCT01968057","A Study of Baricitinib and Ciclosporin in Healthy Participants",[85],[21],[4944,4991],"Ciclosporin",{"nctId":4993,"briefTitle":4994,"status":103,"phases":4995,"primaryCompletion":3776,"completion":3776,"start":3319,"enrollment":1071,"conditions":4996,"interventions":4998},"NCT02263911","A Study of Baricitinib in Healthy Japanese Participants",[85],[4997],"Healthy Participants",[4944],{"nctId":5000,"briefTitle":5001,"status":103,"phases":5002,"primaryCompletion":3049,"completion":3049,"start":4955,"enrollment":233,"conditions":5003,"interventions":5004},"NCT01960140","A Study of Baricitinib and Simvastatin in Healthy Participants",[85],[21],[4944,2092],{"nctId":5006,"briefTitle":5007,"status":103,"phases":5008,"primaryCompletion":2917,"completion":2917,"start":3282,"enrollment":165,"conditions":5009,"interventions":5010},"NCT01859078","A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants",[85],[21],[4944,1093],{"nctId":5012,"briefTitle":5013,"status":103,"phases":5014,"primaryCompletion":1546,"completion":1546,"start":2799,"enrollment":5015,"conditions":5016,"interventions":5017},"NCT02758613","A Study of Baricitinib (LY3009104) in Healthy Chinese Participants",[85],33,[15],[4944],{"nctId":5019,"briefTitle":5020,"status":103,"phases":5021,"primaryCompletion":4980,"completion":4980,"start":5022,"enrollment":12,"conditions":5023,"interventions":5024},"NCT01937026","A Study of Baricitinib and Probenecid in Healthy Participants",[85],"2013-09",[21],[4944,5025],"Probenecid",{"nctId":5027,"briefTitle":5028,"status":103,"phases":5029,"primaryCompletion":1473,"completion":1473,"start":5030,"enrollment":4323,"conditions":5031,"interventions":5032},"NCT02340104","A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants",[85],"2015-01",[21],[4944,5033],"[^13C4D3^15N]-baricitinib",{"nctId":5035,"briefTitle":5036,"status":103,"phases":5037,"primaryCompletion":4980,"completion":4980,"start":4955,"enrollment":1620,"conditions":5038,"interventions":5039},"NCT01925144","A Study of Baricitinib and Omeprazole in Healthy Participants",[85],[21],[4944,1171],{"nctId":5041,"briefTitle":5042,"status":103,"phases":5043,"primaryCompletion":4955,"completion":4955,"start":3027,"enrollment":1082,"conditions":5044,"interventions":5045},"NCT01896726","A Study of Baricitinib and Birth Control Pills in Healthy Females",[85],[21],[4944,5046],"Microgynon",{"trials":5048,"activeCount":97},[5049,5058,5066,5077,5086,5096],{"nctId":5050,"briefTitle":5051,"status":999,"phases":5052,"primaryCompletion":5053,"completion":5053,"start":5054,"enrollment":947,"conditions":5055,"interventions":5057},"NCT03742973","A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA",[86],"2019-09-26","2019-03-28",[5056],"Primary Biliary Cholangitis",[4944],{"nctId":5059,"briefTitle":5060,"status":103,"phases":5061,"primaryCompletion":4122,"completion":3122,"start":4160,"enrollment":5062,"conditions":5063,"interventions":5065},"NCT01490632","A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis",[86],271,[447,1370,5064],"Skin Diseases, Papulosquamous",[4944],{"nctId":5067,"briefTitle":5068,"status":103,"phases":5069,"primaryCompletion":5070,"completion":5071,"start":5072,"enrollment":5073,"conditions":5074,"interventions":5076},"NCT02708095","A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)",[86],"2017-10-12","2017-11-09","2016-03-24",314,[5075],"Systemic Lupus Erythematosus",[4944],{"nctId":5078,"briefTitle":5079,"status":103,"phases":5080,"primaryCompletion":5081,"completion":5082,"start":1547,"enrollment":19,"conditions":5083,"interventions":5084},"NCT02576938","A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis",[86],"2017-02","2017-03",[1271],[4944,5085],"Triamcinolone",{"nctId":5087,"briefTitle":5088,"status":103,"phases":5089,"primaryCompletion":3048,"completion":3049,"start":5090,"enrollment":5091,"conditions":5092,"interventions":5094},"NCT01469013","Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy",[86],"2011-11",145,[5093],"Arthritis, Rheumatoid",[4944,4944,4944,5095],"Methotrexate",{"nctId":5097,"briefTitle":5098,"status":103,"phases":5099,"primaryCompletion":2845,"completion":3319,"start":2966,"enrollment":2206,"conditions":5100,"interventions":5102},"NCT01683409","A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease",[86],[5101],"Diabetic Kidney Disease",[4944],{"trials":5104,"activeCount":1054,"soonestReadout":5158},[5105,5114,5125,5135,5145,5154,5163,5173,5187,5197,5205,5212,5223,5233,5242,5252,5260,5268,5276,5286,5294,5302,5314,5321,5330,5340,5350,5358,5366],{"nctId":5106,"briefTitle":5107,"status":103,"phases":5108,"primaryCompletion":5109,"completion":5109,"start":5110,"enrollment":5111,"conditions":5112,"interventions":5113},"NCT03334422","Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",[87],"2018-12-12","2017-11-27",615,[1271],[4944],{"nctId":5115,"briefTitle":5116,"status":103,"phases":5117,"primaryCompletion":5118,"completion":5119,"start":5120,"enrollment":5121,"conditions":5122,"interventions":5124},"NCT03570749","A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata",[86,87],"2021-02-02","2025-01-29","2018-09-24",784,[5123],"Alopecia Areata",[4944],{"nctId":5126,"briefTitle":5127,"status":103,"phases":5128,"primaryCompletion":1766,"completion":5129,"start":5130,"enrollment":5131,"conditions":5132,"interventions":5133},"NCT03733301","A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis",[87],"2019-08-22","2018-11-16",329,[1271],[4944,5134],"Topical corticosteroid",{"nctId":5136,"briefTitle":5137,"status":103,"phases":5138,"primaryCompletion":5139,"completion":5140,"start":5141,"enrollment":5142,"conditions":5143,"interventions":5144},"NCT03616964","A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)",[87],"2021-09-24","2021-10-20","2018-08-02",778,[5075],[4944],{"nctId":5146,"briefTitle":5147,"status":103,"phases":5148,"primaryCompletion":595,"completion":5149,"start":5150,"enrollment":5151,"conditions":5152,"interventions":5153},"NCT03435081","A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis",[87],"2021-08-16","2018-02-20",440,[1271],[4944],{"nctId":5155,"briefTitle":5156,"status":257,"phases":5157,"primaryCompletion":5158,"completion":443,"start":5159,"enrollment":5160,"conditions":5161,"interventions":5162},"NCT03952559","A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis",[87],"2022-04-24","2019-05-24",516,[1271],[4944,5134],{"nctId":5164,"briefTitle":5165,"status":999,"phases":5166,"primaryCompletion":5167,"completion":5168,"start":5169,"enrollment":5170,"conditions":5171,"interventions":5172},"NCT03559270","A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis",[87],"2021-10-14","2022-06-13","2018-06-27",374,[1271],[4944],{"nctId":5174,"briefTitle":5175,"status":393,"phases":5176,"primaryCompletion":1993,"completion":5177,"start":5178,"enrollment":5179,"conditions":5180,"interventions":5186},"NCT05723198","A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",[87],"2033-09","2023-02-27",595,[5181,5182,5183,5184,1370,5185],"Areata Alopecia","Alopecia","Hypotrichosis","Hair Diseases","Pathological Conditions, Anatomical",[4944],{"nctId":5188,"briefTitle":5189,"status":103,"phases":5190,"primaryCompletion":5191,"completion":5192,"start":5193,"enrollment":5194,"conditions":5195,"interventions":5196},"NCT03334435","A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis",[87],"2020-09-21","2023-07-12","2018-03-28",1645,[1271],[4944],{"nctId":5198,"briefTitle":5199,"status":999,"phases":5200,"primaryCompletion":705,"completion":705,"start":5201,"enrollment":5202,"conditions":5203,"interventions":5204},"NCT03843125","A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)",[87],"2019-09-09",1147,[5075],[4944],{"nctId":5206,"briefTitle":5207,"status":393,"phases":5208,"primaryCompletion":4014,"completion":4014,"start":5209,"enrollment":542,"conditions":5210,"interventions":5211},"NCT07222332","A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)",[87],"2026-02-05",[33],[4944],{"nctId":5213,"briefTitle":5214,"status":103,"phases":5215,"primaryCompletion":1596,"completion":1618,"start":2798,"enrollment":5216,"conditions":5217,"interventions":5219},"NCT01710358","A Study in Moderate to Severe Rheumatoid Arthritis",[87],1307,[5218],"Rheumatoid Arthritis",[5220,4944,5095,5221,5222],"Adalimumab","Adalimumab Placebo","Baricitinib Placebo",{"nctId":5224,"briefTitle":5225,"status":103,"phases":5226,"primaryCompletion":5227,"completion":5228,"start":5229,"enrollment":5230,"conditions":5231,"interventions":5232},"NCT03334396","A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",[87],"2018-12-06","2019-08-16","2017-11-23",660,[1271],[4944],{"nctId":5234,"briefTitle":5235,"status":393,"phases":5236,"primaryCompletion":408,"completion":408,"start":5237,"enrollment":1189,"conditions":5238,"interventions":5240},"NCT04088396","A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)",[87],"2020-02-12",[5239],"Systemic Juvenile Idiopathic Arthritis",[4944,5241],"Tocilizumab",{"nctId":5243,"briefTitle":5244,"status":103,"phases":5245,"primaryCompletion":5246,"completion":5246,"start":5247,"enrollment":5248,"conditions":5249,"interventions":5251},"NCT03773978","A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",[87],"2022-01-26","2018-12-17",220,[5250],"Juvenile Idiopathic Arthritis",[4944],{"nctId":5253,"briefTitle":5254,"status":999,"phases":5255,"primaryCompletion":593,"completion":5256,"start":5141,"enrollment":5257,"conditions":5258,"interventions":5259},"NCT03616912","A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus",[87],"2022-03-09",830,[5075],[4944],{"nctId":5261,"briefTitle":5262,"status":393,"phases":5263,"primaryCompletion":5264,"completion":5264,"start":5265,"enrollment":658,"conditions":5266,"interventions":5267},"NCT07222137","A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults",[87],"2031-07","2026-01-12",[33],[4944],{"nctId":5269,"briefTitle":5270,"status":103,"phases":5271,"primaryCompletion":2845,"completion":3776,"start":4122,"enrollment":5272,"conditions":5273,"interventions":5274},"NCT01721057","A Study in Moderate to Severe Rheumatoid Arthritis Participants",[87],684,[5218],[4944,5275],"cDMARD",{"nctId":5277,"briefTitle":5278,"status":103,"phases":5279,"primaryCompletion":1674,"completion":5280,"start":5281,"enrollment":5282,"conditions":5283,"interventions":5285},"NCT04421027","A Study of Baricitinib (LY3009104) in Participants With COVID-19",[87],"2021-06-10","2020-06-12",1525,[5284],"COVID-19",[4944],{"nctId":5287,"briefTitle":5288,"status":103,"phases":5289,"primaryCompletion":1473,"completion":1474,"start":3048,"enrollment":5290,"conditions":5291,"interventions":5292},"NCT01711359","A Study in Participants With Moderate to Severe Rheumatoid Arthritis",[87],588,[5218],[4944,5095,5222,5293,3032],"MTX Placebo",{"nctId":5295,"briefTitle":5296,"status":257,"phases":5297,"primaryCompletion":154,"completion":4014,"start":5298,"enrollment":1620,"conditions":5299,"interventions":5301},"NCT04088409","A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis",[87],"2019-10-16",[5300],"Uveitis",[4944,5220],{"nctId":5303,"briefTitle":5304,"status":999,"phases":5305,"primaryCompletion":5306,"completion":1010,"start":5307,"enrollment":757,"conditions":5308,"interventions":5313},"NCT04517253","A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS\u002FCANDLE, SAVI, and AGS",[86,87],"2023-04-04","2020-10-27",[5309,5310,5311,5312],"Nakajo-Nishimura Syndrome","Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome","STING-Associated Vasculopathy With Onset in Infancy","Aicardi Goutieres Syndrome",[4944],{"nctId":5315,"briefTitle":5316,"status":393,"phases":5317,"primaryCompletion":5264,"completion":5264,"start":5318,"enrollment":377,"conditions":5319,"interventions":5320},"NCT03773965","A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",[87],"2019-04-05",[5250],[4944],{"nctId":5322,"briefTitle":5323,"status":103,"phases":5324,"primaryCompletion":5325,"completion":5325,"start":5326,"enrollment":5327,"conditions":5328,"interventions":5329},"NCT01885078","An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis",[87],"2020-11-12","2013-06-27",2877,[5218],[4944],{"nctId":5331,"briefTitle":5332,"status":999,"phases":5333,"primaryCompletion":4674,"completion":5334,"start":5335,"enrollment":1677,"conditions":5336,"interventions":5339},"NCT05074420","A Study of Baricitinib (LY3009104) in Children With COVID-19",[87],"2024-11-04","2021-12-21",[5337,5338],"Covid19","Corona Virus Infection",[4944],{"nctId":5341,"briefTitle":5342,"status":103,"phases":5343,"primaryCompletion":5344,"completion":5345,"start":5346,"enrollment":5347,"conditions":5348,"interventions":5349},"NCT03899259","A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata",[87],"2021-01-24","2024-11-19","2019-07-08",606,[5123],[4944],{"nctId":5351,"briefTitle":5352,"status":103,"phases":5353,"primaryCompletion":5354,"completion":2845,"start":3068,"enrollment":5355,"conditions":5356,"interventions":5357},"NCT01721044","A Moderate to Severe Rheumatoid Arthritis Study",[87],"2014-06",527,[5218],[4944,5275],{"nctId":5359,"briefTitle":5360,"status":103,"phases":5361,"primaryCompletion":5362,"completion":571,"start":5363,"enrollment":1995,"conditions":5364,"interventions":5365},"NCT03428100","A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",[87],"2019-11-25","2018-05-15",[1271],[4944,5134],{"nctId":5367,"briefTitle":5368,"status":103,"phases":5369,"primaryCompletion":5370,"completion":5370,"start":3318,"enrollment":583,"conditions":5371,"interventions":5372},"NCT02265705","A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)",[87],"2017-05",[5218],[4944],{"trials":5374,"activeCount":97},[5375,5384],{"nctId":5376,"briefTitle":5377,"status":103,"phases":5378,"primaryCompletion":2267,"completion":2267,"start":5379,"enrollment":5380,"conditions":5381,"interventions":5382},"NCT04086745","A Study of Baricitinib in Participants With Rheumatoid Arthritis",[88],"2020-02-14",1317,[5218],[4944,5383],"TNF Inhibitor",{"nctId":5385,"briefTitle":5386,"status":103,"phases":5387,"primaryCompletion":5388,"completion":5388,"start":5389,"enrollment":5390,"conditions":5391,"interventions":5392},"NCT03915964","A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis",[88],"2025-05-28","2019-04-25",2663,[5218],[4944,5383],{"trials":5394,"activeCount":97},[5395],{"nctId":5396,"briefTitle":5397,"status":2032,"phases":5398,"conditions":5399,"interventions":5404},"NCT01724580","Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes",[],[5400,5401,5402,5403],"Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)","Juvenile Dermatomyositis (JDM)","Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)","Aicardi-Goutières Syndrome (AGS)",[4944],{"intervention":1613,"totalTrials":4323,"cells":5406},{"EARLY_PHASE1":5407,"PHASE1":5409,"PHASE2":5419,"PHASE3":5429,"PHASE4":5447,"NA":5449},{"trials":5408,"activeCount":97},[],{"trials":5410,"activeCount":314,"soonestReadout":3865},[5411,5415],{"nctId":1600,"briefTitle":1601,"status":103,"phases":5412,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":5413,"interventions":5414},[85],[1466,1560,1608,1571,1609,1610],[1513,1538,1468,1612,1510,48,1613],{"nctId":3862,"briefTitle":3863,"status":257,"phases":5416,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":5417,"interventions":5418},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":5420,"activeCount":314,"soonestReadout":1751},[5421,5425],{"nctId":1748,"briefTitle":1749,"status":393,"phases":5422,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":5423,"interventions":5424},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":3883,"briefTitle":3884,"status":103,"phases":5426,"primaryCompletion":3886,"completion":1473,"start":3216,"enrollment":3887,"conditions":5427,"interventions":5428},[86],[1571],[2870,3890,1697,1613,1760,1468],{"trials":5430,"activeCount":1400,"soonestReadout":47},[5431,5435,5439,5443],{"nctId":1908,"briefTitle":1909,"status":393,"phases":5432,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":5433,"interventions":5434},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"nctId":45,"briefTitle":46,"status":257,"phases":5436,"primaryCompletion":47,"completion":462,"start":1977,"enrollment":1978,"conditions":5437,"interventions":5438},[87],[36],[48,1697,1613],{"nctId":4861,"briefTitle":4862,"status":257,"phases":5440,"primaryCompletion":454,"completion":4864,"start":3947,"enrollment":4865,"conditions":5441,"interventions":5442},[87],[1893],[1667,1761,1697,1613,1760],{"nctId":71,"briefTitle":72,"status":257,"phases":5444,"primaryCompletion":73,"completion":1993,"start":1994,"enrollment":1995,"conditions":5445,"interventions":5446},[87],[36],[48,1697,1613,1468],{"trials":5448,"activeCount":97},[],{"trials":5450,"activeCount":97},[],{"intervention":1667,"totalTrials":4323,"cells":5452},{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5485,"PHASE3":5500,"PHASE4":5510,"NA":5512},{"trials":5454,"activeCount":97},[],{"trials":5456,"activeCount":314,"soonestReadout":462},[5457,5464,5472,5481],{"nctId":5458,"briefTitle":5459,"status":103,"phases":5460,"primaryCompletion":819,"completion":819,"start":5461,"enrollment":1082,"conditions":5462,"interventions":5463},"NCT05509816","A Study of Imlunestrant (LY3484356) in Healthy Women",[85],"2022-09-12",[15],[1538,1667],{"nctId":5465,"briefTitle":5466,"status":103,"phases":5467,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":2071,"conditions":5470,"interventions":5471},"NCT05440344","A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function",[85],"2024-02-28","2022-07-05",[312,15],[1667],{"nctId":5473,"briefTitle":5474,"status":103,"phases":5475,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":5478,"interventions":5479},"NCT05444556","A Study of Imlunestrant (LY3484356) in Female Healthy Participants",[85],"2022-11-02","2022-07-07",[15],[1667,1102,1171,5480,2074,2093,1093],"Dextromethorphan",{"nctId":1659,"briefTitle":1660,"status":257,"phases":5482,"primaryCompletion":462,"completion":462,"start":1662,"enrollment":1663,"conditions":5483,"interventions":5484},[85],[36],[1666,1468,1667,48,1668,1669],{"trials":5486,"activeCount":947,"soonestReadout":5495},[5487,5491],{"nctId":1748,"briefTitle":1749,"status":393,"phases":5488,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":5489,"interventions":5490},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":5492,"briefTitle":5493,"status":1060,"phases":5494,"primaryCompletion":5495,"completion":4063,"start":443,"enrollment":2122,"conditions":5496,"interventions":5497},"NCT07287098","A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer",[86],"2029-01",[1893],[1667,5498,5499],"Goserelin","Tamoxifen 20 mg",{"trials":5501,"activeCount":947,"soonestReadout":1985},[5502,5506],{"nctId":4861,"briefTitle":4862,"status":257,"phases":5503,"primaryCompletion":454,"completion":4864,"start":3947,"enrollment":4865,"conditions":5504,"interventions":5505},[87],[1893],[1667,1761,1697,1613,1760],{"nctId":1982,"briefTitle":1983,"status":257,"phases":5507,"primaryCompletion":1985,"completion":1986,"start":1987,"enrollment":1988,"conditions":5508,"interventions":5509},[87],[1893,1478],[1667,1760,1468,48],{"trials":5511,"activeCount":97},[],{"trials":5513,"activeCount":97},[],{"intervention":1760,"totalTrials":1677,"cells":5515},{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5524,"PHASE3":5534,"PHASE4":5548,"NA":5550},{"trials":5517,"activeCount":97},[],{"trials":5519,"activeCount":314,"soonestReadout":3865},[5520],{"nctId":3862,"briefTitle":3863,"status":257,"phases":5521,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":5522,"interventions":5523},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":5525,"activeCount":314,"soonestReadout":1751},[5526,5530],{"nctId":1748,"briefTitle":1749,"status":393,"phases":5527,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":5528,"interventions":5529},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":3883,"briefTitle":3884,"status":103,"phases":5531,"primaryCompletion":3886,"completion":1473,"start":3216,"enrollment":3887,"conditions":5532,"interventions":5533},[86],[1571],[2870,3890,1697,1613,1760,1468],{"trials":5535,"activeCount":1232,"soonestReadout":1985},[5536,5540,5544],{"nctId":1908,"briefTitle":1909,"status":393,"phases":5537,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":5538,"interventions":5539},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"nctId":4861,"briefTitle":4862,"status":257,"phases":5541,"primaryCompletion":454,"completion":4864,"start":3947,"enrollment":4865,"conditions":5542,"interventions":5543},[87],[1893],[1667,1761,1697,1613,1760],{"nctId":1982,"briefTitle":1983,"status":257,"phases":5545,"primaryCompletion":1985,"completion":1986,"start":1987,"enrollment":1988,"conditions":5546,"interventions":5547},[87],[1893,1478],[1667,1760,1468,48],{"trials":5549,"activeCount":97},[],{"trials":5551,"activeCount":97},[],{"intervention":1612,"totalTrials":3051,"cells":5553},{"EARLY_PHASE1":5554,"PHASE1":5556,"PHASE2":5603,"PHASE3":6019,"PHASE4":6108,"NA":6120},{"trials":5555,"activeCount":97},[],{"trials":5557,"activeCount":947,"soonestReadout":454},[5558,5562,5569,5573,5577,5581,5585,5589,5595,5599],{"nctId":2510,"briefTitle":2511,"status":257,"phases":5559,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":5560,"interventions":5561},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":5563,"briefTitle":5564,"status":103,"phases":5565,"primaryCompletion":3419,"completion":2899,"start":3337,"enrollment":1178,"conditions":5566,"interventions":5567},"NCT00415636","Safety and Tolerability of IC83\u002FLY2603618 Administered After Pemetrexed 500 mg\u002Fm2 Every 21 Days in Patients With Cancer",[85],[2824],[5568,5568,5568,5568,5568,2838,2838],"IC83\u002FLY2603618",{"nctId":3465,"briefTitle":3466,"status":103,"phases":5570,"primaryCompletion":3069,"completion":3069,"start":3266,"enrollment":2542,"conditions":5571,"interventions":5572},[85],[1466],[3470,2838,1512],{"nctId":4119,"briefTitle":4120,"status":103,"phases":5574,"primaryCompletion":2864,"completion":4122,"start":3020,"enrollment":1082,"conditions":5575,"interventions":5576},[85],[2824],[3287,4125,1612,1511],{"nctId":1600,"briefTitle":1601,"status":103,"phases":5578,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":5579,"interventions":5580},[85],[1466,1560,1608,1571,1609,1610],[1513,1538,1468,1612,1510,48,1613],{"nctId":2774,"briefTitle":2775,"status":103,"phases":5582,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":5583,"interventions":5584},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"nctId":2626,"briefTitle":2627,"status":393,"phases":5586,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":5587,"interventions":5588},[85],[2516,1717,1610,2632],[2634,1696,1510,1512,1612,1669,2519],{"nctId":5590,"briefTitle":5591,"status":103,"phases":5592,"primaryCompletion":4160,"completion":4160,"start":3094,"enrollment":3041,"conditions":5593,"interventions":5594},"NCT01215916","A Phase 1 Study in Patients With Solid Tumors",[85],[2589],[2804,1612],{"nctId":4157,"briefTitle":4158,"status":103,"phases":5596,"primaryCompletion":4160,"completion":3086,"start":3283,"enrollment":1232,"conditions":5597,"interventions":5598},[85],[1466],[3287,1612,1511],{"nctId":1699,"briefTitle":1700,"status":103,"phases":5600,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":299,"conditions":5601,"interventions":5602},[85],[1706],[48,1612,1511,61,1513,1696],{"trials":5604,"activeCount":314,"soonestReadout":1011},[5605,5609,5613,5619,5626,5633,5637,5641,5648,5652,5660,5664,5674,5678,5682,5686,5694,5698,5702,5706,5710,5721,5725,5732,5736,5740,5744,5750,5754,5758,5765,5769,5773,5777,5781,5785,5789,5793,5797,5803,5811,5815,5819,5823,5827,5831,5837,5845,5852,5856,5864,5878,5886,5890,5894,5898,5904,5908,5914,5918,5927,5931,5939,5945,5949,5957,5961,5965,5969,5975,5979,5986,5990,5999,6006,6012],{"nctId":2830,"briefTitle":2831,"status":103,"phases":5606,"completion":2833,"start":2834,"enrollment":2088,"conditions":5607,"interventions":5608},[86],[2836],[2838,2839],{"nctId":2841,"briefTitle":2842,"status":103,"phases":5610,"primaryCompletion":2844,"completion":2845,"start":2846,"enrollment":2847,"conditions":5611,"interventions":5612},[86],[2849],[1612,1510,1541],{"nctId":5614,"briefTitle":5615,"status":103,"phases":5616,"conditions":5617,"interventions":5618},"NCT00034606","Comparing 3 Schedules of Alimta Plus Gemzar",[86],[1589,2891,1870],[1612],{"nctId":5620,"briefTitle":5621,"status":103,"phases":5622,"completion":3566,"start":5623,"enrollment":251,"conditions":5624,"interventions":5625},"NCT00490373","Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic",[86],"2003-10",[1653],[2838],{"nctId":5627,"briefTitle":5628,"status":103,"phases":5629,"primaryCompletion":3235,"completion":3292,"start":3039,"enrollment":4945,"conditions":5630,"interventions":5632},"NCT00461786","A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer",[86],[2584,5631],"Peritoneal Cancer",[2838],{"nctId":2852,"briefTitle":2853,"status":103,"phases":5634,"completion":2855,"start":2856,"enrollment":2477,"conditions":5635,"interventions":5636},[85,86],[2858],[1612,1510],{"nctId":3500,"briefTitle":3501,"status":999,"phases":5638,"primaryCompletion":3132,"completion":3132,"start":2975,"enrollment":1400,"conditions":5639,"interventions":5640},[86],[3244],[2838,2561],{"nctId":5642,"briefTitle":5643,"status":103,"phases":5644,"completion":3168,"start":3536,"enrollment":5645,"conditions":5646,"interventions":5647},"NCT00065533","Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer",[86],92,[36],[2838],{"nctId":2872,"briefTitle":2873,"status":103,"phases":5649,"completion":2875,"start":2876,"enrollment":1082,"conditions":5650,"interventions":5651},[86],[2878],[2838,2839],{"nctId":5653,"briefTitle":5654,"status":103,"phases":5655,"primaryCompletion":2875,"completion":3292,"start":3194,"enrollment":1741,"conditions":5656,"interventions":5658},"NCT00191984","A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer",[86],[5657],"Metastatic Colorectal Cancer",[2838,5659],"irinotecan",{"nctId":3521,"briefTitle":3522,"status":103,"phases":5661,"primaryCompletion":3251,"completion":3012,"start":3524,"enrollment":3525,"conditions":5662,"interventions":5663},[86],[36],[1612,1512,1511,1875],{"nctId":5665,"briefTitle":5666,"status":103,"phases":5667,"completion":4566,"start":3185,"enrollment":2088,"conditions":5668,"interventions":5673},"NCT00190918","A Trial for Patients With Gestational Trophoblastic Disease",[86],[5669,5670,5671,5672],"Trophoblastic Neoplasms","Uterine Neoplasms","Hydatidiform Mole","Choriocarcinoma",[1612],{"nctId":4201,"briefTitle":4202,"status":103,"phases":5675,"completion":3185,"start":2909,"enrollment":3125,"conditions":5676,"interventions":5677},[85,86],[2622],[1612,1511,4206],{"nctId":4208,"briefTitle":4209,"status":103,"phases":5679,"conditions":5680,"interventions":5681},[86],[1893],[2838,2912],{"nctId":3572,"briefTitle":3573,"status":999,"phases":5683,"primaryCompletion":3575,"completion":2846,"start":3133,"enrollment":2542,"conditions":5684,"interventions":5685},[86],[2891],[2838,2912,2561,1612],{"nctId":5687,"briefTitle":5688,"status":103,"phases":5689,"primaryCompletion":3235,"completion":3235,"start":5690,"enrollment":864,"conditions":5691,"interventions":5693},"NCT00190983","A Trial for Patients With Advanced\u002FRecurrent Cervical Cancer",[86],"2005-02",[5692,5670,3762],"Cervical Intraepithelial Neoplasia",[1612],{"nctId":3579,"briefTitle":3580,"status":103,"phases":5695,"primaryCompletion":3103,"completion":3103,"start":3235,"enrollment":233,"conditions":5696,"interventions":5697},[86],[1610],[2979,2838,2561,2560],{"nctId":2925,"briefTitle":2926,"status":103,"phases":5699,"primaryCompletion":2928,"completion":2929,"start":2930,"enrollment":2931,"conditions":5700,"interventions":5701},[86],[2849],[1612,1510,1512],{"nctId":2935,"briefTitle":2936,"status":103,"phases":5703,"primaryCompletion":2800,"completion":2800,"start":2938,"enrollment":2939,"conditions":5704,"interventions":5705},[85,86],[2941],[2838,2839],{"nctId":3589,"briefTitle":3590,"status":103,"phases":5707,"primaryCompletion":3059,"completion":3059,"start":3592,"enrollment":3593,"conditions":5708,"interventions":5709},[86],[1718],[2979,2838,3106,2561],{"nctId":5711,"briefTitle":5712,"status":103,"phases":5713,"primaryCompletion":3235,"completion":3320,"start":3133,"enrollment":2071,"conditions":5714,"interventions":5720},"NCT00377520","A Trial for Patients With Advanced\u002FRecurrent Endometrial Cancer",[86],[1870,5715,1936,3762,5670,2505,5716,1572,5717,5718,5719],"Neoplasms by Site","Cancer of Endometrium","Cancer of the Endometrium","Endometrium Cancer","Neoplasms, Endometrial",[2838],{"nctId":2952,"briefTitle":2953,"status":103,"phases":5722,"primaryCompletion":2955,"completion":2956,"start":2875,"enrollment":2790,"conditions":5723,"interventions":5724},[86],[1610],[1612,1510,2959],{"nctId":5726,"briefTitle":5727,"status":103,"phases":5728,"primaryCompletion":3132,"completion":3132,"start":2975,"enrollment":5729,"conditions":5730,"interventions":5731},"NCT00530621","Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer",[86],160,[1610],[2979,2838],{"nctId":2971,"briefTitle":2972,"status":999,"phases":5733,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":1548,"conditions":5734,"interventions":5735},[86],[2977],[2979,2838,2839],{"nctId":4249,"briefTitle":4250,"status":103,"phases":5737,"completion":3228,"start":2948,"enrollment":1620,"conditions":5738,"interventions":5739},[86],[36],[2838,2912],{"nctId":2992,"briefTitle":2993,"status":103,"phases":5741,"primaryCompletion":2995,"completion":2995,"start":2855,"enrollment":2996,"conditions":5742,"interventions":5743},[85,86],[2998],[2838,2839],{"nctId":5745,"briefTitle":5746,"status":103,"phases":5747,"primaryCompletion":3545,"completion":3319,"start":3217,"enrollment":224,"conditions":5748,"interventions":5749},"NCT00988858","A Study of Advanced or Metastatic Non-small Cell Lung Cancer",[86],[1694],[3287,1612],{"nctId":3001,"briefTitle":3002,"status":103,"phases":5751,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":2080,"conditions":5752,"interventions":5753},[85,86],[2849],[2838,2839,2561],{"nctId":3009,"briefTitle":3010,"status":103,"phases":5755,"primaryCompletion":2917,"completion":2917,"start":3012,"enrollment":3013,"conditions":5756,"interventions":5757},[86],[2792],[1612,1541,1512,1510],{"nctId":5759,"briefTitle":5760,"status":103,"phases":5761,"conditions":5762,"interventions":5764},"NCT00035061","A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium",[86],[2998,5763],"Metastases, Neoplasm",[2838],{"nctId":4270,"briefTitle":4271,"status":999,"phases":5766,"primaryCompletion":3308,"completion":3308,"start":2875,"enrollment":2733,"conditions":5767,"interventions":5768},[86],[2849],[1612,1511],{"nctId":4276,"briefTitle":4277,"status":103,"phases":5770,"completion":3218,"start":3567,"enrollment":4279,"conditions":5771,"interventions":5772},[86],[1718],[2838,2912],{"nctId":3017,"briefTitle":3018,"status":103,"phases":5774,"primaryCompletion":2899,"completion":3020,"start":2846,"enrollment":2790,"conditions":5775,"interventions":5776},[86],[1718],[2838,2839],{"nctId":3024,"briefTitle":3025,"status":103,"phases":5778,"primaryCompletion":3027,"completion":3028,"start":3029,"enrollment":2733,"conditions":5779,"interventions":5780},[86],[1694],[1612,1510,3032,3033,3034],{"nctId":3045,"briefTitle":3046,"status":103,"phases":5782,"primaryCompletion":3048,"completion":3049,"start":3050,"enrollment":3051,"conditions":5783,"interventions":5784},[86],[1718],[1612,1510,3054],{"nctId":3056,"briefTitle":3057,"status":103,"phases":5786,"primaryCompletion":3059,"completion":3059,"start":3060,"enrollment":1451,"conditions":5787,"interventions":5788},[86],[3062],[2838,2839],{"nctId":3065,"briefTitle":3066,"status":103,"phases":5790,"primaryCompletion":3068,"completion":2965,"start":3069,"enrollment":982,"conditions":5791,"interventions":5792},[86],[2903],[1612,1510,3072],{"nctId":3083,"briefTitle":3084,"status":103,"phases":5794,"primaryCompletion":3086,"completion":2798,"start":3087,"enrollment":1587,"conditions":5795,"interventions":5796},[86],[2792],[1612,1541,1510],{"nctId":5798,"briefTitle":5799,"status":103,"phases":5800,"completion":4642,"start":3168,"enrollment":1692,"conditions":5801,"interventions":5802},"NCT00109096","Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy",[86],[2553,3621],[1612],{"nctId":5804,"briefTitle":5805,"status":103,"phases":5806,"primaryCompletion":3661,"completion":3661,"start":3266,"enrollment":5807,"conditions":5808,"interventions":5809},"NCT00550173","A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer",[86],247,[2849],[2838,5810],"erlotinib",{"nctId":3091,"briefTitle":3092,"status":103,"phases":5812,"primaryCompletion":3094,"completion":3094,"start":2834,"enrollment":3095,"conditions":5813,"interventions":5814},[86],[3097],[2838,2839],{"nctId":4332,"briefTitle":4333,"status":103,"phases":5816,"completion":3133,"start":3161,"enrollment":118,"conditions":5817,"interventions":5818},[86],[3432],[1612,1511],{"nctId":3109,"briefTitle":3110,"status":103,"phases":5820,"primaryCompletion":3112,"completion":3113,"start":3114,"enrollment":1269,"conditions":5821,"interventions":5822},[86],[1589],[3117,1612,1512,1510,1511,1512],{"nctId":2646,"briefTitle":2647,"status":257,"phases":5824,"primaryCompletion":1011,"completion":1011,"start":2649,"enrollment":2650,"conditions":5825,"interventions":5826},[85,86],[1589,2557,2505,2553,2652,2653],[2655,1696,1541,1612,1510,1512],{"nctId":3149,"briefTitle":3150,"status":103,"phases":5828,"primaryCompletion":2800,"completion":3152,"start":3153,"enrollment":1620,"conditions":5829,"interventions":5830},[86],[1718,2901],[2838,2839],{"nctId":5832,"briefTitle":5833,"status":103,"phases":5834,"primaryCompletion":2866,"completion":2866,"start":3060,"enrollment":1178,"conditions":5835,"interventions":5836},"NCT00316225","Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen",[86],[1610,3432,2891],[2838],{"nctId":5838,"briefTitle":5839,"status":103,"phases":5840,"primaryCompletion":2899,"completion":3020,"start":4642,"enrollment":5841,"conditions":5842,"interventions":5844},"NCT00447057","Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)",[86],204,[5843],"Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.",[1612,1721,1612,1721],{"nctId":5846,"briefTitle":5847,"status":103,"phases":5848,"primaryCompletion":3152,"completion":3152,"start":3308,"enrollment":1839,"conditions":5849,"interventions":5850},"NCT00606021","A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",[86],[1694],[2838,5851],"Best Supportive Care",{"nctId":4398,"briefTitle":4399,"status":103,"phases":5853,"completion":3133,"start":3161,"enrollment":118,"conditions":5854,"interventions":5855},[86],[1589],[1612,1511],{"nctId":5857,"briefTitle":5858,"status":103,"phases":5859,"primaryCompletion":5860,"completion":2918,"start":2975,"enrollment":310,"conditions":5861,"interventions":5863},"NCT00523419","Chemotherapy for Patients With Osteosarcoma",[86],"2009-06",[5862],"Osteosarcoma",[1612],{"nctId":5865,"briefTitle":5866,"status":103,"phases":5867,"primaryCompletion":3087,"completion":3087,"start":2975,"enrollment":1767,"conditions":5868,"interventions":5877},"NCT00520936","A Study of Pemetrexed in Children With Recurrent Cancer",[86],[5862,5869,5870,5871,5872,5873,5874,5875,5876],"Medulloblastoma","Sarcoma, Ewing's","Neuroblastoma (Measurable Disease)","Neuroblastoma (Metaiodobenzylguanidine","Positive Evaluable)","Rhabdomyosarcoma","Ependymoma","Non-brainstem High-grade Glioma",[2838],{"nctId":5879,"briefTitle":5880,"status":103,"phases":5881,"primaryCompletion":3338,"completion":3338,"start":3168,"enrollment":5882,"conditions":5883,"interventions":5884},"NCT00190671","A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients",[85,86],103,[36],[2838,5885,2838],"cyclophosphamide",{"nctId":3200,"briefTitle":3201,"status":103,"phases":5887,"primaryCompletion":3068,"completion":3027,"start":3050,"enrollment":963,"conditions":5888,"interventions":5889},[86],[1694],[1612,1510],{"nctId":3707,"briefTitle":3708,"status":103,"phases":5891,"completion":2833,"start":3710,"enrollment":2088,"conditions":5892,"interventions":5893},[86],[36,1478],[1612,1512],{"nctId":3224,"briefTitle":3225,"status":999,"phases":5895,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":757,"conditions":5896,"interventions":5897},[86],[2849],[2838,2839],{"nctId":5899,"briefTitle":5900,"status":103,"phases":5901,"primaryCompletion":3094,"completion":3837,"start":2833,"enrollment":617,"conditions":5902,"interventions":5903},"NCT00149214","Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens",[86],[36],[2838,5885,3143,3106],{"nctId":3240,"briefTitle":3241,"status":999,"phases":5905,"primaryCompletion":2995,"completion":2995,"start":3235,"enrollment":425,"conditions":5906,"interventions":5907},[86],[3244],[2838,2839],{"nctId":5909,"briefTitle":5910,"status":103,"phases":5911,"completion":3133,"start":3339,"enrollment":4475,"conditions":5912,"interventions":5913},"NCT00191750","A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned",[86],[3295],[1612],{"nctId":4495,"briefTitle":4496,"status":103,"phases":5915,"completion":3160,"start":3140,"enrollment":118,"conditions":5916,"interventions":5917},[86],[1589],[2838,2912],{"nctId":5919,"briefTitle":5920,"status":103,"phases":5921,"primaryCompletion":3227,"completion":3227,"start":3566,"enrollment":5922,"conditions":5923,"interventions":5926},"NCT00106002","Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer",[86],37,[36,5924,5925],"Breast Neoplasms, Male","Carcinoma, Ductal",[2838],{"nctId":4513,"briefTitle":4514,"status":103,"phases":5928,"primaryCompletion":3308,"completion":3308,"start":3567,"enrollment":93,"conditions":5929,"interventions":5930},[86],[36,1893],[1612,1511,1511,1612],{"nctId":5932,"briefTitle":5933,"status":103,"phases":5934,"completion":2856,"start":2834,"enrollment":5935,"conditions":5936,"interventions":5938},"NCT00190840","A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer",[86],186,[5937],"Carcinoma, Non-Small Cell Lung",[2838],{"nctId":5940,"briefTitle":5941,"status":103,"phases":5942,"primaryCompletion":3050,"completion":2918,"start":3094,"enrollment":335,"conditions":5943,"interventions":5944},"NCT00609518","A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer",[86],[1694],[2838,3198,3198],{"nctId":3723,"briefTitle":3724,"status":103,"phases":5946,"primaryCompletion":2974,"completion":3217,"start":2855,"enrollment":28,"conditions":5947,"interventions":5948},[86],[1694],[2838,2561],{"nctId":5950,"briefTitle":5951,"status":103,"phases":5952,"completion":3259,"start":5953,"enrollment":4222,"conditions":5954,"interventions":5956},"NCT00192088","A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma",[86],"2004-05",[5955],"Advanced Gastric Carcinoma",[2838,4181],{"nctId":3263,"briefTitle":3264,"status":103,"phases":5958,"primaryCompletion":3266,"completion":3027,"start":3176,"enrollment":3267,"conditions":5959,"interventions":5960},[86],[1718],[2838,2839,2561],{"nctId":4535,"briefTitle":4536,"status":103,"phases":5962,"completion":3228,"start":4538,"enrollment":1620,"conditions":5963,"interventions":5964},[86],[4540],[1612,1511],{"nctId":3279,"briefTitle":3280,"status":103,"phases":5966,"primaryCompletion":3282,"completion":3122,"start":3283,"enrollment":3284,"conditions":5967,"interventions":5968},[85,86],[1694],[1612,1510,3287],{"nctId":5970,"briefTitle":5971,"status":103,"phases":5972,"primaryCompletion":3697,"completion":3329,"start":3086,"enrollment":3177,"conditions":5973,"interventions":5974},"NCT01469000","A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)",[86],[3188],[2959,1612],{"nctId":3289,"briefTitle":3290,"status":999,"phases":5976,"primaryCompletion":3292,"completion":3292,"start":2875,"enrollment":3293,"conditions":5977,"interventions":5978},[85,86],[3244,3295,3296],[2838,2839],{"nctId":5980,"briefTitle":5981,"status":103,"phases":5982,"completion":3235,"start":2948,"enrollment":3095,"conditions":5983,"interventions":5984},"NCT00102219","A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer",[86],[36],[1612,5985],"Doxorubicin",{"nctId":4547,"briefTitle":4548,"status":103,"phases":5987,"completion":2855,"start":4459,"enrollment":118,"conditions":5988,"interventions":5989},[85,86],[2891],[2838,2912],{"nctId":5991,"briefTitle":5992,"status":103,"phases":5993,"primaryCompletion":5022,"completion":5022,"start":4160,"enrollment":251,"conditions":5994,"interventions":5998},"NCT01473563","A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)",[86],[5995,5996,5997],"Nonsquamous Non-Small Cell Neoplasm of Lung","Non-Small Cell Lung Cancer Metastatic","Non-Small Cell Lung Cancer Stage IIIB",[1612],{"nctId":6000,"briefTitle":6001,"status":103,"phases":6002,"primaryCompletion":3575,"completion":3575,"start":3524,"enrollment":5922,"conditions":6003,"interventions":6005},"NCT00330915","A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.",[86],[6004],"Rectal Neoplasms",[2838],{"nctId":6007,"briefTitle":6008,"status":103,"phases":6009,"completion":3259,"start":4221,"enrollment":2080,"conditions":6010,"interventions":6011},"NCT00079872","Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer",[86],[1490],[1612],{"nctId":6013,"briefTitle":6014,"status":103,"phases":6015,"completion":3592,"start":4538,"enrollment":2542,"conditions":6016,"interventions":6018},"NCT00191412","A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver",[86],[6017],"Liver Cancer",[1612],{"trials":6020,"activeCount":947,"soonestReadout":2679},[6021,6025,6029,6033,6040,6044,6048,6052,6056,6063,6067,6071,6078,6082,6089,6096,6100,6104],{"nctId":3315,"briefTitle":3316,"status":103,"phases":6022,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":3321,"conditions":6023,"interventions":6024},[87],[1694],[1612,1510,3324,1875,1669,1512],{"nctId":3326,"briefTitle":3327,"status":103,"phases":6026,"primaryCompletion":2918,"completion":3329,"start":2974,"enrollment":3330,"conditions":6027,"interventions":6028},[87],[1718],[1612,1510,1612],{"nctId":3334,"briefTitle":3335,"status":103,"phases":6030,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":6031,"interventions":6032},[87],[3342],[2838,2912,2839],{"nctId":6034,"briefTitle":6035,"status":103,"phases":6036,"primaryCompletion":3813,"completion":3049,"start":3218,"enrollment":6037,"conditions":6038,"interventions":6039},"NCT00102804","Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)",[87],663,[1718],[1612],{"nctId":3345,"briefTitle":3346,"status":103,"phases":6041,"primaryCompletion":3348,"completion":3318,"start":3217,"enrollment":3349,"conditions":6042,"interventions":6043},[87],[1694],[1612,1510,2959,2959],{"nctId":3362,"briefTitle":3363,"status":103,"phases":6045,"primaryCompletion":3048,"completion":3048,"start":3217,"enrollment":3365,"conditions":6046,"interventions":6047},[87],[1694],[1612,1511,1510],{"nctId":3766,"briefTitle":3767,"status":103,"phases":6049,"primaryCompletion":2899,"completion":2899,"start":3235,"enrollment":3769,"conditions":6050,"interventions":6051},[87],[1718],[2838,3106,2561],{"nctId":3773,"briefTitle":3774,"status":103,"phases":6053,"primaryCompletion":2864,"completion":3776,"start":2928,"enrollment":3330,"conditions":6054,"interventions":6055},[87],[1610],[1612,1612,1669,1512,3054,3054],{"nctId":6057,"briefTitle":6058,"status":103,"phases":6059,"primaryCompletion":2876,"completion":2995,"start":4459,"enrollment":6060,"conditions":6061,"interventions":6062},"NCT00078260","A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer",[87],589,[1718],[2838],{"nctId":3780,"briefTitle":3781,"status":103,"phases":6064,"primaryCompletion":3575,"completion":3575,"start":2855,"enrollment":3783,"conditions":6065,"interventions":6066},[87],[3244],[2838,3107,2561],{"nctId":2676,"briefTitle":2677,"status":257,"phases":6068,"primaryCompletion":2679,"completion":2680,"start":2681,"enrollment":2682,"conditions":6069,"interventions":6070},[87],[1718],[2685,1512,1510,1612,1696],{"nctId":6072,"briefTitle":6073,"status":103,"phases":6074,"completion":3228,"start":6075,"enrollment":2502,"conditions":6076,"interventions":6077},"NCT00190762","A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma",[87],"2001-10",[3432],[1612],{"nctId":3817,"briefTitle":3818,"status":103,"phases":6079,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":6080,"interventions":6081},[87],[3825],[1612,1512,1669,3054],{"nctId":6083,"briefTitle":6084,"status":103,"phases":6085,"primaryCompletion":2928,"completion":2918,"start":2876,"enrollment":6086,"conditions":6087,"interventions":6088},"NCT00391274","Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)",[87],211,[1718],[2838,3106],{"nctId":6090,"briefTitle":6091,"status":103,"phases":6092,"primaryCompletion":6093,"completion":6093,"start":4538,"enrollment":3330,"conditions":6094,"interventions":6095},"NCT00095199","Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer",[87],"2011-07",[1694],[1612,1541,1722],{"nctId":3402,"briefTitle":3403,"status":103,"phases":6097,"primaryCompletion":3405,"completion":3406,"start":3407,"enrollment":3408,"conditions":6098,"interventions":6099},[87],[1694],[1612,1510,1591],{"nctId":2708,"briefTitle":2709,"status":393,"phases":6101,"primaryCompletion":765,"completion":2130,"start":2711,"enrollment":2712,"conditions":6102,"interventions":6103},[87],[1589,1478],[2655,1696,1510,1512,1612],{"nctId":3416,"briefTitle":3417,"status":103,"phases":6105,"primaryCompletion":3419,"completion":3419,"start":3060,"enrollment":3420,"conditions":6106,"interventions":6107},[87],[2792],[2838,2839],{"trials":6109,"activeCount":97},[6110,6114],{"nctId":3834,"briefTitle":3835,"status":103,"phases":6111,"primaryCompletion":3837,"completion":3838,"start":3217,"enrollment":3051,"conditions":6112,"interventions":6113},[88],[1694],[1612,1512],{"nctId":6115,"briefTitle":6116,"status":103,"phases":6117,"primaryCompletion":3320,"completion":3217,"start":2930,"enrollment":5015,"conditions":6118,"interventions":6119},"NCT00380718","Chemotherapy for Patients With Non-Small Cell Lung Cancer",[88],[1610],[2838],{"trials":6121,"activeCount":97},[6122,6129,6136],{"nctId":6123,"briefTitle":6124,"status":103,"phases":6125,"primaryCompletion":3837,"completion":3837,"start":2875,"enrollment":6126,"conditions":6127,"interventions":6128},"NCT00497770","An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed",[],434,[2891],[1612],{"nctId":6130,"briefTitle":6131,"status":103,"phases":6132,"primaryCompletion":3050,"completion":3419,"start":2975,"enrollment":6133,"conditions":6134,"interventions":6135},"NCT00540241","Performance Status During Treatment With Pemetrexed in Patients With NSCLC",[],542,[1694],[1612],{"nctId":3428,"briefTitle":3429,"status":2032,"phases":6137,"conditions":6138,"interventions":6139},[],[3432],[1612,1510],{"intervention":1761,"totalTrials":1054,"cells":6141},{"EARLY_PHASE1":6142,"PHASE1":6144,"PHASE2":6158,"PHASE3":6172,"PHASE4":6185,"NA":6187},{"trials":6143,"activeCount":97},[],{"trials":6145,"activeCount":314,"soonestReadout":3865},[6146,6154],{"nctId":6147,"briefTitle":6148,"status":103,"phases":6149,"primaryCompletion":4420,"completion":6150,"start":6151,"enrollment":2939,"conditions":6152,"interventions":6153},"NCT01393990","A Study of LY2228820 in Participants With Advanced Cancer",[85],"2013-12-14","2008-09-04",[1466],[3623,1538,1761],{"nctId":3862,"briefTitle":3863,"status":257,"phases":6155,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":6156,"interventions":6157},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":6159,"activeCount":947,"soonestReadout":65},[6160,6164,6168],{"nctId":1748,"briefTitle":1749,"status":393,"phases":6161,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":6162,"interventions":6163},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":63,"briefTitle":64,"status":257,"phases":6165,"primaryCompletion":65,"completion":462,"start":923,"enrollment":1808,"conditions":6166,"interventions":6167},[86],[1571],[48,1761,1811],{"nctId":3883,"briefTitle":3884,"status":103,"phases":6169,"primaryCompletion":3886,"completion":1473,"start":3216,"enrollment":3887,"conditions":6170,"interventions":6171},[86],[1571],[2870,3890,1697,1613,1760,1468],{"trials":6173,"activeCount":314,"soonestReadout":454},[6174,6178],{"nctId":4861,"briefTitle":4862,"status":257,"phases":6175,"primaryCompletion":454,"completion":4864,"start":3947,"enrollment":4865,"conditions":6176,"interventions":6177},[87],[1893],[1667,1761,1697,1613,1760],{"nctId":6179,"briefTitle":6180,"status":103,"phases":6181,"conditions":6182,"interventions":6183},"NCT00034125","Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.",[87],[1893],[6184,3890],"LY353381",{"trials":6186,"activeCount":97},[],{"trials":6188,"activeCount":97},[],{"intervention":2685,"totalTrials":1071,"cells":6190},{"EARLY_PHASE1":6191,"PHASE1":6193,"PHASE2":6284,"PHASE3":6305,"PHASE4":6318,"NA":6320},{"trials":6192,"activeCount":97},[],{"trials":6194,"activeCount":97},[6195,6203,6211,6220,6230,6238,6246,6253,6262,6269,6276],{"nctId":6196,"briefTitle":6197,"status":103,"phases":6198,"primaryCompletion":6199,"completion":6199,"start":6200,"enrollment":5922,"conditions":6201,"interventions":6202},"NCT05469100","A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function",[85],"2019-08-07","2018-12-19",[15,147],[2685],{"nctId":6204,"briefTitle":6205,"status":103,"phases":6206,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":1071,"conditions":6209,"interventions":6210},"NCT05469113","A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants",[85],"2019-03-05","2019-01-29",[15],[1102,2685],{"nctId":6212,"briefTitle":6213,"status":103,"phases":6214,"primaryCompletion":6215,"completion":6216,"start":3617,"enrollment":290,"conditions":6217,"interventions":6218},"NCT05338489","A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants",[85],"2018-07-28","2018-08-22",[15],[2685,2562,6219],"Rifampin",{"nctId":6221,"briefTitle":6222,"status":103,"phases":6223,"primaryCompletion":6224,"completion":6225,"start":6226,"enrollment":214,"conditions":6227,"interventions":6229},"NCT05436912","A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants",[85],"2019-10-04","2019-10-30","2018-12-10",[15,6228],"Hepatic Impairment",[2685],{"nctId":6231,"briefTitle":6232,"status":103,"phases":6233,"primaryCompletion":6234,"completion":6234,"start":6235,"enrollment":1082,"conditions":6236,"interventions":6237},"NCT05468164","A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants",[85],"2018-09-13","2018-05-31",[15],[2685,1171],{"nctId":6239,"briefTitle":6240,"status":103,"phases":6241,"primaryCompletion":364,"completion":6242,"start":6243,"enrollment":1071,"conditions":6244,"interventions":6245},"NCT05338476","A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants",[85],"2018-09-18","2018-07-12",[15],[1538,2685],{"nctId":6247,"briefTitle":6248,"status":103,"phases":6249,"primaryCompletion":1557,"completion":1557,"start":5346,"enrollment":1082,"conditions":6250,"interventions":6251},"NCT05338502","Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants",[85],[15],[2685,6252,1171],"Ranitidine",{"nctId":6254,"briefTitle":6255,"status":103,"phases":6256,"primaryCompletion":6257,"completion":6258,"start":6259,"enrollment":12,"conditions":6260,"interventions":6261},"NCT05338515","A Study of Selpercatinib (LY3527723) in Healthy Participants",[85],"2019-03-12","2019-03-26","2019-02-12",[15],[2685],{"nctId":6263,"briefTitle":6264,"status":103,"phases":6265,"primaryCompletion":5120,"completion":5120,"start":364,"enrollment":2477,"conditions":6266,"interventions":6267},"NCT05630287","A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants",[85],[15],[6268,2685,6268],"[14C]-Selpercatinib",{"nctId":6270,"briefTitle":6271,"status":103,"phases":6272,"primaryCompletion":827,"completion":827,"start":6273,"enrollment":165,"conditions":6274,"interventions":6275},"NCT05906836","A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants",[85],"2023-07-27",[15],[2093,2685],{"nctId":6277,"briefTitle":6278,"status":103,"phases":6279,"primaryCompletion":6280,"completion":6280,"start":6281,"enrollment":310,"conditions":6282,"interventions":6283},"NCT05630274","A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants",[85],"2019-06-21","2019-04-16",[15],[2685,1181],{"trials":6285,"activeCount":947,"soonestReadout":6302},[6286,6298],{"nctId":6287,"briefTitle":6288,"status":257,"phases":6289,"primaryCompletion":6290,"completion":1911,"start":6291,"enrollment":214,"conditions":6292,"interventions":6297},"NCT03899792","A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",[85,86],"2024-11-08","2019-06-13",[6293,6294,6295,6296,1506],"Medullary Thyroid Cancer","Infantile Myofibromatosis","Infantile Fibrosarcoma","Papillary Thyroid Cancer",[2685],{"nctId":6299,"briefTitle":6300,"status":257,"phases":6301,"primaryCompletion":6302,"completion":765,"start":1969,"enrollment":3095,"conditions":6303,"interventions":6304},"NCT04280081","A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",[86],"2021-03-25",[1503,6293],[2685],{"trials":6306,"activeCount":947,"soonestReadout":2679},[6307,6311],{"nctId":2676,"briefTitle":2677,"status":257,"phases":6308,"primaryCompletion":2679,"completion":2680,"start":2681,"enrollment":2682,"conditions":6309,"interventions":6310},[87],[1718],[2685,1512,1510,1612,1696],{"nctId":6312,"briefTitle":6313,"status":257,"phases":6314,"primaryCompletion":5265,"completion":581,"start":6315,"enrollment":829,"conditions":6316,"interventions":6317},"NCT04819100","A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)",[87],"2021-12-20",[1589],[2685],{"trials":6319,"activeCount":97},[],{"trials":6321,"activeCount":97},[6322],{"nctId":6323,"briefTitle":6324,"status":2032,"phases":6325,"conditions":6326,"interventions":6328},"NCT03906331","Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation",[],[1694,6293,1504,36,1653,6296,6327],"Other Solid Tumors With Evidence of Activating RET Alteration",[2685],{"intervention":5134,"totalTrials":1677,"cells":6330},{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6335,"PHASE3":6337,"PHASE4":6363,"NA":6365},{"trials":6332,"activeCount":97},[],{"trials":6334,"activeCount":97},[],{"trials":6336,"activeCount":97},[],{"trials":6338,"activeCount":1232,"soonestReadout":5158},[6339,6343,6347,6351,6355,6359],{"nctId":5126,"briefTitle":5127,"status":103,"phases":6340,"primaryCompletion":1766,"completion":5129,"start":5130,"enrollment":5131,"conditions":6341,"interventions":6342},[87],[1271],[4944,5134],{"nctId":5155,"briefTitle":5156,"status":257,"phases":6344,"primaryCompletion":5158,"completion":443,"start":5159,"enrollment":5160,"conditions":6345,"interventions":6346},[87],[1271],[4944,5134],{"nctId":1315,"briefTitle":1316,"status":257,"phases":6348,"primaryCompletion":1318,"completion":420,"start":344,"enrollment":1319,"conditions":6349,"interventions":6350},[87],[1271],[1236,1322],{"nctId":1324,"briefTitle":1325,"status":257,"phases":6352,"primaryCompletion":260,"completion":462,"start":1327,"enrollment":1328,"conditions":6353,"interventions":6354},[87],[1271,1284],[1236,1322],{"nctId":1362,"briefTitle":1363,"status":103,"phases":6356,"primaryCompletion":1365,"completion":1366,"start":665,"enrollment":16,"conditions":6357,"interventions":6358},[87],[1368,1369,1284,1370,1371],[1236,1322],{"nctId":5359,"briefTitle":5360,"status":103,"phases":6360,"primaryCompletion":5362,"completion":571,"start":5363,"enrollment":1995,"conditions":6361,"interventions":6362},[87],[1271],[4944,5134],{"trials":6364,"activeCount":97},[],{"trials":6366,"activeCount":97},[],{"intervention":61,"totalTrials":3309,"cells":6368},{"EARLY_PHASE1":6369,"PHASE1":6371,"PHASE2":6478,"PHASE3":6645,"PHASE4":6721,"NA":6723},{"trials":6370,"activeCount":97},[],{"trials":6372,"activeCount":97},[6373,6382,6386,6395,6399,6406,6412,6418,6422,6434,6443,6451,6457,6461,6470,6474],{"nctId":6374,"briefTitle":6375,"status":103,"phases":6376,"primaryCompletion":6377,"completion":562,"start":6378,"enrollment":22,"conditions":6379,"interventions":6380},"NCT02572687","A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies",[85],"2018-03-27","2016-02-19",[3062,3399,1718,2608],[61,6381],"MEDI4736",{"nctId":1482,"briefTitle":1483,"status":103,"phases":6383,"primaryCompletion":1485,"completion":1486,"start":1487,"enrollment":1488,"conditions":6384,"interventions":6385},[85],[1466,1490,1491],[61,1493,48],{"nctId":6387,"briefTitle":6388,"status":103,"phases":6389,"primaryCompletion":6390,"completion":6390,"start":1475,"enrollment":4323,"conditions":6391,"interventions":6393},"NCT02069041","A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer",[85],"2016-09",[6392],"Carcinoma, Hepatocellular",[61,6394],"FOLFOX4",{"nctId":2751,"briefTitle":2752,"status":103,"phases":6396,"primaryCompletion":1546,"completion":2754,"start":1473,"enrollment":12,"conditions":6397,"interventions":6398},[85],[2756],[61,1843,1510,2758,2520],{"nctId":6400,"briefTitle":6401,"status":103,"phases":6402,"primaryCompletion":3086,"completion":3886,"start":3283,"enrollment":1677,"conditions":6403,"interventions":6404},"NCT01286818","A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)",[85],[2586],[61,1745,6405,2923],"levofolinate",{"nctId":6407,"briefTitle":6408,"status":103,"phases":6409,"primaryCompletion":1596,"completion":1596,"start":3048,"enrollment":165,"conditions":6410,"interventions":6411},"NCT01682135","A Study in Participants With Advanced Solid Tumors",[85],[1503],[61],{"nctId":6413,"briefTitle":6414,"status":103,"phases":6415,"primaryCompletion":3004,"completion":3004,"start":3029,"enrollment":1677,"conditions":6416,"interventions":6417},"NCT01253525","Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas",[85],[4540],[61,1669],{"nctId":2614,"briefTitle":2615,"status":103,"phases":6419,"primaryCompletion":2617,"completion":1462,"start":2618,"enrollment":2619,"conditions":6420,"interventions":6421},[85],[2604,2621,1610,2622,2623],[61,1696],{"nctId":6423,"briefTitle":6424,"status":103,"phases":6425,"primaryCompletion":6426,"completion":6426,"start":6427,"enrollment":864,"conditions":6428,"interventions":6433},"NCT02564198","A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors",[85],"2019-07-16","2015-12-11",[6429,6430,6431,6432],"Pediatric Solid Tumor","Refractory Tumor","Recurrent Tumor","CNS Malignancies",[61],{"nctId":6435,"briefTitle":6436,"status":999,"phases":6437,"primaryCompletion":5229,"completion":6438,"start":6439,"enrollment":28,"conditions":6440,"interventions":6441},"NCT02597036","A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors",[85],"2020-05-24","2015-11-06",[2589],[6442,61,1669],"LY3127804",{"nctId":6444,"briefTitle":6445,"status":999,"phases":6446,"primaryCompletion":6447,"completion":6447,"start":6448,"enrollment":1232,"conditions":6449,"interventions":6450},"NCT04557384","A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer",[85],"2021-05-25","2021-02-23",[1717],[61],{"nctId":6452,"briefTitle":6453,"status":103,"phases":6454,"primaryCompletion":3048,"completion":4420,"start":3152,"enrollment":1054,"conditions":6455,"interventions":6456},"NCT01256567","A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer",[85],[36,1571],[61,1722],{"nctId":1643,"briefTitle":1644,"status":103,"phases":6458,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":1649,"conditions":6459,"interventions":6460},[85],[1503,1651,1652,1653,1654],[1656,61,48,1493,1657],{"nctId":6462,"briefTitle":6463,"status":103,"phases":6464,"primaryCompletion":334,"completion":6465,"start":6466,"enrollment":864,"conditions":6467,"interventions":6468},"NCT02789345","A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer",[85],"2022-05-09","2016-10-24",[1610],[61,1591,6469],"Osimertinib",{"nctId":2817,"briefTitle":2818,"status":103,"phases":6471,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":377,"conditions":6472,"interventions":6473},[85],[2824],[2826,1541,1510,1511,61],{"nctId":1699,"briefTitle":1700,"status":103,"phases":6475,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":299,"conditions":6476,"interventions":6477},[85],[1706],[48,1612,1511,61,1513,1696],{"trials":6479,"activeCount":947,"soonestReadout":60},[6480,6487,6493,6502,6514,6518,6528,6535,6545,6554,6562,6570,6576,6583,6587,6596,6604,6608,6616,6620,6628,6636],{"nctId":6481,"briefTitle":6482,"status":103,"phases":6483,"primaryCompletion":3776,"completion":1546,"start":4122,"enrollment":11,"conditions":6484,"interventions":6486},"NCT01703091","A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer",[86],[6485],"Non-small Cell Lung Cancer Metastatic",[61,1722],{"nctId":6488,"briefTitle":6489,"status":103,"phases":6490,"primaryCompletion":2844,"completion":2844,"start":3094,"enrollment":137,"conditions":6491,"interventions":6492},"NCT00627042","Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy",[86],[2608],[61],{"nctId":6494,"briefTitle":6495,"status":103,"phases":6496,"primaryCompletion":6497,"completion":6498,"start":3515,"enrollment":6499,"conditions":6500,"interventions":6501},"NCT02514551","A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer",[86],"2017-10-27","2018-12-28",245,[2604,3399],[61,1669],{"nctId":6503,"briefTitle":6504,"status":103,"phases":6505,"primaryCompletion":6506,"completion":6507,"start":6508,"enrollment":6509,"conditions":6510,"interventions":6512},"NCT02082210","A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",[85,86],"2017-12-05","2018-01-24","2014-03-07",97,[1466,2604,3399,6511,2585,1718],"Hepatocellular Cancer",[6513,61],"Emibetuzumab",{"nctId":58,"briefTitle":59,"status":257,"phases":6515,"primaryCompletion":60,"completion":462,"start":2882,"enrollment":2883,"conditions":6516,"interventions":6517},[86],[2623,1560,1466],[61,1493,1510,1511],{"nctId":6519,"briefTitle":6520,"status":103,"phases":6521,"primaryCompletion":6522,"completion":6523,"start":6524,"enrollment":5841,"conditions":6525,"interventions":6526},"NCT01246986","A Study of LY2157299 in Participants With Hepatocellular Carcinoma",[86],"2019-06-06","2019-12-24","2011-03-30",[6392],[4101,6527,61],"Sorafenib",{"nctId":6529,"briefTitle":6530,"status":103,"phases":6531,"primaryCompletion":2865,"completion":1474,"start":3216,"enrollment":874,"conditions":6532,"interventions":6534},"NCT00721162","Study of Ramucirumab in Ovarian Cancer",[86],[2584,3620,6533],"Primary Peritoneal Carcinoma",[61],{"nctId":6536,"briefTitle":6537,"status":103,"phases":6538,"primaryCompletion":3049,"completion":3049,"start":3012,"enrollment":6539,"conditions":6540,"interventions":6542},"NCT01111604","A Study of Ramucirumab or Icrucumab in Colorectal Cancer",[86],158,[1504,6541],"Rectal Cancer",[61,6543,6544],"Icrucumab","mFOLFOX-6",{"nctId":6546,"briefTitle":6547,"status":103,"phases":6548,"primaryCompletion":5022,"completion":4098,"start":3069,"enrollment":6549,"conditions":6550,"interventions":6553},"NCT01246960","A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer",[86],168,[6551,6552],"Stomach Cancer","Esophageal Cancer",[61,2520,2521,2923],{"nctId":6555,"briefTitle":6556,"status":384,"phases":6557,"primaryCompletion":3698,"completion":6558,"start":2754,"enrollment":97,"conditions":6559,"interventions":6561},"NCT02831491","A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer",[86],"2018-01",[6560],"Stage IV Non-small Cell Lung Cancer",[61,1722],{"nctId":6563,"briefTitle":6564,"status":103,"phases":6565,"primaryCompletion":6566,"completion":665,"start":6567,"enrollment":903,"conditions":6568,"interventions":6569},"NCT02539225","A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma",[86],"2017-10-25","2015-10-05",[3398,3399],[61,2758,2520,1669],{"nctId":6571,"briefTitle":6572,"status":103,"phases":6573,"primaryCompletion":5030,"completion":1547,"start":3049,"enrollment":214,"conditions":6574,"interventions":6575},"NCT01983878","A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer",[86],[3062],[61],{"nctId":6577,"briefTitle":6578,"status":103,"phases":6579,"primaryCompletion":2844,"completion":2844,"start":3266,"enrollment":3041,"conditions":6580,"interventions":6582},"NCT00515697","A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma",[86],[6581],"Metastatic Renal Cell Carcinoma",[61],{"nctId":3658,"briefTitle":3659,"status":103,"phases":6584,"primaryCompletion":3004,"completion":3661,"start":3662,"enrollment":2542,"conditions":6585,"interventions":6586},[86],[1694],[61,1669,1512],{"nctId":6588,"briefTitle":6589,"status":103,"phases":6590,"primaryCompletion":6591,"completion":6592,"start":6593,"enrollment":1649,"conditions":6594,"interventions":6595},"NCT02443883","A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer",[86],"2016-11-18","2019-06-05","2015-07-07",[2604,3399],[61],{"nctId":6597,"briefTitle":6598,"status":103,"phases":6599,"primaryCompletion":2917,"completion":6600,"start":2798,"enrollment":864,"conditions":6601,"interventions":6602},"NCT01634555","A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI",[86],"2018-02",[2589],[61,1745,6603,2923],"Folinic acid",{"nctId":4404,"briefTitle":4405,"status":999,"phases":6605,"primaryCompletion":4407,"completion":4407,"start":4408,"enrollment":1488,"conditions":6606,"interventions":6607},[85,86],[4410],[61,1511,1722],{"nctId":6609,"briefTitle":6610,"status":103,"phases":6611,"primaryCompletion":1818,"completion":2024,"start":6612,"enrollment":118,"conditions":6613,"interventions":6614},"NCT01515306","A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors",[86],"2012-07-19",[2968],[6615,3222],"ramucirumab",{"nctId":1864,"briefTitle":1865,"status":393,"phases":6617,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":6618,"interventions":6619},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"nctId":6621,"briefTitle":6622,"status":103,"phases":6623,"primaryCompletion":5022,"completion":5354,"start":5090,"enrollment":6624,"conditions":6625,"interventions":6626},"NCT01427933","A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer",[86],141,[36],[61,6627],"Eribulin",{"nctId":6629,"briefTitle":6630,"status":103,"phases":6631,"primaryCompletion":4122,"completion":6632,"start":3545,"enrollment":6633,"conditions":6634,"interventions":6635},"NCT01567163","A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors",[86],"2014-03",22,[2968],[61,1722],{"nctId":6637,"briefTitle":6638,"status":103,"phases":6639,"primaryCompletion":6640,"completion":6641,"start":1867,"enrollment":1620,"conditions":6642,"interventions":6644},"NCT04145349","CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor",[85,86],"2024-06-14","2026-01-23",[6643],"Desmoplastic Small Round Cell Tumor",[61,1874,1875],{"trials":6646,"activeCount":314,"soonestReadout":69},[6647,6657,6667,6674,6683,6689,6693,6703,6710],{"nctId":6648,"briefTitle":6649,"status":103,"phases":6650,"primaryCompletion":6651,"completion":6652,"start":6653,"enrollment":6654,"conditions":6655,"interventions":6656},"NCT02435433","A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein",[87],"2018-03-15","2021-11-19","2015-07-20",399,[2608],[61],{"nctId":6658,"briefTitle":6659,"status":103,"phases":6660,"primaryCompletion":6661,"completion":6662,"start":6663,"enrollment":6664,"conditions":6665,"interventions":6666},"NCT00703326","Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer",[87],"2013-03-31","2020-11-19","2008-08-06",1144,[36],[6615,3106],{"nctId":6668,"briefTitle":6669,"status":103,"phases":6670,"primaryCompletion":3049,"completion":1628,"start":3152,"enrollment":6671,"conditions":6672,"interventions":6673},"NCT01168973","A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy",[87],1253,[1718],[61,1722],{"nctId":6675,"briefTitle":6676,"status":103,"phases":6677,"primaryCompletion":6678,"completion":6679,"start":6680,"enrollment":5151,"conditions":6681,"interventions":6682},"NCT02898077","A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer",[87],"2020-06-30","2021-04-12","2017-03-02",[3399,2604],[61,1669],{"nctId":6684,"briefTitle":6685,"status":103,"phases":6686,"primaryCompletion":3545,"completion":3123,"start":2955,"enrollment":4627,"conditions":6687,"interventions":6688},"NCT00917384","Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma",[87],[3062,4540],[6615],{"nctId":3391,"briefTitle":3392,"status":103,"phases":6690,"primaryCompletion":3394,"completion":1149,"start":3395,"enrollment":3396,"conditions":6691,"interventions":6692},[87],[3398,3399],[61,1843,1510,2783],{"nctId":6694,"briefTitle":6695,"status":103,"phases":6696,"primaryCompletion":6697,"completion":6698,"start":6699,"enrollment":972,"conditions":6700,"interventions":6702},"NCT02426125","A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer",[87],"2017-04-21","2022-07-26","2015-07-13",[6701],"Urothelial Carcinoma",[61,1722],{"nctId":67,"briefTitle":68,"status":257,"phases":6704,"primaryCompletion":69,"completion":462,"start":6705,"enrollment":6706,"conditions":6707,"interventions":6709},[87],"2015-05-06",545,[6708],"Metastatic Non-Small Cell Lung Cancer",[61,1721,2959,6469],{"nctId":6711,"briefTitle":6712,"status":103,"phases":6713,"primaryCompletion":6714,"completion":6715,"start":6716,"enrollment":6717,"conditions":6718,"interventions":6719},"NCT01183780","A Study in Second Line Metastatic Colorectal Cancer",[87],"2014-07-17","2016-06-20","2010-12-02",1072,[1490],[61,1745,6720,2923],"Folinic Acid",{"trials":6722,"activeCount":97},[],{"trials":6724,"activeCount":97},[6725,6731],{"nctId":6726,"briefTitle":6727,"status":2032,"phases":6728,"conditions":6729,"interventions":6730},"NCT02307812","Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France",[],[3062,3399],[61,1669],{"nctId":6732,"briefTitle":6733,"status":2032,"phases":6734,"conditions":6735,"interventions":6738},"NCT02065765","International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer",[],[6736,6737],"Metastatic Gastric Cancer","Metastatic Adenocarcinoma of the Gastroesophageal Junction",[61],{"intervention":1669,"totalTrials":5922,"cells":6740},{"EARLY_PHASE1":6741,"PHASE1":6743,"PHASE2":6765,"PHASE3":6849,"PHASE4":6908,"NA":6910},{"trials":6742,"activeCount":97},[],{"trials":6744,"activeCount":947,"soonestReadout":462},[6745,6749,6753,6757,6761],{"nctId":2576,"briefTitle":2577,"status":103,"phases":6746,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":6747,"interventions":6748},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"nctId":6413,"briefTitle":6414,"status":103,"phases":6750,"primaryCompletion":3004,"completion":3004,"start":3029,"enrollment":1677,"conditions":6751,"interventions":6752},[85],[4540],[61,1669],{"nctId":6435,"briefTitle":6436,"status":999,"phases":6754,"primaryCompletion":5229,"completion":6438,"start":6439,"enrollment":28,"conditions":6755,"interventions":6756},[85],[2589],[6442,61,1669],{"nctId":2626,"briefTitle":2627,"status":393,"phases":6758,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":6759,"interventions":6760},[85],[2516,1717,1610,2632],[2634,1696,1510,1512,1612,1669,2519],{"nctId":1659,"briefTitle":1660,"status":257,"phases":6762,"primaryCompletion":462,"completion":462,"start":1662,"enrollment":1663,"conditions":6763,"interventions":6764},[85],[36],[1666,1468,1667,48,1668,1669],{"trials":6766,"activeCount":97},[6767,6771,6775,6779,6783,6787,6791,6795,6799,6803,6807,6813,6817,6821,6825,6829,6833,6837,6841,6845],{"nctId":3478,"briefTitle":3479,"status":384,"phases":6768,"primaryCompletion":3132,"completion":3132,"start":3132,"enrollment":97,"conditions":6769,"interventions":6770},[86],[2891,1589],[1541,1669,1512],{"nctId":6494,"briefTitle":6495,"status":103,"phases":6772,"primaryCompletion":6497,"completion":6498,"start":3515,"enrollment":6499,"conditions":6773,"interventions":6774},[86],[2604,3399],[61,1669],{"nctId":3484,"briefTitle":3485,"status":103,"phases":6776,"primaryCompletion":2956,"completion":3152,"start":3060,"enrollment":3487,"conditions":6777,"interventions":6778},[86],[1718],[1541,3054,1669,1512],{"nctId":4187,"briefTitle":4188,"status":103,"phases":6780,"primaryCompletion":3094,"completion":3419,"start":3524,"enrollment":28,"conditions":6781,"interventions":6782},[86],[1571],[2912,3222],{"nctId":3533,"briefTitle":3534,"status":103,"phases":6784,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":310,"conditions":6785,"interventions":6786},[85,86],[1589],[3540,3222,2561],{"nctId":3542,"briefTitle":3543,"status":103,"phases":6788,"primaryCompletion":3251,"completion":3545,"start":2930,"enrollment":3546,"conditions":6789,"interventions":6790},[86],[2584,3548,3549],[2979,2561,3222],{"nctId":3563,"briefTitle":3564,"status":103,"phases":6792,"completion":3566,"start":3567,"enrollment":1054,"conditions":6793,"interventions":6794},[86],[3569],[2912,2561,3222],{"nctId":6563,"briefTitle":6564,"status":103,"phases":6796,"primaryCompletion":6566,"completion":665,"start":6567,"enrollment":903,"conditions":6797,"interventions":6798},[86],[3398,3399],[61,2758,2520,1669],{"nctId":3597,"briefTitle":3598,"status":103,"phases":6800,"primaryCompletion":3524,"completion":3524,"start":2834,"enrollment":3041,"conditions":6801,"interventions":6802},[86],[2584,3601,3548],[3603,1669,1512],{"nctId":4263,"briefTitle":4264,"status":103,"phases":6804,"primaryCompletion":2995,"completion":2995,"start":4266,"enrollment":874,"conditions":6805,"interventions":6806},[86],[1571],[2912,3222],{"nctId":6808,"briefTitle":6809,"status":999,"phases":6810,"primaryCompletion":3338,"completion":3338,"start":3266,"enrollment":947,"conditions":6811,"interventions":6812},"NCT00536939","Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer",[86],[36],[3447,3054,1669],{"nctId":3625,"briefTitle":3626,"status":103,"phases":6814,"completion":3185,"start":3628,"enrollment":3095,"conditions":6815,"interventions":6816},[86],[3188],[1511,1512,1669],{"nctId":3642,"briefTitle":3643,"status":103,"phases":6818,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":3647,"conditions":6819,"interventions":6820},[86],[1610],[1541,1512,1669],{"nctId":3658,"briefTitle":3659,"status":103,"phases":6822,"primaryCompletion":3004,"completion":3661,"start":3662,"enrollment":2542,"conditions":6823,"interventions":6824},[86],[1694],[61,1669,1512],{"nctId":3681,"briefTitle":3682,"status":103,"phases":6826,"primaryCompletion":2917,"completion":3684,"start":3685,"enrollment":3686,"conditions":6827,"interventions":6828},[86],[1718],[2545,1669,1512],{"nctId":4439,"briefTitle":4440,"status":103,"phases":6830,"primaryCompletion":2846,"completion":2966,"start":3259,"enrollment":2919,"conditions":6831,"interventions":6832},[86],[36],[2912,3222,2560],{"nctId":6609,"briefTitle":6610,"status":103,"phases":6834,"primaryCompletion":1818,"completion":2024,"start":6612,"enrollment":118,"conditions":6835,"interventions":6836},[86],[2968],[6615,3222],{"nctId":3694,"briefTitle":3695,"status":103,"phases":6838,"primaryCompletion":3697,"completion":3698,"start":3068,"enrollment":2778,"conditions":6839,"interventions":6840},[86],[3700],[1591,1669,1512],{"nctId":4456,"briefTitle":4457,"status":103,"phases":6842,"completion":2930,"start":4459,"enrollment":2080,"conditions":6843,"interventions":6844},[86],[1893],[1511,1669,1722],{"nctId":3213,"briefTitle":3214,"status":103,"phases":6846,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":6847,"interventions":6848},[86],[36],[2912,3222,2561,2839],{"trials":6850,"activeCount":314,"soonestReadout":733},[6851,6855,6859,6863,6867,6871,6875,6879,6888,6892,6900],{"nctId":3315,"briefTitle":3316,"status":103,"phases":6852,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":3321,"conditions":6853,"interventions":6854},[87],[1694],[1612,1510,3324,1875,1669,1512],{"nctId":3757,"briefTitle":3758,"status":103,"phases":6856,"primaryCompletion":2955,"completion":2955,"start":3236,"enrollment":3760,"conditions":6857,"interventions":6858},[87],[3762,3548,2553,3763,3601],[1511,1669,1512],{"nctId":3773,"briefTitle":3774,"status":103,"phases":6860,"primaryCompletion":2864,"completion":3776,"start":2928,"enrollment":3330,"conditions":6861,"interventions":6862},[87],[1610],[1612,1612,1669,1512,3054,3054],{"nctId":6675,"briefTitle":6676,"status":103,"phases":6864,"primaryCompletion":6678,"completion":6679,"start":6680,"enrollment":5151,"conditions":6865,"interventions":6866},[87],[3399,2604],[61,1669],{"nctId":4597,"briefTitle":4598,"status":103,"phases":6868,"primaryCompletion":3012,"completion":3012,"start":2833,"enrollment":4600,"conditions":6869,"interventions":6870},[87],[4602],[1511,1722,1669],{"nctId":3787,"briefTitle":3788,"status":103,"phases":6872,"primaryCompletion":3645,"completion":3216,"start":2909,"enrollment":3790,"conditions":6873,"interventions":6874},[87],[2903],[1669,1722,1512,1541],{"nctId":3794,"briefTitle":3795,"status":393,"phases":6876,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":6877,"interventions":6878},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"nctId":6880,"briefTitle":6881,"status":999,"phases":6882,"primaryCompletion":3837,"completion":3837,"start":6883,"enrollment":6884,"conditions":6885,"interventions":6886},"NCT01006252","A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma",[87],"2009-12",336,[1732],[6887,1669],"Tasisulam-sodium",{"nctId":3817,"briefTitle":3818,"status":103,"phases":6889,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":6890,"interventions":6891},[87],[3825],[1612,1512,1669,3054],{"nctId":6893,"briefTitle":6894,"status":103,"phases":6895,"primaryCompletion":3027,"completion":5081,"start":3152,"enrollment":6896,"conditions":6897,"interventions":6898},"NCT01170663","A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma",[87],665,[3062],[6899,1669],"Ramucirumab (IMC-1211B) DP",{"nctId":6901,"briefTitle":6902,"status":103,"phases":6903,"completion":2856,"start":6904,"conditions":6905,"interventions":6906},"NCT00006459","Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer",[87],"2000-07",[36],[6907,3222],"gemcitabine hydrochloride",{"trials":6909,"activeCount":97},[],{"trials":6911,"activeCount":97},[6912],{"nctId":6726,"briefTitle":6727,"status":2032,"phases":6913,"conditions":6914,"interventions":6915},[],[3062,3399],[61,1669],{"intervention":303,"totalTrials":1548,"cells":6917},{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":7015,"PHASE3":7048,"PHASE4":7158,"NA":7187},{"trials":6919,"activeCount":97},[],{"trials":6921,"activeCount":314,"soonestReadout":420},[6922,6930,6937,6947,6953,6960,6967,6974,6983,6989,6997,7003,7011],{"nctId":6923,"briefTitle":6924,"status":103,"phases":6925,"primaryCompletion":5335,"completion":5335,"start":6926,"enrollment":6927,"conditions":6928,"interventions":6929},"NCT04641312","A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes",[85],"2020-11-25",67,[15,30],[283,303],{"nctId":6931,"briefTitle":6932,"status":103,"phases":6933,"primaryCompletion":4160,"completion":4160,"start":3494,"enrollment":165,"conditions":6934,"interventions":6935},"NCT01432938","A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants",[85],[18],[6936,1172],"dulaglutide",{"nctId":6938,"briefTitle":6939,"status":103,"phases":6940,"primaryCompletion":6941,"completion":6941,"start":6942,"enrollment":6943,"conditions":6944,"interventions":6945},"NCT04515576","A Study of LY3493269 in Participants With Type 2 Diabetes",[85],"2021-03-09","2020-08-25",56,[18],[6946,303],"LY3493269",{"nctId":6948,"briefTitle":6949,"status":103,"phases":6950,"primaryCompletion":3838,"completion":3838,"start":3886,"enrollment":2088,"conditions":6951,"interventions":6952},"NCT01524770","A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe",[85],[18],[303],{"nctId":6954,"briefTitle":6955,"status":257,"phases":6956,"primaryCompletion":420,"completion":420,"start":6957,"enrollment":1082,"conditions":6958,"interventions":6959},"NCT07313813","A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus",[85],"2025-12-29",[301],[303],{"nctId":6961,"briefTitle":6962,"status":103,"phases":6963,"primaryCompletion":3086,"completion":3086,"start":3004,"enrollment":6633,"conditions":6964,"interventions":6965},"NCT01458210","A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants",[85],[18],[6966,303],"Ortho-Cyclen",{"nctId":6968,"briefTitle":6969,"status":103,"phases":6970,"primaryCompletion":1520,"completion":1520,"start":6971,"enrollment":963,"conditions":6972,"interventions":6973},"NCT05407961","A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus",[85],"2022-06-07",[18],[403,303],{"nctId":6975,"briefTitle":6976,"status":103,"phases":6977,"primaryCompletion":6978,"completion":6978,"start":6979,"enrollment":1767,"conditions":6980,"interventions":6981},"NCT04143802","A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)",[85],"2020-12-28","2019-12-18",[18],[6982,303],"LY3437943",{"nctId":6984,"briefTitle":6985,"status":103,"phases":6986,"primaryCompletion":5354,"completion":5354,"start":2966,"enrollment":1189,"conditions":6987,"interventions":6988},"NCT01667900","A Study of Dulaglutide in Chinese Participants",[85],[18,21],[303],{"nctId":6990,"briefTitle":6991,"status":103,"phases":6992,"primaryCompletion":6993,"completion":6993,"start":6994,"enrollment":2071,"conditions":6995,"interventions":6996},"NCT03363906","A Study of Dulaglutide in Healthy Participants",[85],"2018-06-06","2017-12-07",[15],[303,303],{"nctId":6998,"briefTitle":6999,"status":103,"phases":7000,"primaryCompletion":5090,"completion":5090,"start":3494,"enrollment":290,"conditions":7001,"interventions":7002},"NCT01436201","A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants",[85],[18],[1093,303],{"nctId":7004,"briefTitle":7005,"status":103,"phases":7006,"primaryCompletion":7007,"completion":7007,"start":7008,"enrollment":1501,"conditions":7009,"interventions":7010},"NCT05377333","A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes",[85],"2023-11-22","2022-06-02",[18],[283,303],{"nctId":294,"briefTitle":295,"status":103,"phases":7012,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":7013,"interventions":7014},[85],[15,301],[92,303],{"trials":7016,"activeCount":97},[7017,7027,7035,7044],{"nctId":7018,"briefTitle":7019,"status":103,"phases":7020,"primaryCompletion":7021,"completion":7022,"start":7023,"enrollment":7024,"conditions":7025,"interventions":7026},"NCT04867785","A Study of LY3437943 in Participants With Type 2 Diabetes",[86],"2022-07-08","2022-10-27","2021-05-13",281,[30],[6982,303],{"nctId":7028,"briefTitle":7029,"status":103,"phases":7030,"primaryCompletion":7031,"completion":7032,"start":1627,"enrollment":366,"conditions":7033,"interventions":7034},"NCT02973100","A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy",[86],"2017-07-15","2017-08-14",[30],[303],{"nctId":7036,"briefTitle":7037,"status":103,"phases":7038,"primaryCompletion":1336,"completion":1336,"start":7039,"enrollment":7040,"conditions":7041,"interventions":7042},"NCT05048719","A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus",[86],"2021-09-15",383,[30],[7043,303],"LY3502970",{"nctId":361,"briefTitle":362,"status":103,"phases":7045,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":7046,"interventions":7047},[86],[120],[369,303],{"trials":7049,"activeCount":314,"soonestReadout":910},[7050,7057,7064,7072,7076,7084,7096,7105,7111,7119,7128,7134,7138,7148],{"nctId":7051,"briefTitle":7052,"status":393,"phases":7053,"primaryCompletion":910,"completion":910,"start":7054,"enrollment":224,"conditions":7055,"interventions":7056},"NCT06739122","A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)",[87],"2025-01-10",[30],[303],{"nctId":7058,"briefTitle":7059,"status":103,"phases":7060,"primaryCompletion":5081,"completion":5081,"start":4383,"enrollment":1358,"conditions":7061,"interventions":7062},"NCT02597049","A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus",[87],[120],[303,7063,1631],"SGLT2 inhibitor",{"nctId":7065,"briefTitle":7066,"status":103,"phases":7067,"primaryCompletion":3122,"completion":3122,"start":3545,"enrollment":7068,"conditions":7069,"interventions":7070},"NCT01644500","A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus",[87],737,[120],[303,7071],"Glimepiride",{"nctId":479,"briefTitle":480,"status":103,"phases":7073,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":7074,"interventions":7075},[87],[120],[92,303],{"nctId":7077,"briefTitle":7078,"status":103,"phases":7079,"primaryCompletion":1346,"completion":1346,"start":7080,"enrollment":7081,"conditions":7082,"interventions":7083},"NCT04591626","A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes",[87],"2020-12-07",291,[120],[303,506],{"nctId":7085,"briefTitle":7086,"status":103,"phases":7087,"primaryCompletion":7088,"completion":7089,"start":7090,"enrollment":7091,"conditions":7092,"interventions":7094},"NCT04809220","A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes",[87],"2022-10-01","2023-04-26","2021-04-13",591,[620,18,621,622,623,7093,301],"Hypoglycemic Agents",[303,7095],"Oral antihyperglycemics",{"nctId":7097,"briefTitle":7098,"status":103,"phases":7099,"primaryCompletion":2965,"completion":1627,"start":3545,"enrollment":7100,"conditions":7101,"interventions":7102},"NCT01621178","A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)",[87],577,[30,412],[303,7103,7104],"Insulin glargine","Insulin lispro",{"nctId":7106,"briefTitle":7107,"status":103,"phases":7108,"primaryCompletion":3776,"completion":3776,"start":3068,"enrollment":542,"conditions":7109,"interventions":7110},"NCT01769378","Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)",[87],[120],[303,7071],{"nctId":7112,"briefTitle":7113,"status":103,"phases":7114,"primaryCompletion":3122,"completion":3776,"start":3545,"enrollment":7115,"conditions":7116,"interventions":7117},"NCT01648582","A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus",[87],774,[120],[303,7103,1631,7118],"Sulfonylureas",{"nctId":7120,"briefTitle":7121,"status":103,"phases":7122,"primaryCompletion":1585,"completion":7123,"start":7124,"enrollment":7125,"conditions":7126,"interventions":7127},"NCT03495102","A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes",[87],"2019-10-10","2018-04-05",1842,[18],[303],{"nctId":7129,"briefTitle":7130,"status":103,"phases":7131,"primaryCompletion":3250,"completion":3250,"start":4098,"enrollment":542,"conditions":7132,"interventions":7133},"NCT02152371","A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes",[87],[18],[303,506,1631],{"nctId":662,"briefTitle":663,"status":103,"phases":7135,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":7136,"interventions":7137},[87],[30],[92,303],{"nctId":7139,"briefTitle":7140,"status":103,"phases":7141,"primaryCompletion":7142,"completion":7143,"start":7144,"enrollment":7145,"conditions":7146,"interventions":7147},"NCT02963766","A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes",[87],"2021-06-12","2022-01-12","2016-12-29",154,[30],[303],{"nctId":7149,"briefTitle":7150,"status":103,"phases":7151,"primaryCompletion":7152,"completion":7152,"start":7153,"enrollment":7154,"conditions":7155,"interventions":7157},"NCT01394952","Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)",[87],"2018-08-21","2011-07-22",9901,[7156,18],"Cardiovascular Disease",[303],{"trials":7159,"activeCount":97},[7160,7169,7177,7183],{"nctId":7161,"briefTitle":7162,"status":103,"phases":7163,"primaryCompletion":7164,"completion":7164,"start":7165,"enrollment":7166,"conditions":7167,"interventions":7168},"NCT05659537","A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India",[88],"2024-01-16","2022-12-29",212,[18],[303],{"nctId":7170,"briefTitle":7171,"status":103,"phases":7172,"primaryCompletion":7173,"completion":7173,"start":7174,"enrollment":2477,"conditions":7175,"interventions":7176},"NCT03315780","A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes",[88],"2018-02-28","2017-10-28",[30],[303],{"nctId":7178,"briefTitle":7179,"status":103,"phases":7180,"primaryCompletion":1035,"completion":1035,"start":1628,"enrollment":1859,"conditions":7181,"interventions":7182},"NCT02750410","A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes",[88],[30],[303],{"nctId":814,"briefTitle":815,"status":103,"phases":7184,"primaryCompletion":817,"completion":818,"start":819,"enrollment":820,"conditions":7185,"interventions":7186},[88],[30],[92,303],{"trials":7188,"activeCount":97},[],{"intervention":449,"totalTrials":864,"cells":7190},{"EARLY_PHASE1":7191,"PHASE1":7193,"PHASE2":7241,"PHASE3":7249,"PHASE4":7401,"NA":7442},{"trials":7192,"activeCount":97},[],{"trials":7194,"activeCount":97},[7195,7203,7211,7218,7226,7234],{"nctId":7196,"briefTitle":7197,"status":103,"phases":7198,"primaryCompletion":4383,"completion":3123,"start":1618,"enrollment":25,"conditions":7199,"interventions":7200},"NCT02543918","A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants",[85],[15],[449,7201,7202],"Boostrix®","Pneumovax®23",{"nctId":7204,"briefTitle":7205,"status":103,"phases":7206,"primaryCompletion":7207,"completion":7207,"start":7208,"enrollment":165,"conditions":7209,"interventions":7210},"NCT02993471","A Study of Ixekizumab in Participants With Plaque Psoriasis",[85],"2017-11-21","2016-12-22",[447],[867,449],{"nctId":7212,"briefTitle":7213,"status":103,"phases":7214,"primaryCompletion":7215,"completion":7215,"start":6208,"enrollment":4083,"conditions":7216,"interventions":7217},"NCT03848416","A Study of Ixekizumab in Healthy Participants",[85],"2019-06-07",[15],[449],{"nctId":7219,"briefTitle":7220,"status":103,"phases":7221,"primaryCompletion":7222,"completion":7222,"start":7223,"enrollment":310,"conditions":7224,"interventions":7225},"NCT03073213","A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris",[85],"2019-05-14","2017-04-13",[447],[449],{"nctId":7227,"briefTitle":7228,"status":103,"phases":7229,"primaryCompletion":7230,"completion":7230,"start":7231,"enrollment":6499,"conditions":7232,"interventions":7233},"NCT04259346","A Study of Two Formulations of Ixekizumab in Healthy Participants",[85],"2021-02-19","2020-02-05",[15],[449],{"nctId":7235,"briefTitle":7236,"status":999,"phases":7237,"primaryCompletion":7238,"completion":7238,"start":6208,"enrollment":2790,"conditions":7239,"interventions":7240},"NCT03848403","Study of Ixekizumab in Healthy Participants",[85],"2019-07-18",[15],[449],{"trials":7242,"activeCount":97},[7243],{"nctId":7244,"briefTitle":7245,"status":103,"phases":7246,"primaryCompletion":4258,"completion":1546,"start":3251,"enrollment":299,"conditions":7247,"interventions":7248},"NCT01107457","A Study in Participants With Moderate to Severe Psoriasis",[86],[447],[449],{"trials":7250,"activeCount":947,"soonestReadout":7303},[7251,7260,7264,7274,7282,7291,7299,7308,7312,7320,7327,7338,7347,7357,7367,7376,7386,7395],{"nctId":7252,"briefTitle":7253,"status":103,"phases":7254,"primaryCompletion":3776,"completion":7255,"start":4122,"enrollment":7256,"conditions":7257,"interventions":7259},"NCT01695239","A Study of Ixekizumab in Participants With Active Psoriatic Arthritis",[87],"2017-09",417,[7258],"Psoriasis, Arthritic",[449,5220],{"nctId":440,"briefTitle":441,"status":257,"phases":7261,"primaryCompletion":354,"completion":443,"start":444,"enrollment":445,"conditions":7262,"interventions":7263},[87],[447,24],[449,92],{"nctId":7265,"briefTitle":7266,"status":103,"phases":7267,"primaryCompletion":7268,"completion":7269,"start":7270,"enrollment":1109,"conditions":7271,"interventions":7273},"NCT02696798","A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis",[87],"2018-05-18","2019-05-03","2016-04-12",[7272],"Spondyloarthritis",[449],{"nctId":7275,"briefTitle":7276,"status":103,"phases":7277,"primaryCompletion":2754,"completion":7278,"start":1474,"enrollment":7279,"conditions":7280,"interventions":7281},"NCT02513550","A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis",[87],"2017-08-03",1257,[926],[449],{"nctId":7283,"briefTitle":7284,"status":103,"phases":7285,"primaryCompletion":7286,"completion":2985,"start":7287,"enrollment":7288,"conditions":7289,"interventions":7290},"NCT02696785","A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis",[87],"2017-12-08","2016-05-02",341,[7272],[449,5220],{"nctId":7292,"briefTitle":7293,"status":103,"phases":7294,"primaryCompletion":666,"completion":7295,"start":7296,"enrollment":3219,"conditions":7297,"interventions":7298},"NCT04285229","A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis",[87],"2022-03-17","2020-04-10",[7272],[449],{"nctId":7300,"briefTitle":7301,"status":257,"phases":7302,"primaryCompletion":7303,"completion":733,"start":7090,"enrollment":2670,"conditions":7304,"interventions":7307},"NCT04527380","A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis",[87],"2024-02-19",[7305,7306],"Juvenile Psoriatic Arthritis","Enthesitis Related Arthritis",[449,5220],{"nctId":547,"briefTitle":548,"status":103,"phases":7309,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":7310,"interventions":7311},[87],[555,24],[449,92],{"nctId":7313,"briefTitle":7314,"status":384,"phases":7315,"primaryCompletion":3028,"completion":3113,"start":7316,"enrollment":97,"conditions":7317,"interventions":7319},"NCT01870284","Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)",[87],"2014-07",[7318],"Spondylitis, Ankylosing",[449,5220],{"nctId":7321,"briefTitle":7322,"status":103,"phases":7323,"primaryCompletion":2799,"completion":7324,"start":3250,"enrollment":4675,"conditions":7325,"interventions":7326},"NCT02561806","A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis",[87],"2017-10",[926],[449,1049],{"nctId":7328,"briefTitle":7329,"status":103,"phases":7330,"primaryCompletion":7331,"completion":7332,"start":7333,"enrollment":7334,"conditions":7335,"interventions":7337},"NCT03129100","A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis",[87],"2020-05-26","2021-05-27","2017-05-09",773,[7336],"Axial Spondyloarthritis",[449],{"nctId":7339,"briefTitle":7340,"status":103,"phases":7341,"primaryCompletion":7342,"completion":7342,"start":7343,"enrollment":7344,"conditions":7345,"interventions":7346},"NCT02584855","A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis",[87],"2018-10-30","2015-09-14",394,[555],[449],{"nctId":7348,"briefTitle":7349,"status":103,"phases":7350,"primaryCompletion":1266,"completion":7351,"start":7352,"enrollment":7353,"conditions":7354,"interventions":7355},"NCT03073200","Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis",[87],"2021-03-23","2017-03-28",201,[926],[449,7356],"Etanercept",{"nctId":7358,"briefTitle":7359,"status":103,"phases":7360,"primaryCompletion":7361,"completion":7362,"start":3028,"enrollment":7363,"conditions":7364,"interventions":7366},"NCT02718898","A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis",[87],"2017-02-22","2018-02-21",149,[7365,447],"Genital Psoriasis",[449],{"nctId":7368,"briefTitle":7369,"status":103,"phases":7370,"primaryCompletion":7371,"completion":667,"start":7372,"enrollment":7373,"conditions":7374,"interventions":7375},"NCT02757352","A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis",[87],"2019-03-01","2016-08-02",303,[7336],[449],{"nctId":7377,"briefTitle":7378,"status":103,"phases":7379,"primaryCompletion":7380,"completion":7381,"start":7382,"enrollment":1730,"conditions":7383,"interventions":7384},"NCT02634801","A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment",[87],"2016-11-29","2017-11-14","2016-01-20",[926],[7385,5095,449],"Fumaric Acid Esters",{"nctId":7387,"briefTitle":7388,"status":103,"phases":7389,"primaryCompletion":7390,"completion":7390,"start":7391,"enrollment":7392,"conditions":7393,"interventions":7394},"NCT03364309","A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis",[87],"2020-06-04","2018-04-26",438,[926],[449],{"nctId":7396,"briefTitle":7397,"status":103,"phases":7398,"primaryCompletion":1618,"completion":1628,"start":3697,"enrollment":2477,"conditions":7399,"interventions":7400},"NCT02387801","A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis",[87],[447],[449],{"trials":7402,"activeCount":97},[7403,7413,7422,7432],{"nctId":7404,"briefTitle":7405,"status":103,"phases":7406,"primaryCompletion":7407,"completion":7408,"start":1837,"enrollment":7409,"conditions":7410,"interventions":7411},"NCT03573323","A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis",[88],"2019-07-15","2020-01-08",1027,[926],[449,7412],"Guselkumab",{"nctId":7414,"briefTitle":7415,"status":103,"phases":7416,"primaryCompletion":7417,"completion":7418,"start":7419,"enrollment":445,"conditions":7420,"interventions":7421},"NCT05855967","A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India",[88],"2024-08-08","2024-09-23","2023-06-27",[926,555],[449],{"nctId":7423,"briefTitle":7424,"status":103,"phases":7425,"primaryCompletion":7426,"completion":7426,"start":7427,"enrollment":2477,"conditions":7428,"interventions":7431},"NCT03942042","A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis",[88],"2020-07-22","2019-07-05",[7429,7430],"Generalized Pustular Psoriasis","Erythrodermic Psoriasis",[449],{"nctId":7433,"briefTitle":7434,"status":103,"phases":7435,"primaryCompletion":7436,"completion":7437,"start":7438,"enrollment":7439,"conditions":7440,"interventions":7441},"NCT03151551","A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis",[88],"2018-11-15","2019-09-04","2017-08-24",566,[555],[449,5220],{"trials":7443,"activeCount":97},[],{"intervention":7445,"totalTrials":12,"cells":7446},"Galcanezumab",{"EARLY_PHASE1":7447,"PHASE1":7449,"PHASE2":7476,"PHASE3":7497,"PHASE4":7596,"NA":7617},{"trials":7448,"activeCount":97},[],{"trials":7450,"activeCount":97},[7451,7458,7466],{"nctId":7452,"briefTitle":7453,"status":103,"phases":7454,"primaryCompletion":7455,"completion":5071,"start":1546,"enrollment":5729,"conditions":7456,"interventions":7457},"NCT02836613","A Study of Galcanezumab in Healthy Participants.",[85],"2017-02-27",[15],[7445],{"nctId":7459,"briefTitle":7460,"status":103,"phases":7461,"primaryCompletion":7462,"completion":7462,"start":7463,"enrollment":1620,"conditions":7464,"interventions":7465},"NCT04085289","A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants",[85],"2020-05-21","2019-11-20",[15],[7445],{"nctId":7467,"briefTitle":7468,"status":103,"phases":7469,"primaryCompletion":7470,"completion":7471,"start":7472,"enrollment":7473,"conditions":7474,"interventions":7475},"NCT02576951","A Study of Galcanezumab in Healthy Participants",[85],"2016-09-03","2018-01-08","2015-10-19",178,[15],[7445],{"trials":7477,"activeCount":97},[7478,7488],{"nctId":7479,"briefTitle":7480,"status":103,"phases":7481,"primaryCompletion":7482,"completion":7482,"start":7483,"enrollment":7484,"conditions":7485,"interventions":7487},"NCT02959177","A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine",[86],"2019-01-18","2016-11-09",459,[7486],"Migraine",[7445],{"nctId":7489,"briefTitle":7490,"status":103,"phases":7491,"primaryCompletion":7492,"completion":1826,"start":7493,"enrollment":357,"conditions":7494,"interventions":7496},"NCT02163993","A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache",[86],"2015-08-19","2014-07-07",[7495],"Migraine Headache",[7445],{"trials":7498,"activeCount":947,"soonestReadout":2437},[7499,7508,7517,7526,7535,7542,7552,7560,7569,7578,7586],{"nctId":7500,"briefTitle":7501,"status":103,"phases":7502,"primaryCompletion":1033,"completion":1033,"start":7503,"enrollment":3647,"conditions":7504,"interventions":7507},"NCT02797951","A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache",[87],"2016-07-13",[7505,7506],"Episodic Cluster Headache","Chronic Cluster Headache",[7445],{"nctId":7509,"briefTitle":7510,"status":103,"phases":7511,"primaryCompletion":7512,"completion":7512,"start":7513,"enrollment":7514,"conditions":7515,"interventions":7516},"NCT02959190","A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine",[87],"2019-08-10","2017-02-07",311,[7486],[7445],{"nctId":7518,"briefTitle":7519,"status":257,"phases":7520,"primaryCompletion":7521,"completion":2283,"start":6926,"enrollment":7522,"conditions":7523,"interventions":7525},"NCT04616326","A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine",[87],"2025-12-10",312,[7524],"Chronic Migraine",[7445],{"nctId":7527,"briefTitle":7528,"status":103,"phases":7529,"primaryCompletion":7530,"completion":1923,"start":677,"enrollment":7531,"conditions":7532,"interventions":7534},"NCT03963232","A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine",[87],"2021-07-27",520,[7533],"Episodic Migraine",[7445],{"nctId":7536,"briefTitle":7537,"status":257,"phases":7538,"primaryCompletion":2437,"completion":259,"start":7539,"enrollment":2100,"conditions":7540,"interventions":7541},"NCT03432286","A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine",[87],"2018-03-14",[7533],[7445],{"nctId":7543,"briefTitle":7544,"status":103,"phases":7545,"primaryCompletion":7546,"completion":7547,"start":7548,"enrollment":7549,"conditions":7550,"interventions":7551},"NCT02614287","A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura",[87],"2017-05-12","2018-08-14","2015-11-30",270,[7486],[7445],{"nctId":7553,"briefTitle":7554,"status":103,"phases":7555,"primaryCompletion":1826,"completion":7556,"start":7557,"enrollment":3051,"conditions":7558,"interventions":7559},"NCT02397473","A Study Of Galcanezumab In Participants With Episodic Cluster Headache",[87],"2018-06-04","2015-05-22",[7505],[7445],{"nctId":7561,"briefTitle":7562,"status":103,"phases":7563,"primaryCompletion":7564,"completion":7565,"start":7566,"enrollment":1995,"conditions":7567,"interventions":7568},"NCT03559257","A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine",[87],"2019-06-19","2019-09-19","2018-07-31",[7486],[7445],{"nctId":7570,"briefTitle":7571,"status":103,"phases":7572,"primaryCompletion":7573,"completion":7574,"start":7548,"enrollment":7575,"conditions":7576,"interventions":7577},"NCT02614261","Evaluation of Galcanezumab in the Prevention of Chronic Migraine",[87],"2017-03-16","2021-07-14",1117,[7524],[7445],{"nctId":7579,"briefTitle":7580,"status":103,"phases":7581,"primaryCompletion":7582,"completion":1498,"start":7548,"enrollment":7583,"conditions":7584,"interventions":7585},"NCT02614183","Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study",[87],"2017-03-22",862,[7486],[7445],{"nctId":7587,"briefTitle":7588,"status":103,"phases":7589,"primaryCompletion":7590,"completion":7591,"start":7592,"enrollment":7593,"conditions":7594,"interventions":7595},"NCT02614196","Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study",[87],"2017-03-29","2018-10-05","2015-12-04",986,[7486],[7445],{"trials":7597,"activeCount":97},[7598,7608],{"nctId":7599,"briefTitle":7600,"status":103,"phases":7601,"primaryCompletion":7602,"completion":7602,"start":7603,"enrollment":7604,"conditions":7605,"interventions":7606},"NCT05127486","A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine",[88],"2023-05-23","2021-12-06",580,[7486,7533],[7445,7607],"Rimegepant",{"nctId":7609,"briefTitle":7610,"status":103,"phases":7611,"primaryCompletion":7612,"completion":7612,"start":7613,"enrollment":156,"conditions":7614,"interventions":7615},"NCT04294147","A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist",[88],"2021-03-05","2020-10-06",[7486],[7445,7616],"Erenumab",{"trials":7618,"activeCount":97},[],{"intervention":5220,"totalTrials":1054,"cells":7620},{"EARLY_PHASE1":7621,"PHASE1":7623,"PHASE2":7625,"PHASE3":7627,"PHASE4":7653,"NA":7659},{"trials":7622,"activeCount":97},[],{"trials":7624,"activeCount":97},[],{"trials":7626,"activeCount":97},[],{"trials":7628,"activeCount":947,"soonestReadout":154},[7629,7633,7637,7641,7645,7649],{"nctId":7252,"briefTitle":7253,"status":103,"phases":7630,"primaryCompletion":3776,"completion":7255,"start":4122,"enrollment":7256,"conditions":7631,"interventions":7632},[87],[7258],[449,5220],{"nctId":7283,"briefTitle":7284,"status":103,"phases":7634,"primaryCompletion":7286,"completion":2985,"start":7287,"enrollment":7288,"conditions":7635,"interventions":7636},[87],[7272],[449,5220],{"nctId":5213,"briefTitle":5214,"status":103,"phases":7638,"primaryCompletion":1596,"completion":1618,"start":2798,"enrollment":5216,"conditions":7639,"interventions":7640},[87],[5218],[5220,4944,5095,5221,5222],{"nctId":7300,"briefTitle":7301,"status":257,"phases":7642,"primaryCompletion":7303,"completion":733,"start":7090,"enrollment":2670,"conditions":7643,"interventions":7644},[87],[7305,7306],[449,5220],{"nctId":7313,"briefTitle":7314,"status":384,"phases":7646,"primaryCompletion":3028,"completion":3113,"start":7316,"enrollment":97,"conditions":7647,"interventions":7648},[87],[7318],[449,5220],{"nctId":5295,"briefTitle":5296,"status":257,"phases":7650,"primaryCompletion":154,"completion":4014,"start":5298,"enrollment":1620,"conditions":7651,"interventions":7652},[87],[5300],[4944,5220],{"trials":7654,"activeCount":97},[7655],{"nctId":7433,"briefTitle":7434,"status":103,"phases":7656,"primaryCompletion":7436,"completion":7437,"start":7438,"enrollment":7439,"conditions":7657,"interventions":7658},[88],[555],[449,5220],{"trials":7660,"activeCount":97},[],{"intervention":3054,"totalTrials":1062,"cells":7662},{"EARLY_PHASE1":7663,"PHASE1":7665,"PHASE2":7679,"PHASE3":7725,"PHASE4":7739,"NA":7741},{"trials":7664,"activeCount":97},[],{"trials":7666,"activeCount":314,"soonestReadout":853},[7667,7671],{"nctId":2547,"briefTitle":2548,"status":393,"phases":7668,"primaryCompletion":853,"completion":1011,"start":2550,"enrollment":2551,"conditions":7669,"interventions":7670},[85],[2553,2505,2554,1589,2555,2556,2557],[2559,2560,2561,2562,2563],{"nctId":7672,"briefTitle":7673,"status":103,"phases":7674,"primaryCompletion":3419,"completion":2898,"start":2930,"enrollment":137,"conditions":7675,"interventions":7677},"NCT00550927","Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer",[85],[7676],"Unspecified Adult Solid Tumor, Protocol Specific",[2560,7678],"enzastaurin hydrochloride",{"trials":7680,"activeCount":97},[7681,7687,7691,7695,7705,7709,7713,7717,7721],{"nctId":7682,"briefTitle":7683,"status":103,"phases":7684,"primaryCompletion":3685,"completion":5090,"start":3094,"enrollment":195,"conditions":7685,"interventions":7686},"NCT00612586","Study of Enzastaurin With 5-Fluorouracil\u002FLeucovorin (5-FU\u002FLV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer",[86],[1490],[3447,2521,4137,3054],{"nctId":3484,"briefTitle":3485,"status":103,"phases":7688,"primaryCompletion":2956,"completion":3152,"start":3060,"enrollment":3487,"conditions":7689,"interventions":7690},[86],[1718],[1541,3054,1669,1512],{"nctId":3579,"briefTitle":3580,"status":103,"phases":7692,"primaryCompletion":3103,"completion":3103,"start":3235,"enrollment":233,"conditions":7693,"interventions":7694},[86],[1610],[2979,2838,2561,2560],{"nctId":7696,"briefTitle":7697,"status":103,"phases":7698,"primaryCompletion":4955,"completion":4955,"start":3266,"enrollment":7699,"conditions":7700,"interventions":7702},"NCT00586508","Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas",[86],81,[7701],"Recurrent Glioblastoma",[2979,2560,7703,7704],"Enzyme-inducing antiepileptic drugs","Non-enzyme inducing antiepileptic drugs",{"nctId":4255,"briefTitle":4256,"status":103,"phases":7706,"primaryCompletion":4258,"completion":4258,"start":3338,"enrollment":251,"conditions":7707,"interventions":7708},[86],[1571,4260],[1511,3054],{"nctId":6808,"briefTitle":6809,"status":999,"phases":7710,"primaryCompletion":3338,"completion":3338,"start":3266,"enrollment":947,"conditions":7711,"interventions":7712},[86],[36],[3447,3054,1669],{"nctId":3045,"briefTitle":3046,"status":103,"phases":7714,"primaryCompletion":3048,"completion":3049,"start":3050,"enrollment":3051,"conditions":7715,"interventions":7716},[86],[1718],[1612,1510,3054],{"nctId":4439,"briefTitle":4440,"status":103,"phases":7718,"primaryCompletion":2846,"completion":2966,"start":3259,"enrollment":2919,"conditions":7719,"interventions":7720},[86],[36],[2912,3222,2560],{"nctId":4501,"briefTitle":4502,"status":999,"phases":7722,"primaryCompletion":3132,"completion":2928,"start":3259,"enrollment":3125,"conditions":7723,"interventions":7724},[86],[4317],[3540,2560,2912,3540],{"trials":7726,"activeCount":314,"soonestReadout":733},[7727,7731,7735],{"nctId":3773,"briefTitle":3774,"status":103,"phases":7728,"primaryCompletion":2864,"completion":3776,"start":2928,"enrollment":3330,"conditions":7729,"interventions":7730},[87],[1610],[1612,1612,1669,1512,3054,3054],{"nctId":3794,"briefTitle":3795,"status":393,"phases":7732,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":7733,"interventions":7734},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"nctId":3817,"briefTitle":3818,"status":103,"phases":7736,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":7737,"interventions":7738},[87],[3825],[1612,1512,1669,3054],{"trials":7740,"activeCount":97},[],{"trials":7742,"activeCount":97},[],{"intervention":1721,"totalTrials":205,"cells":7744},{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7769,"PHASE3":7804,"PHASE4":7814,"NA":7816},{"trials":7746,"activeCount":97},[],{"trials":7748,"activeCount":97},[7749,7757,7761],{"nctId":7750,"briefTitle":7751,"status":999,"phases":7752,"primaryCompletion":3020,"completion":3020,"start":3419,"enrollment":864,"conditions":7753,"interventions":7755},"NCT01115803","A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors",[85],[5763,1706,2585,7754],"Neuroendocrine Tumors",[7756,1721,1575],"LY2584702",{"nctId":2795,"briefTitle":2796,"status":999,"phases":7758,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":1808,"conditions":7759,"interventions":7760},[85],[2802],[1511,1722,1746,1510,1721,2804],{"nctId":7762,"briefTitle":7763,"status":103,"phases":7764,"primaryCompletion":3122,"completion":3122,"start":3838,"enrollment":1237,"conditions":7765,"interventions":7767},"NCT01602289","A Study of LY2875358 in Japanese Participants With Advanced Cancer",[85],[2589,7766,1589],"Lymphoma",[7768,1721,2959],"LY2875358",{"trials":7770,"activeCount":97},[7771,7778,7782,7788,7796,7800],{"nctId":7772,"briefTitle":7773,"status":103,"phases":7774,"primaryCompletion":1473,"completion":7775,"start":2917,"enrollment":335,"conditions":7776,"interventions":7777},"NCT01900652","A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants",[86],"2016-03",[1589],[6513,1721],{"nctId":1711,"briefTitle":1712,"status":999,"phases":7779,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":425,"conditions":7780,"interventions":7781},[85,86],[1717,1718,1490],[1720,48,1541,1721,1722],{"nctId":7783,"briefTitle":7784,"status":103,"phases":7785,"primaryCompletion":3059,"completion":4980,"start":3005,"enrollment":156,"conditions":7786,"interventions":7787},"NCT00452413","A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer",[85,86],[1718,2968],[2979,5810],{"nctId":7789,"briefTitle":7790,"status":103,"phases":7791,"primaryCompletion":7792,"completion":354,"start":7793,"enrollment":6549,"conditions":7794,"interventions":7795},"NCT01897480","A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations",[86],"2016-03-14","2013-08-28",[1589],[7768,1721],{"nctId":5804,"briefTitle":5805,"status":103,"phases":7797,"primaryCompletion":3661,"completion":3661,"start":3266,"enrollment":5807,"conditions":7798,"interventions":7799},[86],[2849],[2838,5810],{"nctId":5838,"briefTitle":5839,"status":103,"phases":7801,"primaryCompletion":2899,"completion":3020,"start":4642,"enrollment":5841,"conditions":7802,"interventions":7803},[86],[5843],[1612,1721,1612,1721],{"trials":7805,"activeCount":947,"soonestReadout":56},[7806,7810],{"nctId":54,"briefTitle":55,"status":257,"phases":7807,"primaryCompletion":56,"completion":462,"start":1953,"enrollment":1954,"conditions":7808,"interventions":7809},[87],[1694],[48,1721],{"nctId":67,"briefTitle":68,"status":257,"phases":7811,"primaryCompletion":69,"completion":462,"start":6705,"enrollment":6706,"conditions":7812,"interventions":7813},[87],[6708],[61,1721,2959,6469],{"trials":7815,"activeCount":97},[],{"trials":7817,"activeCount":97},[],{"intervention":2655,"totalTrials":4323,"cells":7819},{"EARLY_PHASE1":7820,"PHASE1":7822,"PHASE2":7873,"PHASE3":7879,"PHASE4":7885,"NA":7887},{"trials":7821,"activeCount":97},[],{"trials":7823,"activeCount":97},[7824,7832,7840,7848,7857,7865],{"nctId":7825,"briefTitle":7826,"status":103,"phases":7827,"primaryCompletion":7828,"completion":7828,"start":2181,"enrollment":1071,"conditions":7829,"interventions":7830},"NCT05901311","A Study of [14C]-LY3537982 in Healthy Participants",[85],"2023-08-10",[15],[2655,7831,7831],"[¹⁴C]-LY3537982",{"nctId":7833,"briefTitle":7834,"status":103,"phases":7835,"primaryCompletion":7836,"completion":7836,"start":7837,"enrollment":310,"conditions":7838,"interventions":7839},"NCT07137689","A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function",[85],"2026-04-10","2025-08-18",[147],[2655],{"nctId":7841,"briefTitle":7842,"status":103,"phases":7843,"primaryCompletion":7844,"completion":7844,"start":7845,"enrollment":1548,"conditions":7846,"interventions":7847},"NCT06111521","A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants",[85],"2024-04-01","2023-10-27",[15],[2655,1093,2093,1538,1538],{"nctId":7849,"briefTitle":7850,"status":103,"phases":7851,"primaryCompletion":7852,"completion":7853,"start":7854,"enrollment":2477,"conditions":7855,"interventions":7856},"NCT06235983","A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors",[85],"2025-07-02","2026-03-30","2024-02-29",[2802],[2655],{"nctId":7858,"briefTitle":7859,"status":103,"phases":7860,"primaryCompletion":7861,"completion":7861,"start":7862,"enrollment":118,"conditions":7863,"interventions":7864},"NCT05824858","A Study of the Effect of Food on LY3537982 in Healthy Participants",[85],"2023-06-17","2023-04-12",[15],[2655],{"nctId":7866,"briefTitle":7867,"status":103,"phases":7868,"primaryCompletion":7869,"completion":7869,"start":7870,"enrollment":1620,"conditions":7871,"interventions":7872},"NCT05860933","A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants",[85],"2023-08-28","2023-05-08",[15],[2655,2562,2065],{"trials":7874,"activeCount":314,"soonestReadout":1011},[7875],{"nctId":2646,"briefTitle":2647,"status":257,"phases":7876,"primaryCompletion":1011,"completion":1011,"start":2649,"enrollment":2650,"conditions":7877,"interventions":7878},[85,86],[1589,2557,2505,2553,2652,2653],[2655,1696,1541,1612,1510,1512],{"trials":7880,"activeCount":314,"soonestReadout":765},[7881],{"nctId":2708,"briefTitle":2709,"status":393,"phases":7882,"primaryCompletion":765,"completion":2130,"start":2711,"enrollment":2712,"conditions":7883,"interventions":7884},[87],[1589,1478],[2655,1696,1510,1512,1612],{"trials":7886,"activeCount":97},[],{"trials":7888,"activeCount":97},[],{"intervention":198,"totalTrials":1054,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7903,"PHASE3":7914,"PHASE4":7932,"NA":7934},{"trials":7892,"activeCount":97},[],{"trials":7894,"activeCount":314,"soonestReadout":259},[7895,7899],{"nctId":190,"briefTitle":191,"status":103,"phases":7896,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":7897,"interventions":7898},[85],[18],[92,198],{"nctId":2344,"briefTitle":2345,"status":393,"phases":7900,"primaryCompletion":259,"completion":259,"start":2099,"enrollment":2347,"conditions":7901,"interventions":7902},[85],[620,2349],[610,198],{"trials":7904,"activeCount":97},[7905],{"nctId":7906,"briefTitle":7907,"status":103,"phases":7908,"primaryCompletion":4036,"completion":7909,"start":7910,"enrollment":7911,"conditions":7912,"interventions":7913},"NCT05616013","Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese",[86],"2025-06-14","2022-11-16",507,[24,2090,778],[177,198],{"trials":7915,"activeCount":314,"soonestReadout":420},[7916,7920,7924,7928],{"nctId":2394,"briefTitle":2395,"status":257,"phases":7917,"primaryCompletion":420,"completion":322,"start":2397,"enrollment":2398,"conditions":7918,"interventions":7919},[87],[18],[610,198],{"nctId":2247,"briefTitle":2248,"status":103,"phases":7921,"primaryCompletion":2250,"completion":2250,"start":2251,"enrollment":2252,"conditions":7922,"interventions":7923},[87],[30],[2043,198],{"nctId":672,"briefTitle":673,"status":103,"phases":7925,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":7926,"interventions":7927},[87],[30],[92,198],{"nctId":738,"briefTitle":739,"status":103,"phases":7929,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":7930,"interventions":7931},[87],[24,27],[92,198],{"trials":7933,"activeCount":97},[],{"trials":7935,"activeCount":97},[],{"intervention":2696,"totalTrials":425,"cells":7937},{"EARLY_PHASE1":7938,"PHASE1":7940,"PHASE2":7971,"PHASE3":7973,"PHASE4":7979,"NA":7981},{"trials":7939,"activeCount":97},[],{"trials":7941,"activeCount":314,"soonestReadout":154},[7942,7946,7956,7964],{"nctId":2760,"briefTitle":2761,"status":257,"phases":7943,"primaryCompletion":154,"completion":443,"start":2763,"enrollment":776,"conditions":7944,"interventions":7945},[85],[1505,2765,1850,2766],[2768,1511,1510,2696],{"nctId":7947,"briefTitle":7948,"status":103,"phases":7949,"primaryCompletion":7950,"completion":7950,"start":7951,"enrollment":1767,"conditions":7952,"interventions":7953},"NCT02718911","A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors",[85],"2018-12-14","2016-06-16",[1503],[7954,2696,7955],"LY3022855","Tremelimumab",{"nctId":7957,"briefTitle":7958,"status":103,"phases":7959,"primaryCompletion":5141,"completion":7960,"start":7961,"enrollment":5922,"conditions":7962,"interventions":7963},"NCT02734160","A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer",[85],"2019-04-17","2016-06-15",[4317],[4387,2696],{"nctId":7965,"briefTitle":7966,"status":999,"phases":7967,"primaryCompletion":7968,"completion":7968,"start":6390,"enrollment":3293,"conditions":7969,"interventions":7970},"NCT02737072","A Study of LY2510924 and Durvalumab in Participants With Solid Tumors",[85],"2017-09-25",[1503],[3498,2696],{"trials":7972,"activeCount":97},[],{"trials":7974,"activeCount":314,"soonestReadout":1911},[7975],{"nctId":2687,"briefTitle":2688,"status":393,"phases":7976,"primaryCompletion":1911,"completion":2690,"start":2691,"enrollment":2692,"conditions":7977,"interventions":7978},[87],[1589],[2695,1696,2696],{"trials":7980,"activeCount":97},[],{"trials":7982,"activeCount":97},[],{"intervention":1917,"totalTrials":1232,"cells":7984},{"EARLY_PHASE1":7985,"PHASE1":7987,"PHASE2":8005,"PHASE3":8007,"PHASE4":8013,"NA":8015},{"trials":7986,"activeCount":97},[],{"trials":7988,"activeCount":314,"soonestReadout":443},[7989,7997],{"nctId":7990,"briefTitle":7991,"status":257,"phases":7992,"primaryCompletion":443,"completion":443,"start":7993,"enrollment":4323,"conditions":7994,"interventions":7995},"NCT07519525","A Study of [14C]-LY4064809 in Healthy Participants",[85],"2026-03-27",[15],[1917,7996],"[14C]-LY4064809",{"nctId":7998,"briefTitle":7999,"status":103,"phases":8000,"primaryCompletion":8001,"completion":8001,"start":8002,"enrollment":757,"conditions":8003,"interventions":8004},"NCT07247357","A Study of LY4064809 in Healthy Adult Chinese Participants",[85],"2025-12-16","2025-10-24",[15],[1917],{"trials":8006,"activeCount":97},[],{"trials":8008,"activeCount":314,"soonestReadout":1911},[8009],{"nctId":1908,"briefTitle":1909,"status":393,"phases":8010,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":8011,"interventions":8012},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"trials":8014,"activeCount":97},[],{"trials":8016,"activeCount":97},[],{"intervention":8018,"totalTrials":947,"cells":8019},"Lepodisiran",{"EARLY_PHASE1":8020,"PHASE1":8022,"PHASE2":8032,"PHASE3":8034,"PHASE4":8044,"NA":8046},{"trials":8021,"activeCount":97},[],{"trials":8023,"activeCount":314,"soonestReadout":420},[8024],{"nctId":8025,"briefTitle":8026,"status":393,"phases":8027,"primaryCompletion":420,"completion":420,"start":8028,"enrollment":5015,"conditions":8029,"interventions":8031},"NCT06916078","A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function",[85],"2025-04-23",[8030,15],"Liver Dysfunction",[8018],{"trials":8033,"activeCount":97},[],{"trials":8035,"activeCount":314,"soonestReadout":1280},[8036],{"nctId":8037,"briefTitle":8038,"status":1060,"phases":8039,"primaryCompletion":1280,"completion":1280,"start":443,"enrollment":324,"conditions":8040,"interventions":8043},"NCT07613294","A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk",[87],[8041,2307,8042],"Atherosclerosis","Lipoprotein(a)",[8018],{"trials":8045,"activeCount":97},[],{"trials":8047,"activeCount":97},[],{"intervention":1758,"totalTrials":947,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8054,"PHASE3":8060,"PHASE4":8066,"NA":8068},{"trials":8051,"activeCount":97},[],{"trials":8053,"activeCount":97},[],{"trials":8055,"activeCount":314,"soonestReadout":1751},[8056],{"nctId":1748,"briefTitle":1749,"status":393,"phases":8057,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":8058,"interventions":8059},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"trials":8061,"activeCount":314,"soonestReadout":1911},[8062],{"nctId":1908,"briefTitle":1909,"status":393,"phases":8063,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":8064,"interventions":8065},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"trials":8067,"activeCount":97},[],{"trials":8069,"activeCount":97},[],{"intervention":1759,"totalTrials":947,"cells":8071},{"EARLY_PHASE1":8072,"PHASE1":8074,"PHASE2":8076,"PHASE3":8082,"PHASE4":8088,"NA":8090},{"trials":8073,"activeCount":97},[],{"trials":8075,"activeCount":97},[],{"trials":8077,"activeCount":314,"soonestReadout":1751},[8078],{"nctId":1748,"briefTitle":1749,"status":393,"phases":8079,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":8080,"interventions":8081},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"trials":8083,"activeCount":314,"soonestReadout":1911},[8084],{"nctId":1908,"briefTitle":1909,"status":393,"phases":8085,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":8086,"interventions":8087},[87],[1893,1478],[1917,1758,1759,48,1697,1613,1760,1468],{"trials":8089,"activeCount":97},[],{"trials":8091,"activeCount":97},[],{"intervention":8093,"totalTrials":947,"cells":8094},"LY3650150",{"EARLY_PHASE1":8095,"PHASE1":8097,"PHASE2":8099,"PHASE3":8101,"PHASE4":8121,"NA":8123},{"trials":8096,"activeCount":97},[],{"trials":8098,"activeCount":97},[],{"trials":8100,"activeCount":97},[],{"trials":8102,"activeCount":947,"soonestReadout":408},[8103,8113],{"nctId":8104,"briefTitle":8105,"status":393,"phases":8106,"primaryCompletion":940,"completion":1993,"start":8107,"enrollment":8108,"conditions":8109,"interventions":8111},"NCT06338995","A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)",[87],"2024-04-29",510,[8110],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",[8093,8112],"Standard therapy for INCS",{"nctId":8114,"briefTitle":8115,"status":393,"phases":8116,"primaryCompletion":408,"completion":2446,"start":8117,"enrollment":855,"conditions":8118,"interventions":8120},"NCT06339008","A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)",[87],"2024-04-26",[8119],"Perennial Allergic Rhinitis (PAR)",[8093,8112],{"trials":8122,"activeCount":97},[],{"trials":8124,"activeCount":97},[],{"intervention":8112,"totalTrials":947,"cells":8126},{"EARLY_PHASE1":8127,"PHASE1":8129,"PHASE2":8131,"PHASE3":8133,"PHASE4":8143,"NA":8145},{"trials":8128,"activeCount":97},[],{"trials":8130,"activeCount":97},[],{"trials":8132,"activeCount":97},[],{"trials":8134,"activeCount":947,"soonestReadout":408},[8135,8139],{"nctId":8104,"briefTitle":8105,"status":393,"phases":8136,"primaryCompletion":940,"completion":1993,"start":8107,"enrollment":8108,"conditions":8137,"interventions":8138},[87],[8110],[8093,8112],{"nctId":8114,"briefTitle":8115,"status":393,"phases":8140,"primaryCompletion":408,"completion":2446,"start":8117,"enrollment":855,"conditions":8141,"interventions":8142},[87],[8119],[8093,8112],{"trials":8144,"activeCount":97},[],{"trials":8146,"activeCount":97},[],{"intervention":3802,"totalTrials":947,"cells":8148},{"EARLY_PHASE1":8149,"PHASE1":8151,"PHASE2":8163,"PHASE3":8165,"PHASE4":8171,"NA":8173},{"trials":8150,"activeCount":97},[],{"trials":8152,"activeCount":314,"soonestReadout":8157},[8153],{"nctId":8154,"briefTitle":8155,"status":257,"phases":8156,"primaryCompletion":8157,"completion":420,"start":8158,"enrollment":2571,"conditions":8159,"interventions":8161},"NCT04106219","A Study of LY3295668 Erbumine in Participants With Relapsed\u002FRefractory Neuroblastoma",[85],"2022-04-13","2020-06-11",[8160],"Neuroblastoma",[8162,3802,1874],"LY3295668 Erbumine",{"trials":8164,"activeCount":97},[],{"trials":8166,"activeCount":314,"soonestReadout":733},[8167],{"nctId":3794,"briefTitle":3795,"status":393,"phases":8168,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":8169,"interventions":8170},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"trials":8172,"activeCount":97},[],{"trials":8174,"activeCount":97},[],{"intervention":1906,"totalTrials":4323,"cells":8176},{"EARLY_PHASE1":8177,"PHASE1":8179,"PHASE2":8196,"PHASE3":8237,"PHASE4":8243,"NA":8245},{"trials":8178,"activeCount":97},[],{"trials":8180,"activeCount":97},[8181,8187],{"nctId":8182,"briefTitle":8183,"status":103,"phases":8184,"primaryCompletion":991,"completion":991,"start":2798,"enrollment":5807,"conditions":8185,"interventions":8186},"NCT01695005","A Study of LY3039478 in Participants With Advanced Cancer",[85],[1870,1478,7766],[1508,1906],{"nctId":8188,"briefTitle":8189,"status":999,"phases":8190,"primaryCompletion":8191,"completion":8191,"start":8192,"enrollment":12,"conditions":8193,"interventions":8194},"NCT06119529","A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis",[85],"2024-04-08","2023-11-01",[15,1271],[8195,1906],"LY3872386",{"trials":8197,"activeCount":97},[8198,8206,8213,8221,8229],{"nctId":8199,"briefTitle":8200,"status":103,"phases":8201,"primaryCompletion":2955,"completion":2918,"start":4474,"enrollment":8202,"conditions":8203,"interventions":8204},"NCT00466440","A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients",[86],108,[1903],[2979,3106,8205],"prednisone",{"nctId":8207,"briefTitle":8208,"status":103,"phases":8209,"primaryCompletion":3086,"completion":3068,"start":3005,"enrollment":2670,"conditions":8210,"interventions":8211},"NCT00451178","A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only",[86],[7766],[2979,4357,5885,3143,8212,8205],"vincristine",{"nctId":8214,"briefTitle":8215,"status":103,"phases":8216,"primaryCompletion":8217,"completion":2864,"start":3338,"enrollment":7145,"conditions":8218,"interventions":8219},"NCT00642018","A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer",[86],"2011-08",[1903],[3106,8220,1906],"LY2181308 sodium",{"nctId":8222,"briefTitle":8223,"status":103,"phases":8224,"primaryCompletion":3494,"completion":3494,"start":3216,"enrollment":8225,"conditions":8226,"interventions":8227},"NCT00683475","A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer",[86],138,[1903],[2870,8228,1906,3117],"Mitoxantrone",{"nctId":8230,"briefTitle":8231,"status":103,"phases":8232,"primaryCompletion":2898,"completion":4955,"start":8233,"enrollment":8234,"conditions":8235,"interventions":8236},"NCT01204710","A Study of Olaratumab (IMC-3G3) in Prostate Cancer",[86],"2010-10",123,[1903],[2545,8228,1906],{"trials":8238,"activeCount":314,"soonestReadout":1899},[8239],{"nctId":1896,"briefTitle":1897,"status":257,"phases":8240,"primaryCompletion":1899,"completion":419,"start":1900,"enrollment":1901,"conditions":8241,"interventions":8242},[86,87],[1903],[48,1905,1906],{"trials":8244,"activeCount":97},[],{"trials":8246,"activeCount":97},[],{"intervention":3034,"totalTrials":1054,"cells":8248},{"EARLY_PHASE1":8249,"PHASE1":8251,"PHASE2":8262,"PHASE3":8293,"PHASE4":8299,"NA":8301},{"trials":8250,"activeCount":97},[],{"trials":8252,"activeCount":97},[8253],{"nctId":8254,"briefTitle":8255,"status":103,"phases":8256,"primaryCompletion":1473,"completion":1474,"start":3545,"enrollment":1071,"conditions":8257,"interventions":8258},"NCT01556438","Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma",[85],[1114],[8259,8260,8261,3034],"Tabalumab","Bortezomib IV","Bortezomib SC",{"trials":8263,"activeCount":97},[8264,8274,8281,8285,8289],{"nctId":8265,"briefTitle":8266,"status":103,"phases":8267,"primaryCompletion":8268,"completion":8268,"start":8269,"enrollment":214,"conditions":8270,"interventions":8273},"NCT02518113","A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL\u002FT-LBL",[85,86],"2018-01-15","2015-10-01",[8271,8272],"T-cell Acute Lymphoblastic Leukemia","T-cell Lymphoblastic Lymphoma",[1508,3034],{"nctId":8275,"briefTitle":8276,"status":103,"phases":8277,"primaryCompletion":7316,"completion":7316,"start":3545,"enrollment":5248,"conditions":8278,"interventions":8279},"NCT01602224","A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)",[86],[1114],[3034,8280,8259],"Bortezomib",{"nctId":3024,"briefTitle":3025,"status":103,"phases":8282,"primaryCompletion":3027,"completion":3028,"start":3029,"enrollment":2733,"conditions":8283,"interventions":8284},[86],[1694],[1612,1510,3032,3033,3034],{"nctId":3191,"briefTitle":3192,"status":103,"phases":8286,"completion":3194,"start":3195,"enrollment":757,"conditions":8287,"interventions":8288},[86],[1608],[2912,2839,3198],{"nctId":5940,"briefTitle":5941,"status":103,"phases":8290,"primaryCompletion":3050,"completion":2918,"start":3094,"enrollment":335,"conditions":8291,"interventions":8292},[86],[1694],[2838,3198,3198],{"trials":8294,"activeCount":314,"soonestReadout":4036},[8295],{"nctId":4033,"briefTitle":4034,"status":257,"phases":8296,"primaryCompletion":4036,"completion":940,"start":4037,"enrollment":4038,"conditions":8297,"interventions":8298},[87],[4040,3990,3991,3992,4018,4020,4021,4022],[3936,3034],{"trials":8300,"activeCount":97},[],{"trials":8302,"activeCount":97},[],{"intervention":2695,"totalTrials":425,"cells":8304},{"EARLY_PHASE1":8305,"PHASE1":8307,"PHASE2":8340,"PHASE3":8342,"PHASE4":8348,"NA":8350},{"trials":8306,"activeCount":97},[],{"trials":8308,"activeCount":97},[8309,8317,8325,8333],{"nctId":8310,"briefTitle":8311,"status":103,"phases":8312,"primaryCompletion":8313,"completion":8313,"start":8314,"enrollment":2080,"conditions":8315,"interventions":8316},"NCT07044271","A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants",[85],"2025-11-08","2025-07-11",[15],[2695],{"nctId":8318,"briefTitle":8319,"status":103,"phases":8320,"primaryCompletion":8321,"completion":8321,"start":8322,"enrollment":903,"conditions":8323,"interventions":8324},"NCT07124013","A Study of Olomorasib (LY3537982) in Healthy Japanese Participants",[85],"2026-01-05","2025-09-16",[15],[2695],{"nctId":8326,"briefTitle":8327,"status":103,"phases":8328,"primaryCompletion":8329,"completion":8329,"start":8330,"enrollment":1158,"conditions":8331,"interventions":8332},"NCT07439250","A Study of Olomorasib (LY3537982) in Healthy Participants",[85],"2026-04-17","2026-03-02",[15],[2695,4984],{"nctId":8334,"briefTitle":8335,"status":103,"phases":8336,"primaryCompletion":8337,"completion":8337,"start":2070,"enrollment":1741,"conditions":8338,"interventions":8339},"NCT06719128","A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants",[85],"2025-08-25",[312,15],[2695],{"trials":8341,"activeCount":97},[],{"trials":8343,"activeCount":314,"soonestReadout":1911},[8344],{"nctId":2687,"briefTitle":2688,"status":393,"phases":8345,"primaryCompletion":1911,"completion":2690,"start":2691,"enrollment":2692,"conditions":8346,"interventions":8347},[87],[1589],[2695,1696,2696],{"trials":8349,"activeCount":97},[],{"trials":8351,"activeCount":97},[],{"intervention":2959,"totalTrials":425,"cells":8353},{"EARLY_PHASE1":8354,"PHASE1":8356,"PHASE2":8362,"PHASE3":8372,"PHASE4":8382,"NA":8384},{"trials":8355,"activeCount":97},[],{"trials":8357,"activeCount":97},[8358],{"nctId":7762,"briefTitle":7763,"status":103,"phases":8359,"primaryCompletion":3122,"completion":3122,"start":3838,"enrollment":1237,"conditions":8360,"interventions":8361},[85],[2589,7766,1589],[7768,1721,2959],{"trials":8363,"activeCount":97},[8364,8368],{"nctId":2952,"briefTitle":2953,"status":103,"phases":8365,"primaryCompletion":2955,"completion":2956,"start":2875,"enrollment":2790,"conditions":8366,"interventions":8367},[86],[1610],[1612,1510,2959],{"nctId":5970,"briefTitle":5971,"status":103,"phases":8369,"primaryCompletion":3697,"completion":3329,"start":3086,"enrollment":3177,"conditions":8370,"interventions":8371},[86],[3188],[2959,1612],{"trials":8373,"activeCount":314,"soonestReadout":69},[8374,8378],{"nctId":3345,"briefTitle":3346,"status":103,"phases":8375,"primaryCompletion":3348,"completion":3318,"start":3217,"enrollment":3349,"conditions":8376,"interventions":8377},[87],[1694],[1612,1510,2959,2959],{"nctId":67,"briefTitle":68,"status":257,"phases":8379,"primaryCompletion":69,"completion":462,"start":6705,"enrollment":6706,"conditions":8380,"interventions":8381},[87],[6708],[61,1721,2959,6469],{"trials":8383,"activeCount":97},[],{"trials":8385,"activeCount":97},[],{"intervention":8387,"totalTrials":1232,"cells":8388},"Remternetug",{"EARLY_PHASE1":8389,"PHASE1":8391,"PHASE2":8400,"PHASE3":8402,"PHASE4":8421,"NA":8423},{"trials":8390,"activeCount":97},[],{"trials":8392,"activeCount":97},[8393],{"nctId":8394,"briefTitle":8395,"status":103,"phases":8396,"primaryCompletion":342,"completion":342,"start":8397,"enrollment":1767,"conditions":8398,"interventions":8399},"NCT07056309","A Study of Remternetug (LY3372993) in Healthy Participants",[85],"2025-06-24",[15],[8387,8387],{"trials":8401,"activeCount":97},[],{"trials":8403,"activeCount":314,"soonestReadout":1280},[8404,8412],{"nctId":8405,"briefTitle":8406,"status":103,"phases":8407,"primaryCompletion":344,"completion":8408,"start":766,"enrollment":8409,"conditions":8410,"interventions":8411},"NCT05463731","A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)",[87],"2026-05-12",1667,[4040],[8387,8387],{"nctId":8413,"briefTitle":8414,"status":257,"phases":8415,"primaryCompletion":1280,"completion":8416,"start":8417,"enrollment":8418,"conditions":8419,"interventions":8420},"NCT06653153","A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)",[87],"2030-10","2024-10-24",1400,[4040],[8387],{"trials":8422,"activeCount":97},[],{"trials":8424,"activeCount":97},[],{"intervention":8426,"totalTrials":1232,"cells":8427},"Mirikizumab IV",{"EARLY_PHASE1":8428,"PHASE1":8430,"PHASE2":8432,"PHASE3":8434,"PHASE4":8460,"NA":8462},{"trials":8429,"activeCount":97},[],{"trials":8431,"activeCount":97},[],{"trials":8433,"activeCount":97},[],{"trials":8435,"activeCount":314,"soonestReadout":443},[8436,8443,8451],{"nctId":8437,"briefTitle":8438,"status":393,"phases":8439,"primaryCompletion":443,"completion":420,"start":7007,"enrollment":874,"conditions":8440,"interventions":8441},"NCT05784246","A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis",[87],[735],[8426,8442],"Mirikizumab SC",{"nctId":8444,"briefTitle":8445,"status":384,"phases":8446,"primaryCompletion":962,"completion":8447,"start":531,"enrollment":97,"conditions":8448,"interventions":8449},"NCT04469062","A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis",[87],"2024-06-05",[735],[8426,8442,8450],"Vedolizumab IV",{"nctId":8452,"briefTitle":8453,"status":103,"phases":8454,"primaryCompletion":8455,"completion":1388,"start":8456,"enrollment":8457,"conditions":8458,"interventions":8459},"NCT03524092","A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis",[87],"2021-11-03","2018-10-19",1328,[735],[8442,8426],{"trials":8461,"activeCount":97},[],{"trials":8463,"activeCount":97},[],{"intervention":8442,"totalTrials":1232,"cells":8465},{"EARLY_PHASE1":8466,"PHASE1":8468,"PHASE2":8470,"PHASE3":8472,"PHASE4":8486,"NA":8488},{"trials":8467,"activeCount":97},[],{"trials":8469,"activeCount":97},[],{"trials":8471,"activeCount":97},[],{"trials":8473,"activeCount":314,"soonestReadout":443},[8474,8478,8482],{"nctId":8437,"briefTitle":8438,"status":393,"phases":8475,"primaryCompletion":443,"completion":420,"start":7007,"enrollment":874,"conditions":8476,"interventions":8477},[87],[735],[8426,8442],{"nctId":8444,"briefTitle":8445,"status":384,"phases":8479,"primaryCompletion":962,"completion":8447,"start":531,"enrollment":97,"conditions":8480,"interventions":8481},[87],[735],[8426,8442,8450],{"nctId":8452,"briefTitle":8453,"status":103,"phases":8483,"primaryCompletion":8455,"completion":1388,"start":8456,"enrollment":8457,"conditions":8484,"interventions":8485},[87],[735],[8442,8426],{"trials":8487,"activeCount":97},[],{"trials":8489,"activeCount":97},[],{"intervention":1905,"totalTrials":947,"cells":8491},{"EARLY_PHASE1":8492,"PHASE1":8494,"PHASE2":8500,"PHASE3":8502,"PHASE4":8508,"NA":8510},{"trials":8493,"activeCount":97},[],{"trials":8495,"activeCount":97},[8496],{"nctId":1671,"briefTitle":1672,"status":103,"phases":8497,"primaryCompletion":1674,"completion":1675,"start":1676,"enrollment":1677,"conditions":8498,"interventions":8499},[85],[1466],[48,1680,1681],{"trials":8501,"activeCount":97},[],{"trials":8503,"activeCount":314,"soonestReadout":1899},[8504],{"nctId":1896,"briefTitle":1897,"status":257,"phases":8505,"primaryCompletion":1899,"completion":419,"start":1900,"enrollment":1901,"conditions":8506,"interventions":8507},[86,87],[1903],[48,1905,1906],{"trials":8509,"activeCount":97},[],{"trials":8511,"activeCount":97},[],{"intervention":6469,"totalTrials":947,"cells":8513},{"EARLY_PHASE1":8514,"PHASE1":8516,"PHASE2":8522,"PHASE3":8524,"PHASE4":8530,"NA":8532},{"trials":8515,"activeCount":97},[],{"trials":8517,"activeCount":97},[8518],{"nctId":6462,"briefTitle":6463,"status":103,"phases":8519,"primaryCompletion":334,"completion":6465,"start":6466,"enrollment":864,"conditions":8520,"interventions":8521},[85],[1610],[61,1591,6469],{"trials":8523,"activeCount":97},[],{"trials":8525,"activeCount":314,"soonestReadout":69},[8526],{"nctId":67,"briefTitle":68,"status":257,"phases":8527,"primaryCompletion":69,"completion":462,"start":6705,"enrollment":6706,"conditions":8528,"interventions":8529},[87],[6708],[61,1721,2959,6469],{"trials":8531,"activeCount":97},[],{"trials":8533,"activeCount":97},[],{"intervention":1949,"totalTrials":314,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8542,"PHASE4":8548,"NA":8550},{"trials":8537,"activeCount":97},[],{"trials":8539,"activeCount":97},[],{"trials":8541,"activeCount":97},[],{"trials":8543,"activeCount":314,"soonestReadout":1932},[8544],{"nctId":1929,"briefTitle":1930,"status":257,"phases":8545,"primaryCompletion":1932,"completion":454,"start":1933,"enrollment":1934,"conditions":8546,"interventions":8547},[87],[1522,1478,1936,1937,1938,1939,1940,1941,1942,1680,1943,1944,1945,1906,1681,1946,1947],[48,1949,1950],{"trials":8549,"activeCount":97},[],{"trials":8551,"activeCount":97},[],{"intervention":1950,"totalTrials":314,"cells":8553},{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8560,"PHASE4":8566,"NA":8568},{"trials":8555,"activeCount":97},[],{"trials":8557,"activeCount":97},[],{"trials":8559,"activeCount":97},[],{"trials":8561,"activeCount":314,"soonestReadout":1932},[8562],{"nctId":1929,"briefTitle":1930,"status":257,"phases":8563,"primaryCompletion":1932,"completion":454,"start":1933,"enrollment":1934,"conditions":8564,"interventions":8565},[87],[1522,1478,1936,1937,1938,1939,1940,1941,1942,1680,1943,1944,1945,1906,1681,1946,1947],[48,1949,1950],{"trials":8567,"activeCount":97},[],{"trials":8569,"activeCount":97},[],{"intervention":5241,"totalTrials":314,"cells":8571},{"EARLY_PHASE1":8572,"PHASE1":8574,"PHASE2":8576,"PHASE3":8578,"PHASE4":8584,"NA":8586},{"trials":8573,"activeCount":97},[],{"trials":8575,"activeCount":97},[],{"trials":8577,"activeCount":97},[],{"trials":8579,"activeCount":314,"soonestReadout":408},[8580],{"nctId":5234,"briefTitle":5235,"status":393,"phases":8581,"primaryCompletion":408,"completion":408,"start":5237,"enrollment":1189,"conditions":8582,"interventions":8583},[87],[5239],[4944,5241],{"trials":8585,"activeCount":97},[],{"trials":8587,"activeCount":97},[],{"intervention":1974,"totalTrials":314,"cells":8589},{"EARLY_PHASE1":8590,"PHASE1":8592,"PHASE2":8594,"PHASE3":8596,"PHASE4":8602,"NA":8604},{"trials":8591,"activeCount":97},[],{"trials":8593,"activeCount":97},[],{"trials":8595,"activeCount":97},[],{"trials":8597,"activeCount":314,"soonestReadout":1969},[8598],{"nctId":1966,"briefTitle":1967,"status":257,"phases":8599,"primaryCompletion":1969,"completion":1911,"start":1970,"enrollment":1971,"conditions":8600,"interventions":8601},[87],[36],[48,1974],{"trials":8603,"activeCount":97},[],{"trials":8605,"activeCount":97},[],{"intervention":8607,"totalTrials":314,"cells":8608},"Lepodisiran Sodium",{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8613,"PHASE3":8615,"PHASE4":8626,"NA":8628},{"trials":8610,"activeCount":97},[],{"trials":8612,"activeCount":97},[],{"trials":8614,"activeCount":97},[],{"trials":8616,"activeCount":314,"soonestReadout":941},[8617],{"nctId":8618,"briefTitle":8619,"status":257,"phases":8620,"primaryCompletion":941,"completion":941,"start":8621,"enrollment":8622,"conditions":8623,"interventions":8625},"NCT06292013","A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)",[87],"2024-03-05",17300,[2373,8624],"Elevated Lp(a)",[8607],{"trials":8627,"activeCount":97},[],{"trials":8629,"activeCount":97},[],{"intervention":3801,"totalTrials":314,"cells":8631},{"EARLY_PHASE1":8632,"PHASE1":8634,"PHASE2":8636,"PHASE3":8638,"PHASE4":8644,"NA":8646},{"trials":8633,"activeCount":97},[],{"trials":8635,"activeCount":97},[],{"trials":8637,"activeCount":97},[],{"trials":8639,"activeCount":314,"soonestReadout":733},[8640],{"nctId":3794,"briefTitle":3795,"status":393,"phases":8641,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":8642,"interventions":8643},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"trials":8645,"activeCount":97},[],{"trials":8647,"activeCount":97},[],{"intervention":3803,"totalTrials":314,"cells":8649},{"EARLY_PHASE1":8650,"PHASE1":8652,"PHASE2":8654,"PHASE3":8656,"PHASE4":8662,"NA":8664},{"trials":8651,"activeCount":97},[],{"trials":8653,"activeCount":97},[],{"trials":8655,"activeCount":97},[],{"trials":8657,"activeCount":314,"soonestReadout":733},[8658],{"nctId":3794,"briefTitle":3795,"status":393,"phases":8659,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":8660,"interventions":8661},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"trials":8663,"activeCount":97},[],{"trials":8665,"activeCount":97},[],{"intervention":3804,"totalTrials":314,"cells":8667},{"EARLY_PHASE1":8668,"PHASE1":8670,"PHASE2":8672,"PHASE3":8674,"PHASE4":8680,"NA":8682},{"trials":8669,"activeCount":97},[],{"trials":8671,"activeCount":97},[],{"trials":8673,"activeCount":97},[],{"trials":8675,"activeCount":314,"soonestReadout":733},[8676],{"nctId":3794,"briefTitle":3795,"status":393,"phases":8677,"primaryCompletion":733,"completion":2170,"start":3797,"enrollment":3798,"conditions":8678,"interventions":8679},[87],[2553,3548,3601,1478],[3801,1669,3802,1511,3803,3804,3054,1512],{"trials":8681,"activeCount":97},[],{"trials":8683,"activeCount":97},[],{"intervention":2705,"totalTrials":314,"cells":8685},{"EARLY_PHASE1":8686,"PHASE1":8688,"PHASE2":8690,"PHASE3":8692,"PHASE4":8698,"NA":8700},{"trials":8687,"activeCount":97},[],{"trials":8689,"activeCount":97},[],{"trials":8691,"activeCount":97},[],{"trials":8693,"activeCount":314,"soonestReadout":2701},[8694],{"nctId":2698,"briefTitle":2699,"status":393,"phases":8695,"primaryCompletion":2701,"completion":1912,"start":2702,"enrollment":855,"conditions":8696,"interventions":8697},[87],[2622,2530,1478],[2705,2706,1696],{"trials":8699,"activeCount":97},[],{"trials":8701,"activeCount":97},[],{"intervention":2706,"totalTrials":314,"cells":8703},{"EARLY_PHASE1":8704,"PHASE1":8706,"PHASE2":8708,"PHASE3":8710,"PHASE4":8716,"NA":8718},{"trials":8705,"activeCount":97},[],{"trials":8707,"activeCount":97},[],{"trials":8709,"activeCount":97},[],{"trials":8711,"activeCount":314,"soonestReadout":2701},[8712],{"nctId":2698,"briefTitle":2699,"status":393,"phases":8713,"primaryCompletion":2701,"completion":1912,"start":2702,"enrollment":855,"conditions":8714,"interventions":8715},[87],[2622,2530,1478],[2705,2706,1696],{"trials":8717,"activeCount":97},[],{"trials":8719,"activeCount":97},[],{"intervention":8721,"totalTrials":314,"cells":8722},"Muvalaplin",{"EARLY_PHASE1":8723,"PHASE1":8725,"PHASE2":8727,"PHASE3":8729,"PHASE4":8740,"NA":8742},{"trials":8724,"activeCount":97},[],{"trials":8726,"activeCount":97},[],{"trials":8728,"activeCount":97},[],{"trials":8730,"activeCount":314,"soonestReadout":8735},[8731],{"nctId":8732,"briefTitle":8733,"status":393,"phases":8734,"primaryCompletion":8735,"completion":8735,"start":8736,"enrollment":8737,"conditions":8738,"interventions":8739},"NCT07157774","Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)",[87],"2031-03","2025-09-02",10450,[8624,2373],[8721],{"trials":8741,"activeCount":97},[],{"trials":8743,"activeCount":97},[],{"intervention":1745,"totalTrials":1062,"cells":8745},{"EARLY_PHASE1":8746,"PHASE1":8748,"PHASE2":8773,"PHASE3":8814,"PHASE4":8827,"NA":8829},{"trials":8747,"activeCount":97},[],{"trials":8749,"activeCount":947,"soonestReadout":941},[8750,8761,8765,8769],{"nctId":8751,"briefTitle":8752,"status":103,"phases":8753,"primaryCompletion":8754,"completion":8755,"start":8756,"enrollment":4353,"conditions":8757,"interventions":8758},"NCT02677116","A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer",[85],"2018-10-10","2019-04-03","2016-08-29",[1478],[2545,5985,8759,1745,8760],"Vincristine","Ifosfamide",{"nctId":2510,"briefTitle":2511,"status":257,"phases":8762,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":8763,"interventions":8764},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":6400,"briefTitle":6401,"status":103,"phases":8766,"primaryCompletion":3086,"completion":3886,"start":3283,"enrollment":1677,"conditions":8767,"interventions":8768},[85],[2586],[61,1745,6405,2923],{"nctId":4127,"briefTitle":4128,"status":393,"phases":8770,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":8771,"interventions":8772},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"trials":8774,"activeCount":947,"soonestReadout":1739},[8775,8779,8783,8787,8791,8797,8801,8807],{"nctId":5653,"briefTitle":5654,"status":103,"phases":8776,"primaryCompletion":2875,"completion":3292,"start":3194,"enrollment":1741,"conditions":8777,"interventions":8778},[86],[5657],[2838,5659],{"nctId":1736,"briefTitle":1737,"status":257,"phases":8780,"primaryCompletion":1739,"completion":462,"start":1740,"enrollment":1741,"conditions":8781,"interventions":8782},[86],[1743,1478],[48,1745,1746],{"nctId":1771,"briefTitle":1772,"status":103,"phases":8784,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":128,"conditions":8785,"interventions":8786},[85,86],[1778,1779],[48,1745,1746,1781,1782],{"nctId":6597,"briefTitle":6598,"status":103,"phases":8788,"primaryCompletion":2917,"completion":6600,"start":2798,"enrollment":864,"conditions":8789,"interventions":8790},[86],[2589],[61,1745,6603,2923],{"nctId":8792,"briefTitle":8793,"status":103,"phases":8794,"conditions":8795,"interventions":8796},"NCT00034502","A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.",[85,86],[1490],[2893,5659],{"nctId":1864,"briefTitle":1865,"status":393,"phases":8798,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":8799,"interventions":8800},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"nctId":8802,"briefTitle":8803,"status":999,"phases":8804,"primaryCompletion":3283,"completion":3283,"start":2929,"enrollment":1400,"conditions":8805,"interventions":8806},"NCT00845039","A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab",[86],[1504,6541],[1541,1745,2870],{"nctId":8808,"briefTitle":8809,"status":103,"phases":8810,"primaryCompletion":2929,"completion":2929,"start":4642,"enrollment":893,"conditions":8811,"interventions":8813},"NCT00437268","A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer",[86],[1490,2586,8812],"Colorectal Tumor",[2979,5659,3540],{"trials":8815,"activeCount":97},[8816,8823],{"nctId":8817,"briefTitle":8818,"status":103,"phases":8819,"primaryCompletion":3524,"completion":3235,"start":3195,"enrollment":8820,"conditions":8821,"interventions":8822},"NCT00063141","Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer",[87],1302,[1490],[3540,1745,1745],{"nctId":6711,"briefTitle":6712,"status":103,"phases":8824,"primaryCompletion":6714,"completion":6715,"start":6716,"enrollment":6717,"conditions":8825,"interventions":8826},[87],[1490],[61,1745,6720,2923],{"trials":8828,"activeCount":97},[],{"trials":8830,"activeCount":97},[],{"intervention":110,"totalTrials":4323,"cells":8832},{"EARLY_PHASE1":8833,"PHASE1":8835,"PHASE2":8870,"PHASE3":8890,"PHASE4":8892,"NA":8894},{"trials":8834,"activeCount":97},[],{"trials":8836,"activeCount":947,"soonestReadout":355},[8837,8841,8849,8860,8864],{"nctId":101,"briefTitle":102,"status":103,"phases":8838,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":8839,"interventions":8840},[85],[24,27],[92,110],{"nctId":8842,"briefTitle":8843,"status":103,"phases":8844,"primaryCompletion":8845,"completion":8845,"start":8846,"enrollment":4005,"conditions":8847,"interventions":8848},"NCT05295940","A Study of LY3841136 in Healthy and Overweight Participants",[85],"2024-01-25","2022-03-30",[24,15],[110],{"nctId":8850,"briefTitle":8851,"status":393,"phases":8852,"primaryCompletion":355,"completion":355,"start":8853,"enrollment":165,"conditions":8854,"interventions":8859},"NCT07426380","A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function",[85],"2026-02-24",[8855,8856,8857,4691,147,8858],"Kidney Disease","Renal Insufficiency Chronic","Kidney Failure, Chronic","End Stage Kidney Disease",[110],{"nctId":264,"briefTitle":265,"status":103,"phases":8861,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":8862,"interventions":8863},[85],[24,27],[110,272,92,273],{"nctId":8865,"briefTitle":8866,"status":393,"phases":8867,"primaryCompletion":2283,"completion":2283,"start":4792,"enrollment":214,"conditions":8868,"interventions":8869},"NCT07401862","A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.",[85],[312],[110],{"trials":8871,"activeCount":947,"soonestReadout":419},[8872,8876,8886],{"nctId":391,"briefTitle":392,"status":393,"phases":8873,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":8874,"interventions":8875},[86],[24,27],[401,110,92,402,403],{"nctId":8877,"briefTitle":8878,"status":103,"phases":8879,"primaryCompletion":8880,"completion":8881,"start":8882,"enrollment":3373,"conditions":8883,"interventions":8885},"NCT06230523","A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight",[86],"2025-05-30","2025-08-14","2024-02-05",[24,8884],"Overweight and Obesity",[110],{"nctId":416,"briefTitle":417,"status":257,"phases":8887,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":8888,"interventions":8889},[86],[24,27],[110,92],{"trials":8891,"activeCount":97},[],{"trials":8893,"activeCount":97},[],{"trials":8895,"activeCount":97},[],{"intervention":1541,"totalTrials":3041,"cells":8897},{"EARLY_PHASE1":8898,"PHASE1":8900,"PHASE2":8939,"PHASE3":9073,"PHASE4":9094,"NA":9096},{"trials":8899,"activeCount":97},[],{"trials":8901,"activeCount":947,"soonestReadout":941},[8902,8906,8910,8914,8921,8925,8929,8933],{"nctId":2510,"briefTitle":2511,"status":257,"phases":8903,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":8904,"interventions":8905},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":1527,"briefTitle":1528,"status":103,"phases":8907,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":8908,"interventions":8909},[85],[1466,1534,1535,1490],[1537,1538,48,1539,1511,1540,1541],{"nctId":2774,"briefTitle":2775,"status":103,"phases":8911,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":8912,"interventions":8913},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"nctId":8915,"briefTitle":8916,"status":103,"phases":8917,"primaryCompletion":3160,"completion":3160,"start":4459,"enrollment":8918,"conditions":8919,"interventions":8920},"NCT00207155","An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer",[85],110,[5657],[1541],{"nctId":2785,"briefTitle":2786,"status":103,"phases":8922,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":2790,"conditions":8923,"interventions":8924},[85],[2792],[2781,1510,1541],{"nctId":4127,"briefTitle":4128,"status":393,"phases":8926,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":8927,"interventions":8928},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"nctId":2817,"briefTitle":2818,"status":103,"phases":8930,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":377,"conditions":8931,"interventions":8932},[85],[2824],[2826,1541,1510,1511,61],{"nctId":8934,"briefTitle":8935,"status":103,"phases":8936,"primaryCompletion":3592,"completion":3592,"start":2833,"enrollment":2080,"conditions":8937,"interventions":8938},"NCT00207116","An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma",[85],[1589,1478],[1541],{"trials":8940,"activeCount":314,"soonestReadout":1011},[8941,8945,8949,8955,8959,8963,8971,8975,8979,8983,8987,8993,8997,9004,9008,9012,9016,9020,9026,9030,9034,9041,9045,9052,9059,9063,9067],{"nctId":3478,"briefTitle":3479,"status":384,"phases":8942,"primaryCompletion":3132,"completion":3132,"start":3132,"enrollment":97,"conditions":8943,"interventions":8944},[86],[2891,1589],[1541,1669,1512],{"nctId":2841,"briefTitle":2842,"status":103,"phases":8946,"primaryCompletion":2844,"completion":2845,"start":2846,"enrollment":2847,"conditions":8947,"interventions":8948},[86],[2849],[1612,1510,1541],{"nctId":8950,"briefTitle":8951,"status":103,"phases":8952,"primaryCompletion":3185,"completion":3185,"start":2856,"enrollment":280,"conditions":8953,"interventions":8954},"NCT00362102","A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma",[86],[2586],[1541],{"nctId":3484,"briefTitle":3485,"status":103,"phases":8956,"primaryCompletion":2956,"completion":3152,"start":3060,"enrollment":3487,"conditions":8957,"interventions":8958},[86],[1718],[1541,3054,1669,1512],{"nctId":1711,"briefTitle":1712,"status":999,"phases":8960,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":425,"conditions":8961,"interventions":8962},[85,86],[1717,1718,1490],[1720,48,1541,1721,1722],{"nctId":8964,"briefTitle":8965,"status":103,"phases":8966,"primaryCompletion":2995,"completion":2995,"start":2948,"enrollment":8967,"conditions":8968,"interventions":8970},"NCT00083720","Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy",[86],87,[2557,8969,1477],"Metastases",[3540],{"nctId":2861,"briefTitle":2862,"status":103,"phases":8972,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":8973,"interventions":8974},[86],[1718],[1511,1510,2870,1541,2870,1541,1512],{"nctId":2895,"briefTitle":2896,"status":103,"phases":8976,"primaryCompletion":2898,"completion":2898,"start":2899,"enrollment":1767,"conditions":8977,"interventions":8978},[86],[2891,2901,2902,2903],[1541,1510,1875],{"nctId":3533,"briefTitle":3534,"status":103,"phases":8980,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":310,"conditions":8981,"interventions":8982},[85,86],[1589],[3540,3222,2561],{"nctId":2914,"briefTitle":2915,"status":103,"phases":8984,"primaryCompletion":2917,"completion":1618,"start":2918,"enrollment":2919,"conditions":8985,"interventions":8986},[86],[2921],[1541,1510,1512,2923],{"nctId":8988,"briefTitle":8989,"status":103,"phases":8990,"primaryCompletion":2866,"completion":2866,"start":4474,"enrollment":156,"conditions":8991,"interventions":8992},"NCT00503685","Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy",[86],[1490],[2870,3540],{"nctId":3009,"briefTitle":3010,"status":103,"phases":8994,"primaryCompletion":2917,"completion":2917,"start":3012,"enrollment":3013,"conditions":8995,"interventions":8996},[86],[2792],[1612,1541,1512,1510],{"nctId":8998,"briefTitle":8999,"status":103,"phases":9000,"primaryCompletion":3087,"completion":3087,"start":3103,"enrollment":9001,"conditions":9002,"interventions":9003},"NCT00698841","Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors",[86],79,[1466],[1541],{"nctId":3642,"briefTitle":3643,"status":103,"phases":9005,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":3647,"conditions":9006,"interventions":9007},[86],[1610],[1541,1512,1669],{"nctId":3651,"briefTitle":3652,"status":103,"phases":9009,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":3654,"conditions":9010,"interventions":9011},[86],[1610],[1512,1541],{"nctId":3083,"briefTitle":3084,"status":103,"phases":9013,"primaryCompletion":3086,"completion":2798,"start":3087,"enrollment":1587,"conditions":9014,"interventions":9015},[86],[2792],[1612,1541,1510],{"nctId":2646,"briefTitle":2647,"status":257,"phases":9017,"primaryCompletion":1011,"completion":1011,"start":2649,"enrollment":2650,"conditions":9018,"interventions":9019},[85,86],[1589,2557,2505,2553,2652,2653],[2655,1696,1541,1612,1510,1512],{"nctId":9021,"briefTitle":9022,"status":103,"phases":9023,"primaryCompletion":3168,"completion":3168,"start":3536,"enrollment":1587,"conditions":9024,"interventions":9025},"NCT00063388","Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer",[86],[2849],[1541],{"nctId":3714,"briefTitle":3715,"status":103,"phases":9027,"primaryCompletion":3717,"completion":3250,"start":2918,"enrollment":3718,"conditions":9028,"interventions":9029},[86],[1503],[1541,1512,3721],{"nctId":4501,"briefTitle":4502,"status":999,"phases":9031,"primaryCompletion":3132,"completion":2928,"start":3259,"enrollment":3125,"conditions":9032,"interventions":9033},[86],[4317],[3540,2560,2912,3540],{"nctId":9035,"briefTitle":9036,"status":999,"phases":9037,"primaryCompletion":4474,"completion":4474,"start":3646,"enrollment":9038,"conditions":9039,"interventions":9040},"NCT00082212","A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma",[86],25,[2584],[1541],{"nctId":3247,"briefTitle":3248,"status":103,"phases":9042,"primaryCompletion":3250,"completion":2799,"start":3251,"enrollment":128,"conditions":9043,"interventions":9044},[86],[1503],[1541,1510,3254],{"nctId":9046,"briefTitle":9047,"status":103,"phases":9048,"primaryCompletion":3339,"completion":3077,"start":3140,"enrollment":9049,"conditions":9050,"interventions":9051},"NCT00055419","A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer",[86],744,[2557],[1541],{"nctId":9053,"briefTitle":9054,"status":103,"phases":9055,"primaryCompletion":3337,"completion":3337,"start":3646,"enrollment":233,"conditions":9056,"interventions":9058},"NCT00162110","A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces",[86],[9057],"Mucinous Gastrointestinal Adenocarcinoma",[3540],{"nctId":8802,"briefTitle":8803,"status":999,"phases":9060,"primaryCompletion":3283,"completion":3283,"start":2929,"enrollment":1400,"conditions":9061,"interventions":9062},[86],[1504,6541],[1541,1745,2870],{"nctId":8808,"briefTitle":8809,"status":103,"phases":9064,"primaryCompletion":2929,"completion":2929,"start":4642,"enrollment":893,"conditions":9065,"interventions":9066},[86],[1490,2586,8812],[2979,5659,3540],{"nctId":9068,"briefTitle":9069,"status":103,"phases":9070,"primaryCompletion":3086,"completion":3545,"start":3338,"enrollment":6509,"conditions":9071,"interventions":9072},"NCT00617734","Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck",[86],[2921],[2870,3540],{"trials":9074,"activeCount":97},[9075,9079,9086,9090],{"nctId":3787,"briefTitle":3788,"status":103,"phases":9076,"primaryCompletion":3645,"completion":3216,"start":2909,"enrollment":3790,"conditions":9077,"interventions":9078},[87],[2903],[1669,1722,1512,1541],{"nctId":9080,"briefTitle":9081,"status":103,"phases":9082,"primaryCompletion":2909,"completion":3228,"start":3040,"enrollment":9083,"conditions":9084,"interventions":9085},"NCT00061815","Study of Cetuximab, Oxaliplatin, 5-FU\u002FLV Versus Oxaliplatin, 5-FU\u002FLV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer",[87],102,[1490],[3540,4181,4136,4137,4137,3540],{"nctId":8817,"briefTitle":8818,"status":103,"phases":9087,"primaryCompletion":3524,"completion":3235,"start":3195,"enrollment":8820,"conditions":9088,"interventions":9089},[87],[1490],[3540,1745,1745],{"nctId":6090,"briefTitle":6091,"status":103,"phases":9091,"primaryCompletion":6093,"completion":6093,"start":4538,"enrollment":3330,"conditions":9092,"interventions":9093},[87],[1694],[1612,1541,1722],{"trials":9095,"activeCount":97},[],{"trials":9097,"activeCount":97},[],{"intervention":1746,"totalTrials":1054,"cells":9099},{"EARLY_PHASE1":9100,"PHASE1":9102,"PHASE2":9108,"PHASE3":9144,"PHASE4":9146,"NA":9148},{"trials":9101,"activeCount":97},[],{"trials":9103,"activeCount":97},[9104],{"nctId":2795,"briefTitle":2796,"status":999,"phases":9105,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":1808,"conditions":9106,"interventions":9107},[85],[2802],[1511,1722,1746,1510,1721,2804],{"trials":9109,"activeCount":1232,"soonestReadout":1739},[9110,9114,9122,9132,9136,9140],{"nctId":1736,"briefTitle":1737,"status":257,"phases":9111,"primaryCompletion":1739,"completion":462,"start":1740,"enrollment":1741,"conditions":9112,"interventions":9113},[86],[1743,1478],[48,1745,1746],{"nctId":9115,"briefTitle":9116,"status":103,"phases":9117,"primaryCompletion":1474,"completion":2754,"start":3069,"enrollment":9118,"conditions":9119,"interventions":9120},"NCT01220271","A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma",[85,86],75,[1850],[4101,9121,1746],"Radiation",{"nctId":9123,"briefTitle":9124,"status":103,"phases":9125,"primaryCompletion":6883,"completion":6883,"start":3133,"enrollment":1767,"conditions":9126,"interventions":9130},"NCT00402116","Phase 1\u002F2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients",[85,86],[9127,9128,9129],"Glioblastoma","Glioblastoma Multiforme","Gliosarcoma",[2979,9131],"temozolomide",{"nctId":1771,"briefTitle":1772,"status":103,"phases":9133,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":128,"conditions":9134,"interventions":9135},[85,86],[1778,1779],[48,1745,1746,1781,1782],{"nctId":1845,"briefTitle":1846,"status":257,"phases":9137,"primaryCompletion":765,"completion":396,"start":1848,"enrollment":34,"conditions":9138,"interventions":9139},[86],[1850],[48,1746],{"nctId":1864,"briefTitle":1865,"status":393,"phases":9141,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":9142,"interventions":9143},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"trials":9145,"activeCount":97},[],{"trials":9147,"activeCount":97},[],{"trials":9149,"activeCount":97},[],{"intervention":9151,"totalTrials":1232,"cells":9152},"LY4395089",{"EARLY_PHASE1":9153,"PHASE1":9155,"PHASE2":9163,"PHASE3":9182,"PHASE4":9184,"NA":9186},{"trials":9154,"activeCount":97},[],{"trials":9156,"activeCount":314,"soonestReadout":1309},[9157],{"nctId":9158,"briefTitle":9159,"status":1060,"phases":9160,"primaryCompletion":1309,"completion":1309,"start":443,"enrollment":1062,"conditions":9161,"interventions":9162},"NCT07592572","A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants",[85],[15],[9151,2562,2562],{"trials":9164,"activeCount":947,"soonestReadout":2527},[9165,9176],{"nctId":9166,"briefTitle":9167,"status":393,"phases":9168,"primaryCompletion":2527,"completion":1993,"start":9169,"enrollment":874,"conditions":9170,"interventions":9173},"NCT07483073","A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease",[86],"2026-05-04",[9171,9172],"Colitis, Ulcerative","Crohn Disease",[9174,9175,9151],"Mirikizumab - Intravenous","Mirikizumab - Subcutaneous",{"nctId":9177,"briefTitle":9178,"status":393,"phases":9179,"primaryCompletion":2527,"completion":1993,"start":9169,"enrollment":874,"conditions":9180,"interventions":9181},"NCT07483099","A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease",[86],[9172],[9151,9174,9175],{"trials":9183,"activeCount":97},[],{"trials":9185,"activeCount":97},[],{"trials":9187,"activeCount":97},[],{"intervention":9189,"totalTrials":1232,"cells":9190},"LY4005130",{"EARLY_PHASE1":9191,"PHASE1":9193,"PHASE2":9201,"PHASE3":9218,"PHASE4":9220,"NA":9222},{"trials":9192,"activeCount":97},[],{"trials":9194,"activeCount":314,"soonestReadout":980},[9195],{"nctId":9196,"briefTitle":9197,"status":257,"phases":9198,"primaryCompletion":980,"completion":980,"start":6290,"enrollment":3618,"conditions":9199,"interventions":9200},"NCT06690996","A Study of LY4005130 in Healthy Participants",[85],[15],[9189,9189],{"trials":9202,"activeCount":947,"soonestReadout":940},[9203,9210],{"nctId":9204,"briefTitle":9205,"status":393,"phases":9206,"primaryCompletion":2527,"completion":454,"start":9207,"enrollment":874,"conditions":9208,"interventions":9209},"NCT07533006","A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)",[86],"2026-04-14",[5123],[9189],{"nctId":9211,"briefTitle":9212,"status":393,"phases":9213,"primaryCompletion":940,"completion":395,"start":9207,"enrollment":874,"conditions":9214,"interventions":9217},"NCT07533019","A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo",[86],[9215,9216],"Vitiligo","Non-Segmental Vitiligo (NSV)",[9189],{"trials":9219,"activeCount":97},[],{"trials":9221,"activeCount":97},[],{"trials":9223,"activeCount":97},[],{"intervention":402,"totalTrials":3293,"cells":9225},{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9276,"PHASE3":9297,"PHASE4":9299,"NA":9301},{"trials":9227,"activeCount":97},[],{"trials":9229,"activeCount":314,"soonestReadout":1309},[9230,9238,9245,9252,9259,9267],{"nctId":9231,"briefTitle":9232,"status":103,"phases":9233,"primaryCompletion":9234,"completion":9234,"start":6465,"enrollment":4475,"conditions":9235,"interventions":9236},"NCT05327595","A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)",[85],"2024-04-22",[18],[402,9237,1538],"Atorvastatin",{"nctId":9239,"briefTitle":9240,"status":103,"phases":9241,"primaryCompletion":9242,"completion":9242,"start":2180,"enrollment":214,"conditions":9243,"interventions":9244},"NCT07073170","A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus",[85],"2026-01-27",[30],[402],{"nctId":9246,"briefTitle":9247,"status":103,"phases":9248,"primaryCompletion":9249,"completion":9249,"start":2024,"enrollment":31,"conditions":9250,"interventions":9251},"NCT04758234","A Study of LY3549492 in Healthy Participants",[85],"2022-01-10",[15],[402],{"nctId":9253,"briefTitle":9254,"status":257,"phases":9255,"primaryCompletion":1309,"completion":1309,"start":9256,"enrollment":2080,"conditions":9257,"interventions":9258},"NCT07232732","A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity",[85],"2025-10-27",[15,24,27],[402],{"nctId":9260,"briefTitle":9261,"status":103,"phases":9262,"primaryCompletion":8330,"completion":8330,"start":9263,"enrollment":5645,"conditions":9264,"interventions":9266},"NCT06869018","A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants",[85],"2025-05-07",[15,9265],"Type 2 Diabetes Mellitus (T2D)",[402],{"nctId":9268,"briefTitle":9269,"status":103,"phases":9270,"primaryCompletion":1932,"completion":1932,"start":9271,"enrollment":12,"conditions":9272,"interventions":9274},"NCT06194500","A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants",[85],"2024-01-03",[9273],"Healthy Male",[9275,402,9275],"[14C]-LY3549492",{"trials":9277,"activeCount":314,"soonestReadout":395},[9278,9286,9290],{"nctId":9279,"briefTitle":9280,"status":103,"phases":9281,"primaryCompletion":9282,"completion":9169,"start":741,"enrollment":9283,"conditions":9284,"interventions":9285},"NCT06683508","A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight",[86],"2026-01-07",288,[24,27],[402],{"nctId":391,"briefTitle":392,"status":393,"phases":9287,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":9288,"interventions":9289},[86],[24,27],[401,110,92,402,403],{"nctId":9291,"briefTitle":9292,"status":999,"phases":9293,"primaryCompletion":8881,"completion":8881,"start":9294,"enrollment":314,"conditions":9295,"interventions":9296},"NCT07085468","A Study of LY3549492 in Healthy Weight Adult Participants",[86],"2025-07-21",[15],[402],{"trials":9298,"activeCount":97},[],{"trials":9300,"activeCount":97},[],{"trials":9302,"activeCount":97},[],{"intervention":5885,"totalTrials":1677,"cells":9304},{"EARLY_PHASE1":9305,"PHASE1":9307,"PHASE2":9313,"PHASE3":9335,"PHASE4":9337,"NA":9339},{"trials":9306,"activeCount":97},[],{"trials":9308,"activeCount":314,"soonestReadout":8157},[9309],{"nctId":8154,"briefTitle":8155,"status":257,"phases":9310,"primaryCompletion":8157,"completion":420,"start":8158,"enrollment":2571,"conditions":9311,"interventions":9312},[85],[8160],[8162,3802,1874],{"trials":9314,"activeCount":314,"soonestReadout":940},[9315,9319,9323,9327,9331],{"nctId":8207,"briefTitle":8208,"status":103,"phases":9316,"primaryCompletion":3086,"completion":3068,"start":3005,"enrollment":2670,"conditions":9317,"interventions":9318},[86],[7766],[2979,4357,5885,3143,8212,8205],{"nctId":5879,"briefTitle":5880,"status":103,"phases":9320,"primaryCompletion":3338,"completion":3338,"start":3168,"enrollment":5882,"conditions":9321,"interventions":9322},[85,86],[36],[2838,5885,2838],{"nctId":5899,"briefTitle":5900,"status":103,"phases":9324,"primaryCompletion":3094,"completion":3837,"start":2833,"enrollment":617,"conditions":9325,"interventions":9326},[86],[36],[2838,5885,3143,3106],{"nctId":1864,"briefTitle":1865,"status":393,"phases":9328,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":9329,"interventions":9330},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"nctId":6637,"briefTitle":6638,"status":103,"phases":9332,"primaryCompletion":6640,"completion":6641,"start":1867,"enrollment":1620,"conditions":9333,"interventions":9334},[85,86],[6643],[61,1874,1875],{"trials":9336,"activeCount":97},[],{"trials":9338,"activeCount":97},[],{"trials":9340,"activeCount":97},[],{"intervention":9342,"totalTrials":1400,"cells":9343},"LY4065967",{"EARLY_PHASE1":9344,"PHASE1":9346,"PHASE2":9370,"PHASE3":9380,"PHASE4":9382,"NA":9384},{"trials":9345,"activeCount":97},[],{"trials":9347,"activeCount":314,"soonestReadout":1309},[9348,9355,9363],{"nctId":9349,"briefTitle":9350,"status":1060,"phases":9351,"primaryCompletion":1309,"completion":1309,"start":419,"enrollment":214,"conditions":9352,"interventions":9353},"NCT07607483","A Study of LY4065967 in Healthy Participants",[85],[15],[9342,9354,9342],"LY4065967 Formulated",{"nctId":9356,"briefTitle":9357,"status":103,"phases":9358,"primaryCompletion":9359,"completion":9359,"start":9360,"enrollment":1071,"conditions":9361,"interventions":9362},"NCT07039045","A Study of [14C]-LY4065967 in Healthy Participants",[85],"2025-08-16","2025-06-23",[15],[9342],{"nctId":9364,"briefTitle":9365,"status":103,"phases":9366,"primaryCompletion":9367,"completion":9367,"start":2121,"enrollment":2996,"conditions":9368,"interventions":9369},"NCT06594159","A Study of LY4065967 in Healthy Japanese Participants",[85],"2025-03-11",[15],[9342,2093],{"trials":9371,"activeCount":314,"soonestReadout":715},[9372],{"nctId":9373,"briefTitle":9374,"status":393,"phases":9375,"primaryCompletion":715,"completion":715,"start":9376,"enrollment":658,"conditions":9377,"interventions":9379},"NCT07285018","A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain",[86],"2026-02-16",[9378],"Diabetic Peripheral Neuropathic Pain",[9342],{"trials":9381,"activeCount":97},[],{"trials":9383,"activeCount":97},[],{"trials":9385,"activeCount":97},[],{"intervention":9387,"totalTrials":1232,"cells":9388},"LY3541860",{"EARLY_PHASE1":9389,"PHASE1":9391,"PHASE2":9401,"PHASE3":9419,"PHASE4":9421,"NA":9423},{"trials":9390,"activeCount":97},[],{"trials":9392,"activeCount":97},[9393],{"nctId":9394,"briefTitle":9395,"status":103,"phases":9396,"primaryCompletion":9397,"completion":9397,"start":9398,"enrollment":1501,"conditions":9399,"interventions":9400},"NCT05042310","A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants",[85],"2023-12-27","2021-11-11",[15],[9387],{"trials":9402,"activeCount":947,"soonestReadout":9413},[9403,9409],{"nctId":9404,"briefTitle":9405,"status":257,"phases":9406,"primaryCompletion":942,"completion":443,"start":775,"enrollment":1548,"conditions":9407,"interventions":9408},"NCT06859294","A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis",[86],[5218],[9387],{"nctId":9410,"briefTitle":9411,"status":257,"phases":9412,"primaryCompletion":9413,"completion":1309,"start":9414,"enrollment":9415,"conditions":9416,"interventions":9418},"NCT06220669","A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis",[86],"2025-10-18","2024-03-19",63,[9417],"Multiple Sclerosis",[9387],{"trials":9420,"activeCount":97},[],{"trials":9422,"activeCount":97},[],{"trials":9424,"activeCount":97},[],{"intervention":9426,"totalTrials":1232,"cells":9427},"LY3938577",{"EARLY_PHASE1":9428,"PHASE1":9430,"PHASE2":9449,"PHASE3":9459,"PHASE4":9461,"NA":9463},{"trials":9429,"activeCount":97},[],{"trials":9431,"activeCount":314,"soonestReadout":408},[9432,9441],{"nctId":9433,"briefTitle":9434,"status":393,"phases":9435,"primaryCompletion":408,"completion":408,"start":1034,"enrollment":3618,"conditions":9436,"interventions":9438},"NCT06280703","A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)",[85],[15,9437],"Type 1 Diabetes Mellitus",[9426,700,438,9426,700,9439,9440],"Basal Insulin","Lispro Prandial Insulin",{"nctId":9442,"briefTitle":9443,"status":103,"phases":9444,"primaryCompletion":9445,"completion":9445,"start":397,"enrollment":1587,"conditions":9446,"interventions":9447},"NCT06132126","A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus",[85],"2024-06-28",[15,120],[9426,9448],"Insulin degludec",{"trials":9450,"activeCount":314,"soonestReadout":259},[9451],{"nctId":9452,"briefTitle":9453,"status":393,"phases":9454,"primaryCompletion":259,"completion":462,"start":9455,"enrollment":1692,"conditions":9456,"interventions":9457},"NCT07215312","A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin",[86],"2025-10-13",[18],[9426,9458],"Degludec",{"trials":9460,"activeCount":97},[],{"trials":9462,"activeCount":97},[],{"trials":9464,"activeCount":97},[],{"intervention":945,"totalTrials":1232,"cells":9466},{"EARLY_PHASE1":9467,"PHASE1":9469,"PHASE2":9480,"PHASE3":9497,"PHASE4":9499,"NA":9501},{"trials":9468,"activeCount":97},[],{"trials":9470,"activeCount":97},[9471],{"nctId":9472,"briefTitle":9473,"status":103,"phases":9474,"primaryCompletion":9475,"completion":9475,"start":9476,"enrollment":9477,"conditions":9478,"interventions":9479},"NCT06964776","A Study of LY4268989 (MORF-057) in Healthy Participants",[85],"2026-02-17","2025-05-01",144,[15],[945,1538,1538],{"trials":9481,"activeCount":947,"soonestReadout":940},[9482,9486],{"nctId":937,"briefTitle":938,"status":393,"phases":9483,"primaryCompletion":940,"completion":941,"start":942,"enrollment":324,"conditions":9484,"interventions":9485},[86],[735],[945,588,946],{"nctId":9487,"briefTitle":9488,"status":393,"phases":9489,"primaryCompletion":2680,"completion":5264,"start":9490,"enrollment":9491,"conditions":9492,"interventions":9496},"NCT07415044","LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis",[86],"2026-03-26",1431,[9493,9494,9495],"Ulcerative Colitis (UC)","Ulcerative Colitis, Active Moderate","Ulcerative Colitis, Active Severe",[945],{"trials":9498,"activeCount":97},[],{"trials":9500,"activeCount":97},[],{"trials":9502,"activeCount":97},[],{"intervention":9174,"totalTrials":947,"cells":9504},{"EARLY_PHASE1":9505,"PHASE1":9507,"PHASE2":9509,"PHASE3":9519,"PHASE4":9521,"NA":9523},{"trials":9506,"activeCount":97},[],{"trials":9508,"activeCount":97},[],{"trials":9510,"activeCount":947,"soonestReadout":2527},[9511,9515],{"nctId":9166,"briefTitle":9167,"status":393,"phases":9512,"primaryCompletion":2527,"completion":1993,"start":9169,"enrollment":874,"conditions":9513,"interventions":9514},[86],[9171,9172],[9174,9175,9151],{"nctId":9177,"briefTitle":9178,"status":393,"phases":9516,"primaryCompletion":2527,"completion":1993,"start":9169,"enrollment":874,"conditions":9517,"interventions":9518},[86],[9172],[9151,9174,9175],{"trials":9520,"activeCount":97},[],{"trials":9522,"activeCount":97},[],{"trials":9524,"activeCount":97},[],{"intervention":9175,"totalTrials":947,"cells":9526},{"EARLY_PHASE1":9527,"PHASE1":9529,"PHASE2":9531,"PHASE3":9541,"PHASE4":9543,"NA":9545},{"trials":9528,"activeCount":97},[],{"trials":9530,"activeCount":97},[],{"trials":9532,"activeCount":947,"soonestReadout":2527},[9533,9537],{"nctId":9166,"briefTitle":9167,"status":393,"phases":9534,"primaryCompletion":2527,"completion":1993,"start":9169,"enrollment":874,"conditions":9535,"interventions":9536},[86],[9171,9172],[9174,9175,9151],{"nctId":9177,"briefTitle":9178,"status":393,"phases":9538,"primaryCompletion":2527,"completion":1993,"start":9169,"enrollment":874,"conditions":9539,"interventions":9540},[86],[9172],[9151,9174,9175],{"trials":9542,"activeCount":97},[],{"trials":9544,"activeCount":97},[],{"trials":9546,"activeCount":97},[],{"intervention":916,"totalTrials":947,"cells":9548},{"EARLY_PHASE1":9549,"PHASE1":9551,"PHASE2":9553,"PHASE3":9568,"PHASE4":9570,"NA":9572},{"trials":9550,"activeCount":97},[],{"trials":9552,"activeCount":97},[],{"trials":9554,"activeCount":947,"soonestReadout":2274},[9555,9564],{"nctId":9556,"briefTitle":9557,"status":257,"phases":9558,"primaryCompletion":2274,"completion":420,"start":9559,"enrollment":9560,"conditions":9561,"interventions":9563},"NCT06046729","A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",[86],"2023-10-23",352,[9562],"Hidradenitis Suppurativa",[916],{"nctId":907,"briefTitle":908,"status":393,"phases":9565,"primaryCompletion":910,"completion":911,"start":912,"enrollment":410,"conditions":9566,"interventions":9567},[86],[735,914],[916,588],{"trials":9569,"activeCount":97},[],{"trials":9571,"activeCount":97},[],{"trials":9573,"activeCount":97},[],{"intervention":4768,"totalTrials":947,"cells":9575},{"EARLY_PHASE1":9576,"PHASE1":9578,"PHASE2":9580,"PHASE3":9590,"PHASE4":9592,"NA":9594},{"trials":9577,"activeCount":97},[],{"trials":9579,"activeCount":97},[],{"trials":9581,"activeCount":947,"soonestReadout":2283},[9582,9586],{"nctId":4763,"briefTitle":4764,"status":393,"phases":9583,"primaryCompletion":2283,"completion":940,"start":4721,"enrollment":776,"conditions":9584,"interventions":9585},[86],[24,27,18],[4768,4737,4769,4770],{"nctId":4772,"briefTitle":4773,"status":1060,"phases":9587,"primaryCompletion":395,"completion":396,"start":419,"enrollment":4775,"conditions":9588,"interventions":9589},[86],[27,24],[4768,4737],{"trials":9591,"activeCount":97},[],{"trials":9593,"activeCount":97},[],{"trials":9595,"activeCount":97},[],{"intervention":1631,"totalTrials":1082,"cells":9597},{"EARLY_PHASE1":9598,"PHASE1":9600,"PHASE2":9630,"PHASE3":9660,"PHASE4":9734,"NA":9755},{"trials":9599,"activeCount":97},[],{"trials":9601,"activeCount":97},[9602,9611,9619,9623],{"nctId":9603,"briefTitle":9604,"status":384,"phases":9605,"primaryCompletion":9606,"completion":9606,"start":9607,"enrollment":97,"conditions":9608,"interventions":9609},"NCT05580250","A Study of LY3526318 in Healthy Male Japanese Participants",[85],"2022-12-08","2022-11-22",[15],[9610,1632,2092,1631],"LY3526318",{"nctId":9612,"briefTitle":9613,"status":103,"phases":9614,"primaryCompletion":9615,"completion":9615,"start":7463,"enrollment":3718,"conditions":9616,"interventions":9617},"NCT04156750","A Study of LY3556050 in Healthy Participants",[85],"2020-08-03",[15],[9618,1632,1631],"LY3556050",{"nctId":1624,"briefTitle":1625,"status":103,"phases":9620,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":233,"conditions":9621,"interventions":9622},[85],[15],[48,1631,1632],{"nctId":9624,"briefTitle":9625,"status":103,"phases":9626,"primaryCompletion":629,"completion":629,"start":9627,"enrollment":12,"conditions":9628,"interventions":9629},"NCT05615467","A Study of Effect of LY3556050 on Metformin in Healthy Participants",[85],"2022-11-15",[15],[9618,1631,1632],{"trials":9631,"activeCount":314,"soonestReadout":1751},[9632,9636,9646,9654],{"nctId":1748,"briefTitle":1749,"status":393,"phases":9633,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":9634,"interventions":9635},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"nctId":9637,"briefTitle":9638,"status":999,"phases":9639,"primaryCompletion":1618,"completion":1618,"start":1475,"enrollment":9640,"conditions":9641,"interventions":9642},"NCT02111096","A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus",[86],174,[18],[9643,9644,1631,9645],"LY2409021","Sitagliptin","Sulfonylurea",{"nctId":9647,"briefTitle":9648,"status":999,"phases":9649,"primaryCompletion":1473,"completion":1473,"start":3049,"enrollment":874,"conditions":9650,"interventions":9651},"NCT02020616","A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes",[85,86],[120],[9652,9653,1631],"LY3053102","Exenatide ER",{"nctId":9655,"briefTitle":9656,"status":103,"phases":9657,"primaryCompletion":5030,"completion":5030,"start":6632,"enrollment":7549,"conditions":9658,"interventions":9659},"NCT02091362","A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus",[86],[120],[9643,1631],{"trials":9661,"activeCount":97},[9662,9674,9682,9689,9699,9703,9710,9714,9718,9725],{"nctId":9663,"briefTitle":9664,"status":103,"phases":9665,"primaryCompletion":3320,"completion":3320,"start":2930,"enrollment":9666,"conditions":9667,"interventions":9669},"NCT00401973","Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine",[87],199,[4897,9668],"Schizoaffective Disorders",[9670,9671,9672,9673],"olanzapine","amantadine","metformin","zonisamide",{"nctId":9675,"briefTitle":9676,"status":103,"phases":9677,"primaryCompletion":3020,"completion":3545,"start":3216,"enrollment":9678,"conditions":9679,"interventions":9680},"NCT00734474","A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin",[86,87],1202,[18],[9681,9644,1631],"LY2189265",{"nctId":9683,"briefTitle":9684,"status":103,"phases":9685,"primaryCompletion":4980,"completion":4980,"start":3838,"enrollment":9686,"conditions":9687,"interventions":9688},"NCT01624259","A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes",[87],599,[30],[9681,188,1631],{"nctId":9690,"briefTitle":9691,"status":103,"phases":9692,"primaryCompletion":7547,"completion":9693,"start":9694,"enrollment":9695,"conditions":9696,"interventions":9697},"NCT03214380","A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes",[87],"2019-03-13","2017-07-14",933,[120],[9698,438,506,700,1631,7063],"LY900014",{"nctId":7058,"briefTitle":7059,"status":103,"phases":9700,"primaryCompletion":5081,"completion":5081,"start":4383,"enrollment":1358,"conditions":9701,"interventions":9702},[87],[120],[303,7063,1631],{"nctId":9704,"briefTitle":9705,"status":103,"phases":9706,"primaryCompletion":2865,"completion":3048,"start":3087,"enrollment":9707,"conditions":9708,"interventions":9709},"NCT01075282","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)",[87],810,[18],[506,9681,1631,7071],{"nctId":7112,"briefTitle":7113,"status":103,"phases":9711,"primaryCompletion":3122,"completion":3776,"start":3545,"enrollment":7115,"conditions":9712,"interventions":9713},[87],[120],[303,7103,1631,7118],{"nctId":7129,"briefTitle":7130,"status":103,"phases":9715,"primaryCompletion":3250,"completion":3250,"start":4098,"enrollment":542,"conditions":9716,"interventions":9717},[87],[18],[303,506,1631],{"nctId":9719,"briefTitle":9720,"status":103,"phases":9721,"primaryCompletion":5090,"completion":3838,"start":2956,"enrollment":9722,"conditions":9723,"interventions":9724},"NCT01126580","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)",[87],807,[18],[1631,9681],{"nctId":9726,"briefTitle":9727,"status":103,"phases":9728,"primaryCompletion":5090,"completion":2865,"start":3087,"enrollment":9729,"conditions":9730,"interventions":9731},"NCT01064687","A Study in Participants With Type 2 Diabetes Mellitus",[87],978,[18],[9681,9732,1631,9733],"Exenatide","Pioglitazone",{"trials":9735,"activeCount":97},[9736,9744],{"nctId":9737,"briefTitle":9738,"status":103,"phases":9739,"completion":2833,"start":4459,"enrollment":2413,"conditions":9740,"interventions":9741},"NCT00191464","Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes",[88],[18],[9742,9743,9672],"premeal insulin lispro mixtures","insulin glargine",{"nctId":9745,"briefTitle":9746,"status":999,"phases":9747,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":9749,"interventions":9750},"NCT02072096","A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)",[88],"2014-02",[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],"Acarbose","Linagliptin","Exenatide once weekly","Exenatide twice daily",{"trials":9756,"activeCount":97},[],{"intervention":1722,"totalTrials":1620,"cells":9758},{"EARLY_PHASE1":9759,"PHASE1":9761,"PHASE2":9771,"PHASE3":9856,"PHASE4":9898,"NA":9900},{"trials":9760,"activeCount":97},[],{"trials":9762,"activeCount":97},[9763,9767],{"nctId":2795,"briefTitle":2796,"status":999,"phases":9764,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":1808,"conditions":9765,"interventions":9766},[85],[2802],[1511,1722,1746,1510,1721,2804],{"nctId":6452,"briefTitle":6453,"status":103,"phases":9768,"primaryCompletion":3048,"completion":4420,"start":3152,"enrollment":1054,"conditions":9769,"interventions":9770},[85],[36,1571],[61,1722],{"trials":9772,"activeCount":314,"soonestReadout":940},[9773,9777,9781,9785,9789,9793,9797,9801,9805,9809,9820,9824,9832,9836,9840,9844,9848,9852],{"nctId":6481,"briefTitle":6482,"status":103,"phases":9774,"primaryCompletion":3776,"completion":1546,"start":4122,"enrollment":11,"conditions":9775,"interventions":9776},[86],[6485],[61,1722],{"nctId":1711,"briefTitle":1712,"status":999,"phases":9778,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":425,"conditions":9779,"interventions":9780},[85,86],[1717,1718,1490],[1720,48,1541,1721,1722],{"nctId":8199,"briefTitle":8200,"status":103,"phases":9782,"primaryCompletion":2955,"completion":2918,"start":4474,"enrollment":8202,"conditions":9783,"interventions":9784},[86],[1903],[2979,3106,8205],{"nctId":3589,"briefTitle":3590,"status":103,"phases":9786,"primaryCompletion":3059,"completion":3059,"start":3592,"enrollment":3593,"conditions":9787,"interventions":9788},[86],[1718],[2979,2838,3106,2561],{"nctId":6555,"briefTitle":6556,"status":384,"phases":9790,"primaryCompletion":3698,"completion":6558,"start":2754,"enrollment":97,"conditions":9791,"interventions":9792},[86],[6560],[61,1722],{"nctId":8214,"briefTitle":8215,"status":103,"phases":9794,"primaryCompletion":8217,"completion":2864,"start":3338,"enrollment":7145,"conditions":9795,"interventions":9796},[86],[1903],[3106,8220,1906],{"nctId":3100,"briefTitle":3101,"status":103,"phases":9798,"primaryCompletion":2974,"completion":3103,"start":3040,"enrollment":2867,"conditions":9799,"interventions":9800},[86],[1610],[2912,3106,2839,3107],{"nctId":4363,"briefTitle":4364,"status":103,"phases":9802,"primaryCompletion":3813,"completion":2846,"start":4366,"enrollment":1790,"conditions":9803,"interventions":9804},[86],[36],[1511,3106],{"nctId":4389,"briefTitle":4390,"status":103,"phases":9806,"primaryCompletion":4392,"completion":4393,"start":4394,"enrollment":1282,"conditions":9807,"interventions":9808},[85,86],[1506],[2545,1511,1722],{"nctId":9810,"briefTitle":9811,"status":103,"phases":9812,"primaryCompletion":1473,"completion":1596,"start":3069,"enrollment":4005,"conditions":9813,"interventions":9818},"NCT01282463","Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma",[86],[9814,9815,9816,9817],"Carcinoma of Urinary Tract","Urethral Carcinoma","Carcinoma of Ureter","Carcinoma of Renal Pelvis",[1722,9819,6543],"Ramucirumab DP",{"nctId":4404,"briefTitle":4405,"status":999,"phases":9821,"primaryCompletion":4407,"completion":4407,"start":4408,"enrollment":1488,"conditions":9822,"interventions":9823},[85,86],[4410],[61,1511,1722],{"nctId":9825,"briefTitle":9826,"status":103,"phases":9827,"primaryCompletion":4160,"completion":3838,"start":2956,"enrollment":9828,"conditions":9829,"interventions":9830},"NCT01107444","Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer",[86],180,[1610],[1722,9831],"LY2181308",{"nctId":4456,"briefTitle":4457,"status":103,"phases":9833,"completion":2930,"start":4459,"enrollment":2080,"conditions":9834,"interventions":9835},[86],[1893],[1511,1669,1722],{"nctId":3206,"briefTitle":3207,"status":103,"phases":9837,"completion":3153,"start":3209,"enrollment":1730,"conditions":9838,"interventions":9839},[86],[1589],[1511,3106,2839],{"nctId":5899,"briefTitle":5900,"status":103,"phases":9841,"primaryCompletion":3094,"completion":3837,"start":2833,"enrollment":617,"conditions":9842,"interventions":9843},[86],[36],[2838,5885,3143,3106],{"nctId":1853,"briefTitle":1854,"status":103,"phases":9845,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":1859,"conditions":9846,"interventions":9847},[86],[1861],[48,1722],{"nctId":1864,"briefTitle":1865,"status":393,"phases":9849,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":9850,"interventions":9851},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"nctId":6629,"briefTitle":6630,"status":103,"phases":9853,"primaryCompletion":4122,"completion":6632,"start":3545,"enrollment":6633,"conditions":9854,"interventions":9855},[86],[2968],[61,1722],{"trials":9857,"activeCount":97},[9858,9862,9866,9870,9874,9878,9882,9886,9890,9894],{"nctId":6658,"briefTitle":6659,"status":103,"phases":9859,"primaryCompletion":6661,"completion":6662,"start":6663,"enrollment":6664,"conditions":9860,"interventions":9861},[87],[36],[6615,3106],{"nctId":3766,"briefTitle":3767,"status":103,"phases":9863,"primaryCompletion":2899,"completion":2899,"start":3235,"enrollment":3769,"conditions":9864,"interventions":9865},[87],[1718],[2838,3106,2561],{"nctId":6668,"briefTitle":6669,"status":103,"phases":9867,"primaryCompletion":3049,"completion":1628,"start":3152,"enrollment":6671,"conditions":9868,"interventions":9869},[87],[1718],[61,1722],{"nctId":4597,"briefTitle":4598,"status":103,"phases":9871,"primaryCompletion":3012,"completion":3012,"start":2833,"enrollment":4600,"conditions":9872,"interventions":9873},[87],[4602],[1511,1722,1669],{"nctId":3787,"briefTitle":3788,"status":103,"phases":9875,"primaryCompletion":3645,"completion":3216,"start":2909,"enrollment":3790,"conditions":9876,"interventions":9877},[87],[2903],[1669,1722,1512,1541],{"nctId":6694,"briefTitle":6695,"status":103,"phases":9879,"primaryCompletion":6697,"completion":6698,"start":6699,"enrollment":972,"conditions":9880,"interventions":9881},[87],[6701],[61,1722],{"nctId":6083,"briefTitle":6084,"status":103,"phases":9883,"primaryCompletion":2928,"completion":2918,"start":2876,"enrollment":6086,"conditions":9884,"interventions":9885},[87],[1718],[2838,3106],{"nctId":6090,"briefTitle":6091,"status":103,"phases":9887,"primaryCompletion":6093,"completion":6093,"start":4538,"enrollment":3330,"conditions":9888,"interventions":9889},[87],[1694],[1612,1541,1722],{"nctId":4631,"briefTitle":4632,"status":103,"phases":9891,"primaryCompletion":2974,"completion":2974,"start":4634,"enrollment":564,"conditions":9892,"interventions":9893},[87],[36,1893,4568],[2912,3106,4637],{"nctId":4639,"briefTitle":4640,"status":103,"phases":9895,"completion":4642,"start":3236,"enrollment":542,"conditions":9896,"interventions":9897},[87],[1893],[2912,4637,3106],{"trials":9899,"activeCount":97},[],{"trials":9901,"activeCount":97},[],{"intervention":1875,"totalTrials":1677,"cells":9903},{"EARLY_PHASE1":9904,"PHASE1":9906,"PHASE2":9908,"PHASE3":9930,"PHASE4":9936,"NA":9938},{"trials":9905,"activeCount":97},[],{"trials":9907,"activeCount":97},[],{"trials":9909,"activeCount":314,"soonestReadout":940},[9910,9914,9918,9922,9926],{"nctId":3521,"briefTitle":3522,"status":103,"phases":9911,"primaryCompletion":3251,"completion":3012,"start":3524,"enrollment":3525,"conditions":9912,"interventions":9913},[86],[36],[1612,1512,1511,1875],{"nctId":2895,"briefTitle":2896,"status":103,"phases":9915,"primaryCompletion":2898,"completion":2898,"start":2899,"enrollment":1767,"conditions":9916,"interventions":9917},[86],[2891,2901,2902,2903],[1541,1510,1875],{"nctId":4471,"briefTitle":4472,"status":103,"phases":9919,"completion":4474,"start":3339,"enrollment":4475,"conditions":9920,"interventions":9921},[86],[36],[2912,4478],{"nctId":1864,"briefTitle":1865,"status":393,"phases":9923,"primaryCompletion":940,"completion":940,"start":1867,"enrollment":1868,"conditions":9924,"interventions":9925},[86],[1870,1871,1872],[61,1874,1875,1511,1722,48,1745,1746],{"nctId":6637,"briefTitle":6638,"status":103,"phases":9927,"primaryCompletion":6640,"completion":6641,"start":1867,"enrollment":1620,"conditions":9928,"interventions":9929},[85,86],[6643],[61,1874,1875],{"trials":9931,"activeCount":97},[9932],{"nctId":3315,"briefTitle":3316,"status":103,"phases":9933,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":3321,"conditions":9934,"interventions":9935},[87],[1694],[1612,1510,3324,1875,1669,1512],{"trials":9937,"activeCount":97},[],{"trials":9939,"activeCount":97},[],{"intervention":401,"totalTrials":425,"cells":9941},{"EARLY_PHASE1":9942,"PHASE1":9944,"PHASE2":9973,"PHASE3":9979,"PHASE4":9981,"NA":9983},{"trials":9943,"activeCount":97},[],{"trials":9945,"activeCount":97},[9946,9953,9959,9967],{"nctId":9947,"briefTitle":9948,"status":103,"phases":9949,"primaryCompletion":9950,"completion":9950,"start":6497,"enrollment":6943,"conditions":9951,"interventions":9952},"NCT03325387","A Study of Multiple Doses of LY3305677 in Healthy Participants",[85],"2018-08-03",[15],[401],{"nctId":9954,"briefTitle":9955,"status":103,"phases":9956,"primaryCompletion":7419,"completion":7419,"start":7910,"enrollment":310,"conditions":9957,"interventions":9958},"NCT05623839","A Study of LY3305677 in Participants With Obesity Or Overweight",[85],[27,24],[401],{"nctId":9960,"briefTitle":9961,"status":103,"phases":9962,"primaryCompletion":9963,"completion":9963,"start":9964,"enrollment":290,"conditions":9965,"interventions":9966},"NCT03928379","A Study of LY3305677 in Participants With Type 2 Diabetes",[85],"2021-07-08","2019-10-27",[18],[401],{"nctId":9968,"briefTitle":9969,"status":103,"phases":9970,"primaryCompletion":9694,"completion":9694,"start":1994,"enrollment":1587,"conditions":9971,"interventions":9972},"NCT02972645","A Study of LY3305677 in Healthy Participants",[85],[15],[401],{"trials":9974,"activeCount":314,"soonestReadout":395},[9975],{"nctId":391,"briefTitle":392,"status":393,"phases":9976,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":9977,"interventions":9978},[86],[24,27],[401,110,92,402,403],{"trials":9980,"activeCount":97},[],{"trials":9982,"activeCount":97},[],{"trials":9984,"activeCount":97},[],{"intervention":1493,"totalTrials":425,"cells":9986},{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":10009,"PHASE3":10015,"PHASE4":10017,"NA":10019},{"trials":9988,"activeCount":97},[],{"trials":9990,"activeCount":97},[9991,9995,9999,10005],{"nctId":1482,"briefTitle":1483,"status":103,"phases":9992,"primaryCompletion":1485,"completion":1486,"start":1487,"enrollment":1488,"conditions":9993,"interventions":9994},[85],[1466,1490,1491],[61,1493,48],{"nctId":2727,"briefTitle":2728,"status":103,"phases":9996,"primaryCompletion":2730,"completion":2731,"start":2732,"enrollment":2733,"conditions":9997,"interventions":9998},[85],[1466,1560,2735,1505,2736,1503,1608],[1493,1510,1511],{"nctId":10000,"briefTitle":10001,"status":103,"phases":10002,"primaryCompletion":1628,"completion":1628,"start":2799,"enrollment":290,"conditions":10003,"interventions":10004},"NCT02779738","A Study of Merestinib (LY2801653) in Healthy Participants",[85],[15],[1493],{"nctId":1643,"briefTitle":1644,"status":103,"phases":10006,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":1649,"conditions":10007,"interventions":10008},[85],[1503,1651,1652,1653,1654],[1656,61,48,1493,1657],{"trials":10010,"activeCount":314,"soonestReadout":60},[10011],{"nctId":58,"briefTitle":59,"status":257,"phases":10012,"primaryCompletion":60,"completion":462,"start":2882,"enrollment":2883,"conditions":10013,"interventions":10014},[86],[2623,1560,1466],[61,1493,1510,1511],{"trials":10016,"activeCount":97},[],{"trials":10018,"activeCount":97},[],{"trials":10020,"activeCount":97},[],{"intervention":403,"totalTrials":425,"cells":10022},{"EARLY_PHASE1":10023,"PHASE1":10025,"PHASE2":10052,"PHASE3":10058,"PHASE4":10060,"NA":10062},{"trials":10024,"activeCount":97},[],{"trials":10026,"activeCount":97},[10027,10031,10038,10045],{"nctId":6968,"briefTitle":6969,"status":103,"phases":10028,"primaryCompletion":1520,"completion":1520,"start":6971,"enrollment":963,"conditions":10029,"interventions":10030},[85],[18],[403,303],{"nctId":10032,"briefTitle":10033,"status":103,"phases":10034,"primaryCompletion":2702,"completion":2702,"start":10035,"enrollment":1803,"conditions":10036,"interventions":10037},"NCT06557356","A Study of LY3532226 in Participants With Obesity",[85],"2024-08-16",[24],[403],{"nctId":10039,"briefTitle":10040,"status":103,"phases":10041,"primaryCompletion":2397,"completion":2397,"start":10042,"enrollment":1620,"conditions":10043,"interventions":10044},"NCT05887999","A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus",[85],"2023-06-12",[33],[403],{"nctId":10046,"briefTitle":10047,"status":103,"phases":10048,"primaryCompletion":10049,"completion":10049,"start":5280,"enrollment":2542,"conditions":10050,"interventions":10051},"NCT04923269","A Study of LY3532226 in Healthy Participants",[85],"2021-10-28",[15],[403],{"trials":10053,"activeCount":314,"soonestReadout":395},[10054],{"nctId":391,"briefTitle":392,"status":393,"phases":10055,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":10056,"interventions":10057},[86],[24,27],[401,110,92,402,403],{"trials":10059,"activeCount":97},[],{"trials":10061,"activeCount":97},[],{"trials":10063,"activeCount":97},[],{"intervention":283,"totalTrials":1400,"cells":10065},{"EARLY_PHASE1":10066,"PHASE1":10068,"PHASE2":10082,"PHASE3":10091,"PHASE4":10093,"NA":10095},{"trials":10067,"activeCount":97},[],{"trials":10069,"activeCount":97},[10070,10074,10078],{"nctId":6923,"briefTitle":6924,"status":103,"phases":10071,"primaryCompletion":5335,"completion":5335,"start":6926,"enrollment":6927,"conditions":10072,"interventions":10073},[85],[15,30],[283,303],{"nctId":7004,"briefTitle":7005,"status":103,"phases":10075,"primaryCompletion":7007,"completion":7007,"start":7008,"enrollment":1501,"conditions":10076,"interventions":10077},[85],[18],[283,303],{"nctId":275,"briefTitle":276,"status":103,"phases":10079,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":10080,"interventions":10081},[85],[27,24],[283,92],{"trials":10083,"activeCount":314,"soonestReadout":462},[10084],{"nctId":10085,"briefTitle":10086,"status":393,"phases":10087,"primaryCompletion":462,"completion":322,"start":10088,"enrollment":2502,"conditions":10089,"interventions":10090},"NCT06897475","A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide",[86],"2025-03-28",[30],[283],{"trials":10092,"activeCount":97},[],{"trials":10094,"activeCount":97},[],{"trials":10096,"activeCount":97},[],{"intervention":177,"totalTrials":1400,"cells":10098},{"EARLY_PHASE1":10099,"PHASE1":10101,"PHASE2":10107,"PHASE3":10121,"PHASE4":10123,"NA":10125},{"trials":10100,"activeCount":97},[],{"trials":10102,"activeCount":97},[10103],{"nctId":169,"briefTitle":170,"status":103,"phases":10104,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":10105,"interventions":10106},[85],[15],[177,92,178],{"trials":10108,"activeCount":314,"soonestReadout":321},[10109,10113,10117],{"nctId":318,"briefTitle":319,"status":257,"phases":10110,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":10111,"interventions":10112},[86],[24,27],[177,92,327,328],{"nctId":7906,"briefTitle":7907,"status":103,"phases":10114,"primaryCompletion":4036,"completion":7909,"start":7910,"enrollment":7911,"conditions":10115,"interventions":10116},[86],[24,2090,778],[177,198],{"nctId":382,"briefTitle":383,"status":384,"phases":10118,"primaryCompletion":386,"completion":386,"start":387,"enrollment":97,"conditions":10119,"interventions":10120},[86],[24,27],[177,92,327,328],{"trials":10122,"activeCount":97},[],{"trials":10124,"activeCount":97},[],{"trials":10126,"activeCount":97},[],{"intervention":10128,"totalTrials":1232,"cells":10129},"LY3537021",{"EARLY_PHASE1":10130,"PHASE1":10132,"PHASE2":10149,"PHASE3":10163,"PHASE4":10165,"NA":10167},{"trials":10131,"activeCount":97},[],{"trials":10133,"activeCount":97},[10134,10141],{"nctId":10135,"briefTitle":10136,"status":103,"phases":10137,"primaryCompletion":10138,"completion":10138,"start":3988,"enrollment":22,"conditions":10139,"interventions":10140},"NCT04586907","A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus",[85],"2021-11-30",[15,120],[10128],{"nctId":10142,"briefTitle":10143,"status":103,"phases":10144,"primaryCompletion":10145,"completion":10145,"start":10146,"enrollment":128,"conditions":10147,"interventions":10148},"NCT05444569","A Study of LY3537021 in Healthy Participants",[85],"2023-02-24","2022-08-08",[15],[10128,188],{"trials":10150,"activeCount":314,"soonestReadout":462},[10151],{"nctId":10152,"briefTitle":10153,"status":393,"phases":10154,"primaryCompletion":462,"completion":853,"start":10155,"enrollment":5841,"conditions":10156,"interventions":10160},"NCT07169851","A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer",[86],"2025-11-28",[10157,10158,10159,1870],"Nausea","Vomiting","Drug-Related Side Effects and Adverse Reactions",[10128,10161,10162],"Standard of Care Antiemetic Therapies","Background Chemotherapy",{"trials":10164,"activeCount":97},[],{"trials":10166,"activeCount":97},[],{"trials":10168,"activeCount":97},[],{"intervention":327,"totalTrials":947,"cells":10170},{"EARLY_PHASE1":10171,"PHASE1":10173,"PHASE2":10175,"PHASE3":10185,"PHASE4":10187,"NA":10189},{"trials":10172,"activeCount":97},[],{"trials":10174,"activeCount":97},[],{"trials":10176,"activeCount":314,"soonestReadout":321},[10177,10181],{"nctId":318,"briefTitle":319,"status":257,"phases":10178,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":10179,"interventions":10180},[86],[24,27],[177,92,327,328],{"nctId":382,"briefTitle":383,"status":384,"phases":10182,"primaryCompletion":386,"completion":386,"start":387,"enrollment":97,"conditions":10183,"interventions":10184},[86],[24,27],[177,92,327,328],{"trials":10186,"activeCount":97},[],{"trials":10188,"activeCount":97},[],{"trials":10190,"activeCount":97},[],{"intervention":328,"totalTrials":947,"cells":10192},{"EARLY_PHASE1":10193,"PHASE1":10195,"PHASE2":10197,"PHASE3":10207,"PHASE4":10209,"NA":10211},{"trials":10194,"activeCount":97},[],{"trials":10196,"activeCount":97},[],{"trials":10198,"activeCount":314,"soonestReadout":321},[10199,10203],{"nctId":318,"briefTitle":319,"status":257,"phases":10200,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":10201,"interventions":10202},[86],[24,27],[177,92,327,328],{"nctId":382,"briefTitle":383,"status":384,"phases":10204,"primaryCompletion":386,"completion":386,"start":387,"enrollment":97,"conditions":10205,"interventions":10206},[86],[24,27],[177,92,327,328],{"trials":10208,"activeCount":97},[],{"trials":10210,"activeCount":97},[],{"trials":10212,"activeCount":97},[],{"intervention":10214,"totalTrials":947,"cells":10215},"Mazdutide",{"EARLY_PHASE1":10216,"PHASE1":10218,"PHASE2":10220,"PHASE3":10238,"PHASE4":10240,"NA":10242},{"trials":10217,"activeCount":97},[],{"trials":10219,"activeCount":97},[],{"trials":10221,"activeCount":314,"soonestReadout":420},[10222,10229],{"nctId":10223,"briefTitle":10224,"status":257,"phases":10225,"primaryCompletion":420,"completion":420,"start":10226,"enrollment":542,"conditions":10227,"interventions":10228},"NCT06817356","A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder",[86],"2025-02-06",[4724],[10214],{"nctId":10230,"briefTitle":10231,"status":103,"phases":10232,"primaryCompletion":10233,"completion":10234,"start":397,"enrollment":10235,"conditions":10236,"interventions":10237},"NCT06124807","A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight",[86],"2025-01-22","2025-07-09",179,[24,8884],[10214],{"trials":10239,"activeCount":97},[],{"trials":10241,"activeCount":97},[],{"trials":10243,"activeCount":97},[],{"intervention":10245,"totalTrials":947,"cells":10246},"LY3848575",{"EARLY_PHASE1":10247,"PHASE1":10249,"PHASE2":10258,"PHASE3":10270,"PHASE4":10272,"NA":10274},{"trials":10248,"activeCount":97},[],{"trials":10250,"activeCount":97},[10251],{"nctId":10252,"briefTitle":10253,"status":103,"phases":10254,"primaryCompletion":7303,"completion":7303,"start":10255,"enrollment":2867,"conditions":10256,"interventions":10257},"NCT05727072","A Study of LY3848575 in Healthy Participants",[85],"2023-02-10",[15],[10245,10245],{"trials":10259,"activeCount":314,"soonestReadout":419},[10260],{"nctId":10261,"briefTitle":10262,"status":257,"phases":10263,"primaryCompletion":419,"completion":408,"start":10264,"enrollment":10265,"conditions":10266,"interventions":10269},"NCT06568042","Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy",[86],"2024-08-22",558,[10267,10268],"Neuropathic Pain","Distal Sensory Polyneuropathy",[10245],{"trials":10271,"activeCount":97},[],{"trials":10273,"activeCount":97},[],{"trials":10275,"activeCount":97},[],{"intervention":10277,"totalTrials":314,"cells":10278},"LOXO-292",{"EARLY_PHASE1":10279,"PHASE1":10281,"PHASE2":10283,"PHASE3":10294,"PHASE4":10296,"NA":10298},{"trials":10280,"activeCount":97},[],{"trials":10282,"activeCount":97},[],{"trials":10284,"activeCount":314,"soonestReadout":10289},[10285],{"nctId":10286,"briefTitle":10287,"status":257,"phases":10288,"primaryCompletion":10289,"completion":853,"start":10290,"enrollment":10291,"conditions":10292,"interventions":10293},"NCT03157128","A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",[85,86],"2025-02-14","2017-05-02",857,[1718,6293,1504,2766],[10277],{"trials":10295,"activeCount":97},[],{"trials":10297,"activeCount":97},[],{"trials":10299,"activeCount":97},[],{"intervention":9458,"totalTrials":314,"cells":10301},{"EARLY_PHASE1":10302,"PHASE1":10304,"PHASE2":10306,"PHASE3":10312,"PHASE4":10314,"NA":10316},{"trials":10303,"activeCount":97},[],{"trials":10305,"activeCount":97},[],{"trials":10307,"activeCount":314,"soonestReadout":259},[10308],{"nctId":9452,"briefTitle":9453,"status":393,"phases":10309,"primaryCompletion":259,"completion":462,"start":9455,"enrollment":1692,"conditions":10310,"interventions":10311},[86],[18],[9426,9458],{"trials":10313,"activeCount":97},[],{"trials":10315,"activeCount":97},[],{"trials":10317,"activeCount":97},[],{"intervention":10161,"totalTrials":314,"cells":10319},{"EARLY_PHASE1":10320,"PHASE1":10322,"PHASE2":10324,"PHASE3":10330,"PHASE4":10332,"NA":10334},{"trials":10321,"activeCount":97},[],{"trials":10323,"activeCount":97},[],{"trials":10325,"activeCount":314,"soonestReadout":462},[10326],{"nctId":10152,"briefTitle":10153,"status":393,"phases":10327,"primaryCompletion":462,"completion":853,"start":10155,"enrollment":5841,"conditions":10328,"interventions":10329},[86],[10157,10158,10159,1870],[10128,10161,10162],{"trials":10331,"activeCount":97},[],{"trials":10333,"activeCount":97},[],{"trials":10335,"activeCount":97},[],{"intervention":10162,"totalTrials":314,"cells":10337},{"EARLY_PHASE1":10338,"PHASE1":10340,"PHASE2":10342,"PHASE3":10348,"PHASE4":10350,"NA":10352},{"trials":10339,"activeCount":97},[],{"trials":10341,"activeCount":97},[],{"trials":10343,"activeCount":314,"soonestReadout":462},[10344],{"nctId":10152,"briefTitle":10153,"status":393,"phases":10345,"primaryCompletion":462,"completion":853,"start":10155,"enrollment":5841,"conditions":10346,"interventions":10347},[86],[10157,10158,10159,1870],[10128,10161,10162],{"trials":10349,"activeCount":97},[],{"trials":10351,"activeCount":97},[],{"trials":10353,"activeCount":97},[],{"intervention":1757,"totalTrials":314,"cells":10355},{"EARLY_PHASE1":10356,"PHASE1":10358,"PHASE2":10360,"PHASE3":10366,"PHASE4":10368,"NA":10370},{"trials":10357,"activeCount":97},[],{"trials":10359,"activeCount":97},[],{"trials":10361,"activeCount":314,"soonestReadout":1751},[10362],{"nctId":1748,"briefTitle":1749,"status":393,"phases":10363,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":10364,"interventions":10365},[85,86],[36,1755],[1757,1468,1758,1759,1613,1697,1760,1761,48,1667,1631],{"trials":10367,"activeCount":97},[],{"trials":10369,"activeCount":97},[],{"trials":10371,"activeCount":97},[],{"intervention":43,"totalTrials":314,"cells":10373},{"EARLY_PHASE1":10374,"PHASE1":10376,"PHASE2":10378,"PHASE3":10386,"PHASE4":10388,"NA":10390},{"trials":10375,"activeCount":97},[],{"trials":10377,"activeCount":97},[],{"trials":10379,"activeCount":314,"soonestReadout":42},[10380],{"nctId":40,"briefTitle":41,"status":257,"phases":10381,"primaryCompletion":42,"completion":462,"start":10382,"enrollment":8918,"conditions":10383,"interventions":10385},[86],"2012-05-22",[10384],"Neoplasms, Hematologic",[43],{"trials":10387,"activeCount":97},[],{"trials":10389,"activeCount":97},[],{"trials":10391,"activeCount":97},[],{"intervention":4769,"totalTrials":314,"cells":10393},{"EARLY_PHASE1":10394,"PHASE1":10396,"PHASE2":10398,"PHASE3":10404,"PHASE4":10406,"NA":10408},{"trials":10395,"activeCount":97},[],{"trials":10397,"activeCount":97},[],{"trials":10399,"activeCount":314,"soonestReadout":2283},[10400],{"nctId":4763,"briefTitle":4764,"status":393,"phases":10401,"primaryCompletion":2283,"completion":940,"start":4721,"enrollment":776,"conditions":10402,"interventions":10403},[86],[24,27,18],[4768,4737,4769,4770],{"trials":10405,"activeCount":97},[],{"trials":10407,"activeCount":97},[],{"trials":10409,"activeCount":97},[],{"intervention":4770,"totalTrials":314,"cells":10411},{"EARLY_PHASE1":10412,"PHASE1":10414,"PHASE2":10416,"PHASE3":10422,"PHASE4":10424,"NA":10426},{"trials":10413,"activeCount":97},[],{"trials":10415,"activeCount":97},[],{"trials":10417,"activeCount":314,"soonestReadout":2283},[10418],{"nctId":4763,"briefTitle":4764,"status":393,"phases":10419,"primaryCompletion":2283,"completion":940,"start":4721,"enrollment":776,"conditions":10420,"interventions":10421},[86],[24,27,18],[4768,4737,4769,4770],{"trials":10423,"activeCount":97},[],{"trials":10425,"activeCount":97},[],{"trials":10427,"activeCount":97},[],{"intervention":1811,"totalTrials":314,"cells":10429},{"EARLY_PHASE1":10430,"PHASE1":10432,"PHASE2":10434,"PHASE3":10440,"PHASE4":10442,"NA":10444},{"trials":10431,"activeCount":97},[],{"trials":10433,"activeCount":97},[],{"trials":10435,"activeCount":314,"soonestReadout":65},[10436],{"nctId":63,"briefTitle":64,"status":257,"phases":10437,"primaryCompletion":65,"completion":462,"start":923,"enrollment":1808,"conditions":10438,"interventions":10439},[86],[1571],[48,1761,1811],{"trials":10441,"activeCount":97},[],{"trials":10443,"activeCount":97},[],{"trials":10445,"activeCount":97},[],{"intervention":946,"totalTrials":314,"cells":10447},{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10452,"PHASE3":10458,"PHASE4":10460,"NA":10462},{"trials":10449,"activeCount":97},[],{"trials":10451,"activeCount":97},[],{"trials":10453,"activeCount":314,"soonestReadout":940},[10454],{"nctId":937,"briefTitle":938,"status":393,"phases":10455,"primaryCompletion":940,"completion":941,"start":942,"enrollment":324,"conditions":10456,"interventions":10457},[86],[735],[945,588,946],{"trials":10459,"activeCount":97},[],{"trials":10461,"activeCount":97},[],{"trials":10463,"activeCount":97},[],{"intervention":5498,"totalTrials":314,"cells":10465},{"EARLY_PHASE1":10466,"PHASE1":10468,"PHASE2":10470,"PHASE3":10476,"PHASE4":10478,"NA":10480},{"trials":10467,"activeCount":97},[],{"trials":10469,"activeCount":97},[],{"trials":10471,"activeCount":314,"soonestReadout":5495},[10472],{"nctId":5492,"briefTitle":5493,"status":1060,"phases":10473,"primaryCompletion":5495,"completion":4063,"start":443,"enrollment":2122,"conditions":10474,"interventions":10475},[86],[1893],[1667,5498,5499],{"trials":10477,"activeCount":97},[],{"trials":10479,"activeCount":97},[],{"trials":10481,"activeCount":97},[],{"intervention":5499,"totalTrials":314,"cells":10483},{"EARLY_PHASE1":10484,"PHASE1":10486,"PHASE2":10488,"PHASE3":10494,"PHASE4":10496,"NA":10498},{"trials":10485,"activeCount":97},[],{"trials":10487,"activeCount":97},[],{"trials":10489,"activeCount":314,"soonestReadout":5495},[10490],{"nctId":5492,"briefTitle":5493,"status":1060,"phases":10491,"primaryCompletion":5495,"completion":4063,"start":443,"enrollment":2122,"conditions":10492,"interventions":10493},[86],[1893],[1667,5498,5499],{"trials":10495,"activeCount":97},[],{"trials":10497,"activeCount":97},[],{"trials":10499,"activeCount":97},[],{"intervention":10501,"totalTrials":314,"cells":10502},"LY3016859 ISA",{"EARLY_PHASE1":10503,"PHASE1":10505,"PHASE2":10507,"PHASE3":10521,"PHASE4":10523,"NA":10525},{"trials":10504,"activeCount":97},[],{"trials":10506,"activeCount":97},[],{"trials":10508,"activeCount":314,"soonestReadout":1011},[10509],{"nctId":10510,"briefTitle":10511,"status":393,"phases":10512,"primaryCompletion":1011,"completion":1011,"start":10513,"enrollment":2371,"conditions":10514,"interventions":10517},"NCT05986292","A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain",[86],"2020-01-30",[2424,10515,10516],"Diabetic Neuropathic Pain","Chronic Low-back Pain",[10501,10518,10519,10520],"LY3556050 ISA","LY3526318 ISA","LY3857210 ISA",{"trials":10522,"activeCount":97},[],{"trials":10524,"activeCount":97},[],{"trials":10526,"activeCount":97},[],{"intervention":10518,"totalTrials":314,"cells":10528},{"EARLY_PHASE1":10529,"PHASE1":10531,"PHASE2":10533,"PHASE3":10539,"PHASE4":10541,"NA":10543},{"trials":10530,"activeCount":97},[],{"trials":10532,"activeCount":97},[],{"trials":10534,"activeCount":314,"soonestReadout":1011},[10535],{"nctId":10510,"briefTitle":10511,"status":393,"phases":10536,"primaryCompletion":1011,"completion":1011,"start":10513,"enrollment":2371,"conditions":10537,"interventions":10538},[86],[2424,10515,10516],[10501,10518,10519,10520],{"trials":10540,"activeCount":97},[],{"trials":10542,"activeCount":97},[],{"trials":10544,"activeCount":97},[],{"intervention":10519,"totalTrials":314,"cells":10546},{"EARLY_PHASE1":10547,"PHASE1":10549,"PHASE2":10551,"PHASE3":10557,"PHASE4":10559,"NA":10561},{"trials":10548,"activeCount":97},[],{"trials":10550,"activeCount":97},[],{"trials":10552,"activeCount":314,"soonestReadout":1011},[10553],{"nctId":10510,"briefTitle":10511,"status":393,"phases":10554,"primaryCompletion":1011,"completion":1011,"start":10513,"enrollment":2371,"conditions":10555,"interventions":10556},[86],[2424,10515,10516],[10501,10518,10519,10520],{"trials":10558,"activeCount":97},[],{"trials":10560,"activeCount":97},[],{"trials":10562,"activeCount":97},[],{"intervention":10520,"totalTrials":314,"cells":10564},{"EARLY_PHASE1":10565,"PHASE1":10567,"PHASE2":10569,"PHASE3":10575,"PHASE4":10577,"NA":10579},{"trials":10566,"activeCount":97},[],{"trials":10568,"activeCount":97},[],{"trials":10570,"activeCount":314,"soonestReadout":1011},[10571],{"nctId":10510,"briefTitle":10511,"status":393,"phases":10572,"primaryCompletion":1011,"completion":1011,"start":10513,"enrollment":2371,"conditions":10573,"interventions":10574},[86],[2424,10515,10516],[10501,10518,10519,10520],{"trials":10576,"activeCount":97},[],{"trials":10578,"activeCount":97},[],{"trials":10580,"activeCount":97},[],{"intervention":10582,"totalTrials":314,"cells":10583},"Mevidalen",{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10588,"PHASE3":10597,"PHASE4":10599,"NA":10601},{"trials":10585,"activeCount":97},[],{"trials":10587,"activeCount":97},[],{"trials":10589,"activeCount":314,"soonestReadout":443},[10590],{"nctId":10591,"briefTitle":10592,"status":257,"phases":10593,"primaryCompletion":443,"completion":443,"start":10594,"enrollment":542,"conditions":10595,"interventions":10596},"NCT06538116","A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease",[86],"2024-08-26",[3980],[10582],{"trials":10598,"activeCount":97},[],{"trials":10600,"activeCount":97},[],{"trials":10602,"activeCount":97},[],{"intervention":10604,"totalTrials":314,"cells":10605},"Solbinsiran",{"EARLY_PHASE1":10606,"PHASE1":10608,"PHASE2":10610,"PHASE3":10620,"PHASE4":10622,"NA":10624},{"trials":10607,"activeCount":97},[],{"trials":10609,"activeCount":97},[],{"trials":10611,"activeCount":314,"soonestReadout":2283},[10612],{"nctId":10613,"briefTitle":10614,"status":393,"phases":10615,"primaryCompletion":2283,"completion":1986,"start":10616,"enrollment":874,"conditions":10617,"interventions":10619},"NCT07269210","A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia",[86],"2025-12-08",[10618],"Severe Hypertriglyceridemia",[10604],{"trials":10621,"activeCount":97},[],{"trials":10623,"activeCount":97},[],{"trials":10625,"activeCount":97},[],{"intervention":4929,"totalTrials":314,"cells":10627},{"EARLY_PHASE1":10628,"PHASE1":10630,"PHASE2":10632,"PHASE3":10638,"PHASE4":10640,"NA":10642},{"trials":10629,"activeCount":97},[],{"trials":10631,"activeCount":97},[],{"trials":10633,"activeCount":314,"soonestReadout":1993},[10634],{"nctId":4922,"briefTitle":4923,"status":393,"phases":10635,"primaryCompletion":1993,"completion":1993,"start":4925,"enrollment":717,"conditions":10636,"interventions":10637},[86],[4927],[4877,4929],{"trials":10639,"activeCount":97},[],{"trials":10641,"activeCount":97},[],{"trials":10643,"activeCount":97},[],{"intervention":10645,"totalTrials":314,"cells":10646},"LY4515100",{"EARLY_PHASE1":10647,"PHASE1":10649,"PHASE2":10651,"PHASE3":10664,"PHASE4":10666,"NA":10668},{"trials":10648,"activeCount":97},[],{"trials":10650,"activeCount":97},[],{"trials":10652,"activeCount":314,"soonestReadout":259},[10653],{"nctId":10654,"briefTitle":10655,"status":393,"phases":10656,"primaryCompletion":259,"completion":462,"start":10657,"enrollment":7166,"conditions":10658,"interventions":10663},"NCT07511816","A Study of LY4515100 in Participants With Pain Following Third Molar Removal",[86],"2026-04-01",[10659,10660,10661,10662],"Acute Pain","Molar","Molar, Third","Surgery, Oral",[10645],{"trials":10665,"activeCount":97},[],{"trials":10667,"activeCount":97},[],{"trials":10669,"activeCount":97},[],{"intervention":10671,"totalTrials":1232,"cells":10672},"LY4256984",{"EARLY_PHASE1":10673,"PHASE1":10675,"PHASE2":10699,"PHASE3":10701,"PHASE4":10703,"NA":10705},{"trials":10674,"activeCount":97},[],{"trials":10676,"activeCount":1232,"soonestReadout":1986},[10677,10685,10691],{"nctId":10678,"briefTitle":10679,"status":1060,"phases":10680,"primaryCompletion":10681,"completion":10681,"start":443,"enrollment":310,"conditions":10682,"interventions":10684},"NCT07571200","A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)",[85],"2029-06",[10683],"Amyotrophic Lateral Sclerosis",[10671],{"nctId":10686,"briefTitle":10687,"status":1060,"phases":10688,"primaryCompletion":10681,"completion":10681,"start":443,"enrollment":310,"conditions":10689,"interventions":10690},"NCT07571174","A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis",[85],[10683],[10671],{"nctId":10692,"briefTitle":10693,"status":393,"phases":10694,"primaryCompletion":1986,"completion":395,"start":10695,"enrollment":310,"conditions":10696,"interventions":10698},"NCT07100119","A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis",[85],"2025-08-05",[10697],"ALS (Amyotrophic Lateral Sclerosis)",[10671],{"trials":10700,"activeCount":97},[],{"trials":10702,"activeCount":97},[],{"trials":10704,"activeCount":97},[],{"trials":10706,"activeCount":97},[],{"intervention":2520,"totalTrials":1199,"cells":10708},{"EARLY_PHASE1":10709,"PHASE1":10711,"PHASE2":10725,"PHASE3":10771,"PHASE4":10777,"NA":10779},{"trials":10710,"activeCount":97},[],{"trials":10712,"activeCount":947,"soonestReadout":941},[10713,10717,10721],{"nctId":2510,"briefTitle":2511,"status":257,"phases":10714,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":10715,"interventions":10716},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":2751,"briefTitle":2752,"status":103,"phases":10718,"primaryCompletion":1546,"completion":2754,"start":1473,"enrollment":12,"conditions":10719,"interventions":10720},[85],[2756],[61,1843,1510,2758,2520],{"nctId":4127,"briefTitle":4128,"status":393,"phases":10722,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":10723,"interventions":10724},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"trials":10726,"activeCount":97},[10727,10731,10735,10739,10743,10747,10754,10760,10764],{"nctId":4174,"briefTitle":4175,"status":103,"phases":10728,"completion":3266,"start":3710,"enrollment":25,"conditions":10729,"interventions":10730},[86],[1490],[1511,4179,4180,4181],{"nctId":6546,"briefTitle":6547,"status":103,"phases":10732,"primaryCompletion":5022,"completion":4098,"start":3069,"enrollment":6549,"conditions":10733,"interventions":10734},[86],[6551,6552],[61,2520,2521,2923],{"nctId":6563,"briefTitle":6564,"status":103,"phases":10736,"primaryCompletion":6566,"completion":665,"start":6567,"enrollment":903,"conditions":10737,"interventions":10738},[86],[3398,3399],[61,2758,2520,1669],{"nctId":4350,"briefTitle":4351,"status":103,"phases":10740,"primaryCompletion":3217,"completion":3048,"start":2875,"enrollment":4353,"conditions":10741,"interventions":10742},[86],[4355],[2979,2912,4357,4181],{"nctId":4370,"briefTitle":4371,"status":103,"phases":10744,"completion":3005,"start":3236,"enrollment":34,"conditions":10745,"interventions":10746},[86],[2652],[1511,2520],{"nctId":10748,"briefTitle":10749,"status":103,"phases":10750,"primaryCompletion":3069,"completion":8217,"start":2846,"enrollment":118,"conditions":10751,"interventions":10752},"NCT00862784","A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer",[86],[2586],[3117,2520,6603,10753,10753],"5-FU",{"nctId":10755,"briefTitle":10756,"status":103,"phases":10757,"conditions":10758,"interventions":10759},"NCT00034619","A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.",[86],[1490],[2893,2520],{"nctId":5950,"briefTitle":5951,"status":103,"phases":10761,"completion":3259,"start":5953,"enrollment":4222,"conditions":10762,"interventions":10763},[86],[5955],[2838,4181],{"nctId":10765,"briefTitle":10766,"status":103,"phases":10767,"primaryCompletion":3685,"completion":8233,"start":3813,"enrollment":37,"conditions":10768,"interventions":10769},"NCT00835185","Study of IMC-11F8 in Participants With Colorectal Cancer",[86],[5657],[10770,2520,6603,10753],"IMC-11F8",{"trials":10772,"activeCount":97},[10773],{"nctId":9080,"briefTitle":9081,"status":103,"phases":10774,"primaryCompletion":2909,"completion":3228,"start":3040,"enrollment":9083,"conditions":10775,"interventions":10776},[87],[1490],[3540,4181,4136,4137,4137,3540],{"trials":10778,"activeCount":97},[],{"trials":10780,"activeCount":97},[],{"intervention":2521,"totalTrials":1677,"cells":10782},{"EARLY_PHASE1":10783,"PHASE1":10785,"PHASE2":10799,"PHASE3":10809,"PHASE4":10815,"NA":10817},{"trials":10784,"activeCount":97},[],{"trials":10786,"activeCount":947,"soonestReadout":941},[10787,10791,10795],{"nctId":2510,"briefTitle":2511,"status":257,"phases":10788,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":10789,"interventions":10790},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":2774,"briefTitle":2775,"status":103,"phases":10792,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":10793,"interventions":10794},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"nctId":4127,"briefTitle":4128,"status":393,"phases":10796,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":10797,"interventions":10798},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"trials":10800,"activeCount":97},[10801,10805],{"nctId":7682,"briefTitle":7683,"status":103,"phases":10802,"primaryCompletion":3685,"completion":5090,"start":3094,"enrollment":195,"conditions":10803,"interventions":10804},[86],[1490],[3447,2521,4137,3054],{"nctId":6546,"briefTitle":6547,"status":103,"phases":10806,"primaryCompletion":5022,"completion":4098,"start":3069,"enrollment":6549,"conditions":10807,"interventions":10808},[86],[6551,6552],[61,2520,2521,2923],{"trials":10810,"activeCount":97},[10811],{"nctId":9080,"briefTitle":9081,"status":103,"phases":10812,"primaryCompletion":2909,"completion":3228,"start":3040,"enrollment":9083,"conditions":10813,"interventions":10814},[87],[1490],[3540,4181,4136,4137,4137,3540],{"trials":10816,"activeCount":97},[],{"trials":10818,"activeCount":97},[],{"intervention":1539,"totalTrials":1677,"cells":10820},{"EARLY_PHASE1":10821,"PHASE1":10823,"PHASE2":10837,"PHASE3":10851,"PHASE4":10853,"NA":10855},{"trials":10822,"activeCount":97},[],{"trials":10824,"activeCount":947,"soonestReadout":81},[10825,10829,10833],{"nctId":1527,"briefTitle":1528,"status":103,"phases":10826,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":10827,"interventions":10828},[85],[1466,1534,1535,1490],[1537,1538,48,1539,1511,1540,1541],{"nctId":4127,"briefTitle":4128,"status":393,"phases":10830,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":10831,"interventions":10832},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"nctId":79,"briefTitle":80,"status":257,"phases":10834,"primaryCompletion":81,"completion":1986,"start":2811,"enrollment":2812,"conditions":10835,"interventions":10836},[85],[1503],[82,1656,1511,2815,1510],{"trials":10838,"activeCount":97},[10839,10843,10847],{"nctId":3510,"briefTitle":3511,"status":103,"phases":10840,"primaryCompletion":3513,"completion":3514,"start":3515,"enrollment":31,"conditions":10841,"interventions":10842},[86],[3517],[1591,3519,1512],{"nctId":4231,"briefTitle":4232,"status":999,"phases":10844,"primaryCompletion":1619,"completion":1619,"start":3124,"enrollment":1199,"conditions":10845,"interventions":10846},[85,86],[1653],[3470,2593,1511,1539],{"nctId":4309,"briefTitle":4310,"status":103,"phases":10848,"primaryCompletion":4312,"completion":4313,"start":4314,"enrollment":4315,"conditions":10849,"interventions":10850},[85,86],[4317],[2545,1539,1511],{"trials":10852,"activeCount":97},[],{"trials":10854,"activeCount":97},[],{"trials":10856,"activeCount":97},[],{"intervention":1577,"totalTrials":1400,"cells":10858},{"EARLY_PHASE1":10859,"PHASE1":10861,"PHASE2":10871,"PHASE3":10881,"PHASE4":10883,"NA":10885},{"trials":10860,"activeCount":97},[],{"trials":10862,"activeCount":947,"soonestReadout":1566},[10863,10867],{"nctId":1563,"briefTitle":1564,"status":257,"phases":10864,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":10865,"interventions":10866},[85],[36,1570,1571,1572],[1574,48,1575,1576,1577,1578,1579],{"nctId":3862,"briefTitle":3863,"status":257,"phases":10868,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":10869,"interventions":10870},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":10872,"activeCount":97},[10873,10877],{"nctId":1784,"briefTitle":1785,"status":103,"phases":10874,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":10875,"interventions":10876},[86],[1792,1793],[48,1577,1468,1795],{"nctId":4563,"briefTitle":4564,"status":103,"phases":10878,"completion":4566,"start":4366,"enrollment":1587,"conditions":10879,"interventions":10880},[86],[1893,4568,36],[1511,1577],{"trials":10882,"activeCount":97},[],{"trials":10884,"activeCount":97},[],{"trials":10886,"activeCount":97},[],{"intervention":2562,"totalTrials":1199,"cells":10888},{"EARLY_PHASE1":10889,"PHASE1":10891,"PHASE2":10979,"PHASE3":10981,"PHASE4":10983,"NA":10985},{"trials":10890,"activeCount":97},[],{"trials":10892,"activeCount":947,"soonestReadout":1309},[10893,10897,10906,10915,10919,10923,10930,10938,10945,10953,10962,10968,10972],{"nctId":9158,"briefTitle":9159,"status":1060,"phases":10894,"primaryCompletion":1309,"completion":1309,"start":443,"enrollment":1062,"conditions":10895,"interventions":10896},[85],[15],[9151,2562,2562],{"nctId":10898,"briefTitle":10899,"status":103,"phases":10900,"primaryCompletion":3697,"completion":3697,"start":3319,"enrollment":118,"conditions":10901,"interventions":10902},"NCT02300259","A Study of LY2623091 in Healthy Participants",[85],[21],[10903,2562,2092,10904,10905],"LY2623091","Tadalafil","Diltiazem",{"nctId":10907,"briefTitle":10908,"status":999,"phases":10909,"primaryCompletion":10910,"completion":10910,"start":1156,"enrollment":10911,"conditions":10912,"interventions":10913},"NCT04586920","A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants",[85],"2022-10-14",104,[15],[10914,2562,1538],"LY3509754",{"nctId":6212,"briefTitle":6213,"status":103,"phases":10916,"primaryCompletion":6215,"completion":6216,"start":3617,"enrollment":290,"conditions":10917,"interventions":10918},[85],[15],[2685,2562,6219],{"nctId":2547,"briefTitle":2548,"status":393,"phases":10920,"primaryCompletion":853,"completion":1011,"start":2550,"enrollment":2551,"conditions":10921,"interventions":10922},[85],[2553,2505,2554,1589,2555,2556,2557],[2559,2560,2561,2562,2563],{"nctId":10924,"briefTitle":10925,"status":999,"phases":10926,"primaryCompletion":1462,"completion":1462,"start":10927,"enrollment":2071,"conditions":10928,"interventions":10929},"NCT05205447","Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants",[85],"2022-01-05",[15],[2768,2562,2065],{"nctId":10931,"briefTitle":10932,"status":103,"phases":10933,"primaryCompletion":2820,"completion":2820,"start":10934,"enrollment":137,"conditions":10935,"interventions":10936},"NCT02989389","A Study of LY3323795 in Healthy Participants",[85],"2016-12-12",[15],[10937,2562],"LY3323795",{"nctId":10939,"briefTitle":10940,"status":103,"phases":10941,"primaryCompletion":1462,"completion":1462,"start":10942,"enrollment":2720,"conditions":10943,"interventions":10944},"NCT04840888","A Study of LY3484356 in Healthy Female Participants",[85],"2021-04-26",[15],[1574,1171,2562,2065,1538],{"nctId":10946,"briefTitle":10947,"status":103,"phases":10948,"primaryCompletion":10949,"completion":10949,"start":10950,"enrollment":1488,"conditions":10951,"interventions":10952},"NCT03792139","An Interaction Study of LY3200882 in Healthy Participants",[85],"2019-02-23","2019-01-08",[15],[82,2562],{"nctId":10954,"briefTitle":10955,"status":999,"phases":10956,"primaryCompletion":10957,"completion":10957,"start":10958,"enrollment":214,"conditions":10959,"interventions":10960},"NCT04014361","A Study of LY3154885 in Healthy Participants",[85],"2020-02-09","2019-08-09",[15],[10961,2562,10961],"LY3154885 -",{"nctId":10963,"briefTitle":10964,"status":103,"phases":10965,"primaryCompletion":1547,"completion":1547,"start":3776,"enrollment":1501,"conditions":10966,"interventions":10967},"NCT02323334","A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease",[85],[21,3980],[3982,2562],{"nctId":7866,"briefTitle":7867,"status":103,"phases":10969,"primaryCompletion":7869,"completion":7869,"start":7870,"enrollment":1620,"conditions":10970,"interventions":10971},[85],[15],[2655,2562,2065],{"nctId":10973,"briefTitle":10974,"status":103,"phases":10975,"primaryCompletion":3717,"completion":3717,"start":1473,"enrollment":2867,"conditions":10976,"interventions":10977},"NCT02365571","A Study of LY3154207 in Healthy Participants",[85],[4997],[10978,2562],"LY3154207",{"trials":10980,"activeCount":97},[],{"trials":10982,"activeCount":97},[],{"trials":10984,"activeCount":97},[],{"trials":10986,"activeCount":97},[],{"intervention":1574,"totalTrials":425,"cells":10988},{"EARLY_PHASE1":10989,"PHASE1":10991,"PHASE2":11025,"PHASE3":11027,"PHASE4":11029,"NA":11031},{"trials":10990,"activeCount":97},[],{"trials":10992,"activeCount":947,"soonestReadout":1566},[10993,11002,11006,11010,11018],{"nctId":10994,"briefTitle":10995,"status":103,"phases":10996,"primaryCompletion":10997,"completion":10997,"start":10998,"enrollment":1071,"conditions":10999,"interventions":11000},"NCT04991766","A Study of [¹⁴C]-LY3484356 in Healthy Female Participants",[85],"2022-04-02","2021-08-13",[15],[11001,1574,11001],"[¹⁴C]-LY3484356",{"nctId":1563,"briefTitle":1564,"status":257,"phases":11003,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":11004,"interventions":11005},[85],[36,1570,1571,1572],[1574,48,1575,1576,1577,1578,1579],{"nctId":10939,"briefTitle":10940,"status":103,"phases":11007,"primaryCompletion":1462,"completion":1462,"start":10942,"enrollment":2720,"conditions":11008,"interventions":11009},[85],[15],[1574,1171,2562,2065,1538],{"nctId":11011,"briefTitle":11012,"status":257,"phases":11013,"primaryCompletion":11014,"completion":462,"start":11015,"enrollment":1237,"conditions":11016,"interventions":11017},"NCT05509790","A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer",[85],"2024-02-18","2022-10-09",[1893],[1574],{"nctId":11019,"briefTitle":11020,"status":103,"phases":11021,"primaryCompletion":279,"completion":279,"start":11022,"enrollment":8967,"conditions":11023,"interventions":11024},"NCT04647487","A Study of LY3484356 in Women With Breast Cancer Before Having Surgery",[85],"2021-04-21",[36],[1574],{"trials":11026,"activeCount":97},[],{"trials":11028,"activeCount":97},[],{"trials":11030,"activeCount":97},[],{"trials":11032,"activeCount":97},[],{"intervention":2768,"totalTrials":425,"cells":11034},{"EARLY_PHASE1":11035,"PHASE1":11037,"PHASE2":11076,"PHASE3":11078,"PHASE4":11080,"NA":11082},{"trials":11036,"activeCount":97},[],{"trials":11038,"activeCount":947,"soonestReadout":11051},[11039,11043,11047,11060,11068],{"nctId":2760,"briefTitle":2761,"status":257,"phases":11040,"primaryCompletion":154,"completion":443,"start":2763,"enrollment":776,"conditions":11041,"interventions":11042},[85],[1505,2765,1850,2766],[2768,1511,1510,2696],{"nctId":10924,"briefTitle":10925,"status":999,"phases":11044,"primaryCompletion":1462,"completion":1462,"start":10927,"enrollment":2071,"conditions":11045,"interventions":11046},[85],[15],[2768,2562,2065],{"nctId":11048,"briefTitle":11049,"status":257,"phases":11050,"primaryCompletion":11051,"completion":443,"start":6662,"enrollment":3769,"conditions":11052,"interventions":11057},"NCT04603001","Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations",[85],"2023-07-03",[11053,11054,11055,11056],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)","Chronic Myelomonocytic Leukemia (CMML)","Myeloproliferative Neoplasms (MPNs)",[2768,11058,11059],"Venetoclax","Azacitidine",{"nctId":11061,"briefTitle":11062,"status":103,"phases":11063,"primaryCompletion":11064,"completion":11064,"start":11065,"enrollment":137,"conditions":11066,"interventions":11067},"NCT06181045","A Study of LY3410738 in Healthy Adult Participants",[85],"2021-08-04","2021-02-24",[15],[2768],{"nctId":11069,"briefTitle":11070,"status":103,"phases":11071,"primaryCompletion":1346,"completion":1346,"start":11072,"enrollment":874,"conditions":11073,"interventions":11074},"NCT06181084","A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants",[85],"2021-10-11",[15],[2768,11075],"Esomeprazole",{"trials":11077,"activeCount":97},[],{"trials":11079,"activeCount":97},[],{"trials":11081,"activeCount":97},[],{"trials":11083,"activeCount":97},[],{"intervention":1575,"totalTrials":1232,"cells":11085},{"EARLY_PHASE1":11086,"PHASE1":11088,"PHASE2":11102,"PHASE3":11104,"PHASE4":11106,"NA":11108},{"trials":11087,"activeCount":97},[],{"trials":11089,"activeCount":947,"soonestReadout":1566},[11090,11094,11098],{"nctId":7750,"briefTitle":7751,"status":999,"phases":11091,"primaryCompletion":3020,"completion":3020,"start":3419,"enrollment":864,"conditions":11092,"interventions":11093},[85],[5763,1706,2585,7754],[7756,1721,1575],{"nctId":1563,"briefTitle":1564,"status":257,"phases":11095,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":11096,"interventions":11097},[85],[36,1570,1571,1572],[1574,48,1575,1576,1577,1578,1579],{"nctId":3862,"briefTitle":3863,"status":257,"phases":11099,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":11100,"interventions":11101},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":11103,"activeCount":97},[],{"trials":11105,"activeCount":97},[],{"trials":11107,"activeCount":97},[],{"trials":11109,"activeCount":97},[],{"intervention":2519,"totalTrials":947,"cells":11111},{"EARLY_PHASE1":11112,"PHASE1":11114,"PHASE2":11124,"PHASE3":11126,"PHASE4":11128,"NA":11130},{"trials":11113,"activeCount":97},[],{"trials":11115,"activeCount":947,"soonestReadout":454},[11116,11120],{"nctId":2510,"briefTitle":2511,"status":257,"phases":11117,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":11118,"interventions":11119},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"nctId":2626,"briefTitle":2627,"status":393,"phases":11121,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":11122,"interventions":11123},[85],[2516,1717,1610,2632],[2634,1696,1510,1512,1612,1669,2519],{"trials":11125,"activeCount":97},[],{"trials":11127,"activeCount":97},[],{"trials":11129,"activeCount":97},[],{"trials":11131,"activeCount":97},[],{"intervention":1579,"totalTrials":947,"cells":11133},{"EARLY_PHASE1":11134,"PHASE1":11136,"PHASE2":11146,"PHASE3":11148,"PHASE4":11150,"NA":11152},{"trials":11135,"activeCount":97},[],{"trials":11137,"activeCount":947,"soonestReadout":1566},[11138,11142],{"nctId":1563,"briefTitle":1564,"status":257,"phases":11139,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":11140,"interventions":11141},[85],[36,1570,1571,1572],[1574,48,1575,1576,1577,1578,1579],{"nctId":3862,"briefTitle":3863,"status":257,"phases":11143,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":11144,"interventions":11145},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":11147,"activeCount":97},[],{"trials":11149,"activeCount":97},[],{"trials":11151,"activeCount":97},[],{"trials":11153,"activeCount":97},[],{"intervention":11155,"totalTrials":947,"cells":11156},"LY3971297",{"EARLY_PHASE1":11157,"PHASE1":11159,"PHASE2":11178,"PHASE3":11180,"PHASE4":11182,"NA":11184},{"trials":11158,"activeCount":97},[],{"trials":11160,"activeCount":947,"soonestReadout":408},[11161,11169],{"nctId":11162,"briefTitle":11163,"status":393,"phases":11164,"primaryCompletion":408,"completion":408,"start":11165,"enrollment":1464,"conditions":11166,"interventions":11167},"NCT06148272","A Study of LY3971297 in Healthy Participants",[85],"2023-12-07",[15,24,2156],[11155,11168],"LY3971297 IV",{"nctId":11170,"briefTitle":11171,"status":1060,"phases":11172,"primaryCompletion":1986,"completion":1986,"start":419,"enrollment":963,"conditions":11173,"interventions":11177},"NCT07547540","A Study of LY3971297 in Participants With Heart Failure",[85],[11174,11175,11176],"Heart Failure","Heart Failure, Diastolic","Heart Failure, Systolic",[11155,11155],{"trials":11179,"activeCount":97},[],{"trials":11181,"activeCount":97},[],{"trials":11183,"activeCount":97},[],{"trials":11185,"activeCount":97},[],{"intervention":9439,"totalTrials":947,"cells":11187},{"EARLY_PHASE1":11188,"PHASE1":11190,"PHASE2":11196,"PHASE3":11198,"PHASE4":11200,"NA":11210},{"trials":11189,"activeCount":97},[],{"trials":11191,"activeCount":314,"soonestReadout":408},[11192],{"nctId":9433,"briefTitle":9434,"status":393,"phases":11193,"primaryCompletion":408,"completion":408,"start":1034,"enrollment":3618,"conditions":11194,"interventions":11195},[85],[15,9437],[9426,700,438,9426,700,9439,9440],{"trials":11197,"activeCount":97},[],{"trials":11199,"activeCount":97},[],{"trials":11201,"activeCount":97},[11202],{"nctId":11203,"briefTitle":11204,"status":384,"phases":11205,"primaryCompletion":11206,"completion":11206,"start":5149,"enrollment":97,"conditions":11207,"interventions":11209},"NCT04864977","A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes",[88],"2022-06-06",[30,11208],"Type 2 Diabetes Treated With Insulin",[9439],{"trials":11211,"activeCount":97},[],{"intervention":700,"totalTrials":1071,"cells":11213},{"EARLY_PHASE1":11214,"PHASE1":11216,"PHASE2":11235,"PHASE3":11268,"PHASE4":11337,"NA":11339},{"trials":11215,"activeCount":97},[],{"trials":11217,"activeCount":314,"soonestReadout":408},[11218,11222,11231],{"nctId":9433,"briefTitle":9434,"status":393,"phases":11219,"primaryCompletion":408,"completion":408,"start":1034,"enrollment":3618,"conditions":11220,"interventions":11221},[85],[15,9437],[9426,700,438,9426,700,9439,9440],{"nctId":11223,"briefTitle":11224,"status":103,"phases":11225,"primaryCompletion":11226,"completion":11226,"start":11227,"enrollment":165,"conditions":11228,"interventions":11229},"NCT04276428","A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus",[85],"2020-11-28","2020-02-28",[18],[11230,700],"LY3209590",{"nctId":9442,"briefTitle":9443,"status":103,"phases":11232,"primaryCompletion":9445,"completion":9445,"start":397,"enrollment":1587,"conditions":11233,"interventions":11234},[85],[15,120],[9426,9448],{"trials":11236,"activeCount":97},[11237,11246,11252,11259],{"nctId":11238,"briefTitle":11239,"status":103,"phases":11240,"primaryCompletion":11241,"completion":11241,"start":11242,"enrollment":11243,"conditions":11244,"interventions":11245},"NCT04450407","A Study of LY3209590 in Participants With Type 1 Diabetes",[86],"2021-10-01","2020-07-06",266,[9437],[11230,700],{"nctId":11247,"briefTitle":11248,"status":103,"phases":11249,"primaryCompletion":7332,"completion":7332,"start":1714,"enrollment":1178,"conditions":11250,"interventions":11251},"NCT04585776","A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes",[86],[466],[9698,700],{"nctId":11253,"briefTitle":11254,"status":103,"phases":11255,"primaryCompletion":11256,"completion":11256,"start":7436,"enrollment":6654,"conditions":11257,"interventions":11258},"NCT03736785","A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus",[86],"2020-02-18",[120],[11230,700],{"nctId":11260,"briefTitle":11261,"status":103,"phases":11262,"primaryCompletion":11263,"completion":11263,"start":11264,"enrollment":11265,"conditions":11266,"interventions":11267},"NCT04450394","A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus",[86],"2021-10-08","2020-07-01",278,[120],[11230,700],{"trials":11269,"activeCount":97},[11270,11278,11288,11295,11299,11308,11317,11325,11333],{"nctId":11271,"briefTitle":11272,"status":103,"phases":11273,"primaryCompletion":11274,"completion":11274,"start":11275,"enrollment":743,"conditions":11276,"interventions":11277},"NCT03740919","A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes",[87],"2021-07-02","2019-04-07",[9437],[9698,438,506,700],{"nctId":11279,"briefTitle":11280,"status":103,"phases":11281,"primaryCompletion":2382,"completion":2382,"start":11282,"enrollment":11283,"conditions":11284,"interventions":11286},"NCT05362058","A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time",[87],"2022-06-03",928,[11285,30],"Diabetes",[11287,700],"Insulin Efsitora Alfa",{"nctId":11289,"briefTitle":11290,"status":103,"phases":11291,"primaryCompletion":1034,"completion":1034,"start":11292,"enrollment":7593,"conditions":11293,"interventions":11294},"NCT05275400","A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin",[87],"2022-03-08",[30],[11287,700],{"nctId":9690,"briefTitle":9691,"status":103,"phases":11296,"primaryCompletion":7547,"completion":9693,"start":9694,"enrollment":9695,"conditions":11297,"interventions":11298},[87],[120],[9698,438,506,700,1631,7063],{"nctId":11300,"briefTitle":11301,"status":103,"phases":11302,"primaryCompletion":11303,"completion":11303,"start":11304,"enrollment":11305,"conditions":11306,"interventions":11307},"NCT05463744","A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy",[87],"2024-05-07","2022-08-12",692,[466,11285],[11287,700],{"nctId":11309,"briefTitle":11310,"status":103,"phases":11311,"primaryCompletion":11312,"completion":5129,"start":11313,"enrollment":11314,"conditions":11315,"interventions":11316},"NCT03214367","A Study of LY900014 in Participants With Type 1 Diabetes",[87],"2018-09-06","2017-07-17",1392,[9437],[9698,438,506,700],{"nctId":11318,"briefTitle":11319,"status":103,"phases":11320,"primaryCompletion":1882,"completion":1882,"start":11321,"enrollment":11322,"conditions":11323,"interventions":11324},"NCT03952143","A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes",[87],"2019-05-27",628,[120],[9698,438,506,700],{"nctId":11326,"briefTitle":11327,"status":103,"phases":11328,"primaryCompletion":9249,"completion":9249,"start":11329,"enrollment":11330,"conditions":11331,"interventions":11332},"NCT03952130","A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes",[87],"2019-05-29",354,[9437],[9698,438,506,700],{"nctId":691,"briefTitle":692,"status":103,"phases":11334,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":11335,"interventions":11336},[87],[120],[92,700],{"trials":11338,"activeCount":97},[],{"trials":11340,"activeCount":97},[],{"intervention":2923,"totalTrials":4323,"cells":11342},{"EARLY_PHASE1":11343,"PHASE1":11345,"PHASE2":11355,"PHASE3":11373,"PHASE4":11383,"NA":11385},{"trials":11344,"activeCount":97},[],{"trials":11346,"activeCount":314,"soonestReadout":941},[11347,11351],{"nctId":6400,"briefTitle":6401,"status":103,"phases":11348,"primaryCompletion":3086,"completion":3886,"start":3283,"enrollment":1677,"conditions":11349,"interventions":11350},[85],[2586],[61,1745,6405,2923],{"nctId":4127,"briefTitle":4128,"status":393,"phases":11352,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":11353,"interventions":11354},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"trials":11356,"activeCount":97},[11357,11361,11365,11369],{"nctId":7682,"briefTitle":7683,"status":103,"phases":11358,"primaryCompletion":3685,"completion":5090,"start":3094,"enrollment":195,"conditions":11359,"interventions":11360},[86],[1490],[3447,2521,4137,3054],{"nctId":2914,"briefTitle":2915,"status":103,"phases":11362,"primaryCompletion":2917,"completion":1618,"start":2918,"enrollment":2919,"conditions":11363,"interventions":11364},[86],[2921],[1541,1510,1512,2923],{"nctId":6546,"briefTitle":6547,"status":103,"phases":11366,"primaryCompletion":5022,"completion":4098,"start":3069,"enrollment":6549,"conditions":11367,"interventions":11368},[86],[6551,6552],[61,2520,2521,2923],{"nctId":6597,"briefTitle":6598,"status":103,"phases":11370,"primaryCompletion":2917,"completion":6600,"start":2798,"enrollment":864,"conditions":11371,"interventions":11372},[86],[2589],[61,1745,6603,2923],{"trials":11374,"activeCount":97},[11375,11379],{"nctId":9080,"briefTitle":9081,"status":103,"phases":11376,"primaryCompletion":2909,"completion":3228,"start":3040,"enrollment":9083,"conditions":11377,"interventions":11378},[87],[1490],[3540,4181,4136,4137,4137,3540],{"nctId":6711,"briefTitle":6712,"status":103,"phases":11380,"primaryCompletion":6714,"completion":6715,"start":6716,"enrollment":6717,"conditions":11381,"interventions":11382},[87],[1490],[61,1745,6720,2923],{"trials":11384,"activeCount":97},[],{"trials":11386,"activeCount":97},[],{"intervention":11388,"totalTrials":425,"cells":11389},"LY3041658",{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11423,"PHASE3":11434,"PHASE4":11436,"NA":11438},{"trials":11391,"activeCount":97},[],{"trials":11393,"activeCount":314,"soonestReadout":420},[11394,11402,11409,11415],{"nctId":11395,"briefTitle":11396,"status":103,"phases":11397,"primaryCompletion":11398,"completion":11398,"start":11399,"enrollment":31,"conditions":11400,"interventions":11401},"NCT02148627","Safety Study of LY3041658 in Healthy Participants",[85],"2017-02-11","2014-06-16",[15],[11388,11388],{"nctId":11403,"briefTitle":11404,"status":103,"phases":11405,"primaryCompletion":11406,"completion":11406,"start":7080,"enrollment":1071,"conditions":11407,"interventions":11408},"NCT04653168","A Study of LY3041658 in Healthy Participants",[85],"2021-05-28",[15],[11388],{"nctId":11410,"briefTitle":11411,"status":1060,"phases":11412,"primaryCompletion":420,"completion":420,"start":980,"enrollment":874,"conditions":11413,"interventions":11414},"NCT07545590","A Study of Eltrekibart (LY3041658) in Healthy Participants",[85],[15],[11388,11388],{"nctId":11416,"briefTitle":11417,"status":103,"phases":11418,"primaryCompletion":11419,"completion":11419,"start":11420,"enrollment":874,"conditions":11421,"interventions":11422},"NCT02896868","A Study of LY3041658 in Participants With Skin Diseases",[85],"2019-03-19","2016-11-08",[1370,447],[11388],{"trials":11424,"activeCount":97},[11425],{"nctId":11426,"briefTitle":11427,"status":103,"phases":11428,"primaryCompletion":11429,"completion":11430,"start":11431,"enrollment":1767,"conditions":11432,"interventions":11433},"NCT04493502","A Study of LY3041658 in Adults With Hidradenitis Suppurativa",[86],"2022-03-15","2022-10-13","2020-08-26",[9562],[11388],{"trials":11435,"activeCount":97},[],{"trials":11437,"activeCount":97},[],{"trials":11439,"activeCount":97},[],{"intervention":4357,"totalTrials":1232,"cells":11441},{"EARLY_PHASE1":11442,"PHASE1":11444,"PHASE2":11459,"PHASE3":11469,"PHASE4":11471,"NA":11473},{"trials":11443,"activeCount":97},[],{"trials":11445,"activeCount":314,"soonestReadout":1011},[11446],{"nctId":11447,"briefTitle":11448,"status":393,"phases":11449,"primaryCompletion":1011,"completion":11450,"start":8329,"enrollment":11451,"conditions":11452,"interventions":11456},"NCT07226843","A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",[85],"2030-02",460,[11453,11454,11455],"Lymphoma, Non-Hodgkin's","Lymphoma, Diffuse Large B-Cell","Follicular Lymphoma",[11457,11458],"LY4584180","Rituximab",{"trials":11460,"activeCount":97},[11461,11465],{"nctId":8207,"briefTitle":8208,"status":103,"phases":11462,"primaryCompletion":3086,"completion":3068,"start":3005,"enrollment":2670,"conditions":11463,"interventions":11464},[86],[7766],[2979,4357,5885,3143,8212,8205],{"nctId":4350,"briefTitle":4351,"status":103,"phases":11466,"primaryCompletion":3217,"completion":3048,"start":2875,"enrollment":4353,"conditions":11467,"interventions":11468},[86],[4355],[2979,2912,4357,4181],{"trials":11470,"activeCount":97},[],{"trials":11472,"activeCount":97},[],{"trials":11474,"activeCount":97},[],{"intervention":1551,"totalTrials":1232,"cells":11476},{"EARLY_PHASE1":11477,"PHASE1":11479,"PHASE2":11489,"PHASE3":11495,"PHASE4":11497,"NA":11499},{"trials":11478,"activeCount":97},[],{"trials":11480,"activeCount":314,"soonestReadout":3865},[11481,11485],{"nctId":1543,"briefTitle":1544,"status":103,"phases":11482,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":11483,"interventions":11484},[85],[15],[48,1551],{"nctId":3862,"briefTitle":3863,"status":257,"phases":11486,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":11487,"interventions":11488},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":11490,"activeCount":97},[11491],{"nctId":1822,"briefTitle":1823,"status":103,"phases":11492,"primaryCompletion":1825,"completion":1826,"start":1474,"enrollment":1827,"conditions":11493,"interventions":11494},[86],[36,1829,1830],[48,1551,1697],{"trials":11496,"activeCount":97},[],{"trials":11498,"activeCount":97},[],{"trials":11500,"activeCount":97},[],{"intervention":82,"totalTrials":1232,"cells":11502},{"EARLY_PHASE1":11503,"PHASE1":11505,"PHASE2":11515,"PHASE3":11521,"PHASE4":11523,"NA":11525},{"trials":11504,"activeCount":97},[],{"trials":11506,"activeCount":314,"soonestReadout":81},[11507,11511],{"nctId":10946,"briefTitle":10947,"status":103,"phases":11508,"primaryCompletion":10949,"completion":10949,"start":10950,"enrollment":1488,"conditions":11509,"interventions":11510},[85],[15],[82,2562],{"nctId":79,"briefTitle":80,"status":257,"phases":11512,"primaryCompletion":81,"completion":1986,"start":2811,"enrollment":2812,"conditions":11513,"interventions":11514},[85],[1503],[82,1656,1511,2815,1510],{"trials":11516,"activeCount":97},[11517],{"nctId":2657,"briefTitle":2658,"status":384,"phases":11518,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":97,"conditions":11519,"interventions":11520},[85,86],[1466],[82,1696],{"trials":11522,"activeCount":97},[],{"trials":11524,"activeCount":97},[],{"trials":11526,"activeCount":97},[],{"intervention":3870,"totalTrials":425,"cells":11528},{"EARLY_PHASE1":11529,"PHASE1":11531,"PHASE2":11563,"PHASE3":11565,"PHASE4":11567,"NA":11569},{"trials":11530,"activeCount":97},[],{"trials":11532,"activeCount":314,"soonestReadout":3865},[11533,11540,11549,11554,11559],{"nctId":11534,"briefTitle":11535,"status":103,"phases":11536,"primaryCompletion":1473,"completion":1473,"start":5030,"enrollment":205,"conditions":11537,"interventions":11538},"NCT02327143","A Study of LY2835219 in Healthy Participants",[85],[21],[3870,11539],"¹³C₈-LY2835219",{"nctId":11541,"briefTitle":11542,"status":103,"phases":11543,"primaryCompletion":11544,"completion":11545,"start":11546,"enrollment":2477,"conditions":11547,"interventions":11548},"NCT02014129","A Study of LY2835219 in Japanese Participants With Advanced Cancer",[85],"2015-04-01","2019-08-21","2013-12-18",[1478,7766],[3870],{"nctId":11550,"briefTitle":11535,"status":103,"phases":11551,"primaryCompletion":3319,"completion":3319,"start":3318,"enrollment":290,"conditions":11552,"interventions":11553},"NCT02256267",[85],[21],[3870,6219],{"nctId":11555,"briefTitle":11535,"status":103,"phases":11556,"primaryCompletion":3122,"completion":3122,"start":9748,"enrollment":290,"conditions":11557,"interventions":11558},"NCT02059148",[85],[21],[3870],{"nctId":3862,"briefTitle":3863,"status":257,"phases":11560,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":11561,"interventions":11562},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":11564,"activeCount":97},[],{"trials":11566,"activeCount":97},[],{"trials":11568,"activeCount":97},[],{"trials":11570,"activeCount":97},[],{"intervention":1656,"totalTrials":1400,"cells":11572},{"EARLY_PHASE1":11573,"PHASE1":11575,"PHASE2":11603,"PHASE3":11605,"PHASE4":11607,"NA":11609},{"trials":11574,"activeCount":97},[],{"trials":11576,"activeCount":314,"soonestReadout":81},[11577,11586,11595,11599],{"nctId":11578,"briefTitle":11579,"status":999,"phases":11580,"primaryCompletion":11581,"completion":11582,"start":3684,"enrollment":874,"conditions":11583,"interventions":11584},"NCT03343613","A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors",[85],"2020-02-07","2020-05-04",[1503,1694,2585,2506],[11585,1656],"LY3381916",{"nctId":11587,"briefTitle":11588,"status":103,"phases":11589,"primaryCompletion":1567,"completion":11590,"start":11591,"enrollment":11592,"conditions":11593,"interventions":11594},"NCT03099109","A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed\u002FRefractory Solid Tumors",[85],"2023-08-30","2017-04-12",209,[1503],[1657,1656],{"nctId":1643,"briefTitle":1644,"status":103,"phases":11596,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":1649,"conditions":11597,"interventions":11598},[85],[1503,1651,1652,1653,1654],[1656,61,48,1493,1657],{"nctId":79,"briefTitle":80,"status":257,"phases":11600,"primaryCompletion":81,"completion":1986,"start":2811,"enrollment":2812,"conditions":11601,"interventions":11602},[85],[1503],[82,1656,1511,2815,1510],{"trials":11604,"activeCount":97},[],{"trials":11606,"activeCount":97},[],{"trials":11608,"activeCount":97},[],{"trials":11610,"activeCount":97},[],{"intervention":1666,"totalTrials":1400,"cells":11612},{"EARLY_PHASE1":11613,"PHASE1":11615,"PHASE2":11647,"PHASE3":11649,"PHASE4":11651,"NA":11653},{"trials":11614,"activeCount":97},[],{"trials":11616,"activeCount":314,"soonestReadout":462},[11617,11626,11633,11643],{"nctId":11618,"briefTitle":11619,"status":103,"phases":11620,"primaryCompletion":11621,"completion":11622,"start":9559,"enrollment":1071,"conditions":11623,"interventions":11624},"NCT06102512","A Study of [14C]-LOXO-783 in Healthy Adult Participants",[85],"2023-12-23","2024-01-17",[15],[11625,1666,11625],"[¹⁴C]-LOXO-783",{"nctId":11627,"briefTitle":11628,"status":103,"phases":11629,"primaryCompletion":11621,"completion":11621,"start":11630,"enrollment":137,"conditions":11631,"interventions":11632},"NCT06028425","A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants",[85],"2023-09-01",[15],[1666],{"nctId":11634,"briefTitle":11635,"status":103,"phases":11636,"primaryCompletion":11637,"completion":11637,"start":11638,"enrollment":11639,"conditions":11640,"interventions":11641},"NCT05894928","A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants",[85],"2023-07-09","2023-06-07",21,[15],[1666,11642],"Cholestyramine",{"nctId":1659,"briefTitle":1660,"status":257,"phases":11644,"primaryCompletion":462,"completion":462,"start":1662,"enrollment":1663,"conditions":11645,"interventions":11646},[85],[36],[1666,1468,1667,48,1668,1669],{"trials":11648,"activeCount":97},[],{"trials":11650,"activeCount":97},[],{"trials":11652,"activeCount":97},[],{"trials":11654,"activeCount":97},[],{"intervention":8162,"totalTrials":1232,"cells":11656},{"EARLY_PHASE1":11657,"PHASE1":11659,"PHASE2":11681,"PHASE3":11683,"PHASE4":11685,"NA":11687},{"trials":11658,"activeCount":97},[],{"trials":11660,"activeCount":314,"soonestReadout":8157},[11661,11669,11677],{"nctId":11662,"briefTitle":11663,"status":103,"phases":11664,"primaryCompletion":11665,"completion":11665,"start":11666,"enrollment":425,"conditions":11667,"interventions":11668},"NCT03955939","A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body",[85],"2020-05-14","2019-08-02",[1571],[8162,3871,1538],{"nctId":11670,"briefTitle":11671,"status":103,"phases":11672,"primaryCompletion":11673,"completion":11674,"start":6426,"enrollment":118,"conditions":11675,"interventions":11676},"NCT03898791","A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer",[85],"2020-06-02","2021-03-30",[3244],[8162],{"nctId":8154,"briefTitle":8155,"status":257,"phases":11678,"primaryCompletion":8157,"completion":420,"start":8158,"enrollment":2571,"conditions":11679,"interventions":11680},[85],[8160],[8162,3802,1874],{"trials":11682,"activeCount":97},[],{"trials":11684,"activeCount":97},[],{"trials":11686,"activeCount":97},[],{"trials":11688,"activeCount":97},[],{"intervention":11690,"totalTrials":1232,"cells":11691},"LY3372993",{"EARLY_PHASE1":11692,"PHASE1":11694,"PHASE2":11717,"PHASE3":11719,"PHASE4":11721,"NA":11723},{"trials":11693,"activeCount":97},[],{"trials":11695,"activeCount":314,"soonestReadout":420},[11696,11702,11709],{"nctId":11697,"briefTitle":11698,"status":103,"phases":11699,"primaryCompletion":7222,"completion":7222,"start":1485,"enrollment":214,"conditions":11700,"interventions":11701},"NCT03720548","A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)",[85],[3980],[11690],{"nctId":11703,"briefTitle":11704,"status":257,"phases":11705,"primaryCompletion":420,"completion":322,"start":11706,"enrollment":290,"conditions":11707,"interventions":11708},"NCT07346495","A Study of Remternetug (LY3372993) in Healthy Chinese Participants",[85],"2026-01-31",[15],[11690],{"nctId":11710,"briefTitle":11711,"status":103,"phases":11712,"primaryCompletion":2131,"completion":2131,"start":11713,"enrollment":11714,"conditions":11715,"interventions":11716},"NCT04451408","A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants",[85],"2020-07-07",139,[3980,15],[11690],{"trials":11718,"activeCount":97},[],{"trials":11720,"activeCount":97},[],{"trials":11722,"activeCount":97},[],{"trials":11724,"activeCount":97},[],{"intervention":11726,"totalTrials":947,"cells":11727},"LY4100511",{"EARLY_PHASE1":11728,"PHASE1":11730,"PHASE2":11749,"PHASE3":11751,"PHASE4":11753,"NA":11755},{"trials":11729,"activeCount":97},[],{"trials":11731,"activeCount":314,"soonestReadout":1309},[11732,11741],{"nctId":11733,"briefTitle":11734,"status":103,"phases":11735,"primaryCompletion":11736,"completion":11736,"start":11737,"enrollment":11738,"conditions":11739,"interventions":11740},"NCT06937411","A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants",[85],"2023-10-30","2023-02-13",88,[15],[11726],{"nctId":11742,"briefTitle":11743,"status":257,"phases":11744,"primaryCompletion":1309,"completion":1309,"start":11745,"enrollment":118,"conditions":11746,"interventions":11747},"NCT06916143","Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid",[85],"2025-04-08",[4997],[11726,11748],"Rabeprazole",{"trials":11750,"activeCount":97},[],{"trials":11752,"activeCount":97},[],{"trials":11754,"activeCount":97},[],{"trials":11756,"activeCount":97},[],{"intervention":3871,"totalTrials":947,"cells":11758},{"EARLY_PHASE1":11759,"PHASE1":11761,"PHASE2":11771,"PHASE3":11773,"PHASE4":11775,"NA":11777},{"trials":11760,"activeCount":97},[],{"trials":11762,"activeCount":314,"soonestReadout":3865},[11763,11767],{"nctId":11662,"briefTitle":11663,"status":103,"phases":11764,"primaryCompletion":11665,"completion":11665,"start":11666,"enrollment":425,"conditions":11765,"interventions":11766},[85],[1571],[8162,3871,1538],{"nctId":3862,"briefTitle":3863,"status":257,"phases":11768,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":11769,"interventions":11770},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"trials":11772,"activeCount":97},[],{"trials":11774,"activeCount":97},[],{"trials":11776,"activeCount":97},[],{"trials":11778,"activeCount":97},[],{"intervention":11780,"totalTrials":947,"cells":11781},"Flortaucipir F18",{"EARLY_PHASE1":11782,"PHASE1":11784,"PHASE2":11802,"PHASE3":11804,"PHASE4":11806,"NA":11808},{"trials":11783,"activeCount":97},[],{"trials":11785,"activeCount":314,"soonestReadout":853},[11786,11794],{"nctId":11787,"briefTitle":11788,"status":393,"phases":11789,"primaryCompletion":853,"completion":853,"start":11790,"enrollment":118,"conditions":11791,"interventions":11792},"NCT06297590","A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease",[85],"2024-08-15",[3980],[11793,11780],"LY3954068",{"nctId":11795,"briefTitle":11796,"status":103,"phases":11797,"primaryCompletion":6592,"completion":6592,"start":47,"enrollment":6633,"conditions":11798,"interventions":11799},"NCT03019536","A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease",[85],[3980],[11800,11801,11780],"LY3303560 - IV","Florbetapir F 18",{"trials":11803,"activeCount":97},[],{"trials":11805,"activeCount":97},[],{"trials":11807,"activeCount":97},[],{"trials":11809,"activeCount":97},[],{"intervention":11811,"totalTrials":314,"cells":11812},"LY4214835",{"EARLY_PHASE1":11813,"PHASE1":11815,"PHASE2":11823,"PHASE3":11825,"PHASE4":11827,"NA":11829},{"trials":11814,"activeCount":97},[],{"trials":11816,"activeCount":314,"soonestReadout":322},[11817],{"nctId":11818,"briefTitle":11819,"status":393,"phases":11820,"primaryCompletion":322,"completion":322,"start":1913,"enrollment":2542,"conditions":11821,"interventions":11822},"NCT07258836","A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer",[85],[1870,15],[11811],{"trials":11824,"activeCount":97},[],{"trials":11826,"activeCount":97},[],{"trials":11828,"activeCount":97},[],{"trials":11830,"activeCount":97},[],{"intervention":11832,"totalTrials":314,"cells":11833},"LY4066708",{"EARLY_PHASE1":11834,"PHASE1":11836,"PHASE2":11845,"PHASE3":11847,"PHASE4":11849,"NA":11851},{"trials":11835,"activeCount":97},[],{"trials":11837,"activeCount":314,"soonestReadout":395},[11838],{"nctId":11839,"briefTitle":11840,"status":393,"phases":11841,"primaryCompletion":395,"completion":395,"start":11842,"enrollment":10911,"conditions":11843,"interventions":11844},"NCT07046559","A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants",[85],"2025-05-13",[15,2824],[11832,11832],{"trials":11846,"activeCount":97},[],{"trials":11848,"activeCount":97},[],{"trials":11850,"activeCount":97},[],{"trials":11852,"activeCount":97},[],{"intervention":11854,"totalTrials":314,"cells":11855},"LY4167586",{"EARLY_PHASE1":11856,"PHASE1":11858,"PHASE2":11866,"PHASE3":11868,"PHASE4":11870,"NA":11872},{"trials":11857,"activeCount":97},[],{"trials":11859,"activeCount":314,"soonestReadout":462},[11860],{"nctId":11861,"briefTitle":11862,"status":393,"phases":11863,"primaryCompletion":462,"completion":462,"start":550,"enrollment":25,"conditions":11864,"interventions":11865},"NCT07225556","A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy",[85],[27,24],[11854,11854],{"trials":11867,"activeCount":97},[],{"trials":11869,"activeCount":97},[],{"trials":11871,"activeCount":97},[],{"trials":11873,"activeCount":97},[],{"intervention":9440,"totalTrials":314,"cells":11875},{"EARLY_PHASE1":11876,"PHASE1":11878,"PHASE2":11884,"PHASE3":11886,"PHASE4":11888,"NA":11890},{"trials":11877,"activeCount":97},[],{"trials":11879,"activeCount":314,"soonestReadout":408},[11880],{"nctId":9433,"briefTitle":9434,"status":393,"phases":11881,"primaryCompletion":408,"completion":408,"start":1034,"enrollment":3618,"conditions":11882,"interventions":11883},[85],[15,9437],[9426,700,438,9426,700,9439,9440],{"trials":11885,"activeCount":97},[],{"trials":11887,"activeCount":97},[],{"trials":11889,"activeCount":97},[],{"trials":11891,"activeCount":97},[],{"intervention":2508,"totalTrials":314,"cells":11893},{"EARLY_PHASE1":11894,"PHASE1":11896,"PHASE2":11902,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11895,"activeCount":97},[],{"trials":11897,"activeCount":314,"soonestReadout":1751},[11898],{"nctId":2498,"briefTitle":2499,"status":393,"phases":11899,"primaryCompletion":1751,"completion":1751,"start":2501,"enrollment":2502,"conditions":11900,"interventions":11901},[85],[1589,2504,2505,1478,2506],[2508,1696,1512,1510],{"trials":11903,"activeCount":97},[],{"trials":11905,"activeCount":97},[],{"trials":11907,"activeCount":97},[],{"trials":11909,"activeCount":97},[],{"intervention":2518,"totalTrials":314,"cells":11911},{"EARLY_PHASE1":11912,"PHASE1":11914,"PHASE2":11920,"PHASE3":11922,"PHASE4":11924,"NA":11926},{"trials":11913,"activeCount":97},[],{"trials":11915,"activeCount":314,"soonestReadout":2513},[11916],{"nctId":2510,"briefTitle":2511,"status":257,"phases":11917,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":11918,"interventions":11919},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"trials":11921,"activeCount":97},[],{"trials":11923,"activeCount":97},[],{"trials":11925,"activeCount":97},[],{"trials":11927,"activeCount":97},[],{"intervention":2522,"totalTrials":314,"cells":11929},{"EARLY_PHASE1":11930,"PHASE1":11932,"PHASE2":11938,"PHASE3":11940,"PHASE4":11942,"NA":11944},{"trials":11931,"activeCount":97},[],{"trials":11933,"activeCount":314,"soonestReadout":2513},[11934],{"nctId":2510,"briefTitle":2511,"status":257,"phases":11935,"primaryCompletion":2513,"completion":2513,"start":323,"enrollment":2514,"conditions":11936,"interventions":11937},[85],[1841,1610,1490,1717,2516],[2518,1541,2519,1511,2520,2521,1745,2522,1512,1510,1612,1696],{"trials":11939,"activeCount":97},[],{"trials":11941,"activeCount":97},[],{"trials":11943,"activeCount":97},[],{"trials":11945,"activeCount":97},[],{"intervention":11947,"totalTrials":314,"cells":11948},"LY4302814",{"EARLY_PHASE1":11949,"PHASE1":11951,"PHASE2":11959,"PHASE3":11961,"PHASE4":11963,"NA":11965},{"trials":11950,"activeCount":97},[],{"trials":11952,"activeCount":314,"soonestReadout":1986},[11953],{"nctId":11954,"briefTitle":11955,"status":1060,"phases":11956,"primaryCompletion":1986,"completion":1986,"start":443,"enrollment":658,"conditions":11957,"interventions":11958},"NCT07566338","A Study of LY4302814 in Healthy Participants",[85],[15],[11947,11947],{"trials":11960,"activeCount":97},[],{"trials":11962,"activeCount":97},[],{"trials":11964,"activeCount":97},[],{"trials":11966,"activeCount":97},[],{"intervention":1119,"totalTrials":314,"cells":11968},{"EARLY_PHASE1":11969,"PHASE1":11971,"PHASE2":11977,"PHASE3":11979,"PHASE4":11981,"NA":11983},{"trials":11970,"activeCount":97},[],{"trials":11972,"activeCount":314,"soonestReadout":1107},[11973],{"nctId":1104,"briefTitle":1105,"status":257,"phases":11974,"primaryCompletion":1107,"completion":419,"start":1108,"enrollment":1109,"conditions":11975,"interventions":11976},[85],[1111,1112,1113,1114,1115,1116,1117],[1119,1070],{"trials":11978,"activeCount":97},[],{"trials":11980,"activeCount":97},[],{"trials":11982,"activeCount":97},[],{"trials":11984,"activeCount":97},[],{"intervention":11986,"totalTrials":314,"cells":11987},"LY4006895",{"EARLY_PHASE1":11988,"PHASE1":11990,"PHASE2":11999,"PHASE3":12001,"PHASE4":12003,"NA":12005},{"trials":11989,"activeCount":97},[],{"trials":11991,"activeCount":314,"soonestReadout":715},[11992],{"nctId":11993,"briefTitle":11994,"status":393,"phases":11995,"primaryCompletion":715,"completion":715,"start":11996,"enrollment":269,"conditions":11997,"interventions":11998},"NCT06657768","A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)",[85],"2024-10-29",[3980,15],[11986],{"trials":12000,"activeCount":97},[],{"trials":12002,"activeCount":97},[],{"trials":12004,"activeCount":97},[],{"trials":12006,"activeCount":97},[],{"intervention":1576,"totalTrials":314,"cells":12008},{"EARLY_PHASE1":12009,"PHASE1":12011,"PHASE2":12017,"PHASE3":12019,"PHASE4":12021,"NA":12023},{"trials":12010,"activeCount":97},[],{"trials":12012,"activeCount":314,"soonestReadout":1566},[12013],{"nctId":1563,"briefTitle":1564,"status":257,"phases":12014,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":12015,"interventions":12016},[85],[36,1570,1571,1572],[1574,48,1575,1576,1577,1578,1579],{"trials":12018,"activeCount":97},[],{"trials":12020,"activeCount":97},[],{"trials":12022,"activeCount":97},[],{"trials":12024,"activeCount":97},[],{"intervention":1578,"totalTrials":314,"cells":12026},{"EARLY_PHASE1":12027,"PHASE1":12029,"PHASE2":12035,"PHASE3":12037,"PHASE4":12039,"NA":12041},{"trials":12028,"activeCount":97},[],{"trials":12030,"activeCount":314,"soonestReadout":1566},[12031],{"nctId":1563,"briefTitle":1564,"status":257,"phases":12032,"primaryCompletion":1566,"completion":910,"start":1567,"enrollment":1568,"conditions":12033,"interventions":12034},[85],[36,1570,1571,1572],[1574,48,1575,1576,1577,1578,1579],{"trials":12036,"activeCount":97},[],{"trials":12038,"activeCount":97},[],{"trials":12040,"activeCount":97},[],{"trials":12042,"activeCount":97},[],{"intervention":2533,"totalTrials":314,"cells":12044},{"EARLY_PHASE1":12045,"PHASE1":12047,"PHASE2":12053,"PHASE3":12055,"PHASE4":12057,"NA":12059},{"trials":12046,"activeCount":97},[],{"trials":12048,"activeCount":314,"soonestReadout":2527},[12049],{"nctId":2524,"briefTitle":2525,"status":393,"phases":12050,"primaryCompletion":2527,"completion":2527,"start":1389,"enrollment":2528,"conditions":12051,"interventions":12052},[85],[2530,1478,2531],[2533,1696,2534],{"trials":12054,"activeCount":97},[],{"trials":12056,"activeCount":97},[],{"trials":12058,"activeCount":97},[],{"trials":12060,"activeCount":97},[],{"intervention":2534,"totalTrials":314,"cells":12062},{"EARLY_PHASE1":12063,"PHASE1":12065,"PHASE2":12071,"PHASE3":12073,"PHASE4":12075,"NA":12077},{"trials":12064,"activeCount":97},[],{"trials":12066,"activeCount":314,"soonestReadout":2527},[12067],{"nctId":2524,"briefTitle":2525,"status":393,"phases":12068,"primaryCompletion":2527,"completion":2527,"start":1389,"enrollment":2528,"conditions":12069,"interventions":12070},[85],[2530,1478,2531],[2533,1696,2534],{"trials":12072,"activeCount":97},[],{"trials":12074,"activeCount":97},[],{"trials":12076,"activeCount":97},[],{"trials":12078,"activeCount":97},[],{"intervention":12080,"totalTrials":314,"cells":12081},"LY3849891",{"EARLY_PHASE1":12082,"PHASE1":12084,"PHASE2":12096,"PHASE3":12098,"PHASE4":12100,"NA":12102},{"trials":12083,"activeCount":97},[],{"trials":12085,"activeCount":314,"soonestReadout":443},[12086],{"nctId":12087,"briefTitle":12088,"status":257,"phases":12089,"primaryCompletion":443,"completion":443,"start":12090,"enrollment":12091,"conditions":12092,"interventions":12095},"NCT05395481","A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[85],"2022-06-08",176,[12093,12094],"Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",[12080],{"trials":12097,"activeCount":97},[],{"trials":12099,"activeCount":97},[],{"trials":12101,"activeCount":97},[],{"trials":12103,"activeCount":97},[],{"intervention":2559,"totalTrials":314,"cells":12105},{"EARLY_PHASE1":12106,"PHASE1":12108,"PHASE2":12114,"PHASE3":12116,"PHASE4":12118,"NA":12120},{"trials":12107,"activeCount":97},[],{"trials":12109,"activeCount":314,"soonestReadout":853},[12110],{"nctId":2547,"briefTitle":2548,"status":393,"phases":12111,"primaryCompletion":853,"completion":1011,"start":2550,"enrollment":2551,"conditions":12112,"interventions":12113},[85],[2553,2505,2554,1589,2555,2556,2557],[2559,2560,2561,2562,2563],{"trials":12115,"activeCount":97},[],{"trials":12117,"activeCount":97},[],{"trials":12119,"activeCount":97},[],{"trials":12121,"activeCount":97},[],{"intervention":12123,"totalTrials":314,"cells":12124},"[Ac-225]-PSMA-62",{"EARLY_PHASE1":12125,"PHASE1":12127,"PHASE2":12138,"PHASE3":12140,"PHASE4":12142,"NA":12144},{"trials":12126,"activeCount":97},[],{"trials":12128,"activeCount":314,"soonestReadout":395},[12129],{"nctId":12130,"briefTitle":12131,"status":257,"phases":12132,"primaryCompletion":395,"completion":1210,"start":106,"enrollment":299,"conditions":12133,"interventions":12137},"NCT06229366","[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer",[85],[1903,12134,12135,12136],"Metastatic Castration-resistant Prostate Cancer","Oligometastatic Prostate Carcinoma","Hormone Sensitive Prostate Cancer",[12123,12123],{"trials":12139,"activeCount":97},[],{"trials":12141,"activeCount":97},[],{"trials":12143,"activeCount":97},[],{"trials":12145,"activeCount":97},[],{"intervention":9354,"totalTrials":314,"cells":12147},{"EARLY_PHASE1":12148,"PHASE1":12150,"PHASE2":12156,"PHASE3":12158,"PHASE4":12160,"NA":12162},{"trials":12149,"activeCount":97},[],{"trials":12151,"activeCount":314,"soonestReadout":1309},[12152],{"nctId":9349,"briefTitle":9350,"status":1060,"phases":12153,"primaryCompletion":1309,"completion":1309,"start":419,"enrollment":214,"conditions":12154,"interventions":12155},[85],[15],[9342,9354,9342],{"trials":12157,"activeCount":97},[],{"trials":12159,"activeCount":97},[],{"trials":12161,"activeCount":97},[],{"trials":12163,"activeCount":97},[],{"intervention":12165,"totalTrials":314,"cells":12166},"LY4213663",{"EARLY_PHASE1":12167,"PHASE1":12169,"PHASE2":12179,"PHASE3":12181,"PHASE4":12183,"NA":12185},{"trials":12168,"activeCount":97},[],{"trials":12170,"activeCount":314,"soonestReadout":1993},[12171],{"nctId":12172,"briefTitle":12173,"status":393,"phases":12174,"primaryCompletion":1993,"completion":1993,"start":12175,"enrollment":6624,"conditions":12176,"interventions":12178},"NCT07258849","A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis",[85],"2025-12-02",[12177],"Rheumatoid Arthritis (RA)",[12165,12165],{"trials":12180,"activeCount":97},[],{"trials":12182,"activeCount":97},[],{"trials":12184,"activeCount":97},[],{"trials":12186,"activeCount":97},[],{"intervention":12188,"totalTrials":314,"cells":12189},"LY4006896",{"EARLY_PHASE1":12190,"PHASE1":12192,"PHASE2":12202,"PHASE3":12204,"PHASE4":12206,"NA":12208},{"trials":12191,"activeCount":97},[],{"trials":12193,"activeCount":314,"soonestReadout":4800},[12194],{"nctId":12195,"briefTitle":12196,"status":393,"phases":12197,"primaryCompletion":4800,"completion":4800,"start":12198,"enrollment":1686,"conditions":12199,"interventions":12201},"NCT06809400","A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease",[85],"2025-02-18",[12200],"Parkinson Disease",[12188],{"trials":12203,"activeCount":97},[],{"trials":12205,"activeCount":97},[],{"trials":12207,"activeCount":97},[],{"trials":12209,"activeCount":97},[],{"intervention":12211,"totalTrials":314,"cells":12212},"LY4086940",{"EARLY_PHASE1":12213,"PHASE1":12215,"PHASE2":12224,"PHASE3":12226,"PHASE4":12228,"NA":12230},{"trials":12214,"activeCount":97},[],{"trials":12216,"activeCount":314,"soonestReadout":1309},[12217],{"nctId":12218,"briefTitle":12219,"status":393,"phases":12220,"primaryCompletion":1309,"completion":1309,"start":8028,"enrollment":12221,"conditions":12222,"interventions":12223},"NCT06945419","A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes",[85],216,[15,27,24,30],[12211,12211],{"trials":12225,"activeCount":97},[],{"trials":12227,"activeCount":97},[],{"trials":12229,"activeCount":97},[],{"trials":12231,"activeCount":97},[],{"intervention":11168,"totalTrials":314,"cells":12233},{"EARLY_PHASE1":12234,"PHASE1":12236,"PHASE2":12242,"PHASE3":12244,"PHASE4":12246,"NA":12248},{"trials":12235,"activeCount":97},[],{"trials":12237,"activeCount":314,"soonestReadout":408},[12238],{"nctId":11162,"briefTitle":11163,"status":393,"phases":12239,"primaryCompletion":408,"completion":408,"start":11165,"enrollment":1464,"conditions":12240,"interventions":12241},[85],[15,24,2156],[11155,11168],{"trials":12243,"activeCount":97},[],{"trials":12245,"activeCount":97},[],{"trials":12247,"activeCount":97},[],{"trials":12249,"activeCount":97},[],{"intervention":12251,"totalTrials":314,"cells":12252},"LY4515100 via SAD",{"EARLY_PHASE1":12253,"PHASE1":12255,"PHASE2":12265,"PHASE3":12267,"PHASE4":12269,"NA":12271},{"trials":12254,"activeCount":97},[],{"trials":12256,"activeCount":314,"soonestReadout":1309},[12257],{"nctId":12258,"briefTitle":12259,"status":393,"phases":12260,"primaryCompletion":1309,"completion":1309,"start":12261,"enrollment":233,"conditions":12262,"interventions":12263},"NCT07339722","A Study of LY4515100 in Healthy Participants",[85],"2026-01-15",[15],[12251,12264],"LY4515100 via MAD",{"trials":12266,"activeCount":97},[],{"trials":12268,"activeCount":97},[],{"trials":12270,"activeCount":97},[],{"trials":12272,"activeCount":97},[],{"intervention":12264,"totalTrials":314,"cells":12274},{"EARLY_PHASE1":12275,"PHASE1":12277,"PHASE2":12283,"PHASE3":12285,"PHASE4":12287,"NA":12289},{"trials":12276,"activeCount":97},[],{"trials":12278,"activeCount":314,"soonestReadout":1309},[12279],{"nctId":12258,"briefTitle":12259,"status":393,"phases":12280,"primaryCompletion":1309,"completion":1309,"start":12261,"enrollment":233,"conditions":12281,"interventions":12282},[85],[15],[12251,12264],{"trials":12284,"activeCount":97},[],{"trials":12286,"activeCount":97},[],{"trials":12288,"activeCount":97},[],{"trials":12290,"activeCount":97},[],{"intervention":12292,"totalTrials":314,"cells":12293},"LY4064912",{"EARLY_PHASE1":12294,"PHASE1":12296,"PHASE2":12305,"PHASE3":12307,"PHASE4":12309,"NA":12311},{"trials":12295,"activeCount":97},[],{"trials":12297,"activeCount":314,"soonestReadout":259},[12298],{"nctId":12299,"briefTitle":12300,"status":393,"phases":12301,"primaryCompletion":259,"completion":259,"start":12302,"enrollment":9477,"conditions":12303,"interventions":12304},"NCT07152002","A Study of LY4064912 in Healthy Participants and With Overweight or Obesity",[85],"2025-08-28",[778,15],[12292,12292],{"trials":12306,"activeCount":97},[],{"trials":12308,"activeCount":97},[],{"trials":12310,"activeCount":97},[],{"trials":12312,"activeCount":97},[],{"intervention":12314,"totalTrials":314,"cells":12315},"LY4337713",{"EARLY_PHASE1":12316,"PHASE1":12318,"PHASE2":12329,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12317,"activeCount":97},[],{"trials":12319,"activeCount":314,"soonestReadout":4014},[12320],{"nctId":12321,"briefTitle":12322,"status":393,"phases":12323,"primaryCompletion":4014,"completion":12324,"start":3797,"enrollment":4600,"conditions":12325,"interventions":12328},"NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors",[85],"2033-03",[2553,1893,12326,2557,12327,2756,1505],"Pancreatic Intraductal Neoplasms","Esophageal Neoplasms",[12314],{"trials":12330,"activeCount":97},[],{"trials":12332,"activeCount":97},[],{"trials":12334,"activeCount":97},[],{"trials":12336,"activeCount":97},[],{"intervention":7996,"totalTrials":314,"cells":12338},{"EARLY_PHASE1":12339,"PHASE1":12341,"PHASE2":12347,"PHASE3":12349,"PHASE4":12351,"NA":12353},{"trials":12340,"activeCount":97},[],{"trials":12342,"activeCount":314,"soonestReadout":443},[12343],{"nctId":7990,"briefTitle":7991,"status":257,"phases":12344,"primaryCompletion":443,"completion":443,"start":7993,"enrollment":4323,"conditions":12345,"interventions":12346},[85],[15],[1917,7996],{"trials":12348,"activeCount":97},[],{"trials":12350,"activeCount":97},[],{"trials":12352,"activeCount":97},[],{"trials":12354,"activeCount":97},[],{"intervention":12356,"totalTrials":314,"cells":12357},"LY4052031",{"EARLY_PHASE1":12358,"PHASE1":12360,"PHASE2":12373,"PHASE3":12375,"PHASE4":12377,"NA":12379},{"trials":12359,"activeCount":97},[],{"trials":12361,"activeCount":314,"soonestReadout":940},[12362],{"nctId":12363,"briefTitle":12364,"status":393,"phases":12365,"primaryCompletion":940,"completion":940,"start":615,"enrollment":12366,"conditions":12367,"interventions":12372},"NCT06465069","A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors",[85],420,[2516,12368,1717,12369,2506,1610,6552,1653,2584,12370,2605,1903,12371,3080],"Recurrent Solid Tumor","Urinary Bladder Neoplasm","Cervical Cancer","Renal Pelvis Cancer",[12356],{"trials":12374,"activeCount":97},[],{"trials":12376,"activeCount":97},[],{"trials":12378,"activeCount":97},[],{"trials":12380,"activeCount":97},[],{"intervention":11793,"totalTrials":314,"cells":12382},{"EARLY_PHASE1":12383,"PHASE1":12385,"PHASE2":12391,"PHASE3":12393,"PHASE4":12395,"NA":12397},{"trials":12384,"activeCount":97},[],{"trials":12386,"activeCount":314,"soonestReadout":853},[12387],{"nctId":11787,"briefTitle":11788,"status":393,"phases":12388,"primaryCompletion":853,"completion":853,"start":11790,"enrollment":118,"conditions":12389,"interventions":12390},[85],[3980],[11793,11780],{"trials":12392,"activeCount":97},[],{"trials":12394,"activeCount":97},[],{"trials":12396,"activeCount":97},[],{"trials":12398,"activeCount":97},[],{"intervention":4134,"totalTrials":314,"cells":12400},{"EARLY_PHASE1":12401,"PHASE1":12403,"PHASE2":12409,"PHASE3":12411,"PHASE4":12413,"NA":12415},{"trials":12402,"activeCount":97},[],{"trials":12404,"activeCount":314,"soonestReadout":941},[12405],{"nctId":4127,"briefTitle":4128,"status":393,"phases":12406,"primaryCompletion":941,"completion":941,"start":4130,"enrollment":4131,"conditions":12407,"interventions":12408},[85],[1841,1610,1490],[4134,1541,1511,4135,2520,4136,1745,4137],{"trials":12410,"activeCount":97},[],{"trials":12412,"activeCount":97},[],{"trials":12414,"activeCount":97},[],{"trials":12416,"activeCount":97},[],{"intervention":12418,"totalTrials":314,"cells":12419},"LY4088044",{"EARLY_PHASE1":12420,"PHASE1":12422,"PHASE2":12431,"PHASE3":12433,"PHASE4":12435,"NA":12437},{"trials":12421,"activeCount":97},[],{"trials":12423,"activeCount":314,"soonestReadout":715},[12424],{"nctId":12425,"briefTitle":12426,"status":393,"phases":12427,"primaryCompletion":715,"completion":715,"start":12428,"enrollment":10911,"conditions":12429,"interventions":12430},"NCT07090785","A Study of LY4088044 in Healthy Participants",[85],"2025-07-24",[15],[12418,12418],{"trials":12432,"activeCount":97},[],{"trials":12434,"activeCount":97},[],{"trials":12436,"activeCount":97},[],{"trials":12438,"activeCount":97},[],{"intervention":11058,"totalTrials":314,"cells":12440},{"EARLY_PHASE1":12441,"PHASE1":12443,"PHASE2":12449,"PHASE3":12451,"PHASE4":12453,"NA":12455},{"trials":12442,"activeCount":97},[],{"trials":12444,"activeCount":314,"soonestReadout":11051},[12445],{"nctId":11048,"briefTitle":11049,"status":257,"phases":12446,"primaryCompletion":11051,"completion":443,"start":6662,"enrollment":3769,"conditions":12447,"interventions":12448},[85],[11053,11054,11055,11056],[2768,11058,11059],{"trials":12450,"activeCount":97},[],{"trials":12452,"activeCount":97},[],{"trials":12454,"activeCount":97},[],{"trials":12456,"activeCount":97},[],{"intervention":11059,"totalTrials":314,"cells":12458},{"EARLY_PHASE1":12459,"PHASE1":12461,"PHASE2":12467,"PHASE3":12469,"PHASE4":12471,"NA":12473},{"trials":12460,"activeCount":97},[],{"trials":12462,"activeCount":314,"soonestReadout":11051},[12463],{"nctId":11048,"briefTitle":11049,"status":257,"phases":12464,"primaryCompletion":11051,"completion":443,"start":6662,"enrollment":3769,"conditions":12465,"interventions":12466},[85],[11053,11054,11055,11056],[2768,11058,11059],{"trials":12468,"activeCount":97},[],{"trials":12470,"activeCount":97},[],{"trials":12472,"activeCount":97},[],{"trials":12474,"activeCount":97},[],{"intervention":12476,"totalTrials":314,"cells":12477},"LY4101174",{"EARLY_PHASE1":12478,"PHASE1":12480,"PHASE2":12489,"PHASE3":12491,"PHASE4":12493,"NA":12495},{"trials":12479,"activeCount":97},[],{"trials":12481,"activeCount":314,"soonestReadout":2283},[12482],{"nctId":12483,"briefTitle":12484,"status":257,"phases":12485,"primaryCompletion":2283,"completion":1011,"start":8621,"enrollment":12486,"conditions":12487,"interventions":12488},"NCT06238479","A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors",[85],490,[2516,12368,1717,12369,2506,1610,6552,1653,2584,12370,2605,1903,12371,3080],[12476],{"trials":12490,"activeCount":97},[],{"trials":12492,"activeCount":97},[],{"trials":12494,"activeCount":97},[],{"trials":12496,"activeCount":97},[],{"intervention":2634,"totalTrials":314,"cells":12498},{"EARLY_PHASE1":12499,"PHASE1":12501,"PHASE2":12507,"PHASE3":12509,"PHASE4":12511,"NA":12513},{"trials":12500,"activeCount":97},[],{"trials":12502,"activeCount":314,"soonestReadout":454},[12503],{"nctId":2626,"briefTitle":2627,"status":393,"phases":12504,"primaryCompletion":454,"completion":454,"start":2629,"enrollment":2630,"conditions":12505,"interventions":12506},[85],[2516,1717,1610,2632],[2634,1696,1510,1512,1612,1669,2519],{"trials":12508,"activeCount":97},[],{"trials":12510,"activeCount":97},[],{"trials":12512,"activeCount":97},[],{"trials":12514,"activeCount":97},[],{"intervention":12516,"totalTrials":314,"cells":12517},"LY4298445",{"EARLY_PHASE1":12518,"PHASE1":12520,"PHASE2":12529,"PHASE3":12531,"PHASE4":12533,"NA":12535},{"trials":12519,"activeCount":97},[],{"trials":12521,"activeCount":314,"soonestReadout":1993},[12522],{"nctId":12523,"briefTitle":12524,"status":393,"phases":12525,"primaryCompletion":1993,"completion":1993,"start":12526,"enrollment":9415,"conditions":12527,"interventions":12528},"NCT07276958","A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)",[85],"2026-02-04",[15,5075,5218],[12516,12516],{"trials":12530,"activeCount":97},[],{"trials":12532,"activeCount":97},[],{"trials":12534,"activeCount":97},[],{"trials":12536,"activeCount":97},[],{"intervention":12538,"totalTrials":314,"cells":12539},"LY4057996 SC",{"EARLY_PHASE1":12540,"PHASE1":12542,"PHASE2":12556,"PHASE3":12558,"PHASE4":12560,"NA":12562},{"trials":12541,"activeCount":97},[],{"trials":12543,"activeCount":314,"soonestReadout":462},[12544],{"nctId":12545,"briefTitle":12546,"status":393,"phases":12547,"primaryCompletion":462,"completion":462,"start":12548,"enrollment":19,"conditions":12549,"interventions":12550},"NCT06945406","A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes",[85],"2025-05-16",[33,18],[12538,12551,12552,12553,12554,12555],"LY4057996 IV","Degludec SC","Lispro SC","Degludec IV","Pre-study basal insulin SC",{"trials":12557,"activeCount":97},[],{"trials":12559,"activeCount":97},[],{"trials":12561,"activeCount":97},[],{"trials":12563,"activeCount":97},[],{"intervention":12551,"totalTrials":314,"cells":12565},{"EARLY_PHASE1":12566,"PHASE1":12568,"PHASE2":12574,"PHASE3":12576,"PHASE4":12578,"NA":12580},{"trials":12567,"activeCount":97},[],{"trials":12569,"activeCount":314,"soonestReadout":462},[12570],{"nctId":12545,"briefTitle":12546,"status":393,"phases":12571,"primaryCompletion":462,"completion":462,"start":12548,"enrollment":19,"conditions":12572,"interventions":12573},[85],[33,18],[12538,12551,12552,12553,12554,12555],{"trials":12575,"activeCount":97},[],{"trials":12577,"activeCount":97},[],{"trials":12579,"activeCount":97},[],{"trials":12581,"activeCount":97},[],{"intervention":12552,"totalTrials":314,"cells":12583},{"EARLY_PHASE1":12584,"PHASE1":12586,"PHASE2":12592,"PHASE3":12594,"PHASE4":12596,"NA":12598},{"trials":12585,"activeCount":97},[],{"trials":12587,"activeCount":314,"soonestReadout":462},[12588],{"nctId":12545,"briefTitle":12546,"status":393,"phases":12589,"primaryCompletion":462,"completion":462,"start":12548,"enrollment":19,"conditions":12590,"interventions":12591},[85],[33,18],[12538,12551,12552,12553,12554,12555],{"trials":12593,"activeCount":97},[],{"trials":12595,"activeCount":97},[],{"trials":12597,"activeCount":97},[],{"trials":12599,"activeCount":97},[],{"intervention":12553,"totalTrials":314,"cells":12601},{"EARLY_PHASE1":12602,"PHASE1":12604,"PHASE2":12610,"PHASE3":12612,"PHASE4":12614,"NA":12616},{"trials":12603,"activeCount":97},[],{"trials":12605,"activeCount":314,"soonestReadout":462},[12606],{"nctId":12545,"briefTitle":12546,"status":393,"phases":12607,"primaryCompletion":462,"completion":462,"start":12548,"enrollment":19,"conditions":12608,"interventions":12609},[85],[33,18],[12538,12551,12552,12553,12554,12555],{"trials":12611,"activeCount":97},[],{"trials":12613,"activeCount":97},[],{"trials":12615,"activeCount":97},[],{"trials":12617,"activeCount":97},[],{"intervention":12554,"totalTrials":314,"cells":12619},{"EARLY_PHASE1":12620,"PHASE1":12622,"PHASE2":12628,"PHASE3":12630,"PHASE4":12632,"NA":12634},{"trials":12621,"activeCount":97},[],{"trials":12623,"activeCount":314,"soonestReadout":462},[12624],{"nctId":12545,"briefTitle":12546,"status":393,"phases":12625,"primaryCompletion":462,"completion":462,"start":12548,"enrollment":19,"conditions":12626,"interventions":12627},[85],[33,18],[12538,12551,12552,12553,12554,12555],{"trials":12629,"activeCount":97},[],{"trials":12631,"activeCount":97},[],{"trials":12633,"activeCount":97},[],{"trials":12635,"activeCount":97},[],{"intervention":12555,"totalTrials":314,"cells":12637},{"EARLY_PHASE1":12638,"PHASE1":12640,"PHASE2":12646,"PHASE3":12648,"PHASE4":12650,"NA":12652},{"trials":12639,"activeCount":97},[],{"trials":12641,"activeCount":314,"soonestReadout":462},[12642],{"nctId":12545,"briefTitle":12546,"status":393,"phases":12643,"primaryCompletion":462,"completion":462,"start":12548,"enrollment":19,"conditions":12644,"interventions":12645},[85],[33,18],[12538,12551,12552,12553,12554,12555],{"trials":12647,"activeCount":97},[],{"trials":12649,"activeCount":97},[],{"trials":12651,"activeCount":97},[],{"trials":12653,"activeCount":97},[],{"intervention":12655,"totalTrials":314,"cells":12656},"LY3981314",{"EARLY_PHASE1":12657,"PHASE1":12659,"PHASE2":12667,"PHASE3":12669,"PHASE4":12671,"NA":12673},{"trials":12658,"activeCount":97},[],{"trials":12660,"activeCount":314,"soonestReadout":853},[12661],{"nctId":12662,"briefTitle":12663,"status":257,"phases":12664,"primaryCompletion":853,"completion":853,"start":2053,"enrollment":3284,"conditions":12665,"interventions":12666},"NCT07005284","A Study of LY3981314 in Healthy Participants",[85],[15],[12655],{"trials":12668,"activeCount":97},[],{"trials":12670,"activeCount":97},[],{"trials":12672,"activeCount":97},[],{"trials":12674,"activeCount":97},[],{"intervention":12676,"totalTrials":314,"cells":12677},"LY4257496",{"EARLY_PHASE1":12678,"PHASE1":12680,"PHASE2":12693,"PHASE3":12695,"PHASE4":12697,"NA":12699},{"trials":12679,"activeCount":97},[],{"trials":12681,"activeCount":314,"soonestReadout":4046},[12682],{"nctId":12683,"briefTitle":12684,"status":393,"phases":12685,"primaryCompletion":4046,"completion":12686,"start":12687,"enrollment":12688,"conditions":12689,"interventions":12691},"NCT07114601","A Study of LY4257496 in Participants With Cancer (OMNIRAY)",[85],"2035-04","2025-08-06",421,[1893,2557,12690,2505,1478,2756,12327],"Prostate Neoplasm",[12676,12692],"Standard of Care Anticancer Therapies",{"trials":12694,"activeCount":97},[],{"trials":12696,"activeCount":97},[],{"trials":12698,"activeCount":97},[],{"trials":12700,"activeCount":97},[],{"intervention":12692,"totalTrials":314,"cells":12702},{"EARLY_PHASE1":12703,"PHASE1":12705,"PHASE2":12711,"PHASE3":12713,"PHASE4":12715,"NA":12717},{"trials":12704,"activeCount":97},[],{"trials":12706,"activeCount":314,"soonestReadout":4046},[12707],{"nctId":12683,"briefTitle":12684,"status":393,"phases":12708,"primaryCompletion":4046,"completion":12686,"start":12687,"enrollment":12688,"conditions":12709,"interventions":12710},[85],[1893,2557,12690,2505,1478,2756,12327],[12676,12692],{"trials":12712,"activeCount":97},[],{"trials":12714,"activeCount":97},[],{"trials":12716,"activeCount":97},[],{"trials":12718,"activeCount":97},[],{"intervention":11457,"totalTrials":314,"cells":12720},{"EARLY_PHASE1":12721,"PHASE1":12723,"PHASE2":12729,"PHASE3":12731,"PHASE4":12733,"NA":12735},{"trials":12722,"activeCount":97},[],{"trials":12724,"activeCount":314,"soonestReadout":1011},[12725],{"nctId":11447,"briefTitle":11448,"status":393,"phases":12726,"primaryCompletion":1011,"completion":11450,"start":8329,"enrollment":11451,"conditions":12727,"interventions":12728},[85],[11453,11454,11455],[11457,11458],{"trials":12730,"activeCount":97},[],{"trials":12732,"activeCount":97},[],{"trials":12734,"activeCount":97},[],{"trials":12736,"activeCount":97},[],{"intervention":12738,"totalTrials":314,"cells":12739},"LY3439539",{"EARLY_PHASE1":12740,"PHASE1":12742,"PHASE2":12750,"PHASE3":12752,"PHASE4":12754,"NA":12756},{"trials":12741,"activeCount":97},[],{"trials":12743,"activeCount":314,"soonestReadout":940},[12744],{"nctId":12745,"briefTitle":12746,"status":1060,"phases":12747,"primaryCompletion":940,"completion":940,"start":443,"enrollment":1620,"conditions":12748,"interventions":12749},"NCT07598370","A Study of LY3439539 in Participants With Alzheimer's Disease",[85],[3980],[12738],{"trials":12751,"activeCount":97},[],{"trials":12753,"activeCount":97},[],{"trials":12755,"activeCount":97},[],{"trials":12757,"activeCount":97},[],{"intervention":1668,"totalTrials":314,"cells":12759},{"EARLY_PHASE1":12760,"PHASE1":12762,"PHASE2":12768,"PHASE3":12770,"PHASE4":12772,"NA":12774},{"trials":12761,"activeCount":97},[],{"trials":12763,"activeCount":314,"soonestReadout":462},[12764],{"nctId":1659,"briefTitle":1660,"status":257,"phases":12765,"primaryCompletion":462,"completion":462,"start":1662,"enrollment":1663,"conditions":12766,"interventions":12767},[85],[36],[1666,1468,1667,48,1668,1669],{"trials":12769,"activeCount":97},[],{"trials":12771,"activeCount":97},[],{"trials":12773,"activeCount":97},[],{"trials":12775,"activeCount":97},[],{"intervention":12777,"totalTrials":314,"cells":12778},"LY3867070",{"EARLY_PHASE1":12779,"PHASE1":12781,"PHASE2":12791,"PHASE3":12793,"PHASE4":12795,"NA":12797},{"trials":12780,"activeCount":97},[],{"trials":12782,"activeCount":314,"soonestReadout":420},[12783],{"nctId":12784,"briefTitle":12785,"status":393,"phases":12786,"primaryCompletion":420,"completion":420,"start":12787,"enrollment":12788,"conditions":12789,"interventions":12790},"NCT07021547","A Study of LY3867070 in Healthy Participants",[85],"2025-05-27",196,[15],[12777],{"trials":12792,"activeCount":97},[],{"trials":12794,"activeCount":97},[],{"trials":12796,"activeCount":97},[],{"trials":12798,"activeCount":97},[],{"intervention":11748,"totalTrials":314,"cells":12800},{"EARLY_PHASE1":12801,"PHASE1":12803,"PHASE2":12809,"PHASE3":12811,"PHASE4":12813,"NA":12815},{"trials":12802,"activeCount":97},[],{"trials":12804,"activeCount":314,"soonestReadout":1309},[12805],{"nctId":11742,"briefTitle":11743,"status":257,"phases":12806,"primaryCompletion":1309,"completion":1309,"start":11745,"enrollment":118,"conditions":12807,"interventions":12808},[85],[4997],[11726,11748],{"trials":12810,"activeCount":97},[],{"trials":12812,"activeCount":97},[],{"trials":12814,"activeCount":97},[],{"trials":12816,"activeCount":97},[],{"intervention":12818,"totalTrials":314,"cells":12819},"LY4152199 - IV",{"EARLY_PHASE1":12820,"PHASE1":12822,"PHASE2":12834,"PHASE3":12836,"PHASE4":12838,"NA":12840},{"trials":12821,"activeCount":97},[],{"trials":12823,"activeCount":314,"soonestReadout":1011},[12824],{"nctId":12825,"briefTitle":12826,"status":1060,"phases":12827,"primaryCompletion":1011,"completion":4062,"start":419,"enrollment":12828,"conditions":12829,"interventions":12833},"NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )",[85],215,[1113,1115,12830,12831,1112,1116,12832],"Lymphoma, Large B-Cell, Diffuse","Lymphoma, Follicular","Lymphoma, Mantle Cell",[12818],{"trials":12835,"activeCount":97},[],{"trials":12837,"activeCount":97},[],{"trials":12839,"activeCount":97},[],{"trials":12841,"activeCount":97},[],{"intervention":438,"totalTrials":3125,"cells":12843},{"EARLY_PHASE1":12844,"PHASE1":12846,"PHASE2":13047,"PHASE3":13057,"PHASE4":13185,"NA":13226},{"trials":12845,"activeCount":97},[],{"trials":12847,"activeCount":314,"soonestReadout":408},[12848,12856,12865,12873,12879,12883,12891,12900,12906,12913,12921,12929,12936,12942,12948,12955,12962,12968,12975,12981,12987,12993,12999,13005,13013,13020,13026,13032,13039],{"nctId":12849,"briefTitle":12850,"status":103,"phases":12851,"primaryCompletion":12852,"completion":12852,"start":12853,"enrollment":310,"conditions":12854,"interventions":12855},"NCT04276207","A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps",[85],"2020-08-10","2020-02-25",[33],[9698,438],{"nctId":12857,"briefTitle":12858,"status":103,"phases":12859,"primaryCompletion":12860,"completion":12860,"start":12861,"enrollment":1620,"conditions":12862,"interventions":12864},"NCT03367390","A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)",[85],"2018-02-09","2017-11-08",[12863],"Type1 Diabetes Mellitus",[438],{"nctId":12866,"briefTitle":12867,"status":103,"phases":12868,"primaryCompletion":12869,"completion":12869,"start":12870,"enrollment":214,"conditions":12871,"interventions":12872},"NCT03341299","A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus",[85],"2018-04-03","2017-11-13",[33],[9698,438],{"nctId":12874,"briefTitle":12875,"status":103,"phases":12876,"primaryCompletion":3122,"completion":3122,"start":4098,"enrollment":280,"conditions":12877,"interventions":12878},"NCT02111083","A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants",[85],[21],[438],{"nctId":9433,"briefTitle":9434,"status":393,"phases":12880,"primaryCompletion":408,"completion":408,"start":1034,"enrollment":3618,"conditions":12881,"interventions":12882},[85],[15,9437],[9426,700,438,9426,700,9439,9440],{"nctId":12884,"briefTitle":12885,"status":103,"phases":12886,"primaryCompletion":12887,"completion":12887,"start":12888,"enrollment":137,"conditions":12889,"interventions":12890},"NCT03286751","A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants",[85],"2018-02-06","2017-10-13",[18],[9698,438],{"nctId":12892,"briefTitle":12893,"status":103,"phases":12894,"primaryCompletion":12895,"completion":12895,"start":12896,"enrollment":1082,"conditions":12897,"interventions":12898},"NCT04161976","A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus",[85],"2020-07-14","2019-12-27",[33],[12899,438],"LY900027",{"nctId":12901,"briefTitle":12902,"status":103,"phases":12903,"primaryCompletion":3697,"completion":1618,"start":5030,"enrollment":864,"conditions":12904,"interventions":12905},"NCT02317575","A Study of LY900014 Formulations in Healthy Participants",[85],[21],[9698,438],{"nctId":12907,"briefTitle":12908,"status":103,"phases":12909,"primaryCompletion":1546,"completion":1546,"start":2799,"enrollment":1488,"conditions":12910,"interventions":12911},"NCT02770521","A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants",[85],[15],[12912,9698,438],"Treprostinil",{"nctId":12914,"briefTitle":12915,"status":103,"phases":12916,"primaryCompletion":12917,"completion":12917,"start":12918,"enrollment":1158,"conditions":12919,"interventions":12920},"NCT04049123","A Study of LY900014 in Healthy Chinese Participants",[85],"2020-10-23","2019-11-18",[15],[9698,438],{"nctId":12922,"briefTitle":12923,"status":103,"phases":12924,"primaryCompletion":12925,"completion":6243,"start":12926,"enrollment":1178,"conditions":12927,"interventions":12928},"NCT03407118","A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus",[85],"2018-06-23","2018-02-17",[33],[9698,438],{"nctId":12930,"briefTitle":12931,"status":103,"phases":12932,"primaryCompletion":12933,"completion":12933,"start":365,"enrollment":4475,"conditions":12934,"interventions":12935},"NCT03166124","A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus",[85],"2017-11-18",[33],[9698,438],{"nctId":12937,"briefTitle":12938,"status":103,"phases":12939,"primaryCompletion":3250,"completion":3250,"start":1474,"enrollment":290,"conditions":12940,"interventions":12941},"NCT02525744","A Study of a New LY900014 Formulation in Healthy Participants",[85],[15],[9698,438],{"nctId":12943,"briefTitle":12944,"status":384,"phases":12945,"primaryCompletion":3113,"completion":3113,"start":6558,"enrollment":97,"conditions":12946,"interventions":12947},"NCT02623452","A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy",[85],[33],[438],{"nctId":12949,"briefTitle":12950,"status":103,"phases":12951,"primaryCompletion":1619,"completion":1619,"start":7316,"enrollment":290,"conditions":12952,"interventions":12953},"NCT02197520","A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics",[85],[18],[12954,506,438],"Insulin Peglispro",{"nctId":12956,"briefTitle":12957,"status":103,"phases":12958,"primaryCompletion":5022,"completion":5022,"start":2964,"enrollment":233,"conditions":12959,"interventions":12960},"NCT01871493","A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants",[85],[21],[12961,438],"LY2605541",{"nctId":12963,"briefTitle":12964,"status":103,"phases":12965,"primaryCompletion":1628,"completion":1628,"start":7775,"enrollment":1620,"conditions":12966,"interventions":12967},"NCT02703337","A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy",[85],[18],[9698,438],{"nctId":12969,"briefTitle":12970,"status":103,"phases":12971,"primaryCompletion":7547,"completion":7547,"start":6651,"enrollment":4475,"conditions":12972,"interventions":12973},"NCT03449433","A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus",[85],[33],[9698,438,12974,12974],"Insulin Aspart",{"nctId":12976,"briefTitle":12977,"status":103,"phases":12978,"primaryCompletion":1627,"completion":1627,"start":2754,"enrollment":310,"conditions":12979,"interventions":12980},"NCT02942654","A Study of LY900014 Formulation in Healthy Participants",[85],[15],[9698,438],{"nctId":12982,"briefTitle":12983,"status":103,"phases":12984,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":165,"conditions":12985,"interventions":12986},"NCT02152384","A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements",[85],[33],[12954,438,506],{"nctId":12988,"briefTitle":12989,"status":384,"phases":12990,"primaryCompletion":3113,"completion":3113,"start":6558,"enrollment":97,"conditions":12991,"interventions":12992},"NCT02623478","A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps",[85],[33],[438],{"nctId":12994,"briefTitle":12995,"status":384,"phases":12996,"primaryCompletion":3113,"completion":3113,"start":6558,"enrollment":97,"conditions":12997,"interventions":12998},"NCT02623465","A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy",[85],[18],[438],{"nctId":13000,"briefTitle":13001,"status":103,"phases":13002,"primaryCompletion":1547,"completion":1547,"start":3123,"enrollment":893,"conditions":13003,"interventions":13004},"NCT02636361","A Study of Various Formulations of LY900014 in Healthy Participants",[85],[15],[9698,7104],{"nctId":13006,"briefTitle":13007,"status":103,"phases":13008,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":6943,"conditions":13011,"interventions":13012},"NCT03465878","A Study of LY900014 in Participants With Type 1 Diabetes Mellitus",[85],"2019-11-14","2018-03-26",[9437],[9698,438],{"nctId":13014,"briefTitle":13015,"status":103,"phases":13016,"primaryCompletion":921,"completion":921,"start":13017,"enrollment":290,"conditions":13018,"interventions":13019},"NCT03056456","A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump",[85],"2017-02-23",[33],[9698,438],{"nctId":13021,"briefTitle":13022,"status":103,"phases":13023,"primaryCompletion":1546,"completion":1546,"start":7775,"enrollment":1620,"conditions":13024,"interventions":13025},"NCT02703350","A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy",[85],[33],[9698,438],{"nctId":13027,"briefTitle":13028,"status":103,"phases":13029,"primaryCompletion":1628,"completion":1628,"start":7775,"enrollment":1620,"conditions":13030,"interventions":13031},"NCT02703324","A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps",[85],[33],[9698,438],{"nctId":13033,"briefTitle":13034,"status":103,"phases":13035,"primaryCompletion":13036,"completion":13036,"start":12870,"enrollment":214,"conditions":13037,"interventions":13038},"NCT03341312","A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)",[85],"2018-03-31",[18],[9698,438],{"nctId":13040,"briefTitle":13041,"status":103,"phases":13042,"primaryCompletion":13043,"completion":13043,"start":13044,"enrollment":280,"conditions":13045,"interventions":13046},"NCT03305822","A Study of LY900014 in Participants With Type 2 Diabetes Mellitus",[85],"2017-12-14","2017-10-11",[18],[9698,438],{"trials":13048,"activeCount":97},[13049],{"nctId":13050,"briefTitle":13051,"status":103,"phases":13052,"primaryCompletion":13053,"completion":13053,"start":13054,"enrollment":137,"conditions":13055,"interventions":13056},"NCT03760640","A Study of LY900014 in a Medtronic Pump",[86],"2019-10-07","2019-02-18",[12863],[9698,438],{"trials":13058,"activeCount":97},[13059,13067,13073,13077,13085,13092,13101,13111,13115,13121,13125,13131,13139,13143,13147,13151,13159,13167,13171,13178],{"nctId":13060,"briefTitle":13061,"status":103,"phases":13062,"primaryCompletion":13063,"completion":13063,"start":7362,"enrollment":3309,"conditions":13064,"interventions":13066},"NCT03433677","A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes",[87],"2018-09-04",[13065],"Diabetes Type 1",[9698,7104],{"nctId":13068,"briefTitle":9727,"status":103,"phases":13069,"primaryCompletion":2917,"completion":2917,"start":4160,"enrollment":13070,"conditions":13071,"interventions":13072},"NCT01468987",[87],1369,[18],[12961,506,438],{"nctId":429,"briefTitle":430,"status":103,"phases":13074,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":13075,"interventions":13076},[87],[30],[92,438],{"nctId":13078,"briefTitle":13079,"status":103,"phases":13080,"primaryCompletion":3987,"completion":3987,"start":13081,"enrollment":13082,"conditions":13083,"interventions":13084},"NCT05462756","A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections",[87],"2022-08-11",730,[30,11208],[11287,438,506],{"nctId":13086,"briefTitle":13087,"status":103,"phases":13088,"primaryCompletion":3086,"completion":2898,"start":3029,"enrollment":13089,"conditions":13090,"interventions":13091},"NCT01191268","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)",[87],884,[18],[506,9681,438],{"nctId":13093,"briefTitle":13094,"status":103,"phases":13095,"primaryCompletion":989,"completion":989,"start":13096,"enrollment":3978,"conditions":13097,"interventions":13098},"NCT03338023","A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus",[87],"2018-03-23",[466],[13099,13100,438],"LY2963016","Lantus®",{"nctId":13102,"briefTitle":13103,"status":103,"phases":13104,"primaryCompletion":13105,"completion":13105,"start":13106,"enrollment":13107,"conditions":13108,"interventions":13109},"NCT03830281","A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy",[87],"2020-01-06","2019-02-14",471,[9437],[13110,438],"Ultra-Rapid Lispro",{"nctId":11271,"briefTitle":11272,"status":103,"phases":13112,"primaryCompletion":11274,"completion":11274,"start":11275,"enrollment":743,"conditions":13113,"interventions":13114},[87],[9437],[9698,438,506,700],{"nctId":13116,"briefTitle":13117,"status":103,"phases":13118,"primaryCompletion":1475,"completion":1475,"start":4420,"enrollment":7166,"conditions":13119,"interventions":13120},"NCT01792284","A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus",[87],[9437],[12961,438],{"nctId":9690,"briefTitle":9691,"status":103,"phases":13122,"primaryCompletion":7547,"completion":9693,"start":9694,"enrollment":9695,"conditions":13123,"interventions":13124},[87],[120],[9698,438,506,700,1631,7063],{"nctId":13126,"briefTitle":13127,"status":103,"phases":13128,"primaryCompletion":4420,"completion":4420,"start":4160,"enrollment":3267,"conditions":13129,"interventions":13130},"NCT01474538","Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy",[87],[120],[438,12974],{"nctId":13132,"briefTitle":13133,"status":103,"phases":13134,"primaryCompletion":2966,"completion":3348,"start":8217,"enrollment":13135,"conditions":13136,"interventions":13137},"NCT01421147","A Study in Adults With Type 1 Diabetes",[87],536,[33],[13099,13138,438],"Lantus",{"nctId":11309,"briefTitle":11310,"status":103,"phases":13140,"primaryCompletion":11312,"completion":5129,"start":11313,"enrollment":11314,"conditions":13141,"interventions":13142},[87],[9437],[9698,438,506,700],{"nctId":7097,"briefTitle":7098,"status":103,"phases":13144,"primaryCompletion":2965,"completion":1627,"start":3545,"enrollment":7100,"conditions":13145,"interventions":13146},[87],[30,412],[303,7103,7104],{"nctId":11318,"briefTitle":11319,"status":103,"phases":13148,"primaryCompletion":1882,"completion":1882,"start":11321,"enrollment":11322,"conditions":13149,"interventions":13150},[87],[120],[9698,438,506,700],{"nctId":13152,"briefTitle":13153,"status":999,"phases":13154,"primaryCompletion":5090,"completion":5090,"start":3837,"enrollment":1071,"conditions":13155,"interventions":13157},"NCT01136746","Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin",[87],[13156],"Hyperglycemia",[13158,7104,7103],"Human regular insulin",{"nctId":13160,"briefTitle":13161,"status":103,"phases":13162,"primaryCompletion":3282,"completion":5354,"start":3661,"enrollment":13163,"conditions":13164,"interventions":13165},"NCT01481779","A Study in Participants With Type 1 Diabetes Mellitus",[87],455,[33],[13166,12961,438],"Glargine",{"nctId":11326,"briefTitle":11327,"status":103,"phases":13168,"primaryCompletion":9249,"completion":9249,"start":11329,"enrollment":11330,"conditions":13169,"interventions":13170},[87],[9437],[9698,438,506,700],{"nctId":13172,"briefTitle":13173,"status":103,"phases":13174,"primaryCompletion":3087,"completion":3087,"start":2995,"enrollment":5170,"conditions":13175,"interventions":13176},"NCT00666718","A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients",[87],[18],[506,13177,438],"Insulin Lispro Protamine Suspension",{"nctId":13179,"briefTitle":13180,"status":103,"phases":13181,"primaryCompletion":9748,"completion":9748,"start":3661,"enrollment":13182,"conditions":13183,"interventions":13184},"NCT01454284","A Study in Participants With Type I Diabetes Mellitus",[87],1114,[33],[13166,12961,438],{"trials":13186,"activeCount":97},[13187,13195,13202,13212,13218],{"nctId":13188,"briefTitle":13189,"status":103,"phases":13190,"primaryCompletion":3048,"completion":3048,"start":3283,"enrollment":13191,"conditions":13192,"interventions":13193},"NCT01175811","A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus",[88],402,[18],[13194,506,438],"Insulin Lispro Premix",{"nctId":13196,"briefTitle":13197,"status":103,"phases":13198,"primaryCompletion":6093,"completion":6093,"start":3050,"enrollment":3373,"conditions":13199,"interventions":13200},"NCT00985712","A Study on the Effect of 2 Pen Devices on HbA1c",[88],[33],[438,13201],"Huminsulin Regular",{"nctId":13203,"briefTitle":13204,"status":103,"phases":13205,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":13206,"conditions":13207,"interventions":13209},"NCT00191282","Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes",[88],1116,[18,13208],"Acute Myocardial Infarction",[7104,13210,7103,13210,13211],"Human insulin isophane suspension","Human insulin 30\u002F70",{"nctId":13213,"briefTitle":13214,"status":103,"phases":13215,"primaryCompletion":3068,"completion":3068,"start":3152,"enrollment":7575,"conditions":13216,"interventions":13217},"NCT01215955","Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes",[88],[18],[7104,13166],{"nctId":13219,"briefTitle":13220,"status":103,"phases":13221,"primaryCompletion":2955,"completion":2955,"start":3266,"enrollment":13222,"conditions":13223,"interventions":13224},"NCT00548808","A Study for Type 2 Diabetic Patients",[88],426,[120],[13225,7103,7104],"Insulin lispro low mixture",{"trials":13227,"activeCount":97},[13228,13235,13243,13251,13258,13267],{"nctId":13229,"briefTitle":13230,"status":103,"phases":13231,"primaryCompletion":13232,"completion":13232,"start":5054,"enrollment":757,"conditions":13233,"interventions":13234},"NCT03890003","A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes",[89],"2019-05-06",[9437],[438],{"nctId":13236,"briefTitle":13237,"status":103,"phases":13238,"primaryCompletion":13239,"completion":13239,"start":13240,"enrollment":214,"conditions":13241,"interventions":13242},"NCT05893797","A Study of LY8888AX in Participants Using a Connected Insulin Management Platform",[89],"2024-09-16","2023-10-05",[466,30,11208],[438],{"nctId":13244,"briefTitle":13245,"status":103,"phases":13246,"primaryCompletion":13247,"completion":13247,"start":13248,"enrollment":757,"conditions":13249,"interventions":13250},"NCT03743285","A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)",[89],"2019-01-28","2018-11-14",[9437],[438],{"nctId":13252,"briefTitle":13253,"status":103,"phases":13254,"primaryCompletion":696,"completion":696,"start":13255,"enrollment":757,"conditions":13256,"interventions":13257},"NCT03848767","A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges",[89],"2019-02-20",[9437],[438],{"nctId":13259,"briefTitle":13260,"status":103,"phases":13261,"primaryCompletion":13262,"completion":13263,"start":13264,"enrollment":9001,"conditions":13265,"interventions":13266},"NCT03368807","Assessment of Mealtime Bolus Insulin Behavior",[],"2018-06-12","2018-07-23","2017-12-11",[33,18],[438],{"nctId":13268,"briefTitle":13269,"status":103,"phases":13270,"primaryCompletion":13271,"completion":13271,"start":13272,"enrollment":757,"conditions":13273,"interventions":13274},"NCT03849612","A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus",[89],"2019-03-27","2019-02-21",[9437],[438],{"intervention":1513,"totalTrials":757,"cells":13276},{"EARLY_PHASE1":13277,"PHASE1":13279,"PHASE2":13308,"PHASE3":13331,"PHASE4":13333,"NA":13335},{"trials":13278,"activeCount":97},[],{"trials":13280,"activeCount":314,"soonestReadout":3865},[13281,13288,13292,13296,13300,13304],{"nctId":13282,"briefTitle":13283,"status":103,"phases":13284,"primaryCompletion":13285,"completion":13285,"start":1618,"enrollment":2477,"conditions":13286,"interventions":13287},"NCT02536586","A Study of LY3023414 in Japanese Participants With Advanced Cancer",[85],"2017-02-09",[1477],[1513],{"nctId":1495,"briefTitle":1496,"status":999,"phases":13289,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":13290,"interventions":13291},[85],[1503,36,1504,1505,1506],[1508,1509,48,1510,1511,1512,1513],{"nctId":1600,"briefTitle":1601,"status":103,"phases":13293,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":13294,"interventions":13295},[85],[1466,1560,1608,1571,1609,1610],[1513,1538,1468,1612,1510,48,1613],{"nctId":2774,"briefTitle":2775,"status":103,"phases":13297,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":13298,"interventions":13299},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"nctId":3862,"briefTitle":3863,"status":257,"phases":13301,"primaryCompletion":3865,"completion":462,"start":3866,"enrollment":3867,"conditions":13302,"interventions":13303},[85],[1893],[3870,1613,1697,1761,1760,1575,1577,1513,1468,1579,1551,3871],{"nctId":1699,"briefTitle":1700,"status":103,"phases":13305,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":299,"conditions":13306,"interventions":13307},[85],[1706],[48,1612,1511,61,1513,1696],{"trials":13309,"activeCount":97},[13310,13314,13320],{"nctId":1833,"briefTitle":1834,"status":103,"phases":13311,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":1839,"conditions":13312,"interventions":13313},[86],[1841],[48,1513,1511,1843],{"nctId":13315,"briefTitle":13316,"status":999,"phases":13317,"primaryCompletion":7255,"completion":7255,"start":4097,"enrollment":1178,"conditions":13318,"interventions":13319},"NCT02443337","A Study of LY3023414 and Necitumumab in Squamous Lung Cancer",[86],[6485],[1513,1591],{"nctId":13321,"briefTitle":13322,"status":103,"phases":13323,"primaryCompletion":13324,"completion":13325,"start":13326,"enrollment":299,"conditions":13327,"interventions":13329},"NCT02407054","A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer",[86],"2018-09-26","2020-04-16","2015-04-29",[13328],"Prostate Cancer Metastatic",[1513,13330],"Enzalutamide",{"trials":13332,"activeCount":97},[],{"trials":13334,"activeCount":97},[],{"trials":13336,"activeCount":97},[13337],{"nctId":13338,"briefTitle":13339,"status":13340,"phases":13341,"conditions":13342,"interventions":13343},"NCT02632994","Master Rollover Protocol for Continued Safety Assessment of Study Drug","AVAILABLE",[],[2824],[13344,1513,13345,13346],"LY2503029","LY3838915","LY3847429",{"intervention":13348,"totalTrials":947,"cells":13349},"LOXO-260",{"EARLY_PHASE1":13350,"PHASE1":13352,"PHASE2":13362,"PHASE3":13364,"PHASE4":13366,"NA":13368},{"trials":13351,"activeCount":97},[],{"trials":13353,"activeCount":314,"soonestReadout":13358},[13354],{"nctId":13355,"briefTitle":13356,"status":257,"phases":13357,"primaryCompletion":13358,"completion":419,"start":2013,"enrollment":2790,"conditions":13359,"interventions":13361},"NCT05241834","A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment",[85],"2024-09-17",[1589,13360],"Thyroid Neoplasms",[13348],{"trials":13363,"activeCount":97},[],{"trials":13365,"activeCount":97},[],{"trials":13367,"activeCount":97},[],{"trials":13369,"activeCount":97},[13370],{"nctId":13371,"briefTitle":13372,"status":13373,"phases":13374,"conditions":13375,"interventions":13376},"NCT05225259","Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond\u002Fis no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor","NO_LONGER_AVAILABLE",[],[1589,13360],[13348],{"intervention":4081,"totalTrials":314,"cells":13378},{"EARLY_PHASE1":13379,"PHASE1":13381,"PHASE2":13383,"PHASE3":13385,"PHASE4":13387,"NA":13389},{"trials":13380,"activeCount":97},[],{"trials":13382,"activeCount":97},[],{"trials":13384,"activeCount":97},[],{"trials":13386,"activeCount":97},[],{"trials":13388,"activeCount":97},[],{"trials":13390,"activeCount":314,"soonestReadout":4076},[13391],{"nctId":4073,"briefTitle":4074,"status":393,"phases":13392,"primaryCompletion":4076,"completion":4076,"start":4077,"enrollment":4078,"conditions":13393,"interventions":13394},[],[3980],[3936,4081],{"intervention":13396,"totalTrials":314,"cells":13397},"Florbetapir F 18 PET Scan",{"EARLY_PHASE1":13398,"PHASE1":13400,"PHASE2":13402,"PHASE3":13404,"PHASE4":13406,"NA":13408},{"trials":13399,"activeCount":97},[],{"trials":13401,"activeCount":97},[],{"trials":13403,"activeCount":97},[],{"trials":13405,"activeCount":97},[],{"trials":13407,"activeCount":97},[],{"trials":13409,"activeCount":314,"soonestReadout":13414},[13410],{"nctId":13411,"briefTitle":13412,"status":257,"phases":13413,"primaryCompletion":13414,"completion":13415,"start":13416,"enrollment":8418,"conditions":13417,"interventions":13419},"NCT02951598","A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)",[],"2021-01-30","2026-04-28","2016-10-29",[3980,13418],"Mild Cognitive Impairment",[13396],{"intervention":506,"totalTrials":1189,"cells":13421},{"EARLY_PHASE1":13422,"PHASE1":13424,"PHASE2":13505,"PHASE3":13520,"PHASE4":13691,"NA":13769},{"trials":13423,"activeCount":97},[],{"trials":13425,"activeCount":97},[13426,13433,13439,13445,13453,13457,13463,13470,13477,13485,13489,13499],{"nctId":13427,"briefTitle":13428,"status":103,"phases":13429,"primaryCompletion":13430,"completion":13430,"start":819,"enrollment":1178,"conditions":13431,"interventions":13432},"NCT05596747","A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus",[85],"2023-10-10",[18],[11230,506],{"nctId":13434,"briefTitle":13435,"status":103,"phases":13436,"primaryCompletion":3049,"completion":3049,"start":4420,"enrollment":9038,"conditions":13437,"interventions":13438},"NCT01769404","A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes",[85],[33],[12961,506],{"nctId":13440,"briefTitle":13441,"status":103,"phases":13442,"primaryCompletion":3250,"completion":3250,"start":4980,"enrollment":2071,"conditions":13443,"interventions":13444},"NCT01925989","A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics",[85],[9437],[12961,506],{"nctId":13446,"briefTitle":13447,"status":103,"phases":13448,"primaryCompletion":13449,"completion":13449,"start":13450,"enrollment":2790,"conditions":13451,"interventions":13452},"NCT03367377","A Study of LY3209590 in Participants With Type 2 Diabetes",[85],"2018-10-03","2018-01-03",[18],[11230,506],{"nctId":12949,"briefTitle":12950,"status":103,"phases":13454,"primaryCompletion":1619,"completion":1619,"start":7316,"enrollment":290,"conditions":13455,"interventions":13456},[85],[18],[12954,506,438],{"nctId":13458,"briefTitle":13459,"status":103,"phases":13460,"primaryCompletion":3776,"completion":3776,"start":4955,"enrollment":1158,"conditions":13461,"interventions":13462},"NCT01771250","A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes",[85],[33],[12954,506],{"nctId":13464,"briefTitle":13465,"status":103,"phases":13466,"primaryCompletion":13467,"completion":13467,"start":7574,"enrollment":31,"conditions":13468,"interventions":13469},"NCT04957914","A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus",[85],"2022-10-17",[120],[506,11230],{"nctId":13471,"briefTitle":13472,"status":103,"phases":13473,"primaryCompletion":13474,"completion":13474,"start":13324,"enrollment":1189,"conditions":13475,"interventions":13476},"NCT03555305","A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants",[85],"2019-11-04",[15],[506,13138],{"nctId":13478,"briefTitle":13479,"status":103,"phases":13480,"primaryCompletion":13481,"completion":13481,"start":13482,"enrollment":4475,"conditions":13483,"interventions":13484},"NCT02942914","A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes",[85],"2017-10-18","2016-12-20",[18],[11230,506],{"nctId":12982,"briefTitle":12983,"status":103,"phases":13486,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":165,"conditions":13487,"interventions":13488},[85],[33],[12954,438,506],{"nctId":13490,"briefTitle":13491,"status":103,"phases":13492,"primaryCompletion":13493,"completion":13493,"start":13494,"enrollment":3654,"conditions":13495,"interventions":13496},"NCT03025009","A Study of LY3192767 in Healthy Participants",[85],"2018-04-11","2017-03-06",[15],[13497,13498,506],"LY3192767","Basal Insulin Peglispro",{"nctId":13500,"briefTitle":13501,"status":103,"phases":13502,"primaryCompletion":4980,"completion":4980,"start":4420,"enrollment":3284,"conditions":13503,"interventions":13504},"NCT01784211","A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes",[85],[33],[12961,506],{"trials":13506,"activeCount":97},[13507,13514],{"nctId":13508,"briefTitle":13509,"status":103,"phases":13510,"primaryCompletion":3152,"completion":4258,"start":3685,"enrollment":13511,"conditions":13512,"interventions":13513},"NCT01027871","A Study for Patients With Type 2 Diabetes",[86],289,[18],[12961,9743],{"nctId":13515,"briefTitle":13516,"status":103,"phases":13517,"primaryCompletion":3152,"completion":4258,"start":3685,"enrollment":8225,"conditions":13518,"interventions":13519},"NCT01049412","A Study for Patients With Type 1 Diabetes",[86],[33],[12961,7103],{"trials":13521,"activeCount":97},[13522,13526,13530,13534,13538,13544,13548,13555,13561,13565,13572,13576,13584,13591,13597,13601,13605,13613,13619,13623,13627,13631,13635,13639,13646,13653,13657,13665,13673,13679,13683,13687],{"nctId":13068,"briefTitle":9727,"status":103,"phases":13523,"primaryCompletion":2917,"completion":2917,"start":4160,"enrollment":13070,"conditions":13524,"interventions":13525},[87],[18],[12961,506,438],{"nctId":13078,"briefTitle":13079,"status":103,"phases":13527,"primaryCompletion":3987,"completion":3987,"start":13081,"enrollment":13082,"conditions":13528,"interventions":13529},[87],[30,11208],[11287,438,506],{"nctId":13086,"briefTitle":13087,"status":103,"phases":13531,"primaryCompletion":3086,"completion":2898,"start":3029,"enrollment":13089,"conditions":13532,"interventions":13533},[87],[18],[506,9681,438],{"nctId":11271,"briefTitle":11272,"status":103,"phases":13535,"primaryCompletion":11274,"completion":11274,"start":11275,"enrollment":743,"conditions":13536,"interventions":13537},[87],[9437],[9698,438,506,700],{"nctId":13539,"briefTitle":13540,"status":103,"phases":13541,"primaryCompletion":4097,"completion":4097,"start":4098,"enrollment":4353,"conditions":13542,"interventions":13543},"NCT02132637","A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes",[87],[120],[12954,506],{"nctId":9690,"briefTitle":9691,"status":103,"phases":13545,"primaryCompletion":7547,"completion":9693,"start":9694,"enrollment":9695,"conditions":13546,"interventions":13547},[87],[120],[9698,438,506,700,1631,7063],{"nctId":13549,"briefTitle":13550,"status":103,"phases":13551,"primaryCompletion":3292,"completion":3292,"start":2875,"enrollment":299,"conditions":13552,"interventions":13553},"NCT00437112","Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes",[87],[18],[13554,506],"Human Insulin Inhalation Powder",{"nctId":13556,"briefTitle":13557,"status":384,"phases":13558,"primaryCompletion":4383,"completion":2965,"start":1473,"enrollment":97,"conditions":13559,"interventions":13560},"NCT02106364","A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus",[87],[18],[12954,506],{"nctId":497,"briefTitle":498,"status":103,"phases":13562,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":13563,"interventions":13564},[87],[120],[92,506],{"nctId":13566,"briefTitle":13567,"status":103,"phases":13568,"primaryCompletion":3575,"completion":3575,"start":2855,"enrollment":13569,"conditions":13570,"interventions":13571},"NCT00355849","Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes",[87],555,[18],[13554,506],{"nctId":7077,"briefTitle":7078,"status":103,"phases":13573,"primaryCompletion":1346,"completion":1346,"start":7080,"enrollment":7081,"conditions":13574,"interventions":13575},[87],[120],[303,506],{"nctId":13577,"briefTitle":13578,"status":103,"phases":13579,"primaryCompletion":3697,"completion":3697,"start":3027,"enrollment":13580,"conditions":13581,"interventions":13582},"NCT01894568","A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment",[87],388,[120],[12954,506,13583],"Oral Antihyperglycemic Medications",{"nctId":13585,"briefTitle":13586,"status":103,"phases":13587,"primaryCompletion":1377,"completion":1377,"start":13588,"enrollment":3420,"conditions":13589,"interventions":13590},"NCT05662332","A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)",[87],"2023-01-14",[30,413],[11287,506],{"nctId":13592,"briefTitle":13593,"status":103,"phases":13594,"primaryCompletion":3132,"completion":3132,"start":3813,"enrollment":13107,"conditions":13595,"interventions":13596},"NCT00510952","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)",[87],[18],[13177,506],{"nctId":11309,"briefTitle":11310,"status":103,"phases":13598,"primaryCompletion":11312,"completion":5129,"start":11313,"enrollment":11314,"conditions":13599,"interventions":13600},[87],[9437],[9698,438,506,700],{"nctId":7097,"briefTitle":7098,"status":103,"phases":13602,"primaryCompletion":2965,"completion":1627,"start":3545,"enrollment":7100,"conditions":13603,"interventions":13604},[87],[30,412],[303,7103,7104],{"nctId":13606,"briefTitle":13607,"status":103,"phases":13608,"primaryCompletion":13609,"completion":13609,"start":13610,"enrollment":2919,"conditions":13611,"interventions":13612},"NCT04605991","A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)",[87],"2022-02-04","2020-11-04",[30],[9698,506],{"nctId":13614,"briefTitle":13615,"status":103,"phases":13616,"primaryCompletion":3282,"completion":3049,"start":2865,"enrollment":2236,"conditions":13617,"interventions":13618},"NCT01582451","A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus",[87],[18],[12961,7103],{"nctId":9704,"briefTitle":9705,"status":103,"phases":13620,"primaryCompletion":2865,"completion":3048,"start":3087,"enrollment":9707,"conditions":13621,"interventions":13622},[87],[18],[506,9681,1631,7071],{"nctId":11318,"briefTitle":11319,"status":103,"phases":13624,"primaryCompletion":1882,"completion":1882,"start":11321,"enrollment":11322,"conditions":13625,"interventions":13626},[87],[120],[9698,438,506,700],{"nctId":13152,"briefTitle":13153,"status":999,"phases":13628,"primaryCompletion":5090,"completion":5090,"start":3837,"enrollment":1071,"conditions":13629,"interventions":13630},[87],[13156],[13158,7104,7103],{"nctId":7112,"briefTitle":7113,"status":103,"phases":13632,"primaryCompletion":3122,"completion":3776,"start":3545,"enrollment":7115,"conditions":13633,"interventions":13634},[87],[120],[303,7103,1631,7118],{"nctId":590,"briefTitle":591,"status":103,"phases":13636,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":13637,"interventions":13638},[87],[30],[92,506],{"nctId":13640,"briefTitle":13641,"status":103,"phases":13642,"primaryCompletion":3027,"completion":3027,"start":2864,"enrollment":3823,"conditions":13643,"interventions":13644},"NCT01584232","A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus",[87],[120],[9681,7103,7118,13645],"Biguanide",{"nctId":13647,"briefTitle":13648,"status":103,"phases":13649,"primaryCompletion":6883,"completion":6883,"start":3266,"enrollment":13650,"conditions":13651,"interventions":13652},"NCT00560417","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide",[87],339,[18],[13177,506],{"nctId":7129,"briefTitle":7130,"status":103,"phases":13654,"primaryCompletion":3250,"completion":3250,"start":4098,"enrollment":542,"conditions":13655,"interventions":13656},[87],[18],[303,506,1631],{"nctId":13658,"briefTitle":13659,"status":103,"phases":13660,"primaryCompletion":3292,"completion":3292,"start":2947,"enrollment":13661,"conditions":13662,"interventions":13663},"NCT00127634","Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes",[87],385,[33],[13554,13664,506],"Injectable Insulin",{"nctId":13666,"briefTitle":13667,"status":103,"phases":13668,"primaryCompletion":3292,"completion":3292,"start":2855,"enrollment":13669,"conditions":13670,"interventions":13671},"NCT00356109","Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes",[87],494,[33],[13554,13672,506],"Injectable insulin",{"nctId":13674,"briefTitle":13675,"status":103,"phases":13676,"primaryCompletion":3292,"completion":3292,"start":3645,"enrollment":2790,"conditions":13677,"interventions":13678},"NCT00447213","A Study for Patients With Type 1 Diabetes Mellitus",[86,87],[33],[7103,13554,13664],{"nctId":11326,"briefTitle":11327,"status":103,"phases":13680,"primaryCompletion":9249,"completion":9249,"start":11329,"enrollment":11330,"conditions":13681,"interventions":13682},[87],[9437],[9698,438,506,700],{"nctId":2301,"briefTitle":2302,"status":103,"phases":13684,"primaryCompletion":2304,"completion":2304,"start":155,"enrollment":2305,"conditions":13685,"interventions":13686},[87],[30,24,778,27,2307,412],[2043,506],{"nctId":13172,"briefTitle":13173,"status":103,"phases":13688,"primaryCompletion":3087,"completion":3087,"start":2995,"enrollment":5170,"conditions":13689,"interventions":13690},[87],[18],[506,13177,438],{"trials":13692,"activeCount":97},[13693,13697,13707,13715,13719,13723,13731,13739,13743,13751,13757,13761],{"nctId":13188,"briefTitle":13189,"status":103,"phases":13694,"primaryCompletion":3048,"completion":3048,"start":3283,"enrollment":13191,"conditions":13695,"interventions":13696},[88],[18],[13194,506,438],{"nctId":13698,"briefTitle":13699,"status":103,"phases":13700,"primaryCompletion":3217,"completion":3217,"start":3176,"enrollment":13701,"conditions":13702,"interventions":13703},"NCT00279201","The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",[88],2091,[18],[7103,13704,13705,13706],"Lispro Low Mix","Lispro Mid Mix","Lispro",{"nctId":13708,"briefTitle":13709,"status":103,"phases":13710,"primaryCompletion":13711,"completion":13711,"start":126,"enrollment":13712,"conditions":13713,"interventions":13714},"NCT04153981","A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India",[88],"2021-07-30",304,[120],[506],{"nctId":9737,"briefTitle":9738,"status":103,"phases":13716,"completion":2833,"start":4459,"enrollment":2413,"conditions":13717,"interventions":13718},[88],[18],[9742,9743,9672],{"nctId":13203,"briefTitle":13204,"status":103,"phases":13720,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":13206,"conditions":13721,"interventions":13722},[88],[18,13208],[7104,13210,7103,13210,13211],{"nctId":13724,"briefTitle":13725,"status":103,"phases":13726,"primaryCompletion":8736,"completion":8736,"start":13727,"enrollment":658,"conditions":13728,"interventions":13729},"NCT06370715","A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India",[88],"2024-04-18",[18],[13730,506],"Insulin Lispro-aabc",{"nctId":13732,"briefTitle":13733,"status":103,"phases":13734,"primaryCompletion":3320,"completion":3320,"start":2855,"enrollment":13735,"conditions":13736,"interventions":13737},"NCT00377858","Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)",[88],484,[18],[13738,7103],"Insulin lispro mid mixture",{"nctId":9745,"briefTitle":9746,"status":999,"phases":13740,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":13741,"interventions":13742},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"nctId":13744,"briefTitle":13745,"status":103,"phases":13746,"primaryCompletion":3048,"completion":3048,"start":3069,"enrollment":514,"conditions":13747,"interventions":13748},"NCT01175824","Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies",[88],[18],[13749,506,13750],"Insulin Lispro Low Mixture","Prandial Insulin Lispro",{"nctId":13752,"briefTitle":13753,"status":103,"phases":13754,"primaryCompletion":3029,"completion":3029,"start":2995,"enrollment":810,"conditions":13755,"interventions":13756},"NCT00664534","Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast",[88],[18],[506,13194],{"nctId":13219,"briefTitle":13220,"status":103,"phases":13758,"primaryCompletion":2955,"completion":2955,"start":3266,"enrollment":13222,"conditions":13759,"interventions":13760},[88],[120],[13225,7103,7104],{"nctId":13762,"briefTitle":13763,"status":103,"phases":13764,"completion":2947,"start":13765,"enrollment":874,"conditions":13766,"interventions":13767},"NCT00191178","Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes",[88],"2003-08",[30],[13768,9743],"insulin lispro protamine suspension:insulin lispro rDNA origin low mix",{"trials":13770,"activeCount":97},[],{"intervention":13772,"totalTrials":1488,"cells":13773},"Atomoxetine Hydrochloride",{"EARLY_PHASE1":13774,"PHASE1":13776,"PHASE2":13778,"PHASE3":13787,"PHASE4":13865,"NA":13941},{"trials":13775,"activeCount":97},[],{"trials":13777,"activeCount":97},[],{"trials":13779,"activeCount":97},[13780],{"nctId":13781,"briefTitle":13782,"status":103,"phases":13783,"completion":5623,"start":3195,"enrollment":5922,"conditions":13784,"interventions":13786},"NCT00485628","Safety Study in Outpatient Japanese Children With ADHD",[86],[13785],"Attention Deficit Hyperactivity Disorder",[13772],{"trials":13788,"activeCount":97},[13789,13796,13803,13810,13818,13824,13831,13837,13843,13850,13857],{"nctId":13790,"briefTitle":13791,"status":103,"phases":13792,"primaryCompletion":2955,"completion":2955,"start":3153,"enrollment":8,"conditions":13793,"interventions":13794},"NCT00191386","Long-Term Study of Atomoxetine in Children With Attention-Deficit\u002FHyperactivity Disorder (AD\u002FHD)",[87],[13785],[13795],"Atomoxetine hydrochloride",{"nctId":13797,"briefTitle":13798,"status":103,"phases":13799,"completion":3218,"start":4448,"enrollment":1062,"conditions":13800,"interventions":13801},"NCT00485550","Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy",[87],[13785],[13772,13802],"Methylphenidate Hydrochloride",{"nctId":13804,"briefTitle":13805,"status":103,"phases":13806,"completion":2948,"start":4459,"enrollment":13807,"conditions":13808,"interventions":13809},"NCT00486083","Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD",[87],330,[13785],[13772,13802],{"nctId":13811,"briefTitle":13812,"status":103,"phases":13813,"primaryCompletion":8217,"completion":4955,"start":3575,"enrollment":13814,"conditions":13815,"interventions":13816},"NCT00700427","A Long Term Study of a Medication for Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[87],2017,[13785],[13817],"atomoxetine hydrochloride",{"nctId":13819,"briefTitle":13820,"status":103,"phases":13821,"completion":4266,"start":3194,"enrollment":776,"conditions":13822,"interventions":13823},"NCT00191659","Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children\u002FAdolescents",[87],[13785],[13772],{"nctId":13825,"briefTitle":13826,"status":103,"phases":13827,"primaryCompletion":3094,"completion":3094,"start":3153,"enrollment":13828,"conditions":13829,"interventions":13830},"NCT00191945","Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[87],151,[13785],[13772],{"nctId":13832,"briefTitle":13833,"status":103,"phases":13834,"primaryCompletion":2974,"completion":2974,"start":3266,"enrollment":3546,"conditions":13835,"interventions":13836},"NCT00568685","Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[87],[13785],[13772,13795,13795],{"nctId":13838,"briefTitle":13839,"status":103,"phases":13840,"completion":3646,"start":4221,"enrollment":1839,"conditions":13841,"interventions":13842},"NCT00485459","Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD",[87],[13785],[13772],{"nctId":13844,"briefTitle":13845,"status":103,"phases":13846,"completion":13847,"start":5623,"enrollment":19,"conditions":13848,"interventions":13849},"NCT00191009","Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease",[86,87],"2006-01",[3980],[13817],{"nctId":13851,"briefTitle":13852,"status":103,"phases":13853,"completion":3168,"start":3567,"enrollment":13854,"conditions":13855,"interventions":13856},"NCT00485407","Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine",[87],377,[13785],[13772],{"nctId":13858,"briefTitle":13859,"status":103,"phases":13860,"primaryCompletion":3168,"completion":3266,"start":4459,"enrollment":13861,"conditions":13862,"interventions":13864},"NCT00191698","Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD",[87],226,[13785,13863],"Oppositional Defiant Disorder",[13817],{"trials":13866,"activeCount":97},[13867,13873,13880,13886,13892,13901,13907,13914,13921,13927,13934],{"nctId":13868,"briefTitle":13869,"status":103,"phases":13870,"completion":4538,"start":3194,"enrollment":28,"conditions":13871,"interventions":13872},"NCT00485875","Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD",[88],[13785],[13772],{"nctId":13874,"briefTitle":13875,"status":103,"phases":13876,"completion":3005,"start":3168,"enrollment":5151,"conditions":13877,"interventions":13879},"NCT00190879","Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder",[88],[13785,13878],"Comorbid Social Anxiety Disorder",[13795],{"nctId":13881,"briefTitle":13882,"status":103,"phases":13883,"completion":2948,"start":4221,"enrollment":2477,"conditions":13884,"interventions":13885},"NCT00485849","A Study of Atomoxetine for Attention Deficit and Hyperactive\u002FImpulsive Behaviour Problems in Children With ASD",[88],[13785],[13772],{"nctId":13887,"briefTitle":13888,"status":103,"phases":13889,"primaryCompletion":3103,"completion":3103,"start":3813,"enrollment":1348,"conditions":13890,"interventions":13891},"NCT00510276","Treatment of Attention-Deficit\u002FHyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes",[88],[13785],[13795],{"nctId":13893,"briefTitle":13894,"status":103,"phases":13895,"completion":4538,"start":3710,"enrollment":13896,"conditions":13897,"interventions":13899},"NCT00485862","Combination Therapy in Patients With Depression",[88],214,[13898],"Depressive Symptoms",[13772,13900],"Sertraline",{"nctId":13902,"briefTitle":13903,"status":103,"phases":13904,"completion":3524,"start":2833,"enrollment":233,"conditions":13905,"interventions":13906},"NCT00216918","Neuropsychological Functioning in Children With Attention-Deficit\u002FHyperactivity Disorder.",[88],[13785],[13772],{"nctId":13908,"briefTitle":13909,"status":103,"phases":13910,"completion":3133,"start":3039,"enrollment":5151,"conditions":13911,"interventions":13913},"NCT00190736","Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)",[88],[13912],"ADHD",[13772],{"nctId":13915,"briefTitle":13916,"status":103,"phases":13917,"completion":2947,"start":3078,"enrollment":4775,"conditions":13918,"interventions":13920},"NCT00190931","A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit\u002FHyperactivity Disorder",[88],[13919],"Attention Deficit Disorder With Hyperactivity",[13772],{"nctId":13922,"briefTitle":13923,"status":103,"phases":13924,"completion":3194,"start":2834,"enrollment":820,"conditions":13925,"interventions":13926},"NCT00486122","Evaluation of Continuous Symptom Treatment of ADHD",[88],[13785],[13772],{"nctId":13928,"briefTitle":13929,"status":103,"phases":13930,"primaryCompletion":3059,"completion":3050,"start":3039,"enrollment":13931,"conditions":13932,"interventions":13933},"NCT00190775","A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[88],502,[13785],[13772],{"nctId":13935,"briefTitle":13936,"status":103,"phases":13937,"primaryCompletion":3227,"completion":3227,"start":3566,"enrollment":3487,"conditions":13938,"interventions":13940},"NCT00191906","Comparison of Atomoxetine and Placebo in Children With Attention-Deficit\u002FHyperactivity Disorder (ADHD) and\u002For Reading Disorder (RD)",[88],[13785,13939],"Reading Disorder",[13772],{"trials":13942,"activeCount":97},[],{"intervention":13944,"totalTrials":205,"cells":13945},"Fluoxetine",{"EARLY_PHASE1":13946,"PHASE1":13948,"PHASE2":13958,"PHASE3":13960,"PHASE4":14011,"NA":14038},{"trials":13947,"activeCount":97},[],{"trials":13949,"activeCount":97},[13950],{"nctId":13951,"briefTitle":13952,"status":103,"phases":13953,"primaryCompletion":4258,"completion":4258,"start":8233,"enrollment":1082,"conditions":13954,"interventions":13956},"NCT01243957","A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.",[85],[13955],"Major Depressive Disorder",[13957,13944],"LY2216684",{"trials":13959,"activeCount":97},[],{"trials":13961,"activeCount":97},[13962,13969,13977,13985,13991,13997,14005],{"nctId":13963,"briefTitle":13964,"status":103,"phases":13965,"primaryCompletion":7316,"completion":7316,"start":3124,"enrollment":13966,"conditions":13967,"interventions":13968},"NCT01808612","A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing",[87],513,[13955],[13944],{"nctId":13970,"briefTitle":13971,"status":999,"phases":13972,"primaryCompletion":4383,"completion":4383,"start":2898,"enrollment":12091,"conditions":13973,"interventions":13975},"NCT01687478","A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression",[87],[13974],"Treatment Resistant Depression",[13976,13944],"Olanzapine",{"nctId":13978,"briefTitle":13979,"status":103,"phases":13980,"primaryCompletion":3886,"completion":3886,"start":2955,"enrollment":13981,"conditions":13982,"interventions":13983},"NCT00958568","A Study in Relapse Prevention of Treatment-Resistant Depression",[87],892,[13974],[13984,13944],"Olanzapine and Fluoxetine combination",{"nctId":13986,"briefTitle":13987,"status":103,"phases":13988,"primaryCompletion":1596,"completion":1596,"start":3282,"enrollment":776,"conditions":13989,"interventions":13990},"NCT01808651","A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing",[87],[13955],[13944],{"nctId":13992,"briefTitle":13993,"status":103,"phases":13994,"completion":2947,"start":3677,"enrollment":2122,"conditions":13995,"interventions":13996},"NCT00035321","The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression",[87],[13955],[13976,13944],{"nctId":13998,"briefTitle":13999,"status":103,"phases":14000,"primaryCompletion":3283,"completion":3494,"start":2866,"enrollment":1995,"conditions":14001,"interventions":14002},"NCT00849693","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder",[87],[13955],[14003,14004,14004],"fluoxetine","duloxetine",{"nctId":14006,"briefTitle":13999,"status":103,"phases":14007,"primaryCompletion":3837,"completion":3004,"start":2866,"enrollment":14008,"conditions":14009,"interventions":14010},"NCT00849901",[87],337,[13955],[14004,14003],{"trials":14012,"activeCount":97},[14013,14020,14028],{"nctId":14014,"briefTitle":14015,"status":103,"phases":14016,"completion":3592,"start":5953,"enrollment":658,"conditions":14017,"interventions":14019},"NCT00191399","Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response",[88],[14018],"Depression, Bipolar",[13976,13944],{"nctId":14021,"briefTitle":14022,"status":103,"phases":14023,"completion":4538,"start":3078,"enrollment":14024,"conditions":14025,"interventions":14026},"NCT00485771","Olanzapine\u002FFluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression",[88],403,[4919],[13976,13944,14027],"Lamotrigine",{"nctId":14029,"briefTitle":14030,"status":103,"phases":14031,"primaryCompletion":3103,"completion":2866,"start":3292,"enrollment":2514,"conditions":14032,"interventions":14034},"NCT00666757","A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression",[88],[14033],"Depression",[14004,14003,14035,14036,14037],"citalopram","paroxetine","sertraline",{"trials":14039,"activeCount":97},[],{"intervention":14041,"totalTrials":205,"cells":14042},"Drotrecogin alfa",{"EARLY_PHASE1":14043,"PHASE1":14045,"PHASE2":14047,"PHASE3":14066,"PHASE4":14097,"NA":14139},{"trials":14044,"activeCount":97},[],{"trials":14046,"activeCount":97},[],{"trials":14048,"activeCount":97},[14049,14058],{"nctId":14050,"briefTitle":14051,"status":103,"phases":14052,"primaryCompletion":3308,"completion":3308,"start":3039,"enrollment":128,"conditions":14053,"interventions":14055},"NCT00191724","Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study",[86],[14054],"Submassive Pulmonary Embolism",[14056,14057,14056,14056,14056],"Drotrecogin Alfa","Enoxaparin",{"nctId":14059,"briefTitle":14060,"status":103,"phases":14061,"primaryCompletion":2955,"completion":2955,"start":2930,"enrollment":14062,"conditions":14063,"interventions":14065},"NCT00386425","Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)",[86],486,[14064],"Severe Sepsis",[14041],{"trials":14067,"activeCount":97},[14068,14076,14083,14090],{"nctId":14069,"briefTitle":14070,"status":103,"phases":14071,"completion":5690,"start":3274,"enrollment":14072,"conditions":14073,"interventions":14075},"NCT00568737","The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death",[87],2640,[14074],"Sepsis",[14041],{"nctId":14077,"briefTitle":14078,"status":103,"phases":14079,"completion":3005,"start":3194,"enrollment":776,"conditions":14080,"interventions":14082},"NCT00190788","Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion",[87],[14074,14081],"Hypotension",[14056],{"nctId":14084,"briefTitle":14085,"status":103,"phases":14086,"primaryCompletion":3494,"completion":3086,"start":3338,"enrollment":14087,"conditions":14088,"interventions":14089},"NCT00604214","Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock",[87],1696,[14074],[14041],{"nctId":14091,"briefTitle":14092,"status":103,"phases":14093,"completion":3566,"start":3274,"enrollment":14094,"conditions":14095,"interventions":14096},"NCT00049764","Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis",[87],474,[14074],[14041],{"trials":14098,"activeCount":97},[14099,14109,14118,14126,14132],{"nctId":14100,"briefTitle":14101,"status":103,"phases":14102,"completion":14103,"start":3161,"enrollment":14104,"conditions":14105,"interventions":14106},"NCT00049777","A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)",[88],"2005-08",2000,[14074],[14056,14107,14108],"Unfractionated heparin","Low molecular weight heparin",{"nctId":14110,"briefTitle":14111,"status":103,"phases":14112,"completion":5623,"start":3040,"enrollment":1054,"conditions":14113,"interventions":14117},"NCT00067730","A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation",[88],[14074,14114,14115,14116],"Hematologic Neoplasms","Hematopoietic Stem Cell Transplantation","Infection",[14056],{"nctId":14119,"briefTitle":14120,"status":103,"phases":14121,"completion":3266,"start":3228,"enrollment":4222,"conditions":14122,"interventions":14124},"NCT00279214","Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock",[88],[14074,14123],"Septic Shock",[14125],"drotrecogin alfa",{"nctId":14127,"briefTitle":14128,"status":103,"phases":14129,"completion":5623,"start":3169,"enrollment":2206,"conditions":14130,"interventions":14131},"NCT00568893","An Open Label Study of Severe Sepsis in Adults",[88],[14064],[14125],{"nctId":14133,"briefTitle":14134,"status":103,"phases":14135,"start":14136,"conditions":14137,"interventions":14138},"NCT00045760","The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis",[88],"2002-09",[14074],[14041],{"trials":14140,"activeCount":97},[],{"intervention":14142,"totalTrials":4323,"cells":14143},"Raloxifene",{"EARLY_PHASE1":14144,"PHASE1":14146,"PHASE2":14148,"PHASE3":14161,"PHASE4":14186,"NA":14217},{"trials":14145,"activeCount":97},[],{"trials":14147,"activeCount":97},[],{"trials":14149,"activeCount":97},[14150],{"nctId":14151,"briefTitle":14152,"status":103,"phases":14153,"completion":5953,"start":4634,"enrollment":658,"conditions":14154,"interventions":14157},"NCT00332553","Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen",[86],[14155,14156],"Vasomotor Symptoms","Endometrial Safety",[14142,14158,14159,14160],"medroxyprogesterone acetate","estrogen","17 beta estradiol",{"trials":14162,"activeCount":97},[14163,14172,14179],{"nctId":14164,"briefTitle":14165,"status":103,"phases":14166,"conditions":14167,"interventions":14169},"NCT00046137","Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis",[87],[14168],"Osteoporosis, Postmenopausal",[14170,14171],"teriparatide","raloxifene",{"nctId":14173,"briefTitle":14174,"status":103,"phases":14175,"primaryCompletion":2800,"completion":2800,"start":2876,"enrollment":2413,"conditions":14176,"interventions":14177},"NCT00383422","Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis",[87],[14168],[14178,14142],"Arzoxifene",{"nctId":14180,"briefTitle":14181,"status":103,"phases":14182,"completion":3228,"start":14183,"enrollment":2371,"conditions":14184,"interventions":14185},"NCT00190593","Raloxifene Use for The Heart",[87],"1998-06",[2307,1893],[14171],{"trials":14187,"activeCount":97},[14188,14195,14203,14209],{"nctId":14189,"briefTitle":14190,"status":103,"phases":14191,"completion":2834,"start":3195,"enrollment":1178,"conditions":14192,"interventions":14194},"NCT00532428","Long Term Effects of Raloxifene Treatment on Bone Quality",[88],[14193],"Osteoporosis, Post-Menopausal",[14142,14142],{"nctId":14196,"briefTitle":14197,"status":103,"phases":14198,"completion":3228,"start":14199,"enrollment":9707,"conditions":14200,"interventions":14201},"NCT00191425","2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium\u002FVit D in Severe Postmenopausal Osteoporosis",[88],"2002-08",[14168],[14202,14142],"Teriparatide",{"nctId":14204,"briefTitle":14205,"status":103,"phases":14206,"completion":13765,"start":3040,"enrollment":3219,"conditions":14207,"interventions":14208},"NCT00532246","Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo",[88],[14193],[14171],{"nctId":14210,"briefTitle":14211,"status":103,"phases":14212,"completion":3005,"start":3646,"enrollment":776,"conditions":14213,"interventions":14215},"NCT00079924","Effects of Teriparatide in Postmenopausal Women With Osteoporosis",[88],[14214],"Postmenopausal Osteoporosis",[14170,14216,14171],"aldrenodate",{"trials":14218,"activeCount":97},[],{"intervention":188,"totalTrials":1054,"cells":14220},{"EARLY_PHASE1":14221,"PHASE1":14223,"PHASE2":14248,"PHASE3":14250,"PHASE4":14263,"NA":14269},{"trials":14222,"activeCount":97},[],{"trials":14224,"activeCount":97},[14225,14229,14237,14241],{"nctId":180,"briefTitle":181,"status":103,"phases":14226,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":14227,"interventions":14228},[85],[24,27],[92,188],{"nctId":14230,"briefTitle":14231,"status":103,"phases":14232,"primaryCompletion":7124,"completion":7124,"start":14233,"enrollment":4475,"conditions":14234,"interventions":14235},"NCT03115099","A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes",[85],"2017-05-31",[18],[14236,188,9644],"LY3325656",{"nctId":10142,"briefTitle":10143,"status":103,"phases":14238,"primaryCompletion":10145,"completion":10145,"start":10146,"enrollment":128,"conditions":14239,"interventions":14240},[85],[15],[10128,188],{"nctId":14242,"briefTitle":14243,"status":103,"phases":14244,"primaryCompletion":3776,"completion":3776,"start":2964,"enrollment":1767,"conditions":14245,"interventions":14246},"NCT01870297","A Study of LY3025876 in Participants With Diabetes",[85],[120],[14247,188],"LY3025876",{"trials":14249,"activeCount":97},[],{"trials":14251,"activeCount":97},[14252,14256],{"nctId":9683,"briefTitle":9684,"status":103,"phases":14253,"primaryCompletion":4980,"completion":4980,"start":3838,"enrollment":9686,"conditions":14254,"interventions":14255},[87],[30],[9681,188,1631],{"nctId":14257,"briefTitle":14258,"status":103,"phases":14259,"primaryCompletion":4955,"completion":4098,"start":3886,"enrollment":14260,"conditions":14261,"interventions":14262},"NCT01558271","A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus",[87],492,[120],[9681,188],{"trials":14264,"activeCount":97},[14265],{"nctId":9745,"briefTitle":9746,"status":999,"phases":14266,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":14267,"interventions":14268},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":14270,"activeCount":97},[],{"intervention":13166,"totalTrials":1677,"cells":14272},{"EARLY_PHASE1":14273,"PHASE1":14275,"PHASE2":14277,"PHASE3":14279,"PHASE4":14304,"NA":14317},{"trials":14274,"activeCount":97},[],{"trials":14276,"activeCount":97},[],{"trials":14278,"activeCount":97},[],{"trials":14280,"activeCount":97},[14281,14289,14296,14300],{"nctId":14282,"briefTitle":14283,"status":103,"phases":14284,"completion":3567,"start":3274,"enrollment":1451,"conditions":14285,"interventions":14287},"NCT00551356","Lispro Mix 25 vs. Glargine in Type 2 Diabetics",[87],[14286],"Diabetes Mellitus Type 2",[14288,13166],"Insulin lispro mix 25",{"nctId":14290,"briefTitle":14291,"status":103,"phases":14292,"primaryCompletion":3112,"completion":3112,"start":5090,"enrollment":14293,"conditions":14294,"interventions":14295},"NCT01435616","A Study in Patients With Type 2 Diabetes Mellitus",[87],1538,[18],[13166,12961],{"nctId":13160,"briefTitle":13161,"status":103,"phases":14297,"primaryCompletion":3282,"completion":5354,"start":3661,"enrollment":13163,"conditions":14298,"interventions":14299},[87],[33],[13166,12961,438],{"nctId":13179,"briefTitle":13180,"status":103,"phases":14301,"primaryCompletion":9748,"completion":9748,"start":3661,"enrollment":13182,"conditions":14302,"interventions":14303},[87],[33],[13166,12961,438],{"trials":14305,"activeCount":97},[14306,14310],{"nctId":13213,"briefTitle":13214,"status":103,"phases":14307,"primaryCompletion":3068,"completion":3068,"start":3152,"enrollment":7575,"conditions":14308,"interventions":14309},[88],[18],[7104,13166],{"nctId":14311,"briefTitle":14312,"status":103,"phases":14313,"completion":2909,"start":3536,"enrollment":1158,"conditions":14314,"interventions":14315},"NCT00551538","24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75\u002F25 vs. Glargine",[88],[30],[14316,13166],"Lispro mix 75\u002F25",{"trials":14318,"activeCount":97},[],{"intervention":2065,"totalTrials":1677,"cells":14320},{"EARLY_PHASE1":14321,"PHASE1":14323,"PHASE2":14341,"PHASE3":14343,"PHASE4":14355,"NA":14363},{"trials":14322,"activeCount":97},[],{"trials":14324,"activeCount":97},[14325,14329,14333,14337],{"nctId":2058,"briefTitle":2059,"status":103,"phases":14326,"primaryCompletion":2061,"completion":2061,"start":2062,"enrollment":1620,"conditions":14327,"interventions":14328},[85],[15],[2043,2065],{"nctId":10924,"briefTitle":10925,"status":999,"phases":14330,"primaryCompletion":1462,"completion":1462,"start":10927,"enrollment":2071,"conditions":14331,"interventions":14332},[85],[15],[2768,2562,2065],{"nctId":10939,"briefTitle":10940,"status":103,"phases":14334,"primaryCompletion":1462,"completion":1462,"start":10942,"enrollment":2720,"conditions":14335,"interventions":14336},[85],[15],[1574,1171,2562,2065,1538],{"nctId":7866,"briefTitle":7867,"status":103,"phases":14338,"primaryCompletion":7869,"completion":7869,"start":7870,"enrollment":1620,"conditions":14339,"interventions":14340},[85],[15],[2655,2562,2065],{"trials":14342,"activeCount":97},[],{"trials":14344,"activeCount":97},[14345],{"nctId":14346,"briefTitle":14347,"status":103,"phases":14348,"primaryCompletion":2929,"completion":2929,"start":3228,"enrollment":11714,"conditions":14349,"interventions":14351},"NCT00266630","Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder",[87],[14350],"Manic or Mixed Episode Associated With Bipolar I Disorder",[9670,14352,14353,14354],"lithium","valproate","carbamazepine",{"trials":14356,"activeCount":97},[14357],{"nctId":14358,"briefTitle":14359,"status":103,"phases":14360,"completion":3524,"start":3039,"enrollment":2080,"conditions":14361,"interventions":14362},"NCT00190892","Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania",[88],[4919],[9670,14354],{"trials":14364,"activeCount":97},[],{"intervention":14366,"totalTrials":1677,"cells":14367},"risperidone",{"EARLY_PHASE1":14368,"PHASE1":14370,"PHASE2":14372,"PHASE3":14382,"PHASE4":14393,"NA":14424},{"trials":14369,"activeCount":97},[],{"trials":14371,"activeCount":97},[],{"trials":14373,"activeCount":97},[14374],{"nctId":14375,"briefTitle":14376,"status":103,"phases":14377,"primaryCompletion":2865,"completion":2865,"start":3419,"enrollment":1753,"conditions":14378,"interventions":14379},"NCT01086748","A Study in Schizophrenia Patients",[86],[4897],[14380,14381],"Risperidone","LY2140023",{"trials":14383,"activeCount":97},[14384],{"nctId":14385,"briefTitle":14386,"status":999,"phases":14387,"primaryCompletion":2798,"completion":2798,"start":2918,"enrollment":14388,"conditions":14389,"interventions":14390},"NCT01129674","A Long-Term, Open-Label, Study on Schizophrenia",[86,87],1210,[4897],[14381,13976,14391,14380,14392],"Aripiprazole","Quetiapine",{"trials":14394,"activeCount":97},[14395,14402,14409,14417],{"nctId":14396,"briefTitle":14397,"status":103,"phases":14398,"primaryCompletion":3575,"completion":3575,"start":5623,"enrollment":2206,"conditions":14399,"interventions":14401},"NCT00190749","Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder",[88],[4897,14400],"Schizoaffective Disorder",[9670,14366],{"nctId":14403,"briefTitle":14404,"status":103,"phases":14405,"primaryCompletion":3227,"completion":3227,"start":3259,"enrollment":11322,"conditions":14406,"interventions":14408},"NCT00337662","Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia",[88],[4897,14400,14407],"Schizophreniform Disorder",[9670,14366,14366],{"nctId":14410,"briefTitle":14411,"status":103,"phases":14412,"completion":14199,"start":14413,"enrollment":14414,"conditions":14415,"interventions":14416},"NCT00034580","Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder",[88],"2001-08",326,[4919],[9670,14366],{"nctId":14418,"briefTitle":14419,"status":103,"phases":14420,"completion":4459,"start":3195,"enrollment":3267,"conditions":14421,"interventions":14422},"NCT00485498","Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics",[88],[4897],[14423,14380],"Olanzapine Hydrochloride",{"trials":14425,"activeCount":97},[],{"intervention":14423,"totalTrials":1677,"cells":14427},{"EARLY_PHASE1":14428,"PHASE1":14430,"PHASE2":14432,"PHASE3":14440,"PHASE4":14456,"NA":14477},{"trials":14429,"activeCount":97},[],{"trials":14431,"activeCount":97},[],{"trials":14433,"activeCount":97},[14434],{"nctId":14435,"briefTitle":14436,"status":103,"phases":14437,"completion":3646,"start":3194,"enrollment":1178,"conditions":14438,"interventions":14439},"NCT00485810","Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia",[85,86],[4897],[14423],{"trials":14441,"activeCount":97},[14442,14449],{"nctId":14443,"briefTitle":14444,"status":103,"phases":14445,"completion":4538,"start":3339,"enrollment":2088,"conditions":14446,"interventions":14447},"NCT00485901","Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia",[87],[4897],[14423,14448],"Haloperidol",{"nctId":14450,"briefTitle":14451,"status":103,"phases":14452,"completion":3168,"start":4459,"enrollment":410,"conditions":14453,"interventions":14454},"NCT00485680","Olanzapine Versus Comparator in the Treatment of Bipolar Disorder",[87],[4919],[14423,14455],"Lithium Carbonate",{"trials":14457,"activeCount":97},[14458,14465,14473],{"nctId":14459,"briefTitle":14460,"status":103,"phases":14461,"completion":2834,"start":3161,"enrollment":118,"conditions":14462,"interventions":14464},"NCT00485823","Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia",[88],[14463],"Schizophrenic Disorders",[14423],{"nctId":14466,"briefTitle":14467,"status":103,"phases":14468,"completion":5623,"start":3140,"enrollment":14469,"conditions":14470,"interventions":14471},"NCT00486005","Weight Gain Management in Patients With Schizophrenia",[88],74,[4897],[14423,14472],"Nizatidine",{"nctId":14418,"briefTitle":14419,"status":103,"phases":14474,"completion":4459,"start":3195,"enrollment":3267,"conditions":14475,"interventions":14476},[88],[4897],[14423,14380],{"trials":14478,"activeCount":97},[],{"intervention":14480,"totalTrials":425,"cells":14481},"Escitalopram",{"EARLY_PHASE1":14482,"PHASE1":14484,"PHASE2":14493,"PHASE3":14501,"PHASE4":14511,"NA":14529},{"trials":14483,"activeCount":97},[],{"trials":14485,"activeCount":97},[14486],{"nctId":14487,"briefTitle":14488,"status":103,"phases":14489,"completion":3005,"start":2930,"enrollment":1548,"conditions":14490,"interventions":14491},"NCT00414323","Evaluation of the Effects of Duloxetine on Norepinephrine",[85],[13955],[14492,14480],"Duloxetine",{"trials":14494,"activeCount":97},[14495],{"nctId":14496,"briefTitle":14497,"status":103,"phases":14498,"primaryCompletion":3338,"completion":3338,"start":3060,"enrollment":474,"conditions":14499,"interventions":14500},"NCT00420004","A Study for Participants With Major Depression",[86],[13955],[13957,14480],{"trials":14502,"activeCount":97},[14503],{"nctId":14504,"briefTitle":14505,"status":103,"phases":14506,"completion":3153,"start":3078,"enrollment":14507,"conditions":14508,"interventions":14509},"NCT00073411","Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression",[87],675,[14033],[14004,14510],"escitalopram",{"trials":14512,"activeCount":97},[14513,14521],{"nctId":14514,"briefTitle":14515,"status":103,"phases":14516,"primaryCompletion":3152,"completion":3152,"start":14517,"enrollment":14518,"conditions":14519,"interventions":14520},"NCT00985504","A Study of Patients With Major Depressive Disorder and Residual Apathy",[88],"2009-09",483,[13955],[14492,14480],{"nctId":14522,"briefTitle":14523,"status":103,"phases":14524,"primaryCompletion":3087,"completion":3419,"start":2974,"enrollment":14525,"conditions":14526,"interventions":14527},"NCT00810069","Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder",[88],840,[13955],[14528,14480],"Duloxetine Hydrochloride",{"trials":14530,"activeCount":97},[],{"intervention":9644,"totalTrials":425,"cells":14532},{"EARLY_PHASE1":14533,"PHASE1":14535,"PHASE2":14547,"PHASE3":14553,"PHASE4":14559,"NA":14565},{"trials":14534,"activeCount":97},[],{"trials":14536,"activeCount":97},[14537,14543],{"nctId":14538,"briefTitle":14539,"status":103,"phases":14540,"primaryCompletion":2864,"completion":2864,"start":8217,"enrollment":864,"conditions":14541,"interventions":14542},"NCT01408888","A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes",[85],[18],[9681,9644],{"nctId":14230,"briefTitle":14231,"status":103,"phases":14544,"primaryCompletion":7124,"completion":7124,"start":14233,"enrollment":4475,"conditions":14545,"interventions":14546},[85],[18],[14236,188,9644],{"trials":14548,"activeCount":97},[14549],{"nctId":9637,"briefTitle":9638,"status":999,"phases":14550,"primaryCompletion":1618,"completion":1618,"start":1475,"enrollment":9640,"conditions":14551,"interventions":14552},[86],[18],[9643,9644,1631,9645],{"trials":14554,"activeCount":97},[14555],{"nctId":9675,"briefTitle":9676,"status":103,"phases":14556,"primaryCompletion":3020,"completion":3545,"start":3216,"enrollment":9678,"conditions":14557,"interventions":14558},[86,87],[18],[9681,9644,1631],{"trials":14560,"activeCount":97},[14561],{"nctId":9745,"briefTitle":9746,"status":999,"phases":14562,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":14563,"interventions":14564},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":14566,"activeCount":97},[],{"intervention":7071,"totalTrials":425,"cells":14568},{"EARLY_PHASE1":14569,"PHASE1":14571,"PHASE2":14573,"PHASE3":14582,"PHASE4":14596,"NA":14602},{"trials":14570,"activeCount":97},[],{"trials":14572,"activeCount":97},[],{"trials":14574,"activeCount":97},[14575],{"nctId":14576,"briefTitle":14577,"status":384,"phases":14578,"primaryCompletion":2898,"completion":2898,"start":3494,"enrollment":2502,"conditions":14579,"interventions":14580},"NCT01408095","A Study in Patients With Type 2 Diabetes",[86],[18],[14581,7071],"LY2608204",{"trials":14583,"activeCount":97},[14584,14588,14592],{"nctId":7065,"briefTitle":7066,"status":103,"phases":14585,"primaryCompletion":3122,"completion":3122,"start":3545,"enrollment":7068,"conditions":14586,"interventions":14587},[87],[120],[303,7071],{"nctId":7106,"briefTitle":7107,"status":103,"phases":14589,"primaryCompletion":3776,"completion":3776,"start":3068,"enrollment":542,"conditions":14590,"interventions":14591},[87],[120],[303,7071],{"nctId":9704,"briefTitle":9705,"status":103,"phases":14593,"primaryCompletion":2865,"completion":3048,"start":3087,"enrollment":9707,"conditions":14594,"interventions":14595},[87],[18],[506,9681,1631,7071],{"trials":14597,"activeCount":97},[14598],{"nctId":9745,"briefTitle":9746,"status":999,"phases":14599,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":14600,"interventions":14601},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":14603,"activeCount":97},[],{"intervention":14178,"totalTrials":425,"cells":14605},{"EARLY_PHASE1":14606,"PHASE1":14608,"PHASE2":14610,"PHASE3":14620,"PHASE4":14640,"NA":14649},{"trials":14607,"activeCount":97},[],{"trials":14609,"activeCount":97},[],{"trials":14611,"activeCount":97},[14612],{"nctId":14613,"briefTitle":14614,"status":103,"phases":14615,"primaryCompletion":3050,"completion":3050,"start":2928,"enrollment":4279,"conditions":14616,"interventions":14618},"NCT00767299","A Study of Arzoxifene to Treat Korean Women With Osteoporosis",[86],[14617],"Osteoporosis",[14619],"arzoxifene",{"trials":14621,"activeCount":97},[14622,14629,14633],{"nctId":14623,"briefTitle":14624,"status":103,"phases":14625,"primaryCompletion":5860,"completion":3217,"start":3194,"enrollment":14626,"conditions":14627,"interventions":14628},"NCT00088010","Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer",[87],9369,[14168],[14178],{"nctId":14173,"briefTitle":14174,"status":103,"phases":14630,"primaryCompletion":2800,"completion":2800,"start":2876,"enrollment":2413,"conditions":14631,"interventions":14632},[87],[14168],[14178,14142],{"nctId":14634,"briefTitle":14635,"status":103,"phases":14636,"completion":2875,"start":3746,"enrollment":542,"conditions":14637,"interventions":14639},"NCT00085956","Effects of Arzoxifene on Bone Mass and the Uterus",[87],[14638],"Postmenopausal Bone Loss",[14178],{"trials":14641,"activeCount":97},[14642],{"nctId":14643,"briefTitle":14644,"status":103,"phases":14645,"completion":3645,"start":14646,"enrollment":2790,"conditions":14647,"interventions":14648},"NCT00190697","A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment",[88],"2001-01",[36,1572,2584],[14619],{"trials":14650,"activeCount":97},[],{"intervention":14652,"totalTrials":1400,"cells":14653},"Pregabalin",{"EARLY_PHASE1":14654,"PHASE1":14656,"PHASE2":14658,"PHASE3":14671,"PHASE4":14680,"NA":14699},{"trials":14655,"activeCount":97},[],{"trials":14657,"activeCount":97},[],{"trials":14659,"activeCount":97},[14660],{"nctId":14661,"briefTitle":14662,"status":103,"phases":14663,"primaryCompletion":2956,"completion":2918,"start":2974,"enrollment":14664,"conditions":14665,"interventions":14667},"NCT00785577","A Study for Treatment of Pain in Patients With Diabetic Neuropathy.",[86],273,[14666],"Diabetic Neuropathy, Painful",[14652,14668,14669,14670],"LY545694 21 mg","LY545694 49 mg","LY545694 105 mg",{"trials":14672,"activeCount":97},[14673],{"nctId":14674,"briefTitle":14675,"status":103,"phases":14676,"primaryCompletion":5090,"completion":5090,"start":3419,"enrollment":14677,"conditions":14678,"interventions":14679},"NCT01089556","A Study in Painful Diabetic Neuropathy",[87],811,[14666],[14492,14652],{"trials":14681,"activeCount":97},[14682,14689],{"nctId":14683,"briefTitle":14684,"status":103,"phases":14685,"primaryCompletion":14686,"completion":14686,"start":3697,"enrollment":13712,"conditions":14687,"interventions":14688},"NCT02417935","A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)",[88],"2017-05-13",[9378],[14492,14652],{"nctId":14690,"briefTitle":14691,"status":103,"phases":14692,"primaryCompletion":2955,"completion":3217,"start":3133,"enrollment":14693,"conditions":14694,"interventions":14695},"NCT00385671","An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain",[88],407,[14666],[14696,14697,14698],"duloxetine hydrochloride","pregabalin","gabapentin",{"trials":14700,"activeCount":97},[],{"intervention":14702,"totalTrials":1400,"cells":14703},"sildenafil",{"EARLY_PHASE1":14704,"PHASE1":14706,"PHASE2":14708,"PHASE3":14710,"PHASE4":14721,"NA":14744},{"trials":14705,"activeCount":97},[],{"trials":14707,"activeCount":97},[],{"trials":14709,"activeCount":97},[],{"trials":14711,"activeCount":97},[14712],{"nctId":14713,"briefTitle":14714,"status":103,"phases":14715,"completion":5953,"start":3274,"enrollment":14716,"conditions":14717,"interventions":14719},"NCT00547287","Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations",[87],2760,[14718],"Impotence",[14720,14702],"tadalafil",{"trials":14722,"activeCount":97},[14723,14729,14736],{"nctId":14724,"briefTitle":14725,"status":103,"phases":14726,"completion":3168,"start":3194,"enrollment":5729,"conditions":14727,"interventions":14728},"NCT00547352","Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection",[88],[14718],[14720,14702],{"nctId":14730,"briefTitle":14731,"status":103,"phases":14732,"completion":3646,"start":5623,"enrollment":14733,"conditions":14734,"interventions":14735},"NCT00547092","Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection",[88],386,[14718],[14720,14702],{"nctId":14737,"briefTitle":14738,"status":103,"phases":14739,"primaryCompletion":3838,"completion":3545,"start":3020,"enrollment":7040,"conditions":14740,"interventions":14742},"NCT01352507","A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China",[88],[14741],"Erectile Dysfunction",[10904,14743],"Sildenafil",{"trials":14745,"activeCount":97},[],{"intervention":14747,"totalTrials":1400,"cells":14748},"Risedronate",{"EARLY_PHASE1":14749,"PHASE1":14751,"PHASE2":14753,"PHASE3":14755,"PHASE4":14773,"NA":14790},{"trials":14750,"activeCount":97},[],{"trials":14752,"activeCount":97},[],{"trials":14754,"activeCount":97},[],{"trials":14756,"activeCount":97},[14757,14767],{"nctId":14758,"briefTitle":14759,"status":103,"phases":14760,"primaryCompletion":5860,"completion":2918,"start":3524,"enrollment":14761,"conditions":14762,"interventions":14765},"NCT00343252","Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis",[87],712,[14168,14763,14764],"Back Pain","Spinal Fracture",[14170,14766],"risedronate",{"nctId":14768,"briefTitle":14769,"status":103,"phases":14770,"primaryCompletion":8233,"completion":8233,"start":4566,"enrollment":5645,"conditions":14771,"interventions":14772},"NCT00503399","Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis",[87],[14617],[14202,14747],{"trials":14774,"activeCount":97},[14775,14784],{"nctId":14776,"briefTitle":14777,"status":103,"phases":14778,"primaryCompletion":1546,"completion":1546,"start":2798,"enrollment":14779,"conditions":14780,"interventions":14781},"NCT01709110","VERtebral Fracture Treatment Comparisons in Osteoporotic Women",[88],1366,[14214],[14202,14747,14782,14783],"Calcium","Vitamin D",{"nctId":14785,"briefTitle":14786,"status":103,"phases":14787,"primaryCompletion":1474,"completion":1474,"start":2846,"enrollment":1827,"conditions":14788,"interventions":14789},"NCT00887354","A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture",[88],[14617],[14202,14747],{"trials":14791,"activeCount":97},[],{"intervention":14793,"totalTrials":1400,"cells":14794},"haloperidol",{"EARLY_PHASE1":14795,"PHASE1":14797,"PHASE2":14799,"PHASE3":14801,"PHASE4":14813,"NA":14829},{"trials":14796,"activeCount":97},[],{"trials":14798,"activeCount":97},[],{"trials":14800,"activeCount":97},[],{"trials":14802,"activeCount":97},[14803,14807],{"nctId":14443,"briefTitle":14444,"status":103,"phases":14804,"completion":4538,"start":3339,"enrollment":2088,"conditions":14805,"interventions":14806},[87],[4897],[14423,14448],{"nctId":14808,"briefTitle":14809,"status":103,"phases":14810,"primaryCompletion":3662,"completion":3662,"start":2947,"enrollment":1827,"conditions":14811,"interventions":14812},"NCT00129220","Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder",[87],[4919],[9670,14793],{"trials":14814,"activeCount":97},[14815,14822],{"nctId":14816,"briefTitle":14817,"status":999,"phases":14818,"primaryCompletion":3566,"completion":3566,"start":2948,"enrollment":205,"conditions":14819,"interventions":14820},"NCT00767715","A Study in the Treatment of Acute Mania",[88],[4919],[9670,14793,14821],"zuclopentixol",{"nctId":14823,"briefTitle":14824,"status":103,"phases":14825,"completion":3259,"start":13765,"enrollment":14826,"conditions":14827,"interventions":14828},"NCT00191555","Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment",[88],360,[4897],[9670,14793],{"trials":14830,"activeCount":97},[],{"intervention":14036,"totalTrials":1232,"cells":14832},{"EARLY_PHASE1":14833,"PHASE1":14835,"PHASE2":14837,"PHASE3":14848,"PHASE4":14858,"NA":14864},{"trials":14834,"activeCount":97},[],{"trials":14836,"activeCount":97},[],{"trials":14838,"activeCount":97},[14839],{"nctId":14840,"briefTitle":14841,"status":103,"phases":14842,"completion":3337,"start":2909,"enrollment":14843,"conditions":14844,"interventions":14846},"NCT00191022","Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder",[86],185,[14845],"Social Phobia",[14847,14036],"LY686017",{"trials":14849,"activeCount":97},[14850],{"nctId":14851,"briefTitle":14852,"status":103,"phases":14853,"completion":3168,"start":4448,"enrollment":14854,"conditions":14855,"interventions":14856},"NCT00489775","Duloxetine Versus Paroxetine for Major Depression",[87],480,[13955],[14492,14857],"Paroxetine",{"trials":14859,"activeCount":97},[14860],{"nctId":14029,"briefTitle":14030,"status":103,"phases":14861,"primaryCompletion":3103,"completion":2866,"start":3292,"enrollment":2514,"conditions":14862,"interventions":14863},[88],[14033],[14004,14003,14035,14036,14037],{"trials":14865,"activeCount":97},[],{"intervention":13706,"totalTrials":1232,"cells":14867},{"EARLY_PHASE1":14868,"PHASE1":14870,"PHASE2":14878,"PHASE3":14880,"PHASE4":14882,"NA":14894},{"trials":14869,"activeCount":97},[],{"trials":14871,"activeCount":97},[14872],{"nctId":14873,"briefTitle":14874,"status":103,"phases":14875,"primaryCompletion":1618,"completion":1618,"start":3776,"enrollment":31,"conditions":14876,"interventions":14877},"NCT02293551","A Study of Lispro Formulations in Healthy Participants",[85],[21],[13706],{"trials":14879,"activeCount":97},[],{"trials":14881,"activeCount":97},[],{"trials":14883,"activeCount":97},[14884,14888],{"nctId":13698,"briefTitle":13699,"status":103,"phases":14885,"primaryCompletion":3217,"completion":3217,"start":3176,"enrollment":13701,"conditions":14886,"interventions":14887},[88],[18],[7103,13704,13705,13706],{"nctId":14889,"briefTitle":14890,"status":103,"phases":14891,"primaryCompletion":4420,"completion":4420,"start":8233,"enrollment":1767,"conditions":14892,"interventions":14893},"NCT01159938","A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes",[88],[18],[13706],{"trials":14895,"activeCount":97},[],{"intervention":14391,"totalTrials":1232,"cells":14897},{"EARLY_PHASE1":14898,"PHASE1":14900,"PHASE2":14902,"PHASE3":14904,"PHASE4":14910,"NA":14925},{"trials":14899,"activeCount":97},[],{"trials":14901,"activeCount":97},[],{"trials":14903,"activeCount":97},[],{"trials":14905,"activeCount":97},[14906],{"nctId":14385,"briefTitle":14386,"status":999,"phases":14907,"primaryCompletion":2798,"completion":2798,"start":2918,"enrollment":14388,"conditions":14908,"interventions":14909},[86,87],[4897],[14381,13976,14391,14380,14392],{"trials":14911,"activeCount":97},[14912,14918],{"nctId":14913,"briefTitle":14914,"status":103,"phases":14915,"completion":2855,"start":3339,"enrollment":2122,"conditions":14916,"interventions":14917},"NCT00103571","Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia",[88],[4897],[13976,14391],{"nctId":14919,"briefTitle":14920,"status":103,"phases":14921,"completion":4566,"start":5623,"enrollment":14922,"conditions":14923,"interventions":14924},"NCT00088049","Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia",[88],560,[4897],[13976,14391],{"trials":14926,"activeCount":97},[],{"intervention":14928,"totalTrials":1232,"cells":14929},"Insulin Lispro low mixture",{"EARLY_PHASE1":14930,"PHASE1":14932,"PHASE2":14934,"PHASE3":14936,"PHASE4":14938,"NA":14954},{"trials":14931,"activeCount":97},[],{"trials":14933,"activeCount":97},[],{"trials":14935,"activeCount":97},[],{"trials":14937,"activeCount":97},[],{"trials":14939,"activeCount":97},[14940,14946,14950],{"nctId":14941,"briefTitle":14942,"status":103,"phases":14943,"completion":14199,"start":14413,"enrollment":1692,"conditions":14944,"interventions":14945},"NCT00036504","Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin",[88],[120],[14928],{"nctId":13744,"briefTitle":13745,"status":103,"phases":14947,"primaryCompletion":3048,"completion":3048,"start":3069,"enrollment":514,"conditions":14948,"interventions":14949},[88],[18],[13749,506,13750],{"nctId":13219,"briefTitle":13220,"status":103,"phases":14951,"primaryCompletion":2955,"completion":2955,"start":3266,"enrollment":13222,"conditions":14952,"interventions":14953},[88],[120],[13225,7103,7104],{"trials":14955,"activeCount":97},[],{"intervention":13900,"totalTrials":1232,"cells":14957},{"EARLY_PHASE1":14958,"PHASE1":14960,"PHASE2":14968,"PHASE3":14970,"PHASE4":14972,"NA":14982},{"trials":14959,"activeCount":97},[],{"trials":14961,"activeCount":97},[14962],{"nctId":14963,"briefTitle":14964,"status":103,"phases":14965,"primaryCompletion":4258,"completion":4258,"start":3029,"enrollment":1082,"conditions":14966,"interventions":14967},"NCT01250873","A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline",[85],[13955],[13957,13900],{"trials":14969,"activeCount":97},[],{"trials":14971,"activeCount":97},[],{"trials":14973,"activeCount":97},[14974,14978],{"nctId":13893,"briefTitle":13894,"status":103,"phases":14975,"completion":4538,"start":3710,"enrollment":13896,"conditions":14976,"interventions":14977},[88],[13898],[13772,13900],{"nctId":14029,"briefTitle":14030,"status":103,"phases":14979,"primaryCompletion":3103,"completion":2866,"start":3292,"enrollment":2514,"conditions":14980,"interventions":14981},[88],[14033],[14004,14003,14035,14036,14037],{"trials":14983,"activeCount":97},[],{"intervention":14392,"totalTrials":947,"cells":14985},{"EARLY_PHASE1":14986,"PHASE1":14988,"PHASE2":14990,"PHASE3":14992,"PHASE4":14998,"NA":15006},{"trials":14987,"activeCount":97},[],{"trials":14989,"activeCount":97},[],{"trials":14991,"activeCount":97},[],{"trials":14993,"activeCount":97},[14994],{"nctId":14385,"briefTitle":14386,"status":999,"phases":14995,"primaryCompletion":2798,"completion":2798,"start":2918,"enrollment":14388,"conditions":14996,"interventions":14997},[86,87],[4897],[14381,13976,14391,14380,14392],{"trials":14999,"activeCount":97},[15000],{"nctId":15001,"briefTitle":15002,"status":103,"phases":15003,"completion":3592,"start":3339,"enrollment":2630,"conditions":15004,"interventions":15005},"NCT00090012","Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder",[88],[4897,14400],[13976,14392],{"trials":15007,"activeCount":97},[],{"intervention":15009,"totalTrials":947,"cells":15010},"Human regular U-500 insulin",{"EARLY_PHASE1":15011,"PHASE1":15013,"PHASE2":15015,"PHASE3":15017,"PHASE4":15026,"NA":15036},{"trials":15012,"activeCount":97},[],{"trials":15014,"activeCount":97},[],{"trials":15016,"activeCount":97},[],{"trials":15018,"activeCount":97},[15019],{"nctId":15020,"briefTitle":15021,"status":103,"phases":15022,"primaryCompletion":7333,"completion":7333,"start":15023,"enrollment":12366,"conditions":15024,"interventions":15025},"NCT02561078","An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus",[87],"2015-10-20",[120],[15009,15009],{"trials":15027,"activeCount":97},[15028],{"nctId":15029,"briefTitle":15030,"status":103,"phases":15031,"primaryCompletion":4098,"completion":4098,"start":4420,"enrollment":15032,"conditions":15033,"interventions":15034},"NCT01774968","Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes",[88],325,[18],[15035],"Human Regular U-500 Insulin",{"trials":15037,"activeCount":97},[],{"intervention":13194,"totalTrials":947,"cells":15039},{"EARLY_PHASE1":15040,"PHASE1":15042,"PHASE2":15044,"PHASE3":15046,"PHASE4":15048,"NA":15058},{"trials":15041,"activeCount":97},[],{"trials":15043,"activeCount":97},[],{"trials":15045,"activeCount":97},[],{"trials":15047,"activeCount":97},[],{"trials":15049,"activeCount":97},[15050,15054],{"nctId":13188,"briefTitle":13189,"status":103,"phases":15051,"primaryCompletion":3048,"completion":3048,"start":3283,"enrollment":13191,"conditions":15052,"interventions":15053},[88],[18],[13194,506,438],{"nctId":13752,"briefTitle":13753,"status":103,"phases":15055,"primaryCompletion":3029,"completion":3029,"start":2995,"enrollment":810,"conditions":15056,"interventions":15057},[88],[18],[506,13194],{"trials":15059,"activeCount":97},[],{"intervention":15061,"totalTrials":947,"cells":15062},"raloxifene HCl",{"EARLY_PHASE1":15063,"PHASE1":15065,"PHASE2":15067,"PHASE3":15069,"PHASE4":15081,"NA":15089},{"trials":15064,"activeCount":97},[],{"trials":15066,"activeCount":97},[],{"trials":15068,"activeCount":97},[],{"trials":15070,"activeCount":97},[15071],{"nctId":15072,"briefTitle":15073,"status":103,"phases":15074,"primaryCompletion":15075,"completion":15075,"start":15076,"enrollment":15077,"conditions":15078,"interventions":15079},"NCT00670319","Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis",[87],"1999-09","1994-11",7705,[14168],[15080,15080],"Raloxifene HCL",{"trials":15082,"activeCount":97},[15083],{"nctId":15084,"briefTitle":15085,"status":103,"phases":15086,"completion":2947,"start":6075,"enrollment":13807,"conditions":15087,"interventions":15088},"NCT00035256","Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis",[88],[14168],[14170,15061],{"trials":15090,"activeCount":97},[],{"intervention":13211,"totalTrials":947,"cells":15092},{"EARLY_PHASE1":15093,"PHASE1":15095,"PHASE2":15097,"PHASE3":15099,"PHASE4":15101,"NA":15114},{"trials":15094,"activeCount":97},[],{"trials":15096,"activeCount":97},[],{"trials":15098,"activeCount":97},[],{"trials":15100,"activeCount":97},[],{"trials":15102,"activeCount":97},[15103,15110],{"nctId":15104,"briefTitle":15105,"status":103,"phases":15106,"primaryCompletion":3308,"completion":3308,"start":3337,"enrollment":195,"conditions":15107,"interventions":15108},"NCT00420095","A Study for Patients With Diabetes Mellitus (IOPA)",[88],[33,18],[13211,15109],"Insulin lispro low mix",{"nctId":13203,"briefTitle":13204,"status":103,"phases":15111,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":13206,"conditions":15112,"interventions":15113},[88],[18,13208],[7104,13210,7103,13210,13211],{"trials":15115,"activeCount":97},[],{"intervention":5383,"totalTrials":947,"cells":15117},{"EARLY_PHASE1":15118,"PHASE1":15120,"PHASE2":15122,"PHASE3":15124,"PHASE4":15126,"NA":15136},{"trials":15119,"activeCount":97},[],{"trials":15121,"activeCount":97},[],{"trials":15123,"activeCount":97},[],{"trials":15125,"activeCount":97},[],{"trials":15127,"activeCount":97},[15128,15132],{"nctId":5376,"briefTitle":5377,"status":103,"phases":15129,"primaryCompletion":2267,"completion":2267,"start":5379,"enrollment":5380,"conditions":15130,"interventions":15131},[88],[5218],[4944,5383],{"nctId":5385,"briefTitle":5386,"status":103,"phases":15133,"primaryCompletion":5388,"completion":5388,"start":5389,"enrollment":5390,"conditions":15134,"interventions":15135},[88],[5218],[4944,5383],{"trials":15137,"activeCount":97},[],{"intervention":15139,"totalTrials":947,"cells":15140},"Sibutramine",{"EARLY_PHASE1":15141,"PHASE1":15143,"PHASE2":15145,"PHASE3":15155,"PHASE4":15157,"NA":15167},{"trials":15142,"activeCount":97},[],{"trials":15144,"activeCount":97},[],{"trials":15146,"activeCount":97},[15147],{"nctId":15148,"briefTitle":15149,"status":999,"phases":15150,"primaryCompletion":2918,"completion":2918,"start":3050,"enrollment":15151,"conditions":15152,"interventions":15153},"NCT00993421","A Weight Loss Study in Overweight Men and Women",[86],343,[24],[15154,15139,2334],"LY377604",{"trials":15156,"activeCount":97},[],{"trials":15158,"activeCount":97},[15159],{"nctId":15160,"briefTitle":15161,"status":103,"phases":15162,"completion":2834,"start":15163,"enrollment":2206,"conditions":15164,"interventions":15166},"NCT00044187","The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder",[88],"2001-04",[4897,15165,4919],"Psychotic Disorders",[15139],{"trials":15168,"activeCount":97},[],{"intervention":9733,"totalTrials":947,"cells":15170},{"EARLY_PHASE1":15171,"PHASE1":15173,"PHASE2":15175,"PHASE3":15177,"PHASE4":15183,"NA":15189},{"trials":15172,"activeCount":97},[],{"trials":15174,"activeCount":97},[],{"trials":15176,"activeCount":97},[],{"trials":15178,"activeCount":97},[15179],{"nctId":9726,"briefTitle":9727,"status":103,"phases":15180,"primaryCompletion":5090,"completion":2865,"start":3087,"enrollment":9729,"conditions":15181,"interventions":15182},[87],[18],[9681,9732,1631,9733],{"trials":15184,"activeCount":97},[15185],{"nctId":9745,"briefTitle":9746,"status":999,"phases":15186,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":15187,"interventions":15188},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":15190,"activeCount":97},[],{"intervention":15192,"totalTrials":947,"cells":15193},"Venlafaxine Extended Release",{"EARLY_PHASE1":15194,"PHASE1":15196,"PHASE2":15198,"PHASE3":15200,"PHASE4":15202,"NA":15216},{"trials":15195,"activeCount":97},[],{"trials":15197,"activeCount":97},[],{"trials":15199,"activeCount":97},[],{"trials":15201,"activeCount":97},[],{"trials":15203,"activeCount":97},[15204,15210],{"nctId":15205,"briefTitle":15206,"status":103,"phases":15207,"completion":2938,"start":3195,"enrollment":14854,"conditions":15208,"interventions":15209},"NCT00067912","Duloxetine vs. Active Comparator for the Treatment of Depression",[88],[14033],[14528,15192],{"nctId":15211,"briefTitle":15212,"status":103,"phases":15213,"completion":5953,"start":3567,"enrollment":2413,"conditions":15214,"interventions":15215},"NCT00071695","Duloxetine vs. Active Comparator in the Treatment of Patients With Depression",[88],[14033],[14528,15192],{"trials":15217,"activeCount":97},[],{"intervention":2018,"totalTrials":947,"cells":15219},{"EARLY_PHASE1":15220,"PHASE1":15222,"PHASE2":15224,"PHASE3":15226,"PHASE4":15228,"NA":15238},{"trials":15221,"activeCount":97},[],{"trials":15223,"activeCount":97},[],{"trials":15225,"activeCount":97},[],{"trials":15227,"activeCount":97},[],{"trials":15229,"activeCount":97},[15230,15234],{"nctId":2010,"briefTitle":2011,"status":384,"phases":15231,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":97,"conditions":15232,"interventions":15233},[88],[1571],[48,2018],{"nctId":2020,"briefTitle":2021,"status":103,"phases":15235,"primaryCompletion":2023,"completion":2023,"start":2024,"enrollment":776,"conditions":15236,"interventions":15237},[88],[1893,1478],[48,2018,1468],{"trials":15239,"activeCount":97},[],{"intervention":15241,"totalTrials":947,"cells":15242},"Calcium Supplement",{"EARLY_PHASE1":15243,"PHASE1":15245,"PHASE2":15247,"PHASE3":15249,"PHASE4":15261,"NA":15272},{"trials":15244,"activeCount":97},[],{"trials":15246,"activeCount":97},[],{"trials":15248,"activeCount":97},[],{"trials":15250,"activeCount":97},[15251],{"nctId":15252,"briefTitle":15253,"status":103,"phases":15254,"primaryCompletion":15255,"completion":15255,"start":15256,"enrollment":15257,"conditions":15258,"interventions":15259},"NCT00670501","Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis",[87],"1999-04","1996-08",1637,[14168],[14170,14170,15241,15260],"Vitamin D Supplement",{"trials":15262,"activeCount":97},[15263],{"nctId":15264,"briefTitle":15265,"status":103,"phases":15266,"primaryCompletion":5354,"completion":5354,"start":3068,"enrollment":3013,"conditions":15267,"interventions":15268},"NCT01753856","Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis",[88],[14617],[14202,15269,15270,15271,15241,14783],"Denosumab","Demeclocycline","Tetracycline",{"trials":15273,"activeCount":97},[],{"intervention":15275,"totalTrials":947,"cells":15276},"Oral Olanzapine",{"EARLY_PHASE1":15277,"PHASE1":15279,"PHASE2":15281,"PHASE3":15283,"PHASE4":15292,"NA":15302},{"trials":15278,"activeCount":97},[],{"trials":15280,"activeCount":97},[],{"trials":15282,"activeCount":97},[],{"trials":15284,"activeCount":97},[15285],{"nctId":15286,"briefTitle":15287,"status":103,"phases":15288,"completion":2876,"start":3194,"enrollment":2113,"conditions":15289,"interventions":15290},"NCT00088491","Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia",[87],[14463],[15291,15275],"Intramuscular Olanzapine Depot",{"trials":15293,"activeCount":97},[15294],{"nctId":15295,"briefTitle":15296,"status":103,"phases":15297,"primaryCompletion":3227,"completion":3227,"start":3592,"enrollment":7363,"conditions":15298,"interventions":15299},"NCT00303602","Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)",[88],[4897,14400,4919],[15300,15301],"Sublingual orally disintegrating olanzapine","Oral olanzapine",{"trials":15303,"activeCount":97},[],{"intervention":14783,"totalTrials":947,"cells":15305},{"EARLY_PHASE1":15306,"PHASE1":15308,"PHASE2":15310,"PHASE3":15312,"PHASE4":15314,"NA":15324},{"trials":15307,"activeCount":97},[],{"trials":15309,"activeCount":97},[],{"trials":15311,"activeCount":97},[],{"trials":15313,"activeCount":97},[],{"trials":15315,"activeCount":97},[15316,15320],{"nctId":14776,"briefTitle":14777,"status":103,"phases":15317,"primaryCompletion":1546,"completion":1546,"start":2798,"enrollment":14779,"conditions":15318,"interventions":15319},[88],[14214],[14202,14747,14782,14783],{"nctId":15264,"briefTitle":15265,"status":103,"phases":15321,"primaryCompletion":5354,"completion":5354,"start":3068,"enrollment":3013,"conditions":15322,"interventions":15323},[88],[14617],[14202,15269,15270,15271,15241,14783],{"trials":15325,"activeCount":97},[],{"intervention":15327,"totalTrials":314,"cells":15328},"Osmotic-release oral system methylphenidate",{"EARLY_PHASE1":15329,"PHASE1":15331,"PHASE2":15333,"PHASE3":15335,"PHASE4":15337,"NA":15346},{"trials":15330,"activeCount":97},[],{"trials":15332,"activeCount":97},[],{"trials":15334,"activeCount":97},[],{"trials":15336,"activeCount":97},[],{"trials":15338,"activeCount":97},[15339],{"nctId":15340,"briefTitle":15341,"status":999,"phases":15342,"primaryCompletion":2844,"completion":2844,"start":2918,"enrollment":1488,"conditions":15343,"interventions":15344},"NCT01127646","A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents",[88],[13785],[15345,15327],"Atomoxetine",{"trials":15347,"activeCount":97},[],{"intervention":7607,"totalTrials":314,"cells":15349},{"EARLY_PHASE1":15350,"PHASE1":15352,"PHASE2":15354,"PHASE3":15356,"PHASE4":15358,"NA":15364},{"trials":15351,"activeCount":97},[],{"trials":15353,"activeCount":97},[],{"trials":15355,"activeCount":97},[],{"trials":15357,"activeCount":97},[],{"trials":15359,"activeCount":97},[15360],{"nctId":7599,"briefTitle":7600,"status":103,"phases":15361,"primaryCompletion":7602,"completion":7602,"start":7603,"enrollment":7604,"conditions":15362,"interventions":15363},[88],[7486,7533],[7445,7607],{"trials":15365,"activeCount":97},[],{"intervention":15367,"totalTrials":314,"cells":15368},"Insulin Biphasic Aspart 30\u002F70",{"EARLY_PHASE1":15369,"PHASE1":15371,"PHASE2":15373,"PHASE3":15375,"PHASE4":15377,"NA":15387},{"trials":15370,"activeCount":97},[],{"trials":15372,"activeCount":97},[],{"trials":15374,"activeCount":97},[],{"trials":15376,"activeCount":97},[],{"trials":15378,"activeCount":97},[15379],{"nctId":15380,"briefTitle":15381,"status":103,"phases":15382,"primaryCompletion":2866,"completion":2866,"start":2876,"enrollment":4675,"conditions":15383,"interventions":15384},"NCT00393705","Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30\u002F70 (S019)",[88],[18],[15367,15385,15386,15385],"insulin lispro LM","insulin lispro MM",{"trials":15388,"activeCount":97},[],{"intervention":15385,"totalTrials":314,"cells":15390},{"EARLY_PHASE1":15391,"PHASE1":15393,"PHASE2":15395,"PHASE3":15397,"PHASE4":15399,"NA":15405},{"trials":15392,"activeCount":97},[],{"trials":15394,"activeCount":97},[],{"trials":15396,"activeCount":97},[],{"trials":15398,"activeCount":97},[],{"trials":15400,"activeCount":97},[15401],{"nctId":15380,"briefTitle":15381,"status":103,"phases":15402,"primaryCompletion":2866,"completion":2866,"start":2876,"enrollment":4675,"conditions":15403,"interventions":15404},[88],[18],[15367,15385,15386,15385],{"trials":15406,"activeCount":97},[],{"intervention":15386,"totalTrials":314,"cells":15408},{"EARLY_PHASE1":15409,"PHASE1":15411,"PHASE2":15413,"PHASE3":15415,"PHASE4":15417,"NA":15423},{"trials":15410,"activeCount":97},[],{"trials":15412,"activeCount":97},[],{"trials":15414,"activeCount":97},[],{"trials":15416,"activeCount":97},[],{"trials":15418,"activeCount":97},[15419],{"nctId":15380,"briefTitle":15381,"status":103,"phases":15420,"primaryCompletion":2866,"completion":2866,"start":2876,"enrollment":4675,"conditions":15421,"interventions":15422},[88],[18],[15367,15385,15386,15385],{"trials":15424,"activeCount":97},[],{"intervention":15426,"totalTrials":314,"cells":15427},"Alpha1 Blocker",{"EARLY_PHASE1":15428,"PHASE1":15430,"PHASE2":15432,"PHASE3":15434,"PHASE4":15436,"NA":15446},{"trials":15429,"activeCount":97},[],{"trials":15431,"activeCount":97},[],{"trials":15433,"activeCount":97},[],{"trials":15435,"activeCount":97},[],{"trials":15437,"activeCount":97},[15438],{"nctId":15439,"briefTitle":15440,"status":103,"phases":15441,"primaryCompletion":1547,"completion":1547,"start":3697,"enrollment":15442,"conditions":15443,"interventions":15445},"NCT02431754","A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).",[88],171,[15444],"Benign Prostatic Hyperplasia",[10904,15426],{"trials":15447,"activeCount":97},[],{"intervention":13201,"totalTrials":314,"cells":15449},{"EARLY_PHASE1":15450,"PHASE1":15452,"PHASE2":15454,"PHASE3":15456,"PHASE4":15458,"NA":15464},{"trials":15451,"activeCount":97},[],{"trials":15453,"activeCount":97},[],{"trials":15455,"activeCount":97},[],{"trials":15457,"activeCount":97},[],{"trials":15459,"activeCount":97},[15460],{"nctId":13196,"briefTitle":13197,"status":103,"phases":15461,"primaryCompletion":6093,"completion":6093,"start":3050,"enrollment":3373,"conditions":15462,"interventions":15463},[88],[33],[438,13201],{"trials":15465,"activeCount":97},[],{"intervention":15467,"totalTrials":314,"cells":15468},"Alendronate",{"EARLY_PHASE1":15469,"PHASE1":15471,"PHASE2":15473,"PHASE3":15475,"PHASE4":15477,"NA":15486},{"trials":15470,"activeCount":97},[],{"trials":15472,"activeCount":97},[],{"trials":15474,"activeCount":97},[],{"trials":15476,"activeCount":97},[],{"trials":15478,"activeCount":97},[15479],{"nctId":15480,"briefTitle":15481,"status":103,"phases":15482,"primaryCompletion":3536,"completion":3536,"start":15163,"enrollment":15483,"conditions":15484,"interventions":15485},"NCT02416271","The Forteo Alendronate Comparator Trial",[88],203,[14617],[14202,15467],{"trials":15487,"activeCount":97},[],{"intervention":15489,"totalTrials":314,"cells":15490},"ziprasidone",{"EARLY_PHASE1":15491,"PHASE1":15493,"PHASE2":15495,"PHASE3":15497,"PHASE4":15499,"NA":15508},{"trials":15492,"activeCount":97},[],{"trials":15494,"activeCount":97},[],{"trials":15496,"activeCount":97},[],{"trials":15498,"activeCount":97},[],{"trials":15500,"activeCount":97},[15501],{"nctId":15502,"briefTitle":15503,"status":103,"phases":15504,"completion":3040,"start":3186,"enrollment":15505,"conditions":15506,"interventions":15507},"NCT00034801","Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia",[88],378,[14033,4897,14400],[9670,15489],{"trials":15509,"activeCount":97},[],{"intervention":13704,"totalTrials":314,"cells":15511},{"EARLY_PHASE1":15512,"PHASE1":15514,"PHASE2":15516,"PHASE3":15518,"PHASE4":15520,"NA":15526},{"trials":15513,"activeCount":97},[],{"trials":15515,"activeCount":97},[],{"trials":15517,"activeCount":97},[],{"trials":15519,"activeCount":97},[],{"trials":15521,"activeCount":97},[15522],{"nctId":13698,"briefTitle":13699,"status":103,"phases":15523,"primaryCompletion":3217,"completion":3217,"start":3176,"enrollment":13701,"conditions":15524,"interventions":15525},[88],[18],[7103,13704,13705,13706],{"trials":15527,"activeCount":97},[],{"intervention":13705,"totalTrials":314,"cells":15529},{"EARLY_PHASE1":15530,"PHASE1":15532,"PHASE2":15534,"PHASE3":15536,"PHASE4":15538,"NA":15544},{"trials":15531,"activeCount":97},[],{"trials":15533,"activeCount":97},[],{"trials":15535,"activeCount":97},[],{"trials":15537,"activeCount":97},[],{"trials":15539,"activeCount":97},[15540],{"nctId":13698,"briefTitle":13699,"status":103,"phases":15541,"primaryCompletion":3217,"completion":3217,"start":3176,"enrollment":13701,"conditions":15542,"interventions":15543},[88],[18],[7103,13704,13705,13706],{"trials":15545,"activeCount":97},[],{"intervention":15109,"totalTrials":314,"cells":15547},{"EARLY_PHASE1":15548,"PHASE1":15550,"PHASE2":15552,"PHASE3":15554,"PHASE4":15556,"NA":15562},{"trials":15549,"activeCount":97},[],{"trials":15551,"activeCount":97},[],{"trials":15553,"activeCount":97},[],{"trials":15555,"activeCount":97},[],{"trials":15557,"activeCount":97},[15558],{"nctId":15104,"briefTitle":15105,"status":103,"phases":15559,"primaryCompletion":3308,"completion":3308,"start":3337,"enrollment":195,"conditions":15560,"interventions":15561},[88],[33,18],[13211,15109],{"trials":15563,"activeCount":97},[],{"intervention":15565,"totalTrials":314,"cells":15566},"raloxifene HCI and alendronate Na",{"EARLY_PHASE1":15567,"PHASE1":15569,"PHASE2":15571,"PHASE3":15573,"PHASE4":15575,"NA":15583},{"trials":15568,"activeCount":97},[],{"trials":15570,"activeCount":97},[],{"trials":15572,"activeCount":97},[],{"trials":15574,"activeCount":97},[],{"trials":15576,"activeCount":97},[15577],{"nctId":15578,"briefTitle":15579,"status":103,"phases":15580,"conditions":15581,"interventions":15582},"NCT00035971","EVA: Evista Alendronate Comparison",[88],[14617],[15565],{"trials":15584,"activeCount":97},[],{"intervention":15586,"totalTrials":314,"cells":15587},"Insulin Analog Mid Mixture",{"EARLY_PHASE1":15588,"PHASE1":15590,"PHASE2":15592,"PHASE3":15594,"PHASE4":15596,"NA":15608},{"trials":15589,"activeCount":97},[],{"trials":15591,"activeCount":97},[],{"trials":15593,"activeCount":97},[],{"trials":15595,"activeCount":97},[],{"trials":15597,"activeCount":97},[15598],{"nctId":15599,"briefTitle":15600,"status":103,"phases":15601,"primaryCompletion":2579,"completion":15602,"start":15603,"enrollment":15604,"conditions":15605,"interventions":15606},"NCT03018938","A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus",[88],"2019-07-12","2017-02-06",814,[120],[15586,15607],"Basal Insulin Analog",{"trials":15609,"activeCount":97},[],{"intervention":15607,"totalTrials":314,"cells":15611},{"EARLY_PHASE1":15612,"PHASE1":15614,"PHASE2":15616,"PHASE3":15618,"PHASE4":15620,"NA":15626},{"trials":15613,"activeCount":97},[],{"trials":15615,"activeCount":97},[],{"trials":15617,"activeCount":97},[],{"trials":15619,"activeCount":97},[],{"trials":15621,"activeCount":97},[15622],{"nctId":15599,"briefTitle":15600,"status":103,"phases":15623,"primaryCompletion":2579,"completion":15602,"start":15603,"enrollment":15604,"conditions":15624,"interventions":15625},[88],[120],[15586,15607],{"trials":15627,"activeCount":97},[],{"intervention":15629,"totalTrials":314,"cells":15630},"Sildenafil Citrate",{"EARLY_PHASE1":15631,"PHASE1":15633,"PHASE2":15635,"PHASE3":15637,"PHASE4":15639,"NA":15648},{"trials":15632,"activeCount":97},[],{"trials":15634,"activeCount":97},[],{"trials":15636,"activeCount":97},[],{"trials":15638,"activeCount":97},[],{"trials":15640,"activeCount":97},[15641],{"nctId":15642,"briefTitle":15643,"status":103,"phases":15644,"primaryCompletion":3020,"completion":3020,"start":2956,"enrollment":15645,"conditions":15646,"interventions":15647},"NCT01122264","A Study in Patients With Erectile Dysfunction",[88],770,[14741],[10904,15629],{"trials":15649,"activeCount":97},[],{"intervention":15651,"totalTrials":314,"cells":15652},"Lispro Mix 50\u002F50",{"EARLY_PHASE1":15653,"PHASE1":15655,"PHASE2":15657,"PHASE3":15659,"PHASE4":15661,"NA":15669},{"trials":15654,"activeCount":97},[],{"trials":15656,"activeCount":97},[],{"trials":15658,"activeCount":97},[],{"trials":15660,"activeCount":97},[],{"trials":15662,"activeCount":97},[15663],{"nctId":15664,"briefTitle":15665,"status":103,"phases":15666,"primaryCompletion":3069,"completion":3069,"start":14517,"enrollment":3525,"conditions":15667,"interventions":15668},"NCT00971997","A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients",[88],[18],[15651],{"trials":15670,"activeCount":97},[],{"intervention":15672,"totalTrials":314,"cells":15673},"Humatrope",{"EARLY_PHASE1":15674,"PHASE1":15676,"PHASE2":15678,"PHASE3":15680,"PHASE4":15682,"NA":15691},{"trials":15675,"activeCount":97},[],{"trials":15677,"activeCount":97},[],{"trials":15679,"activeCount":97},[],{"trials":15681,"activeCount":97},[],{"trials":15683,"activeCount":97},[15684],{"nctId":15685,"briefTitle":15686,"status":103,"phases":15687,"primaryCompletion":1618,"completion":1618,"start":3176,"enrollment":3013,"conditions":15688,"interventions":15690},"NCT00266656","Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome",[88],[15689],"Turner Syndrome",[15672],{"trials":15692,"activeCount":97},[],{"intervention":14107,"totalTrials":314,"cells":15694},{"EARLY_PHASE1":15695,"PHASE1":15697,"PHASE2":15699,"PHASE3":15701,"PHASE4":15703,"NA":15709},{"trials":15696,"activeCount":97},[],{"trials":15698,"activeCount":97},[],{"trials":15700,"activeCount":97},[],{"trials":15702,"activeCount":97},[],{"trials":15704,"activeCount":97},[15705],{"nctId":14100,"briefTitle":14101,"status":103,"phases":15706,"completion":14103,"start":3161,"enrollment":14104,"conditions":15707,"interventions":15708},[88],[14074],[14056,14107,14108],{"trials":15710,"activeCount":97},[],{"intervention":14108,"totalTrials":314,"cells":15712},{"EARLY_PHASE1":15713,"PHASE1":15715,"PHASE2":15717,"PHASE3":15719,"PHASE4":15721,"NA":15727},{"trials":15714,"activeCount":97},[],{"trials":15716,"activeCount":97},[],{"trials":15718,"activeCount":97},[],{"trials":15720,"activeCount":97},[],{"trials":15722,"activeCount":97},[15723],{"nctId":14100,"briefTitle":14101,"status":103,"phases":15724,"completion":14103,"start":3161,"enrollment":14104,"conditions":15725,"interventions":15726},[88],[14074],[14056,14107,14108],{"trials":15728,"activeCount":97},[],{"intervention":9742,"totalTrials":314,"cells":15730},{"EARLY_PHASE1":15731,"PHASE1":15733,"PHASE2":15735,"PHASE3":15737,"PHASE4":15739,"NA":15745},{"trials":15732,"activeCount":97},[],{"trials":15734,"activeCount":97},[],{"trials":15736,"activeCount":97},[],{"trials":15738,"activeCount":97},[],{"trials":15740,"activeCount":97},[15741],{"nctId":9737,"briefTitle":9738,"status":103,"phases":15742,"completion":2833,"start":4459,"enrollment":2413,"conditions":15743,"interventions":15744},[88],[18],[9742,9743,9672],{"trials":15746,"activeCount":97},[],{"intervention":13210,"totalTrials":314,"cells":15748},{"EARLY_PHASE1":15749,"PHASE1":15751,"PHASE2":15753,"PHASE3":15755,"PHASE4":15757,"NA":15763},{"trials":15750,"activeCount":97},[],{"trials":15752,"activeCount":97},[],{"trials":15754,"activeCount":97},[],{"trials":15756,"activeCount":97},[],{"trials":15758,"activeCount":97},[15759],{"nctId":13203,"briefTitle":13204,"status":103,"phases":15760,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":13206,"conditions":15761,"interventions":15762},[88],[18,13208],[7104,13210,7103,13210,13211],{"trials":15764,"activeCount":97},[],{"intervention":15766,"totalTrials":314,"cells":15767},"Strontium ranelate",{"EARLY_PHASE1":15768,"PHASE1":15770,"PHASE2":15772,"PHASE3":15774,"PHASE4":15776,"NA":15784},{"trials":15769,"activeCount":97},[],{"trials":15771,"activeCount":97},[],{"trials":15773,"activeCount":97},[],{"trials":15775,"activeCount":97},[],{"trials":15777,"activeCount":97},[15778],{"nctId":15779,"briefTitle":15780,"status":103,"phases":15781,"completion":3337,"start":2833,"enrollment":93,"conditions":15782,"interventions":15783},"NCT00239629","Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial",[88],[14214],[14202,15766],{"trials":15785,"activeCount":97},[],{"intervention":13730,"totalTrials":314,"cells":15787},{"EARLY_PHASE1":15788,"PHASE1":15790,"PHASE2":15792,"PHASE3":15794,"PHASE4":15796,"NA":15802},{"trials":15789,"activeCount":97},[],{"trials":15791,"activeCount":97},[],{"trials":15793,"activeCount":97},[],{"trials":15795,"activeCount":97},[],{"trials":15797,"activeCount":97},[15798],{"nctId":13724,"briefTitle":13725,"status":103,"phases":15799,"primaryCompletion":8736,"completion":8736,"start":13727,"enrollment":658,"conditions":15800,"interventions":15801},[88],[18],[13730,506],{"trials":15803,"activeCount":97},[],{"intervention":7412,"totalTrials":314,"cells":15805},{"EARLY_PHASE1":15806,"PHASE1":15808,"PHASE2":15810,"PHASE3":15812,"PHASE4":15814,"NA":15820},{"trials":15807,"activeCount":97},[],{"trials":15809,"activeCount":97},[],{"trials":15811,"activeCount":97},[],{"trials":15813,"activeCount":97},[],{"trials":15815,"activeCount":97},[15816],{"nctId":7404,"briefTitle":7405,"status":103,"phases":15817,"primaryCompletion":7407,"completion":7408,"start":1837,"enrollment":7409,"conditions":15818,"interventions":15819},[88],[926],[449,7412],{"trials":15821,"activeCount":97},[],{"intervention":13738,"totalTrials":314,"cells":15823},{"EARLY_PHASE1":15824,"PHASE1":15826,"PHASE2":15828,"PHASE3":15830,"PHASE4":15832,"NA":15838},{"trials":15825,"activeCount":97},[],{"trials":15827,"activeCount":97},[],{"trials":15829,"activeCount":97},[],{"trials":15831,"activeCount":97},[],{"trials":15833,"activeCount":97},[15834],{"nctId":13732,"briefTitle":13733,"status":103,"phases":15835,"primaryCompletion":3320,"completion":3320,"start":2855,"enrollment":13735,"conditions":15836,"interventions":15837},[88],[18],[13738,7103],{"trials":15839,"activeCount":97},[],{"intervention":14472,"totalTrials":314,"cells":15841},{"EARLY_PHASE1":15842,"PHASE1":15844,"PHASE2":15846,"PHASE3":15848,"PHASE4":15850,"NA":15856},{"trials":15843,"activeCount":97},[],{"trials":15845,"activeCount":97},[],{"trials":15847,"activeCount":97},[],{"trials":15849,"activeCount":97},[],{"trials":15851,"activeCount":97},[15852],{"nctId":14466,"briefTitle":14467,"status":103,"phases":15853,"completion":5623,"start":3140,"enrollment":14469,"conditions":15854,"interventions":15855},[88],[4897],[14423,14472],{"trials":15857,"activeCount":97},[],{"intervention":14821,"totalTrials":314,"cells":15859},{"EARLY_PHASE1":15860,"PHASE1":15862,"PHASE2":15864,"PHASE3":15866,"PHASE4":15868,"NA":15874},{"trials":15861,"activeCount":97},[],{"trials":15863,"activeCount":97},[],{"trials":15865,"activeCount":97},[],{"trials":15867,"activeCount":97},[],{"trials":15869,"activeCount":97},[15870],{"nctId":14816,"briefTitle":14817,"status":999,"phases":15871,"primaryCompletion":3566,"completion":3566,"start":2948,"enrollment":205,"conditions":15872,"interventions":15873},[88],[4919],[9670,14793,14821],{"trials":15875,"activeCount":97},[],{"intervention":15877,"totalTrials":314,"cells":15878},"olanzapine therapy",{"EARLY_PHASE1":15879,"PHASE1":15881,"PHASE2":15883,"PHASE3":15885,"PHASE4":15887,"NA":15896},{"trials":15880,"activeCount":97},[],{"trials":15882,"activeCount":97},[],{"trials":15884,"activeCount":97},[],{"trials":15886,"activeCount":97},[],{"trials":15888,"activeCount":97},[15889],{"nctId":15890,"briefTitle":15891,"status":103,"phases":15892,"primaryCompletion":2975,"completion":2975,"start":3259,"enrollment":15893,"conditions":15894,"interventions":15895},"NCT00324051","Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet",[88],284,[4897],[15877],{"trials":15897,"activeCount":97},[],{"intervention":2008,"totalTrials":314,"cells":15899},{"EARLY_PHASE1":15900,"PHASE1":15902,"PHASE2":15904,"PHASE3":15906,"PHASE4":15908,"NA":15914},{"trials":15901,"activeCount":97},[],{"trials":15903,"activeCount":97},[],{"trials":15905,"activeCount":97},[],{"trials":15907,"activeCount":97},[],{"trials":15909,"activeCount":97},[15910],{"nctId":2001,"briefTitle":2002,"status":999,"phases":15911,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":1400,"conditions":15912,"interventions":15913},[88],[1571],[48,1468,2008],{"trials":15915,"activeCount":97},[],{"intervention":7616,"totalTrials":314,"cells":15917},{"EARLY_PHASE1":15918,"PHASE1":15920,"PHASE2":15922,"PHASE3":15924,"PHASE4":15926,"NA":15932},{"trials":15919,"activeCount":97},[],{"trials":15921,"activeCount":97},[],{"trials":15923,"activeCount":97},[],{"trials":15925,"activeCount":97},[],{"trials":15927,"activeCount":97},[15928],{"nctId":7609,"briefTitle":7610,"status":103,"phases":15929,"primaryCompletion":7612,"completion":7612,"start":7613,"enrollment":156,"conditions":15930,"interventions":15931},[88],[7486],[7445,7616],{"trials":15933,"activeCount":97},[],{"intervention":15935,"totalTrials":314,"cells":15936},"Zoledronic Acid",{"EARLY_PHASE1":15937,"PHASE1":15939,"PHASE2":15941,"PHASE3":15943,"PHASE4":15945,"NA":15954},{"trials":15938,"activeCount":97},[],{"trials":15940,"activeCount":97},[],{"trials":15942,"activeCount":97},[],{"trials":15944,"activeCount":97},[],{"trials":15946,"activeCount":97},[15947],{"nctId":15948,"briefTitle":15949,"status":103,"phases":15950,"primaryCompletion":8233,"completion":2864,"start":3059,"enrollment":3013,"conditions":15951,"interventions":15953},"NCT00927186","Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women",[88],[15952],"Osteoporosis, Post-menopausal",[14202,15935],{"trials":15955,"activeCount":97},[],{"intervention":9751,"totalTrials":314,"cells":15957},{"EARLY_PHASE1":15958,"PHASE1":15960,"PHASE2":15962,"PHASE3":15964,"PHASE4":15966,"NA":15972},{"trials":15959,"activeCount":97},[],{"trials":15961,"activeCount":97},[],{"trials":15963,"activeCount":97},[],{"trials":15965,"activeCount":97},[],{"trials":15967,"activeCount":97},[15968],{"nctId":9745,"briefTitle":9746,"status":999,"phases":15969,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":15970,"interventions":15971},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":15973,"activeCount":97},[],{"intervention":9752,"totalTrials":314,"cells":15975},{"EARLY_PHASE1":15976,"PHASE1":15978,"PHASE2":15980,"PHASE3":15982,"PHASE4":15984,"NA":15990},{"trials":15977,"activeCount":97},[],{"trials":15979,"activeCount":97},[],{"trials":15981,"activeCount":97},[],{"trials":15983,"activeCount":97},[],{"trials":15985,"activeCount":97},[15986],{"nctId":9745,"briefTitle":9746,"status":999,"phases":15987,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":15988,"interventions":15989},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":15991,"activeCount":97},[],{"intervention":9753,"totalTrials":314,"cells":15993},{"EARLY_PHASE1":15994,"PHASE1":15996,"PHASE2":15998,"PHASE3":16000,"PHASE4":16002,"NA":16008},{"trials":15995,"activeCount":97},[],{"trials":15997,"activeCount":97},[],{"trials":15999,"activeCount":97},[],{"trials":16001,"activeCount":97},[],{"trials":16003,"activeCount":97},[16004],{"nctId":9745,"briefTitle":9746,"status":999,"phases":16005,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":16006,"interventions":16007},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":16009,"activeCount":97},[],{"intervention":9754,"totalTrials":314,"cells":16011},{"EARLY_PHASE1":16012,"PHASE1":16014,"PHASE2":16016,"PHASE3":16018,"PHASE4":16020,"NA":16026},{"trials":16013,"activeCount":97},[],{"trials":16015,"activeCount":97},[],{"trials":16017,"activeCount":97},[],{"trials":16019,"activeCount":97},[],{"trials":16021,"activeCount":97},[16022],{"nctId":9745,"briefTitle":9746,"status":999,"phases":16023,"primaryCompletion":3250,"completion":3250,"start":9748,"enrollment":2987,"conditions":16024,"interventions":16025},[88],[18],[7071,1631,9733,9751,9752,9644,188,506,9753,9754],{"trials":16027,"activeCount":97},[],{"intervention":16029,"totalTrials":314,"cells":16030},"Insulin Lispro Mix25",{"EARLY_PHASE1":16031,"PHASE1":16033,"PHASE2":16035,"PHASE3":16037,"PHASE4":16039,"NA":16048},{"trials":16032,"activeCount":97},[],{"trials":16034,"activeCount":97},[],{"trials":16036,"activeCount":97},[],{"trials":16038,"activeCount":97},[],{"trials":16040,"activeCount":97},[16041],{"nctId":16042,"briefTitle":16043,"status":103,"phases":16044,"primaryCompletion":3122,"completion":3122,"start":3068,"enrollment":14024,"conditions":16045,"interventions":16046},"NCT01773473","Comparison of Insulin Mix25 Versus Mix50",[88],[120],[16029,16047],"Insulin Lispro Mix50",{"trials":16049,"activeCount":97},[],{"intervention":16047,"totalTrials":314,"cells":16051},{"EARLY_PHASE1":16052,"PHASE1":16054,"PHASE2":16056,"PHASE3":16058,"PHASE4":16060,"NA":16066},{"trials":16053,"activeCount":97},[],{"trials":16055,"activeCount":97},[],{"trials":16057,"activeCount":97},[],{"trials":16059,"activeCount":97},[],{"trials":16061,"activeCount":97},[16062],{"nctId":16042,"briefTitle":16043,"status":103,"phases":16063,"primaryCompletion":3122,"completion":3122,"start":3068,"enrollment":14024,"conditions":16064,"interventions":16065},[88],[120],[16029,16047],{"trials":16067,"activeCount":97},[],{"intervention":16069,"totalTrials":314,"cells":16070},"Topical Testosterone Solution",{"EARLY_PHASE1":16071,"PHASE1":16073,"PHASE2":16075,"PHASE3":16077,"PHASE4":16079,"NA":16088},{"trials":16072,"activeCount":97},[],{"trials":16074,"activeCount":97},[],{"trials":16076,"activeCount":97},[],{"trials":16078,"activeCount":97},[],{"trials":16080,"activeCount":97},[16081],{"nctId":16082,"briefTitle":16083,"status":103,"phases":16084,"primaryCompletion":3112,"completion":3112,"start":3027,"enrollment":2340,"conditions":16085,"interventions":16087},"NCT01893281","The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel",[88],[16086],"Hypogonadism",[16069],{"trials":16089,"activeCount":97},[],{"intervention":16091,"totalTrials":314,"cells":16092},"Aspara-CA 600 mg",{"EARLY_PHASE1":16093,"PHASE1":16095,"PHASE2":16097,"PHASE3":16099,"PHASE4":16101,"NA":16110},{"trials":16094,"activeCount":97},[],{"trials":16096,"activeCount":97},[],{"trials":16098,"activeCount":97},[],{"trials":16100,"activeCount":97},[],{"trials":16102,"activeCount":97},[16103],{"nctId":16104,"briefTitle":16105,"status":103,"phases":16106,"primaryCompletion":4160,"completion":4160,"start":8217,"enrollment":1620,"conditions":16107,"interventions":16108},"NCT01430104","A Study of Teriparatide in Japanese Osteoporosis Patients",[88],[14617],[14202,16091,16109],"Alfarol 1.0 µg",{"trials":16111,"activeCount":97},[],{"intervention":16109,"totalTrials":314,"cells":16113},{"EARLY_PHASE1":16114,"PHASE1":16116,"PHASE2":16118,"PHASE3":16120,"PHASE4":16122,"NA":16128},{"trials":16115,"activeCount":97},[],{"trials":16117,"activeCount":97},[],{"trials":16119,"activeCount":97},[],{"trials":16121,"activeCount":97},[],{"trials":16123,"activeCount":97},[16124],{"nctId":16104,"briefTitle":16105,"status":103,"phases":16125,"primaryCompletion":4160,"completion":4160,"start":8217,"enrollment":1620,"conditions":16126,"interventions":16127},[88],[14617],[14202,16091,16109],{"trials":16129,"activeCount":97},[],{"intervention":14316,"totalTrials":314,"cells":16131},{"EARLY_PHASE1":16132,"PHASE1":16134,"PHASE2":16136,"PHASE3":16138,"PHASE4":16140,"NA":16146},{"trials":16133,"activeCount":97},[],{"trials":16135,"activeCount":97},[],{"trials":16137,"activeCount":97},[],{"trials":16139,"activeCount":97},[],{"trials":16141,"activeCount":97},[16142],{"nctId":14311,"briefTitle":14312,"status":103,"phases":16143,"completion":2909,"start":3536,"enrollment":1158,"conditions":16144,"interventions":16145},[88],[30],[14316,13166],{"trials":16147,"activeCount":97},[],{"intervention":14027,"totalTrials":314,"cells":16149},{"EARLY_PHASE1":16150,"PHASE1":16152,"PHASE2":16154,"PHASE3":16156,"PHASE4":16158,"NA":16164},{"trials":16151,"activeCount":97},[],{"trials":16153,"activeCount":97},[],{"trials":16155,"activeCount":97},[],{"trials":16157,"activeCount":97},[],{"trials":16159,"activeCount":97},[16160],{"nctId":14021,"briefTitle":14022,"status":103,"phases":16161,"completion":4538,"start":3078,"enrollment":14024,"conditions":16162,"interventions":16163},[88],[4919],[13976,13944,14027],{"trials":16165,"activeCount":97},[],{"intervention":14698,"totalTrials":314,"cells":16167},{"EARLY_PHASE1":16168,"PHASE1":16170,"PHASE2":16172,"PHASE3":16174,"PHASE4":16176,"NA":16182},{"trials":16169,"activeCount":97},[],{"trials":16171,"activeCount":97},[],{"trials":16173,"activeCount":97},[],{"trials":16175,"activeCount":97},[],{"trials":16177,"activeCount":97},[16178],{"nctId":14690,"briefTitle":14691,"status":103,"phases":16179,"primaryCompletion":2955,"completion":3217,"start":3133,"enrollment":14693,"conditions":16180,"interventions":16181},[88],[14666],[14696,14697,14698],{"trials":16183,"activeCount":97},[],{"intervention":13750,"totalTrials":314,"cells":16185},{"EARLY_PHASE1":16186,"PHASE1":16188,"PHASE2":16190,"PHASE3":16192,"PHASE4":16194,"NA":16200},{"trials":16187,"activeCount":97},[],{"trials":16189,"activeCount":97},[],{"trials":16191,"activeCount":97},[],{"trials":16193,"activeCount":97},[],{"trials":16195,"activeCount":97},[16196],{"nctId":13744,"briefTitle":13745,"status":103,"phases":16197,"primaryCompletion":3048,"completion":3048,"start":3069,"enrollment":514,"conditions":16198,"interventions":16199},[88],[18],[13749,506,13750],{"trials":16201,"activeCount":97},[],{"intervention":16203,"totalTrials":314,"cells":16204},"divalproex sodium",{"EARLY_PHASE1":16205,"PHASE1":16207,"PHASE2":16209,"PHASE3":16211,"PHASE4":16213,"NA":16221},{"trials":16206,"activeCount":97},[],{"trials":16208,"activeCount":97},[],{"trials":16210,"activeCount":97},[],{"trials":16212,"activeCount":97},[],{"trials":16214,"activeCount":97},[16215],{"nctId":16216,"briefTitle":16217,"status":103,"phases":16218,"completion":3060,"start":2948,"enrollment":1568,"conditions":16219,"interventions":16220},"NCT00094549","Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder",[88],[4919],[9670,16203],{"trials":16222,"activeCount":97},[],{"intervention":14216,"totalTrials":314,"cells":16224},{"EARLY_PHASE1":16225,"PHASE1":16227,"PHASE2":16229,"PHASE3":16231,"PHASE4":16233,"NA":16239},{"trials":16226,"activeCount":97},[],{"trials":16228,"activeCount":97},[],{"trials":16230,"activeCount":97},[],{"trials":16232,"activeCount":97},[],{"trials":16234,"activeCount":97},[16235],{"nctId":14210,"briefTitle":14211,"status":103,"phases":16236,"completion":3005,"start":3646,"enrollment":776,"conditions":16237,"interventions":16238},[88],[14214],[14170,14216,14171],{"trials":16240,"activeCount":97},[],{"intervention":16242,"totalTrials":314,"cells":16243},"Lispro Mixture Therapy",{"EARLY_PHASE1":16244,"PHASE1":16246,"PHASE2":16248,"PHASE3":16250,"PHASE4":16252,"NA":16261},{"trials":16245,"activeCount":97},[],{"trials":16247,"activeCount":97},[],{"trials":16249,"activeCount":97},[],{"trials":16251,"activeCount":97},[],{"trials":16253,"activeCount":97},[16254],{"nctId":16255,"briefTitle":16256,"status":103,"phases":16257,"completion":4266,"start":3746,"enrollment":542,"conditions":16258,"interventions":16259},"NCT00110370","Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes",[88],[18],[16242,16260],"Glargine Basal-Bolus Therapy",{"trials":16262,"activeCount":97},[],{"intervention":16260,"totalTrials":314,"cells":16264},{"EARLY_PHASE1":16265,"PHASE1":16267,"PHASE2":16269,"PHASE3":16271,"PHASE4":16273,"NA":16279},{"trials":16266,"activeCount":97},[],{"trials":16268,"activeCount":97},[],{"trials":16270,"activeCount":97},[],{"trials":16272,"activeCount":97},[],{"trials":16274,"activeCount":97},[16275],{"nctId":16255,"briefTitle":16256,"status":103,"phases":16276,"completion":4266,"start":3746,"enrollment":542,"conditions":16277,"interventions":16278},[88],[18],[16242,16260],{"trials":16280,"activeCount":97},[],{"intervention":16282,"totalTrials":314,"cells":16283},"Dulaglutide Pen",{"EARLY_PHASE1":16284,"PHASE1":16286,"PHASE2":16288,"PHASE3":16290,"PHASE4":16292,"NA":16302},{"trials":16285,"activeCount":97},[],{"trials":16287,"activeCount":97},[],{"trials":16289,"activeCount":97},[],{"trials":16291,"activeCount":97},[],{"trials":16293,"activeCount":97},[16294],{"nctId":16295,"briefTitle":16296,"status":103,"phases":16297,"primaryCompletion":16298,"completion":16298,"start":3896,"enrollment":7522,"conditions":16299,"interventions":16300},"NCT03724981","A Study Comparing the Dulaglutide Pen and the Semaglutide Pen",[88],"2019-04-12",[18],[16282,16301],"Semaglutide Pen",{"trials":16303,"activeCount":97},[],{"intervention":16301,"totalTrials":314,"cells":16305},{"EARLY_PHASE1":16306,"PHASE1":16308,"PHASE2":16310,"PHASE3":16312,"PHASE4":16314,"NA":16320},{"trials":16307,"activeCount":97},[],{"trials":16309,"activeCount":97},[],{"trials":16311,"activeCount":97},[],{"trials":16313,"activeCount":97},[],{"trials":16315,"activeCount":97},[16316],{"nctId":16295,"briefTitle":16296,"status":103,"phases":16317,"primaryCompletion":16298,"completion":16298,"start":3896,"enrollment":7522,"conditions":16318,"interventions":16319},[88],[18],[16282,16301],{"trials":16321,"activeCount":97},[],{"intervention":13768,"totalTrials":314,"cells":16323},{"EARLY_PHASE1":16324,"PHASE1":16326,"PHASE2":16328,"PHASE3":16330,"PHASE4":16332,"NA":16338},{"trials":16325,"activeCount":97},[],{"trials":16327,"activeCount":97},[],{"trials":16329,"activeCount":97},[],{"trials":16331,"activeCount":97},[],{"trials":16333,"activeCount":97},[16334],{"nctId":13762,"briefTitle":13763,"status":103,"phases":16335,"completion":2947,"start":13765,"enrollment":874,"conditions":16336,"interventions":16337},[88],[30],[13768,9743],{"trials":16339,"activeCount":97},[],{"intervention":16341,"totalTrials":314,"cells":16342},"divalproex",{"EARLY_PHASE1":16343,"PHASE1":16345,"PHASE2":16347,"PHASE3":16349,"PHASE4":16351,"NA":16361},{"trials":16344,"activeCount":97},[],{"trials":16346,"activeCount":97},[],{"trials":16348,"activeCount":97},[],{"trials":16350,"activeCount":97},[],{"trials":16352,"activeCount":97},[16353],{"nctId":16354,"briefTitle":16355,"status":103,"phases":16356,"primaryCompletion":3094,"completion":3094,"start":3060,"enrollment":16357,"conditions":16358,"interventions":16360},"NCT00402324","A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients",[88],202,[16359],"Bipolar I Disorder",[9670,16341],{"trials":16362,"activeCount":97},[],{"intervention":14035,"totalTrials":314,"cells":16364},{"EARLY_PHASE1":16365,"PHASE1":16367,"PHASE2":16369,"PHASE3":16371,"PHASE4":16373,"NA":16379},{"trials":16366,"activeCount":97},[],{"trials":16368,"activeCount":97},[],{"trials":16370,"activeCount":97},[],{"trials":16372,"activeCount":97},[],{"trials":16374,"activeCount":97},[16375],{"nctId":14029,"briefTitle":14030,"status":103,"phases":16376,"primaryCompletion":3103,"completion":2866,"start":3292,"enrollment":2514,"conditions":16377,"interventions":16378},[88],[14033],[14004,14003,14035,14036,14037],{"trials":16380,"activeCount":97},[],{"intervention":14782,"totalTrials":314,"cells":16382},{"EARLY_PHASE1":16383,"PHASE1":16385,"PHASE2":16387,"PHASE3":16389,"PHASE4":16391,"NA":16397},{"trials":16384,"activeCount":97},[],{"trials":16386,"activeCount":97},[],{"trials":16388,"activeCount":97},[],{"trials":16390,"activeCount":97},[],{"trials":16392,"activeCount":97},[16393],{"nctId":14776,"briefTitle":14777,"status":103,"phases":16394,"primaryCompletion":1546,"completion":1546,"start":2798,"enrollment":14779,"conditions":16395,"interventions":16396},[88],[14214],[14202,14747,14782,14783],{"trials":16398,"activeCount":97},[],{"intervention":16400,"totalTrials":314,"cells":16401},"Olanzapine Fluoxetine Combination",{"EARLY_PHASE1":16402,"PHASE1":16404,"PHASE2":16406,"PHASE3":16408,"PHASE4":16410,"NA":16419},{"trials":16403,"activeCount":97},[],{"trials":16405,"activeCount":97},[],{"trials":16407,"activeCount":97},[],{"trials":16409,"activeCount":97},[],{"trials":16411,"activeCount":97},[16412],{"nctId":16413,"briefTitle":16414,"status":103,"phases":16415,"primaryCompletion":3086,"completion":3086,"start":2846,"enrollment":7081,"conditions":16416,"interventions":16418},"NCT00844857","A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression",[88],[16417],"Bipolar Depression",[16400],{"trials":16420,"activeCount":97},[],{"intervention":15300,"totalTrials":314,"cells":16422},{"EARLY_PHASE1":16423,"PHASE1":16425,"PHASE2":16427,"PHASE3":16429,"PHASE4":16431,"NA":16437},{"trials":16424,"activeCount":97},[],{"trials":16426,"activeCount":97},[],{"trials":16428,"activeCount":97},[],{"trials":16430,"activeCount":97},[],{"trials":16432,"activeCount":97},[16433],{"nctId":15295,"briefTitle":15296,"status":103,"phases":16434,"primaryCompletion":3227,"completion":3227,"start":3592,"enrollment":7363,"conditions":16435,"interventions":16436},[88],[4897,14400,4919],[15300,15301],{"trials":16438,"activeCount":97},[],{"intervention":15269,"totalTrials":314,"cells":16440},{"EARLY_PHASE1":16441,"PHASE1":16443,"PHASE2":16445,"PHASE3":16447,"PHASE4":16449,"NA":16455},{"trials":16442,"activeCount":97},[],{"trials":16444,"activeCount":97},[],{"trials":16446,"activeCount":97},[],{"trials":16448,"activeCount":97},[],{"trials":16450,"activeCount":97},[16451],{"nctId":15264,"briefTitle":15265,"status":103,"phases":16452,"primaryCompletion":5354,"completion":5354,"start":3068,"enrollment":3013,"conditions":16453,"interventions":16454},[88],[14617],[14202,15269,15270,15271,15241,14783],{"trials":16456,"activeCount":97},[],{"intervention":15270,"totalTrials":314,"cells":16458},{"EARLY_PHASE1":16459,"PHASE1":16461,"PHASE2":16463,"PHASE3":16465,"PHASE4":16467,"NA":16473},{"trials":16460,"activeCount":97},[],{"trials":16462,"activeCount":97},[],{"trials":16464,"activeCount":97},[],{"trials":16466,"activeCount":97},[],{"trials":16468,"activeCount":97},[16469],{"nctId":15264,"briefTitle":15265,"status":103,"phases":16470,"primaryCompletion":5354,"completion":5354,"start":3068,"enrollment":3013,"conditions":16471,"interventions":16472},[88],[14617],[14202,15269,15270,15271,15241,14783],{"trials":16474,"activeCount":97},[],{"intervention":15271,"totalTrials":314,"cells":16476},{"EARLY_PHASE1":16477,"PHASE1":16479,"PHASE2":16481,"PHASE3":16483,"PHASE4":16485,"NA":16491},{"trials":16478,"activeCount":97},[],{"trials":16480,"activeCount":97},[],{"trials":16482,"activeCount":97},[],{"trials":16484,"activeCount":97},[],{"trials":16486,"activeCount":97},[16487],{"nctId":15264,"briefTitle":15265,"status":103,"phases":16488,"primaryCompletion":5354,"completion":5354,"start":3068,"enrollment":3013,"conditions":16489,"interventions":16490},[88],[14617],[14202,15269,15270,15271,15241,14783],{"trials":16492,"activeCount":97},[],{"intervention":16494,"totalTrials":314,"cells":16495},"duloxetine HCl",{"EARLY_PHASE1":16496,"PHASE1":16498,"PHASE2":16500,"PHASE3":16502,"PHASE4":16504,"NA":16514},{"trials":16497,"activeCount":97},[],{"trials":16499,"activeCount":97},[],{"trials":16501,"activeCount":97},[],{"trials":16503,"activeCount":97},[],{"trials":16505,"activeCount":97},[16506],{"nctId":16507,"briefTitle":16508,"status":103,"phases":16509,"completion":2947,"start":4221,"enrollment":16510,"conditions":16511,"interventions":16513},"NCT00190905","Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.",[88],4000,[16512],"Stress Urinary Incontinence",[16494],{"trials":16515,"activeCount":97},[],{"intervention":2979,"totalTrials":1548,"cells":16517},{"EARLY_PHASE1":16518,"PHASE1":16520,"PHASE2":16549,"PHASE3":16704,"PHASE4":16722,"NA":16724},{"trials":16519,"activeCount":97},[],{"trials":16521,"activeCount":97},[16522,16526,16534,16542],{"nctId":3441,"briefTitle":3442,"status":103,"phases":16523,"primaryCompletion":3027,"completion":3027,"start":3337,"enrollment":1189,"conditions":16524,"interventions":16525},[85],[3445],[3447,1512],{"nctId":16527,"briefTitle":16528,"status":103,"phases":16529,"primaryCompletion":2798,"completion":4122,"start":8217,"enrollment":1199,"conditions":16530,"interventions":16532},"NCT01388335","A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin",[85],[1503,16531],"Lymphoma, Malignant",[16533,2979],"warfarin",{"nctId":16535,"briefTitle":16536,"status":103,"phases":16537,"primaryCompletion":16538,"completion":16539,"start":5090,"enrollment":893,"conditions":16540,"interventions":16541},"NCT01432951","A Study of Enzastaurin in Chinese Patients With Advanced and\u002For Metastatic Solid Tumors or Lymphoma",[85],"2013-01-11","2018-01-05",[1503,16531],[3447],{"nctId":16543,"briefTitle":16544,"status":103,"phases":16545,"primaryCompletion":3320,"completion":3320,"start":3005,"enrollment":12,"conditions":16546,"interventions":16548},"NCT00452257","A Study of Enzastaurin in Patients With Leukemia",[85],[16547],"Leukemia, Lymphocytic",[2979],{"trials":16550,"activeCount":97},[16551,16555,16559,16565,16569,16573,16580,16584,16588,16594,16598,16602,16606,16613,16619,16623,16627,16634,16638,16642,16646,16656,16662,16668,16677,16683,16690,16694,16700],{"nctId":7682,"briefTitle":7683,"status":103,"phases":16552,"primaryCompletion":3685,"completion":5090,"start":3094,"enrollment":195,"conditions":16553,"interventions":16554},[86],[1490],[3447,2521,4137,3054],{"nctId":3542,"briefTitle":3543,"status":103,"phases":16556,"primaryCompletion":3251,"completion":3545,"start":2930,"enrollment":3546,"conditions":16557,"interventions":16558},[86],[2584,3548,3549],[2979,2561,3222],{"nctId":16560,"briefTitle":16561,"status":103,"phases":16562,"primaryCompletion":4258,"completion":4258,"start":3060,"enrollment":3051,"conditions":16563,"interventions":16564},"NCT00415363","Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy",[86],[1694,3244],[2979],{"nctId":8199,"briefTitle":8200,"status":103,"phases":16566,"primaryCompletion":2955,"completion":2918,"start":4474,"enrollment":8202,"conditions":16567,"interventions":16568},[86],[1903],[2979,3106,8205],{"nctId":3579,"briefTitle":3580,"status":103,"phases":16570,"primaryCompletion":3103,"completion":3103,"start":3235,"enrollment":233,"conditions":16571,"interventions":16572},[86],[1610],[2979,2838,2561,2560],{"nctId":16574,"briefTitle":16575,"status":103,"phases":16576,"primaryCompletion":3114,"completion":2966,"start":2800,"enrollment":6943,"conditions":16577,"interventions":16579},"NCT00718419","A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma",[86],[16578,1114],"Waldenstrom's Macroglobulinemia",[3447],{"nctId":8207,"briefTitle":8208,"status":103,"phases":16581,"primaryCompletion":3086,"completion":3068,"start":3005,"enrollment":2670,"conditions":16582,"interventions":16583},[86],[7766],[2979,4357,5885,3143,8212,8205],{"nctId":3589,"briefTitle":3590,"status":103,"phases":16585,"primaryCompletion":3059,"completion":3059,"start":3592,"enrollment":3593,"conditions":16586,"interventions":16587},[86],[1718],[2979,2838,3106,2561],{"nctId":16589,"briefTitle":16590,"status":103,"phases":16591,"primaryCompletion":3292,"completion":3776,"start":3337,"enrollment":165,"conditions":16592,"interventions":16593},"NCT00420381","Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer",[86],[2584,1870,2901],[2979],{"nctId":5726,"briefTitle":5727,"status":103,"phases":16595,"primaryCompletion":3132,"completion":3132,"start":2975,"enrollment":5729,"conditions":16596,"interventions":16597},[86],[1610],[2979,2838],{"nctId":2971,"briefTitle":2972,"status":999,"phases":16599,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":1548,"conditions":16600,"interventions":16601},[86],[2977],[2979,2838,2839],{"nctId":7696,"briefTitle":7697,"status":103,"phases":16603,"primaryCompletion":4955,"completion":4955,"start":3266,"enrollment":7699,"conditions":16604,"interventions":16605},[86],[7701],[2979,2560,7703,7704],{"nctId":16607,"briefTitle":16608,"status":103,"phases":16609,"completion":3060,"start":3236,"enrollment":2080,"conditions":16610,"interventions":16612},"NCT00190723","A Study of LY317615 in Patients With Brain Tumors",[86],[16611],"Malignant Glioma",[3447],{"nctId":16614,"briefTitle":16615,"status":103,"phases":16616,"primaryCompletion":3114,"completion":3114,"start":3227,"enrollment":233,"conditions":16617,"interventions":16618},"NCT00414960","A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers",[86],[2977],[3447],{"nctId":6808,"briefTitle":6809,"status":999,"phases":16620,"primaryCompletion":3338,"completion":3338,"start":3266,"enrollment":947,"conditions":16621,"interventions":16622},[86],[36],[3447,3054,1669],{"nctId":7783,"briefTitle":7784,"status":103,"phases":16624,"primaryCompletion":3059,"completion":4980,"start":3005,"enrollment":156,"conditions":16625,"interventions":16626},[85,86],[1718,2968],[2979,5810],{"nctId":16628,"briefTitle":16629,"status":103,"phases":16630,"primaryCompletion":3685,"completion":3087,"start":3320,"enrollment":9038,"conditions":16631,"interventions":16633},"NCT00744991","A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma",[86],[16632],"Cutaneous T-Cell Lymphoma",[3447],{"nctId":4299,"briefTitle":4300,"status":103,"phases":16635,"primaryCompletion":3292,"completion":3292,"start":3176,"enrollment":2206,"conditions":16636,"interventions":16637},[86],[2556],[2979,2912],{"nctId":9123,"briefTitle":9124,"status":103,"phases":16639,"primaryCompletion":6883,"completion":6883,"start":3133,"enrollment":1767,"conditions":16640,"interventions":16641},[85,86],[9127,9128,9129],[2979,9131],{"nctId":4350,"briefTitle":4351,"status":103,"phases":16643,"primaryCompletion":3217,"completion":3048,"start":2875,"enrollment":4353,"conditions":16644,"interventions":16645},[86],[4355],[2979,2912,4357,4181],{"nctId":16647,"briefTitle":16648,"status":103,"phases":16649,"primaryCompletion":16650,"completion":16651,"start":16652,"enrollment":1237,"conditions":16653,"interventions":16654},"NCT00709995","A Study for Participants With Metastatic Renal Cell Carcinoma",[86],"2010-02-15","2018-09-05","2008-06-30",[6581],[3447,16655],"Sunitinib",{"nctId":16657,"briefTitle":16658,"status":103,"phases":16659,"primaryCompletion":2864,"completion":3776,"start":3005,"enrollment":1587,"conditions":16660,"interventions":16661},"NCT00475644","A Study of Enzastaurin in Participants With Follicular Lymphoma",[86],[12831],[3447],{"nctId":16663,"briefTitle":16664,"status":103,"phases":16665,"primaryCompletion":3059,"completion":3059,"start":3592,"enrollment":1488,"conditions":16666,"interventions":16667},"NCT00309140","An Open Label Study of Oral Enzastaurin in Participants With Cancer",[86],[1870,2824],[2979],{"nctId":16669,"briefTitle":16670,"status":103,"phases":16671,"primaryCompletion":3419,"completion":16672,"start":3266,"enrollment":3654,"conditions":16673,"interventions":16676},"NCT00542919","A Study for Patients With Non-Hodgkin's Lymphomas",[86],"2018-02-27",[16674,16675],"T-Cell Lymphoma","B-Cell Lymphoma",[2979],{"nctId":16678,"briefTitle":16679,"status":999,"phases":16680,"primaryCompletion":2866,"completion":2866,"start":4642,"enrollment":1302,"conditions":16681,"interventions":16682},"NCT00437294","Enzastaurin in Combination of Capecitabine to Treat Breast Cancer",[86],[36],[2979,4637],{"nctId":16684,"briefTitle":16685,"status":103,"phases":16686,"primaryCompletion":3292,"completion":3292,"start":2938,"enrollment":874,"conditions":16687,"interventions":16689},"NCT00088205","Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma",[86],[16688],"Mantle-Cell Lymphoma",[2979],{"nctId":8808,"briefTitle":8809,"status":103,"phases":16691,"primaryCompletion":2929,"completion":2929,"start":4642,"enrollment":893,"conditions":16692,"interventions":16693},[86],[1490,2586,8812],[2979,5659,3540],{"nctId":16695,"briefTitle":16696,"status":103,"phases":16697,"primaryCompletion":5860,"completion":4258,"start":3337,"enrollment":93,"conditions":16698,"interventions":16699},"NCT00428714","Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy",[86],[1903],[2979],{"nctId":3892,"briefTitle":3893,"status":103,"phases":16701,"primaryCompletion":3895,"completion":3896,"start":3897,"enrollment":1606,"conditions":16702,"interventions":16703},[86],[36],[2979,3900],{"trials":16705,"activeCount":97},[16706,16714],{"nctId":16707,"briefTitle":16708,"status":103,"phases":16709,"primaryCompletion":3348,"completion":3027,"start":3524,"enrollment":16710,"conditions":16711,"interventions":16713},"NCT00332202","PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin",[87],758,[16712],"Non Hodgkin Lymphoma",[2979],{"nctId":16715,"briefTitle":16716,"status":103,"phases":16717,"primaryCompletion":3813,"completion":4098,"start":13847,"enrollment":16718,"conditions":16719,"interventions":16720},"NCT00295815","Enzastaurin Versus Lomustine in Glioblastoma",[87],397,[9127],[2979,16721],"lomustine",{"trials":16723,"activeCount":97},[],{"trials":16725,"activeCount":97},[],{"intervention":9698,"totalTrials":1620,"cells":16727},{"EARLY_PHASE1":16728,"PHASE1":16730,"PHASE2":16820,"PHASE3":16830,"PHASE4":16860,"NA":16862},{"trials":16729,"activeCount":97},[],{"trials":16731,"activeCount":97},[16732,16736,16740,16744,16748,16752,16756,16760,16764,16768,16772,16778,16782,16786,16790,16794,16798,16802,16806,16810,16816],{"nctId":12849,"briefTitle":12850,"status":103,"phases":16733,"primaryCompletion":12852,"completion":12852,"start":12853,"enrollment":310,"conditions":16734,"interventions":16735},[85],[33],[9698,438],{"nctId":12866,"briefTitle":12867,"status":103,"phases":16737,"primaryCompletion":12869,"completion":12869,"start":12870,"enrollment":214,"conditions":16738,"interventions":16739},[85],[33],[9698,438],{"nctId":12884,"briefTitle":12885,"status":103,"phases":16741,"primaryCompletion":12887,"completion":12887,"start":12888,"enrollment":137,"conditions":16742,"interventions":16743},[85],[18],[9698,438],{"nctId":12901,"briefTitle":12902,"status":103,"phases":16745,"primaryCompletion":3697,"completion":1618,"start":5030,"enrollment":864,"conditions":16746,"interventions":16747},[85],[21],[9698,438],{"nctId":12907,"briefTitle":12908,"status":103,"phases":16749,"primaryCompletion":1546,"completion":1546,"start":2799,"enrollment":1488,"conditions":16750,"interventions":16751},[85],[15],[12912,9698,438],{"nctId":12914,"briefTitle":12915,"status":103,"phases":16753,"primaryCompletion":12917,"completion":12917,"start":12918,"enrollment":1158,"conditions":16754,"interventions":16755},[85],[15],[9698,438],{"nctId":12922,"briefTitle":12923,"status":103,"phases":16757,"primaryCompletion":12925,"completion":6243,"start":12926,"enrollment":1178,"conditions":16758,"interventions":16759},[85],[33],[9698,438],{"nctId":12930,"briefTitle":12931,"status":103,"phases":16761,"primaryCompletion":12933,"completion":12933,"start":365,"enrollment":4475,"conditions":16762,"interventions":16763},[85],[33],[9698,438],{"nctId":12937,"briefTitle":12938,"status":103,"phases":16765,"primaryCompletion":3250,"completion":3250,"start":1474,"enrollment":290,"conditions":16766,"interventions":16767},[85],[15],[9698,438],{"nctId":12963,"briefTitle":12964,"status":103,"phases":16769,"primaryCompletion":1628,"completion":1628,"start":7775,"enrollment":1620,"conditions":16770,"interventions":16771},[85],[18],[9698,438],{"nctId":16773,"briefTitle":16774,"status":103,"phases":16775,"primaryCompletion":5071,"completion":5071,"start":7032,"enrollment":165,"conditions":16776,"interventions":16777},"NCT03232983","A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants",[85],[18],[9698,9698],{"nctId":12969,"briefTitle":12970,"status":103,"phases":16779,"primaryCompletion":7547,"completion":7547,"start":6651,"enrollment":4475,"conditions":16780,"interventions":16781},[85],[33],[9698,438,12974,12974],{"nctId":12976,"briefTitle":12977,"status":103,"phases":16783,"primaryCompletion":1627,"completion":1627,"start":2754,"enrollment":310,"conditions":16784,"interventions":16785},[85],[15],[9698,438],{"nctId":13000,"briefTitle":13001,"status":103,"phases":16787,"primaryCompletion":1547,"completion":1547,"start":3123,"enrollment":893,"conditions":16788,"interventions":16789},[85],[15],[9698,7104],{"nctId":13006,"briefTitle":13007,"status":103,"phases":16791,"primaryCompletion":13009,"completion":13009,"start":13010,"enrollment":6943,"conditions":16792,"interventions":16793},[85],[9437],[9698,438],{"nctId":13014,"briefTitle":13015,"status":103,"phases":16795,"primaryCompletion":921,"completion":921,"start":13017,"enrollment":290,"conditions":16796,"interventions":16797},[85],[33],[9698,438],{"nctId":13021,"briefTitle":13022,"status":103,"phases":16799,"primaryCompletion":1546,"completion":1546,"start":7775,"enrollment":1620,"conditions":16800,"interventions":16801},[85],[33],[9698,438],{"nctId":13027,"briefTitle":13028,"status":103,"phases":16803,"primaryCompletion":1628,"completion":1628,"start":7775,"enrollment":1620,"conditions":16804,"interventions":16805},[85],[33],[9698,438],{"nctId":13033,"briefTitle":13034,"status":103,"phases":16807,"primaryCompletion":13036,"completion":13036,"start":12870,"enrollment":214,"conditions":16808,"interventions":16809},[85],[18],[9698,438],{"nctId":16811,"briefTitle":16812,"status":103,"phases":16813,"primaryCompletion":2799,"completion":2799,"start":3028,"enrollment":290,"conditions":16814,"interventions":16815},"NCT02752087","A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants",[85],[15],[9698],{"nctId":13040,"briefTitle":13041,"status":103,"phases":16817,"primaryCompletion":13043,"completion":13043,"start":13044,"enrollment":280,"conditions":16818,"interventions":16819},[85],[18],[9698,438],{"trials":16821,"activeCount":97},[16822,16826],{"nctId":13050,"briefTitle":13051,"status":103,"phases":16823,"primaryCompletion":13053,"completion":13053,"start":13054,"enrollment":137,"conditions":16824,"interventions":16825},[86],[12863],[9698,438],{"nctId":11247,"briefTitle":11248,"status":103,"phases":16827,"primaryCompletion":7332,"completion":7332,"start":1714,"enrollment":1178,"conditions":16828,"interventions":16829},[86],[466],[9698,700],{"trials":16831,"activeCount":97},[16832,16836,16840,16844,16848,16852,16856],{"nctId":13060,"briefTitle":13061,"status":103,"phases":16833,"primaryCompletion":13063,"completion":13063,"start":7362,"enrollment":3309,"conditions":16834,"interventions":16835},[87],[13065],[9698,7104],{"nctId":11271,"briefTitle":11272,"status":103,"phases":16837,"primaryCompletion":11274,"completion":11274,"start":11275,"enrollment":743,"conditions":16838,"interventions":16839},[87],[9437],[9698,438,506,700],{"nctId":9690,"briefTitle":9691,"status":103,"phases":16841,"primaryCompletion":7547,"completion":9693,"start":9694,"enrollment":9695,"conditions":16842,"interventions":16843},[87],[120],[9698,438,506,700,1631,7063],{"nctId":11309,"briefTitle":11310,"status":103,"phases":16845,"primaryCompletion":11312,"completion":5129,"start":11313,"enrollment":11314,"conditions":16846,"interventions":16847},[87],[9437],[9698,438,506,700],{"nctId":13606,"briefTitle":13607,"status":103,"phases":16849,"primaryCompletion":13609,"completion":13609,"start":13610,"enrollment":2919,"conditions":16850,"interventions":16851},[87],[30],[9698,506],{"nctId":11318,"briefTitle":11319,"status":103,"phases":16853,"primaryCompletion":1882,"completion":1882,"start":11321,"enrollment":11322,"conditions":16854,"interventions":16855},[87],[120],[9698,438,506,700],{"nctId":11326,"briefTitle":11327,"status":103,"phases":16857,"primaryCompletion":9249,"completion":9249,"start":11329,"enrollment":11330,"conditions":16858,"interventions":16859},[87],[9437],[9698,438,506,700],{"trials":16861,"activeCount":97},[],{"trials":16863,"activeCount":97},[],{"intervention":13957,"totalTrials":893,"cells":16865},{"EARLY_PHASE1":16866,"PHASE1":16868,"PHASE2":16970,"PHASE3":16983,"PHASE4":17041,"NA":17043},{"trials":16867,"activeCount":97},[],{"trials":16869,"activeCount":97},[16870,16876,16883,16890,16897,16903,16910,16918,16924,16928,16932,16938,16945,16951,16957,16964],{"nctId":16871,"briefTitle":16872,"status":103,"phases":16873,"primaryCompletion":3069,"completion":3069,"start":8233,"enrollment":214,"conditions":16874,"interventions":16875},"NCT01241435","A Study of LY2216684 in Participants With Impaired Hepatic Function",[85],[4937],[13957],{"nctId":16877,"briefTitle":16878,"status":103,"phases":16879,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":128,"conditions":16880,"interventions":16881},"NCT01263093","A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel",[85],[13955],[16882,13957],"Clopidogrel",{"nctId":16884,"briefTitle":16885,"status":103,"phases":16886,"primaryCompletion":3494,"completion":3494,"start":6093,"enrollment":6633,"conditions":16887,"interventions":16888},"NCT01389752","A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects",[85],[4937],[13957,16889],"Activated Charcoal",{"nctId":16891,"briefTitle":16892,"status":103,"phases":16893,"primaryCompletion":3494,"completion":3494,"start":3020,"enrollment":165,"conditions":16894,"interventions":16895},"NCT01380691","A Study of LY2216684 in Healthy Participants",[85],[13955],[13957,16896],"Alcoholic beverage",{"nctId":16898,"briefTitle":16899,"status":103,"phases":16900,"primaryCompletion":3283,"completion":3283,"start":3152,"enrollment":1620,"conditions":16901,"interventions":16902},"NCT01266590","A Study of LY2216684 and Digoxin in Healthy Subjects",[85],[13955],[13957,1093],{"nctId":16904,"briefTitle":16905,"status":103,"phases":16906,"primaryCompletion":4258,"completion":4258,"start":3152,"enrollment":11639,"conditions":16907,"interventions":16908},"NCT01263106","A Study of LY2216684 and Theophylline in Healthy Subjects",[85],[13955],[13957,16909],"Theophylline",{"nctId":16911,"briefTitle":16912,"status":103,"phases":16913,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":118,"conditions":16914,"interventions":16915},"NCT01263197","A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",[85],[13955],[13957,16916,16917],"albuterol","propranolol",{"nctId":16919,"briefTitle":16920,"status":103,"phases":16921,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":290,"conditions":16922,"interventions":16923},"NCT01263223","A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors",[85],[13955],[13957],{"nctId":14963,"briefTitle":14964,"status":103,"phases":16925,"primaryCompletion":4258,"completion":4258,"start":3029,"enrollment":1082,"conditions":16926,"interventions":16927},[85],[13955],[13957,13900],{"nctId":13951,"briefTitle":13952,"status":103,"phases":16929,"primaryCompletion":4258,"completion":4258,"start":8233,"enrollment":1082,"conditions":16930,"interventions":16931},[85],[13955],[13957,13944],{"nctId":16933,"briefTitle":16934,"status":103,"phases":16935,"primaryCompletion":4160,"completion":4160,"start":3004,"enrollment":1062,"conditions":16936,"interventions":16937},"NCT01460407","A Study to Evaluate the Effect of Clarithromycin on LY2216684",[85],[4937],[13957,1480],{"nctId":16939,"briefTitle":16940,"status":103,"phases":16941,"primaryCompletion":4160,"completion":4160,"start":3020,"enrollment":1082,"conditions":16942,"interventions":16943},"NCT01373931","A Study of LY2216684 in Healthy Females",[85],[4937],[13957,16944],"Ortho Cyclen",{"nctId":16946,"briefTitle":16947,"status":103,"phases":16948,"primaryCompletion":3283,"completion":3283,"start":3152,"enrollment":12,"conditions":16949,"interventions":16950},"NCT01263119","A Study of LY2216684 and Warfarin in Healthy Subjects",[85],[13955],[1172,13957],{"nctId":16952,"briefTitle":16953,"status":103,"phases":16954,"primaryCompletion":8217,"completion":8217,"start":6093,"enrollment":290,"conditions":16955,"interventions":16956},"NCT01389765","A Study to Evaluate the Effect of Food on LY2216684",[85],[4937],[13957],{"nctId":16958,"briefTitle":16959,"status":103,"phases":16960,"primaryCompletion":3283,"completion":3283,"start":3152,"enrollment":165,"conditions":16961,"interventions":16962},"NCT01275144","A Study of the Effect of LY2216684 on Lorazepam",[85],[13955],[13957,16963],"Lorazepam",{"nctId":16965,"briefTitle":16966,"status":103,"phases":16967,"primaryCompletion":2966,"completion":2966,"start":3004,"enrollment":12,"conditions":16968,"interventions":16969},"NCT01460381","A Study to Evaluate the Effect of Genotype on LY2216684",[85],[4937],[13957,2074],{"trials":16971,"activeCount":97},[16972,16976],{"nctId":14496,"briefTitle":14497,"status":103,"phases":16973,"primaryCompletion":3338,"completion":3338,"start":3060,"enrollment":474,"conditions":16974,"interventions":16975},[86],[13955],[13957,14480],{"nctId":16977,"briefTitle":16978,"status":103,"phases":16979,"primaryCompletion":3685,"completion":3685,"start":3103,"enrollment":16980,"conditions":16981,"interventions":16982},"NCT00840034","A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder",[86],227,[4937],[13957],{"trials":16984,"activeCount":97},[16985,16991,16998,17007,17014,17021,17028,17034],{"nctId":16986,"briefTitle":16987,"status":103,"phases":16988,"primaryCompletion":3087,"completion":3837,"start":2928,"enrollment":2551,"conditions":16989,"interventions":16990},"NCT00795821","A Study in Adult Patients With Major Depressive Disorder",[86,87],[4937],[13957],{"nctId":16992,"briefTitle":16993,"status":103,"phases":16994,"primaryCompletion":3152,"completion":3152,"start":5860,"enrollment":2630,"conditions":16995,"interventions":16996},"NCT00922636","A Study of Pediatric Patients With Attention Deficit\u002FHyperactivity Disorder",[86,87],[13785],[13957,16997],"Methylphenidate",{"nctId":16999,"briefTitle":17000,"status":103,"phases":17001,"primaryCompletion":2917,"completion":2917,"start":3837,"enrollment":17002,"conditions":17003,"interventions":17005},"NCT01187407","A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment",[87],1480,[17004],"Major Depressive Disorder (MDD)",[13957,17006],"SSRI",{"nctId":17008,"briefTitle":17009,"status":103,"phases":17010,"primaryCompletion":4955,"completion":4955,"start":3029,"enrollment":17011,"conditions":17012,"interventions":17013},"NCT01173601","A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder",[87],1416,[13955],[13957,17006],{"nctId":17015,"briefTitle":17016,"status":103,"phases":17017,"primaryCompletion":4122,"completion":4122,"start":8233,"enrollment":17018,"conditions":17019,"interventions":17020},"NCT01155661","A Safety Study in Participants With Major Depressive Disorder",[87],608,[4937],[13957,17006],{"nctId":17022,"briefTitle":17023,"status":103,"phases":17024,"primaryCompletion":3348,"completion":3348,"start":3837,"enrollment":17025,"conditions":17026,"interventions":17027},"NCT01185340","A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor",[87],1056,[13955],[13957,17006],{"nctId":17029,"briefTitle":17030,"status":103,"phases":17031,"primaryCompletion":3112,"completion":3112,"start":8217,"enrollment":9283,"conditions":17032,"interventions":17033},"NCT01370499","A Study of LY2216684 in Participants With Major Depression Disorder",[87],[13955],[13957,17006],{"nctId":17035,"briefTitle":17036,"status":103,"phases":17037,"primaryCompletion":4980,"completion":4980,"start":2844,"enrollment":17038,"conditions":17039,"interventions":17040},"NCT01299272","A Study in Prevention of Re-emergence of Depression Symptoms",[87],1249,[13955],[13957,17006],{"trials":17042,"activeCount":97},[],{"trials":17044,"activeCount":97},[],{"intervention":17046,"totalTrials":9038,"cells":17047},"Lasmiditan",{"EARLY_PHASE1":17048,"PHASE1":17050,"PHASE2":17194,"PHASE3":17218,"PHASE4":17252,"NA":17254},{"trials":17049,"activeCount":97},[],{"trials":17051,"activeCount":97},[17052,17061,17069,17076,17082,17090,17098,17105,17114,17123,17131,17138,17145,17153,17162,17171,17180,17186],{"nctId":17053,"briefTitle":17054,"status":103,"phases":17055,"primaryCompletion":17056,"completion":17056,"start":17057,"enrollment":963,"conditions":17058,"interventions":17059},"NCT03012334","The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants",[85],"2017-06-08","2017-01-16",[7486],[17046,17060],"Alprazolam",{"nctId":17062,"briefTitle":17063,"status":103,"phases":17064,"primaryCompletion":8268,"completion":8268,"start":17065,"enrollment":1071,"conditions":17066,"interventions":17068},"NCT03247790","A Study of Lasmiditan in Participants With Migraine",[85],"2017-08-16",[17067],"Migraine Disorders",[17046],{"nctId":17070,"briefTitle":17071,"status":103,"phases":17072,"primaryCompletion":7032,"completion":7032,"start":17073,"enrollment":1548,"conditions":17074,"interventions":17075},"NCT03182920","A Study of Lasmiditan in Healthy Participants",[85],"2017-06-16",[15],[17046],{"nctId":17077,"briefTitle":17078,"status":103,"phases":17079,"primaryCompletion":1498,"completion":1498,"start":5169,"enrollment":2071,"conditions":17080,"interventions":17081},"NCT03579940","A Study of Lasmiditan in Healthy Japanese and Caucasian Participants",[85],[15],[17046],{"nctId":17083,"briefTitle":17084,"status":103,"phases":17085,"primaryCompletion":17086,"completion":17086,"start":17087,"enrollment":128,"conditions":17088,"interventions":17089},"NCT04881747","A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants",[85],"2021-07-24","2021-05-14",[15],[17046],{"nctId":17091,"briefTitle":17092,"status":103,"phases":17093,"primaryCompletion":17094,"completion":17094,"start":17095,"enrollment":214,"conditions":17096,"interventions":17097},"NCT03406260","A Study of Lasmiditan in Healthy Elderly Participants",[85],"2018-04-13","2018-01-25",[15],[17046],{"nctId":17099,"briefTitle":17100,"status":103,"phases":17101,"primaryCompletion":12925,"completion":12925,"start":13010,"enrollment":4353,"conditions":17102,"interventions":17103},"NCT03459612","A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants",[85],[15],[17046,17104],"Diphenhydramine",{"nctId":17106,"briefTitle":17107,"status":103,"phases":17108,"primaryCompletion":17109,"completion":17109,"start":17110,"enrollment":233,"conditions":17111,"interventions":17112},"NCT03310411","A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants",[85],"2017-12-23","2017-10-17",[15],[17046,17113],"Sumatriptan",{"nctId":17115,"briefTitle":17116,"status":103,"phases":17117,"primaryCompletion":17118,"completion":17118,"start":17119,"enrollment":37,"conditions":17120,"interventions":17121},"NCT03270644","A Study of Lasmiditan and Propranolol in Healthy Participants",[85],"2017-11-22","2017-08-31",[15],[17046,17122],"Propranolol",{"nctId":17124,"briefTitle":17125,"status":103,"phases":17126,"primaryCompletion":17127,"completion":17127,"start":17128,"enrollment":1071,"conditions":17129,"interventions":17130},"NCT03009162","Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function",[85],"2017-06-02","2017-04-01",[7486],[17046],{"nctId":17132,"briefTitle":17133,"status":103,"phases":17134,"primaryCompletion":1379,"completion":1379,"start":17135,"enrollment":214,"conditions":17136,"interventions":17137},"NCT04081324","A Study of Lasmiditan in Healthy Chinese Participants",[85],"2019-11-13",[15],[17046],{"nctId":17139,"briefTitle":17140,"status":103,"phases":17141,"primaryCompletion":17142,"completion":136,"start":309,"enrollment":12,"conditions":17143,"interventions":17144},"NCT03988088","A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine",[85],"2020-01-19",[7486],[17046],{"nctId":17146,"briefTitle":17147,"status":103,"phases":17148,"primaryCompletion":17149,"completion":17149,"start":676,"enrollment":6509,"conditions":17150,"interventions":17151},"NCT04749914","A Study of Lasmiditan in Healthy Volunteers",[85],"2021-07-06",[15],[17046,17152,2093],"Dabigatran Etexilate",{"nctId":17154,"briefTitle":17155,"status":103,"phases":17156,"primaryCompletion":17157,"completion":17157,"start":17158,"enrollment":2790,"conditions":17159,"interventions":17160},"NCT03252015","A Study of Multiple Doses of Lasmiditan in Healthy Participants",[85],"2018-01-02","2017-08-15",[15],[17161,17046],"Probe Drug Cocktail",{"nctId":17163,"briefTitle":17164,"status":103,"phases":17165,"primaryCompletion":17166,"completion":17166,"start":56,"enrollment":107,"conditions":17167,"interventions":17170},"NCT03286218","A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users",[85],"2017-11-20",[17168,17169],"Recreational Drug Use","Prescription Drug Abuse (Not Dependent)",[17046,17060],{"nctId":17172,"briefTitle":17173,"status":103,"phases":17174,"primaryCompletion":17175,"completion":17175,"start":17176,"enrollment":1620,"conditions":17177,"interventions":17178},"NCT03308669","A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate",[85],"2017-12-02","2017-10-16",[15],[17046,17179],"Topiramate",{"nctId":17181,"briefTitle":17182,"status":103,"phases":17183,"primaryCompletion":1473,"completion":1596,"start":5030,"enrollment":1620,"conditions":17184,"interventions":17185},"NCT02233296","Food-Effect Study in Healthy Participants",[85],[15],[17046],{"nctId":17187,"briefTitle":17188,"status":103,"phases":17189,"primaryCompletion":17190,"completion":17190,"start":17191,"enrollment":6943,"conditions":17192,"interventions":17193},"NCT03465436","A Study of Lasmiditan on the Heart in Healthy Participants",[85],"2011-12-20","2011-09-16",[15],[17046,17046,1181],{"trials":17195,"activeCount":97},[17196,17202,17209],{"nctId":17197,"briefTitle":17198,"status":103,"phases":17199,"primaryCompletion":4474,"completion":4474,"start":2930,"enrollment":2206,"conditions":17200,"interventions":17201},"NCT00384774","A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine",[86],[7486],[17046],{"nctId":17203,"briefTitle":17204,"status":103,"phases":17205,"primaryCompletion":3087,"completion":3087,"start":3059,"enrollment":17206,"conditions":17207,"interventions":17208},"NCT00883051","Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment",[86],512,[17067],[17046],{"nctId":17210,"briefTitle":17211,"status":103,"phases":17212,"primaryCompletion":17213,"completion":17213,"start":17214,"enrollment":17215,"conditions":17216,"interventions":17217},"NCT03962738","A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine",[86],"2020-06-08","2019-05-31",846,[7486],[17046],{"trials":17219,"activeCount":97},[17220,17228,17237,17244],{"nctId":17221,"briefTitle":17222,"status":999,"phases":17223,"primaryCompletion":17224,"completion":17224,"start":1379,"enrollment":17225,"conditions":17226,"interventions":17227},"NCT04396236","A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",[87],"2025-11-12",851,[7486],[17046],{"nctId":17229,"briefTitle":17230,"status":103,"phases":17231,"primaryCompletion":17232,"completion":17232,"start":17233,"enrollment":17234,"conditions":17235,"interventions":17236},"NCT02565186","An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine",[87],"2019-08-20","2015-10-07",2171,[17067],[17046],{"nctId":17238,"briefTitle":17239,"status":999,"phases":17240,"primaryCompletion":17241,"completion":17241,"start":6678,"enrollment":7439,"conditions":17242,"interventions":17243},"NCT04396574","A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",[87],"2025-12-04",[7486],[17046],{"nctId":17245,"briefTitle":17246,"status":103,"phases":17247,"primaryCompletion":5281,"completion":9963,"start":17248,"enrollment":17249,"conditions":17250,"interventions":17251},"NCT03670810","A Study of Lasmiditan (LY573144) Over Four Migraine Attacks",[87],"2019-06-24",1633,[7486],[17046],{"trials":17253,"activeCount":97},[],{"trials":17255,"activeCount":97},[],{"intervention":17257,"totalTrials":11639,"cells":17258},"Evacetrapib",{"EARLY_PHASE1":17259,"PHASE1":17261,"PHASE2":17369,"PHASE3":17371,"PHASE4":17402,"NA":17404},{"trials":17260,"activeCount":97},[],{"trials":17262,"activeCount":97},[17263,17269,17275,17282,17288,17294,17300,17307,17313,17319,17325,17331,17337,17343,17349,17356,17363],{"nctId":17264,"briefTitle":17265,"status":103,"phases":17266,"primaryCompletion":5022,"completion":5022,"start":3027,"enrollment":893,"conditions":17267,"interventions":17268},"NCT01908582","A Study of Evacetrapib and Rifampin in Healthy Participants",[85],[21],[17257,6219],{"nctId":17270,"briefTitle":17271,"status":103,"phases":17272,"primaryCompletion":2964,"completion":2964,"start":3348,"enrollment":1237,"conditions":17273,"interventions":17274},"NCT01825876","A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants",[85],[21],[17257,1172],{"nctId":17276,"briefTitle":17277,"status":103,"phases":17278,"primaryCompletion":4420,"completion":4420,"start":4122,"enrollment":290,"conditions":17279,"interventions":17280},"NCT01736254","A Study of Evacetrapib in Healthy Participants",[85],[21],[17257,17281],"Gemfibrozil",{"nctId":17283,"briefTitle":17284,"status":103,"phases":17285,"primaryCompletion":3282,"completion":3282,"start":4122,"enrollment":1488,"conditions":17286,"interventions":17287},"NCT01746732","A Study of Evacetrapib in Healthy Female Participants",[85],[21],[6966,17257],{"nctId":17289,"briefTitle":17290,"status":103,"phases":17291,"primaryCompletion":4383,"completion":4383,"start":4097,"enrollment":2347,"conditions":17292,"interventions":17293},"NCT02497391","A Study of Different Particle Sizes of Evacetrapib in Healthy Participants",[85],[15],[17257],{"nctId":17295,"briefTitle":17296,"status":103,"phases":17297,"primaryCompletion":3697,"completion":3697,"start":5030,"enrollment":3718,"conditions":17298,"interventions":17299},"NCT02365558","A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants",[85],[15],[17257,1171],{"nctId":17301,"briefTitle":17302,"status":103,"phases":17303,"primaryCompletion":3123,"completion":3123,"start":4098,"enrollment":2670,"conditions":17304,"interventions":17306},"NCT02168803","A Study of Evacetrapib in Participants With Abnormal Cholesterol",[85],[17305],"Dyslipidemia",[17257],{"nctId":17308,"briefTitle":17309,"status":103,"phases":17310,"primaryCompletion":4955,"completion":4955,"start":3348,"enrollment":1082,"conditions":17311,"interventions":17312},"NCT01825889","A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants",[85],[7156],[17257],{"nctId":17314,"briefTitle":17315,"status":103,"phases":17316,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":28,"conditions":17317,"interventions":17318},"NCT02156492","A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants",[85],[21],[17257,2092,9237],{"nctId":17320,"briefTitle":17321,"status":103,"phases":17322,"primaryCompletion":2845,"completion":2845,"start":5354,"enrollment":290,"conditions":17323,"interventions":17324},"NCT02161731","Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants",[85],[21],[17257,1172],{"nctId":17326,"briefTitle":17327,"status":103,"phases":17328,"primaryCompletion":3697,"completion":3697,"start":2845,"enrollment":118,"conditions":17329,"interventions":17330},"NCT02226653","A Study of Evacetrapib in Healthy Japanese Participants",[85],[21],[17257],{"nctId":17332,"briefTitle":17333,"status":103,"phases":17334,"primaryCompletion":4955,"completion":4955,"start":3348,"enrollment":310,"conditions":17335,"interventions":17336},"NCT01836185","A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment",[85],[312],[17257],{"nctId":17338,"briefTitle":17339,"status":103,"phases":17340,"primaryCompletion":5022,"completion":5022,"start":3027,"enrollment":1071,"conditions":17341,"interventions":17342},"NCT01897493","A Study of Evacetrapib and Digoxin in Healthy Participants",[85],[21],[17257,1093],{"nctId":17344,"briefTitle":17345,"status":103,"phases":17346,"primaryCompletion":4980,"completion":4980,"start":3027,"enrollment":874,"conditions":17347,"interventions":17348},"NCT01903434","A Study of Evacetrapib (LY2484595) in Healthy Participants",[85],[21],[17257],{"nctId":17350,"briefTitle":17351,"status":103,"phases":17352,"primaryCompletion":3112,"completion":3112,"start":4955,"enrollment":290,"conditions":17353,"interventions":17354},"NCT01958489","A Study of Evacetrapib in Japanese and Non-Japanese Participants",[85],[21],[17257,17355],"Pravastatin",{"nctId":17357,"briefTitle":17358,"status":103,"phases":17359,"primaryCompletion":3319,"completion":3319,"start":3318,"enrollment":4323,"conditions":17360,"interventions":17361},"NCT02271425","A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants",[85],[21],[17257,17362],"Evacetrapib Intravenous",{"nctId":17364,"briefTitle":17365,"status":103,"phases":17366,"primaryCompletion":2964,"completion":2964,"start":3124,"enrollment":233,"conditions":17367,"interventions":17368},"NCT01810432","Study of Food on Evacetrapib (LY2484595) in Healthy Participants",[85],[21],[17257],{"trials":17370,"activeCount":97},[],{"trials":17372,"activeCount":97},[17373,17381,17388,17396],{"nctId":17374,"briefTitle":17375,"status":999,"phases":17376,"primaryCompletion":4383,"completion":4383,"start":5030,"enrollment":7363,"conditions":17377,"interventions":17379},"NCT02260648","A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia",[87],[17378],"Hypercholesterolemia",[17257,17380,9237],"Ezetimibe",{"nctId":17382,"briefTitle":17383,"status":999,"phases":17384,"primaryCompletion":7775,"completion":1546,"start":2798,"enrollment":17385,"conditions":17386,"interventions":17387},"NCT01687998","A Study of Evacetrapib in High-Risk Vascular Disease",[87],12092,[2307],[17257],{"nctId":17389,"briefTitle":17390,"status":999,"phases":17391,"primaryCompletion":3123,"completion":3123,"start":3318,"enrollment":17392,"conditions":17393,"interventions":17395},"NCT02227784","A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol",[87],366,[17394],"Hyperlipidemia",[17257,9237,17380],{"nctId":17397,"briefTitle":17398,"status":999,"phases":17399,"primaryCompletion":4097,"completion":3123,"start":3319,"enrollment":31,"conditions":17400,"interventions":17401},"NCT02260635","A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia",[87],[17378],[17257],{"trials":17403,"activeCount":97},[],{"trials":17405,"activeCount":97},[],{"intervention":17407,"totalTrials":2733,"cells":17408},"Prasugrel",{"EARLY_PHASE1":17409,"PHASE1":17411,"PHASE2":17456,"PHASE3":17511,"PHASE4":17549,"NA":17551},{"trials":17410,"activeCount":97},[],{"trials":17412,"activeCount":97},[17413,17423,17430,17437,17444,17450],{"nctId":17414,"briefTitle":17415,"status":103,"phases":17416,"primaryCompletion":3004,"completion":3004,"start":3419,"enrollment":17417,"conditions":17418,"interventions":17420},"NCT01107912","Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease",[85],155,[17419],"Coronary Artery Disease",[17421,17422],"prasugrel","clopidogrel",{"nctId":17424,"briefTitle":17425,"status":103,"phases":17426,"primaryCompletion":3004,"completion":3004,"start":3494,"enrollment":12,"conditions":17427,"interventions":17429},"NCT01430091","A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet",[85],[17428],"Sickle Cell Disease",[17407,17407],{"nctId":17431,"briefTitle":17432,"status":103,"phases":17433,"primaryCompletion":4258,"completion":4258,"start":2899,"enrollment":893,"conditions":17434,"interventions":17436},"NCT01178099","An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults",[85],[17435],"Anemia, Sickle Cell",[17407],{"nctId":17438,"briefTitle":17439,"status":999,"phases":17440,"primaryCompletion":3152,"completion":3152,"start":3050,"enrollment":864,"conditions":17441,"interventions":17443},"NCT01107899","Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes",[85],[17442],"Acute Coronary Syndromes",[17422,17421],{"nctId":17445,"briefTitle":17446,"status":103,"phases":17447,"primaryCompletion":8217,"completion":8217,"start":3419,"enrollment":1767,"conditions":17448,"interventions":17449},"NCT01107925","Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease",[85],[17419],[17421,17422],{"nctId":17451,"briefTitle":17452,"status":103,"phases":17453,"primaryCompletion":2929,"completion":2929,"start":2866,"enrollment":1620,"conditions":17454,"interventions":17455},"NCT01591317","Study of Prasugrel in Korean Healthy Male Volunteers",[85],[21],[17407],{"trials":17457,"activeCount":97},[17458,17465,17472,17478,17484,17492,17499,17505],{"nctId":17459,"briefTitle":17460,"status":103,"phases":17461,"primaryCompletion":3020,"completion":3020,"start":2899,"enrollment":28,"conditions":17462,"interventions":17464},"NCT01167023","Prasugrel Versus Placebo in Adult Sickle Cell Disease",[86],[17463],"Sickle Cell Anemia",[17407],{"nctId":17466,"briefTitle":17467,"status":103,"phases":17468,"primaryCompletion":5090,"completion":5090,"start":2956,"enrollment":820,"conditions":17469,"interventions":17471},"NCT01115738","Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients",[86],[17470],"Acute Coronary Syndrome",[17407,16882],{"nctId":17473,"briefTitle":17474,"status":103,"phases":17475,"primaryCompletion":3048,"completion":3048,"start":5090,"enrollment":5015,"conditions":17476,"interventions":17477},"NCT01476696","A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease",[86],[17428],[17407],{"nctId":17479,"briefTitle":17480,"status":103,"phases":17481,"primaryCompletion":3662,"completion":3662,"start":2995,"enrollment":1548,"conditions":17482,"interventions":17483},"NCT00642174","Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)",[86],[620,17419],[17421,16882],{"nctId":17485,"briefTitle":17486,"status":999,"phases":17487,"primaryCompletion":3069,"completion":3069,"start":3059,"enrollment":17488,"conditions":17489,"interventions":17491},"NCT00910299","Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)",[86],423,[17490],"Coronary Artery Disease (CAD)",[17407,16882],{"nctId":17493,"briefTitle":17494,"status":103,"phases":17495,"primaryCompletion":4448,"completion":4448,"start":3195,"enrollment":464,"conditions":17496,"interventions":17498},"NCT00059215","A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)",[86],[2307,17497],"Heart Diseases",[17407,16882],{"nctId":17500,"briefTitle":17501,"status":103,"phases":17502,"primaryCompletion":3235,"completion":3235,"start":4642,"enrollment":6943,"conditions":17503,"interventions":17504},"NCT00385944","The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)",[86],[17470],[17407,16882],{"nctId":17506,"briefTitle":17507,"status":103,"phases":17508,"primaryCompletion":4474,"completion":4474,"start":2855,"enrollment":7353,"conditions":17509,"interventions":17510},"NCT00357968","Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting",[86],[17419],[17407,16882],{"trials":17512,"activeCount":97},[17513,17519,17526,17534,17542],{"nctId":17514,"briefTitle":17515,"status":999,"phases":17516,"primaryCompletion":4097,"completion":3123,"start":3348,"enrollment":7288,"conditions":17517,"interventions":17518},"NCT01794000","A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)",[87],[17428],[17407],{"nctId":17520,"briefTitle":17521,"status":103,"phases":17522,"primaryCompletion":3068,"completion":4420,"start":6883,"enrollment":17523,"conditions":17524,"interventions":17525},"NCT01015287","A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction",[87],4033,[17442],[17407],{"nctId":17527,"briefTitle":17528,"status":103,"phases":17529,"primaryCompletion":2864,"completion":2864,"start":3575,"enrollment":17530,"conditions":17531,"interventions":17532},"NCT00699998","A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects",[87],9326,[17470],[16882,17407,17533],"Commercially-available Aspirin",{"nctId":17535,"briefTitle":17536,"status":103,"phases":17537,"primaryCompletion":4566,"completion":4566,"start":3646,"enrollment":17538,"conditions":17539,"interventions":17541},"NCT00097591","A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention",[87],13619,[17540,17442],"Coronary Arteriosclerosis",[17407,16882],{"nctId":17543,"briefTitle":17544,"status":103,"phases":17545,"primaryCompletion":2918,"completion":2918,"start":3103,"enrollment":17546,"conditions":17547,"interventions":17548},"NCT00830960","A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome",[87],720,[17470],[17407,16882],{"trials":17550,"activeCount":97},[],{"trials":17552,"activeCount":97},[],{"intervention":9681,"totalTrials":2733,"cells":17554},{"EARLY_PHASE1":17555,"PHASE1":17557,"PHASE2":17604,"PHASE3":17625,"PHASE4":17668,"NA":17670},{"trials":17556,"activeCount":97},[],{"trials":17558,"activeCount":97},[17559,17563,17569,17575,17582,17588,17595],{"nctId":14538,"briefTitle":14539,"status":103,"phases":17560,"primaryCompletion":2864,"completion":2864,"start":8217,"enrollment":864,"conditions":17561,"interventions":17562},[85],[18],[9681,9644],{"nctId":17564,"briefTitle":17565,"status":103,"phases":17566,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":2071,"conditions":17567,"interventions":17568},"NCT01250834","LY2189265 and Atorvastatin Interaction Study",[85],[21],[9237,9681],{"nctId":17570,"briefTitle":17571,"status":103,"phases":17572,"primaryCompletion":5090,"completion":5090,"start":3029,"enrollment":893,"conditions":17573,"interventions":17574},"NCT01253304","A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment",[85],[18],[9681],{"nctId":17576,"briefTitle":17577,"status":103,"phases":17578,"primaryCompletion":8217,"completion":8217,"start":3837,"enrollment":4945,"conditions":17579,"interventions":17580},"NCT01324388","A Study of the Effect of LY2189265 on Two Blood Pressure Drugs",[85],[18],[9681,2334,17581],"Lisinopril",{"nctId":17583,"briefTitle":17584,"status":103,"phases":17585,"primaryCompletion":6093,"completion":6093,"start":3114,"enrollment":280,"conditions":17586,"interventions":17587},"NCT01215968","A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus",[85],[18],[9681],{"nctId":17589,"briefTitle":17590,"status":103,"phases":17591,"primaryCompletion":8217,"completion":8217,"start":3283,"enrollment":1620,"conditions":17592,"interventions":17594},"NCT01301092","A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.",[85],[17593],"Diabetes Mellitus, Type II",[9681],{"nctId":17596,"briefTitle":17597,"status":103,"phases":17598,"primaryCompletion":8217,"completion":8217,"start":3283,"enrollment":310,"conditions":17599,"interventions":17600},"NCT01300260","Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose",[85],[18],[9681,17601,17602,17603],"Insulin","Glucose","Glucagon",{"trials":17605,"activeCount":97},[17606,17612,17619],{"nctId":17607,"briefTitle":17608,"status":103,"phases":17609,"primaryCompletion":3494,"completion":3661,"start":2918,"enrollment":3790,"conditions":17610,"interventions":17611},"NCT01149421","A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes",[86],[18],[9681],{"nctId":17613,"briefTitle":17614,"status":103,"phases":17615,"primaryCompletion":3662,"completion":3662,"start":2995,"enrollment":17616,"conditions":17617,"interventions":17618},"NCT00630825","A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus",[86],262,[14286],[9681],{"nctId":17620,"briefTitle":17621,"status":103,"phases":17622,"primaryCompletion":3152,"completion":3152,"start":3050,"enrollment":5091,"conditions":17623,"interventions":17624},"NCT01001104","A Study of LY2189265 in Japanese Patients With Type 2 Diabetes",[86],[18],[9681],{"trials":17626,"activeCount":97},[17627,17631,17635,17639,17648,17652,17656,17660,17664],{"nctId":13086,"briefTitle":13087,"status":103,"phases":17628,"primaryCompletion":3086,"completion":2898,"start":3029,"enrollment":13089,"conditions":17629,"interventions":17630},[87],[18],[506,9681,438],{"nctId":9675,"briefTitle":9676,"status":103,"phases":17632,"primaryCompletion":3020,"completion":3545,"start":3216,"enrollment":9678,"conditions":17633,"interventions":17634},[86,87],[18],[9681,9644,1631],{"nctId":9683,"briefTitle":9684,"status":103,"phases":17636,"primaryCompletion":4980,"completion":4980,"start":3838,"enrollment":9686,"conditions":17637,"interventions":17638},[87],[30],[9681,188,1631],{"nctId":17640,"briefTitle":14258,"status":103,"phases":17641,"primaryCompletion":3049,"completion":3049,"start":5090,"enrollment":7344,"conditions":17642,"interventions":17643},"NCT01468181",[87],[120],[9681,7118,17644,17645,17646,17647],"Biguanides","alpha-glucosidase inhibitor","Thiazolidinedione","Glinides",{"nctId":9704,"briefTitle":9705,"status":103,"phases":17649,"primaryCompletion":2865,"completion":3048,"start":3087,"enrollment":9707,"conditions":17650,"interventions":17651},[87],[18],[506,9681,1631,7071],{"nctId":13640,"briefTitle":13641,"status":103,"phases":17653,"primaryCompletion":3027,"completion":3027,"start":2864,"enrollment":3823,"conditions":17654,"interventions":17655},[87],[120],[9681,7103,7118,13645],{"nctId":9719,"briefTitle":9720,"status":103,"phases":17657,"primaryCompletion":5090,"completion":3838,"start":2956,"enrollment":9722,"conditions":17658,"interventions":17659},[87],[18],[1631,9681],{"nctId":9726,"briefTitle":9727,"status":103,"phases":17661,"primaryCompletion":5090,"completion":2865,"start":3087,"enrollment":9729,"conditions":17662,"interventions":17663},[87],[18],[9681,9732,1631,9733],{"nctId":14257,"briefTitle":14258,"status":103,"phases":17665,"primaryCompletion":4955,"completion":4098,"start":3886,"enrollment":14260,"conditions":17666,"interventions":17667},[87],[120],[9681,188],{"trials":17669,"activeCount":97},[],{"trials":17671,"activeCount":97},[],{"intervention":12961,"totalTrials":1237,"cells":17673},{"EARLY_PHASE1":17674,"PHASE1":17676,"PHASE2":17718,"PHASE3":17728,"PHASE4":17762,"NA":17764},{"trials":17675,"activeCount":97},[],{"trials":17677,"activeCount":97},[17678,17684,17688,17692,17698,17704,17708,17714],{"nctId":17679,"briefTitle":17680,"status":103,"phases":17681,"primaryCompletion":3027,"completion":3027,"start":3124,"enrollment":251,"conditions":17682,"interventions":17683},"NCT01818245","A Study of LY2605541 in Healthy Participants and in the Elderly",[85],[21],[12961],{"nctId":13434,"briefTitle":13435,"status":103,"phases":17685,"primaryCompletion":3049,"completion":3049,"start":4420,"enrollment":9038,"conditions":17686,"interventions":17687},[85],[33],[12961,506],{"nctId":13440,"briefTitle":13441,"status":103,"phases":17689,"primaryCompletion":3250,"completion":3250,"start":4980,"enrollment":2071,"conditions":17690,"interventions":17691},[85],[9437],[12961,506],{"nctId":17693,"briefTitle":17694,"status":103,"phases":17695,"primaryCompletion":4955,"completion":4955,"start":3545,"enrollment":6633,"conditions":17696,"interventions":17697},"NCT01654380","A Study of LY2605541 Versus Insulin Glargine on Blood Sugar",[85],[21,33],[12961],{"nctId":17699,"briefTitle":17700,"status":103,"phases":17701,"primaryCompletion":5022,"completion":5022,"start":4122,"enrollment":1548,"conditions":17702,"interventions":17703},"NCT01751399","A Single Dose Study of LY2605541 in Participants With Liver Impairment",[85],[21,312,18],[12961],{"nctId":12956,"briefTitle":12957,"status":103,"phases":17705,"primaryCompletion":5022,"completion":5022,"start":2964,"enrollment":233,"conditions":17706,"interventions":17707},[85],[21],[12961,438],{"nctId":17709,"briefTitle":17710,"status":103,"phases":17711,"primaryCompletion":5022,"completion":5022,"start":2964,"enrollment":12,"conditions":17712,"interventions":17713},"NCT01877265","A Study of LY2605541 in Healthy Participants",[85],[21],[12961],{"nctId":13500,"briefTitle":13501,"status":103,"phases":17715,"primaryCompletion":4980,"completion":4980,"start":4420,"enrollment":3284,"conditions":17716,"interventions":17717},[85],[33],[12961,506],{"trials":17719,"activeCount":97},[17720,17724],{"nctId":13508,"briefTitle":13509,"status":103,"phases":17721,"primaryCompletion":3152,"completion":4258,"start":3685,"enrollment":13511,"conditions":17722,"interventions":17723},[86],[18],[12961,9743],{"nctId":13515,"briefTitle":13516,"status":103,"phases":17725,"primaryCompletion":3152,"completion":4258,"start":3685,"enrollment":8225,"conditions":17726,"interventions":17727},[86],[33],[12961,7103],{"trials":17729,"activeCount":97},[17730,17734,17738,17746,17750,17754,17758],{"nctId":13068,"briefTitle":9727,"status":103,"phases":17731,"primaryCompletion":2917,"completion":2917,"start":4160,"enrollment":13070,"conditions":17732,"interventions":17733},[87],[18],[12961,506,438],{"nctId":13116,"briefTitle":13117,"status":103,"phases":17735,"primaryCompletion":1475,"completion":1475,"start":4420,"enrollment":7166,"conditions":17736,"interventions":17737},[87],[9437],[12961,438],{"nctId":17739,"briefTitle":17740,"status":103,"phases":17741,"primaryCompletion":4098,"completion":4098,"start":3124,"enrollment":17742,"conditions":17743,"interventions":17744},"NCT01790438","A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes",[87],641,[18],[12961,17745,13583],"Human Insulin NPH",{"nctId":14290,"briefTitle":14291,"status":103,"phases":17747,"primaryCompletion":3112,"completion":3112,"start":5090,"enrollment":14293,"conditions":17748,"interventions":17749},[87],[18],[13166,12961],{"nctId":13614,"briefTitle":13615,"status":103,"phases":17751,"primaryCompletion":3282,"completion":3049,"start":2865,"enrollment":2236,"conditions":17752,"interventions":17753},[87],[18],[12961,7103],{"nctId":13160,"briefTitle":13161,"status":103,"phases":17755,"primaryCompletion":3282,"completion":5354,"start":3661,"enrollment":13163,"conditions":17756,"interventions":17757},[87],[33],[13166,12961,438],{"nctId":13179,"briefTitle":13180,"status":103,"phases":17759,"primaryCompletion":9748,"completion":9748,"start":3661,"enrollment":13182,"conditions":17760,"interventions":17761},[87],[33],[13166,12961,438],{"trials":17763,"activeCount":97},[],{"trials":17765,"activeCount":97},[],{"intervention":17767,"totalTrials":1071,"cells":17768},"LY2127399",{"EARLY_PHASE1":17769,"PHASE1":17771,"PHASE2":17785,"PHASE3":17835,"PHASE4":17888,"NA":17890},{"trials":17770,"activeCount":97},[],{"trials":17772,"activeCount":97},[17773,17779],{"nctId":17774,"briefTitle":17775,"status":103,"phases":17776,"primaryCompletion":8217,"completion":8217,"start":14517,"enrollment":310,"conditions":17777,"interventions":17778},"NCT01253226","A Study for Japanese Participants With Rheumatoid Arthritis (RA)",[85],[5218],[17767],{"nctId":17780,"briefTitle":17781,"status":103,"phases":17782,"primaryCompletion":5022,"completion":6632,"start":2956,"enrollment":893,"conditions":17783,"interventions":17784},"NCT01253291","A Study of Japanese Rheumatoid Arthritis Participants",[85],[5218],[17767],{"trials":17786,"activeCount":97},[17787,17793,17799,17805,17812,17822,17828],{"nctId":17788,"briefTitle":17789,"status":103,"phases":17790,"primaryCompletion":3087,"completion":2956,"start":3575,"enrollment":1692,"conditions":17791,"interventions":17792},"NCT00689728","A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy",[86],[5093],[17767],{"nctId":17794,"briefTitle":17795,"status":103,"phases":17796,"primaryCompletion":3685,"completion":3152,"start":3132,"enrollment":6539,"conditions":17797,"interventions":17798},"NCT00785928","A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy",[86],[5218],[17767],{"nctId":17800,"briefTitle":17801,"status":999,"phases":17802,"primaryCompletion":3282,"completion":3282,"start":2865,"enrollment":947,"conditions":17803,"interventions":17804},"NCT01576549","A Study of LY2127399 in Rheumatoid Arthritis",[86],[5218],[17767],{"nctId":17806,"briefTitle":17807,"status":103,"phases":17808,"primaryCompletion":3283,"completion":3838,"start":2846,"enrollment":6499,"conditions":17809,"interventions":17811},"NCT00882999","A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",[86],[17810],"Relapsing-Remitting Multiple Sclerosis",[17767],{"nctId":17813,"briefTitle":17814,"status":103,"phases":17815,"primaryCompletion":17816,"completion":17817,"start":17818,"enrollment":17819,"conditions":17820,"interventions":17821},"NCT00308282","A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis",[86],"2007-06-18","2007-10-18","2006-03-28",136,[5093],[17767],{"nctId":17823,"briefTitle":17824,"status":103,"phases":17825,"primaryCompletion":6632,"completion":6632,"start":3069,"enrollment":12,"conditions":17826,"interventions":17827},"NCT01200290","A Study in Participants With End-Stage Renal Disease",[86],[8857],[17767],{"nctId":17829,"briefTitle":17830,"status":103,"phases":17831,"primaryCompletion":4258,"completion":3661,"start":3103,"enrollment":17832,"conditions":17833,"interventions":17834},"NCT00837811","An Open Label Extension Study in Participants With Rheumatoid Arthritis",[86],182,[5218],[17767],{"trials":17836,"activeCount":97},[17837,17847,17854,17861,17868,17875,17882],{"nctId":17838,"briefTitle":17839,"status":103,"phases":17840,"primaryCompletion":7316,"completion":1619,"start":3152,"enrollment":17841,"conditions":17842,"interventions":17845},"NCT01196091","A Study of LY2127399 in Participants With Systemic Lupus Erythematosus",[87],1164,[5075,17843,17844],"Connective Tissue Disease","Autoimmune Disease",[17767,17846],"Standard of Care",{"nctId":17848,"briefTitle":17849,"status":999,"phases":17850,"primaryCompletion":3124,"completion":3112,"start":4258,"enrollment":17851,"conditions":17852,"interventions":17853},"NCT01202773","A Study in Participants With Rheumatoid Arthritis",[87],456,[5218],[17767],{"nctId":17855,"briefTitle":17856,"status":103,"phases":17857,"primaryCompletion":4122,"completion":3027,"start":4258,"enrollment":17858,"conditions":17859,"interventions":17860},"NCT01202760","A Rheumatoid Arthritis Study in Participants",[87],1004,[5218],[17767],{"nctId":17862,"briefTitle":17863,"status":999,"phases":17864,"primaryCompletion":4122,"completion":3112,"start":3152,"enrollment":17865,"conditions":17866,"interventions":17867},"NCT01198002","A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate",[87],1041,[5218],[17767,5095],{"nctId":17869,"briefTitle":17870,"status":999,"phases":17871,"primaryCompletion":3250,"completion":3250,"start":3661,"enrollment":17872,"conditions":17873,"interventions":17874},"NCT01488708","On Open-Label Study in Participants With Systemic Lupus Erythematosus",[87],1518,[5075,17843,17844],[17767],{"nctId":17876,"briefTitle":17877,"status":999,"phases":17878,"primaryCompletion":9748,"completion":9748,"start":3020,"enrollment":17879,"conditions":17880,"interventions":17881},"NCT01215942","An Open Label Study for Participants With Rheumatoid Arthritis",[87],1086,[5218],[17767],{"nctId":17883,"briefTitle":17839,"status":103,"phases":17884,"primaryCompletion":3122,"completion":1596,"start":4258,"enrollment":17885,"conditions":17886,"interventions":17887},"NCT01205438",[87],1124,[5075,17843,17844],[17767],{"trials":17889,"activeCount":97},[],{"trials":17891,"activeCount":97},[],{"intervention":16882,"totalTrials":1062,"cells":17893},{"EARLY_PHASE1":17894,"PHASE1":17896,"PHASE2":17914,"PHASE3":17950,"PHASE4":17964,"NA":17966},{"trials":17895,"activeCount":97},[],{"trials":17897,"activeCount":97},[17898,17902,17906,17910],{"nctId":17414,"briefTitle":17415,"status":103,"phases":17899,"primaryCompletion":3004,"completion":3004,"start":3419,"enrollment":17417,"conditions":17900,"interventions":17901},[85],[17419],[17421,17422],{"nctId":16877,"briefTitle":16878,"status":103,"phases":17903,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":128,"conditions":17904,"interventions":17905},[85],[13955],[16882,13957],{"nctId":17438,"briefTitle":17439,"status":999,"phases":17907,"primaryCompletion":3152,"completion":3152,"start":3050,"enrollment":864,"conditions":17908,"interventions":17909},[85],[17442],[17422,17421],{"nctId":17445,"briefTitle":17446,"status":103,"phases":17911,"primaryCompletion":8217,"completion":8217,"start":3419,"enrollment":1767,"conditions":17912,"interventions":17913},[85],[17419],[17421,17422],{"trials":17915,"activeCount":97},[17916,17926,17930,17934,17938,17942,17946],{"nctId":17917,"briefTitle":17918,"status":103,"phases":17919,"primaryCompletion":2928,"completion":2928,"start":3185,"enrollment":11714,"conditions":17920,"interventions":17921},"NCT00356135","Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event",[86],[17540,17470],[17922,17422,17923,17924,17925],"prasugrel 10 mg","prasugrel placebo","prasugrel 60 mg","clopidogrel placebo",{"nctId":17466,"briefTitle":17467,"status":103,"phases":17927,"primaryCompletion":5090,"completion":5090,"start":2956,"enrollment":820,"conditions":17928,"interventions":17929},[86],[17470],[17407,16882],{"nctId":17479,"briefTitle":17480,"status":103,"phases":17931,"primaryCompletion":3662,"completion":3662,"start":2995,"enrollment":1548,"conditions":17932,"interventions":17933},[86],[620,17419],[17421,16882],{"nctId":17485,"briefTitle":17486,"status":999,"phases":17935,"primaryCompletion":3069,"completion":3069,"start":3059,"enrollment":17488,"conditions":17936,"interventions":17937},[86],[17490],[17407,16882],{"nctId":17493,"briefTitle":17494,"status":103,"phases":17939,"primaryCompletion":4448,"completion":4448,"start":3195,"enrollment":464,"conditions":17940,"interventions":17941},[86],[2307,17497],[17407,16882],{"nctId":17500,"briefTitle":17501,"status":103,"phases":17943,"primaryCompletion":3235,"completion":3235,"start":4642,"enrollment":6943,"conditions":17944,"interventions":17945},[86],[17470],[17407,16882],{"nctId":17506,"briefTitle":17507,"status":103,"phases":17947,"primaryCompletion":4474,"completion":4474,"start":2855,"enrollment":7353,"conditions":17948,"interventions":17949},[86],[17419],[17407,16882],{"trials":17951,"activeCount":97},[17952,17956,17960],{"nctId":17527,"briefTitle":17528,"status":103,"phases":17953,"primaryCompletion":2864,"completion":2864,"start":3575,"enrollment":17530,"conditions":17954,"interventions":17955},[87],[17470],[16882,17407,17533],{"nctId":17535,"briefTitle":17536,"status":103,"phases":17957,"primaryCompletion":4566,"completion":4566,"start":3646,"enrollment":17538,"conditions":17958,"interventions":17959},[87],[17540,17442],[17407,16882],{"nctId":17543,"briefTitle":17544,"status":103,"phases":17961,"primaryCompletion":2918,"completion":2918,"start":3103,"enrollment":17546,"conditions":17962,"interventions":17963},[87],[17470],[17407,16882],{"trials":17965,"activeCount":97},[],{"trials":17967,"activeCount":97},[],{"intervention":1591,"totalTrials":1199,"cells":17969},{"EARLY_PHASE1":17970,"PHASE1":17972,"PHASE2":17986,"PHASE3":18022,"PHASE4":18032,"NA":18034},{"trials":17971,"activeCount":97},[],{"trials":17973,"activeCount":97},[17974,17978,17982],{"nctId":1581,"briefTitle":1582,"status":103,"phases":17975,"primaryCompletion":1584,"completion":1585,"start":1586,"enrollment":1587,"conditions":17976,"interventions":17977},[85],[1589,1478],[1591,48],{"nctId":2565,"briefTitle":2566,"status":103,"phases":17979,"primaryCompletion":2568,"completion":2569,"start":2570,"enrollment":2571,"conditions":17980,"interventions":17981},[85],[2573],[1591,1696],{"nctId":6462,"briefTitle":6463,"status":103,"phases":17983,"primaryCompletion":334,"completion":6465,"start":6466,"enrollment":864,"conditions":17984,"interventions":17985},[85],[1610],[61,1591,6469],{"trials":17987,"activeCount":97},[17988,17992,17996,18000,18004,18008,18012,18016],{"nctId":3510,"briefTitle":3511,"status":103,"phases":17989,"primaryCompletion":3513,"completion":3514,"start":3515,"enrollment":31,"conditions":17990,"interventions":17991},[86],[3517],[1591,3519,1512],{"nctId":2961,"briefTitle":2962,"status":103,"phases":17993,"primaryCompletion":2964,"completion":2965,"start":2966,"enrollment":1548,"conditions":17994,"interventions":17995},[86],[2968],[1591,1511,1510],{"nctId":2981,"briefTitle":2982,"status":103,"phases":17997,"primaryCompletion":2984,"completion":2985,"start":2986,"enrollment":2987,"conditions":17998,"interventions":17999},[85,86],[2989],[1591,1511,1510],{"nctId":3119,"briefTitle":3120,"status":103,"phases":18001,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":18002,"interventions":18003},[86],[1610],[1591,1511,1510],{"nctId":3694,"briefTitle":3695,"status":103,"phases":18005,"primaryCompletion":3697,"completion":3698,"start":3068,"enrollment":2778,"conditions":18006,"interventions":18007},[86],[3700],[1591,1669,1512],{"nctId":13315,"briefTitle":13316,"status":999,"phases":18009,"primaryCompletion":7255,"completion":7255,"start":4097,"enrollment":1178,"conditions":18010,"interventions":18011},[86],[6485],[1513,1591],{"nctId":3733,"briefTitle":3734,"status":384,"phases":18013,"primaryCompletion":3736,"completion":3737,"start":2754,"enrollment":97,"conditions":18014,"interventions":18015},[86],[3739,3740],[1591,1511,1512],{"nctId":18017,"briefTitle":18018,"status":103,"phases":18019,"primaryCompletion":4098,"completion":1619,"start":2966,"enrollment":9118,"conditions":18020,"interventions":18021},"NCT01624467","A Study of Necitumumab Monotherapy and the QT\u002FQTc Interval in Patient With Advanced Solid Tumors",[86],[2589],[1591],{"trials":18023,"activeCount":97},[18024,18028],{"nctId":3377,"briefTitle":3378,"status":103,"phases":18025,"primaryCompletion":3380,"completion":3381,"start":3382,"enrollment":3383,"conditions":18026,"interventions":18027},[87],[1694],[1591,1511,1510],{"nctId":3402,"briefTitle":3403,"status":103,"phases":18029,"primaryCompletion":3405,"completion":3406,"start":3407,"enrollment":3408,"conditions":18030,"interventions":18031},[87],[1694],[1612,1510,1591],{"trials":18033,"activeCount":97},[],{"trials":18035,"activeCount":97},[],{"intervention":9237,"totalTrials":2477,"cells":18037},{"EARLY_PHASE1":18038,"PHASE1":18040,"PHASE2":18089,"PHASE3":18113,"PHASE4":18123,"NA":18125},{"trials":18039,"activeCount":97},[],{"trials":18041,"activeCount":97},[18042,18046,18055,18065,18073,18077,18081],{"nctId":9231,"briefTitle":9232,"status":103,"phases":18043,"primaryCompletion":9234,"completion":9234,"start":6465,"enrollment":4475,"conditions":18044,"interventions":18045},[85],[18],[402,9237,1538],{"nctId":18047,"briefTitle":18048,"status":103,"phases":18049,"primaryCompletion":18050,"completion":18050,"start":7775,"enrollment":874,"conditions":18051,"interventions":18053},"NCT02714569","A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia",[85],"2017-02-15",[18052],"Dyslipidemias",[18054,9237,2092],"LY3202328",{"nctId":18056,"briefTitle":18057,"status":103,"phases":18058,"primaryCompletion":11256,"completion":11256,"start":18059,"enrollment":310,"conditions":18060,"interventions":18061},"NCT04047940","A Study of LY900020 in Healthy Chinese Participants",[85],"2019-11-29",[15],[18062,18063,9237,18064],"LY900020","Metformin XR","Valsartan",{"nctId":18066,"briefTitle":18067,"status":103,"phases":18068,"primaryCompletion":18069,"completion":18069,"start":1969,"enrollment":1767,"conditions":18070,"interventions":18071},"NCT04270370","A Study of LY3478045 in Healthy Participants",[85],"2021-06-23",[15],[18072,9237],"LY3478045",{"nctId":17314,"briefTitle":17315,"status":103,"phases":18074,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":28,"conditions":18075,"interventions":18076},[85],[21],[17257,2092,9237],{"nctId":17564,"briefTitle":17565,"status":103,"phases":18078,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":2071,"conditions":18079,"interventions":18080},[85],[21],[9237,9681],{"nctId":18082,"briefTitle":18083,"status":103,"phases":18084,"primaryCompletion":18085,"completion":18085,"start":18086,"enrollment":2931,"conditions":18087,"interventions":18088},"NCT03929744","A Study of LY3502970 in Healthy Participants",[85],"2020-11-02","2019-06-12",[15],[7043,9237,2092,1538],{"trials":18090,"activeCount":97},[18091,18098,18105],{"nctId":18092,"briefTitle":18093,"status":103,"phases":18094,"primaryCompletion":3886,"completion":3886,"start":3020,"enrollment":3647,"conditions":18095,"interventions":18096},"NCT01375075","A Study of LY2484595 in Japanese Subjects",[86],[18052],[18097,9237],"LY2484595",{"nctId":18099,"briefTitle":18100,"status":103,"phases":18101,"primaryCompletion":3020,"completion":3020,"start":3251,"enrollment":18102,"conditions":18103,"interventions":18104},"NCT01105975","A Study of LY2484595 in Patients With High LDL-C or Low HDL-C",[86],398,[17305],[18097,9237,2092,2093],{"nctId":18106,"briefTitle":18107,"status":103,"phases":18108,"completion":3133,"start":2947,"enrollment":542,"conditions":18109,"interventions":18110},"NCT00133380","A Study in People With High Cholesterol",[86],[17378],[18111,18112],"PPAR alpha","atorvastatin",{"trials":18114,"activeCount":97},[18115,18119],{"nctId":17374,"briefTitle":17375,"status":999,"phases":18116,"primaryCompletion":4383,"completion":4383,"start":5030,"enrollment":7363,"conditions":18117,"interventions":18118},[87],[17378],[17257,17380,9237],{"nctId":17389,"briefTitle":17390,"status":999,"phases":18120,"primaryCompletion":3123,"completion":3123,"start":3318,"enrollment":17392,"conditions":18121,"interventions":18122},[87],[17394],[17257,9237,17380],{"trials":18124,"activeCount":97},[],{"trials":18126,"activeCount":97},[],{"intervention":5985,"totalTrials":205,"cells":18128},{"EARLY_PHASE1":18129,"PHASE1":18131,"PHASE2":18173,"PHASE3":18197,"PHASE4":18207,"NA":18209},{"trials":18130,"activeCount":97},[],{"trials":18132,"activeCount":97},[18133,18137,18145,18154,18164],{"nctId":8751,"briefTitle":8752,"status":103,"phases":18134,"primaryCompletion":8754,"completion":8755,"start":8756,"enrollment":4353,"conditions":18135,"interventions":18136},[85],[1478],[2545,5985,8759,1745,8760],{"nctId":18138,"briefTitle":18139,"status":103,"phases":18140,"primaryCompletion":18141,"completion":18141,"start":18142,"enrollment":4945,"conditions":18143,"interventions":18144},"NCT02783599","A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma",[85],"2018-07-05","2016-10-11",[1506],[2545,5985],{"nctId":18146,"briefTitle":18147,"status":103,"phases":18148,"primaryCompletion":18149,"completion":18150,"start":18151,"enrollment":9038,"conditions":18152,"interventions":18153},"NCT02377752","A Study of Olaratumab in Japanese Participants With Advanced Cancer",[85],"2018-08-27","2020-01-14","2015-03-23",[1477],[2545,5985],{"nctId":18155,"briefTitle":18156,"status":103,"phases":18157,"primaryCompletion":18158,"completion":18159,"start":18160,"enrollment":3309,"conditions":18161,"interventions":18163},"NCT02326025","A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma",[85],"2015-05-20","2018-11-02","2015-01-22",[18162],"Sarcoma, Soft Tissue",[2545,5985],{"nctId":18165,"briefTitle":18166,"status":103,"phases":18167,"primaryCompletion":18168,"completion":18169,"start":13481,"enrollment":290,"conditions":18170,"interventions":18171},"NCT03283696","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",[85],"2019-04-29","2019-08-25",[1506],[2545,5985,8760,18172],"Mesna",{"trials":18174,"activeCount":97},[18175,18179,18185,18189,18193],{"nctId":8207,"briefTitle":8208,"status":103,"phases":18176,"primaryCompletion":3086,"completion":3068,"start":3005,"enrollment":2670,"conditions":18177,"interventions":18178},[86],[7766],[2979,4357,5885,3143,8212,8205],{"nctId":18180,"briefTitle":18181,"status":103,"phases":18182,"primaryCompletion":3122,"completion":3028,"start":8233,"enrollment":4005,"conditions":18183,"interventions":18184},"NCT01185964","A Study of Olaratumab in Soft Tissue Sarcoma",[85,86],[18162],[2545,3143],{"nctId":3137,"briefTitle":3138,"status":103,"phases":18186,"primaryCompletion":2846,"completion":2846,"start":3140,"enrollment":156,"conditions":18187,"interventions":18188},[86],[36],[2912,3143,2839],{"nctId":5899,"briefTitle":5900,"status":103,"phases":18190,"primaryCompletion":3094,"completion":3837,"start":2833,"enrollment":617,"conditions":18191,"interventions":18192},[86],[36],[2838,5885,3143,3106],{"nctId":5980,"briefTitle":5981,"status":103,"phases":18194,"completion":3235,"start":2948,"enrollment":3095,"conditions":18195,"interventions":18196},[86],[36],[1612,5985],{"trials":18198,"activeCount":97},[18199],{"nctId":18200,"briefTitle":18201,"status":103,"phases":18202,"primaryCompletion":18203,"completion":1647,"start":7343,"enrollment":18204,"conditions":18205,"interventions":18206},"NCT02451943","A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma",[87],"2018-12-05",509,[1506],[2545,5985],{"trials":18208,"activeCount":97},[],{"trials":18210,"activeCount":97},[],{"intervention":13099,"totalTrials":205,"cells":18212},{"EARLY_PHASE1":18213,"PHASE1":18215,"PHASE2":18255,"PHASE3":18257,"PHASE4":18291,"NA":18293},{"trials":18214,"activeCount":97},[],{"trials":18216,"activeCount":97},[18217,18224,18231,18237,18243,18249],{"nctId":18218,"briefTitle":18219,"status":103,"phases":18220,"primaryCompletion":18221,"completion":18221,"start":1691,"enrollment":1686,"conditions":18222,"interventions":18223},"NCT02955953","A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants",[85],"2017-01-04",[15],[13099],{"nctId":18225,"briefTitle":18226,"status":103,"phases":18227,"primaryCompletion":4420,"completion":4420,"start":2898,"enrollment":4279,"conditions":18228,"interventions":18229},"NCT01688635","A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants",[85],[15],[13099,18230],"US Approved Lantus",{"nctId":18232,"briefTitle":18233,"status":103,"phases":18234,"primaryCompletion":2898,"completion":2898,"start":3545,"enrollment":290,"conditions":18235,"interventions":18236},"NCT01634165","A Study of LY2963016 in Healthy Participants",[85],[21],[13099,13138],{"nctId":18238,"briefTitle":18239,"status":103,"phases":18240,"primaryCompletion":6093,"completion":6093,"start":3020,"enrollment":1071,"conditions":18241,"interventions":18242},"NCT01374178","A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects",[85],[620],[13099,13138],{"nctId":18244,"briefTitle":18245,"status":103,"phases":18246,"primaryCompletion":3545,"completion":3545,"start":2865,"enrollment":1082,"conditions":18247,"interventions":18248},"NCT01600950","A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus",[85],[33],[13099,13138],{"nctId":18250,"briefTitle":18251,"status":103,"phases":18252,"primaryCompletion":3545,"completion":3545,"start":5090,"enrollment":4475,"conditions":18253,"interventions":18254},"NCT01476345","A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants",[85],[620],[13099,13138],{"trials":18256,"activeCount":97},[],{"trials":18258,"activeCount":97},[18259,18263,18271,18275,18283],{"nctId":13093,"briefTitle":13094,"status":103,"phases":18260,"primaryCompletion":989,"completion":989,"start":13096,"enrollment":3978,"conditions":18261,"interventions":18262},[87],[466],[13099,13100,438],{"nctId":18264,"briefTitle":18265,"status":103,"phases":18266,"primaryCompletion":18267,"completion":18267,"start":18268,"enrollment":13135,"conditions":18269,"interventions":18270},"NCT03338010","A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus",[87],"2020-03-18","2018-03-22",[30],[13099,13100],{"nctId":13132,"briefTitle":13133,"status":103,"phases":18272,"primaryCompletion":2966,"completion":3348,"start":8217,"enrollment":13135,"conditions":18273,"interventions":18274},[87],[33],[13099,13138,438],{"nctId":18276,"briefTitle":18277,"status":103,"phases":18278,"primaryCompletion":2898,"completion":2898,"start":3494,"enrollment":18279,"conditions":18280,"interventions":18281},"NCT01421459","A Study in Adults With Type 2 Diabetes",[87],759,[18],[13099,13138,18282],"OAMs",{"nctId":18284,"briefTitle":18285,"status":103,"phases":18286,"primaryCompletion":1546,"completion":1546,"start":3776,"enrollment":1978,"conditions":18287,"interventions":18288},"NCT02302716","A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus",[87],[18],[13099,18289,18290],"LANTUS®","Oral Antihyperglycemic Medication",{"trials":18292,"activeCount":97},[],{"trials":18294,"activeCount":97},[],{"intervention":18296,"totalTrials":757,"cells":18297},"Nasal Glucagon",{"EARLY_PHASE1":18298,"PHASE1":18300,"PHASE2":18338,"PHASE3":18340,"PHASE4":18376,"NA":18378},{"trials":18299,"activeCount":97},[],{"trials":18301,"activeCount":97},[18302,18312,18318,18324,18330],{"nctId":18303,"briefTitle":18304,"status":103,"phases":18305,"primaryCompletion":18306,"completion":18307,"start":18308,"enrollment":2790,"conditions":18309,"interventions":18310},"NCT03339453","A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus",[85],"2017-12-17","2018-01-13","2017-11-10",[139,33],[18296,18311],"Intramuscular Glucagon",{"nctId":18313,"briefTitle":18314,"status":103,"phases":18315,"primaryCompletion":3004,"completion":5090,"start":3004,"enrollment":1071,"conditions":18316,"interventions":18317},"NCT02778113","A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults",[85],[15],[18296,17603],{"nctId":18319,"briefTitle":18320,"status":999,"phases":18321,"primaryCompletion":5354,"completion":3122,"start":5354,"enrollment":2477,"conditions":18322,"interventions":18323},"NCT02806960","A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes",[85],[33,18],[18296],{"nctId":18325,"briefTitle":18326,"status":103,"phases":18327,"primaryCompletion":3697,"completion":3697,"start":5030,"enrollment":310,"conditions":18328,"interventions":18329},"NCT02806973","A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes",[85],[33,18],[18296],{"nctId":18331,"briefTitle":18332,"status":103,"phases":18333,"primaryCompletion":3348,"completion":3348,"start":3124,"enrollment":214,"conditions":18334,"interventions":18336},"NCT02778100","A Study of Nasal Glucagon in Participants With a Common Cold",[85],[18335],"Common Cold",[18296,18337],"Oxymetazoline",{"trials":18339,"activeCount":97},[],{"trials":18341,"activeCount":97},[18342,18348,18354,18362,18368],{"nctId":18343,"briefTitle":18344,"status":103,"phases":18345,"primaryCompletion":1474,"completion":1474,"start":1596,"enrollment":893,"conditions":18346,"interventions":18347},"NCT02402933","Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents",[87],[139,620],[18296],{"nctId":18349,"briefTitle":18350,"status":103,"phases":18351,"primaryCompletion":5030,"completion":5030,"start":4980,"enrollment":118,"conditions":18352,"interventions":18353},"NCT01997411","Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes",[86,87],[33],[18296,18311],{"nctId":18355,"briefTitle":18356,"status":103,"phases":18357,"primaryCompletion":1474,"completion":1474,"start":4098,"enrollment":18358,"conditions":18359,"interventions":18361},"NCT02171130","Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia",[87],129,[139,620,18360],"Drug-Specific Antibodies",[18296],{"nctId":18363,"briefTitle":18364,"status":103,"phases":18365,"primaryCompletion":5030,"completion":5030,"start":4980,"enrollment":3095,"conditions":18366,"interventions":18367},"NCT01994746","Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults",[87],[33],[18296,18311],{"nctId":18369,"briefTitle":18370,"status":103,"phases":18371,"primaryCompletion":3049,"completion":3049,"start":5022,"enrollment":9118,"conditions":18372,"interventions":18374},"NCT01959334","Evaluate the Immunogenicity of a Novel Glucagon Formulation",[87],[18373,620],"Drug-specific Antibodies",[18296,18375],"Glucagon IM",{"trials":18377,"activeCount":97},[],{"trials":18379,"activeCount":97},[],{"intervention":13554,"totalTrials":757,"cells":18381},{"EARLY_PHASE1":18382,"PHASE1":18384,"PHASE2":18386,"PHASE3":18397,"PHASE4":18449,"NA":18451},{"trials":18383,"activeCount":97},[],{"trials":18385,"activeCount":97},[],{"trials":18387,"activeCount":97},[18388],{"nctId":18389,"briefTitle":18390,"status":103,"phases":18391,"completion":3746,"start":3195,"enrollment":18392,"conditions":18393,"interventions":18394},"NCT00063128","Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.",[86],119,[33],[18395,18396],"insulin","human insulin inhalation powder",{"trials":18398,"activeCount":97},[18399,18408,18415,18419,18423,18430,18434,18438,18442],{"nctId":18400,"briefTitle":18401,"status":103,"phases":18402,"primaryCompletion":3292,"completion":3292,"start":14103,"enrollment":18403,"conditions":18404,"interventions":18406},"NCT00157339","Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD",[87],299,[620,4904,18405],"Pulmonary Disease, Chronic Obstructive",[13554,18407],"injected insulin",{"nctId":18409,"briefTitle":18410,"status":103,"phases":18411,"primaryCompletion":3292,"completion":3292,"start":3524,"enrollment":18412,"conditions":18413,"interventions":18414},"NCT00330473","A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes",[87],1019,[18],[13554,17601],{"nctId":13549,"briefTitle":13550,"status":103,"phases":18416,"primaryCompletion":3292,"completion":3292,"start":2875,"enrollment":299,"conditions":18417,"interventions":18418},[87],[18],[13554,506],{"nctId":13566,"briefTitle":13567,"status":103,"phases":18420,"primaryCompletion":3575,"completion":3575,"start":2855,"enrollment":13569,"conditions":18421,"interventions":18422},[87],[18],[13554,506],{"nctId":18424,"briefTitle":18425,"status":103,"phases":18426,"primaryCompletion":3292,"completion":3292,"start":4266,"enrollment":18427,"conditions":18428,"interventions":18429},"NCT00325364","Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes",[87],415,[18],[13554,13672],{"nctId":13658,"briefTitle":13659,"status":103,"phases":18431,"primaryCompletion":3292,"completion":3292,"start":2947,"enrollment":13661,"conditions":18432,"interventions":18433},[87],[33],[13554,13664,506],{"nctId":13666,"briefTitle":13667,"status":103,"phases":18435,"primaryCompletion":3292,"completion":3292,"start":2855,"enrollment":13669,"conditions":18436,"interventions":18437},[87],[33],[13554,13672,506],{"nctId":13674,"briefTitle":13675,"status":103,"phases":18439,"primaryCompletion":3292,"completion":3292,"start":3645,"enrollment":2790,"conditions":18440,"interventions":18441},[86,87],[33],[7103,13554,13664],{"nctId":18443,"briefTitle":18444,"status":103,"phases":18445,"primaryCompletion":3292,"completion":3292,"start":4566,"enrollment":18358,"conditions":18446,"interventions":18447},"NCT00490854","A Study for Patients With Type 2 Diabetes Mellitus",[86,87],[18],[13554,18448],"Neutral protamine hagedorn insulin",{"trials":18450,"activeCount":97},[],{"trials":18452,"activeCount":97},[],{"intervention":1843,"totalTrials":4323,"cells":18454},{"EARLY_PHASE1":18455,"PHASE1":18457,"PHASE2":18467,"PHASE3":18484,"PHASE4":18498,"NA":18500},{"trials":18456,"activeCount":97},[],{"trials":18458,"activeCount":97},[18459,18463],{"nctId":2751,"briefTitle":2752,"status":103,"phases":18460,"primaryCompletion":1546,"completion":2754,"start":1473,"enrollment":12,"conditions":18461,"interventions":18462},[85],[2756],[61,1843,1510,2758,2520],{"nctId":2576,"briefTitle":2577,"status":103,"phases":18464,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":18465,"interventions":18466},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":18468,"activeCount":97},[18469,18476,18480],{"nctId":18470,"briefTitle":18471,"status":103,"phases":18472,"primaryCompletion":4955,"completion":3698,"start":3837,"enrollment":3546,"conditions":18473,"interventions":18474},"NCT01234402","Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients",[86],[36],[9819,18475,1843],"IMC-18F1",{"nctId":1833,"briefTitle":1834,"status":103,"phases":18477,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":1839,"conditions":18478,"interventions":18479},[86],[1841],[48,1513,1511,1843],{"nctId":16678,"briefTitle":16679,"status":999,"phases":18481,"primaryCompletion":2866,"completion":2866,"start":4642,"enrollment":1302,"conditions":18482,"interventions":18483},[86],[36],[2979,4637],{"trials":18485,"activeCount":97},[18486,18490,18494],{"nctId":3391,"briefTitle":3392,"status":103,"phases":18487,"primaryCompletion":3394,"completion":1149,"start":3395,"enrollment":3396,"conditions":18488,"interventions":18489},[87],[3398,3399],[61,1843,1510,2783],{"nctId":4631,"briefTitle":4632,"status":103,"phases":18491,"primaryCompletion":2974,"completion":2974,"start":4634,"enrollment":564,"conditions":18492,"interventions":18493},[87],[36,1893,4568],[2912,3106,4637],{"nctId":4639,"briefTitle":4640,"status":103,"phases":18495,"completion":4642,"start":3236,"enrollment":542,"conditions":18496,"interventions":18497},[87],[1893],[2912,4637,3106],{"trials":18499,"activeCount":97},[],{"trials":18501,"activeCount":97},[],{"intervention":12954,"totalTrials":4323,"cells":18503},{"EARLY_PHASE1":18504,"PHASE1":18506,"PHASE2":18533,"PHASE3":18535,"PHASE4":18549,"NA":18551},{"trials":18505,"activeCount":97},[],{"trials":18507,"activeCount":97},[18508,18515,18521,18525,18529],{"nctId":18509,"briefTitle":18510,"status":103,"phases":18511,"primaryCompletion":1596,"completion":1596,"start":1475,"enrollment":290,"conditions":18512,"interventions":18513},"NCT02109029","A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue",[85],[33],[12954,18514],"Human Insulin",{"nctId":18516,"briefTitle":18517,"status":103,"phases":18518,"primaryCompletion":3112,"completion":3112,"start":3049,"enrollment":205,"conditions":18519,"interventions":18520},"NCT01995526","A Study of Insulin Peglispro in Healthy Male Japanese Participants",[85],[21],[12954],{"nctId":12949,"briefTitle":12950,"status":103,"phases":18522,"primaryCompletion":1619,"completion":1619,"start":7316,"enrollment":290,"conditions":18523,"interventions":18524},[85],[18],[12954,506,438],{"nctId":13458,"briefTitle":13459,"status":103,"phases":18526,"primaryCompletion":3776,"completion":3776,"start":4955,"enrollment":1158,"conditions":18527,"interventions":18528},[85],[33],[12954,506],{"nctId":12982,"briefTitle":12983,"status":103,"phases":18530,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":165,"conditions":18531,"interventions":18532},[85],[33],[12954,438,506],{"trials":18534,"activeCount":97},[],{"trials":18536,"activeCount":97},[18537,18541,18545],{"nctId":13539,"briefTitle":13540,"status":103,"phases":18538,"primaryCompletion":4097,"completion":4097,"start":4098,"enrollment":4353,"conditions":18539,"interventions":18540},[87],[120],[12954,506],{"nctId":13556,"briefTitle":13557,"status":384,"phases":18542,"primaryCompletion":4383,"completion":2965,"start":1473,"enrollment":97,"conditions":18543,"interventions":18544},[87],[18],[12954,506],{"nctId":13577,"briefTitle":13578,"status":103,"phases":18546,"primaryCompletion":3697,"completion":3697,"start":3027,"enrollment":13580,"conditions":18547,"interventions":18548},[87],[120],[12954,506,13583],{"trials":18550,"activeCount":97},[],{"trials":18552,"activeCount":97},[],{"intervention":18554,"totalTrials":1054,"cells":18555},"Solanezumab",{"EARLY_PHASE1":18556,"PHASE1":18558,"PHASE2":18567,"PHASE3":18582,"PHASE4":18613,"NA":18615},{"trials":18557,"activeCount":97},[],{"trials":18559,"activeCount":97},[18560],{"nctId":18561,"briefTitle":18562,"status":999,"phases":18563,"primaryCompletion":1627,"completion":1627,"start":3123,"enrollment":2088,"conditions":18564,"interventions":18565},"NCT02614131","A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)",[85],[15,4040,13418],[18566,18554],"LY2599666",{"trials":18568,"activeCount":97},[18569,18575],{"nctId":18570,"briefTitle":18571,"status":103,"phases":18572,"primaryCompletion":3059,"completion":3059,"start":3320,"enrollment":5015,"conditions":18573,"interventions":18574},"NCT00749216","Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease",[86],[4040],[18554],{"nctId":18576,"briefTitle":18577,"status":103,"phases":18578,"primaryCompletion":2966,"completion":2966,"start":3012,"enrollment":224,"conditions":18579,"interventions":18580},"NCT01148498","A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's",[86],[4040],[18581],"solanezumab",{"trials":18583,"activeCount":97},[18584,18590,18597,18606],{"nctId":18585,"briefTitle":18586,"status":999,"phases":18587,"primaryCompletion":5370,"completion":5370,"start":2965,"enrollment":893,"conditions":18588,"interventions":18589},"NCT02760602","A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease",[87],[4040],[18554],{"nctId":18591,"briefTitle":18592,"status":999,"phases":18593,"primaryCompletion":7316,"completion":5081,"start":3152,"enrollment":18594,"conditions":18595,"interventions":18596},"NCT01127633","Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease",[87],1457,[4040],[18554],{"nctId":18598,"briefTitle":18599,"status":103,"phases":18600,"primaryCompletion":629,"completion":278,"start":18601,"enrollment":18602,"conditions":18603,"interventions":18605},"NCT02008357","Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss",[87],"2014-02-28",1169,[18604],"Cognition Disorders",[18554],{"nctId":18607,"briefTitle":18608,"status":999,"phases":18609,"primaryCompletion":1685,"completion":5081,"start":3027,"enrollment":18610,"conditions":18611,"interventions":18612},"NCT01900665","Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo",[87],2129,[4040],[18554],{"trials":18614,"activeCount":97},[],{"trials":18616,"activeCount":97},[],{"intervention":2591,"totalTrials":1054,"cells":18618},{"EARLY_PHASE1":18619,"PHASE1":18621,"PHASE2":18650,"PHASE3":18665,"PHASE4":18675,"NA":18677},{"trials":18620,"activeCount":97},[],{"trials":18622,"activeCount":97},[18623,18630,18634,18642],{"nctId":18624,"briefTitle":18625,"status":103,"phases":18626,"primaryCompletion":7539,"completion":7539,"start":18627,"enrollment":2477,"conditions":18628,"interventions":18629},"NCT04194892","A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants",[85],"2018-01-19",[15],[2591],{"nctId":2576,"briefTitle":2577,"status":103,"phases":18631,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":18632,"interventions":18633},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"nctId":18635,"briefTitle":18636,"status":103,"phases":18637,"primaryCompletion":18638,"completion":18638,"start":3977,"enrollment":2477,"conditions":18639,"interventions":18641},"NCT03381547","A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)",[85],"2018-02-11",[18640],"Healthy Adult Subjects",[2591],{"nctId":18643,"briefTitle":18644,"status":103,"phases":18645,"primaryCompletion":18646,"completion":18646,"start":18647,"enrollment":290,"conditions":18648,"interventions":18649},"NCT03267732","A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)",[85],"2017-10-30","2017-09-05",[18640],[2591],{"trials":18651,"activeCount":97},[18652,18661],{"nctId":18653,"briefTitle":18654,"status":999,"phases":18655,"primaryCompletion":18656,"completion":18657,"start":18268,"enrollment":251,"conditions":18658,"interventions":18659},"NCT03382912","Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer",[86],"2019-08-28","2020-03-03",[1694],[2591,18660],"Nivolumab",{"nctId":2665,"briefTitle":2666,"status":999,"phases":18662,"primaryCompletion":2668,"completion":989,"start":2669,"enrollment":2670,"conditions":18663,"interventions":18664},[86],[1694],[2591,1696],{"trials":18666,"activeCount":97},[18667],{"nctId":18668,"briefTitle":18669,"status":103,"phases":18670,"primaryCompletion":5201,"completion":989,"start":18671,"enrollment":18672,"conditions":18673,"interventions":18674},"NCT02923921","Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer",[87],"2017-03-01",567,[1653],[2591,2593],{"trials":18676,"activeCount":97},[],{"trials":18678,"activeCount":97},[],{"intervention":2893,"totalTrials":1054,"cells":18680},{"EARLY_PHASE1":18681,"PHASE1":18683,"PHASE2":18693,"PHASE3":18715,"PHASE4":18724,"NA":18726},{"trials":18682,"activeCount":97},[],{"trials":18684,"activeCount":97},[18685],{"nctId":18686,"briefTitle":18687,"status":103,"phases":18688,"conditions":18689,"interventions":18690},"NCT00034463","ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer",[85],[8969,2824],[2893,18691,18692],"folic acid","multi-vitamins",{"trials":18694,"activeCount":97},[18695,18699,18703,18707,18711],{"nctId":2887,"briefTitle":2888,"status":103,"phases":18696,"conditions":18697,"interventions":18698},[86],[2891],[2893,2561,2839],{"nctId":3674,"briefTitle":3675,"status":103,"phases":18700,"completion":3161,"start":3677,"enrollment":2088,"conditions":18701,"interventions":18702},[86],[1589],[2893,1512],{"nctId":10755,"briefTitle":10756,"status":103,"phases":18704,"conditions":18705,"interventions":18706},[86],[1490],[2893,2520],{"nctId":4425,"briefTitle":4426,"status":103,"phases":18708,"conditions":18709,"interventions":18710},[86],[2998],[2893,2912],{"nctId":8792,"briefTitle":8793,"status":103,"phases":18712,"conditions":18713,"interventions":18714},[85,86],[1490],[2893,5659],{"trials":18716,"activeCount":97},[18717],{"nctId":18718,"briefTitle":18719,"status":103,"phases":18720,"conditions":18721,"interventions":18722},"NCT00035035","A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.",[87],[2652,5763],[18723,2893],"GEMZAR",{"trials":18725,"activeCount":97},[],{"trials":18727,"activeCount":97},[],{"intervention":4387,"totalTrials":1054,"cells":18729},{"EARLY_PHASE1":18730,"PHASE1":18732,"PHASE2":18750,"PHASE3":18776,"PHASE4":18785,"NA":18787},{"trials":18731,"activeCount":97},[],{"trials":18733,"activeCount":97},[18734,18740,18744],{"nctId":18735,"briefTitle":18736,"status":103,"phases":18737,"primaryCompletion":2965,"completion":2965,"start":3028,"enrollment":233,"conditions":18738,"interventions":18739},"NCT02752919","Study of Galunisertib in Healthy Participants",[85],[15],[4387],{"nctId":7957,"briefTitle":7958,"status":103,"phases":18741,"primaryCompletion":5141,"completion":7960,"start":7961,"enrollment":5922,"conditions":18742,"interventions":18743},[85],[4317],[4387,2696],{"nctId":18745,"briefTitle":18746,"status":103,"phases":18747,"primaryCompletion":1628,"completion":1628,"start":3717,"enrollment":757,"conditions":18748,"interventions":18749},"NCT02304419","A Study of Galunisertib on the Immune System in Participants With Cancer",[85],[1477],[4387],{"trials":18751,"activeCount":97},[18752,18761,18772],{"nctId":18753,"briefTitle":18754,"status":103,"phases":18755,"primaryCompletion":18756,"completion":912,"start":18757,"enrollment":6539,"conditions":18758,"interventions":18759},"NCT01582269","A Study in Recurrent Glioblastoma (GB)",[86],"2014-07-26","2012-04-26",[9127],[4387,18760],"Lomustine",{"nctId":18762,"briefTitle":18763,"status":103,"phases":18764,"primaryCompletion":18765,"completion":18766,"start":18767,"enrollment":2542,"conditions":18768,"interventions":18771},"NCT02423343","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma",[85,86],"2018-12-13","2020-07-08","2015-01-01",[1503,18769,18770],"Non-Small Cell Lung Cancer Recurrent","Hepatocellular Carcinoma Recurrent",[4387,18660],{"nctId":4380,"briefTitle":4381,"status":103,"phases":18773,"primaryCompletion":4383,"completion":1627,"start":3020,"enrollment":4384,"conditions":18774,"interventions":18775},[85,86],[1870,1478,1653],[4387,1511],{"trials":18777,"activeCount":97},[18778],{"nctId":18779,"briefTitle":18780,"status":103,"phases":18781,"primaryCompletion":7775,"completion":7255,"start":6632,"enrollment":4222,"conditions":18782,"interventions":18784},"NCT02008318","A Study of Galunisertib in Participants With Myelodysplastic Syndromes",[86,87],[18783],"Myelodysplastic Syndromes",[4387],{"trials":18786,"activeCount":97},[],{"trials":18788,"activeCount":97},[],{"intervention":13138,"totalTrials":1054,"cells":18790},{"EARLY_PHASE1":18791,"PHASE1":18793,"PHASE2":18815,"PHASE3":18817,"PHASE4":18827,"NA":18829},{"trials":18792,"activeCount":97},[],{"trials":18794,"activeCount":97},[18795,18799,18803,18807,18811],{"nctId":18232,"briefTitle":18233,"status":103,"phases":18796,"primaryCompletion":2898,"completion":2898,"start":3545,"enrollment":290,"conditions":18797,"interventions":18798},[85],[21],[13099,13138],{"nctId":18238,"briefTitle":18239,"status":103,"phases":18800,"primaryCompletion":6093,"completion":6093,"start":3020,"enrollment":1071,"conditions":18801,"interventions":18802},[85],[620],[13099,13138],{"nctId":18244,"briefTitle":18245,"status":103,"phases":18804,"primaryCompletion":3545,"completion":3545,"start":2865,"enrollment":1082,"conditions":18805,"interventions":18806},[85],[33],[13099,13138],{"nctId":13471,"briefTitle":13472,"status":103,"phases":18808,"primaryCompletion":13474,"completion":13474,"start":13324,"enrollment":1189,"conditions":18809,"interventions":18810},[85],[15],[506,13138],{"nctId":18250,"briefTitle":18251,"status":103,"phases":18812,"primaryCompletion":3545,"completion":3545,"start":5090,"enrollment":4475,"conditions":18813,"interventions":18814},[85],[620],[13099,13138],{"trials":18816,"activeCount":97},[],{"trials":18818,"activeCount":97},[18819,18823],{"nctId":13132,"briefTitle":13133,"status":103,"phases":18820,"primaryCompletion":2966,"completion":3348,"start":8217,"enrollment":13135,"conditions":18821,"interventions":18822},[87],[33],[13099,13138,438],{"nctId":18276,"briefTitle":18277,"status":103,"phases":18824,"primaryCompletion":2898,"completion":2898,"start":3494,"enrollment":18279,"conditions":18825,"interventions":18826},[87],[18],[13099,13138,18282],{"trials":18828,"activeCount":97},[],{"trials":18830,"activeCount":97},[],{"intervention":5095,"totalTrials":1054,"cells":18832},{"EARLY_PHASE1":18833,"PHASE1":18835,"PHASE2":18845,"PHASE3":18858,"PHASE4":18876,"NA":18878},{"trials":18834,"activeCount":97},[],{"trials":18836,"activeCount":97},[18837],{"nctId":18838,"briefTitle":18839,"status":103,"phases":18840,"primaryCompletion":18841,"completion":18841,"start":5476,"enrollment":3041,"conditions":18842,"interventions":18843},"NCT05602675","A Drug Interaction Study of LY3871801 in Healthy Participants",[85],"2023-03-29",[15],[18844,5095,1172,5480,1538,1102],"LY3871801",{"trials":18846,"activeCount":97},[18847,18854],{"nctId":18848,"briefTitle":18849,"status":103,"phases":18850,"primaryCompletion":4160,"completion":6632,"start":8233,"enrollment":1319,"conditions":18851,"interventions":18852},"NCT01185353","A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy",[86],[5093],[18853,5095],"LY3009104",{"nctId":5087,"briefTitle":5088,"status":103,"phases":18855,"primaryCompletion":3048,"completion":3049,"start":5090,"enrollment":5091,"conditions":18856,"interventions":18857},[86],[5093],[4944,4944,4944,5095],{"trials":18859,"activeCount":97},[18860,18864,18868,18872],{"nctId":5213,"briefTitle":5214,"status":103,"phases":18861,"primaryCompletion":1596,"completion":1618,"start":2798,"enrollment":5216,"conditions":18862,"interventions":18863},[87],[5218],[5220,4944,5095,5221,5222],{"nctId":17862,"briefTitle":17863,"status":999,"phases":18865,"primaryCompletion":4122,"completion":3112,"start":3152,"enrollment":17865,"conditions":18866,"interventions":18867},[87],[5218],[17767,5095],{"nctId":5287,"briefTitle":5288,"status":103,"phases":18869,"primaryCompletion":1473,"completion":1474,"start":3048,"enrollment":5290,"conditions":18870,"interventions":18871},[87],[5218],[4944,5095,5222,5293,3032],{"nctId":7377,"briefTitle":7378,"status":103,"phases":18873,"primaryCompletion":7380,"completion":7381,"start":7382,"enrollment":1730,"conditions":18874,"interventions":18875},[87],[926],[7385,5095,449],{"trials":18877,"activeCount":97},[],{"trials":18879,"activeCount":97},[],{"intervention":17006,"totalTrials":1677,"cells":18881},{"EARLY_PHASE1":18882,"PHASE1":18884,"PHASE2":18886,"PHASE3":18888,"PHASE4":18914,"NA":18916},{"trials":18883,"activeCount":97},[],{"trials":18885,"activeCount":97},[],{"trials":18887,"activeCount":97},[],{"trials":18889,"activeCount":97},[18890,18894,18898,18902,18906,18910],{"nctId":16999,"briefTitle":17000,"status":103,"phases":18891,"primaryCompletion":2917,"completion":2917,"start":3837,"enrollment":17002,"conditions":18892,"interventions":18893},[87],[17004],[13957,17006],{"nctId":17008,"briefTitle":17009,"status":103,"phases":18895,"primaryCompletion":4955,"completion":4955,"start":3029,"enrollment":17011,"conditions":18896,"interventions":18897},[87],[13955],[13957,17006],{"nctId":17015,"briefTitle":17016,"status":103,"phases":18899,"primaryCompletion":4122,"completion":4122,"start":8233,"enrollment":17018,"conditions":18900,"interventions":18901},[87],[4937],[13957,17006],{"nctId":17022,"briefTitle":17023,"status":103,"phases":18903,"primaryCompletion":3348,"completion":3348,"start":3837,"enrollment":17025,"conditions":18904,"interventions":18905},[87],[13955],[13957,17006],{"nctId":17029,"briefTitle":17030,"status":103,"phases":18907,"primaryCompletion":3112,"completion":3112,"start":8217,"enrollment":9283,"conditions":18908,"interventions":18909},[87],[13955],[13957,17006],{"nctId":17035,"briefTitle":17036,"status":103,"phases":18911,"primaryCompletion":4980,"completion":4980,"start":2844,"enrollment":17038,"conditions":18912,"interventions":18913},[87],[13955],[13957,17006],{"trials":18915,"activeCount":97},[],{"trials":18917,"activeCount":97},[],{"intervention":3324,"totalTrials":425,"cells":18919},{"EARLY_PHASE1":18920,"PHASE1":18922,"PHASE2":18924,"PHASE3":18938,"PHASE4":18948,"NA":18950},{"trials":18921,"activeCount":97},[],{"trials":18923,"activeCount":97},[],{"trials":18925,"activeCount":97},[18926,18930,18934],{"nctId":3491,"briefTitle":3492,"status":103,"phases":18927,"primaryCompletion":3112,"completion":1628,"start":3494,"enrollment":963,"conditions":18928,"interventions":18929},[86],[3496],[3498,1512,3324],{"nctId":3556,"briefTitle":3557,"status":999,"phases":18931,"primaryCompletion":1473,"completion":1473,"start":3068,"enrollment":893,"conditions":18932,"interventions":18933},[85,86],[2504],[3561,1512,3324],{"nctId":3100,"briefTitle":3101,"status":103,"phases":18935,"primaryCompletion":2974,"completion":3103,"start":3040,"enrollment":2867,"conditions":18936,"interventions":18937},[86],[1610],[2912,3106,2839,3107],{"trials":18939,"activeCount":97},[18940,18944],{"nctId":3315,"briefTitle":3316,"status":103,"phases":18941,"primaryCompletion":3318,"completion":3319,"start":3320,"enrollment":3321,"conditions":18942,"interventions":18943},[87],[1694],[1612,1510,3324,1875,1669,1512],{"nctId":3780,"briefTitle":3781,"status":103,"phases":18945,"primaryCompletion":3575,"completion":3575,"start":2855,"enrollment":3783,"conditions":18946,"interventions":18947},[87],[3244],[2838,3107,2561],{"trials":18949,"activeCount":97},[],{"trials":18951,"activeCount":97},[],{"intervention":11287,"totalTrials":425,"cells":18953},{"EARLY_PHASE1":18954,"PHASE1":18956,"PHASE2":18958,"PHASE3":18960,"PHASE4":18982,"NA":18984},{"trials":18955,"activeCount":97},[],{"trials":18957,"activeCount":97},[],{"trials":18959,"activeCount":97},[],{"trials":18961,"activeCount":97},[18962,18966,18970,18974,18978],{"nctId":13078,"briefTitle":13079,"status":103,"phases":18963,"primaryCompletion":3987,"completion":3987,"start":13081,"enrollment":13082,"conditions":18964,"interventions":18965},[87],[30,11208],[11287,438,506],{"nctId":11279,"briefTitle":11280,"status":103,"phases":18967,"primaryCompletion":2382,"completion":2382,"start":11282,"enrollment":11283,"conditions":18968,"interventions":18969},[87],[11285,30],[11287,700],{"nctId":11289,"briefTitle":11290,"status":103,"phases":18971,"primaryCompletion":1034,"completion":1034,"start":11292,"enrollment":7593,"conditions":18972,"interventions":18973},[87],[30],[11287,700],{"nctId":11300,"briefTitle":11301,"status":103,"phases":18975,"primaryCompletion":11303,"completion":11303,"start":11304,"enrollment":11305,"conditions":18976,"interventions":18977},[87],[466,11285],[11287,700],{"nctId":13585,"briefTitle":13586,"status":103,"phases":18979,"primaryCompletion":1377,"completion":1377,"start":13588,"enrollment":3420,"conditions":18980,"interventions":18981},[87],[30,413],[11287,506],{"trials":18983,"activeCount":97},[],{"trials":18985,"activeCount":97},[],{"intervention":13177,"totalTrials":425,"cells":18987},{"EARLY_PHASE1":18988,"PHASE1":18990,"PHASE2":18992,"PHASE3":18994,"PHASE4":19024,"NA":19026},{"trials":18989,"activeCount":97},[],{"trials":18991,"activeCount":97},[],{"trials":18993,"activeCount":97},[],{"trials":18995,"activeCount":97},[18996,19004,19008,19012,19020],{"nctId":18997,"briefTitle":18998,"status":103,"phases":18999,"primaryCompletion":3216,"completion":3216,"start":4474,"enrollment":19000,"conditions":19001,"interventions":19002},"NCT00487240","Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes",[87],387,[33],[13177,19003],"Insulin Levemir",{"nctId":13592,"briefTitle":13593,"status":103,"phases":19005,"primaryCompletion":3132,"completion":3132,"start":3813,"enrollment":13107,"conditions":19006,"interventions":19007},[87],[18],[13177,506],{"nctId":13647,"briefTitle":13648,"status":103,"phases":19009,"primaryCompletion":6883,"completion":6883,"start":3266,"enrollment":13650,"conditions":19010,"interventions":19011},[87],[18],[13177,506],{"nctId":19013,"briefTitle":19014,"status":103,"phases":19015,"primaryCompletion":3320,"completion":3320,"start":3813,"enrollment":19016,"conditions":19017,"interventions":19018},"NCT00494013","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)",[87],442,[14286],[13177,19019],"Detemir",{"nctId":13172,"briefTitle":13173,"status":103,"phases":19021,"primaryCompletion":3087,"completion":3087,"start":2995,"enrollment":5170,"conditions":19022,"interventions":19023},[87],[18],[506,13177,438],{"trials":19025,"activeCount":97},[],{"trials":19027,"activeCount":97},[],{"intervention":14381,"totalTrials":425,"cells":19029},{"EARLY_PHASE1":19030,"PHASE1":19032,"PHASE2":19050,"PHASE3":19063,"PHASE4":19069,"NA":19071},{"trials":19031,"activeCount":97},[],{"trials":19033,"activeCount":97},[19034,19043],{"nctId":19035,"briefTitle":19036,"status":103,"phases":19037,"primaryCompletion":3004,"completion":3004,"start":3494,"enrollment":1620,"conditions":19038,"interventions":19040},"NCT01440478","The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects",[85],[19039],"Healthy Subjects",[14381,19041,19042],"Ammonium chloride","Sodium bicarbonate",{"nctId":19044,"briefTitle":19045,"status":103,"phases":19046,"primaryCompletion":3027,"completion":3027,"start":2864,"enrollment":251,"conditions":19047,"interventions":19048},"NCT01524237","A Study of LY2979165 and LY2140023 in Healthy Volunteers",[85],[21],[19049,14381],"LY2979165",{"trials":19051,"activeCount":97},[19052,19059],{"nctId":19053,"briefTitle":19054,"status":103,"phases":19055,"primaryCompletion":3132,"completion":3132,"start":2975,"enrollment":19056,"conditions":19057,"interventions":19058},"NCT00520923","A Study for Patients With Schizophrenia",[86],654,[4897],[14381,14381,14381,14381,13976],{"nctId":14375,"briefTitle":14376,"status":103,"phases":19060,"primaryCompletion":2865,"completion":2865,"start":3419,"enrollment":1753,"conditions":19061,"interventions":19062},[86],[4897],[14380,14381],{"trials":19064,"activeCount":97},[19065],{"nctId":14385,"briefTitle":14386,"status":999,"phases":19066,"primaryCompletion":2798,"completion":2798,"start":2918,"enrollment":14388,"conditions":19067,"interventions":19068},[86,87],[4897],[14381,13976,14391,14380,14392],{"trials":19070,"activeCount":97},[],{"trials":19072,"activeCount":97},[],{"intervention":19074,"totalTrials":1400,"cells":19075},"Lasmiditan 200 mg",{"EARLY_PHASE1":19076,"PHASE1":19078,"PHASE2":19095,"PHASE3":19097,"PHASE4":19118,"NA":19120},{"trials":19077,"activeCount":97},[],{"trials":19079,"activeCount":97},[19080,19088],{"nctId":19081,"briefTitle":19082,"status":103,"phases":19083,"primaryCompletion":7223,"completion":7223,"start":19084,"enrollment":137,"conditions":19085,"interventions":19086},"NCT03076970","Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants",[85],"2017-03-21",[7486],[19087,17113],"lasmiditan 200 mg",{"nctId":19089,"briefTitle":19090,"status":103,"phases":19091,"primaryCompletion":11313,"completion":11313,"start":19092,"enrollment":290,"conditions":19093,"interventions":19094},"NCT03040479","Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function",[85],"2017-03-14",[7486],[19087],{"trials":19096,"activeCount":97},[],{"trials":19098,"activeCount":97},[19099,19110],{"nctId":19100,"briefTitle":19101,"status":103,"phases":19102,"primaryCompletion":19103,"completion":19103,"start":2799,"enrollment":19104,"conditions":19105,"interventions":19107},"NCT02605174","Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",[87],"2017-06-30",3005,[19106],"Migraine With or Without Aura",[19108,19109,19074],"Lasmiditan 50 mg","Lasmiditan 100 mg",{"nctId":19111,"briefTitle":19112,"status":103,"phases":19113,"primaryCompletion":1546,"completion":1628,"start":3697,"enrollment":19114,"conditions":19115,"interventions":19117},"NCT02439320","Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:",[87],2231,[19116],"Acute Migraine",[19109,19074],{"trials":19119,"activeCount":97},[],{"trials":19121,"activeCount":97},[],{"intervention":15291,"totalTrials":1400,"cells":19123},{"EARLY_PHASE1":19124,"PHASE1":19126,"PHASE2":19134,"PHASE3":19136,"PHASE4":19156,"NA":19158},{"trials":19125,"activeCount":97},[],{"trials":19127,"activeCount":97},[19128],{"nctId":19129,"briefTitle":19130,"status":103,"phases":19131,"conditions":19132,"interventions":19133},"NCT00094640","Pharmacokinetic Characterization of Intramuscular Olanzapine Depot",[85],[4897,14400],[15291],{"trials":19135,"activeCount":97},[],{"trials":19137,"activeCount":97},[19138,19146,19152],{"nctId":19139,"briefTitle":19140,"status":103,"phases":19141,"primaryCompletion":3152,"completion":3152,"start":3077,"enrollment":19142,"conditions":19143,"interventions":19144},"NCT00088465","Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder",[87],931,[14463,14400],[19145],"Intramuscular olanzapine depot",{"nctId":19147,"briefTitle":19148,"status":103,"phases":19149,"completion":3566,"start":3194,"enrollment":13191,"conditions":19150,"interventions":19151},"NCT00088478","Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia",[87],[4897],[15291],{"nctId":15286,"briefTitle":15287,"status":103,"phases":19153,"completion":2876,"start":3194,"enrollment":2113,"conditions":19154,"interventions":19155},[87],[14463],[15291,15275],{"trials":19157,"activeCount":97},[],{"trials":19159,"activeCount":97},[],{"intervention":6603,"totalTrials":1400,"cells":19161},{"EARLY_PHASE1":19162,"PHASE1":19164,"PHASE2":19166,"PHASE3":19180,"PHASE4":19186,"NA":19188},{"trials":19163,"activeCount":97},[],{"trials":19165,"activeCount":97},[],{"trials":19167,"activeCount":97},[19168,19172,19176],{"nctId":10748,"briefTitle":10749,"status":103,"phases":19169,"primaryCompletion":3069,"completion":8217,"start":2846,"enrollment":118,"conditions":19170,"interventions":19171},[86],[2586],[3117,2520,6603,10753,10753],{"nctId":6597,"briefTitle":6598,"status":103,"phases":19173,"primaryCompletion":2917,"completion":6600,"start":2798,"enrollment":864,"conditions":19174,"interventions":19175},[86],[2589],[61,1745,6603,2923],{"nctId":10765,"briefTitle":10766,"status":103,"phases":19177,"primaryCompletion":3685,"completion":8233,"start":3813,"enrollment":37,"conditions":19178,"interventions":19179},[86],[5657],[10770,2520,6603,10753],{"trials":19181,"activeCount":97},[19182],{"nctId":6711,"briefTitle":6712,"status":103,"phases":19183,"primaryCompletion":6714,"completion":6715,"start":6716,"enrollment":6717,"conditions":19184,"interventions":19185},[87],[1490],[61,1745,6720,2923],{"trials":19187,"activeCount":97},[],{"trials":19189,"activeCount":97},[],{"intervention":13672,"totalTrials":1400,"cells":19191},{"EARLY_PHASE1":19192,"PHASE1":19194,"PHASE2":19196,"PHASE3":19198,"PHASE4":19216,"NA":19218},{"trials":19193,"activeCount":97},[],{"trials":19195,"activeCount":97},[],{"trials":19197,"activeCount":97},[],{"trials":19199,"activeCount":97},[19200,19204,19208,19212],{"nctId":18424,"briefTitle":18425,"status":103,"phases":19201,"primaryCompletion":3292,"completion":3292,"start":4266,"enrollment":18427,"conditions":19202,"interventions":19203},[87],[18],[13554,13672],{"nctId":13658,"briefTitle":13659,"status":103,"phases":19205,"primaryCompletion":3292,"completion":3292,"start":2947,"enrollment":13661,"conditions":19206,"interventions":19207},[87],[33],[13554,13664,506],{"nctId":13666,"briefTitle":13667,"status":103,"phases":19209,"primaryCompletion":3292,"completion":3292,"start":2855,"enrollment":13669,"conditions":19210,"interventions":19211},[87],[33],[13554,13672,506],{"nctId":13674,"briefTitle":13675,"status":103,"phases":19213,"primaryCompletion":3292,"completion":3292,"start":3645,"enrollment":2790,"conditions":19214,"interventions":19215},[86,87],[33],[7103,13554,13664],{"trials":19217,"activeCount":97},[],{"trials":19219,"activeCount":97},[],{"intervention":18311,"totalTrials":1232,"cells":19221},{"EARLY_PHASE1":19222,"PHASE1":19224,"PHASE2":19230,"PHASE3":19232,"PHASE4":19242,"NA":19244},{"trials":19223,"activeCount":97},[],{"trials":19225,"activeCount":97},[19226],{"nctId":18303,"briefTitle":18304,"status":103,"phases":19227,"primaryCompletion":18306,"completion":18307,"start":18308,"enrollment":2790,"conditions":19228,"interventions":19229},[85],[139,33],[18296,18311],{"trials":19231,"activeCount":97},[],{"trials":19233,"activeCount":97},[19234,19238],{"nctId":18349,"briefTitle":18350,"status":103,"phases":19235,"primaryCompletion":5030,"completion":5030,"start":4980,"enrollment":118,"conditions":19236,"interventions":19237},[86,87],[33],[18296,18311],{"nctId":18363,"briefTitle":18364,"status":103,"phases":19239,"primaryCompletion":5030,"completion":5030,"start":4980,"enrollment":3095,"conditions":19240,"interventions":19241},[87],[33],[18296,18311],{"trials":19243,"activeCount":97},[],{"trials":19245,"activeCount":97},[],{"intervention":17601,"totalTrials":1232,"cells":19247},{"EARLY_PHASE1":19248,"PHASE1":19250,"PHASE2":19256,"PHASE3":19262,"PHASE4":19268,"NA":19270},{"trials":19249,"activeCount":97},[],{"trials":19251,"activeCount":97},[19252],{"nctId":17596,"briefTitle":17597,"status":103,"phases":19253,"primaryCompletion":8217,"completion":8217,"start":3283,"enrollment":310,"conditions":19254,"interventions":19255},[85],[18],[9681,17601,17602,17603],{"trials":19257,"activeCount":97},[19258],{"nctId":18389,"briefTitle":18390,"status":103,"phases":19259,"completion":3746,"start":3195,"enrollment":18392,"conditions":19260,"interventions":19261},[86],[33],[18395,18396],{"trials":19263,"activeCount":97},[19264],{"nctId":18409,"briefTitle":18410,"status":103,"phases":19265,"primaryCompletion":3292,"completion":3292,"start":3524,"enrollment":18412,"conditions":19266,"interventions":19267},[87],[18],[13554,17601],{"trials":19269,"activeCount":97},[],{"trials":19271,"activeCount":97},[],{"intervention":19273,"totalTrials":1232,"cells":19274},"LY3819253",{"EARLY_PHASE1":19275,"PHASE1":19277,"PHASE2":19293,"PHASE3":19295,"PHASE4":19307,"NA":19309},{"trials":19276,"activeCount":97},[],{"trials":19278,"activeCount":97},[19279,19286],{"nctId":19280,"briefTitle":19281,"status":103,"phases":19282,"primaryCompletion":11431,"completion":11431,"start":19283,"enrollment":893,"conditions":19284,"interventions":19285},"NCT04411628","A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19",[85],"2020-05-28",[5284],[19273],{"nctId":19287,"briefTitle":19288,"status":103,"phases":19289,"primaryCompletion":6978,"completion":6978,"start":19290,"enrollment":9038,"conditions":19291,"interventions":19292},"NCT04537910","A Study of LY3819253 (LY-CoV555) in Healthy Participants",[85],"2020-09-02",[15],[19273],{"trials":19294,"activeCount":97},[],{"trials":19296,"activeCount":97},[19297],{"nctId":19298,"briefTitle":19299,"status":103,"phases":19300,"primaryCompletion":2540,"completion":2540,"start":19301,"enrollment":19302,"conditions":19303,"interventions":19304},"NCT04427501","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness",[86,87],"2020-06-17",3307,[5284],[19273,19305,19306],"LY3832479","LY3853113",{"trials":19308,"activeCount":97},[],{"trials":19310,"activeCount":97},[],{"intervention":9819,"totalTrials":1232,"cells":19312},{"EARLY_PHASE1":19313,"PHASE1":19315,"PHASE2":19317,"PHASE3":19327,"PHASE4":19336,"NA":19338},{"trials":19314,"activeCount":97},[],{"trials":19316,"activeCount":97},[],{"trials":19318,"activeCount":97},[19319,19323],{"nctId":18470,"briefTitle":18471,"status":103,"phases":19320,"primaryCompletion":4955,"completion":3698,"start":3837,"enrollment":3546,"conditions":19321,"interventions":19322},[86],[36],[9819,18475,1843],{"nctId":9810,"briefTitle":9811,"status":103,"phases":19324,"primaryCompletion":1473,"completion":1596,"start":3069,"enrollment":4005,"conditions":19325,"interventions":19326},[86],[9814,9815,9816,9817],[1722,9819,6543],{"trials":19328,"activeCount":97},[19329],{"nctId":19330,"briefTitle":19331,"status":103,"phases":19332,"primaryCompletion":6632,"completion":1596,"start":8233,"enrollment":19333,"conditions":19334,"interventions":19335},"NCT01140347","A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib",[87],565,[2608],[9819],{"trials":19337,"activeCount":97},[],{"trials":19339,"activeCount":97},[],{"intervention":13100,"totalTrials":1232,"cells":19341},{"EARLY_PHASE1":19342,"PHASE1":19344,"PHASE2":19346,"PHASE3":19348,"PHASE4":19362,"NA":19364},{"trials":19343,"activeCount":97},[],{"trials":19345,"activeCount":97},[],{"trials":19347,"activeCount":97},[],{"trials":19349,"activeCount":97},[19350,19354,19358],{"nctId":13093,"briefTitle":13094,"status":103,"phases":19351,"primaryCompletion":989,"completion":989,"start":13096,"enrollment":3978,"conditions":19352,"interventions":19353},[87],[466],[13099,13100,438],{"nctId":18264,"briefTitle":18265,"status":103,"phases":19355,"primaryCompletion":18267,"completion":18267,"start":18268,"enrollment":13135,"conditions":19356,"interventions":19357},[87],[30],[13099,13100],{"nctId":18284,"briefTitle":18285,"status":103,"phases":19359,"primaryCompletion":1546,"completion":1546,"start":3776,"enrollment":1978,"conditions":19360,"interventions":19361},[87],[18],[13099,18289,18290],{"trials":19363,"activeCount":97},[],{"trials":19365,"activeCount":97},[],{"intervention":17380,"totalTrials":1232,"cells":19367},{"EARLY_PHASE1":19368,"PHASE1":19370,"PHASE2":19372,"PHASE3":19382,"PHASE4":19392,"NA":19394},{"trials":19369,"activeCount":97},[],{"trials":19371,"activeCount":97},[],{"trials":19373,"activeCount":97},[19374],{"nctId":19375,"briefTitle":19376,"status":103,"phases":19377,"primaryCompletion":1475,"completion":5354,"start":2964,"enrollment":5355,"conditions":19378,"interventions":19379},"NCT01890967","A Study of LY3015014 in Participants With High Cholesterol",[86],[17378],[19380,19381,17380],"LY3015014","Statin",{"trials":19383,"activeCount":97},[19384,19388],{"nctId":17374,"briefTitle":17375,"status":999,"phases":19385,"primaryCompletion":4383,"completion":4383,"start":5030,"enrollment":7363,"conditions":19386,"interventions":19387},[87],[17378],[17257,17380,9237],{"nctId":17389,"briefTitle":17390,"status":999,"phases":19389,"primaryCompletion":3123,"completion":3123,"start":3318,"enrollment":17392,"conditions":19390,"interventions":19391},[87],[17394],[17257,9237,17380],{"trials":19393,"activeCount":97},[],{"trials":19395,"activeCount":97},[],{"intervention":19397,"totalTrials":1232,"cells":19398},"Testosterone MD-Lotion",{"EARLY_PHASE1":19399,"PHASE1":19401,"PHASE2":19403,"PHASE3":19411,"PHASE4":19425,"NA":19427},{"trials":19400,"activeCount":97},[],{"trials":19402,"activeCount":97},[],{"trials":19404,"activeCount":97},[19405],{"nctId":19406,"briefTitle":19407,"status":103,"phases":19408,"primaryCompletion":3308,"completion":3308,"start":3235,"enrollment":11639,"conditions":19409,"interventions":19410},"NCT00857961","A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations",[86],[16086],[19397],{"trials":19412,"activeCount":97},[19413,19419],{"nctId":19414,"briefTitle":19415,"status":103,"phases":19416,"primaryCompletion":2955,"completion":2955,"start":3132,"enrollment":2571,"conditions":19417,"interventions":19418},"NCT00857454","A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations",[87],[16086],[19397],{"nctId":19420,"briefTitle":19421,"status":103,"phases":19422,"primaryCompletion":3059,"completion":3059,"start":3575,"enrollment":17417,"conditions":19423,"interventions":19424},"NCT00702650","A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations",[87],[16086],[19397],{"trials":19426,"activeCount":97},[],{"trials":19428,"activeCount":97},[],{"intervention":4610,"totalTrials":1232,"cells":19430},{"EARLY_PHASE1":19431,"PHASE1":19433,"PHASE2":19443,"PHASE3":19451,"PHASE4":19457,"NA":19459},{"trials":19432,"activeCount":97},[],{"trials":19434,"activeCount":97},[19435],{"nctId":19436,"briefTitle":19437,"status":103,"phases":19438,"primaryCompletion":3086,"completion":3086,"start":3662,"enrollment":1178,"conditions":19439,"interventions":19440},"NCT01214668","Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors",[85],[2589],[19441,19442],"LY573636-sodium","Liposomal Doxorubicin",{"trials":19444,"activeCount":97},[19445],{"nctId":19446,"briefTitle":19447,"status":103,"phases":19448,"primaryCompletion":3004,"completion":9748,"start":5860,"enrollment":174,"conditions":19449,"interventions":19450},"NCT00913835","A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer",[86],[2553],[2545,4610],{"trials":19452,"activeCount":97},[19453],{"nctId":4605,"briefTitle":4606,"status":103,"phases":19454,"completion":3228,"start":3209,"enrollment":1730,"conditions":19455,"interventions":19456},[87],[3762,3548,2553,3763,3601],[1511,4610],{"trials":19458,"activeCount":97},[],{"trials":19460,"activeCount":97},[],{"intervention":19462,"totalTrials":1232,"cells":19463},"LY450139",{"EARLY_PHASE1":19464,"PHASE1":19466,"PHASE2":19474,"PHASE3":19476,"PHASE4":19492,"NA":19494},{"trials":19465,"activeCount":97},[],{"trials":19467,"activeCount":97},[19468],{"nctId":19469,"briefTitle":19470,"status":103,"phases":19471,"primaryCompletion":2975,"completion":2975,"start":3185,"enrollment":2071,"conditions":19472,"interventions":19473},"NCT00765115","A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.",[85],[3980],[19462],{"trials":19475,"activeCount":97},[],{"trials":19477,"activeCount":97},[19478,19485],{"nctId":19479,"briefTitle":19480,"status":103,"phases":19481,"primaryCompletion":2844,"completion":2844,"start":3338,"enrollment":19482,"conditions":19483,"interventions":19484},"NCT00594568","Effect of LY450139 on the Long Term Progression of Alzheimer's Disease",[87],1537,[4040],[19462],{"nctId":19486,"briefTitle":19487,"status":103,"phases":19488,"primaryCompletion":3069,"completion":3069,"start":3320,"enrollment":19489,"conditions":19490,"interventions":19491},"NCT00762411","Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",[87],1111,[4040],[19462],{"trials":19493,"activeCount":97},[],{"trials":19495,"activeCount":97},[],{"intervention":2593,"totalTrials":1232,"cells":19497},{"EARLY_PHASE1":19498,"PHASE1":19500,"PHASE2":19506,"PHASE3":19512,"PHASE4":19518,"NA":19520},{"trials":19499,"activeCount":97},[],{"trials":19501,"activeCount":97},[19502],{"nctId":2576,"briefTitle":2577,"status":103,"phases":19503,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":19504,"interventions":19505},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":19507,"activeCount":97},[19508],{"nctId":4231,"briefTitle":4232,"status":999,"phases":19509,"primaryCompletion":1619,"completion":1619,"start":3124,"enrollment":1199,"conditions":19510,"interventions":19511},[85,86],[1653],[3470,2593,1511,1539],{"trials":19513,"activeCount":97},[19514],{"nctId":18668,"briefTitle":18669,"status":103,"phases":19515,"primaryCompletion":5201,"completion":989,"start":18671,"enrollment":18672,"conditions":19516,"interventions":19517},[87],[1653],[2591,2593],{"trials":19519,"activeCount":97},[],{"trials":19521,"activeCount":97},[],{"intervention":19523,"totalTrials":1232,"cells":19524},"LY2062430",{"EARLY_PHASE1":19525,"PHASE1":19527,"PHASE2":19529,"PHASE3":19537,"PHASE4":19551,"NA":19553},{"trials":19526,"activeCount":97},[],{"trials":19528,"activeCount":97},[],{"trials":19530,"activeCount":97},[19531],{"nctId":19532,"briefTitle":19533,"status":103,"phases":19534,"primaryCompletion":3292,"completion":3292,"start":3259,"enrollment":9038,"conditions":19535,"interventions":19536},"NCT00329082","Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers",[86],[4040],[19523],{"trials":19538,"activeCount":97},[19539,19546],{"nctId":19540,"briefTitle":19541,"status":103,"phases":19542,"primaryCompletion":3838,"completion":3838,"start":2929,"enrollment":19543,"conditions":19544,"interventions":19545},"NCT00904683","Effect of LY2062430 on the Progression of Alzheimer's Disease",[87],1040,[4040],[19523],{"nctId":19547,"briefTitle":19541,"status":103,"phases":19548,"primaryCompletion":2864,"completion":2864,"start":2929,"enrollment":2275,"conditions":19549,"interventions":19550},"NCT00905372",[87],[4040],[19523],{"trials":19552,"activeCount":97},[],{"trials":19554,"activeCount":97},[],{"intervention":18760,"totalTrials":1232,"cells":19556},{"EARLY_PHASE1":19557,"PHASE1":19559,"PHASE2":19568,"PHASE3":19574,"PHASE4":19580,"NA":19582},{"trials":19558,"activeCount":97},[],{"trials":19560,"activeCount":97},[19561],{"nctId":19562,"briefTitle":19563,"status":103,"phases":19564,"primaryCompletion":10382,"completion":444,"start":19565,"enrollment":1587,"conditions":19566,"interventions":19567},"NCT01682187","A Dose-Escalation Study in Participants With Recurrent Malignant Glioma",[85],"2005-12-15",[1850],[4101,18760],{"trials":19569,"activeCount":97},[19570],{"nctId":18753,"briefTitle":18754,"status":103,"phases":19571,"primaryCompletion":18756,"completion":912,"start":18757,"enrollment":6539,"conditions":19572,"interventions":19573},[86],[9127],[4387,18760],{"trials":19575,"activeCount":97},[19576],{"nctId":16715,"briefTitle":16716,"status":103,"phases":19577,"primaryCompletion":3813,"completion":4098,"start":13847,"enrollment":16718,"conditions":19578,"interventions":19579},[87],[9127],[2979,16721],{"trials":19581,"activeCount":97},[],{"trials":19583,"activeCount":97},[],{"intervention":19305,"totalTrials":1232,"cells":19585},{"EARLY_PHASE1":19586,"PHASE1":19588,"PHASE2":19603,"PHASE3":19605,"PHASE4":19611,"NA":19613},{"trials":19587,"activeCount":97},[],{"trials":19589,"activeCount":97},[19590,19597],{"nctId":19591,"briefTitle":19592,"status":103,"phases":19593,"primaryCompletion":19594,"completion":19594,"start":4054,"enrollment":893,"conditions":19595,"interventions":19596},"NCT04441931","A Study of LY3832479 (LY-CoV016) in Healthy Participants",[85],"2020-10-02",[15],[19305],{"nctId":19598,"briefTitle":19599,"status":103,"phases":19600,"primaryCompletion":1530,"completion":1530,"start":18085,"enrollment":12,"conditions":19601,"interventions":19602},"NCT04611789","A Study of LY3832479 (LY-CoV016) in Healthy Participants 1",[85],[15],[19305],{"trials":19604,"activeCount":97},[],{"trials":19606,"activeCount":97},[19607],{"nctId":19298,"briefTitle":19299,"status":103,"phases":19608,"primaryCompletion":2540,"completion":2540,"start":19301,"enrollment":19302,"conditions":19609,"interventions":19610},[86,87],[5284],[19273,19305,19306],{"trials":19612,"activeCount":97},[],{"trials":19614,"activeCount":97},[],{"intervention":7118,"totalTrials":1232,"cells":19616},{"EARLY_PHASE1":19617,"PHASE1":19619,"PHASE2":19621,"PHASE3":19623,"PHASE4":19637,"NA":19639},{"trials":19618,"activeCount":97},[],{"trials":19620,"activeCount":97},[],{"trials":19622,"activeCount":97},[],{"trials":19624,"activeCount":97},[19625,19629,19633],{"nctId":17640,"briefTitle":14258,"status":103,"phases":19626,"primaryCompletion":3049,"completion":3049,"start":5090,"enrollment":7344,"conditions":19627,"interventions":19628},[87],[120],[9681,7118,17644,17645,17646,17647],{"nctId":7112,"briefTitle":7113,"status":103,"phases":19630,"primaryCompletion":3122,"completion":3776,"start":3545,"enrollment":7115,"conditions":19631,"interventions":19632},[87],[120],[303,7103,1631,7118],{"nctId":13640,"briefTitle":13641,"status":103,"phases":19634,"primaryCompletion":3027,"completion":3027,"start":2864,"enrollment":3823,"conditions":19635,"interventions":19636},[87],[120],[9681,7103,7118,13645],{"trials":19638,"activeCount":97},[],{"trials":19640,"activeCount":97},[],{"intervention":19642,"totalTrials":1232,"cells":19643},"Tamsulosin",{"EARLY_PHASE1":19644,"PHASE1":19646,"PHASE2":19648,"PHASE3":19656,"PHASE4":19674,"NA":19676},{"trials":19645,"activeCount":97},[],{"trials":19647,"activeCount":97},[],{"trials":19649,"activeCount":97},[19650],{"nctId":19651,"briefTitle":19652,"status":103,"phases":19653,"primaryCompletion":3575,"completion":3575,"start":3235,"enrollment":13828,"conditions":19654,"interventions":19655},"NCT00540124","Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men",[86],[15444],[10904,19642],{"trials":19657,"activeCount":97},[19658,19665],{"nctId":19659,"briefTitle":19660,"status":103,"phases":19661,"primaryCompletion":2918,"completion":2918,"start":2866,"enrollment":19662,"conditions":19663,"interventions":19664},"NCT00861757","Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia",[87],612,[15444],[10904,19642],{"nctId":19666,"briefTitle":19667,"status":103,"phases":19668,"primaryCompletion":4258,"completion":4258,"start":3050,"enrollment":19669,"conditions":19670,"interventions":19672},"NCT00970632","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia",[87],511,[19671],"Benign Prostatic Hyperplasia (BPH)",[19673,19642],"Tadalafil 5 mg",{"trials":19675,"activeCount":97},[],{"trials":19677,"activeCount":97},[],{"intervention":19679,"totalTrials":1232,"cells":19680},"teriparatide 20 micrograms\u002Fday subcutaneous",{"EARLY_PHASE1":19681,"PHASE1":19683,"PHASE2":19685,"PHASE3":19687,"PHASE4":19709,"NA":19711},{"trials":19682,"activeCount":97},[],{"trials":19684,"activeCount":97},[],{"trials":19686,"activeCount":97},[],{"trials":19688,"activeCount":97},[19689,19696,19703],{"nctId":19690,"briefTitle":19691,"status":103,"phases":19692,"completion":3194,"start":3161,"enrollment":9415,"conditions":19693,"interventions":19694},"NCT00543218","PTH Comparison in Post Menopausal Women",[87],[14193],[19679,19695],"calcitonin 100 IU\u002Fday subcutaneous",{"nctId":19697,"briefTitle":19698,"status":103,"phases":19699,"completion":3646,"start":13765,"enrollment":2790,"conditions":19700,"interventions":19701},"NCT00542984","Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis",[87],[14168],[19679,19702],"salmon calcitonin 100 IU\u002Fday subcutaneous",{"nctId":19704,"briefTitle":19705,"status":103,"phases":19706,"completion":3077,"start":3710,"enrollment":10911,"conditions":19707,"interventions":19708},"NCT00543023","A Study of the Treatment of Postmenopausal Women With Osteoporosis",[87],[14193],[19679,19702],{"trials":19710,"activeCount":97},[],{"trials":19712,"activeCount":97},[],{"intervention":3032,"totalTrials":1232,"cells":19714},{"EARLY_PHASE1":19715,"PHASE1":19717,"PHASE2":19723,"PHASE3":19729,"PHASE4":19735,"NA":19737},{"trials":19716,"activeCount":97},[],{"trials":19718,"activeCount":97},[19719],{"nctId":18686,"briefTitle":18687,"status":103,"phases":19720,"conditions":19721,"interventions":19722},[85],[8969,2824],[2893,18691,18692],{"trials":19724,"activeCount":97},[19725],{"nctId":3024,"briefTitle":3025,"status":103,"phases":19726,"primaryCompletion":3027,"completion":3028,"start":3029,"enrollment":2733,"conditions":19727,"interventions":19728},[86],[1694],[1612,1510,3032,3033,3034],{"trials":19730,"activeCount":97},[19731],{"nctId":5287,"briefTitle":5288,"status":103,"phases":19732,"primaryCompletion":1473,"completion":1474,"start":3048,"enrollment":5290,"conditions":19733,"interventions":19734},[87],[5218],[4944,5095,5222,5293,3032],{"trials":19736,"activeCount":97},[],{"trials":19738,"activeCount":97},[],{"intervention":19740,"totalTrials":1232,"cells":19741},"dirucotide",{"EARLY_PHASE1":19742,"PHASE1":19744,"PHASE2":19746,"PHASE3":19748,"PHASE4":19771,"NA":19773},{"trials":19743,"activeCount":97},[],{"trials":19745,"activeCount":97},[],{"trials":19747,"activeCount":97},[],{"trials":19749,"activeCount":97},[19750,19758,19765],{"nctId":19751,"briefTitle":19752,"status":103,"phases":19753,"primaryCompletion":2929,"completion":2929,"start":2909,"enrollment":19754,"conditions":19755,"interventions":19757},"NCT00869726","A Study for Patients With Secondary Progressive Multiple Sclerosis",[86,87],596,[19756],"Secondary Progressive Multiple Sclerosis",[19740],{"nctId":19759,"briefTitle":19760,"status":103,"phases":19761,"primaryCompletion":14517,"completion":14517,"start":2930,"enrollment":3593,"conditions":19762,"interventions":19764},"NCT00869986","A Study for Patients With Relapsing Remitting Multiple Sclerosis",[86,87],[19763],"Relapsing Remitting Multiple Sclerosis",[19740],{"nctId":19766,"briefTitle":19767,"status":999,"phases":19768,"primaryCompletion":14517,"completion":14517,"start":2875,"enrollment":2227,"conditions":19769,"interventions":19770},"NCT00870155","A Study for Patients With Multiple Sclerosis",[86,87],[19756],[19740],{"trials":19772,"activeCount":97},[],{"trials":19774,"activeCount":97},[],{"intervention":19109,"totalTrials":947,"cells":19776},{"EARLY_PHASE1":19777,"PHASE1":19779,"PHASE2":19781,"PHASE3":19783,"PHASE4":19793,"NA":19795},{"trials":19778,"activeCount":97},[],{"trials":19780,"activeCount":97},[],{"trials":19782,"activeCount":97},[],{"trials":19784,"activeCount":97},[19785,19789],{"nctId":19100,"briefTitle":19101,"status":103,"phases":19786,"primaryCompletion":19103,"completion":19103,"start":2799,"enrollment":19104,"conditions":19787,"interventions":19788},[87],[19106],[19108,19109,19074],{"nctId":19111,"briefTitle":19112,"status":103,"phases":19790,"primaryCompletion":1546,"completion":1628,"start":3697,"enrollment":19114,"conditions":19791,"interventions":19792},[87],[19116],[19109,19074],{"trials":19794,"activeCount":97},[],{"trials":19796,"activeCount":97},[],{"intervention":13802,"totalTrials":947,"cells":19798},{"EARLY_PHASE1":19799,"PHASE1":19801,"PHASE2":19803,"PHASE3":19805,"PHASE4":19815,"NA":19817},{"trials":19800,"activeCount":97},[],{"trials":19802,"activeCount":97},[],{"trials":19804,"activeCount":97},[],{"trials":19806,"activeCount":97},[19807,19811],{"nctId":13797,"briefTitle":13798,"status":103,"phases":19808,"completion":3218,"start":4448,"enrollment":1062,"conditions":19809,"interventions":19810},[87],[13785],[13772,13802],{"nctId":13804,"briefTitle":13805,"status":103,"phases":19812,"completion":2948,"start":4459,"enrollment":13807,"conditions":19813,"interventions":19814},[87],[13785],[13772,13802],{"trials":19816,"activeCount":97},[],{"trials":19818,"activeCount":97},[],{"intervention":19820,"totalTrials":947,"cells":19821},"Etesevimab",{"EARLY_PHASE1":19822,"PHASE1":19824,"PHASE2":19826,"PHASE3":19840,"PHASE4":19853,"NA":19855},{"trials":19823,"activeCount":97},[],{"trials":19825,"activeCount":97},[],{"trials":19827,"activeCount":97},[19828],{"nctId":19829,"briefTitle":19830,"status":103,"phases":19831,"primaryCompletion":7530,"completion":19832,"start":19833,"enrollment":19834,"conditions":19835,"interventions":19836},"NCT04634409","A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness",[86],"2021-10-18","2020-10-29",1755,[5284],[19837,19820,19838,19839],"Bamlanivimab","VIR-7831","Bebtelovimab",{"trials":19841,"activeCount":97},[19842],{"nctId":19843,"briefTitle":19844,"status":103,"phases":19845,"primaryCompletion":19846,"completion":19847,"start":19848,"enrollment":19849,"conditions":19850,"interventions":19852},"NCT04497987","A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff",[87],"2021-01-16","2021-05-20","2020-08-02",1180,[5284,19851],"SARS-CoV2",[19837,19820],{"trials":19854,"activeCount":97},[],{"trials":19856,"activeCount":97},[],{"intervention":19858,"totalTrials":947,"cells":19859},"Ethinyl estradiol",{"EARLY_PHASE1":19860,"PHASE1":19862,"PHASE2":19874,"PHASE3":19876,"PHASE4":19887,"NA":19889},{"trials":19861,"activeCount":97},[],{"trials":19863,"activeCount":97},[19864],{"nctId":19865,"briefTitle":19866,"status":103,"phases":19867,"primaryCompletion":19868,"completion":19868,"start":19869,"enrollment":1741,"conditions":19870,"interventions":19871},"NCT06039826","A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese",[85],"2024-07-11","2023-09-12",[27],[6982,19872,19873],"Ethinyl Estradiol","Drospirenone",{"trials":19875,"activeCount":97},[],{"trials":19877,"activeCount":97},[19878],{"nctId":19879,"briefTitle":19880,"status":103,"phases":19881,"primaryCompletion":3227,"completion":3227,"start":19882,"enrollment":7145,"conditions":19883,"interventions":19884},"NCT00191113","Somatropin Treatment to Final Height in Turner Syndrome",[87],"1989-02",[15689],[19885,19858,19886],"Somatropin","Medroxyprogesterone acetate",{"trials":19888,"activeCount":97},[],{"trials":19890,"activeCount":97},[],{"intervention":19886,"totalTrials":947,"cells":19892},{"EARLY_PHASE1":19893,"PHASE1":19895,"PHASE2":19897,"PHASE3":19903,"PHASE4":19909,"NA":19911},{"trials":19894,"activeCount":97},[],{"trials":19896,"activeCount":97},[],{"trials":19898,"activeCount":97},[19899],{"nctId":14151,"briefTitle":14152,"status":103,"phases":19900,"completion":5953,"start":4634,"enrollment":658,"conditions":19901,"interventions":19902},[86],[14155,14156],[14142,14158,14159,14160],{"trials":19904,"activeCount":97},[19905],{"nctId":19879,"briefTitle":19880,"status":103,"phases":19906,"primaryCompletion":3227,"completion":3227,"start":19882,"enrollment":7145,"conditions":19907,"interventions":19908},[87],[15689],[19885,19858,19886],{"trials":19910,"activeCount":97},[],{"trials":19912,"activeCount":97},[],{"intervention":19914,"totalTrials":947,"cells":19915},"50 mg etanercept",{"EARLY_PHASE1":19916,"PHASE1":19918,"PHASE2":19920,"PHASE3":19922,"PHASE4":19945,"NA":19947},{"trials":19917,"activeCount":97},[],{"trials":19919,"activeCount":97},[],{"trials":19921,"activeCount":97},[],{"trials":19923,"activeCount":97},[19924,19934],{"nctId":19925,"briefTitle":19926,"status":103,"phases":19927,"primaryCompletion":19928,"completion":309,"start":19929,"enrollment":19930,"conditions":19931,"interventions":19932},"NCT01646177","A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)",[87],"2014-05-22","2012-07-28",1346,[447],[19914,19933],"80 mg ixekizumab",{"nctId":19935,"briefTitle":19936,"status":103,"phases":19937,"primaryCompletion":19938,"completion":19939,"start":19940,"enrollment":19941,"conditions":19942,"interventions":19943},"NCT01597245","A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)",[87],"2014-03-25","2019-06-18","2012-05-18",1224,[447],[19944,19914],"80 mg ixekizumab Dosing Regimen",{"trials":19946,"activeCount":97},[],{"trials":19948,"activeCount":97},[],{"intervention":19933,"totalTrials":947,"cells":19950},{"EARLY_PHASE1":19951,"PHASE1":19953,"PHASE2":19955,"PHASE3":19957,"PHASE4":19969,"NA":19971},{"trials":19952,"activeCount":97},[],{"trials":19954,"activeCount":97},[],{"trials":19956,"activeCount":97},[],{"trials":19958,"activeCount":97},[19959,19963],{"nctId":19925,"briefTitle":19926,"status":103,"phases":19960,"primaryCompletion":19928,"completion":309,"start":19929,"enrollment":19930,"conditions":19961,"interventions":19962},[87],[447],[19914,19933],{"nctId":19964,"briefTitle":19965,"status":103,"phases":19966,"primaryCompletion":5022,"completion":7255,"start":3838,"enrollment":4279,"conditions":19967,"interventions":19968},"NCT01624233","A Study in Japanese Participants With Moderate-to-Severe Psoriasis",[87],[447],[19933],{"trials":19970,"activeCount":97},[],{"trials":19972,"activeCount":97},[],{"intervention":7063,"totalTrials":947,"cells":19974},{"EARLY_PHASE1":19975,"PHASE1":19977,"PHASE2":19979,"PHASE3":19981,"PHASE4":19991,"NA":19993},{"trials":19976,"activeCount":97},[],{"trials":19978,"activeCount":97},[],{"trials":19980,"activeCount":97},[],{"trials":19982,"activeCount":97},[19983,19987],{"nctId":9690,"briefTitle":9691,"status":103,"phases":19984,"primaryCompletion":7547,"completion":9693,"start":9694,"enrollment":9695,"conditions":19985,"interventions":19986},[87],[120],[9698,438,506,700,1631,7063],{"nctId":7058,"briefTitle":7059,"status":103,"phases":19988,"primaryCompletion":5081,"completion":5081,"start":4383,"enrollment":1358,"conditions":19989,"interventions":19990},[87],[120],[303,7063,1631],{"trials":19992,"activeCount":97},[],{"trials":19994,"activeCount":97},[],{"intervention":3640,"totalTrials":947,"cells":19996},{"EARLY_PHASE1":19997,"PHASE1":19999,"PHASE2":20001,"PHASE3":20007,"PHASE4":20015,"NA":20017},{"trials":19998,"activeCount":97},[],{"trials":20000,"activeCount":97},[],{"trials":20002,"activeCount":97},[20003],{"nctId":3632,"briefTitle":3633,"status":103,"phases":20004,"start":3635,"conditions":20005,"interventions":20006},[86],[1589,3637,3638],[1511,1512,3640],{"trials":20008,"activeCount":97},[20009],{"nctId":20010,"briefTitle":20011,"status":103,"phases":20012,"start":4366,"conditions":20013,"interventions":20014},"NCT00034268","A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer",[87],[1589],[3640],{"trials":20016,"activeCount":97},[],{"trials":20018,"activeCount":97},[],{"intervention":19673,"totalTrials":947,"cells":20020},{"EARLY_PHASE1":20021,"PHASE1":20023,"PHASE2":20025,"PHASE3":20035,"PHASE4":20041,"NA":20043},{"trials":20022,"activeCount":97},[],{"trials":20024,"activeCount":97},[],{"trials":20026,"activeCount":97},[20027],{"nctId":20028,"briefTitle":20029,"status":103,"phases":20030,"primaryCompletion":5860,"completion":3251,"start":2974,"enrollment":20031,"conditions":20032,"interventions":20033},"NCT00783094","Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension",[86],422,[15444],[20034,19673],"Tadalafil 2.5 mg",{"trials":20036,"activeCount":97},[20037],{"nctId":19666,"briefTitle":19667,"status":103,"phases":20038,"primaryCompletion":4258,"completion":4258,"start":3050,"enrollment":19669,"conditions":20039,"interventions":20040},[87],[19671],[19673,19642],{"trials":20042,"activeCount":97},[],{"trials":20044,"activeCount":97},[],{"intervention":5222,"totalTrials":947,"cells":20046},{"EARLY_PHASE1":20047,"PHASE1":20049,"PHASE2":20051,"PHASE3":20053,"PHASE4":20063,"NA":20065},{"trials":20048,"activeCount":97},[],{"trials":20050,"activeCount":97},[],{"trials":20052,"activeCount":97},[],{"trials":20054,"activeCount":97},[20055,20059],{"nctId":5213,"briefTitle":5214,"status":103,"phases":20056,"primaryCompletion":1596,"completion":1618,"start":2798,"enrollment":5216,"conditions":20057,"interventions":20058},[87],[5218],[5220,4944,5095,5221,5222],{"nctId":5287,"briefTitle":5288,"status":103,"phases":20060,"primaryCompletion":1473,"completion":1474,"start":3048,"enrollment":5290,"conditions":20061,"interventions":20062},[87],[5218],[4944,5095,5222,5293,3032],{"trials":20064,"activeCount":97},[],{"trials":20066,"activeCount":97},[],{"intervention":13583,"totalTrials":947,"cells":20068},{"EARLY_PHASE1":20069,"PHASE1":20071,"PHASE2":20073,"PHASE3":20075,"PHASE4":20085,"NA":20087},{"trials":20070,"activeCount":97},[],{"trials":20072,"activeCount":97},[],{"trials":20074,"activeCount":97},[],{"trials":20076,"activeCount":97},[20077,20081],{"nctId":17739,"briefTitle":17740,"status":103,"phases":20078,"primaryCompletion":4098,"completion":4098,"start":3124,"enrollment":17742,"conditions":20079,"interventions":20080},[87],[18],[12961,17745,13583],{"nctId":13577,"briefTitle":13578,"status":103,"phases":20082,"primaryCompletion":3697,"completion":3697,"start":3027,"enrollment":13580,"conditions":20083,"interventions":20084},[87],[120],[12954,506,13583],{"trials":20086,"activeCount":97},[],{"trials":20088,"activeCount":97},[],{"intervention":12974,"totalTrials":947,"cells":20090},{"EARLY_PHASE1":20091,"PHASE1":20093,"PHASE2":20099,"PHASE3":20101,"PHASE4":20107,"NA":20109},{"trials":20092,"activeCount":97},[],{"trials":20094,"activeCount":97},[20095],{"nctId":12969,"briefTitle":12970,"status":103,"phases":20096,"primaryCompletion":7547,"completion":7547,"start":6651,"enrollment":4475,"conditions":20097,"interventions":20098},[85],[33],[9698,438,12974,12974],{"trials":20100,"activeCount":97},[],{"trials":20102,"activeCount":97},[20103],{"nctId":13126,"briefTitle":13127,"status":103,"phases":20104,"primaryCompletion":4420,"completion":4420,"start":4160,"enrollment":3267,"conditions":20105,"interventions":20106},[87],[120],[438,12974],{"trials":20108,"activeCount":97},[],{"trials":20110,"activeCount":97},[],{"intervention":2783,"totalTrials":947,"cells":20112},{"EARLY_PHASE1":20113,"PHASE1":20115,"PHASE2":20121,"PHASE3":20123,"PHASE4":20129,"NA":20131},{"trials":20114,"activeCount":97},[],{"trials":20116,"activeCount":97},[20117],{"nctId":2774,"briefTitle":2775,"status":103,"phases":20118,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":20119,"interventions":20120},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"trials":20122,"activeCount":97},[],{"trials":20124,"activeCount":97},[20125],{"nctId":3391,"briefTitle":3392,"status":103,"phases":20126,"primaryCompletion":3394,"completion":1149,"start":3395,"enrollment":3396,"conditions":20127,"interventions":20128},[87],[3398,3399],[61,1843,1510,2783],{"trials":20130,"activeCount":97},[],{"trials":20132,"activeCount":97},[],{"intervention":5275,"totalTrials":947,"cells":20134},{"EARLY_PHASE1":20135,"PHASE1":20137,"PHASE2":20139,"PHASE3":20141,"PHASE4":20151,"NA":20153},{"trials":20136,"activeCount":97},[],{"trials":20138,"activeCount":97},[],{"trials":20140,"activeCount":97},[],{"trials":20142,"activeCount":97},[20143,20147],{"nctId":5269,"briefTitle":5270,"status":103,"phases":20144,"primaryCompletion":2845,"completion":3776,"start":4122,"enrollment":5272,"conditions":20145,"interventions":20146},[87],[5218],[4944,5275],{"nctId":5351,"briefTitle":5352,"status":103,"phases":20148,"primaryCompletion":5354,"completion":2845,"start":3068,"enrollment":5355,"conditions":20149,"interventions":20150},[87],[5218],[4944,5275],{"trials":20152,"activeCount":97},[],{"trials":20154,"activeCount":97},[],{"intervention":20156,"totalTrials":947,"cells":20157},"venlafaxine",{"EARLY_PHASE1":20158,"PHASE1":20160,"PHASE2":20162,"PHASE3":20164,"PHASE4":20179,"NA":20181},{"trials":20159,"activeCount":97},[],{"trials":20161,"activeCount":97},[],{"trials":20163,"activeCount":97},[],{"trials":20165,"activeCount":97},[20166,20173],{"nctId":20167,"briefTitle":20168,"status":103,"phases":20169,"completion":3337,"start":3566,"enrollment":14922,"conditions":20170,"interventions":20172},"NCT00122837","A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder",[87],[20171],"Anxiety Disorder",[14492,20156],{"nctId":20174,"briefTitle":20168,"status":103,"phases":20175,"completion":3228,"start":2948,"enrollment":14854,"conditions":20176,"interventions":20178},"NCT00122850",[87],[20177],"Anxiety Disorders",[14492,20156],{"trials":20180,"activeCount":97},[],{"trials":20182,"activeCount":97},[],{"intervention":19702,"totalTrials":947,"cells":20184},{"EARLY_PHASE1":20185,"PHASE1":20187,"PHASE2":20189,"PHASE3":20191,"PHASE4":20201,"NA":20203},{"trials":20186,"activeCount":97},[],{"trials":20188,"activeCount":97},[],{"trials":20190,"activeCount":97},[],{"trials":20192,"activeCount":97},[20193,20197],{"nctId":19697,"briefTitle":19698,"status":103,"phases":20194,"completion":3646,"start":13765,"enrollment":2790,"conditions":20195,"interventions":20196},[87],[14168],[19679,19702],{"nctId":19704,"briefTitle":19705,"status":103,"phases":20198,"completion":3077,"start":3710,"enrollment":10911,"conditions":20199,"interventions":20200},[87],[14193],[19679,19702],{"trials":20202,"activeCount":97},[],{"trials":20204,"activeCount":97},[],{"intervention":1049,"totalTrials":947,"cells":20206},{"EARLY_PHASE1":20207,"PHASE1":20209,"PHASE2":20211,"PHASE3":20213,"PHASE4":20223,"NA":20225},{"trials":20208,"activeCount":97},[],{"trials":20210,"activeCount":97},[],{"trials":20212,"activeCount":97},[],{"trials":20214,"activeCount":97},[20215,20219],{"nctId":7321,"briefTitle":7322,"status":103,"phases":20216,"primaryCompletion":2799,"completion":7324,"start":3250,"enrollment":4675,"conditions":20217,"interventions":20218},[87],[926],[449,1049],{"nctId":1040,"briefTitle":1041,"status":103,"phases":20220,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":1046,"conditions":20221,"interventions":20222},[87],[585],[588,588,1049,1049],{"trials":20224,"activeCount":97},[],{"trials":20226,"activeCount":97},[],{"intervention":20228,"totalTrials":947,"cells":20229},"Tabalumab Auto-Injector",{"EARLY_PHASE1":20230,"PHASE1":20232,"PHASE2":20234,"PHASE3":20236,"PHASE4":20252,"NA":20254},{"trials":20231,"activeCount":97},[],{"trials":20233,"activeCount":97},[],{"trials":20235,"activeCount":97},[],{"trials":20237,"activeCount":97},[20238,20246],{"nctId":20239,"briefTitle":20240,"status":999,"phases":20241,"primaryCompletion":3318,"completion":4383,"start":3112,"enrollment":13861,"conditions":20242,"interventions":20244},"NCT02041091","A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus",[87],[20243],"Lupus Erythematosus, Systemic",[20228,20245],"Tabalumab Prefilled Syringe",{"nctId":20247,"briefTitle":20248,"status":999,"phases":20249,"primaryCompletion":2917,"completion":2917,"start":2898,"enrollment":4323,"conditions":20250,"interventions":20251},"NCT01676701","Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)",[87],[5218],[20228,20245],{"trials":20253,"activeCount":97},[],{"trials":20255,"activeCount":97},[],{"intervention":20245,"totalTrials":947,"cells":20257},{"EARLY_PHASE1":20258,"PHASE1":20260,"PHASE2":20262,"PHASE3":20264,"PHASE4":20274,"NA":20276},{"trials":20259,"activeCount":97},[],{"trials":20261,"activeCount":97},[],{"trials":20263,"activeCount":97},[],{"trials":20265,"activeCount":97},[20266,20270],{"nctId":20239,"briefTitle":20240,"status":999,"phases":20267,"primaryCompletion":3318,"completion":4383,"start":3112,"enrollment":13861,"conditions":20268,"interventions":20269},[87],[20243],[20228,20245],{"nctId":20247,"briefTitle":20248,"status":999,"phases":20271,"primaryCompletion":2917,"completion":2917,"start":2898,"enrollment":4323,"conditions":20272,"interventions":20273},[87],[5218],[20228,20245],{"trials":20275,"activeCount":97},[],{"trials":20277,"activeCount":97},[],{"intervention":20279,"totalTrials":947,"cells":20280},"Ruboxistaurin mesylate",{"EARLY_PHASE1":20281,"PHASE1":20283,"PHASE2":20285,"PHASE3":20287,"PHASE4":20304,"NA":20306},{"trials":20282,"activeCount":97},[],{"trials":20284,"activeCount":97},[],{"trials":20286,"activeCount":97},[],{"trials":20288,"activeCount":97},[20289,20296],{"nctId":20290,"briefTitle":20291,"status":103,"phases":20292,"completion":2876,"start":3209,"enrollment":4775,"conditions":20293,"interventions":20295},"NCT00044421","Treatment of Peripheral Neuropathy in Patients With Diabetes",[87],[20294,620],"Diabetic Neuropathies",[20279],{"nctId":20297,"briefTitle":20298,"status":103,"phases":20299,"completion":2856,"start":3209,"enrollment":776,"conditions":20300,"interventions":20303},"NCT00044395","Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes",[87],[20294,20301,20302],"Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus, Non-Insulin-Dependent",[20279],{"trials":20305,"activeCount":97},[],{"trials":20307,"activeCount":97},[],{"intervention":18290,"totalTrials":947,"cells":20309},{"EARLY_PHASE1":20310,"PHASE1":20312,"PHASE2":20314,"PHASE3":20316,"PHASE4":20326,"NA":20328},{"trials":20311,"activeCount":97},[],{"trials":20313,"activeCount":97},[],{"trials":20315,"activeCount":97},[],{"trials":20317,"activeCount":97},[20318,20322],{"nctId":18284,"briefTitle":18285,"status":103,"phases":20319,"primaryCompletion":1546,"completion":1546,"start":3776,"enrollment":1978,"conditions":20320,"interventions":20321},[87],[18],[13099,18289,18290],{"nctId":747,"briefTitle":748,"status":103,"phases":20323,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":20324,"interventions":20325},[87],[120],[92,756],{"trials":20327,"activeCount":97},[],{"trials":20329,"activeCount":97},[],{"intervention":14288,"totalTrials":314,"cells":20331},{"EARLY_PHASE1":20332,"PHASE1":20334,"PHASE2":20336,"PHASE3":20338,"PHASE4":20344,"NA":20346},{"trials":20333,"activeCount":97},[],{"trials":20335,"activeCount":97},[],{"trials":20337,"activeCount":97},[],{"trials":20339,"activeCount":97},[20340],{"nctId":14282,"briefTitle":14283,"status":103,"phases":20341,"completion":3567,"start":3274,"enrollment":1451,"conditions":20342,"interventions":20343},[87],[14286],[14288,13166],{"trials":20345,"activeCount":97},[],{"trials":20347,"activeCount":97},[],{"intervention":20349,"totalTrials":314,"cells":20350},"insulin lispro injection [rDNA origin] Low Mix",{"EARLY_PHASE1":20351,"PHASE1":20353,"PHASE2":20355,"PHASE3":20357,"PHASE4":20366,"NA":20368},{"trials":20352,"activeCount":97},[],{"trials":20354,"activeCount":97},[],{"trials":20356,"activeCount":97},[],{"trials":20358,"activeCount":97},[20359],{"nctId":20360,"briefTitle":20361,"status":103,"phases":20362,"completion":4266,"start":2833,"enrollment":20363,"conditions":20364,"interventions":20365},"NCT00231725","Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin",[87],370,[120],[20349],{"trials":20367,"activeCount":97},[],{"trials":20369,"activeCount":97},[],{"intervention":19108,"totalTrials":314,"cells":20371},{"EARLY_PHASE1":20372,"PHASE1":20374,"PHASE2":20376,"PHASE3":20378,"PHASE4":20384,"NA":20386},{"trials":20373,"activeCount":97},[],{"trials":20375,"activeCount":97},[],{"trials":20377,"activeCount":97},[],{"trials":20379,"activeCount":97},[20380],{"nctId":19100,"briefTitle":19101,"status":103,"phases":20381,"primaryCompletion":19103,"completion":19103,"start":2799,"enrollment":19104,"conditions":20382,"interventions":20383},[87],[19106],[19108,19109,19074],{"trials":20385,"activeCount":97},[],{"trials":20387,"activeCount":97},[],{"intervention":20389,"totalTrials":314,"cells":20390},"Humalog Mix 50",{"EARLY_PHASE1":20391,"PHASE1":20393,"PHASE2":20395,"PHASE3":20397,"PHASE4":20406,"NA":20408},{"trials":20392,"activeCount":97},[],{"trials":20394,"activeCount":97},[],{"trials":20396,"activeCount":97},[],{"trials":20398,"activeCount":97},[20399],{"nctId":20400,"briefTitle":20401,"status":103,"phases":20402,"completion":4266,"start":3218,"enrollment":2080,"conditions":20403,"interventions":20404},"NCT00191581","Local Registration Trial in China Humalog Mix 50",[87],[33,18],[20389,20405],"Human Insulin Mix 50:50",{"trials":20407,"activeCount":97},[],{"trials":20409,"activeCount":97},[],{"intervention":20405,"totalTrials":314,"cells":20411},{"EARLY_PHASE1":20412,"PHASE1":20414,"PHASE2":20416,"PHASE3":20418,"PHASE4":20424,"NA":20426},{"trials":20413,"activeCount":97},[],{"trials":20415,"activeCount":97},[],{"trials":20417,"activeCount":97},[],{"trials":20419,"activeCount":97},[20420],{"nctId":20400,"briefTitle":20401,"status":103,"phases":20421,"completion":4266,"start":3218,"enrollment":2080,"conditions":20422,"interventions":20423},[87],[33,18],[20389,20405],{"trials":20425,"activeCount":97},[],{"trials":20427,"activeCount":97},[],{"intervention":20429,"totalTrials":314,"cells":20430},"Rapid-Acting Intramuscular Olanzapine",{"EARLY_PHASE1":20431,"PHASE1":20433,"PHASE2":20435,"PHASE3":20437,"PHASE4":20445,"NA":20447},{"trials":20432,"activeCount":97},[],{"trials":20434,"activeCount":97},[],{"trials":20436,"activeCount":97},[],{"trials":20438,"activeCount":97},[20439],{"nctId":20440,"briefTitle":20441,"status":103,"phases":20442,"primaryCompletion":3069,"completion":3069,"start":14517,"enrollment":4279,"conditions":20443,"interventions":20444},"NCT00970281","A Study of Olanzapine in Patients With Schizophrenia",[87],[4897],[20429],{"trials":20446,"activeCount":97},[],{"trials":20448,"activeCount":97},[],{"intervention":17846,"totalTrials":314,"cells":20450},{"EARLY_PHASE1":20451,"PHASE1":20453,"PHASE2":20455,"PHASE3":20457,"PHASE4":20463,"NA":20465},{"trials":20452,"activeCount":97},[],{"trials":20454,"activeCount":97},[],{"trials":20456,"activeCount":97},[],{"trials":20458,"activeCount":97},[20459],{"nctId":17838,"briefTitle":17839,"status":103,"phases":20460,"primaryCompletion":7316,"completion":1619,"start":3152,"enrollment":17841,"conditions":20461,"interventions":20462},[87],[5075,17843,17844],[17767,17846],{"trials":20464,"activeCount":97},[],{"trials":20466,"activeCount":97},[],{"intervention":20468,"totalTrials":314,"cells":20469},"semagacestat",{"EARLY_PHASE1":20470,"PHASE1":20472,"PHASE2":20474,"PHASE3":20476,"PHASE4":20484,"NA":20486},{"trials":20471,"activeCount":97},[],{"trials":20473,"activeCount":97},[],{"trials":20475,"activeCount":97},[],{"trials":20477,"activeCount":97},[20478],{"nctId":20479,"briefTitle":20480,"status":103,"phases":20481,"primaryCompletion":3069,"completion":3069,"start":6883,"enrollment":9828,"conditions":20482,"interventions":20483},"NCT01035138","A Study of Semagacestat for Alzheimer's Patients",[87],[4040],[20468],{"trials":20485,"activeCount":97},[],{"trials":20487,"activeCount":97},[],{"intervention":20489,"totalTrials":314,"cells":20490},"ERA as specific PAH treatment",{"EARLY_PHASE1":20491,"PHASE1":20493,"PHASE2":20495,"PHASE3":20497,"PHASE4":20508,"NA":20510},{"trials":20492,"activeCount":97},[],{"trials":20494,"activeCount":97},[],{"trials":20496,"activeCount":97},[],{"trials":20498,"activeCount":97},[20499],{"nctId":20500,"briefTitle":20501,"status":103,"phases":20502,"primaryCompletion":20503,"completion":665,"start":20504,"enrollment":1548,"conditions":20505,"interventions":20507},"NCT01824290","A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)",[87],"2019-03-18","2014-02-05",[20506],"Hypertension, Pulmonary",[10904,20489],{"trials":20509,"activeCount":97},[],{"trials":20511,"activeCount":97},[],{"intervention":20513,"totalTrials":314,"cells":20514},"Rapid Acting Intramuscular Olanzapine",{"EARLY_PHASE1":20515,"PHASE1":20517,"PHASE2":20519,"PHASE3":20521,"PHASE4":20530,"NA":20532},{"trials":20516,"activeCount":97},[],{"trials":20518,"activeCount":97},[],{"trials":20520,"activeCount":97},[],{"trials":20522,"activeCount":97},[20523],{"nctId":20524,"briefTitle":20525,"status":103,"phases":20526,"primaryCompletion":2800,"completion":2800,"start":3338,"enrollment":3718,"conditions":20527,"interventions":20528},"NCT00640510","A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia",[87],[4897],[20513,20529],"Isotonic sodium chloride solution",{"trials":20531,"activeCount":97},[],{"trials":20533,"activeCount":97},[],{"intervention":20529,"totalTrials":314,"cells":20535},{"EARLY_PHASE1":20536,"PHASE1":20538,"PHASE2":20540,"PHASE3":20542,"PHASE4":20548,"NA":20550},{"trials":20537,"activeCount":97},[],{"trials":20539,"activeCount":97},[],{"trials":20541,"activeCount":97},[],{"trials":20543,"activeCount":97},[20544],{"nctId":20524,"briefTitle":20525,"status":103,"phases":20545,"primaryCompletion":2800,"completion":2800,"start":3338,"enrollment":3718,"conditions":20546,"interventions":20547},[87],[4897],[20513,20529],{"trials":20549,"activeCount":97},[],{"trials":20551,"activeCount":97},[],{"intervention":9671,"totalTrials":314,"cells":20553},{"EARLY_PHASE1":20554,"PHASE1":20556,"PHASE2":20558,"PHASE3":20560,"PHASE4":20566,"NA":20568},{"trials":20555,"activeCount":97},[],{"trials":20557,"activeCount":97},[],{"trials":20559,"activeCount":97},[],{"trials":20561,"activeCount":97},[20562],{"nctId":9663,"briefTitle":9664,"status":103,"phases":20563,"primaryCompletion":3320,"completion":3320,"start":2930,"enrollment":9666,"conditions":20564,"interventions":20565},[87],[4897,9668],[9670,9671,9672,9673],{"trials":20567,"activeCount":97},[],{"trials":20569,"activeCount":97},[],{"intervention":9673,"totalTrials":314,"cells":20571},{"EARLY_PHASE1":20572,"PHASE1":20574,"PHASE2":20576,"PHASE3":20578,"PHASE4":20584,"NA":20586},{"trials":20573,"activeCount":97},[],{"trials":20575,"activeCount":97},[],{"trials":20577,"activeCount":97},[],{"trials":20579,"activeCount":97},[20580],{"nctId":9663,"briefTitle":9664,"status":103,"phases":20581,"primaryCompletion":3320,"completion":3320,"start":2930,"enrollment":9666,"conditions":20582,"interventions":20583},[87],[4897,9668],[9670,9671,9672,9673],{"trials":20585,"activeCount":97},[],{"trials":20587,"activeCount":97},[],{"intervention":18407,"totalTrials":314,"cells":20589},{"EARLY_PHASE1":20590,"PHASE1":20592,"PHASE2":20594,"PHASE3":20596,"PHASE4":20602,"NA":20604},{"trials":20591,"activeCount":97},[],{"trials":20593,"activeCount":97},[],{"trials":20595,"activeCount":97},[],{"trials":20597,"activeCount":97},[20598],{"nctId":18400,"briefTitle":18401,"status":103,"phases":20599,"primaryCompletion":3292,"completion":3292,"start":14103,"enrollment":18403,"conditions":20600,"interventions":20601},[87],[620,4904,18405],[13554,18407],{"trials":20603,"activeCount":97},[],{"trials":20605,"activeCount":97},[],{"intervention":13110,"totalTrials":314,"cells":20607},{"EARLY_PHASE1":20608,"PHASE1":20610,"PHASE2":20612,"PHASE3":20614,"PHASE4":20620,"NA":20622},{"trials":20609,"activeCount":97},[],{"trials":20611,"activeCount":97},[],{"trials":20613,"activeCount":97},[],{"trials":20615,"activeCount":97},[20616],{"nctId":13102,"briefTitle":13103,"status":103,"phases":20617,"primaryCompletion":13105,"completion":13105,"start":13106,"enrollment":13107,"conditions":20618,"interventions":20619},[87],[9437],[13110,438],{"trials":20621,"activeCount":97},[],{"trials":20623,"activeCount":97},[],{"intervention":17533,"totalTrials":314,"cells":20625},{"EARLY_PHASE1":20626,"PHASE1":20628,"PHASE2":20630,"PHASE3":20632,"PHASE4":20638,"NA":20640},{"trials":20627,"activeCount":97},[],{"trials":20629,"activeCount":97},[],{"trials":20631,"activeCount":97},[],{"trials":20633,"activeCount":97},[20634],{"nctId":17527,"briefTitle":17528,"status":103,"phases":20635,"primaryCompletion":2864,"completion":2864,"start":3575,"enrollment":17530,"conditions":20636,"interventions":20637},[87],[17470],[16882,17407,17533],{"trials":20639,"activeCount":97},[],{"trials":20641,"activeCount":97},[],{"intervention":20643,"totalTrials":314,"cells":20644},"Testosterone Solution",{"EARLY_PHASE1":20645,"PHASE1":20647,"PHASE2":20649,"PHASE3":20651,"PHASE4":20660,"NA":20662},{"trials":20646,"activeCount":97},[],{"trials":20648,"activeCount":97},[],{"trials":20650,"activeCount":97},[],{"trials":20652,"activeCount":97},[20653],{"nctId":20654,"briefTitle":20655,"status":103,"phases":20656,"primaryCompletion":3318,"completion":3697,"start":3282,"enrollment":20657,"conditions":20658,"interventions":20659},"NCT01816295","A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy",[87],715,[16086],[20643],{"trials":20661,"activeCount":97},[],{"trials":20663,"activeCount":97},[],{"intervention":20665,"totalTrials":314,"cells":20666},"Insulin Lispro 6 Day",{"EARLY_PHASE1":20667,"PHASE1":20669,"PHASE2":20671,"PHASE3":20673,"PHASE4":20682,"NA":20684},{"trials":20668,"activeCount":97},[],{"trials":20670,"activeCount":97},[],{"trials":20672,"activeCount":97},[],{"trials":20674,"activeCount":97},[20675],{"nctId":20676,"briefTitle":20677,"status":103,"phases":20678,"primaryCompletion":4160,"completion":4160,"start":3029,"enrollment":2931,"conditions":20679,"interventions":20680},"NCT01134107","Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use",[87],[33],[20665,20681],"Insulin Aspart 6 Day",{"trials":20683,"activeCount":97},[],{"trials":20685,"activeCount":97},[],{"intervention":20681,"totalTrials":314,"cells":20687},{"EARLY_PHASE1":20688,"PHASE1":20690,"PHASE2":20692,"PHASE3":20694,"PHASE4":20700,"NA":20702},{"trials":20689,"activeCount":97},[],{"trials":20691,"activeCount":97},[],{"trials":20693,"activeCount":97},[],{"trials":20695,"activeCount":97},[20696],{"nctId":20676,"briefTitle":20677,"status":103,"phases":20697,"primaryCompletion":4160,"completion":4160,"start":3029,"enrollment":2931,"conditions":20698,"interventions":20699},[87],[33],[20665,20681],{"trials":20701,"activeCount":97},[],{"trials":20703,"activeCount":97},[],{"intervention":20705,"totalTrials":314,"cells":20706},"Edivoxetine",{"EARLY_PHASE1":20707,"PHASE1":20709,"PHASE2":20711,"PHASE3":20713,"PHASE4":20721,"NA":20723},{"trials":20708,"activeCount":97},[],{"trials":20710,"activeCount":97},[],{"trials":20712,"activeCount":97},[],{"trials":20714,"activeCount":97},[20715],{"nctId":20716,"briefTitle":20717,"status":999,"phases":20718,"primaryCompletion":4097,"completion":4097,"start":14517,"enrollment":687,"conditions":20719,"interventions":20720},"NCT00965419","A Study of Pediatric Participants With Attention Deficit\u002FHyperactivity Disorder",[86,87],[13785],[20705],{"trials":20722,"activeCount":97},[],{"trials":20724,"activeCount":97},[],{"intervention":20726,"totalTrials":314,"cells":20727},"atomoxetine 0.5 mg\u002Fkg\u002Fday",{"EARLY_PHASE1":20728,"PHASE1":20730,"PHASE2":20732,"PHASE3":20734,"PHASE4":20744,"NA":20746},{"trials":20729,"activeCount":97},[],{"trials":20731,"activeCount":97},[],{"trials":20733,"activeCount":97},[],{"trials":20735,"activeCount":97},[20736],{"nctId":20737,"briefTitle":20738,"status":103,"phases":20739,"primaryCompletion":2855,"completion":3292,"start":2948,"enrollment":11714,"conditions":20740,"interventions":20741},"NCT00192023","An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit\u002FHyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).",[87],[13785,13863],[20726,20742,20743],"atomoxetine 1.2 mg\u002Fkg\u002Fday","atomoxetine 1.2-1.4 mg\u002Fkg\u002Fday",{"trials":20745,"activeCount":97},[],{"trials":20747,"activeCount":97},[],{"intervention":20742,"totalTrials":314,"cells":20749},{"EARLY_PHASE1":20750,"PHASE1":20752,"PHASE2":20754,"PHASE3":20756,"PHASE4":20762,"NA":20764},{"trials":20751,"activeCount":97},[],{"trials":20753,"activeCount":97},[],{"trials":20755,"activeCount":97},[],{"trials":20757,"activeCount":97},[20758],{"nctId":20737,"briefTitle":20738,"status":103,"phases":20759,"primaryCompletion":2855,"completion":3292,"start":2948,"enrollment":11714,"conditions":20760,"interventions":20761},[87],[13785,13863],[20726,20742,20743],{"trials":20763,"activeCount":97},[],{"trials":20765,"activeCount":97},[],{"intervention":20743,"totalTrials":314,"cells":20767},{"EARLY_PHASE1":20768,"PHASE1":20770,"PHASE2":20772,"PHASE3":20774,"PHASE4":20780,"NA":20782},{"trials":20769,"activeCount":97},[],{"trials":20771,"activeCount":97},[],{"trials":20773,"activeCount":97},[],{"trials":20775,"activeCount":97},[20776],{"nctId":20737,"briefTitle":20738,"status":103,"phases":20777,"primaryCompletion":2855,"completion":3292,"start":2948,"enrollment":11714,"conditions":20778,"interventions":20779},[87],[13785,13863],[20726,20742,20743],{"trials":20781,"activeCount":97},[],{"trials":20783,"activeCount":97},[],{"intervention":4009,"totalTrials":314,"cells":20785},{"EARLY_PHASE1":20786,"PHASE1":20788,"PHASE2":20790,"PHASE3":20792,"PHASE4":20798,"NA":20800},{"trials":20787,"activeCount":97},[],{"trials":20789,"activeCount":97},[],{"trials":20791,"activeCount":97},[],{"trials":20793,"activeCount":97},[20794],{"nctId":3999,"briefTitle":4000,"status":103,"phases":20795,"primaryCompletion":4002,"completion":4003,"start":4004,"enrollment":4005,"conditions":20796,"interventions":20797},[87],[4007,3980],[3936,4009],{"trials":20799,"activeCount":97},[],{"trials":20801,"activeCount":97},[],{"intervention":20803,"totalTrials":314,"cells":20804},"Ixekizumab 80 mg Q4W",{"EARLY_PHASE1":20805,"PHASE1":20807,"PHASE2":20809,"PHASE3":20811,"PHASE4":20824,"NA":20826},{"trials":20806,"activeCount":97},[],{"trials":20808,"activeCount":97},[],{"trials":20810,"activeCount":97},[],{"trials":20812,"activeCount":97},[20813],{"nctId":20814,"briefTitle":20815,"status":103,"phases":20816,"primaryCompletion":20817,"completion":20818,"start":20819,"enrollment":20820,"conditions":20821,"interventions":20822},"NCT02349295","A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis",[87],"2016-09-09","2019-06-26","2014-12-31",363,[555],[20803,20823],"Ixekizumab 80 mg Q2W",{"trials":20825,"activeCount":97},[],{"trials":20827,"activeCount":97},[],{"intervention":20823,"totalTrials":314,"cells":20829},{"EARLY_PHASE1":20830,"PHASE1":20832,"PHASE2":20834,"PHASE3":20836,"PHASE4":20842,"NA":20844},{"trials":20831,"activeCount":97},[],{"trials":20833,"activeCount":97},[],{"trials":20835,"activeCount":97},[],{"trials":20837,"activeCount":97},[20838],{"nctId":20814,"briefTitle":20815,"status":103,"phases":20839,"primaryCompletion":20817,"completion":20818,"start":20819,"enrollment":20820,"conditions":20840,"interventions":20841},[87],[555],[20803,20823],{"trials":20843,"activeCount":97},[],{"trials":20845,"activeCount":97},[],{"intervention":16997,"totalTrials":314,"cells":20847},{"EARLY_PHASE1":20848,"PHASE1":20850,"PHASE2":20852,"PHASE3":20854,"PHASE4":20860,"NA":20862},{"trials":20849,"activeCount":97},[],{"trials":20851,"activeCount":97},[],{"trials":20853,"activeCount":97},[],{"trials":20855,"activeCount":97},[20856],{"nctId":16992,"briefTitle":16993,"status":103,"phases":20857,"primaryCompletion":3152,"completion":3152,"start":5860,"enrollment":2630,"conditions":20858,"interventions":20859},[86,87],[13785],[13957,16997],{"trials":20861,"activeCount":97},[],{"trials":20863,"activeCount":97},[],{"intervention":20865,"totalTrials":314,"cells":20866},"Alendronate Sodium",{"EARLY_PHASE1":20867,"PHASE1":20869,"PHASE2":20871,"PHASE3":20873,"PHASE4":20882,"NA":20884},{"trials":20868,"activeCount":97},[],{"trials":20870,"activeCount":97},[],{"trials":20872,"activeCount":97},[],{"trials":20874,"activeCount":97},[20875],{"nctId":20876,"briefTitle":20877,"status":103,"phases":20878,"primaryCompletion":3185,"completion":3308,"start":3274,"enrollment":20879,"conditions":20880,"interventions":20881},"NCT00051558","Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis",[87],428,[14617],[14202,20865],{"trials":20883,"activeCount":97},[],{"trials":20885,"activeCount":97},[],{"intervention":2165,"totalTrials":314,"cells":20887},{"EARLY_PHASE1":20888,"PHASE1":20890,"PHASE2":20892,"PHASE3":20894,"PHASE4":20900,"NA":20902},{"trials":20889,"activeCount":97},[],{"trials":20891,"activeCount":97},[],{"trials":20893,"activeCount":97},[],{"trials":20895,"activeCount":97},[20896],{"nctId":2159,"briefTitle":2160,"status":103,"phases":20897,"primaryCompletion":172,"completion":172,"start":375,"enrollment":2162,"conditions":20898,"interventions":20899},[87],[30],[2043,2165],{"trials":20901,"activeCount":97},[],{"trials":20903,"activeCount":97},[],{"intervention":20905,"totalTrials":314,"cells":20906},"Duloxetine 60 mg",{"EARLY_PHASE1":20907,"PHASE1":20909,"PHASE2":20911,"PHASE3":20913,"PHASE4":20922,"NA":20924},{"trials":20908,"activeCount":97},[],{"trials":20910,"activeCount":97},[],{"trials":20912,"activeCount":97},[],{"trials":20914,"activeCount":97},[20915],{"nctId":20916,"briefTitle":20917,"status":103,"phases":20918,"primaryCompletion":3049,"completion":3049,"start":3886,"enrollment":1901,"conditions":20919,"interventions":20921},"NCT01552057","A Study of Duloxetine in Fibromyalgia",[87],[20920],"Fibromyalgia",[20905],{"trials":20923,"activeCount":97},[],{"trials":20925,"activeCount":97},[],{"intervention":17644,"totalTrials":314,"cells":20927},{"EARLY_PHASE1":20928,"PHASE1":20930,"PHASE2":20932,"PHASE3":20934,"PHASE4":20940,"NA":20942},{"trials":20929,"activeCount":97},[],{"trials":20931,"activeCount":97},[],{"trials":20933,"activeCount":97},[],{"trials":20935,"activeCount":97},[20936],{"nctId":17640,"briefTitle":14258,"status":103,"phases":20937,"primaryCompletion":3049,"completion":3049,"start":5090,"enrollment":7344,"conditions":20938,"interventions":20939},[87],[120],[9681,7118,17644,17645,17646,17647],{"trials":20941,"activeCount":97},[],{"trials":20943,"activeCount":97},[],{"intervention":17645,"totalTrials":314,"cells":20945},{"EARLY_PHASE1":20946,"PHASE1":20948,"PHASE2":20950,"PHASE3":20952,"PHASE4":20958,"NA":20960},{"trials":20947,"activeCount":97},[],{"trials":20949,"activeCount":97},[],{"trials":20951,"activeCount":97},[],{"trials":20953,"activeCount":97},[20954],{"nctId":17640,"briefTitle":14258,"status":103,"phases":20955,"primaryCompletion":3049,"completion":3049,"start":5090,"enrollment":7344,"conditions":20956,"interventions":20957},[87],[120],[9681,7118,17644,17645,17646,17647],{"trials":20959,"activeCount":97},[],{"trials":20961,"activeCount":97},[],{"intervention":17646,"totalTrials":314,"cells":20963},{"EARLY_PHASE1":20964,"PHASE1":20966,"PHASE2":20968,"PHASE3":20970,"PHASE4":20976,"NA":20978},{"trials":20965,"activeCount":97},[],{"trials":20967,"activeCount":97},[],{"trials":20969,"activeCount":97},[],{"trials":20971,"activeCount":97},[20972],{"nctId":17640,"briefTitle":14258,"status":103,"phases":20973,"primaryCompletion":3049,"completion":3049,"start":5090,"enrollment":7344,"conditions":20974,"interventions":20975},[87],[120],[9681,7118,17644,17645,17646,17647],{"trials":20977,"activeCount":97},[],{"trials":20979,"activeCount":97},[],{"intervention":17647,"totalTrials":314,"cells":20981},{"EARLY_PHASE1":20982,"PHASE1":20984,"PHASE2":20986,"PHASE3":20988,"PHASE4":20994,"NA":20996},{"trials":20983,"activeCount":97},[],{"trials":20985,"activeCount":97},[],{"trials":20987,"activeCount":97},[],{"trials":20989,"activeCount":97},[20990],{"nctId":17640,"briefTitle":14258,"status":103,"phases":20991,"primaryCompletion":3049,"completion":3049,"start":5090,"enrollment":7344,"conditions":20992,"interventions":20993},[87],[120],[9681,7118,17644,17645,17646,17647],{"trials":20995,"activeCount":97},[],{"trials":20997,"activeCount":97},[],{"intervention":995,"totalTrials":314,"cells":20999},{"EARLY_PHASE1":21000,"PHASE1":21002,"PHASE2":21004,"PHASE3":21006,"PHASE4":21012,"NA":21014},{"trials":21001,"activeCount":97},[],{"trials":21003,"activeCount":97},[],{"trials":21005,"activeCount":97},[],{"trials":21007,"activeCount":97},[21008],{"nctId":986,"briefTitle":987,"status":103,"phases":21009,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":21010,"interventions":21011},[87],[447],[588,995],{"trials":21013,"activeCount":97},[],{"trials":21015,"activeCount":97},[],{"intervention":8450,"totalTrials":314,"cells":21017},{"EARLY_PHASE1":21018,"PHASE1":21020,"PHASE2":21022,"PHASE3":21024,"PHASE4":21030,"NA":21032},{"trials":21019,"activeCount":97},[],{"trials":21021,"activeCount":97},[],{"trials":21023,"activeCount":97},[],{"trials":21025,"activeCount":97},[21026],{"nctId":8444,"briefTitle":8445,"status":384,"phases":21027,"primaryCompletion":962,"completion":8447,"start":531,"enrollment":97,"conditions":21028,"interventions":21029},[87],[735],[8426,8442,8450],{"trials":21031,"activeCount":97},[],{"trials":21033,"activeCount":97},[],{"intervention":21035,"totalTrials":314,"cells":21036},"somatropin, rDNA origin, for",{"EARLY_PHASE1":21037,"PHASE1":21039,"PHASE2":21041,"PHASE3":21043,"PHASE4":21053,"NA":21055},{"trials":21038,"activeCount":97},[],{"trials":21040,"activeCount":97},[],{"trials":21042,"activeCount":97},[],{"trials":21044,"activeCount":97},[21045],{"nctId":21046,"briefTitle":21047,"status":103,"phases":21048,"completion":13847,"start":21049,"enrollment":205,"conditions":21050,"interventions":21052},"NCT00191074","Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature",[87],"2001-02",[21051],"Growth Disorder",[21035],{"trials":21054,"activeCount":97},[],{"trials":21056,"activeCount":97},[],{"intervention":19003,"totalTrials":314,"cells":21058},{"EARLY_PHASE1":21059,"PHASE1":21061,"PHASE2":21063,"PHASE3":21065,"PHASE4":21071,"NA":21073},{"trials":21060,"activeCount":97},[],{"trials":21062,"activeCount":97},[],{"trials":21064,"activeCount":97},[],{"trials":21066,"activeCount":97},[21067],{"nctId":18997,"briefTitle":18998,"status":103,"phases":21068,"primaryCompletion":3216,"completion":3216,"start":4474,"enrollment":19000,"conditions":21069,"interventions":21070},[87],[33],[13177,19003],{"trials":21072,"activeCount":97},[],{"trials":21074,"activeCount":97},[],{"intervention":5221,"totalTrials":314,"cells":21076},{"EARLY_PHASE1":21077,"PHASE1":21079,"PHASE2":21081,"PHASE3":21083,"PHASE4":21089,"NA":21091},{"trials":21078,"activeCount":97},[],{"trials":21080,"activeCount":97},[],{"trials":21082,"activeCount":97},[],{"trials":21084,"activeCount":97},[21085],{"nctId":5213,"briefTitle":5214,"status":103,"phases":21086,"primaryCompletion":1596,"completion":1618,"start":2798,"enrollment":5216,"conditions":21087,"interventions":21088},[87],[5218],[5220,4944,5095,5221,5222],{"trials":21090,"activeCount":97},[],{"trials":21092,"activeCount":97},[],{"intervention":13984,"totalTrials":314,"cells":21094},{"EARLY_PHASE1":21095,"PHASE1":21097,"PHASE2":21099,"PHASE3":21101,"PHASE4":21107,"NA":21109},{"trials":21096,"activeCount":97},[],{"trials":21098,"activeCount":97},[],{"trials":21100,"activeCount":97},[],{"trials":21102,"activeCount":97},[21103],{"nctId":13978,"briefTitle":13979,"status":103,"phases":21104,"primaryCompletion":3886,"completion":3886,"start":2955,"enrollment":13981,"conditions":21105,"interventions":21106},[87],[13974],[13984,13944],{"trials":21108,"activeCount":97},[],{"trials":21110,"activeCount":97},[],{"intervention":21112,"totalTrials":314,"cells":21113},"olanzapine pamoate depot",{"EARLY_PHASE1":21114,"PHASE1":21116,"PHASE2":21118,"PHASE3":21120,"PHASE4":21129,"NA":21131},{"trials":21115,"activeCount":97},[],{"trials":21117,"activeCount":97},[],{"trials":21119,"activeCount":97},[],{"trials":21121,"activeCount":97},[21122],{"nctId":21123,"briefTitle":21124,"status":103,"phases":21125,"primaryCompletion":14517,"completion":14517,"start":4266,"enrollment":21126,"conditions":21127,"interventions":21128},"NCT00320489","Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia",[87],524,[4897],[9670,21112],{"trials":21130,"activeCount":97},[],{"trials":21132,"activeCount":97},[],{"intervention":17745,"totalTrials":314,"cells":21134},{"EARLY_PHASE1":21135,"PHASE1":21137,"PHASE2":21139,"PHASE3":21141,"PHASE4":21147,"NA":21149},{"trials":21136,"activeCount":97},[],{"trials":21138,"activeCount":97},[],{"trials":21140,"activeCount":97},[],{"trials":21142,"activeCount":97},[21143],{"nctId":17739,"briefTitle":17740,"status":103,"phases":21144,"primaryCompletion":4098,"completion":4098,"start":3124,"enrollment":17742,"conditions":21145,"interventions":21146},[87],[18],[12961,17745,13583],{"trials":21148,"activeCount":97},[],{"trials":21150,"activeCount":97},[],{"intervention":19695,"totalTrials":314,"cells":21152},{"EARLY_PHASE1":21153,"PHASE1":21155,"PHASE2":21157,"PHASE3":21159,"PHASE4":21165,"NA":21167},{"trials":21154,"activeCount":97},[],{"trials":21156,"activeCount":97},[],{"trials":21158,"activeCount":97},[],{"trials":21160,"activeCount":97},[21161],{"nctId":19690,"briefTitle":19691,"status":103,"phases":21162,"completion":3194,"start":3161,"enrollment":9415,"conditions":21163,"interventions":21164},[87],[14193],[19679,19695],{"trials":21166,"activeCount":97},[],{"trials":21168,"activeCount":97},[],{"intervention":21170,"totalTrials":314,"cells":21171},"5 mg Tadalafil",{"EARLY_PHASE1":21172,"PHASE1":21174,"PHASE2":21176,"PHASE3":21178,"PHASE4":21189,"NA":21191},{"trials":21173,"activeCount":97},[],{"trials":21175,"activeCount":97},[],{"trials":21177,"activeCount":97},[],{"trials":21179,"activeCount":97},[21180],{"nctId":21181,"briefTitle":21182,"status":103,"phases":21183,"primaryCompletion":3123,"completion":3123,"start":5022,"enrollment":21184,"conditions":21185,"interventions":21187},"NCT01937871","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)",[87],909,[21186,14741],"Benign Prostate Hyperplasia",[21170,21188],"0.2 mg Tamsulosin",{"trials":21190,"activeCount":97},[],{"trials":21192,"activeCount":97},[],{"intervention":21188,"totalTrials":314,"cells":21194},{"EARLY_PHASE1":21195,"PHASE1":21197,"PHASE2":21199,"PHASE3":21201,"PHASE4":21207,"NA":21209},{"trials":21196,"activeCount":97},[],{"trials":21198,"activeCount":97},[],{"trials":21200,"activeCount":97},[],{"trials":21202,"activeCount":97},[21203],{"nctId":21181,"briefTitle":21182,"status":103,"phases":21204,"primaryCompletion":3123,"completion":3123,"start":5022,"enrollment":21184,"conditions":21205,"interventions":21206},[87],[21186,14741],[21170,21188],{"trials":21208,"activeCount":97},[],{"trials":21210,"activeCount":97},[],{"intervention":7095,"totalTrials":314,"cells":21212},{"EARLY_PHASE1":21213,"PHASE1":21215,"PHASE2":21217,"PHASE3":21219,"PHASE4":21225,"NA":21227},{"trials":21214,"activeCount":97},[],{"trials":21216,"activeCount":97},[],{"trials":21218,"activeCount":97},[],{"trials":21220,"activeCount":97},[21221],{"nctId":7085,"briefTitle":7086,"status":103,"phases":21222,"primaryCompletion":7088,"completion":7089,"start":7090,"enrollment":7091,"conditions":21223,"interventions":21224},[87],[620,18,621,622,623,7093,301],[303,7095],{"trials":21226,"activeCount":97},[],{"trials":21228,"activeCount":97},[],{"intervention":21230,"totalTrials":314,"cells":21231},"Glucagon Nasal Powder",{"EARLY_PHASE1":21232,"PHASE1":21234,"PHASE2":21236,"PHASE3":21238,"PHASE4":21248,"NA":21250},{"trials":21233,"activeCount":97},[],{"trials":21235,"activeCount":97},[],{"trials":21237,"activeCount":97},[],{"trials":21239,"activeCount":97},[21240],{"nctId":21241,"briefTitle":21242,"status":103,"phases":21243,"primaryCompletion":21244,"completion":21244,"start":7362,"enrollment":9118,"conditions":21245,"interventions":21246},"NCT03421379","A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus",[87],"2018-08-20",[620],[21230,21247],"Glucagon Hydrochloride Solution",{"trials":21249,"activeCount":97},[],{"trials":21251,"activeCount":97},[],{"intervention":21247,"totalTrials":314,"cells":21253},{"EARLY_PHASE1":21254,"PHASE1":21256,"PHASE2":21258,"PHASE3":21260,"PHASE4":21266,"NA":21268},{"trials":21255,"activeCount":97},[],{"trials":21257,"activeCount":97},[],{"trials":21259,"activeCount":97},[],{"trials":21261,"activeCount":97},[21262],{"nctId":21241,"briefTitle":21242,"status":103,"phases":21263,"primaryCompletion":21244,"completion":21244,"start":7362,"enrollment":9118,"conditions":21264,"interventions":21265},[87],[620],[21230,21247],{"trials":21267,"activeCount":97},[],{"trials":21269,"activeCount":97},[],{"intervention":21271,"totalTrials":314,"cells":21272},"Finasteride",{"EARLY_PHASE1":21273,"PHASE1":21275,"PHASE2":21277,"PHASE3":21279,"PHASE4":21289,"NA":21291},{"trials":21274,"activeCount":97},[],{"trials":21276,"activeCount":97},[],{"trials":21278,"activeCount":97},[],{"trials":21280,"activeCount":97},[21281],{"nctId":21282,"briefTitle":21283,"status":103,"phases":21284,"primaryCompletion":3086,"completion":2865,"start":3114,"enrollment":21285,"conditions":21286,"interventions":21288},"NCT01139762","A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms",[87],696,[15444,21287],"Enlarged Prostate",[10904,21271],{"trials":21290,"activeCount":97},[],{"trials":21292,"activeCount":97},[],{"intervention":1964,"totalTrials":314,"cells":21294},{"EARLY_PHASE1":21295,"PHASE1":21297,"PHASE2":21299,"PHASE3":21301,"PHASE4":21307,"NA":21309},{"trials":21296,"activeCount":97},[],{"trials":21298,"activeCount":97},[],{"trials":21300,"activeCount":97},[],{"trials":21302,"activeCount":97},[21303],{"nctId":1958,"briefTitle":1959,"status":999,"phases":21304,"primaryCompletion":1961,"completion":1961,"start":686,"enrollment":335,"conditions":21305,"interventions":21306},[87],[1893],[48,1964],{"trials":21308,"activeCount":97},[],{"trials":21310,"activeCount":97},[],{"intervention":14352,"totalTrials":314,"cells":21312},{"EARLY_PHASE1":21313,"PHASE1":21315,"PHASE2":21317,"PHASE3":21319,"PHASE4":21325,"NA":21327},{"trials":21314,"activeCount":97},[],{"trials":21316,"activeCount":97},[],{"trials":21318,"activeCount":97},[],{"trials":21320,"activeCount":97},[21321],{"nctId":14346,"briefTitle":14347,"status":103,"phases":21322,"primaryCompletion":2929,"completion":2929,"start":3228,"enrollment":11714,"conditions":21323,"interventions":21324},[87],[14350],[9670,14352,14353,14354],{"trials":21326,"activeCount":97},[],{"trials":21328,"activeCount":97},[],{"intervention":14353,"totalTrials":314,"cells":21330},{"EARLY_PHASE1":21331,"PHASE1":21333,"PHASE2":21335,"PHASE3":21337,"PHASE4":21343,"NA":21345},{"trials":21332,"activeCount":97},[],{"trials":21334,"activeCount":97},[],{"trials":21336,"activeCount":97},[],{"trials":21338,"activeCount":97},[21339],{"nctId":14346,"briefTitle":14347,"status":103,"phases":21340,"primaryCompletion":2929,"completion":2929,"start":3228,"enrollment":11714,"conditions":21341,"interventions":21342},[87],[14350],[9670,14352,14353,14354],{"trials":21344,"activeCount":97},[],{"trials":21346,"activeCount":97},[],{"intervention":21348,"totalTrials":314,"cells":21349},"Insulin lispro 2 day reservoir in-use",{"EARLY_PHASE1":21350,"PHASE1":21352,"PHASE2":21354,"PHASE3":21356,"PHASE4":21365,"NA":21367},{"trials":21351,"activeCount":97},[],{"trials":21353,"activeCount":97},[],{"trials":21355,"activeCount":97},[],{"trials":21357,"activeCount":97},[21358],{"nctId":21359,"briefTitle":20677,"status":103,"phases":21360,"primaryCompletion":8217,"completion":8217,"start":3251,"enrollment":1803,"conditions":21361,"interventions":21362},"NCT01109316",[87],[33],[21348,21363,21364],"Insulin lispro 6 day reservoir in-use","Insulin aspart 6 day reservoir in-use",{"trials":21366,"activeCount":97},[],{"trials":21368,"activeCount":97},[],{"intervention":21363,"totalTrials":314,"cells":21370},{"EARLY_PHASE1":21371,"PHASE1":21373,"PHASE2":21375,"PHASE3":21377,"PHASE4":21383,"NA":21385},{"trials":21372,"activeCount":97},[],{"trials":21374,"activeCount":97},[],{"trials":21376,"activeCount":97},[],{"trials":21378,"activeCount":97},[21379],{"nctId":21359,"briefTitle":20677,"status":103,"phases":21380,"primaryCompletion":8217,"completion":8217,"start":3251,"enrollment":1803,"conditions":21381,"interventions":21382},[87],[33],[21348,21363,21364],{"trials":21384,"activeCount":97},[],{"trials":21386,"activeCount":97},[],{"intervention":21364,"totalTrials":314,"cells":21388},{"EARLY_PHASE1":21389,"PHASE1":21391,"PHASE2":21393,"PHASE3":21395,"PHASE4":21401,"NA":21403},{"trials":21390,"activeCount":97},[],{"trials":21392,"activeCount":97},[],{"trials":21394,"activeCount":97},[],{"trials":21396,"activeCount":97},[21397],{"nctId":21359,"briefTitle":20677,"status":103,"phases":21398,"primaryCompletion":8217,"completion":8217,"start":3251,"enrollment":1803,"conditions":21399,"interventions":21400},[87],[33],[21348,21363,21364],{"trials":21402,"activeCount":97},[],{"trials":21404,"activeCount":97},[],{"intervention":21406,"totalTrials":314,"cells":21407},"Ixekizumab Auto-Injector",{"EARLY_PHASE1":21408,"PHASE1":21410,"PHASE2":21412,"PHASE3":21414,"PHASE4":21423,"NA":21425},{"trials":21409,"activeCount":97},[],{"trials":21411,"activeCount":97},[],{"trials":21413,"activeCount":97},[],{"trials":21415,"activeCount":97},[21416],{"nctId":21417,"briefTitle":21418,"status":103,"phases":21419,"primaryCompletion":4098,"completion":3717,"start":3124,"enrollment":5841,"conditions":21420,"interventions":21421},"NCT01777191","Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis",[87],[926],[21406,21422],"Ixekizumab Prefilled Syringe",{"trials":21424,"activeCount":97},[],{"trials":21426,"activeCount":97},[],{"intervention":21422,"totalTrials":314,"cells":21428},{"EARLY_PHASE1":21429,"PHASE1":21431,"PHASE2":21433,"PHASE3":21435,"PHASE4":21441,"NA":21443},{"trials":21430,"activeCount":97},[],{"trials":21432,"activeCount":97},[],{"trials":21434,"activeCount":97},[],{"trials":21436,"activeCount":97},[21437],{"nctId":21417,"briefTitle":21418,"status":103,"phases":21438,"primaryCompletion":4098,"completion":3717,"start":3124,"enrollment":5841,"conditions":21439,"interventions":21440},[87],[926],[21406,21422],{"trials":21442,"activeCount":97},[],{"trials":21444,"activeCount":97},[],{"intervention":18282,"totalTrials":314,"cells":21446},{"EARLY_PHASE1":21447,"PHASE1":21449,"PHASE2":21451,"PHASE3":21453,"PHASE4":21459,"NA":21461},{"trials":21448,"activeCount":97},[],{"trials":21450,"activeCount":97},[],{"trials":21452,"activeCount":97},[],{"trials":21454,"activeCount":97},[21455],{"nctId":18276,"briefTitle":18277,"status":103,"phases":21456,"primaryCompletion":2898,"completion":2898,"start":3494,"enrollment":18279,"conditions":21457,"interventions":21458},[87],[18],[13099,13138,18282],{"trials":21460,"activeCount":97},[],{"trials":21462,"activeCount":97},[],{"intervention":6887,"totalTrials":314,"cells":21464},{"EARLY_PHASE1":21465,"PHASE1":21467,"PHASE2":21469,"PHASE3":21471,"PHASE4":21477,"NA":21479},{"trials":21466,"activeCount":97},[],{"trials":21468,"activeCount":97},[],{"trials":21470,"activeCount":97},[],{"trials":21472,"activeCount":97},[21473],{"nctId":6880,"briefTitle":6881,"status":999,"phases":21474,"primaryCompletion":3837,"completion":3837,"start":6883,"enrollment":6884,"conditions":21475,"interventions":21476},[87],[1732],[6887,1669],{"trials":21478,"activeCount":97},[],{"trials":21480,"activeCount":97},[],{"intervention":21482,"totalTrials":314,"cells":21483},"Tirzepatide Dose 1",{"EARLY_PHASE1":21484,"PHASE1":21486,"PHASE2":21488,"PHASE3":21490,"PHASE4":21503,"NA":21505},{"trials":21485,"activeCount":97},[],{"trials":21487,"activeCount":97},[],{"trials":21489,"activeCount":97},[],{"trials":21491,"activeCount":97},[21492],{"nctId":21493,"briefTitle":21494,"status":103,"phases":21495,"primaryCompletion":21496,"completion":21497,"start":8157,"enrollment":4083,"conditions":21498,"interventions":21501},"NCT05260021","A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both",[87],"2024-07-30","2025-01-28",[21499,620,18,413,21500,621,623,622],"Type2 Diabetes","T2DM (Type 2 Diabetes Mellitus)",[21482,21502],"Tirzepatide Dose 2",{"trials":21504,"activeCount":97},[],{"trials":21506,"activeCount":97},[],{"intervention":21502,"totalTrials":314,"cells":21508},{"EARLY_PHASE1":21509,"PHASE1":21511,"PHASE2":21513,"PHASE3":21515,"PHASE4":21521,"NA":21523},{"trials":21510,"activeCount":97},[],{"trials":21512,"activeCount":97},[],{"trials":21514,"activeCount":97},[],{"trials":21516,"activeCount":97},[21517],{"nctId":21493,"briefTitle":21494,"status":103,"phases":21518,"primaryCompletion":21496,"completion":21497,"start":8157,"enrollment":4083,"conditions":21519,"interventions":21520},[87],[21499,620,18,413,21500,621,623,622],[21482,21502],{"trials":21522,"activeCount":97},[],{"trials":21524,"activeCount":97},[],{"intervention":13158,"totalTrials":314,"cells":21526},{"EARLY_PHASE1":21527,"PHASE1":21529,"PHASE2":21531,"PHASE3":21533,"PHASE4":21539,"NA":21541},{"trials":21528,"activeCount":97},[],{"trials":21530,"activeCount":97},[],{"trials":21532,"activeCount":97},[],{"trials":21534,"activeCount":97},[21535],{"nctId":13152,"briefTitle":13153,"status":999,"phases":21536,"primaryCompletion":5090,"completion":5090,"start":3837,"enrollment":1071,"conditions":21537,"interventions":21538},[87],[13156],[13158,7104,7103],{"trials":21540,"activeCount":97},[],{"trials":21542,"activeCount":97},[],{"intervention":21544,"totalTrials":314,"cells":21545},"Other standard therapy for ADHD",{"EARLY_PHASE1":21546,"PHASE1":21548,"PHASE2":21550,"PHASE3":21552,"PHASE4":21560,"NA":21562},{"trials":21547,"activeCount":97},[],{"trials":21549,"activeCount":97},[],{"trials":21551,"activeCount":97},[],{"trials":21553,"activeCount":97},[21554],{"nctId":21555,"briefTitle":21556,"status":103,"phases":21557,"primaryCompletion":2866,"completion":3059,"start":4642,"enrollment":6654,"conditions":21558,"interventions":21559},"NCT00447278","A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit\u002FHyperactivity Disorder (ADHD) Children and Adolescents",[87],[13785],[15345,21544],{"trials":21561,"activeCount":97},[],{"trials":21563,"activeCount":97},[],{"intervention":5293,"totalTrials":314,"cells":21565},{"EARLY_PHASE1":21566,"PHASE1":21568,"PHASE2":21570,"PHASE3":21572,"PHASE4":21578,"NA":21580},{"trials":21567,"activeCount":97},[],{"trials":21569,"activeCount":97},[],{"trials":21571,"activeCount":97},[],{"trials":21573,"activeCount":97},[21574],{"nctId":5287,"briefTitle":5288,"status":103,"phases":21575,"primaryCompletion":1473,"completion":1474,"start":3048,"enrollment":5290,"conditions":21576,"interventions":21577},[87],[5218],[4944,5095,5222,5293,3032],{"trials":21579,"activeCount":97},[],{"trials":21581,"activeCount":97},[],{"intervention":18723,"totalTrials":314,"cells":21583},{"EARLY_PHASE1":21584,"PHASE1":21586,"PHASE2":21588,"PHASE3":21590,"PHASE4":21596,"NA":21598},{"trials":21585,"activeCount":97},[],{"trials":21587,"activeCount":97},[],{"trials":21589,"activeCount":97},[],{"trials":21591,"activeCount":97},[21592],{"nctId":18718,"briefTitle":18719,"status":103,"phases":21593,"conditions":21594,"interventions":21595},[87],[2652,5763],[18723,2893],{"trials":21597,"activeCount":97},[],{"trials":21599,"activeCount":97},[],{"intervention":21601,"totalTrials":314,"cells":21602},"Somatropin (rDNA origin) for",{"EARLY_PHASE1":21603,"PHASE1":21605,"PHASE2":21607,"PHASE3":21609,"PHASE4":21619,"NA":21621},{"trials":21604,"activeCount":97},[],{"trials":21606,"activeCount":97},[],{"trials":21608,"activeCount":97},[],{"trials":21610,"activeCount":97},[21611],{"nctId":21612,"briefTitle":21613,"status":103,"phases":21614,"primaryCompletion":3339,"completion":3114,"start":21615,"enrollment":9118,"conditions":21616,"interventions":21618},"NCT00190658","Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome",[87],"2000-02",[21617],"Failure to Thrive",[21601],{"trials":21620,"activeCount":97},[],{"trials":21622,"activeCount":97},[],{"intervention":21624,"totalTrials":314,"cells":21625},"tadalafil once a day [T(OaD)]",{"EARLY_PHASE1":21626,"PHASE1":21628,"PHASE2":21630,"PHASE3":21632,"PHASE4":21642,"NA":21644},{"trials":21627,"activeCount":97},[],{"trials":21629,"activeCount":97},[],{"trials":21631,"activeCount":97},[],{"trials":21633,"activeCount":97},[21634],{"nctId":21635,"briefTitle":21636,"status":103,"phases":21637,"primaryCompletion":14517,"completion":14517,"start":3216,"enrollment":15505,"conditions":21638,"interventions":21639},"NCT00734604","A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.",[87],[14741],[21624,21640,21641],"sildenafil citrate as needed [S(PRN)]","tadalafil as needed [T(PRN)]",{"trials":21643,"activeCount":97},[],{"trials":21645,"activeCount":97},[],{"intervention":21640,"totalTrials":314,"cells":21647},{"EARLY_PHASE1":21648,"PHASE1":21650,"PHASE2":21652,"PHASE3":21654,"PHASE4":21660,"NA":21662},{"trials":21649,"activeCount":97},[],{"trials":21651,"activeCount":97},[],{"trials":21653,"activeCount":97},[],{"trials":21655,"activeCount":97},[21656],{"nctId":21635,"briefTitle":21636,"status":103,"phases":21657,"primaryCompletion":14517,"completion":14517,"start":3216,"enrollment":15505,"conditions":21658,"interventions":21659},[87],[14741],[21624,21640,21641],{"trials":21661,"activeCount":97},[],{"trials":21663,"activeCount":97},[],{"intervention":21641,"totalTrials":314,"cells":21665},{"EARLY_PHASE1":21666,"PHASE1":21668,"PHASE2":21670,"PHASE3":21672,"PHASE4":21678,"NA":21680},{"trials":21667,"activeCount":97},[],{"trials":21669,"activeCount":97},[],{"trials":21671,"activeCount":97},[],{"trials":21673,"activeCount":97},[21674],{"nctId":21635,"briefTitle":21636,"status":103,"phases":21675,"primaryCompletion":14517,"completion":14517,"start":3216,"enrollment":15505,"conditions":21676,"interventions":21677},[87],[14741],[21624,21640,21641],{"trials":21679,"activeCount":97},[],{"trials":21681,"activeCount":97},[],{"intervention":13645,"totalTrials":314,"cells":21683},{"EARLY_PHASE1":21684,"PHASE1":21686,"PHASE2":21688,"PHASE3":21690,"PHASE4":21696,"NA":21698},{"trials":21685,"activeCount":97},[],{"trials":21687,"activeCount":97},[],{"trials":21689,"activeCount":97},[],{"trials":21691,"activeCount":97},[21692],{"nctId":13640,"briefTitle":13641,"status":103,"phases":21693,"primaryCompletion":3027,"completion":3027,"start":2864,"enrollment":3823,"conditions":21694,"interventions":21695},[87],[120],[9681,7103,7118,13645],{"trials":21697,"activeCount":97},[],{"trials":21699,"activeCount":97},[],{"intervention":6899,"totalTrials":314,"cells":21701},{"EARLY_PHASE1":21702,"PHASE1":21704,"PHASE2":21706,"PHASE3":21708,"PHASE4":21714,"NA":21716},{"trials":21703,"activeCount":97},[],{"trials":21705,"activeCount":97},[],{"trials":21707,"activeCount":97},[],{"trials":21709,"activeCount":97},[21710],{"nctId":6893,"briefTitle":6894,"status":103,"phases":21711,"primaryCompletion":3027,"completion":5081,"start":3152,"enrollment":6896,"conditions":21712,"interventions":21713},[87],[3062],[6899,1669],{"trials":21715,"activeCount":97},[],{"trials":21717,"activeCount":97},[],{"intervention":14455,"totalTrials":314,"cells":21719},{"EARLY_PHASE1":21720,"PHASE1":21722,"PHASE2":21724,"PHASE3":21726,"PHASE4":21732,"NA":21734},{"trials":21721,"activeCount":97},[],{"trials":21723,"activeCount":97},[],{"trials":21725,"activeCount":97},[],{"trials":21727,"activeCount":97},[21728],{"nctId":14450,"briefTitle":14451,"status":103,"phases":21729,"completion":3168,"start":4459,"enrollment":410,"conditions":21730,"interventions":21731},[87],[4919],[14423,14455],{"trials":21733,"activeCount":97},[],{"trials":21735,"activeCount":97},[],{"intervention":21737,"totalTrials":314,"cells":21738},"Duloxetine hydrochloride - 40 mg",{"EARLY_PHASE1":21739,"PHASE1":21741,"PHASE2":21743,"PHASE3":21745,"PHASE4":21754,"NA":21756},{"trials":21740,"activeCount":97},[],{"trials":21742,"activeCount":97},[],{"trials":21744,"activeCount":97},[],{"trials":21746,"activeCount":97},[21747],{"nctId":21748,"briefTitle":21749,"status":103,"phases":21750,"primaryCompletion":2866,"completion":2866,"start":3266,"enrollment":13650,"conditions":21751,"interventions":21752},"NCT00552175","A Study for the Treatment of Diabetic Peripheral Neuropathic Pain",[87],[20294],[21737,21753],"Duloxetine hydrochloride - 60 mg",{"trials":21755,"activeCount":97},[],{"trials":21757,"activeCount":97},[],{"intervention":21753,"totalTrials":314,"cells":21759},{"EARLY_PHASE1":21760,"PHASE1":21762,"PHASE2":21764,"PHASE3":21766,"PHASE4":21772,"NA":21774},{"trials":21761,"activeCount":97},[],{"trials":21763,"activeCount":97},[],{"trials":21765,"activeCount":97},[],{"trials":21767,"activeCount":97},[21768],{"nctId":21748,"briefTitle":21749,"status":103,"phases":21769,"primaryCompletion":2866,"completion":2866,"start":3266,"enrollment":13650,"conditions":21770,"interventions":21771},[87],[20294],[21737,21753],{"trials":21773,"activeCount":97},[],{"trials":21775,"activeCount":97},[],{"intervention":19019,"totalTrials":314,"cells":21777},{"EARLY_PHASE1":21778,"PHASE1":21780,"PHASE2":21782,"PHASE3":21784,"PHASE4":21790,"NA":21792},{"trials":21779,"activeCount":97},[],{"trials":21781,"activeCount":97},[],{"trials":21783,"activeCount":97},[],{"trials":21785,"activeCount":97},[21786],{"nctId":19013,"briefTitle":19014,"status":103,"phases":21787,"primaryCompletion":3320,"completion":3320,"start":3813,"enrollment":19016,"conditions":21788,"interventions":21789},[87],[14286],[13177,19019],{"trials":21791,"activeCount":97},[],{"trials":21793,"activeCount":97},[],{"intervention":18448,"totalTrials":314,"cells":21795},{"EARLY_PHASE1":21796,"PHASE1":21798,"PHASE2":21800,"PHASE3":21802,"PHASE4":21808,"NA":21810},{"trials":21797,"activeCount":97},[],{"trials":21799,"activeCount":97},[],{"trials":21801,"activeCount":97},[],{"trials":21803,"activeCount":97},[21804],{"nctId":18443,"briefTitle":18444,"status":103,"phases":21805,"primaryCompletion":3292,"completion":3292,"start":4566,"enrollment":18358,"conditions":21806,"interventions":21807},[86,87],[18],[13554,18448],{"trials":21809,"activeCount":97},[],{"trials":21811,"activeCount":97},[],{"intervention":6907,"totalTrials":314,"cells":21813},{"EARLY_PHASE1":21814,"PHASE1":21816,"PHASE2":21818,"PHASE3":21820,"PHASE4":21826,"NA":21828},{"trials":21815,"activeCount":97},[],{"trials":21817,"activeCount":97},[],{"trials":21819,"activeCount":97},[],{"trials":21821,"activeCount":97},[21822],{"nctId":6901,"briefTitle":6902,"status":103,"phases":21823,"completion":2856,"start":6904,"conditions":21824,"interventions":21825},[87],[36],[6907,3222],{"trials":21827,"activeCount":97},[],{"trials":21829,"activeCount":97},[],{"intervention":21831,"totalTrials":314,"cells":21832},"Galcanezumab 300 mg",{"EARLY_PHASE1":21833,"PHASE1":21835,"PHASE2":21837,"PHASE3":21839,"PHASE4":21848,"NA":21850},{"trials":21834,"activeCount":97},[],{"trials":21836,"activeCount":97},[],{"trials":21838,"activeCount":97},[],{"trials":21840,"activeCount":97},[21841],{"nctId":21842,"briefTitle":21843,"status":103,"phases":21844,"primaryCompletion":6377,"completion":2005,"start":21845,"enrollment":2502,"conditions":21846,"interventions":21847},"NCT02438826","A Study of Galcanezumab in Participants With Chronic Cluster Headache",[87],"2015-06-18",[7506],[21831],{"trials":21849,"activeCount":97},[],{"trials":21851,"activeCount":97},[],{"intervention":7356,"totalTrials":314,"cells":21853},{"EARLY_PHASE1":21854,"PHASE1":21856,"PHASE2":21858,"PHASE3":21860,"PHASE4":21866,"NA":21868},{"trials":21855,"activeCount":97},[],{"trials":21857,"activeCount":97},[],{"trials":21859,"activeCount":97},[],{"trials":21861,"activeCount":97},[21862],{"nctId":7348,"briefTitle":7349,"status":103,"phases":21863,"primaryCompletion":1266,"completion":7351,"start":7352,"enrollment":7353,"conditions":21864,"interventions":21865},[87],[926],[449,7356],{"trials":21867,"activeCount":97},[],{"trials":21869,"activeCount":97},[],{"intervention":19944,"totalTrials":314,"cells":21871},{"EARLY_PHASE1":21872,"PHASE1":21874,"PHASE2":21876,"PHASE3":21878,"PHASE4":21884,"NA":21886},{"trials":21873,"activeCount":97},[],{"trials":21875,"activeCount":97},[],{"trials":21877,"activeCount":97},[],{"trials":21879,"activeCount":97},[21880],{"nctId":19935,"briefTitle":19936,"status":103,"phases":21881,"primaryCompletion":19938,"completion":19939,"start":19940,"enrollment":19941,"conditions":21882,"interventions":21883},[87],[447],[19944,19914],{"trials":21885,"activeCount":97},[],{"trials":21887,"activeCount":97},[],{"intervention":15260,"totalTrials":314,"cells":21889},{"EARLY_PHASE1":21890,"PHASE1":21892,"PHASE2":21894,"PHASE3":21896,"PHASE4":21902,"NA":21904},{"trials":21891,"activeCount":97},[],{"trials":21893,"activeCount":97},[],{"trials":21895,"activeCount":97},[],{"trials":21897,"activeCount":97},[21898],{"nctId":15252,"briefTitle":15253,"status":103,"phases":21899,"primaryCompletion":15255,"completion":15255,"start":15256,"enrollment":15257,"conditions":21900,"interventions":21901},[87],[14168],[14170,14170,15241,15260],{"trials":21903,"activeCount":97},[],{"trials":21905,"activeCount":97},[],{"intervention":21907,"totalTrials":314,"cells":21908},"Lebrikizumab Pen",{"EARLY_PHASE1":21909,"PHASE1":21911,"PHASE2":21913,"PHASE3":21915,"PHASE4":21925,"NA":21927},{"trials":21910,"activeCount":97},[],{"trials":21912,"activeCount":97},[],{"trials":21914,"activeCount":97},[],{"trials":21916,"activeCount":97},[21917],{"nctId":21918,"briefTitle":21919,"status":103,"phases":21920,"primaryCompletion":21921,"completion":21921,"start":21922,"enrollment":224,"conditions":21923,"interventions":21924},"NCT06444165","Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis",[87],"2024-06-10","2024-06-04",[1271],[21907],{"trials":21926,"activeCount":97},[],{"trials":21928,"activeCount":97},[],{"intervention":21930,"totalTrials":314,"cells":21931},"leuprorelin",{"EARLY_PHASE1":21932,"PHASE1":21934,"PHASE2":21936,"PHASE3":21938,"PHASE4":21948,"NA":21950},{"trials":21933,"activeCount":97},[],{"trials":21935,"activeCount":97},[],{"trials":21937,"activeCount":97},[],{"trials":21939,"activeCount":97},[21940],{"nctId":21941,"briefTitle":21942,"status":103,"phases":21943,"primaryCompletion":4097,"completion":4097,"start":3524,"enrollment":4279,"conditions":21944,"interventions":21946},"NCT00355030","Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature",[87],[21945],"Idiopathic Short Stature (ISS)",[21947,21930],"somatropin",{"trials":21949,"activeCount":97},[],{"trials":21951,"activeCount":97},[],{"intervention":19306,"totalTrials":314,"cells":21953},{"EARLY_PHASE1":21954,"PHASE1":21956,"PHASE2":21958,"PHASE3":21960,"PHASE4":21966,"NA":21968},{"trials":21955,"activeCount":97},[],{"trials":21957,"activeCount":97},[],{"trials":21959,"activeCount":97},[],{"trials":21961,"activeCount":97},[21962],{"nctId":19298,"briefTitle":19299,"status":103,"phases":21963,"primaryCompletion":2540,"completion":2540,"start":19301,"enrollment":19302,"conditions":21964,"interventions":21965},[86,87],[5284],[19273,19305,19306],{"trials":21967,"activeCount":97},[],{"trials":21969,"activeCount":97},[],{"intervention":21971,"totalTrials":314,"cells":21972},"80 mg Ixekizumab Dosing Regimens 1, 2, and 3",{"EARLY_PHASE1":21973,"PHASE1":21975,"PHASE2":21977,"PHASE3":21979,"PHASE4":21991,"NA":21993},{"trials":21974,"activeCount":97},[],{"trials":21976,"activeCount":97},[],{"trials":21978,"activeCount":97},[],{"trials":21980,"activeCount":97},[21981],{"nctId":21982,"briefTitle":21983,"status":103,"phases":21984,"primaryCompletion":21985,"completion":21986,"start":21987,"enrollment":21988,"conditions":21989,"interventions":21990},"NCT01474512","A Phase 3 Study in Participants With Moderate to Severe Psoriasis",[87],"2014-06-24","2018-09-20","2011-11-16",1296,[447],[21971],{"trials":21992,"activeCount":97},[],{"trials":21994,"activeCount":97},[],{"intervention":21996,"totalTrials":314,"cells":21997},"BEC2 Vaccine",{"EARLY_PHASE1":21998,"PHASE1":22000,"PHASE2":22002,"PHASE3":22004,"PHASE4":22014,"NA":22016},{"trials":21999,"activeCount":97},[],{"trials":22001,"activeCount":97},[],{"trials":22003,"activeCount":97},[],{"trials":22005,"activeCount":97},[22006],{"nctId":22007,"briefTitle":22008,"status":103,"phases":22009,"primaryCompletion":3236,"completion":3236,"start":22010,"enrollment":3357,"conditions":22011,"interventions":22013},"NCT00037713","Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG",[87],"1998-09",[22012],"Carcinoma, Small Cell Lung",[21996],{"trials":22015,"activeCount":97},[],{"trials":22017,"activeCount":97},[],{"intervention":22019,"totalTrials":314,"cells":22020},"Salmon Calcitonin",{"EARLY_PHASE1":22021,"PHASE1":22023,"PHASE2":22025,"PHASE3":22027,"PHASE4":22036,"NA":22038},{"trials":22022,"activeCount":97},[],{"trials":22024,"activeCount":97},[],{"trials":22026,"activeCount":97},[],{"trials":22028,"activeCount":97},[22029],{"nctId":22030,"briefTitle":22031,"status":103,"phases":22032,"primaryCompletion":2800,"completion":2800,"start":3060,"enrollment":22033,"conditions":22034,"interventions":22035},"NCT00414973","A Study for Patients With Osteoporosis",[87],364,[14617],[14202,22019],{"trials":22037,"activeCount":97},[],{"trials":22039,"activeCount":97},[],{"intervention":6184,"totalTrials":314,"cells":22041},{"EARLY_PHASE1":22042,"PHASE1":22044,"PHASE2":22046,"PHASE3":22048,"PHASE4":22054,"NA":22056},{"trials":22043,"activeCount":97},[],{"trials":22045,"activeCount":97},[],{"trials":22047,"activeCount":97},[],{"trials":22049,"activeCount":97},[22050],{"nctId":6179,"briefTitle":6180,"status":103,"phases":22051,"conditions":22052,"interventions":22053},[87],[1893],[6184,3890],{"trials":22055,"activeCount":97},[],{"trials":22057,"activeCount":97},[],{"intervention":7385,"totalTrials":314,"cells":22059},{"EARLY_PHASE1":22060,"PHASE1":22062,"PHASE2":22064,"PHASE3":22066,"PHASE4":22072,"NA":22074},{"trials":22061,"activeCount":97},[],{"trials":22063,"activeCount":97},[],{"trials":22065,"activeCount":97},[],{"trials":22067,"activeCount":97},[22068],{"nctId":7377,"briefTitle":7378,"status":103,"phases":22069,"primaryCompletion":7380,"completion":7381,"start":7382,"enrollment":1730,"conditions":22070,"interventions":22071},[87],[926],[7385,5095,449],{"trials":22073,"activeCount":97},[],{"trials":22075,"activeCount":97},[],{"intervention":9732,"totalTrials":314,"cells":22077},{"EARLY_PHASE1":22078,"PHASE1":22080,"PHASE2":22082,"PHASE3":22084,"PHASE4":22090,"NA":22092},{"trials":22079,"activeCount":97},[],{"trials":22081,"activeCount":97},[],{"trials":22083,"activeCount":97},[],{"trials":22085,"activeCount":97},[22086],{"nctId":9726,"briefTitle":9727,"status":103,"phases":22087,"primaryCompletion":5090,"completion":2865,"start":3087,"enrollment":9729,"conditions":22088,"interventions":22089},[87],[18],[9681,9732,1631,9733],{"trials":22091,"activeCount":97},[],{"trials":22093,"activeCount":97},[],{"intervention":22095,"totalTrials":314,"cells":22096},"Pomaglumetad methionil",{"EARLY_PHASE1":22097,"PHASE1":22099,"PHASE2":22101,"PHASE3":22103,"PHASE4":22111,"NA":22113},{"trials":22098,"activeCount":97},[],{"trials":22100,"activeCount":97},[],{"trials":22102,"activeCount":97},[],{"trials":22104,"activeCount":97},[22105],{"nctId":22106,"briefTitle":22107,"status":999,"phases":22108,"primaryCompletion":2798,"completion":2798,"start":4160,"enrollment":820,"conditions":22109,"interventions":22110},"NCT01487083","A Long-Term Study in Schizophrenia",[87],[4897],[22095],{"trials":22112,"activeCount":97},[],{"trials":22114,"activeCount":97},[],{"intervention":18375,"totalTrials":314,"cells":22116},{"EARLY_PHASE1":22117,"PHASE1":22119,"PHASE2":22121,"PHASE3":22123,"PHASE4":22129,"NA":22131},{"trials":22118,"activeCount":97},[],{"trials":22120,"activeCount":97},[],{"trials":22122,"activeCount":97},[],{"trials":22124,"activeCount":97},[22125],{"nctId":18369,"briefTitle":18370,"status":103,"phases":22126,"primaryCompletion":3049,"completion":3049,"start":5022,"enrollment":9118,"conditions":22127,"interventions":22128},[87],[18373,620],[18296,18375],{"trials":22130,"activeCount":97},[],{"trials":22132,"activeCount":97},[],{"intervention":22134,"totalTrials":314,"cells":22135},"simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder",{"EARLY_PHASE1":22136,"PHASE1":22138,"PHASE2":22140,"PHASE3":22142,"PHASE4":22152,"NA":22154},{"trials":22137,"activeCount":97},[],{"trials":22139,"activeCount":97},[],{"trials":22141,"activeCount":97},[],{"trials":22143,"activeCount":97},[22144],{"nctId":22145,"briefTitle":22146,"status":103,"phases":22147,"primaryCompletion":3292,"completion":3292,"start":2876,"enrollment":22148,"conditions":22149,"interventions":22150},"NCT00391209","Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus",[87],379,[18],[22134,22151],"intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder",{"trials":22153,"activeCount":97},[],{"trials":22155,"activeCount":97},[],{"intervention":22151,"totalTrials":314,"cells":22157},{"EARLY_PHASE1":22158,"PHASE1":22160,"PHASE2":22162,"PHASE3":22164,"PHASE4":22170,"NA":22172},{"trials":22159,"activeCount":97},[],{"trials":22161,"activeCount":97},[],{"trials":22163,"activeCount":97},[],{"trials":22165,"activeCount":97},[22166],{"nctId":22145,"briefTitle":22146,"status":103,"phases":22167,"primaryCompletion":3292,"completion":3292,"start":2876,"enrollment":22148,"conditions":22168,"interventions":22169},[87],[18],[22134,22151],{"trials":22171,"activeCount":97},[],{"trials":22173,"activeCount":97},[],{"intervention":7043,"totalTrials":1071,"cells":22175},{"EARLY_PHASE1":22176,"PHASE1":22178,"PHASE2":22281,"PHASE3":22295,"PHASE4":22297,"NA":22299},{"trials":22177,"activeCount":97},[],{"trials":22179,"activeCount":97},[22180,22188,22196,22203,22210,22218,22225,22232,22239,22245,22249,22258,22266,22274],{"nctId":22181,"briefTitle":22182,"status":103,"phases":22183,"primaryCompletion":22184,"completion":22184,"start":13467,"enrollment":310,"conditions":22185,"interventions":22186},"NCT05573230","A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants",[85],"2023-01-17",[15],[1538,7043,22187],"Cyclosporine",{"nctId":22189,"briefTitle":22190,"status":103,"phases":22191,"primaryCompletion":22192,"completion":22192,"start":22193,"enrollment":3041,"conditions":22194,"interventions":22195},"NCT05341089","A Study of Two Different Formulations of LY3502970 in Healthy Participants",[85],"2022-09-01","2022-05-17",[15],[7043],{"nctId":22197,"briefTitle":22198,"status":103,"phases":22199,"primaryCompletion":2131,"completion":2131,"start":22200,"enrollment":864,"conditions":22201,"interventions":22202},"NCT05882032","A Study of LY3502970 in Participants With Impaired and Normal Liver Function",[85],"2023-06-13",[15,312],[7043],{"nctId":22204,"briefTitle":22205,"status":103,"phases":22206,"primaryCompletion":22207,"completion":22207,"start":1397,"enrollment":893,"conditions":22208,"interventions":22209},"NCT05051566","A Multiple Dose Study of LY3502970 in Healthy Participants",[85],"2022-04-04",[15],[7043,11075],{"nctId":22211,"briefTitle":22212,"status":103,"phases":22213,"primaryCompletion":22214,"completion":22215,"start":7089,"enrollment":251,"conditions":22216,"interventions":22217},"NCT05841238","A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants",[85],"2023-09-14","2023-11-13",[15,2090],[7043],{"nctId":22219,"briefTitle":22220,"status":103,"phases":22221,"primaryCompletion":22222,"completion":22222,"start":356,"enrollment":290,"conditions":22223,"interventions":22224},"NCT06023095","A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities",[85],"2024-07-29",[27,24],[7043],{"nctId":22226,"briefTitle":22227,"status":103,"phases":22228,"primaryCompletion":1817,"completion":1817,"start":22229,"enrollment":28,"conditions":22230,"interventions":22231},"NCT05086445","A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus",[85],"2021-11-12",[18],[7043],{"nctId":22233,"briefTitle":22234,"status":103,"phases":22235,"primaryCompletion":22236,"completion":22236,"start":766,"enrollment":893,"conditions":22237,"interventions":22238},"NCT05469126","A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants",[85],"2022-11-03",[15],[7043,1480],{"nctId":22240,"briefTitle":22241,"status":103,"phases":22242,"primaryCompletion":4002,"completion":4002,"start":222,"enrollment":1767,"conditions":22243,"interventions":22244},"NCT05313802","A Study of LY3502970 in Healthy Overweight and Obese Participants",[85],[15,2090],[7043],{"nctId":18082,"briefTitle":18083,"status":103,"phases":22246,"primaryCompletion":18085,"completion":18085,"start":18086,"enrollment":2931,"conditions":22247,"interventions":22248},[85],[15],[7043,9237,2092,1538],{"nctId":22250,"briefTitle":22251,"status":103,"phases":22252,"primaryCompletion":22253,"completion":22253,"start":22254,"enrollment":757,"conditions":22255,"interventions":22256},"NCT06085482","A Phase I Study of LY3502970 in Healthy Participants",[85],"2024-01-05","2023-10-19",[15],[7043,22257],"[14C]-LY3502970",{"nctId":22259,"briefTitle":22260,"status":103,"phases":22261,"primaryCompletion":22262,"completion":22262,"start":22263,"enrollment":3718,"conditions":22264,"interventions":22265},"NCT05110794","A Multiple-Dose Study of LY3502970 in Healthy Participants",[85],"2022-02-10","2021-11-05",[15],[7043],{"nctId":22267,"briefTitle":22268,"status":103,"phases":22269,"primaryCompletion":22270,"completion":22270,"start":22271,"enrollment":290,"conditions":22272,"interventions":22273},"NCT05936138","A Study of LY3502970 in Participants With Normal and Impaired Renal Function",[85],"2024-04-11","2023-07-13",[147,15],[7043],{"nctId":22275,"briefTitle":22276,"status":103,"phases":22277,"primaryCompletion":1345,"completion":1345,"start":22278,"enrollment":4353,"conditions":22279,"interventions":22280},"NCT04426474","A Study of LY3502970 in Participants With Type 2 Diabetes",[85],"2020-10-08",[18],[7043],{"trials":22282,"activeCount":97},[22283,22287],{"nctId":7036,"briefTitle":7037,"status":103,"phases":22284,"primaryCompletion":1336,"completion":1336,"start":7039,"enrollment":7040,"conditions":22285,"interventions":22286},[86],[30],[7043,303],{"nctId":22288,"briefTitle":22289,"status":103,"phases":22290,"primaryCompletion":22291,"completion":9607,"start":22292,"enrollment":3978,"conditions":22293,"interventions":22294},"NCT05051579","A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities",[86],"2022-08-25","2021-09-29",[24,8884],[7043],{"trials":22296,"activeCount":97},[],{"trials":22298,"activeCount":97},[],{"trials":22300,"activeCount":97},[],{"intervention":9643,"totalTrials":1062,"cells":22302},{"EARLY_PHASE1":22303,"PHASE1":22305,"PHASE2":22368,"PHASE3":22390,"PHASE4":22392,"NA":22394},{"trials":22304,"activeCount":97},[],{"trials":22306,"activeCount":97},[22307,22313,22319,22325,22331,22337,22343,22349,22355,22362],{"nctId":22308,"briefTitle":22309,"status":103,"phases":22310,"primaryCompletion":4980,"completion":4980,"start":3282,"enrollment":1620,"conditions":22311,"interventions":22312},"NCT01836198","The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream",[85],[21],[9643,17281,4983,1480],{"nctId":22314,"briefTitle":22315,"status":103,"phases":22316,"primaryCompletion":3886,"completion":3886,"start":3004,"enrollment":6927,"conditions":22317,"interventions":22318},"NCT01460368","A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart",[85],[18],[9643,1181],{"nctId":22320,"briefTitle":22321,"status":103,"phases":22322,"primaryCompletion":5022,"completion":5022,"start":2864,"enrollment":1620,"conditions":22323,"interventions":22324},"NCT01588366","The Effects of LY2409021 on the Liver",[85],[18],[9643],{"nctId":22326,"briefTitle":22327,"status":103,"phases":22328,"primaryCompletion":2974,"completion":2974,"start":3338,"enrollment":2088,"conditions":22329,"interventions":22330},"NCT01606397","A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes",[85],[18],[9643],{"nctId":22332,"briefTitle":22333,"status":103,"phases":22334,"primaryCompletion":3338,"completion":3338,"start":3266,"enrollment":11639,"conditions":22335,"interventions":22336},"NCT01606423","The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants",[85],[21],[9643],{"nctId":22338,"briefTitle":22339,"status":103,"phases":22340,"primaryCompletion":2845,"completion":2845,"start":3122,"enrollment":1071,"conditions":22341,"interventions":22342},"NCT02217618","A Study of LY2409021 in Healthy Participants",[85],[4997],[9643],{"nctId":22344,"briefTitle":22345,"status":103,"phases":22346,"primaryCompletion":2898,"completion":2898,"start":3545,"enrollment":1082,"conditions":22347,"interventions":22348},"NCT01640834","Study of LY2409021 in Participants With Type 1 Diabetes",[85],[33],[9643,17603],{"nctId":22350,"briefTitle":22351,"status":103,"phases":22352,"primaryCompletion":3235,"completion":3235,"start":3005,"enrollment":310,"conditions":22353,"interventions":22354},"NCT01606371","A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes",[85],[18],[9643],{"nctId":22356,"briefTitle":22357,"status":103,"phases":22358,"primaryCompletion":3122,"completion":3122,"start":2917,"enrollment":128,"conditions":22359,"interventions":22361},"NCT01929109","A Study of LY2409021 in Participants With Different Levels of Kidney Function",[85],[8857,22360],"Renal Insufficiency, Chronic",[9643],{"nctId":22363,"briefTitle":22364,"status":999,"phases":22365,"primaryCompletion":3717,"completion":3717,"start":1596,"enrollment":12,"conditions":22366,"interventions":22367},"NCT02385084","A Study of LY2409021 Formulations in Healthy Participants",[85],[15],[9643],{"trials":22369,"activeCount":97},[22370,22376,22382,22386],{"nctId":22371,"briefTitle":22372,"status":103,"phases":22373,"primaryCompletion":3087,"completion":3087,"start":2866,"enrollment":8967,"conditions":22374,"interventions":22375},"NCT00871572","A Study for Participants With Type 2 Diabetes Mellitus",[86],[18],[9643],{"nctId":22377,"briefTitle":22378,"status":103,"phases":22379,"primaryCompletion":3086,"completion":3886,"start":4258,"enrollment":3373,"conditions":22380,"interventions":22381},"NCT01241448","A Study of LY2409021 in Patients With Type 2 Diabetes",[86],[18],[9643],{"nctId":9637,"briefTitle":9638,"status":999,"phases":22383,"primaryCompletion":1618,"completion":1618,"start":1475,"enrollment":9640,"conditions":22384,"interventions":22385},[86],[18],[9643,9644,1631,9645],{"nctId":9655,"briefTitle":9656,"status":103,"phases":22387,"primaryCompletion":5030,"completion":5030,"start":6632,"enrollment":7549,"conditions":22388,"interventions":22389},[86],[120],[9643,1631],{"trials":22391,"activeCount":97},[],{"trials":22393,"activeCount":97},[],{"trials":22395,"activeCount":97},[],{"intervention":11230,"totalTrials":1062,"cells":22397},{"EARLY_PHASE1":22398,"PHASE1":22400,"PHASE2":22466,"PHASE3":22480,"PHASE4":22482,"NA":22484},{"trials":22399,"activeCount":97},[],{"trials":22401,"activeCount":97},[22402,22406,22410,22418,22426,22430,22434,22441,22445,22452,22459],{"nctId":13427,"briefTitle":13428,"status":103,"phases":22403,"primaryCompletion":13430,"completion":13430,"start":819,"enrollment":1178,"conditions":22404,"interventions":22405},[85],[18],[11230,506],{"nctId":11223,"briefTitle":11224,"status":103,"phases":22407,"primaryCompletion":11226,"completion":11226,"start":11227,"enrollment":165,"conditions":22408,"interventions":22409},[85],[18],[11230,700],{"nctId":22411,"briefTitle":22412,"status":103,"phases":22413,"primaryCompletion":22414,"completion":22414,"start":22415,"enrollment":2088,"conditions":22416,"interventions":22417},"NCT04768842","A Study of Two Different Formulations of LY3209590 in Healthy Participants",[85],"2021-09-03","2021-03-03",[15],[11230],{"nctId":22419,"briefTitle":22420,"status":103,"phases":22421,"primaryCompletion":22422,"completion":22422,"start":22423,"enrollment":6927,"conditions":22424,"interventions":22425},"NCT05914688","A Study to Compare Two Formulations of LY3209590 in Healthy Participants",[85],"2024-01-18","2023-06-26",[15],[11230,11230],{"nctId":13446,"briefTitle":13447,"status":103,"phases":22427,"primaryCompletion":13449,"completion":13449,"start":13450,"enrollment":2790,"conditions":22428,"interventions":22429},[85],[18],[11230,506],{"nctId":13464,"briefTitle":13465,"status":103,"phases":22431,"primaryCompletion":13467,"completion":13467,"start":7574,"enrollment":31,"conditions":22432,"interventions":22433},[85],[120],[506,11230],{"nctId":22435,"briefTitle":22436,"status":103,"phases":22437,"primaryCompletion":11321,"completion":11321,"start":22438,"enrollment":1178,"conditions":22439,"interventions":22440},"NCT03603704","A Study of LY3209590 in Japanese Participants With Type 2 Diabetes",[85],"2018-08-17",[18],[11230],{"nctId":13478,"briefTitle":13479,"status":103,"phases":22442,"primaryCompletion":13481,"completion":13481,"start":13482,"enrollment":4475,"conditions":22443,"interventions":22444},[85],[18],[11230,506],{"nctId":22446,"briefTitle":22447,"status":103,"phases":22448,"primaryCompletion":22449,"completion":22449,"start":11165,"enrollment":6943,"conditions":22450,"interventions":22451},"NCT06169982","A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes",[85],"2024-07-18",[18],[11230],{"nctId":22453,"briefTitle":22454,"status":103,"phases":22455,"primaryCompletion":22456,"completion":22456,"start":279,"enrollment":6549,"conditions":22457,"interventions":22458},"NCT05615532","A Relative Bioavailability Study of LY3209590 in Healthy Participants",[85],"2023-06-28",[15],[11230,11230],{"nctId":22460,"briefTitle":22461,"status":103,"phases":22462,"primaryCompletion":22463,"completion":22463,"start":912,"enrollment":1158,"conditions":22464,"interventions":22465},"NCT06362265","A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus",[85],"2026-01-02",[120],[11230],{"trials":22467,"activeCount":97},[22468,22472,22476],{"nctId":11238,"briefTitle":11239,"status":103,"phases":22469,"primaryCompletion":11241,"completion":11241,"start":11242,"enrollment":11243,"conditions":22470,"interventions":22471},[86],[9437],[11230,700],{"nctId":11253,"briefTitle":11254,"status":103,"phases":22473,"primaryCompletion":11256,"completion":11256,"start":7436,"enrollment":6654,"conditions":22474,"interventions":22475},[86],[120],[11230,700],{"nctId":11260,"briefTitle":11261,"status":103,"phases":22477,"primaryCompletion":11263,"completion":11263,"start":11264,"enrollment":11265,"conditions":22478,"interventions":22479},[86],[120],[11230,700],{"trials":22481,"activeCount":97},[],{"trials":22483,"activeCount":97},[],{"trials":22485,"activeCount":97},[],{"intervention":6982,"totalTrials":1199,"cells":22487},{"EARLY_PHASE1":22488,"PHASE1":22490,"PHASE2":22564,"PHASE3":22578,"PHASE4":22580,"NA":22582},{"trials":22489,"activeCount":97},[],{"trials":22491,"activeCount":97},[22492,22498,22506,22510,22518,22525,22532,22538,22545,22552,22556],{"nctId":22493,"briefTitle":22494,"status":103,"phases":22495,"primaryCompletion":6273,"completion":6273,"start":1531,"enrollment":310,"conditions":22496,"interventions":22497},"NCT05548231","A Study of LY3437943 in Chinese Participants With Obesity Or Overweight",[85],[27,24],[6982],{"nctId":22499,"briefTitle":22500,"status":103,"phases":22501,"primaryCompletion":22502,"completion":22502,"start":22503,"enrollment":22,"conditions":22504,"interventions":22505},"NCT05959096","A Study of LY3437943 in Healthy Participants With a High Body Mass Index",[85],"2024-07-25","2023-07-18",[15],[6982,6982],{"nctId":6975,"briefTitle":6976,"status":103,"phases":22507,"primaryCompletion":6978,"completion":6978,"start":6979,"enrollment":1767,"conditions":22508,"interventions":22509},[85],[18],[6982,303],{"nctId":22511,"briefTitle":22512,"status":103,"phases":22513,"primaryCompletion":22514,"completion":22514,"start":22515,"enrollment":22,"conditions":22516,"interventions":22517},"NCT06313528","A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943",[85],"2025-08-26","2024-03-20",[24],[6982],{"nctId":22519,"briefTitle":22520,"status":103,"phases":22521,"primaryCompletion":22522,"completion":22522,"start":9693,"enrollment":34,"conditions":22523,"interventions":22524},"NCT03841630","A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants",[85],"2019-07-25",[15],[6982],{"nctId":22526,"briefTitle":22527,"status":103,"phases":22528,"primaryCompletion":22529,"completion":22529,"start":22271,"enrollment":4222,"conditions":22530,"interventions":22531},"NCT05916560","A Study of LY3437943 in Participants With Impaired and Normal Liver Function",[85],"2025-03-02",[15,312],[6982],{"nctId":22533,"briefTitle":22534,"status":103,"phases":22535,"primaryCompletion":10145,"completion":10145,"start":7021,"enrollment":310,"conditions":22536,"interventions":22537},"NCT05445232","A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants",[85],[24],[6982,1538,1172,1170],{"nctId":22539,"briefTitle":22540,"status":103,"phases":22541,"primaryCompletion":22542,"completion":22542,"start":7910,"enrollment":864,"conditions":22543,"interventions":22544},"NCT05611957","A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function",[85],"2023-09-05",[15,147],[6982],{"nctId":22546,"briefTitle":22547,"status":103,"phases":22548,"primaryCompletion":1922,"completion":1922,"start":22549,"enrollment":3654,"conditions":22550,"interventions":22551},"NCT06003465","A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices",[85],"2023-08-29",[15],[6982],{"nctId":19865,"briefTitle":19866,"status":103,"phases":22553,"primaryCompletion":19868,"completion":19868,"start":19869,"enrollment":1741,"conditions":22554,"interventions":22555},[85],[27],[6982,19872,19873],{"nctId":22557,"briefTitle":22558,"status":103,"phases":22559,"primaryCompletion":22560,"completion":22560,"start":22561,"enrollment":2867,"conditions":22562,"interventions":22563},"NCT04823208","A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)",[85],"2022-06-23","2021-05-24",[18],[6982],{"trials":22565,"activeCount":97},[22566,22574],{"nctId":22567,"briefTitle":22568,"status":103,"phases":22569,"primaryCompletion":22570,"completion":9607,"start":19847,"enrollment":22571,"conditions":22572,"interventions":22573},"NCT04881760","A Study of LY3437943 in Participants Who Have Obesity or Are Overweight",[86],"2022-05-16",338,[24,27],[6982],{"nctId":7018,"briefTitle":7019,"status":103,"phases":22575,"primaryCompletion":7021,"completion":7022,"start":7023,"enrollment":7024,"conditions":22576,"interventions":22577},[86],[30],[6982,303],{"trials":22579,"activeCount":97},[],{"trials":22581,"activeCount":97},[],{"trials":22583,"activeCount":97},[],{"intervention":2870,"totalTrials":205,"cells":22585},{"EARLY_PHASE1":22586,"PHASE1":22588,"PHASE2":22602,"PHASE3":22650,"PHASE4":22652,"NA":22654},{"trials":22587,"activeCount":97},[],{"trials":22589,"activeCount":97},[22590,22596],{"nctId":22591,"briefTitle":22592,"status":103,"phases":22593,"primaryCompletion":4258,"completion":4258,"start":2856,"enrollment":290,"conditions":22594,"interventions":22595},"NCT00785538","A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available",[85],[2802],[2870,2870,2870,2870,2870,2870],{"nctId":22597,"briefTitle":22598,"status":103,"phases":22599,"primaryCompletion":3235,"completion":3266,"start":4266,"enrollment":1071,"conditions":22600,"interventions":22601},"NCT00785941","A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available",[85],[2802],[2870,2870,2870,2870,2870],{"trials":22603,"activeCount":97},[22604,22608,22612,22619,22627,22631,22638,22642,22646],{"nctId":2861,"briefTitle":2862,"status":103,"phases":22605,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":22606,"interventions":22607},[86],[1718],[1511,1510,2870,1541,2870,1541,1512],{"nctId":8988,"briefTitle":8989,"status":103,"phases":22609,"primaryCompletion":2866,"completion":2866,"start":4474,"enrollment":156,"conditions":22610,"interventions":22611},[86],[1490],[2870,3540],{"nctId":22613,"briefTitle":22614,"status":103,"phases":22615,"primaryCompletion":3661,"completion":2917,"start":3813,"enrollment":2542,"conditions":22616,"interventions":22618},"NCT00520481","Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer",[86],[22617],"Adenocarcinoma of the Prostate",[2870],{"nctId":22620,"briefTitle":22621,"status":103,"phases":22622,"primaryCompletion":8233,"completion":3086,"start":2800,"enrollment":2847,"conditions":22623,"interventions":22626},"NCT00668148","A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",[86],[22624,5874,2610,22625,4410],"Ewing's Sarcoma \u002FPeripheral Neuroectodermal Tumor (PNET)","Adipocytic Sarcoma",[2870,2870,2870,2870,2870],{"nctId":8222,"briefTitle":8223,"status":103,"phases":22628,"primaryCompletion":3494,"completion":3494,"start":3216,"enrollment":8225,"conditions":22629,"interventions":22630},[86],[1903],[2870,8228,1906,3117],{"nctId":22632,"briefTitle":22633,"status":103,"phases":22634,"primaryCompletion":2798,"completion":4098,"start":2929,"enrollment":128,"conditions":22635,"interventions":22636},"NCT00906373","A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver",[86],[2608],[2870,22637,6527],"IMC-A12 (cixutumumab) - 20 mg\u002Fkg",{"nctId":3883,"briefTitle":3884,"status":103,"phases":22639,"primaryCompletion":3886,"completion":1473,"start":3216,"enrollment":3887,"conditions":22640,"interventions":22641},[86],[1571],[2870,3890,1697,1613,1760,1468],{"nctId":8802,"briefTitle":8803,"status":999,"phases":22643,"primaryCompletion":3283,"completion":3283,"start":2929,"enrollment":1400,"conditions":22644,"interventions":22645},[86],[1504,6541],[1541,1745,2870],{"nctId":9068,"briefTitle":9069,"status":103,"phases":22647,"primaryCompletion":3086,"completion":3545,"start":3338,"enrollment":6509,"conditions":22648,"interventions":22649},[86],[2921],[2870,3540],{"trials":22651,"activeCount":97},[],{"trials":22653,"activeCount":97},[],{"trials":22655,"activeCount":97},[],{"intervention":2092,"totalTrials":3293,"cells":22657},{"EARLY_PHASE1":22658,"PHASE1":22660,"PHASE2":22698,"PHASE3":22704,"PHASE4":22706,"NA":22708},{"trials":22659,"activeCount":97},[],{"trials":22661,"activeCount":97},[22662,22670,22674,22678,22682,22686,22690,22694],{"nctId":22663,"briefTitle":22664,"status":999,"phases":22665,"primaryCompletion":3348,"completion":3348,"start":3838,"enrollment":3041,"conditions":22666,"interventions":22667},"NCT01632566","A Multiple-dose Study of LY3031207 in Healthy Participants",[85],[21],[22668,22669,2092],"LY3031207","Celecoxib",{"nctId":9603,"briefTitle":9604,"status":384,"phases":22671,"primaryCompletion":9606,"completion":9606,"start":9607,"enrollment":97,"conditions":22672,"interventions":22673},[85],[15],[9610,1632,2092,1631],{"nctId":18047,"briefTitle":18048,"status":103,"phases":22675,"primaryCompletion":18050,"completion":18050,"start":7775,"enrollment":874,"conditions":22676,"interventions":22677},[85],[18052],[18054,9237,2092],{"nctId":10898,"briefTitle":10899,"status":103,"phases":22679,"primaryCompletion":3697,"completion":3697,"start":3319,"enrollment":118,"conditions":22680,"interventions":22681},[85],[21],[10903,2562,2092,10904,10905],{"nctId":5000,"briefTitle":5001,"status":103,"phases":22683,"primaryCompletion":3049,"completion":3049,"start":4955,"enrollment":233,"conditions":22684,"interventions":22685},[85],[21],[4944,2092],{"nctId":17314,"briefTitle":17315,"status":103,"phases":22687,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":28,"conditions":22688,"interventions":22689},[85],[21],[17257,2092,9237],{"nctId":18082,"briefTitle":18083,"status":103,"phases":22691,"primaryCompletion":18085,"completion":18085,"start":18086,"enrollment":2931,"conditions":22692,"interventions":22693},[85],[15],[7043,9237,2092,1538],{"nctId":2084,"briefTitle":2085,"status":103,"phases":22695,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":22696,"interventions":22697},[85],[15,2090,27],[2043,2092,1093,2093,217,1538,2094],{"trials":22699,"activeCount":97},[22700],{"nctId":18099,"briefTitle":18100,"status":103,"phases":22701,"primaryCompletion":3020,"completion":3020,"start":3251,"enrollment":18102,"conditions":22702,"interventions":22703},[86],[17305],[18097,9237,2092,2093],{"trials":22705,"activeCount":97},[],{"trials":22707,"activeCount":97},[],{"trials":22709,"activeCount":97},[],{"intervention":2781,"totalTrials":4323,"cells":22711},{"EARLY_PHASE1":22712,"PHASE1":22714,"PHASE2":22762,"PHASE3":22778,"PHASE4":22780,"NA":22782},{"trials":22713,"activeCount":97},[],{"trials":22715,"activeCount":97},[22716,22727,22737,22744,22748,22752],{"nctId":22717,"briefTitle":22718,"status":103,"phases":22719,"primaryCompletion":22720,"completion":22720,"start":3087,"enrollment":658,"conditions":22721,"interventions":22726},"NCT01115790","A Phase 1 Study in Participants With Advanced Cancer",[85],"2016-01",[1466,22722,22723,22724,22725,1589],"Squamous Cell Carcinoma","Carcinoma, Squamous Cell of Head and Neck","Lung Squamous Cell Carcinoma Stage IV","Anal Squamous Cell Carcinoma",[2781],{"nctId":22728,"briefTitle":22729,"status":103,"phases":22730,"primaryCompletion":22731,"completion":22731,"start":22732,"enrollment":3293,"conditions":22733,"interventions":22734},"NCT02860780","A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer",[85],"2017-05-15","2016-08-10",[1466,1560,1490,1610],[22735,22736],"prexasertib","ralimetinib",{"nctId":22738,"briefTitle":22739,"status":103,"phases":22740,"primaryCompletion":22741,"completion":22741,"start":3250,"enrollment":2477,"conditions":22742,"interventions":22743},"NCT02514603","A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers",[85],"2017-04-10",[1477],[2781],{"nctId":2774,"briefTitle":2775,"status":103,"phases":22745,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":22746,"interventions":22747},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"nctId":2785,"briefTitle":2786,"status":103,"phases":22749,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":2790,"conditions":22750,"interventions":22751},[85],[2792],[2781,1510,1541],{"nctId":22753,"briefTitle":22754,"status":103,"phases":22755,"primaryCompletion":22756,"completion":22757,"start":22758,"enrollment":1677,"conditions":22759,"interventions":22760},"NCT02778126","A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer",[85],"2017-04-29","2017-07-27","2016-09-22",[1466],[22761,2781],"[¹⁴C]Prexasertib",{"trials":22763,"activeCount":97},[22764,22772],{"nctId":22765,"briefTitle":22766,"status":103,"phases":22767,"primaryCompletion":513,"completion":22768,"start":22769,"enrollment":982,"conditions":22770,"interventions":22771},"NCT03414047","A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer",[86],"2020-10-03","2018-04-10",[2584],[2781],{"nctId":22773,"briefTitle":22774,"status":103,"phases":22775,"primaryCompletion":4963,"completion":6259,"start":298,"enrollment":2931,"conditions":22776,"interventions":22777},"NCT02735980","A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer",[86],[3244],[2781],{"trials":22779,"activeCount":97},[],{"trials":22781,"activeCount":97},[],{"trials":22783,"activeCount":97},[],{"intervention":4101,"totalTrials":4323,"cells":22785},{"EARLY_PHASE1":22786,"PHASE1":22788,"PHASE2":22819,"PHASE3":22837,"PHASE4":22839,"NA":22841},{"trials":22787,"activeCount":97},[],{"trials":22789,"activeCount":97},[22790,22794,22803,22809,22813],{"nctId":4094,"briefTitle":4095,"status":103,"phases":22791,"primaryCompletion":2845,"completion":4097,"start":4098,"enrollment":1677,"conditions":22792,"interventions":22793},[85],[2652],[4101,1511],{"nctId":22795,"briefTitle":22796,"status":103,"phases":22797,"primaryCompletion":22798,"completion":22799,"start":22800,"enrollment":3293,"conditions":22801,"interventions":22802},"NCT02240433","A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)",[85],"2017-07-19","2019-12-25","2014-11-12",[2608],[4101,6527],{"nctId":22804,"briefTitle":22805,"status":103,"phases":22806,"primaryCompletion":4980,"completion":3049,"start":4955,"enrollment":1071,"conditions":22807,"interventions":22808},"NCT01965808","A Study of LY2157299 in Healthy Participants",[85],[21],[4101],{"nctId":19562,"briefTitle":19563,"status":103,"phases":22810,"primaryCompletion":10382,"completion":444,"start":19565,"enrollment":1587,"conditions":22811,"interventions":22812},[85],[1850],[4101,18760],{"nctId":22814,"briefTitle":22815,"status":103,"phases":22816,"primaryCompletion":5354,"completion":5354,"start":3048,"enrollment":2477,"conditions":22817,"interventions":22818},"NCT01722825","Study of LY2157299 in Japanese Participants With Cancer",[85],[1870,1478],[4101],{"trials":22820,"activeCount":97},[22821,22825,22833],{"nctId":6519,"briefTitle":6520,"status":103,"phases":22822,"primaryCompletion":6522,"completion":6523,"start":6524,"enrollment":5841,"conditions":22823,"interventions":22824},[86],[6392],[4101,6527,61],{"nctId":22826,"briefTitle":22827,"status":103,"phases":22828,"primaryCompletion":19103,"completion":22829,"start":22830,"enrollment":1803,"conditions":22831,"interventions":22832},"NCT02178358","A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma",[86],"2021-02-18","2014-08-08",[2608],[4101,6527],{"nctId":9115,"briefTitle":9116,"status":103,"phases":22834,"primaryCompletion":1474,"completion":2754,"start":3069,"enrollment":9118,"conditions":22835,"interventions":22836},[85,86],[1850],[4101,9121,1746],{"trials":22838,"activeCount":97},[],{"trials":22840,"activeCount":97},[],{"trials":22842,"activeCount":97},[],{"intervention":3117,"totalTrials":4323,"cells":22844},{"EARLY_PHASE1":22845,"PHASE1":22847,"PHASE2":22868,"PHASE3":22896,"PHASE4":22898,"NA":22900},{"trials":22846,"activeCount":97},[],{"trials":22848,"activeCount":97},[22849,22856,22862],{"nctId":22850,"briefTitle":22851,"status":103,"phases":22852,"primaryCompletion":3662,"completion":3662,"start":3160,"enrollment":9038,"conditions":22853,"interventions":22854},"NCT00786383","Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy",[85],[2824],[3117,22855,22855,22855,22855],"1121B",{"nctId":22857,"briefTitle":22858,"status":103,"phases":22859,"primaryCompletion":3283,"completion":3283,"start":14517,"enrollment":1158,"conditions":22860,"interventions":22861},"NCT01005355","Study of IMC-1121B in Patients With Advanced Solid Tumors",[85],[2802],[3117],{"nctId":22863,"briefTitle":22864,"status":103,"phases":22865,"primaryCompletion":5860,"completion":5860,"start":4538,"enrollment":5922,"conditions":22866,"interventions":22867},"NCT00793975","Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy",[85],[2802],[3117,22855,22855,22855,22855,22855,22855],{"trials":22869,"activeCount":97},[22870,22874,22878,22882,22888],{"nctId":3109,"briefTitle":3110,"status":103,"phases":22871,"primaryCompletion":3112,"completion":3113,"start":3114,"enrollment":1269,"conditions":22872,"interventions":22873},[86],[1589],[3117,1612,1512,1510,1511,1512],{"nctId":8222,"briefTitle":8223,"status":103,"phases":22875,"primaryCompletion":3494,"completion":3494,"start":3216,"enrollment":8225,"conditions":22876,"interventions":22877},[86],[1903],[2870,8228,1906,3117],{"nctId":10748,"briefTitle":10749,"status":103,"phases":22879,"primaryCompletion":3069,"completion":8217,"start":2846,"enrollment":118,"conditions":22880,"interventions":22881},[86],[2586],[3117,2520,6603,10753,10753],{"nctId":22883,"briefTitle":22884,"status":103,"phases":22885,"primaryCompletion":3251,"completion":4098,"start":3217,"enrollment":4353,"conditions":22886,"interventions":22887},"NCT01017731","Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes",[86],[2824,1503],[3117,1181,17104],{"nctId":22889,"briefTitle":22890,"status":103,"phases":22891,"primaryCompletion":2844,"completion":2844,"start":3266,"enrollment":1839,"conditions":22892,"interventions":22894},"NCT00533702","A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma",[86],[22893],"Metastatic Malignant Melanoma",[3117,22895],"Dacarbazine",{"trials":22897,"activeCount":97},[],{"trials":22899,"activeCount":97},[],{"trials":22901,"activeCount":97},[],{"intervention":22669,"totalTrials":1054,"cells":22903},{"EARLY_PHASE1":22904,"PHASE1":22906,"PHASE2":22940,"PHASE3":22956,"PHASE4":22958,"NA":22960},{"trials":22905,"activeCount":97},[],{"trials":22907,"activeCount":97},[22908,22912,22919,22927,22934],{"nctId":22663,"briefTitle":22664,"status":999,"phases":22909,"primaryCompletion":3348,"completion":3348,"start":3838,"enrollment":3041,"conditions":22910,"interventions":22911},[85],[21],[22668,22669,2092],{"nctId":22913,"briefTitle":22914,"status":103,"phases":22915,"primaryCompletion":3049,"completion":3049,"start":3282,"enrollment":118,"conditions":22916,"interventions":22917},"NCT01849055","A Multiple Dose Study of LY3023703 in Healthy Participants",[85],[21],[22918,22669],"LY3023703",{"nctId":22920,"briefTitle":22921,"status":103,"phases":22922,"primaryCompletion":22923,"completion":22923,"start":22924,"enrollment":864,"conditions":22925,"interventions":22926},"NCT01449630","A Study of LY3031207 in Healthy Subjects",[85],"2012-04-02","2011-10-24",[21],[22668,22669],{"nctId":22928,"briefTitle":22929,"status":103,"phases":22930,"primaryCompletion":1475,"completion":1475,"start":4955,"enrollment":4475,"conditions":22931,"interventions":22932},"NCT01968070","A Study of LY3127760 in Healthy Participants",[85],[21],[22933,22669],"LY3127760",{"nctId":22935,"briefTitle":22936,"status":103,"phases":22937,"primaryCompletion":2898,"completion":2898,"start":3838,"enrollment":1620,"conditions":22938,"interventions":22939},"NCT01632579","A Single Dose Study of LY3023703 in Healthy Participants",[85],[21],[22918,22669],{"trials":22941,"activeCount":97},[22942,22948],{"nctId":22943,"briefTitle":22944,"status":103,"phases":22945,"primaryCompletion":4955,"completion":4955,"start":2964,"enrollment":19,"conditions":22946,"interventions":22947},"NCT01872910","A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal",[86],[10659],[22918,22669],{"nctId":22949,"briefTitle":22950,"status":999,"phases":22951,"primaryCompletion":3697,"completion":1619,"start":7316,"enrollment":22952,"conditions":22953,"interventions":22954},"NCT02192190","A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain",[86],268,[2424],[22955,22669],"LY2951742",{"trials":22957,"activeCount":97},[],{"trials":22959,"activeCount":97},[],{"trials":22961,"activeCount":97},[],{"intervention":10978,"totalTrials":1054,"cells":22963},{"EARLY_PHASE1":22964,"PHASE1":22966,"PHASE2":23010,"PHASE3":23020,"PHASE4":23022,"NA":23024},{"trials":22965,"activeCount":97},[],{"trials":22967,"activeCount":97},[22968,22975,22983,22990,22997,23006],{"nctId":22969,"briefTitle":22970,"status":103,"phases":22971,"primaryCompletion":7775,"completion":7775,"start":4383,"enrollment":1071,"conditions":22972,"interventions":22973},"NCT02603861","A Study of LY3154207 on Sleep in Healthy Male Participants",[85],[15],[10978,22974],"Modafinil",{"nctId":22976,"briefTitle":22977,"status":103,"phases":22978,"primaryCompletion":22979,"completion":22979,"start":22980,"enrollment":1071,"conditions":22981,"interventions":22982},"NCT04258826","A Study to Evaluate LY3154207 on the Brain of Healthy Participants",[85],"2022-01-28","2021-01-15",[15],[10978],{"nctId":22984,"briefTitle":22985,"status":103,"phases":22986,"primaryCompletion":22987,"completion":22987,"start":6280,"enrollment":214,"conditions":22988,"interventions":22989},"NCT03942029","A Drug Interaction Study of LY3154207 in Healthy Participants",[85],"2019-12-28",[15],[10978,10978,4984],{"nctId":22991,"briefTitle":22992,"status":103,"phases":22993,"primaryCompletion":1485,"completion":1485,"start":1498,"enrollment":4323,"conditions":22994,"interventions":22995},"NCT03616795","Study of LY3154207 in Healthy Participants",[85],[15],[10978,22996],"[14C]-LY3154207",{"nctId":22998,"briefTitle":22999,"status":103,"phases":23000,"primaryCompletion":23001,"completion":23001,"start":23002,"enrollment":4475,"conditions":23003,"interventions":23005},"NCT02562768","A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease",[85],"2017-03-03","2015-09-30",[23004],"Parkinson's Disease",[10978],{"nctId":10973,"briefTitle":10974,"status":103,"phases":23007,"primaryCompletion":3717,"completion":3717,"start":1473,"enrollment":2867,"conditions":23008,"interventions":23009},[85],[4997],[10978,2562],{"trials":23011,"activeCount":97},[23012],{"nctId":23013,"briefTitle":23014,"status":103,"phases":23015,"primaryCompletion":23016,"completion":23016,"start":5071,"enrollment":810,"conditions":23017,"interventions":23019},"NCT03305809","A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)",[86],"2020-07-10",[23018],"Lewy Body Dementia",[10978],{"trials":23021,"activeCount":97},[],{"trials":23023,"activeCount":97},[],{"trials":23025,"activeCount":97},[],{"intervention":9610,"totalTrials":1054,"cells":23027},{"EARLY_PHASE1":23028,"PHASE1":23030,"PHASE2":23057,"PHASE3":23080,"PHASE4":23082,"NA":23084},{"trials":23029,"activeCount":97},[],{"trials":23031,"activeCount":97},[23032,23036,23043,23049],{"nctId":9603,"briefTitle":9604,"status":384,"phases":23033,"primaryCompletion":9606,"completion":9606,"start":9607,"enrollment":97,"conditions":23034,"interventions":23035},[85],[15],[9610,1632,2092,1631],{"nctId":23037,"briefTitle":23038,"status":103,"phases":23039,"primaryCompletion":11022,"completion":11022,"start":23040,"enrollment":1071,"conditions":23041,"interventions":23042},"NCT04682119","A Safety Study of LY3526318 in Healthy Participants",[85],"2020-12-29",[15],[9610],{"nctId":23044,"briefTitle":23045,"status":999,"phases":23046,"primaryCompletion":989,"completion":989,"start":6280,"enrollment":3284,"conditions":23047,"interventions":23048},"NCT03977974","A Study of LY3526318 in Healthy Participants",[85],[15],[9610],{"nctId":23050,"briefTitle":23051,"status":103,"phases":23052,"primaryCompletion":11227,"completion":23053,"start":23054,"enrollment":1071,"conditions":23055,"interventions":23056},"NCT04183283","A Study of LY3526318 in Healthy Women",[85],"2020-03-06","2019-12-12",[15],[9610],{"trials":23058,"activeCount":97},[23059,23066,23074],{"nctId":23060,"briefTitle":23061,"status":103,"phases":23062,"primaryCompletion":11206,"completion":11206,"start":23063,"enrollment":5729,"conditions":23064,"interventions":23065},"NCT05080660","Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis",[86],"2021-10-12",[2191,2440],[9610],{"nctId":23067,"briefTitle":23068,"status":103,"phases":23069,"primaryCompletion":23070,"completion":23070,"start":23071,"enrollment":1859,"conditions":23072,"interventions":23073},"NCT05086289","Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain",[86],"2022-06-17","2021-10-25",[10516],[9610],{"nctId":23075,"briefTitle":23076,"status":103,"phases":23077,"primaryCompletion":11430,"completion":11430,"start":5246,"enrollment":17417,"conditions":23078,"interventions":23079},"NCT05177094","Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain",[86],[9378],[9610],{"trials":23081,"activeCount":97},[],{"trials":23083,"activeCount":97},[],{"trials":23085,"activeCount":97},[],{"intervention":1181,"totalTrials":1054,"cells":23087},{"EARLY_PHASE1":23088,"PHASE1":23090,"PHASE2":23121,"PHASE3":23127,"PHASE4":23129,"NA":23131},{"trials":23089,"activeCount":97},[],{"trials":23091,"activeCount":97},[23092,23096,23102,23109,23113,23117],{"nctId":22314,"briefTitle":22315,"status":103,"phases":23093,"primaryCompletion":3886,"completion":3886,"start":3004,"enrollment":6927,"conditions":23094,"interventions":23095},[85],[18],[9643,1181],{"nctId":23097,"briefTitle":23098,"status":103,"phases":23099,"primaryCompletion":3838,"completion":3838,"start":3086,"enrollment":1767,"conditions":23100,"interventions":23101},"NCT01537887","A Study of LY2484595 on the Electrical Activity of the Heart",[85],[21],[18097,1181],{"nctId":23103,"briefTitle":23104,"status":103,"phases":23105,"primaryCompletion":3282,"completion":3282,"start":3086,"enrollment":28,"conditions":23106,"interventions":23107},"NCT01536951","A Study of LY3009104 in Healthy Participants",[85],[4997],[18853,23108],"moxifloxacin",{"nctId":6277,"briefTitle":6278,"status":103,"phases":23110,"primaryCompletion":6280,"completion":6280,"start":6281,"enrollment":310,"conditions":23111,"interventions":23112},[85],[15],[2685,1181],{"nctId":17187,"briefTitle":17188,"status":103,"phases":23114,"primaryCompletion":17190,"completion":17190,"start":17191,"enrollment":6943,"conditions":23115,"interventions":23116},[85],[15],[17046,17046,1181],{"nctId":1174,"briefTitle":1175,"status":103,"phases":23118,"primaryCompletion":666,"completion":666,"start":1177,"enrollment":1178,"conditions":23119,"interventions":23120},[85],[15],[1070,1181],{"trials":23122,"activeCount":97},[23123],{"nctId":22883,"briefTitle":22884,"status":103,"phases":23124,"primaryCompletion":3251,"completion":4098,"start":3217,"enrollment":4353,"conditions":23125,"interventions":23126},[86],[2824,1503],[3117,1181,17104],{"trials":23128,"activeCount":97},[],{"trials":23130,"activeCount":97},[],{"trials":23132,"activeCount":97},[],{"intervention":9618,"totalTrials":1054,"cells":23134},{"EARLY_PHASE1":23135,"PHASE1":23137,"PHASE2":23153,"PHASE3":23184,"PHASE4":23186,"NA":23188},{"trials":23136,"activeCount":97},[],{"trials":23138,"activeCount":97},[23139,23143,23147],{"nctId":9612,"briefTitle":9613,"status":103,"phases":23140,"primaryCompletion":9615,"completion":9615,"start":7463,"enrollment":3718,"conditions":23141,"interventions":23142},[85],[15],[9618,1632,1631],{"nctId":9624,"briefTitle":9625,"status":103,"phases":23144,"primaryCompletion":629,"completion":629,"start":9627,"enrollment":12,"conditions":23145,"interventions":23146},[85],[15],[9618,1631,1632],{"nctId":23148,"briefTitle":23149,"status":103,"phases":23150,"primaryCompletion":17127,"completion":17127,"start":923,"enrollment":1839,"conditions":23151,"interventions":23152},"NCT05341102","A Study of Single and Repeated Doses of LY3556050 in Healthy Participants",[85],[15],[9618],{"trials":23154,"activeCount":97},[23155,23161,23168,23175],{"nctId":23156,"briefTitle":23157,"status":999,"phases":23158,"primaryCompletion":5168,"completion":5168,"start":2539,"enrollment":4353,"conditions":23159,"interventions":23160},"NCT04707157","Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain",[86],[9378],[9618],{"nctId":23162,"briefTitle":23163,"status":103,"phases":23164,"primaryCompletion":23165,"completion":23165,"start":19847,"enrollment":3546,"conditions":23166,"interventions":23167},"NCT04874636","Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain",[86],"2022-02-09",[10516],[9618],{"nctId":23169,"briefTitle":23170,"status":103,"phases":23171,"primaryCompletion":23172,"completion":23172,"start":5325,"enrollment":16357,"conditions":23173,"interventions":23174},"NCT04627038","Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis",[86],"2021-10-21",[2191],[9618],{"nctId":23176,"briefTitle":23177,"status":103,"phases":23178,"primaryCompletion":23179,"completion":23179,"start":13240,"enrollment":23180,"conditions":23181,"interventions":23183},"NCT06074562","A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain",[86],"2025-06-11",405,[23182],"Diabetic Peripheral Neuropathy",[9618],{"trials":23185,"activeCount":97},[],{"trials":23187,"activeCount":97},[],{"trials":23189,"activeCount":97},[],{"intervention":2093,"totalTrials":1054,"cells":23191},{"EARLY_PHASE1":23192,"PHASE1":23194,"PHASE2":23220,"PHASE3":23226,"PHASE4":23228,"NA":23230},{"trials":23193,"activeCount":97},[],{"trials":23195,"activeCount":97},[23196,23200,23204,23208,23212,23216],{"nctId":7841,"briefTitle":7842,"status":103,"phases":23197,"primaryCompletion":7844,"completion":7844,"start":7845,"enrollment":1548,"conditions":23198,"interventions":23199},[85],[15],[2655,1093,2093,1538,1538],{"nctId":5473,"briefTitle":5474,"status":103,"phases":23201,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":23202,"interventions":23203},[85],[15],[1667,1102,1171,5480,2074,2093,1093],{"nctId":17146,"briefTitle":17147,"status":103,"phases":23205,"primaryCompletion":17149,"completion":17149,"start":676,"enrollment":6509,"conditions":23206,"interventions":23207},[85],[15],[17046,17152,2093],{"nctId":6270,"briefTitle":6271,"status":103,"phases":23209,"primaryCompletion":827,"completion":827,"start":6273,"enrollment":165,"conditions":23210,"interventions":23211},[85],[15],[2093,2685],{"nctId":2084,"briefTitle":2085,"status":103,"phases":23213,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":23214,"interventions":23215},[85],[15,2090,27],[2043,2092,1093,2093,217,1538,2094],{"nctId":9364,"briefTitle":9365,"status":103,"phases":23217,"primaryCompletion":9367,"completion":9367,"start":2121,"enrollment":2996,"conditions":23218,"interventions":23219},[85],[15],[9342,2093],{"trials":23221,"activeCount":97},[23222],{"nctId":18099,"briefTitle":18100,"status":103,"phases":23223,"primaryCompletion":3020,"completion":3020,"start":3251,"enrollment":18102,"conditions":23224,"interventions":23225},[86],[17305],[18097,9237,2092,2093],{"trials":23227,"activeCount":97},[],{"trials":23229,"activeCount":97},[],{"trials":23231,"activeCount":97},[],{"intervention":19441,"totalTrials":1677,"cells":23233},{"EARLY_PHASE1":23234,"PHASE1":23236,"PHASE2":23250,"PHASE3":23276,"PHASE4":23278,"NA":23280},{"trials":23235,"activeCount":97},[],{"trials":23237,"activeCount":97},[23238,23242],{"nctId":19436,"briefTitle":19437,"status":103,"phases":23239,"primaryCompletion":3086,"completion":3086,"start":3662,"enrollment":1178,"conditions":23240,"interventions":23241},[85],[2589],[19441,19442],{"nctId":23243,"briefTitle":23244,"status":103,"phases":23245,"primaryCompletion":4160,"completion":4160,"start":3216,"enrollment":1488,"conditions":23246,"interventions":23249},"NCT00718159","Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia",[85],[23247,23248],"Acute Myeloid Leukemia","Essential Thrombocythemia",[19441],{"trials":23251,"activeCount":97},[23252,23258,23264,23270],{"nctId":23253,"briefTitle":23254,"status":103,"phases":23255,"primaryCompletion":3069,"completion":3069,"start":14517,"enrollment":4222,"conditions":23256,"interventions":23257},"NCT00992225","A Study of LY573636-sodium in Patients With Metastatic Breast Cancer",[86],[36],[19441],{"nctId":23259,"briefTitle":23260,"status":103,"phases":23261,"primaryCompletion":3087,"completion":3087,"start":3813,"enrollment":2670,"conditions":23262,"interventions":23263},"NCT00490451","A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma",[86],[18162],[19441],{"nctId":23265,"briefTitle":23266,"status":103,"phases":23267,"primaryCompletion":3283,"completion":3661,"start":2875,"enrollment":5882,"conditions":23268,"interventions":23269},"NCT00428610","A Study of Chemotherapy Treatment for Patients With Ovarian Cancer",[86],[2584,3620,3621],[19441],{"nctId":23271,"briefTitle":23272,"status":103,"phases":23273,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":251,"conditions":23274,"interventions":23275},"NCT00363766","Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer",[86],[2849],[19441],{"trials":23277,"activeCount":97},[],{"trials":23279,"activeCount":97},[],{"trials":23281,"activeCount":97},[],{"intervention":1508,"totalTrials":1677,"cells":23283},{"EARLY_PHASE1":23284,"PHASE1":23286,"PHASE2":23317,"PHASE3":23323,"PHASE4":23325,"NA":23327},{"trials":23285,"activeCount":97},[],{"trials":23287,"activeCount":97},[23288,23294,23300,23304,23313],{"nctId":23289,"briefTitle":23290,"status":103,"phases":23291,"primaryCompletion":2754,"completion":2754,"start":6390,"enrollment":1677,"conditions":23292,"interventions":23293},"NCT02917733","A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants",[85],[15],[1508],{"nctId":23295,"briefTitle":23296,"status":103,"phases":23297,"primaryCompletion":7427,"completion":2473,"start":20817,"enrollment":205,"conditions":23298,"interventions":23299},"NCT02836600","A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors",[85],[1717],[1508],{"nctId":1495,"briefTitle":1496,"status":999,"phases":23301,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":23302,"interventions":23303},[85],[1503,36,1504,1505,1506],[1508,1509,48,1510,1511,1512,1513],{"nctId":23305,"briefTitle":23306,"status":103,"phases":23307,"primaryCompletion":23308,"completion":23308,"start":23309,"enrollment":2477,"conditions":23310,"interventions":23311},"NCT02906618","Study of LY3039478 in Healthy Participants",[85],"2016-11-11","2016-10-04",[15],[1508,23312],"13C 15N 2H-LY3039478 IV",{"nctId":8182,"briefTitle":8183,"status":103,"phases":23314,"primaryCompletion":991,"completion":991,"start":2798,"enrollment":5807,"conditions":23315,"interventions":23316},[85],[1870,1478,7766],[1508,1906],{"trials":23318,"activeCount":97},[23319],{"nctId":8265,"briefTitle":8266,"status":103,"phases":23320,"primaryCompletion":8268,"completion":8268,"start":8269,"enrollment":214,"conditions":23321,"interventions":23322},[85,86],[8271,8272],[1508,3034],{"trials":23324,"activeCount":97},[],{"trials":23326,"activeCount":97},[],{"trials":23328,"activeCount":97},[],{"intervention":23330,"totalTrials":1677,"cells":23331},"LY2886721",{"EARLY_PHASE1":23332,"PHASE1":23334,"PHASE2":23366,"PHASE3":23374,"PHASE4":23376,"NA":23378},{"trials":23333,"activeCount":97},[],{"trials":23335,"activeCount":97},[23336,23342,23348,23354,23360],{"nctId":23337,"briefTitle":23338,"status":103,"phases":23339,"primaryCompletion":3069,"completion":3069,"start":3152,"enrollment":137,"conditions":23340,"interventions":23341},"NCT01227252","A Safety Study of LY2886721 Multiple Doses in Healthy Subjects",[85],[4040],[23330],{"nctId":23343,"briefTitle":23344,"status":103,"phases":23345,"primaryCompletion":6093,"completion":6093,"start":3020,"enrollment":1677,"conditions":23346,"interventions":23347},"NCT01367262","Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants",[85],[21],[23330],{"nctId":23349,"briefTitle":23350,"status":103,"phases":23351,"primaryCompletion":3282,"completion":3282,"start":3124,"enrollment":214,"conditions":23352,"interventions":23353},"NCT01807026","A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease",[85],[3980,21],[23330],{"nctId":23355,"briefTitle":23356,"status":103,"phases":23357,"primaryCompletion":3545,"completion":3545,"start":3086,"enrollment":1620,"conditions":23358,"interventions":23359},"NCT01534273","A Study of LY2886721 in Healthy Participants",[85],[21],[23330],{"nctId":23361,"briefTitle":23362,"status":103,"phases":23363,"primaryCompletion":8233,"completion":8233,"start":2918,"enrollment":233,"conditions":23364,"interventions":23365},"NCT01133405","A Safety Study of LY2886721 Single Doses in Healthy Subjects",[85],[4040],[23330],{"trials":23367,"activeCount":97},[23368],{"nctId":23369,"briefTitle":23370,"status":999,"phases":23371,"primaryCompletion":2917,"completion":2917,"start":3886,"enrollment":2790,"conditions":23372,"interventions":23373},"NCT01561430","Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",[85,86],[4040],[23330],{"trials":23375,"activeCount":97},[],{"trials":23377,"activeCount":97},[],{"trials":23379,"activeCount":97},[],{"intervention":23381,"totalTrials":1677,"cells":23382},"LY2523355",{"EARLY_PHASE1":23383,"PHASE1":23385,"PHASE2":23407,"PHASE3":23431,"PHASE4":23433,"NA":23435},{"trials":23384,"activeCount":97},[],{"trials":23386,"activeCount":97},[23387,23394,23401],{"nctId":23388,"briefTitle":23389,"status":103,"phases":23390,"primaryCompletion":4160,"completion":3838,"start":3292,"enrollment":9415,"conditions":23391,"interventions":23392},"NCT01214642","A Dose-Escalation Study for Patients With Advanced Cancer",[85],[1466],[23393,23381],"pegfilgrastim",{"nctId":23395,"briefTitle":23396,"status":999,"phases":23397,"primaryCompletion":3283,"completion":3283,"start":3575,"enrollment":5015,"conditions":23398,"interventions":23400},"NCT01214655","A Study for Patients With Acute Leukemia",[85],[23399],"Acute Leukemia",[23381],{"nctId":23402,"briefTitle":23403,"status":103,"phases":23404,"primaryCompletion":2865,"completion":2865,"start":4566,"enrollment":31,"conditions":23405,"interventions":23406},"NCT01214629","A Study for Participants With Advanced Cancer",[85],[1466,1560],[23381,23381,23393],{"trials":23408,"activeCount":97},[23409,23416,23424],{"nctId":23410,"briefTitle":23411,"status":103,"phases":23412,"primaryCompletion":3545,"completion":3545,"start":6883,"enrollment":2867,"conditions":23413,"interventions":23414},"NCT01025284","A Study for Participants With Small-Cell Lung Cancer",[86],[3244],[23381,23415],"Granulocyte colony-stimulating factor",{"nctId":23417,"briefTitle":23418,"status":103,"phases":23419,"primaryCompletion":2966,"completion":5022,"start":8217,"enrollment":3041,"conditions":23420,"interventions":23421},"NCT01416389","A Study of LY2523355 in Participants With Breast Cancer",[86],[1571],[23381,23422,23393,23423],"ixabepilone","filgrastim",{"nctId":23425,"briefTitle":23426,"status":103,"phases":23427,"primaryCompletion":4122,"completion":4122,"start":3069,"enrollment":5882,"conditions":23428,"interventions":23430},"NCT01059643","A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck",[86],[2584,1694,1903,1490,3062,6552,23429],"Cancer of Head and Neck",[23381,23393],{"trials":23432,"activeCount":97},[],{"trials":23434,"activeCount":97},[],{"trials":23436,"activeCount":97},[],{"intervention":3287,"totalTrials":1677,"cells":23438},{"EARLY_PHASE1":23439,"PHASE1":23441,"PHASE2":23455,"PHASE3":23469,"PHASE4":23471,"NA":23473},{"trials":23440,"activeCount":97},[],{"trials":23442,"activeCount":97},[23443,23447,23451],{"nctId":4119,"briefTitle":4120,"status":103,"phases":23444,"primaryCompletion":2864,"completion":4122,"start":3020,"enrollment":1082,"conditions":23445,"interventions":23446},[85],[2824],[3287,4125,1612,1511],{"nctId":4143,"briefTitle":4144,"status":103,"phases":23448,"primaryCompletion":2964,"completion":1546,"start":2844,"enrollment":1237,"conditions":23449,"interventions":23450},[85],[2589],[3287,1511],{"nctId":4157,"briefTitle":4158,"status":103,"phases":23452,"primaryCompletion":4160,"completion":3086,"start":3283,"enrollment":1232,"conditions":23453,"interventions":23454},[85],[1466],[3287,1612,1511],{"trials":23456,"activeCount":97},[23457,23461,23465],{"nctId":5745,"briefTitle":5746,"status":103,"phases":23458,"primaryCompletion":3545,"completion":3319,"start":3217,"enrollment":224,"conditions":23459,"interventions":23460},[86],[1694],[3287,1612],{"nctId":4417,"briefTitle":4418,"status":103,"phases":23462,"primaryCompletion":4420,"completion":3049,"start":3103,"enrollment":4421,"conditions":23463,"interventions":23464},[85,86],[2652],[3287,1511],{"nctId":3279,"briefTitle":3280,"status":103,"phases":23466,"primaryCompletion":3282,"completion":3122,"start":3283,"enrollment":3284,"conditions":23467,"interventions":23468},[85,86],[1694],[1612,1510,3287],{"trials":23470,"activeCount":97},[],{"trials":23472,"activeCount":97},[],{"trials":23474,"activeCount":97},[],{"intervention":18853,"totalTrials":425,"cells":23476},{"EARLY_PHASE1":23477,"PHASE1":23479,"PHASE2":23505,"PHASE3":23511,"PHASE4":23513,"NA":23515},{"trials":23478,"activeCount":97},[],{"trials":23480,"activeCount":97},[23481,23488,23494,23501],{"nctId":23482,"briefTitle":23483,"status":103,"phases":23484,"primaryCompletion":3494,"completion":3494,"start":6093,"enrollment":1158,"conditions":23485,"interventions":23487},"NCT01398475","A Relative Bioavailability and Food Effect Study of New Formulations",[85],[23486,5093],"Chronic Inflammatory Disorder",[18853],{"nctId":23489,"briefTitle":23490,"status":103,"phases":23491,"primaryCompletion":3837,"completion":3837,"start":3283,"enrollment":1677,"conditions":23492,"interventions":23493},"NCT01299285","Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects",[85],[21],[18853],{"nctId":23495,"briefTitle":23496,"status":103,"phases":23497,"primaryCompletion":3069,"completion":3069,"start":3029,"enrollment":3718,"conditions":23498,"interventions":23500},"NCT01247350","A Study of LY3009104(Baricitinib) for Healthy Subjects",[85],[23499],"Healthy Volunteer",[18853],{"nctId":23103,"briefTitle":23104,"status":103,"phases":23502,"primaryCompletion":3282,"completion":3282,"start":3086,"enrollment":28,"conditions":23503,"interventions":23504},[85],[4997],[18853,23108],{"trials":23506,"activeCount":97},[23507],{"nctId":18848,"briefTitle":18849,"status":103,"phases":23508,"primaryCompletion":4160,"completion":6632,"start":8233,"enrollment":1319,"conditions":23509,"interventions":23510},[86],[5093],[18853,5095],{"trials":23512,"activeCount":97},[],{"trials":23514,"activeCount":97},[],{"trials":23516,"activeCount":97},[],{"intervention":23518,"totalTrials":425,"cells":23519},"LY3372689",{"EARLY_PHASE1":23520,"PHASE1":23522,"PHASE2":23554,"PHASE3":23565,"PHASE4":23567,"NA":23569},{"trials":23521,"activeCount":97},[],{"trials":23523,"activeCount":97},[23524,23532,23540,23547],{"nctId":23525,"briefTitle":23526,"status":103,"phases":23527,"primaryCompletion":23528,"completion":23528,"start":23529,"enrollment":1400,"conditions":23530,"interventions":23531},"NCT04392271","A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants",[85],"2020-10-14","2020-08-06",[15],[23518],{"nctId":23533,"briefTitle":23534,"status":103,"phases":23535,"primaryCompletion":23536,"completion":17248,"start":23537,"enrollment":1488,"conditions":23538,"interventions":23539},"NCT03819270","A Safety Study of LY3372689 Given By Mouth to Healthy Participants",[85],"2019-06-23","2019-02-05",[15],[23518],{"nctId":23541,"briefTitle":23542,"status":103,"phases":23543,"primaryCompletion":23544,"completion":23544,"start":922,"enrollment":1237,"conditions":23545,"interventions":23546},"NCT03944031","A Study of the Effects of LY3372689 on the Brain in Healthy Participants",[85],"2020-02-19",[15],[23518],{"nctId":23548,"briefTitle":23549,"status":103,"phases":23550,"primaryCompletion":5237,"completion":5237,"start":23551,"enrollment":31,"conditions":23552,"interventions":23553},"NCT04106206","A Safety Study of LY3372689 in Healthy Participants",[85],"2019-10-23",[15],[23518],{"trials":23555,"activeCount":97},[23556],{"nctId":23557,"briefTitle":23558,"status":103,"phases":23559,"primaryCompletion":23560,"completion":23561,"start":1397,"enrollment":23562,"conditions":23563,"interventions":23564},"NCT05063539","A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease",[86],"2024-07-09","2025-05-22",327,[3980],[23518,23518],{"trials":23566,"activeCount":97},[],{"trials":23568,"activeCount":97},[],{"trials":23570,"activeCount":97},[],{"intervention":10903,"totalTrials":425,"cells":23572},{"EARLY_PHASE1":23573,"PHASE1":23575,"PHASE2":23594,"PHASE3":23610,"PHASE4":23612,"NA":23614},{"trials":23574,"activeCount":97},[],{"trials":23576,"activeCount":97},[23577,23581,23587],{"nctId":10898,"briefTitle":10899,"status":103,"phases":23578,"primaryCompletion":3697,"completion":3697,"start":3319,"enrollment":118,"conditions":23579,"interventions":23580},[85],[21],[10903,2562,2092,10904,10905],{"nctId":23582,"briefTitle":23583,"status":103,"phases":23584,"primaryCompletion":3319,"completion":3319,"start":2845,"enrollment":1677,"conditions":23585,"interventions":23586},"NCT02242981","A Study of How the Body Breaks Down and Eliminates LY2623091",[85],[21],[10903],{"nctId":23588,"briefTitle":23589,"status":103,"phases":23590,"primaryCompletion":4258,"completion":4258,"start":8233,"enrollment":310,"conditions":23591,"interventions":23592},"NCT01237899","Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance",[85],[412],[10903,23593],"Eplerenone",{"trials":23595,"activeCount":97},[23596,23602],{"nctId":23597,"briefTitle":23598,"status":103,"phases":23599,"primaryCompletion":3124,"completion":3124,"start":3494,"enrollment":137,"conditions":23600,"interventions":23601},"NCT01427972","A Study of LY2623091 in Male and Females With Chronic Kidney Disease",[86],[412],[10903,23593],{"nctId":23603,"briefTitle":23604,"status":103,"phases":23605,"primaryCompletion":1596,"completion":1596,"start":3122,"enrollment":13712,"conditions":23606,"interventions":23608},"NCT02194465","A Study of LY2623091 in Participants With High Blood Pressure",[86],[23607],"Primary Hypertension",[10903,10904,23609],"Spironolactone",{"trials":23611,"activeCount":97},[],{"trials":23613,"activeCount":97},[],{"trials":23615,"activeCount":97},[],{"intervention":23617,"totalTrials":425,"cells":23618},"LY3473329",{"EARLY_PHASE1":23619,"PHASE1":23621,"PHASE2":23654,"PHASE3":23665,"PHASE4":23667,"NA":23669},{"trials":23620,"activeCount":97},[],{"trials":23622,"activeCount":97},[23623,23630,23638,23646],{"nctId":23624,"briefTitle":23625,"status":103,"phases":23626,"primaryCompletion":23627,"completion":23627,"start":9398,"enrollment":290,"conditions":23628,"interventions":23629},"NCT05038787","A Study of LY3473329 in Healthy Japanese Participants",[85],"2022-04-07",[15],[23617],{"nctId":23631,"briefTitle":23632,"status":103,"phases":23633,"primaryCompletion":23634,"completion":23634,"start":8621,"enrollment":1071,"conditions":23635,"interventions":23636},"NCT06342596","A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants",[85],"2024-05-01",[15],[23637,23637,23617],"[14C]-LY3473329",{"nctId":23639,"briefTitle":23640,"status":103,"phases":23641,"primaryCompletion":23642,"completion":23642,"start":23643,"enrollment":1302,"conditions":23644,"interventions":23645},"NCT04472676","A Study of LY3473329 in Healthy Participants",[85],"2021-11-09","2020-08-18",[15],[23617],{"nctId":23647,"briefTitle":23648,"status":103,"phases":23649,"primaryCompletion":23650,"completion":23650,"start":23651,"enrollment":128,"conditions":23652,"interventions":23653},"NCT05778864","A Study of LY3473329 in Participants With Impaired and Normal Renal Function",[85],"2024-09-06","2023-03-17",[147],[23617],{"trials":23655,"activeCount":97},[23656],{"nctId":23657,"briefTitle":23658,"status":103,"phases":23659,"primaryCompletion":23660,"completion":23660,"start":23661,"enrollment":1409,"conditions":23662,"interventions":23664},"NCT05563246","A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events",[86],"2024-03-14","2022-11-24",[23663],"Lipoprotein Disorder",[23617],{"trials":23666,"activeCount":97},[],{"trials":23668,"activeCount":97},[],{"trials":23670,"activeCount":97},[],{"intervention":23672,"totalTrials":425,"cells":23673},"LY2495655",{"EARLY_PHASE1":23674,"PHASE1":23676,"PHASE2":23690,"PHASE3":23713,"PHASE4":23715,"NA":23717},{"trials":23675,"activeCount":97},[],{"trials":23677,"activeCount":97},[23678,23684],{"nctId":23679,"briefTitle":23680,"status":103,"phases":23681,"primaryCompletion":2865,"completion":2865,"start":2844,"enrollment":128,"conditions":23682,"interventions":23683},"NCT01341470","A Study of LY2495655 in Healthy Subjects",[85],[23499],[23672],{"nctId":23685,"briefTitle":23686,"status":103,"phases":23687,"primaryCompletion":3048,"completion":22720,"start":3308,"enrollment":864,"conditions":23688,"interventions":23689},"NCT01524224","A Dose-Escalation Study in Participants With Advanced Cancer",[85],[1466],[23672],{"trials":23691,"activeCount":97},[23692,23699,23706],{"nctId":23693,"briefTitle":23694,"status":103,"phases":23695,"primaryCompletion":9748,"completion":9748,"start":6093,"enrollment":4775,"conditions":23696,"interventions":23698},"NCT01369511","A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement",[86],[23697],"Muscular Atrophy",[23672],{"nctId":23700,"briefTitle":23701,"status":103,"phases":23702,"primaryCompletion":5022,"completion":3049,"start":2865,"enrollment":7353,"conditions":23703,"interventions":23705},"NCT01604408","A Study in Older Participants Who Have Fallen and Have Muscle Weakness",[86],[23704],"Muscle Weakness",[23672],{"nctId":23707,"briefTitle":23708,"status":103,"phases":23709,"primaryCompletion":3318,"completion":22720,"start":4160,"enrollment":174,"conditions":23710,"interventions":23711},"NCT01505530","A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer",[86],[1653],[23672,23712],"Standard of Care Chemotherapy",{"trials":23714,"activeCount":97},[],{"trials":23716,"activeCount":97},[],{"trials":23718,"activeCount":97},[],{"intervention":3561,"totalTrials":1400,"cells":23720},{"EARLY_PHASE1":23721,"PHASE1":23723,"PHASE2":23745,"PHASE3":23751,"PHASE4":23753,"NA":23755},{"trials":23722,"activeCount":97},[],{"trials":23724,"activeCount":97},[23725,23731,23738],{"nctId":23726,"briefTitle":23727,"status":103,"phases":23728,"primaryCompletion":2799,"completion":2984,"start":2917,"enrollment":2733,"conditions":23729,"interventions":23730},"NCT01919398","A Study of LY2940680 in Japanese Participants With Advanced Cancers",[85],[1478],[3561],{"nctId":23732,"briefTitle":23733,"status":103,"phases":23734,"primaryCompletion":4122,"completion":4122,"start":2898,"enrollment":1620,"conditions":23735,"interventions":23736},"NCT01681186","A Study of LY2940680 in Healthy Participants",[85],[4997],[3561,3561,23737],"Lansoprazole",{"nctId":23739,"briefTitle":23740,"status":384,"phases":23741,"primaryCompletion":1546,"completion":1546,"start":3027,"enrollment":97,"conditions":23742,"interventions":23744},"NCT01697514","A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma",[85],[23743,5874],"Medulloblastoma, Childhood",[3561,3561],{"trials":23746,"activeCount":97},[23747],{"nctId":3556,"briefTitle":3557,"status":999,"phases":23748,"primaryCompletion":1473,"completion":1473,"start":3068,"enrollment":893,"conditions":23749,"interventions":23750},[85,86],[2504],[3561,1512,3324],{"trials":23752,"activeCount":97},[],{"trials":23754,"activeCount":97},[],{"trials":23756,"activeCount":97},[],{"intervention":23758,"totalTrials":1400,"cells":23759},"LY3857210",{"EARLY_PHASE1":23760,"PHASE1":23762,"PHASE2":23771,"PHASE3":23796,"PHASE4":23798,"NA":23800},{"trials":23761,"activeCount":97},[],{"trials":23763,"activeCount":97},[23764],{"nctId":23765,"briefTitle":23766,"status":103,"phases":23767,"primaryCompletion":23768,"completion":23768,"start":7295,"enrollment":757,"conditions":23769,"interventions":23770},"NCT05292040","A Study of LY3857210 in Healthy Participants",[85],"2022-12-14",[15],[23758],{"trials":23772,"activeCount":97},[23773,23781,23790],{"nctId":23774,"briefTitle":23775,"status":103,"phases":23776,"primaryCompletion":23777,"completion":23778,"start":9606,"enrollment":8225,"conditions":23779,"interventions":23780},"NCT05630196","A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain",[86],"2023-06-09","2023-06-15",[10516],[23758],{"nctId":23782,"briefTitle":23783,"status":103,"phases":23784,"primaryCompletion":23785,"completion":2438,"start":23786,"enrollment":23787,"conditions":23788,"interventions":23789},"NCT05620576","A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).",[86],"2023-07-19","2022-11-14",131,[9378],[23758],{"nctId":23791,"briefTitle":23792,"status":103,"phases":23793,"primaryCompletion":2181,"completion":10042,"start":9607,"enrollment":3219,"conditions":23794,"interventions":23795},"NCT05620563","A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain",[86],[2191],[23758],{"trials":23797,"activeCount":97},[],{"trials":23799,"activeCount":97},[],{"trials":23801,"activeCount":97},[],{"intervention":23803,"totalTrials":1400,"cells":23804},"LY3819469",{"EARLY_PHASE1":23805,"PHASE1":23807,"PHASE2":23832,"PHASE3":23842,"PHASE4":23844,"NA":23846},{"trials":23806,"activeCount":97},[],{"trials":23808,"activeCount":97},[23809,23817,23825],{"nctId":23810,"briefTitle":23811,"status":103,"phases":23812,"primaryCompletion":23813,"completion":23813,"start":23814,"enrollment":2071,"conditions":23815,"interventions":23816},"NCT05932446","A Study to Compare Two Formulations of LY3819469 in Healthy Participants",[85],"2023-11-07","2023-06-30",[15],[23803],{"nctId":23818,"briefTitle":23819,"status":103,"phases":23820,"primaryCompletion":23821,"completion":23821,"start":23822,"enrollment":1587,"conditions":23823,"interventions":23824},"NCT04914546","A Study of LY3819469 in Healthy Participants",[85],"2022-11-09","2021-06-14",[15],[23803],{"nctId":23826,"briefTitle":23827,"status":103,"phases":23828,"primaryCompletion":23829,"completion":23829,"start":724,"enrollment":893,"conditions":23830,"interventions":23831},"NCT05841277","A Study of LY3819469 in Participants With Impaired and Normal Renal Function",[85],"2024-01-09",[147,15],[23803],{"trials":23833,"activeCount":97},[23834],{"nctId":23835,"briefTitle":23836,"status":103,"phases":23837,"primaryCompletion":9559,"completion":23838,"start":23839,"enrollment":2413,"conditions":23840,"interventions":23841},"NCT05565742","A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]",[86],"2024-10-17","2022-10-20",[23663],[23803],{"trials":23843,"activeCount":97},[],{"trials":23845,"activeCount":97},[],{"trials":23847,"activeCount":97},[],{"intervention":23849,"totalTrials":1400,"cells":23850},"LY3016859",{"EARLY_PHASE1":23851,"PHASE1":23853,"PHASE2":23855,"PHASE3":23884,"PHASE4":23886,"NA":23888},{"trials":23852,"activeCount":97},[],{"trials":23854,"activeCount":97},[],{"trials":23856,"activeCount":97},[23857,23864,23871,23878],{"nctId":23858,"briefTitle":23859,"status":103,"phases":23860,"primaryCompletion":9963,"completion":9398,"start":23861,"enrollment":174,"conditions":23862,"interventions":23863},"NCT04476108","Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain",[86],"2020-07-15",[9378],[23849],{"nctId":23865,"briefTitle":23866,"status":103,"phases":23867,"primaryCompletion":501,"completion":23868,"start":11264,"enrollment":195,"conditions":23869,"interventions":23870},"NCT04456686","Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis",[86],"2021-08-26",[2191],[23849],{"nctId":23872,"briefTitle":23873,"status":103,"phases":23874,"primaryCompletion":1474,"completion":1474,"start":3124,"enrollment":874,"conditions":23875,"interventions":23877},"NCT01774981","Study of LY3016859 in Participants With Diabetic Nephropathy",[85,86],[23876],"Diabetic Nephropathy",[23849],{"nctId":23879,"briefTitle":23880,"status":103,"phases":23881,"primaryCompletion":1132,"completion":1987,"start":6942,"enrollment":7363,"conditions":23882,"interventions":23883},"NCT04529096","Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain",[86],[10516],[23849],{"trials":23885,"activeCount":97},[],{"trials":23887,"activeCount":97},[],{"trials":23889,"activeCount":97},[],{"intervention":6527,"totalTrials":1400,"cells":23891},{"EARLY_PHASE1":23892,"PHASE1":23894,"PHASE2":23900,"PHASE3":23914,"PHASE4":23916,"NA":23918},{"trials":23893,"activeCount":97},[],{"trials":23895,"activeCount":97},[23896],{"nctId":22795,"briefTitle":22796,"status":103,"phases":23897,"primaryCompletion":22798,"completion":22799,"start":22800,"enrollment":3293,"conditions":23898,"interventions":23899},[85],[2608],[4101,6527],{"trials":23901,"activeCount":97},[23902,23906,23910],{"nctId":6519,"briefTitle":6520,"status":103,"phases":23903,"primaryCompletion":6522,"completion":6523,"start":6524,"enrollment":5841,"conditions":23904,"interventions":23905},[86],[6392],[4101,6527,61],{"nctId":22826,"briefTitle":22827,"status":103,"phases":23907,"primaryCompletion":19103,"completion":22829,"start":22830,"enrollment":1803,"conditions":23908,"interventions":23909},[86],[2608],[4101,6527],{"nctId":22632,"briefTitle":22633,"status":103,"phases":23911,"primaryCompletion":2798,"completion":4098,"start":2929,"enrollment":128,"conditions":23912,"interventions":23913},[86],[2608],[2870,22637,6527],{"trials":23915,"activeCount":97},[],{"trials":23917,"activeCount":97},[],{"trials":23919,"activeCount":97},[],{"intervention":18097,"totalTrials":1400,"cells":23921},{"EARLY_PHASE1":23922,"PHASE1":23924,"PHASE2":23936,"PHASE3":23946,"PHASE4":23948,"NA":23950},{"trials":23923,"activeCount":97},[],{"trials":23925,"activeCount":97},[23926,23932],{"nctId":23927,"briefTitle":23928,"status":103,"phases":23929,"primaryCompletion":3086,"completion":3086,"start":3004,"enrollment":2720,"conditions":23930,"interventions":23931},"NCT01448824","A Study of LY2484595 on Pharmacokinetics in Healthy Participants",[85],[4997],[18097,4983],{"nctId":23097,"briefTitle":23098,"status":103,"phases":23933,"primaryCompletion":3838,"completion":3838,"start":3086,"enrollment":1767,"conditions":23934,"interventions":23935},[85],[21],[18097,1181],{"trials":23937,"activeCount":97},[23938,23942],{"nctId":18092,"briefTitle":18093,"status":103,"phases":23939,"primaryCompletion":3886,"completion":3886,"start":3020,"enrollment":3647,"conditions":23940,"interventions":23941},[86],[18052],[18097,9237],{"nctId":18099,"briefTitle":18100,"status":103,"phases":23943,"primaryCompletion":3020,"completion":3020,"start":3251,"enrollment":18102,"conditions":23944,"interventions":23945},[86],[17305],[18097,9237,2092,2093],{"trials":23947,"activeCount":97},[],{"trials":23949,"activeCount":97},[],{"trials":23951,"activeCount":97},[],{"intervention":18844,"totalTrials":1400,"cells":23953},{"EARLY_PHASE1":23954,"PHASE1":23956,"PHASE2":23975,"PHASE3":23984,"PHASE4":23986,"NA":23988},{"trials":23955,"activeCount":97},[],{"trials":23957,"activeCount":97},[23958,23965,23971],{"nctId":23959,"briefTitle":23960,"status":103,"phases":23961,"primaryCompletion":23962,"completion":23962,"start":2198,"enrollment":310,"conditions":23963,"interventions":23964},"NCT05960851","A Study of LY3871801 in Healthy Asian and Non-Asian Participants",[85],"2023-10-25",[15],[18844],{"nctId":23966,"briefTitle":23967,"status":103,"phases":23968,"primaryCompletion":1923,"completion":1923,"start":13609,"enrollment":1158,"conditions":23969,"interventions":23970},"NCT05222399","A Study of LY3871801 in Healthy Participants",[85],[15],[18844],{"nctId":18838,"briefTitle":18839,"status":103,"phases":23972,"primaryCompletion":18841,"completion":18841,"start":5476,"enrollment":3041,"conditions":23973,"interventions":23974},[85],[15],[18844,5095,1172,5480,1538,1102],{"trials":23976,"activeCount":97},[23977],{"nctId":23978,"briefTitle":23979,"status":103,"phases":23980,"primaryCompletion":10616,"completion":23981,"start":7602,"enrollment":1649,"conditions":23982,"interventions":23983},"NCT05848258","An Adaptive Phase 2a\u002F2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis",[86],"2026-04-22",[5218],[18844],{"trials":23985,"activeCount":97},[],{"trials":23987,"activeCount":97},[],{"trials":23989,"activeCount":97},[],{"intervention":3982,"totalTrials":1400,"cells":23991},{"EARLY_PHASE1":23992,"PHASE1":23994,"PHASE2":24008,"PHASE3":24021,"PHASE4":24023,"NA":24025},{"trials":23993,"activeCount":97},[],{"trials":23995,"activeCount":97},[23996,24004],{"nctId":23997,"briefTitle":23998,"status":103,"phases":23999,"primaryCompletion":24000,"completion":24000,"start":24001,"enrollment":893,"conditions":24002,"interventions":24003},"NCT03023826","A Study of LY3202626 in Healthy Participants",[85],"2017-04-04","2017-01-15",[15],[3982,3982,3982],{"nctId":10963,"briefTitle":10964,"status":103,"phases":24005,"primaryCompletion":1547,"completion":1547,"start":3776,"enrollment":1501,"conditions":24006,"interventions":24007},[85],[21,3980],[3982,2562],{"trials":24009,"activeCount":97},[24010,24014],{"nctId":3972,"briefTitle":3973,"status":103,"phases":24011,"primaryCompletion":3975,"completion":3976,"start":3977,"enrollment":3978,"conditions":24012,"interventions":24013},[86],[3980],[3936,3982],{"nctId":24015,"briefTitle":24016,"status":999,"phases":24017,"primaryCompletion":24018,"completion":24018,"start":7951,"enrollment":1109,"conditions":24019,"interventions":24020},"NCT02791191","A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia",[86],"2018-07-02",[4040],[3982],{"trials":24022,"activeCount":97},[],{"trials":24024,"activeCount":97},[],{"trials":24026,"activeCount":97},[],{"intervention":23393,"totalTrials":1400,"cells":24028},{"EARLY_PHASE1":24029,"PHASE1":24031,"PHASE2":24041,"PHASE3":24051,"PHASE4":24053,"NA":24055},{"trials":24030,"activeCount":97},[],{"trials":24032,"activeCount":97},[24033,24037],{"nctId":23388,"briefTitle":23389,"status":103,"phases":24034,"primaryCompletion":4160,"completion":3838,"start":3292,"enrollment":9415,"conditions":24035,"interventions":24036},[85],[1466],[23393,23381],{"nctId":23402,"briefTitle":23403,"status":103,"phases":24038,"primaryCompletion":2865,"completion":2865,"start":4566,"enrollment":31,"conditions":24039,"interventions":24040},[85],[1466,1560],[23381,23381,23393],{"trials":24042,"activeCount":97},[24043,24047],{"nctId":23417,"briefTitle":23418,"status":103,"phases":24044,"primaryCompletion":2966,"completion":5022,"start":8217,"enrollment":3041,"conditions":24045,"interventions":24046},[86],[1571],[23381,23422,23393,23423],{"nctId":23425,"briefTitle":23426,"status":103,"phases":24048,"primaryCompletion":4122,"completion":4122,"start":3069,"enrollment":5882,"conditions":24049,"interventions":24050},[86],[2584,1694,1903,1490,3062,6552,23429],[23381,23393],{"trials":24052,"activeCount":97},[],{"trials":24054,"activeCount":97},[],{"trials":24056,"activeCount":97},[],{"intervention":24058,"totalTrials":1400,"cells":24059},"LY3454738",{"EARLY_PHASE1":24060,"PHASE1":24062,"PHASE2":24079,"PHASE3":24097,"PHASE4":24099,"NA":24101},{"trials":24061,"activeCount":97},[],{"trials":24063,"activeCount":97},[24064,24072],{"nctId":24065,"briefTitle":24066,"status":103,"phases":24067,"primaryCompletion":24068,"completion":24068,"start":24069,"enrollment":269,"conditions":24070,"interventions":24071},"NCT03750643","A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis",[85],"2021-09-07","2018-11-29",[1368],[24058,24058],{"nctId":24073,"briefTitle":24074,"status":103,"phases":24075,"primaryCompletion":24076,"completion":24076,"start":1520,"enrollment":1620,"conditions":24077,"interventions":24078},"NCT06173895","A Relative Bioavailability Study of LY3454738 in Healthy Participants",[85],"2024-05-02",[15],[24058],{"trials":24080,"activeCount":97},[24081,24089],{"nctId":24082,"briefTitle":24083,"status":999,"phases":24084,"primaryCompletion":912,"completion":24085,"start":24086,"enrollment":1808,"conditions":24087,"interventions":24088},"NCT05911841","A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis",[86],"2025-03-14","2023-06-21",[1271],[24058],{"nctId":24090,"briefTitle":24091,"status":999,"phases":24092,"primaryCompletion":11065,"completion":11065,"start":24093,"enrollment":251,"conditions":24094,"interventions":24096},"NCT04159701","A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria",[86],"2019-11-15",[24095],"Chronic Spontaneous Urticaria",[24058],{"trials":24098,"activeCount":97},[],{"trials":24100,"activeCount":97},[],{"trials":24102,"activeCount":97},[],{"intervention":7768,"totalTrials":1400,"cells":24104},{"EARLY_PHASE1":24105,"PHASE1":24107,"PHASE2":24125,"PHASE3":24137,"PHASE4":24139,"NA":24141},{"trials":24106,"activeCount":97},[],{"trials":24108,"activeCount":97},[24109,24121],{"nctId":24110,"briefTitle":24111,"status":103,"phases":24112,"primaryCompletion":24113,"completion":24114,"start":24115,"enrollment":195,"conditions":24116,"interventions":24117},"NCT01287546","A Study of LY2875358 in Participants With Advanced Cancer",[85],"2015-01-08","2016-10-26","2010-04-13",[1466],[7768,24118,24119,24120],"LY2875358 + erlotinib","LY2875358 at Part A highest dose","LY2875358 at Part A highest dose + trametinib",{"nctId":7762,"briefTitle":7763,"status":103,"phases":24122,"primaryCompletion":3122,"completion":3122,"start":3838,"enrollment":1237,"conditions":24123,"interventions":24124},[85],[2589,7766,1589],[7768,1721,2959],{"trials":24126,"activeCount":97},[24127,24131],{"nctId":7789,"briefTitle":7790,"status":103,"phases":24128,"primaryCompletion":7792,"completion":354,"start":7793,"enrollment":6549,"conditions":24129,"interventions":24130},[86],[1589],[7768,1721],{"nctId":24132,"briefTitle":24133,"status":103,"phases":24134,"primaryCompletion":3122,"completion":3776,"start":2917,"enrollment":1158,"conditions":24135,"interventions":24136},"NCT01874938","A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer",[86],[3062],[7768],{"trials":24138,"activeCount":97},[],{"trials":24140,"activeCount":97},[],{"trials":24142,"activeCount":97},[],{"intervention":22955,"totalTrials":1400,"cells":24144},{"EARLY_PHASE1":24145,"PHASE1":24147,"PHASE2":24162,"PHASE3":24176,"PHASE4":24178,"NA":24180},{"trials":24146,"activeCount":97},[],{"trials":24148,"activeCount":97},[24149,24156],{"nctId":24150,"briefTitle":24151,"status":103,"phases":24152,"primaryCompletion":2864,"completion":2864,"start":3069,"enrollment":9415,"conditions":24153,"interventions":24155},"NCT01337596","A Study of LY2951742 in Healthy Volunteers",[85],[24154],"Migraines",[22955],{"nctId":24157,"briefTitle":24158,"status":103,"phases":24159,"primaryCompletion":5030,"completion":5030,"start":5354,"enrollment":34,"conditions":24160,"interventions":24161},"NCT02104765","A Study of LY2951742 in Healthy Japanese and Caucasian Participants",[85],[17067],[22955],{"trials":24163,"activeCount":97},[24164,24172],{"nctId":24165,"briefTitle":24166,"status":103,"phases":24167,"primaryCompletion":3027,"completion":24168,"start":24169,"enrollment":3593,"conditions":24170,"interventions":24171},"NCT01625988","A Study of LY2951742 in Participants With Migraine",[86],"2013-09-18","2012-06-28",[7495],[22955],{"nctId":22949,"briefTitle":22950,"status":999,"phases":24173,"primaryCompletion":3697,"completion":1619,"start":7316,"enrollment":22952,"conditions":24174,"interventions":24175},[86],[2424],[22955,22669],{"trials":24177,"activeCount":97},[],{"trials":24179,"activeCount":97},[],{"trials":24181,"activeCount":97},[],{"intervention":22918,"totalTrials":1232,"cells":24183},{"EARLY_PHASE1":24184,"PHASE1":24186,"PHASE2":24196,"PHASE3":24202,"PHASE4":24204,"NA":24206},{"trials":24185,"activeCount":97},[],{"trials":24187,"activeCount":97},[24188,24192],{"nctId":22913,"briefTitle":22914,"status":103,"phases":24189,"primaryCompletion":3049,"completion":3049,"start":3282,"enrollment":118,"conditions":24190,"interventions":24191},[85],[21],[22918,22669],{"nctId":22935,"briefTitle":22936,"status":103,"phases":24193,"primaryCompletion":2898,"completion":2898,"start":3838,"enrollment":1620,"conditions":24194,"interventions":24195},[85],[21],[22918,22669],{"trials":24197,"activeCount":97},[24198],{"nctId":22943,"briefTitle":22944,"status":103,"phases":24199,"primaryCompletion":4955,"completion":4955,"start":2964,"enrollment":19,"conditions":24200,"interventions":24201},[86],[10659],[22918,22669],{"trials":24203,"activeCount":97},[],{"trials":24205,"activeCount":97},[],{"trials":24207,"activeCount":97},[],{"intervention":10770,"totalTrials":1232,"cells":24209},{"EARLY_PHASE1":24210,"PHASE1":24212,"PHASE2":24227,"PHASE3":24233,"PHASE4":24235,"NA":24237},{"trials":24211,"activeCount":97},[],{"trials":24213,"activeCount":97},[24214,24221],{"nctId":24215,"briefTitle":24216,"status":103,"phases":24217,"primaryCompletion":2875,"completion":2875,"start":3646,"enrollment":874,"conditions":24218,"interventions":24219},"NCT00801177","Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy",[85],[2589],[10770,10770,10770,24220,10770,10770,10770,10770,10770,10770,10770,10770],"IMC-11F8 I.V.",{"nctId":24222,"briefTitle":24223,"status":103,"phases":24224,"primaryCompletion":3086,"completion":3086,"start":3685,"enrollment":1158,"conditions":24225,"interventions":24226},"NCT01088464","Study of IMC-11F8 in Participants With Advanced Solid Tumors",[85],[1870],[10770,10770,10770],{"trials":24228,"activeCount":97},[24229],{"nctId":10765,"briefTitle":10766,"status":103,"phases":24230,"primaryCompletion":3685,"completion":8233,"start":3813,"enrollment":37,"conditions":24231,"interventions":24232},[86],[5657],[10770,2520,6603,10753],{"trials":24234,"activeCount":97},[],{"trials":24236,"activeCount":97},[],{"trials":24238,"activeCount":97},[],{"intervention":24240,"totalTrials":1232,"cells":24241},"Tasisulam",{"EARLY_PHASE1":24242,"PHASE1":24244,"PHASE2":24259,"PHASE3":24268,"PHASE4":24270,"NA":24272},{"trials":24243,"activeCount":97},[],{"trials":24245,"activeCount":97},[24246,24253],{"nctId":24247,"briefTitle":24248,"status":999,"phases":24249,"primaryCompletion":3152,"completion":3152,"start":2899,"enrollment":1400,"conditions":24250,"interventions":24251},"NCT01185548","A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma",[85],[7766,1466],[24252,24240],"Tolbutamide",{"nctId":24254,"briefTitle":24255,"status":999,"phases":24256,"primaryCompletion":4258,"completion":4258,"start":3114,"enrollment":205,"conditions":24257,"interventions":24258},"NCT01209832","A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients",[85],[1466],[24240,1538],{"trials":24260,"activeCount":97},[24261],{"nctId":24262,"briefTitle":24263,"status":103,"phases":24264,"primaryCompletion":3494,"completion":4097,"start":2930,"enrollment":2206,"conditions":24265,"interventions":24266},"NCT00383292","A Study of Tasisulam in Treating Participants With Malignant Melanoma",[86],[1534],[24267],"tasisulam",{"trials":24269,"activeCount":97},[],{"trials":24271,"activeCount":97},[],{"trials":24273,"activeCount":97},[],{"intervention":3498,"totalTrials":1232,"cells":24275},{"EARLY_PHASE1":24276,"PHASE1":24278,"PHASE2":24284,"PHASE3":24297,"PHASE4":24299,"NA":24301},{"trials":24277,"activeCount":97},[],{"trials":24279,"activeCount":97},[24280],{"nctId":7965,"briefTitle":7966,"status":999,"phases":24281,"primaryCompletion":7968,"completion":7968,"start":6390,"enrollment":3293,"conditions":24282,"interventions":24283},[85],[1503],[3498,2696],{"trials":24285,"activeCount":97},[24286,24290],{"nctId":3491,"briefTitle":3492,"status":103,"phases":24287,"primaryCompletion":3112,"completion":1628,"start":3494,"enrollment":963,"conditions":24288,"interventions":24289},[86],[3496],[3498,1512,3324],{"nctId":24291,"briefTitle":24292,"status":999,"phases":24293,"primaryCompletion":2845,"completion":5081,"start":8217,"enrollment":8918,"conditions":24294,"interventions":24296},"NCT01391130","A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma",[86],[24295],"Metastatic Clear Cell Renal Cell Carcinoma",[3498,16655],{"trials":24298,"activeCount":97},[],{"trials":24300,"activeCount":97},[],{"trials":24302,"activeCount":97},[],{"intervention":19380,"totalTrials":1232,"cells":24304},{"EARLY_PHASE1":24305,"PHASE1":24307,"PHASE2":24321,"PHASE3":24327,"PHASE4":24329,"NA":24331},{"trials":24306,"activeCount":97},[],{"trials":24308,"activeCount":97},[24309,24315],{"nctId":24310,"briefTitle":24311,"status":103,"phases":24312,"primaryCompletion":3124,"completion":3124,"start":2966,"enrollment":1199,"conditions":24313,"interventions":24314},"NCT01671085","A Study of LY3015014 in Healthy Participants With High Cholesterol",[85],[21,17378],[19380],{"nctId":24316,"briefTitle":24317,"status":103,"phases":24318,"primaryCompletion":4420,"completion":4420,"start":3838,"enrollment":4945,"conditions":24319,"interventions":24320},"NCT01618916","A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol",[85],[21],[19380],{"trials":24322,"activeCount":97},[24323],{"nctId":19375,"briefTitle":19376,"status":103,"phases":24324,"primaryCompletion":1475,"completion":5354,"start":2964,"enrollment":5355,"conditions":24325,"interventions":24326},[86],[17378],[19380,19381,17380],{"trials":24328,"activeCount":97},[],{"trials":24330,"activeCount":97},[],{"trials":24332,"activeCount":97},[],{"intervention":17113,"totalTrials":1232,"cells":24334},{"EARLY_PHASE1":24335,"PHASE1":24337,"PHASE2":24347,"PHASE3":24356,"PHASE4":24358,"NA":24360},{"trials":24336,"activeCount":97},[],{"trials":24338,"activeCount":97},[24339,24343],{"nctId":19081,"briefTitle":19082,"status":103,"phases":24340,"primaryCompletion":7223,"completion":7223,"start":19084,"enrollment":137,"conditions":24341,"interventions":24342},[85],[7486],[19087,17113],{"nctId":17106,"briefTitle":17107,"status":103,"phases":24344,"primaryCompletion":17109,"completion":17109,"start":17110,"enrollment":233,"conditions":24345,"interventions":24346},[85],[15],[17046,17113],{"trials":24348,"activeCount":97},[24349],{"nctId":24350,"briefTitle":24351,"status":999,"phases":24352,"primaryCompletion":2929,"completion":2929,"start":2974,"enrollment":2080,"conditions":24353,"interventions":24354},"NCT00804973","Study in Participants With Acute Migraines Headaches",[86],[7495],[24355,17113],"LY2590443",{"trials":24357,"activeCount":97},[],{"trials":24359,"activeCount":97},[],{"trials":24361,"activeCount":97},[],{"intervention":24363,"totalTrials":1232,"cells":24364},"LY2439821",{"EARLY_PHASE1":24365,"PHASE1":24367,"PHASE2":24381,"PHASE3":24390,"PHASE4":24392,"NA":24394},{"trials":24366,"activeCount":97},[],{"trials":24368,"activeCount":97},[24369,24375],{"nctId":24370,"briefTitle":24371,"status":103,"phases":24372,"primaryCompletion":3068,"completion":3068,"start":3152,"enrollment":165,"conditions":24373,"interventions":24374},"NCT01236118","A Study of LY2439821 in Rheumatoid Arthritis",[85],[5218],[24363],{"nctId":24376,"briefTitle":24377,"status":103,"phases":24378,"primaryCompletion":4160,"completion":4160,"start":2956,"enrollment":310,"conditions":24379,"interventions":24380},"NCT01253265","A Study in Rheumatoid Arthritis",[85],[5218],[24363],{"trials":24382,"activeCount":97},[24383],{"nctId":24384,"briefTitle":24385,"status":103,"phases":24386,"primaryCompletion":3837,"completion":3838,"start":2955,"enrollment":24387,"conditions":24388,"interventions":24389},"NCT00966875","A Study in Patients With Rheumatoid Arthritis",[86],448,[5218],[24363],{"trials":24391,"activeCount":97},[],{"trials":24393,"activeCount":97},[],{"trials":24395,"activeCount":97},[],{"intervention":3470,"totalTrials":1232,"cells":24397},{"EARLY_PHASE1":24398,"PHASE1":24400,"PHASE2":24406,"PHASE3":24419,"PHASE4":24421,"NA":24423},{"trials":24399,"activeCount":97},[],{"trials":24401,"activeCount":97},[24402],{"nctId":3465,"briefTitle":3466,"status":103,"phases":24403,"primaryCompletion":3069,"completion":3069,"start":3266,"enrollment":2542,"conditions":24404,"interventions":24405},[85],[1466],[3470,2838,1512],{"trials":24407,"activeCount":97},[24408,24412],{"nctId":4231,"briefTitle":4232,"status":999,"phases":24409,"primaryCompletion":1619,"completion":1619,"start":3124,"enrollment":1199,"conditions":24410,"interventions":24411},[85,86],[1653],[3470,2593,1511,1539],{"nctId":24413,"briefTitle":24414,"status":103,"phases":24415,"primaryCompletion":4122,"completion":4122,"start":3029,"enrollment":1082,"conditions":24416,"interventions":24418},"NCT01214603","A Study in Participants With Acute Leukemia",[86],[24417],"Leukemia",[3470],{"trials":24420,"activeCount":97},[],{"trials":24422,"activeCount":97},[],{"trials":24424,"activeCount":97},[],{"intervention":24426,"totalTrials":1232,"cells":24427},"LY2624803",{"EARLY_PHASE1":24428,"PHASE1":24430,"PHASE2":24445,"PHASE3":24456,"PHASE4":24458,"NA":24460},{"trials":24429,"activeCount":97},[],{"trials":24431,"activeCount":97},[24432,24439],{"nctId":24433,"briefTitle":24434,"status":103,"phases":24435,"primaryCompletion":3152,"completion":3152,"start":8233,"enrollment":11639,"conditions":24436,"interventions":24438},"NCT01236105","Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject",[85],[24437],"Insomnia",[24426],{"nctId":24440,"briefTitle":24441,"status":999,"phases":24442,"primaryCompletion":3029,"completion":3029,"start":3029,"enrollment":97,"conditions":24443,"interventions":24444},"NCT01257178","A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment",[85],[24437],[24426],{"trials":24446,"activeCount":97},[24447],{"nctId":24448,"briefTitle":24449,"status":103,"phases":24450,"primaryCompletion":3087,"completion":3087,"start":3132,"enrollment":2406,"conditions":24451,"interventions":24454},"NCT00784875","An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia",[86],[24452,24453],"Primary Insomnia","Secondary Insomnia",[24426,24426,24455],"zolpidem",{"trials":24457,"activeCount":97},[],{"trials":24459,"activeCount":97},[],{"trials":24461,"activeCount":97},[],{"intervention":24463,"totalTrials":1232,"cells":24464},"LY2452473",{"EARLY_PHASE1":24465,"PHASE1":24467,"PHASE2":24482,"PHASE3":24491,"PHASE4":24493,"NA":24495},{"trials":24466,"activeCount":97},[],{"trials":24468,"activeCount":97},[24469,24475],{"nctId":24470,"briefTitle":24471,"status":103,"phases":24472,"primaryCompletion":3283,"completion":3283,"start":4258,"enrollment":1677,"conditions":24473,"interventions":24474},"NCT01275157","Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects",[85],[21],[24463],{"nctId":24476,"briefTitle":24477,"status":103,"phases":24478,"primaryCompletion":3494,"completion":3494,"start":6093,"enrollment":290,"conditions":24479,"interventions":24480},"NCT01401543","A Bioavailability Study of LY2452473 and Tadalafil",[85],[14741],[24463,10904,24481],"LY900010",{"trials":24483,"activeCount":97},[24484],{"nctId":24485,"briefTitle":24486,"status":103,"phases":24487,"primaryCompletion":5090,"completion":5090,"start":8233,"enrollment":24488,"conditions":24489,"interventions":24490},"NCT01160289","A Study of LY900010 in Erectile Dysfunction",[86],410,[14741],[24463,14720],{"trials":24492,"activeCount":97},[],{"trials":24494,"activeCount":97},[],{"trials":24496,"activeCount":97},[],{"intervention":3072,"totalTrials":1232,"cells":24498},{"EARLY_PHASE1":24499,"PHASE1":24501,"PHASE2":24510,"PHASE3":24523,"PHASE4":24525,"NA":24527},{"trials":24500,"activeCount":97},[],{"trials":24502,"activeCount":97},[24503],{"nctId":24504,"briefTitle":24505,"status":103,"phases":24506,"primaryCompletion":4122,"completion":3697,"start":3217,"enrollment":11639,"conditions":24507,"interventions":24509},"NCT01007032","A Study of IMC-A12 in Advanced Solid Tumors",[85],[24508],"Tumors",[3072],{"trials":24511,"activeCount":97},[24512,24516],{"nctId":3065,"briefTitle":3066,"status":103,"phases":24513,"primaryCompletion":3068,"completion":2965,"start":3069,"enrollment":982,"conditions":24514,"interventions":24515},[86],[2903],[1612,1510,3072],{"nctId":24517,"briefTitle":24518,"status":103,"phases":24519,"primaryCompletion":6093,"completion":2799,"start":3103,"enrollment":4222,"conditions":24520,"interventions":24521},"NCT00781911","A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer",[86],[2901,7754],[3072,24522],"depot octreotide",{"trials":24524,"activeCount":97},[],{"trials":24526,"activeCount":97},[],{"trials":24528,"activeCount":97},[],{"intervention":24530,"totalTrials":1232,"cells":24531},"LY3361237",{"EARLY_PHASE1":24532,"PHASE1":24534,"PHASE2":24550,"PHASE3":24560,"PHASE4":24562,"NA":24564},{"trials":24533,"activeCount":97},[],{"trials":24535,"activeCount":97},[24536,24543],{"nctId":24537,"briefTitle":24538,"status":103,"phases":24539,"primaryCompletion":676,"completion":676,"start":24540,"enrollment":165,"conditions":24541,"interventions":24542},"NCT03933943","A Study of LY3361237 in Participants With Systemic Lupus Erythematosus",[85],"2019-05-21",[20243],[24530],{"nctId":24544,"briefTitle":24545,"status":103,"phases":24546,"primaryCompletion":24547,"completion":24547,"start":7530,"enrollment":11639,"conditions":24548,"interventions":24549},"NCT04975295","A Study of LY3361237 in Participants With Psoriasis",[85],"2022-11-29",[447],[24530],{"trials":24551,"activeCount":97},[24552],{"nctId":24553,"briefTitle":24554,"status":999,"phases":24555,"primaryCompletion":24556,"completion":24556,"start":24557,"enrollment":22,"conditions":24558,"interventions":24559},"NCT05123586","A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus",[86],"2023-12-29","2022-03-07",[5075],[24530],{"trials":24561,"activeCount":97},[],{"trials":24563,"activeCount":97},[],{"trials":24565,"activeCount":97},[],{"intervention":2334,"totalTrials":1232,"cells":24567},{"EARLY_PHASE1":24568,"PHASE1":24570,"PHASE2":24580,"PHASE3":24586,"PHASE4":24588,"NA":24590},{"trials":24569,"activeCount":97},[],{"trials":24571,"activeCount":97},[24572,24576],{"nctId":2327,"briefTitle":2328,"status":103,"phases":24573,"primaryCompletion":2330,"completion":2330,"start":2331,"enrollment":1620,"conditions":24574,"interventions":24575},[85],[15],[610,2334],{"nctId":17576,"briefTitle":17577,"status":103,"phases":24577,"primaryCompletion":8217,"completion":8217,"start":3837,"enrollment":4945,"conditions":24578,"interventions":24579},[85],[18],[9681,2334,17581],{"trials":24581,"activeCount":97},[24582],{"nctId":15148,"briefTitle":15149,"status":999,"phases":24583,"primaryCompletion":2918,"completion":2918,"start":3050,"enrollment":15151,"conditions":24584,"interventions":24585},[86],[24],[15154,15139,2334],{"trials":24587,"activeCount":97},[],{"trials":24589,"activeCount":97},[],{"trials":24591,"activeCount":97},[],{"intervention":18660,"totalTrials":1232,"cells":24593},{"EARLY_PHASE1":24594,"PHASE1":24596,"PHASE2":24602,"PHASE3":24612,"PHASE4":24614,"NA":24616},{"trials":24595,"activeCount":97},[],{"trials":24597,"activeCount":97},[24598],{"nctId":2576,"briefTitle":2577,"status":103,"phases":24599,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":24600,"interventions":24601},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":24603,"activeCount":97},[24604,24608],{"nctId":18762,"briefTitle":18763,"status":103,"phases":24605,"primaryCompletion":18765,"completion":18766,"start":18767,"enrollment":2542,"conditions":24606,"interventions":24607},[85,86],[1503,18769,18770],[4387,18660],{"nctId":18653,"briefTitle":18654,"status":999,"phases":24609,"primaryCompletion":18656,"completion":18657,"start":18268,"enrollment":251,"conditions":24610,"interventions":24611},[86],[1694],[2591,18660],{"trials":24613,"activeCount":97},[],{"trials":24615,"activeCount":97},[],{"trials":24617,"activeCount":97},[],{"intervention":16655,"totalTrials":1232,"cells":24619},{"EARLY_PHASE1":24620,"PHASE1":24622,"PHASE2":24632,"PHASE3":24642,"PHASE4":24644,"NA":24646},{"trials":24621,"activeCount":97},[],{"trials":24623,"activeCount":97},[24624],{"nctId":24625,"briefTitle":24626,"status":103,"phases":24627,"primaryCompletion":3086,"completion":3086,"start":2800,"enrollment":11639,"conditions":24628,"interventions":24630},"NCT01258348","A Phase 1b Trial in Patients With Renal Cell Cancer",[85],[24629],"Metastatic Renal Cell Cancer",[24631,16655],"Drug: LY573636-sodium",{"trials":24633,"activeCount":97},[24634,24638],{"nctId":16647,"briefTitle":16648,"status":103,"phases":24635,"primaryCompletion":16650,"completion":16651,"start":16652,"enrollment":1237,"conditions":24636,"interventions":24637},[86],[6581],[3447,16655],{"nctId":24291,"briefTitle":24292,"status":999,"phases":24639,"primaryCompletion":2845,"completion":5081,"start":8217,"enrollment":8918,"conditions":24640,"interventions":24641},[86],[24295],[3498,16655],{"trials":24643,"activeCount":97},[],{"trials":24645,"activeCount":97},[],{"trials":24647,"activeCount":97},[],{"intervention":24649,"totalTrials":1232,"cells":24650},"LY3337641",{"EARLY_PHASE1":24651,"PHASE1":24653,"PHASE2":24669,"PHASE3":24680,"PHASE4":24682,"NA":24684},{"trials":24652,"activeCount":97},[],{"trials":24654,"activeCount":97},[24655,24662],{"nctId":24656,"briefTitle":24657,"status":103,"phases":24658,"primaryCompletion":3616,"completion":3616,"start":24659,"enrollment":214,"conditions":24660,"interventions":24661},"NCT03083561","A Study of LY3337641 in Japanese and Caucasian Healthy Participants",[85],"2017-03-15",[15],[24649],{"nctId":24663,"briefTitle":24664,"status":103,"phases":24665,"primaryCompletion":14233,"completion":14233,"start":24000,"enrollment":864,"conditions":24666,"interventions":24667},"NCT03099148","A Study of LY3337641 in Healthy Participants",[85],[15],[24668,24649,24649],"Reference Formulation",{"trials":24670,"activeCount":97},[24671],{"nctId":24672,"briefTitle":24673,"status":999,"phases":24674,"primaryCompletion":24675,"completion":24676,"start":24677,"enrollment":16,"conditions":24678,"interventions":24679},"NCT02628028","A Study of LY3337641 in Rheumatoid Arthritis",[86],"2018-04-25","2018-08-15","2016-08-22",[5218],[24649],{"trials":24681,"activeCount":97},[],{"trials":24683,"activeCount":97},[],{"trials":24685,"activeCount":97},[],{"intervention":18111,"totalTrials":1232,"cells":24687},{"EARLY_PHASE1":24688,"PHASE1":24690,"PHASE2":24692,"PHASE3":24712,"PHASE4":24714,"NA":24716},{"trials":24689,"activeCount":97},[],{"trials":24691,"activeCount":97},[],{"trials":24693,"activeCount":97},[24694,24702,24708],{"nctId":24695,"briefTitle":24696,"status":103,"phases":24697,"completion":2930,"start":3133,"enrollment":3546,"conditions":24698,"interventions":24700},"NCT00374855","A Study in People With Mild Hypertension",[86],[24699],"Mild Hypertension",[18111,24701],"Hydrochlorothiazide",{"nctId":24703,"briefTitle":24704,"status":103,"phases":24705,"completion":2876,"start":2947,"enrollment":542,"conditions":24706,"interventions":24707},"NCT00116519","A Study in People With Abnormal Fat Levels in the Blood",[86],[17305],[18111],{"nctId":18106,"briefTitle":18107,"status":103,"phases":24709,"completion":3133,"start":2947,"enrollment":542,"conditions":24710,"interventions":24711},[86],[17378],[18111,18112],{"trials":24713,"activeCount":97},[],{"trials":24715,"activeCount":97},[],{"trials":24717,"activeCount":97},[],{"intervention":8759,"totalTrials":947,"cells":24719},{"EARLY_PHASE1":24720,"PHASE1":24722,"PHASE2":24728,"PHASE3":24734,"PHASE4":24736,"NA":24738},{"trials":24721,"activeCount":97},[],{"trials":24723,"activeCount":97},[24724],{"nctId":8751,"briefTitle":8752,"status":103,"phases":24725,"primaryCompletion":8754,"completion":8755,"start":8756,"enrollment":4353,"conditions":24726,"interventions":24727},[85],[1478],[2545,5985,8759,1745,8760],{"trials":24729,"activeCount":97},[24730],{"nctId":8207,"briefTitle":8208,"status":103,"phases":24731,"primaryCompletion":3086,"completion":3068,"start":3005,"enrollment":2670,"conditions":24732,"interventions":24733},[86],[7766],[2979,4357,5885,3143,8212,8205],{"trials":24735,"activeCount":97},[],{"trials":24737,"activeCount":97},[],{"trials":24739,"activeCount":97},[],{"intervention":18475,"totalTrials":947,"cells":24741},{"EARLY_PHASE1":24742,"PHASE1":24744,"PHASE2":24752,"PHASE3":24758,"PHASE4":24760,"NA":24762},{"trials":24743,"activeCount":97},[],{"trials":24745,"activeCount":97},[24746],{"nctId":24747,"briefTitle":24748,"status":103,"phases":24749,"primaryCompletion":2866,"completion":3217,"start":3185,"enrollment":2071,"conditions":24750,"interventions":24751},"NCT00782002","Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy",[85],[2802],[18475],{"trials":24753,"activeCount":97},[24754],{"nctId":18470,"briefTitle":18471,"status":103,"phases":24755,"primaryCompletion":4955,"completion":3698,"start":3837,"enrollment":3546,"conditions":24756,"interventions":24757},[86],[36],[9819,18475,1843],{"trials":24759,"activeCount":97},[],{"trials":24761,"activeCount":97},[],{"trials":24763,"activeCount":97},[],{"intervention":6513,"totalTrials":947,"cells":24765},{"EARLY_PHASE1":24766,"PHASE1":24768,"PHASE2":24770,"PHASE3":24780,"PHASE4":24782,"NA":24784},{"trials":24767,"activeCount":97},[],{"trials":24769,"activeCount":97},[],{"trials":24771,"activeCount":97},[24772,24776],{"nctId":7772,"briefTitle":7773,"status":103,"phases":24773,"primaryCompletion":1473,"completion":7775,"start":2917,"enrollment":335,"conditions":24774,"interventions":24775},[86],[1589],[6513,1721],{"nctId":6503,"briefTitle":6504,"status":103,"phases":24777,"primaryCompletion":6506,"completion":6507,"start":6508,"enrollment":6509,"conditions":24778,"interventions":24779},[85,86],[1466,2604,3399,6511,2585,1718],[6513,61],{"trials":24781,"activeCount":97},[],{"trials":24783,"activeCount":97},[],{"trials":24785,"activeCount":97},[],{"intervention":24787,"totalTrials":947,"cells":24788},"LY2428757",{"EARLY_PHASE1":24789,"PHASE1":24791,"PHASE2":24800,"PHASE3":24807,"PHASE4":24809,"NA":24811},{"trials":24790,"activeCount":97},[],{"trials":24792,"activeCount":97},[24793],{"nctId":24794,"briefTitle":24795,"status":103,"phases":24796,"primaryCompletion":2956,"completion":2956,"start":3103,"enrollment":23787,"conditions":24797,"interventions":24798},"NCT00853151","A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes",[85],[18],[24787,24799],"TT223",{"trials":24801,"activeCount":97},[24802],{"nctId":24803,"briefTitle":18444,"status":103,"phases":24804,"primaryCompletion":3685,"completion":3685,"start":2928,"enrollment":5807,"conditions":24805,"interventions":24806},"NCT00804986",[86],[18],[24787],{"trials":24808,"activeCount":97},[],{"trials":24810,"activeCount":97},[],{"trials":24812,"activeCount":97},[],{"intervention":24814,"totalTrials":947,"cells":24815},"LY3462817",{"EARLY_PHASE1":24816,"PHASE1":24818,"PHASE2":24827,"PHASE3":24837,"PHASE4":24839,"NA":24841},{"trials":24817,"activeCount":97},[],{"trials":24819,"activeCount":97},[24820],{"nctId":24821,"briefTitle":24822,"status":103,"phases":24823,"primaryCompletion":828,"completion":828,"start":24824,"enrollment":5015,"conditions":24825,"interventions":24826},"NCT05440136","A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants",[85],"2022-06-28",[15],[24814,24814],{"trials":24828,"activeCount":97},[24829],{"nctId":24830,"briefTitle":24831,"status":103,"phases":24832,"primaryCompletion":9249,"completion":24833,"start":695,"enrollment":24834,"conditions":24835,"interventions":24836},"NCT04634253","A Study of LY3462817 in Participants With Rheumatoid Arthritis",[86],"2022-06-29",98,[5218],[24814],{"trials":24838,"activeCount":97},[],{"trials":24840,"activeCount":97},[],{"trials":24842,"activeCount":97},[],{"intervention":8259,"totalTrials":947,"cells":24844},{"EARLY_PHASE1":24845,"PHASE1":24847,"PHASE2":24853,"PHASE3":24859,"PHASE4":24861,"NA":24863},{"trials":24846,"activeCount":97},[],{"trials":24848,"activeCount":97},[24849],{"nctId":8254,"briefTitle":8255,"status":103,"phases":24850,"primaryCompletion":1473,"completion":1474,"start":3545,"enrollment":1071,"conditions":24851,"interventions":24852},[85],[1114],[8259,8260,8261,3034],{"trials":24854,"activeCount":97},[24855],{"nctId":8275,"briefTitle":8276,"status":103,"phases":24856,"primaryCompletion":7316,"completion":7316,"start":3545,"enrollment":5248,"conditions":24857,"interventions":24858},[86],[1114],[3034,8280,8259],{"trials":24860,"activeCount":97},[],{"trials":24862,"activeCount":97},[],{"trials":24864,"activeCount":97},[],{"intervention":273,"totalTrials":947,"cells":24866},{"EARLY_PHASE1":24867,"PHASE1":24869,"PHASE2":24875,"PHASE3":24881,"PHASE4":24883,"NA":24885},{"trials":24868,"activeCount":97},[],{"trials":24870,"activeCount":97},[24871],{"nctId":264,"briefTitle":265,"status":103,"phases":24872,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":24873,"interventions":24874},[85],[24,27],[110,272,92,273],{"trials":24876,"activeCount":97},[24877],{"nctId":339,"briefTitle":340,"status":103,"phases":24878,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":24879,"interventions":24880},[86],[24],[92,348,273,349],{"trials":24882,"activeCount":97},[],{"trials":24884,"activeCount":97},[],{"trials":24886,"activeCount":97},[],{"intervention":23593,"totalTrials":947,"cells":24888},{"EARLY_PHASE1":24889,"PHASE1":24891,"PHASE2":24897,"PHASE3":24903,"PHASE4":24905,"NA":24907},{"trials":24890,"activeCount":97},[],{"trials":24892,"activeCount":97},[24893],{"nctId":23588,"briefTitle":23589,"status":103,"phases":24894,"primaryCompletion":4258,"completion":4258,"start":8233,"enrollment":310,"conditions":24895,"interventions":24896},[85],[412],[10903,23593],{"trials":24898,"activeCount":97},[24899],{"nctId":23597,"briefTitle":23598,"status":103,"phases":24900,"primaryCompletion":3124,"completion":3124,"start":3494,"enrollment":137,"conditions":24901,"interventions":24902},[86],[412],[10903,23593],{"trials":24904,"activeCount":97},[],{"trials":24906,"activeCount":97},[],{"trials":24908,"activeCount":97},[],{"intervention":24910,"totalTrials":947,"cells":24911},"Enzastaurin Hydrochloride",{"EARLY_PHASE1":24912,"PHASE1":24914,"PHASE2":24920,"PHASE3":24928,"PHASE4":24930,"NA":24932},{"trials":24913,"activeCount":97},[],{"trials":24915,"activeCount":97},[24916],{"nctId":7672,"briefTitle":7673,"status":103,"phases":24917,"primaryCompletion":3419,"completion":2898,"start":2930,"enrollment":137,"conditions":24918,"interventions":24919},[85],[7676],[2560,7678],{"trials":24921,"activeCount":97},[24922],{"nctId":24923,"briefTitle":24924,"status":103,"phases":24925,"completion":2975,"start":2930,"enrollment":2542,"conditions":24926,"interventions":24927},"NCT00386087","Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy",[86],[1893],[24910],{"trials":24929,"activeCount":97},[],{"trials":24931,"activeCount":97},[],{"trials":24933,"activeCount":97},[],{"intervention":24935,"totalTrials":947,"cells":24936},"LY3375880",{"EARLY_PHASE1":24937,"PHASE1":24939,"PHASE2":24950,"PHASE3":24958,"PHASE4":24960,"NA":24962},{"trials":24938,"activeCount":97},[],{"trials":24940,"activeCount":97},[24941],{"nctId":24942,"briefTitle":24943,"status":103,"phases":24944,"primaryCompletion":7565,"completion":7565,"start":24945,"enrollment":24946,"conditions":24947,"interventions":24948},"NCT03913260","A Study of Different Injectable Formulations of LY3375880 in Healthy Participants",[85],"2019-05-01",83,[15],[24935,24949],"Buffer Matrix",{"trials":24951,"activeCount":97},[24952],{"nctId":24953,"briefTitle":24954,"status":999,"phases":24955,"primaryCompletion":81,"completion":81,"start":6259,"enrollment":17819,"conditions":24956,"interventions":24957},"NCT03831191","A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis",[86],[1271],[24935],{"trials":24959,"activeCount":97},[],{"trials":24961,"activeCount":97},[],{"trials":24963,"activeCount":97},[],{"intervention":9652,"totalTrials":947,"cells":24965},{"EARLY_PHASE1":24966,"PHASE1":24968,"PHASE2":24976,"PHASE3":24982,"PHASE4":24984,"NA":24986},{"trials":24967,"activeCount":97},[],{"trials":24969,"activeCount":97},[24970],{"nctId":24971,"briefTitle":24972,"status":103,"phases":24973,"primaryCompletion":3027,"completion":3027,"start":4122,"enrollment":2542,"conditions":24974,"interventions":24975},"NCT01736241","A Study of LY3053102 in Healthy Participants",[85],[21],[9652],{"trials":24977,"activeCount":97},[24978],{"nctId":9647,"briefTitle":9648,"status":999,"phases":24979,"primaryCompletion":1473,"completion":1473,"start":3049,"enrollment":874,"conditions":24980,"interventions":24981},[85,86],[120],[9652,9653,1631],{"trials":24983,"activeCount":97},[],{"trials":24985,"activeCount":97},[],{"trials":24987,"activeCount":97},[],{"intervention":24989,"totalTrials":947,"cells":24990},"LY2189102",{"EARLY_PHASE1":24991,"PHASE1":24993,"PHASE2":24995,"PHASE3":25009,"PHASE4":25011,"NA":25013},{"trials":24992,"activeCount":97},[],{"trials":24994,"activeCount":97},[],{"trials":24996,"activeCount":97},[24997,25003],{"nctId":24998,"briefTitle":24999,"status":103,"phases":25000,"primaryCompletion":3266,"completion":3266,"start":3228,"enrollment":3487,"conditions":25001,"interventions":25002},"NCT00380744","A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis",[85,86],[5093],[24989],{"nctId":25004,"briefTitle":25005,"status":103,"phases":25006,"primaryCompletion":3029,"completion":3029,"start":5860,"enrollment":1839,"conditions":25007,"interventions":25008},"NCT00942188","A Study of LY2189102 in Patients With Type 2 Diabetes",[86],[30],[24989],{"trials":25010,"activeCount":97},[],{"trials":25012,"activeCount":97},[],{"trials":25014,"activeCount":97},[],{"intervention":2758,"totalTrials":947,"cells":25016},{"EARLY_PHASE1":25017,"PHASE1":25019,"PHASE2":25025,"PHASE3":25031,"PHASE4":25033,"NA":25035},{"trials":25018,"activeCount":97},[],{"trials":25020,"activeCount":97},[25021],{"nctId":2751,"briefTitle":2752,"status":103,"phases":25022,"primaryCompletion":1546,"completion":2754,"start":1473,"enrollment":12,"conditions":25023,"interventions":25024},[85],[2756],[61,1843,1510,2758,2520],{"trials":25026,"activeCount":97},[25027],{"nctId":6563,"briefTitle":6564,"status":103,"phases":25028,"primaryCompletion":6566,"completion":665,"start":6567,"enrollment":903,"conditions":25029,"interventions":25030},[86],[3398,3399],[61,2758,2520,1669],{"trials":25032,"activeCount":97},[],{"trials":25034,"activeCount":97},[],{"trials":25036,"activeCount":97},[],{"intervention":6543,"totalTrials":947,"cells":25038},{"EARLY_PHASE1":25039,"PHASE1":25041,"PHASE2":25043,"PHASE3":25053,"PHASE4":25055,"NA":25057},{"trials":25040,"activeCount":97},[],{"trials":25042,"activeCount":97},[],{"trials":25044,"activeCount":97},[25045,25049],{"nctId":6536,"briefTitle":6537,"status":103,"phases":25046,"primaryCompletion":3049,"completion":3049,"start":3012,"enrollment":6539,"conditions":25047,"interventions":25048},[86],[1504,6541],[61,6543,6544],{"nctId":9810,"briefTitle":9811,"status":103,"phases":25050,"primaryCompletion":1473,"completion":1596,"start":3069,"enrollment":4005,"conditions":25051,"interventions":25052},[86],[9814,9815,9816,9817],[1722,9819,6543],{"trials":25054,"activeCount":97},[],{"trials":25056,"activeCount":97},[],{"trials":25058,"activeCount":97},[],{"intervention":14581,"totalTrials":947,"cells":25060},{"EARLY_PHASE1":25061,"PHASE1":25063,"PHASE2":25071,"PHASE3":25077,"PHASE4":25079,"NA":25081},{"trials":25062,"activeCount":97},[],{"trials":25064,"activeCount":97},[25065],{"nctId":25066,"briefTitle":25067,"status":103,"phases":25068,"primaryCompletion":3837,"completion":3837,"start":3029,"enrollment":1082,"conditions":25069,"interventions":25070},"NCT01247363","A Study of LY2608204 in Patients With Type 2 Diabetes",[85],[18],[14581],{"trials":25072,"activeCount":97},[25073],{"nctId":14576,"briefTitle":14577,"status":384,"phases":25074,"primaryCompletion":2898,"completion":2898,"start":3494,"enrollment":2502,"conditions":25075,"interventions":25076},[86],[18],[14581,7071],{"trials":25078,"activeCount":97},[],{"trials":25080,"activeCount":97},[],{"trials":25082,"activeCount":97},[],{"intervention":25084,"totalTrials":947,"cells":25085},"Enzastaurin HCl",{"EARLY_PHASE1":25086,"PHASE1":25088,"PHASE2":25090,"PHASE3":25106,"PHASE4":25108,"NA":25110},{"trials":25087,"activeCount":97},[],{"trials":25089,"activeCount":97},[],{"trials":25091,"activeCount":97},[25092,25099],{"nctId":25093,"briefTitle":25094,"status":103,"phases":25095,"primaryCompletion":3338,"completion":3338,"start":14103,"enrollment":165,"conditions":25096,"interventions":25098},"NCT00192114","Enzastaurin for Patients With Metastatic Colorectal Cancer",[86],[25097],"Colonic Neoplasms",[25084],{"nctId":25100,"briefTitle":25101,"status":103,"phases":25102,"completion":2875,"start":3218,"enrollment":2088,"conditions":25103,"interventions":25104},"NCT00105092","Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.",[86],[2903],[25105],"Enzastaurin HCL",{"trials":25107,"activeCount":97},[],{"trials":25109,"activeCount":97},[],{"trials":25111,"activeCount":97},[],{"intervention":25113,"totalTrials":947,"cells":25114},"LY3451838",{"EARLY_PHASE1":25115,"PHASE1":25117,"PHASE2":25125,"PHASE3":25134,"PHASE4":25136,"NA":25138},{"trials":25116,"activeCount":97},[],{"trials":25118,"activeCount":97},[25119],{"nctId":25120,"briefTitle":25121,"status":103,"phases":25122,"primaryCompletion":232,"completion":232,"start":900,"enrollment":1451,"conditions":25123,"interventions":25124},"NCT03692949","A Study of LY3451838 in Healthy Participants",[85],[15],[25113,25113,25113,25113,25113,25113,25113],{"trials":25126,"activeCount":97},[25127],{"nctId":25128,"briefTitle":25129,"status":103,"phases":25130,"primaryCompletion":23821,"completion":23821,"start":25131,"enrollment":280,"conditions":25132,"interventions":25133},"NCT04498910","A Study of LY3451838 in Participants With Migraine",[86],"2020-11-16",[7486],[25113],{"trials":25135,"activeCount":97},[],{"trials":25137,"activeCount":97},[],{"trials":25139,"activeCount":97},[],{"intervention":9831,"totalTrials":947,"cells":25141},{"EARLY_PHASE1":25142,"PHASE1":25144,"PHASE2":25146,"PHASE3":25158,"PHASE4":25160,"NA":25162},{"trials":25143,"activeCount":97},[],{"trials":25145,"activeCount":97},[],{"trials":25147,"activeCount":97},[25148,25154],{"nctId":25149,"briefTitle":25150,"status":384,"phases":25151,"primaryCompletion":4258,"completion":4258,"start":3216,"enrollment":874,"conditions":25152,"interventions":25153},"NCT00415155","A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma",[85,86],[2608],[9831],{"nctId":9825,"briefTitle":9826,"status":103,"phases":25155,"primaryCompletion":4160,"completion":3838,"start":2956,"enrollment":9828,"conditions":25156,"interventions":25157},[86],[1610],[1722,9831],{"trials":25159,"activeCount":97},[],{"trials":25161,"activeCount":97},[],{"trials":25163,"activeCount":97},[],{"intervention":3623,"totalTrials":947,"cells":25165},{"EARLY_PHASE1":25166,"PHASE1":25168,"PHASE2":25174,"PHASE3":25180,"PHASE4":25182,"NA":25184},{"trials":25167,"activeCount":97},[],{"trials":25169,"activeCount":97},[25170],{"nctId":6147,"briefTitle":6148,"status":103,"phases":25171,"primaryCompletion":4420,"completion":6150,"start":6151,"enrollment":2939,"conditions":25172,"interventions":25173},[85],[1466],[3623,1538,1761],{"trials":25175,"activeCount":97},[25176],{"nctId":3613,"briefTitle":3614,"status":103,"phases":25177,"primaryCompletion":3616,"completion":3617,"start":3545,"enrollment":3618,"conditions":25178,"interventions":25179},[85,86],[3569,3620,3621],[3623,1512,1511],{"trials":25181,"activeCount":97},[],{"trials":25183,"activeCount":97},[],{"trials":25185,"activeCount":97},[],{"intervention":8220,"totalTrials":947,"cells":25187},{"EARLY_PHASE1":25188,"PHASE1":25190,"PHASE2":25192,"PHASE3":25206,"PHASE4":25208,"NA":25210},{"trials":25189,"activeCount":97},[],{"trials":25191,"activeCount":97},[],{"trials":25193,"activeCount":97},[25194,25198],{"nctId":8214,"briefTitle":8215,"status":103,"phases":25195,"primaryCompletion":8217,"completion":2864,"start":3338,"enrollment":7145,"conditions":25196,"interventions":25197},[86],[1903],[3106,8220,1906],{"nctId":25199,"briefTitle":25200,"status":103,"phases":25201,"primaryCompletion":3685,"completion":3685,"start":3338,"enrollment":290,"conditions":25202,"interventions":25203},"NCT00620321","A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[86],[23247],[8220,25204,25205],"cytarabine","idarubicin",{"trials":25207,"activeCount":97},[],{"trials":25209,"activeCount":97},[],{"trials":25211,"activeCount":97},[],{"intervention":25213,"totalTrials":947,"cells":25214},"LY2599506",{"EARLY_PHASE1":25215,"PHASE1":25217,"PHASE2":25219,"PHASE3":25234,"PHASE4":25236,"NA":25238},{"trials":25216,"activeCount":97},[],{"trials":25218,"activeCount":97},[],{"trials":25220,"activeCount":97},[25221,25227],{"nctId":25222,"briefTitle":25223,"status":999,"phases":25224,"primaryCompletion":2899,"completion":2899,"start":6883,"enrollment":2340,"conditions":25225,"interventions":25226},"NCT01024244","A Study of LY2599506 in Patients With Type 2 Diabetes",[86],[18],[25213],{"nctId":25228,"briefTitle":25229,"status":999,"phases":25230,"primaryCompletion":2918,"completion":2918,"start":3087,"enrollment":280,"conditions":25231,"interventions":25232},"NCT01029795","A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus",[86],[18],[25213,25233],"Glyburide",{"trials":25235,"activeCount":97},[],{"trials":25237,"activeCount":97},[],{"trials":25239,"activeCount":97},[],{"intervention":6442,"totalTrials":947,"cells":25241},{"EARLY_PHASE1":25242,"PHASE1":25244,"PHASE2":25250,"PHASE3":25261,"PHASE4":25263,"NA":25265},{"trials":25243,"activeCount":97},[],{"trials":25245,"activeCount":97},[25246],{"nctId":6435,"briefTitle":6436,"status":999,"phases":25247,"primaryCompletion":5229,"completion":6438,"start":6439,"enrollment":28,"conditions":25248,"interventions":25249},[85],[2589],[6442,61,1669],{"trials":25251,"activeCount":97},[25252],{"nctId":25253,"briefTitle":25254,"status":999,"phases":25255,"primaryCompletion":25256,"completion":25256,"start":25257,"enrollment":2347,"conditions":25258,"interventions":25260},"NCT04342897","A Study of LY3127804 in Participants With COVID-19",[86],"2020-10-12","2020-04-20",[5284,25259],"Pneumonia",[6442],{"trials":25262,"activeCount":97},[],{"trials":25264,"activeCount":97},[],{"trials":25266,"activeCount":97},[],{"intervention":25268,"totalTrials":947,"cells":25269},"LY3561774",{"EARLY_PHASE1":25270,"PHASE1":25272,"PHASE2":25281,"PHASE3":25295,"PHASE4":25297,"NA":25299},{"trials":25271,"activeCount":97},[],{"trials":25273,"activeCount":97},[25274],{"nctId":25275,"briefTitle":25276,"status":103,"phases":25277,"primaryCompletion":22193,"completion":22193,"start":25278,"enrollment":14469,"conditions":25279,"interventions":25280},"NCT04644809","A Study of LY3561774 in Participants With Dyslipidemia",[85],"2020-11-30",[18052],[25268],{"trials":25282,"activeCount":97},[25283],{"nctId":25284,"briefTitle":25285,"status":103,"phases":25286,"primaryCompletion":25287,"completion":25288,"start":25289,"enrollment":924,"conditions":25290,"interventions":25294},"NCT05256654","A Study of LY3561774 in Participants With Mixed Dyslipidemia",[86],"2024-03-04","2024-05-23","2022-07-20",[18052,25291,25292,25293],"Lipid Metabolism Disorders","Metabolic Diseases","Hyperlipoproteinemia",[25268],{"trials":25296,"activeCount":97},[],{"trials":25298,"activeCount":97},[],{"trials":25300,"activeCount":97},[],{"intervention":17104,"totalTrials":947,"cells":25302},{"EARLY_PHASE1":25303,"PHASE1":25305,"PHASE2":25311,"PHASE3":25317,"PHASE4":25319,"NA":25321},{"trials":25304,"activeCount":97},[],{"trials":25306,"activeCount":97},[25307],{"nctId":17099,"briefTitle":17100,"status":103,"phases":25308,"primaryCompletion":12925,"completion":12925,"start":13010,"enrollment":4353,"conditions":25309,"interventions":25310},[85],[15],[17046,17104],{"trials":25312,"activeCount":97},[25313],{"nctId":22883,"briefTitle":22884,"status":103,"phases":25314,"primaryCompletion":3251,"completion":4098,"start":3217,"enrollment":4353,"conditions":25315,"interventions":25316},[86],[2824,1503],[3117,1181,17104],{"trials":25318,"activeCount":97},[],{"trials":25320,"activeCount":97},[],{"trials":25322,"activeCount":97},[],{"intervention":25324,"totalTrials":947,"cells":25325},"LY451395",{"EARLY_PHASE1":25326,"PHASE1":25328,"PHASE2":25330,"PHASE3":25344,"PHASE4":25346,"NA":25348},{"trials":25327,"activeCount":97},[],{"trials":25329,"activeCount":97},[],{"trials":25331,"activeCount":97},[25332,25338],{"nctId":25333,"briefTitle":25334,"status":103,"phases":25335,"completion":3710,"start":3274,"enrollment":776,"conditions":25336,"interventions":25337},"NCT00051909","Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease",[86],[4040],[25324],{"nctId":25339,"briefTitle":25340,"status":103,"phases":25341,"primaryCompletion":3020,"completion":3020,"start":3103,"enrollment":1803,"conditions":25342,"interventions":25343},"NCT00843518","Treatment for Aggression and Agitation in Patients With Alzheimer's Disease",[86],[4040],[25324],{"trials":25345,"activeCount":97},[],{"trials":25347,"activeCount":97},[],{"trials":25349,"activeCount":97},[],{"intervention":14847,"totalTrials":947,"cells":25351},{"EARLY_PHASE1":25352,"PHASE1":25354,"PHASE2":25356,"PHASE3":25369,"PHASE4":25371,"NA":25373},{"trials":25353,"activeCount":97},[],{"trials":25355,"activeCount":97},[],{"trials":25357,"activeCount":97},[25358,25362],{"nctId":14840,"briefTitle":14841,"status":103,"phases":25359,"completion":3337,"start":2909,"enrollment":14843,"conditions":25360,"interventions":25361},[86],[14845],[14847,14036],{"nctId":25363,"briefTitle":25364,"status":103,"phases":25365,"primaryCompletion":3059,"completion":3059,"start":2928,"enrollment":377,"conditions":25366,"interventions":25368},"NCT00805441","A Study in the Treatment of Alcohol Dependence.",[86],[25367],"Alcohol Dependence",[14847],{"trials":25370,"activeCount":97},[],{"trials":25372,"activeCount":97},[],{"trials":25374,"activeCount":97},[],{"intervention":14669,"totalTrials":947,"cells":25376},{"EARLY_PHASE1":25377,"PHASE1":25379,"PHASE2":25381,"PHASE3":25394,"PHASE4":25396,"NA":25398},{"trials":25378,"activeCount":97},[],{"trials":25380,"activeCount":97},[],{"trials":25382,"activeCount":97},[25383,25387],{"nctId":14661,"briefTitle":14662,"status":103,"phases":25384,"primaryCompletion":2956,"completion":2918,"start":2974,"enrollment":14664,"conditions":25385,"interventions":25386},[86],[14666],[14652,14668,14669,14670],{"nctId":25388,"briefTitle":25389,"status":103,"phases":25390,"primaryCompletion":3685,"completion":3685,"start":2974,"enrollment":3219,"conditions":25391,"interventions":25393},"NCT00790790","A Study in the Treatment of Osteoarthritis Knee Pain",[86],[25392],"Osteoarthritis Knee Pain",[14669,14670],{"trials":25395,"activeCount":97},[],{"trials":25397,"activeCount":97},[],{"trials":25399,"activeCount":97},[],{"intervention":14670,"totalTrials":947,"cells":25401},{"EARLY_PHASE1":25402,"PHASE1":25404,"PHASE2":25406,"PHASE3":25416,"PHASE4":25418,"NA":25420},{"trials":25403,"activeCount":97},[],{"trials":25405,"activeCount":97},[],{"trials":25407,"activeCount":97},[25408,25412],{"nctId":14661,"briefTitle":14662,"status":103,"phases":25409,"primaryCompletion":2956,"completion":2918,"start":2974,"enrollment":14664,"conditions":25410,"interventions":25411},[86],[14666],[14652,14668,14669,14670],{"nctId":25388,"briefTitle":25389,"status":103,"phases":25413,"primaryCompletion":3685,"completion":3685,"start":2974,"enrollment":3219,"conditions":25414,"interventions":25415},[86],[25392],[14669,14670],{"trials":25417,"activeCount":97},[],{"trials":25419,"activeCount":97},[],{"trials":25421,"activeCount":97},[],{"intervention":25423,"totalTrials":947,"cells":25424},"arzoxifene hydrochloride",{"EARLY_PHASE1":25425,"PHASE1":25427,"PHASE2":25429,"PHASE3":25446,"PHASE4":25448,"NA":25450},{"trials":25426,"activeCount":97},[],{"trials":25428,"activeCount":97},[],{"trials":25430,"activeCount":97},[25431,25438],{"nctId":25432,"briefTitle":25433,"status":103,"phases":25434,"completion":15163,"start":25435,"conditions":25436,"interventions":25437},"NCT00003669","Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer",[86],"1998-11",[1572],[25423],{"nctId":25439,"briefTitle":25440,"status":103,"phases":25441,"completion":14646,"start":25442,"conditions":25443,"interventions":25445},"NCT00003670","Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer",[86],"1998-10",[2584,25444],"Primary Peritoneal Cavity Cancer",[25423],{"trials":25447,"activeCount":97},[],{"trials":25449,"activeCount":97},[],{"trials":25451,"activeCount":97},[],{"intervention":8228,"totalTrials":947,"cells":25453},{"EARLY_PHASE1":25454,"PHASE1":25456,"PHASE2":25458,"PHASE3":25468,"PHASE4":25470,"NA":25472},{"trials":25455,"activeCount":97},[],{"trials":25457,"activeCount":97},[],{"trials":25459,"activeCount":97},[25460,25464],{"nctId":8222,"briefTitle":8223,"status":103,"phases":25461,"primaryCompletion":3494,"completion":3494,"start":3216,"enrollment":8225,"conditions":25462,"interventions":25463},[86],[1903],[2870,8228,1906,3117],{"nctId":8230,"briefTitle":8231,"status":103,"phases":25465,"primaryCompletion":2898,"completion":4955,"start":8233,"enrollment":8234,"conditions":25466,"interventions":25467},[86],[1903],[2545,8228,1906],{"trials":25469,"activeCount":97},[],{"trials":25471,"activeCount":97},[],{"trials":25473,"activeCount":97},[],{"intervention":25475,"totalTrials":947,"cells":25476},"Peresolimab",{"EARLY_PHASE1":25477,"PHASE1":25479,"PHASE2":25488,"PHASE3":25506,"PHASE4":25508,"NA":25510},{"trials":25478,"activeCount":97},[],{"trials":25480,"activeCount":97},[25481],{"nctId":25482,"briefTitle":25483,"status":103,"phases":25484,"primaryCompletion":1299,"completion":1299,"start":25485,"enrollment":3654,"conditions":25486,"interventions":25487},"NCT05959109","A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants",[85],"2023-07-21",[15],[25475],{"trials":25489,"activeCount":97},[25490],{"nctId":25491,"briefTitle":25492,"status":999,"phases":25493,"primaryCompletion":25494,"completion":25495,"start":845,"enrollment":25496,"conditions":25497,"interventions":25505},"NCT05516758","A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis",[86],"2023-11-20","2025-01-17",491,[5218,25498,25499,25500,25501,25502,25503,25504],"Arthritis","Joint Diseases","Musculoskeletal Diseases","Rheumatic Diseases","Connective Tissue Diseases","Autoimmune Diseases","Immune System Diseases",[25475],{"trials":25507,"activeCount":97},[],{"trials":25509,"activeCount":97},[],{"trials":25511,"activeCount":97},[],{"intervention":25513,"totalTrials":947,"cells":25514},"LOXO-305",{"EARLY_PHASE1":25515,"PHASE1":25517,"PHASE2":25527,"PHASE3":25538,"PHASE4":25540,"NA":25542},{"trials":25516,"activeCount":97},[],{"trials":25518,"activeCount":97},[25519],{"nctId":25520,"briefTitle":25521,"status":103,"phases":25522,"primaryCompletion":3821,"completion":3821,"start":25523,"enrollment":3293,"conditions":25524,"interventions":25525},"NCT06180954","A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants",[85],"2020-09-23",[15],[25526,25513,25526],"[14C]-LOXO-305",{"trials":25528,"activeCount":97},[25529],{"nctId":25530,"briefTitle":25531,"status":103,"phases":25532,"primaryCompletion":640,"completion":6957,"start":17087,"enrollment":8967,"conditions":25533,"interventions":25537},"NCT04849416","A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)",[86],[25534,1113,1117,12830,25535,25536,1111],"Leukemia, Lymphoid","Lymphoma, B-Cell","Lymphoma, B-Cell, Marginal Zone",[25513],{"trials":25539,"activeCount":97},[],{"trials":25541,"activeCount":97},[],{"trials":25543,"activeCount":97},[],{"intervention":10753,"totalTrials":947,"cells":25545},{"EARLY_PHASE1":25546,"PHASE1":25548,"PHASE2":25550,"PHASE3":25560,"PHASE4":25562,"NA":25564},{"trials":25547,"activeCount":97},[],{"trials":25549,"activeCount":97},[],{"trials":25551,"activeCount":97},[25552,25556],{"nctId":10748,"briefTitle":10749,"status":103,"phases":25553,"primaryCompletion":3069,"completion":8217,"start":2846,"enrollment":118,"conditions":25554,"interventions":25555},[86],[2586],[3117,2520,6603,10753,10753],{"nctId":10765,"briefTitle":10766,"status":103,"phases":25557,"primaryCompletion":3685,"completion":8233,"start":3813,"enrollment":37,"conditions":25558,"interventions":25559},[86],[5657],[10770,2520,6603,10753],{"trials":25561,"activeCount":97},[],{"trials":25563,"activeCount":97},[],{"trials":25565,"activeCount":97},[],{"intervention":23609,"totalTrials":947,"cells":25567},{"EARLY_PHASE1":25568,"PHASE1":25570,"PHASE2":25579,"PHASE3":25585,"PHASE4":25587,"NA":25589},{"trials":25569,"activeCount":97},[],{"trials":25571,"activeCount":97},[25572],{"nctId":25573,"briefTitle":25574,"status":103,"phases":25575,"primaryCompletion":5022,"completion":5022,"start":3282,"enrollment":290,"conditions":25576,"interventions":25577},"NCT01821703","A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants",[85],[21],[25578,23609],"LY3045697",{"trials":25580,"activeCount":97},[25581],{"nctId":23603,"briefTitle":23604,"status":103,"phases":25582,"primaryCompletion":1596,"completion":1596,"start":3122,"enrollment":13712,"conditions":25583,"interventions":25584},[86],[23607],[10903,10904,23609],{"trials":25586,"activeCount":97},[],{"trials":25588,"activeCount":97},[],{"trials":25590,"activeCount":97},[],{"intervention":3180,"totalTrials":947,"cells":25592},{"EARLY_PHASE1":25593,"PHASE1":25595,"PHASE2":25597,"PHASE3":25607,"PHASE4":25609,"NA":25611},{"trials":25594,"activeCount":97},[],{"trials":25596,"activeCount":97},[],{"trials":25598,"activeCount":97},[25599,25603],{"nctId":3173,"briefTitle":3174,"status":103,"phases":25600,"completion":3176,"start":2834,"enrollment":3177,"conditions":25601,"interventions":25602},[86],[1589],[1511,3180,2839],{"nctId":4507,"briefTitle":4508,"status":103,"phases":25604,"completion":2856,"start":3169,"enrollment":2206,"conditions":25605,"interventions":25606},[86],[1653],[1511,3180],{"trials":25608,"activeCount":97},[],{"trials":25610,"activeCount":97},[],{"trials":25612,"activeCount":97},[],{"intervention":14057,"totalTrials":947,"cells":25614},{"EARLY_PHASE1":25615,"PHASE1":25617,"PHASE2":25619,"PHASE3":25635,"PHASE4":25637,"NA":25639},{"trials":25616,"activeCount":97},[],{"trials":25618,"activeCount":97},[],{"trials":25620,"activeCount":97},[25621,25625],{"nctId":14050,"briefTitle":14051,"status":103,"phases":25622,"primaryCompletion":3308,"completion":3308,"start":3039,"enrollment":128,"conditions":25623,"interventions":25624},[86],[14054],[14056,14057,14056,14056,14056],{"nctId":25626,"briefTitle":25627,"status":103,"phases":25628,"completion":3153,"start":4459,"enrollment":19669,"conditions":25629,"interventions":25632},"NCT00074828","New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery",[86],[25630,25631],"Total Knee Replacement","Total Hip Replacement",[25633,25634],"LY517717","enoxaparin",{"trials":25636,"activeCount":97},[],{"trials":25638,"activeCount":97},[],{"trials":25640,"activeCount":97},[],{"intervention":25642,"totalTrials":947,"cells":25643},"LY3540378",{"EARLY_PHASE1":25644,"PHASE1":25646,"PHASE2":25657,"PHASE3":25668,"PHASE4":25670,"NA":25672},{"trials":25645,"activeCount":97},[],{"trials":25647,"activeCount":97},[25648],{"nctId":25649,"briefTitle":25650,"status":103,"phases":25651,"primaryCompletion":25652,"completion":25652,"start":25653,"enrollment":25654,"conditions":25655,"interventions":25656},"NCT04768855","A Study of LY3540378 in Healthy Participants",[85],"2022-05-30","2021-03-17",134,[15],[25642,25642],{"trials":25658,"activeCount":97},[25659],{"nctId":25660,"briefTitle":25661,"status":999,"phases":25662,"primaryCompletion":10233,"completion":10233,"start":25663,"enrollment":25664,"conditions":25665,"interventions":25667},"NCT05592275","A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)",[86],"2023-02-03",332,[11174,25666],"Heart Failure With Preserved Ejection Fraction",[25642],{"trials":25669,"activeCount":97},[],{"trials":25671,"activeCount":97},[],{"trials":25673,"activeCount":97},[],{"intervention":25675,"totalTrials":314,"cells":25676},"naveglitazar",{"EARLY_PHASE1":25677,"PHASE1":25679,"PHASE2":25681,"PHASE3":25689,"PHASE4":25691,"NA":25693},{"trials":25678,"activeCount":97},[],{"trials":25680,"activeCount":97},[],{"trials":25682,"activeCount":97},[25683],{"nctId":25684,"briefTitle":25685,"status":103,"phases":25686,"conditions":25687,"interventions":25688},"NCT00065312","An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes",[86],[20302],[25675],{"trials":25690,"activeCount":97},[],{"trials":25692,"activeCount":97},[],{"trials":25694,"activeCount":97},[],{"intervention":19838,"totalTrials":314,"cells":25696},{"EARLY_PHASE1":25697,"PHASE1":25699,"PHASE2":25701,"PHASE3":25707,"PHASE4":25709,"NA":25711},{"trials":25698,"activeCount":97},[],{"trials":25700,"activeCount":97},[],{"trials":25702,"activeCount":97},[25703],{"nctId":19829,"briefTitle":19830,"status":103,"phases":25704,"primaryCompletion":7530,"completion":19832,"start":19833,"enrollment":19834,"conditions":25705,"interventions":25706},[86],[5284],[19837,19820,19838,19839],{"trials":25708,"activeCount":97},[],{"trials":25710,"activeCount":97},[],{"trials":25712,"activeCount":97},[],{"intervention":19839,"totalTrials":314,"cells":25714},{"EARLY_PHASE1":25715,"PHASE1":25717,"PHASE2":25719,"PHASE3":25725,"PHASE4":25727,"NA":25729},{"trials":25716,"activeCount":97},[],{"trials":25718,"activeCount":97},[],{"trials":25720,"activeCount":97},[25721],{"nctId":19829,"briefTitle":19830,"status":103,"phases":25722,"primaryCompletion":7530,"completion":19832,"start":19833,"enrollment":19834,"conditions":25723,"interventions":25724},[86],[5284],[19837,19820,19838,19839],{"trials":25726,"activeCount":97},[],{"trials":25728,"activeCount":97},[],{"trials":25730,"activeCount":97},[],{"intervention":1720,"totalTrials":314,"cells":25732},{"EARLY_PHASE1":25733,"PHASE1":25735,"PHASE2":25737,"PHASE3":25743,"PHASE4":25745,"NA":25747},{"trials":25734,"activeCount":97},[],{"trials":25736,"activeCount":97},[],{"trials":25738,"activeCount":97},[25739],{"nctId":1711,"briefTitle":1712,"status":999,"phases":25740,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":425,"conditions":25741,"interventions":25742},[85,86],[1717,1718,1490],[1720,48,1541,1721,1722],{"trials":25744,"activeCount":97},[],{"trials":25746,"activeCount":97},[],{"trials":25748,"activeCount":97},[],{"intervention":25750,"totalTrials":314,"cells":25751},"Zagotenemab",{"EARLY_PHASE1":25752,"PHASE1":25754,"PHASE2":25756,"PHASE3":25767,"PHASE4":25769,"NA":25771},{"trials":25753,"activeCount":97},[],{"trials":25755,"activeCount":97},[],{"trials":25757,"activeCount":97},[25758],{"nctId":25759,"briefTitle":25760,"status":103,"phases":25761,"primaryCompletion":25762,"completion":23071,"start":25763,"enrollment":14826,"conditions":25764,"interventions":25766},"NCT03518073","A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease",[86],"2021-08-23","2018-04-30",[25765],"Alzheimer Disease (AD)",[25750],{"trials":25768,"activeCount":97},[],{"trials":25770,"activeCount":97},[],{"trials":25772,"activeCount":97},[],{"intervention":19381,"totalTrials":314,"cells":25774},{"EARLY_PHASE1":25775,"PHASE1":25777,"PHASE2":25779,"PHASE3":25785,"PHASE4":25787,"NA":25789},{"trials":25776,"activeCount":97},[],{"trials":25778,"activeCount":97},[],{"trials":25780,"activeCount":97},[25781],{"nctId":19375,"briefTitle":19376,"status":103,"phases":25782,"primaryCompletion":1475,"completion":5354,"start":2964,"enrollment":5355,"conditions":25783,"interventions":25784},[86],[17378],[19380,19381,17380],{"trials":25786,"activeCount":97},[],{"trials":25788,"activeCount":97},[],{"trials":25790,"activeCount":97},[],{"intervention":4179,"totalTrials":314,"cells":25792},{"EARLY_PHASE1":25793,"PHASE1":25795,"PHASE2":25797,"PHASE3":25803,"PHASE4":25805,"NA":25807},{"trials":25794,"activeCount":97},[],{"trials":25796,"activeCount":97},[],{"trials":25798,"activeCount":97},[25799],{"nctId":4174,"briefTitle":4175,"status":103,"phases":25800,"completion":3266,"start":3710,"enrollment":25,"conditions":25801,"interventions":25802},[86],[1490],[1511,4179,4180,4181],{"trials":25804,"activeCount":97},[],{"trials":25806,"activeCount":97},[],{"trials":25808,"activeCount":97},[],{"intervention":4180,"totalTrials":314,"cells":25810},{"EARLY_PHASE1":25811,"PHASE1":25813,"PHASE2":25815,"PHASE3":25821,"PHASE4":25823,"NA":25825},{"trials":25812,"activeCount":97},[],{"trials":25814,"activeCount":97},[],{"trials":25816,"activeCount":97},[25817],{"nctId":4174,"briefTitle":4175,"status":103,"phases":25818,"completion":3266,"start":3710,"enrollment":25,"conditions":25819,"interventions":25820},[86],[1490],[1511,4179,4180,4181],{"trials":25822,"activeCount":97},[],{"trials":25824,"activeCount":97},[],{"trials":25826,"activeCount":97},[],{"intervention":25828,"totalTrials":314,"cells":25829},"Pemetrexed 500 mg\u002Fm2",{"EARLY_PHASE1":25830,"PHASE1":25832,"PHASE2":25834,"PHASE3":25843,"PHASE4":25845,"NA":25847},{"trials":25831,"activeCount":97},[],{"trials":25833,"activeCount":97},[],{"trials":25835,"activeCount":97},[25836],{"nctId":25837,"briefTitle":25838,"status":103,"phases":25839,"primaryCompletion":3132,"completion":3132,"start":2948,"enrollment":13861,"conditions":25840,"interventions":25841},"NCT00191191","To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)",[86],[1610],[25828,25842],"Pemetrexed 1000 mg\u002Fm2",{"trials":25844,"activeCount":97},[],{"trials":25846,"activeCount":97},[],{"trials":25848,"activeCount":97},[],{"intervention":25842,"totalTrials":314,"cells":25850},{"EARLY_PHASE1":25851,"PHASE1":25853,"PHASE2":25855,"PHASE3":25861,"PHASE4":25863,"NA":25865},{"trials":25852,"activeCount":97},[],{"trials":25854,"activeCount":97},[],{"trials":25856,"activeCount":97},[25857],{"nctId":25837,"briefTitle":25838,"status":103,"phases":25858,"primaryCompletion":3132,"completion":3132,"start":2948,"enrollment":13861,"conditions":25859,"interventions":25860},[86],[1610],[25828,25842],{"trials":25862,"activeCount":97},[],{"trials":25864,"activeCount":97},[],{"trials":25866,"activeCount":97},[],{"intervention":25868,"totalTrials":314,"cells":25869},"LY317615",{"EARLY_PHASE1":25870,"PHASE1":25872,"PHASE2":25874,"PHASE3":25882,"PHASE4":25884,"NA":25886},{"trials":25871,"activeCount":97},[],{"trials":25873,"activeCount":97},[],{"trials":25875,"activeCount":97},[25876],{"nctId":25877,"briefTitle":25878,"status":103,"phases":25879,"primaryCompletion":3320,"completion":3320,"start":3635,"enrollment":224,"conditions":25880,"interventions":25881},"NCT00042666","A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.",[86],[1608],[25868],{"trials":25883,"activeCount":97},[],{"trials":25885,"activeCount":97},[],{"trials":25887,"activeCount":97},[],{"intervention":25889,"totalTrials":314,"cells":25890},"LY2382770",{"EARLY_PHASE1":25891,"PHASE1":25893,"PHASE2":25895,"PHASE3":25904,"PHASE4":25906,"NA":25908},{"trials":25892,"activeCount":97},[],{"trials":25894,"activeCount":97},[],{"trials":25896,"activeCount":97},[25897],{"nctId":25898,"briefTitle":25899,"status":999,"phases":25900,"primaryCompletion":4098,"completion":7316,"start":2899,"enrollment":7256,"conditions":25901,"interventions":25903},"NCT01113801","A Study in Participants With Diabetic Kidney Disease",[86],[5101,23876,25902],"Diabetic Glomerulosclerosis",[25889],{"trials":25905,"activeCount":97},[],{"trials":25907,"activeCount":97},[],{"trials":25909,"activeCount":97},[],{"intervention":348,"totalTrials":314,"cells":25911},{"EARLY_PHASE1":25912,"PHASE1":25914,"PHASE2":25916,"PHASE3":25922,"PHASE4":25924,"NA":25926},{"trials":25913,"activeCount":97},[],{"trials":25915,"activeCount":97},[],{"trials":25917,"activeCount":97},[25918],{"nctId":339,"briefTitle":340,"status":103,"phases":25919,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":25920,"interventions":25921},[86],[24],[92,348,273,349],{"trials":25923,"activeCount":97},[],{"trials":25925,"activeCount":97},[],{"trials":25927,"activeCount":97},[],{"intervention":349,"totalTrials":314,"cells":25929},{"EARLY_PHASE1":25930,"PHASE1":25932,"PHASE2":25934,"PHASE3":25940,"PHASE4":25942,"NA":25944},{"trials":25931,"activeCount":97},[],{"trials":25933,"activeCount":97},[],{"trials":25935,"activeCount":97},[25936],{"nctId":339,"briefTitle":340,"status":103,"phases":25937,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":25938,"interventions":25939},[86],[24],[92,348,273,349],{"trials":25941,"activeCount":97},[],{"trials":25943,"activeCount":97},[],{"trials":25945,"activeCount":97},[],{"intervention":4206,"totalTrials":314,"cells":25947},{"EARLY_PHASE1":25948,"PHASE1":25950,"PHASE2":25952,"PHASE3":25958,"PHASE4":25960,"NA":25962},{"trials":25949,"activeCount":97},[],{"trials":25951,"activeCount":97},[],{"trials":25953,"activeCount":97},[25954],{"nctId":4201,"briefTitle":4202,"status":103,"phases":25955,"completion":3185,"start":2909,"enrollment":3125,"conditions":25956,"interventions":25957},[85,86],[2622],[1612,1511,4206],{"trials":25959,"activeCount":97},[],{"trials":25961,"activeCount":97},[],{"trials":25963,"activeCount":97},[],{"intervention":25965,"totalTrials":314,"cells":25966},"Pemetrexed - Before Protocol Amendment",{"EARLY_PHASE1":25967,"PHASE1":25969,"PHASE2":25971,"PHASE3":25980,"PHASE4":25982,"NA":25984},{"trials":25968,"activeCount":97},[],{"trials":25970,"activeCount":97},[],{"trials":25972,"activeCount":97},[25973],{"nctId":25974,"briefTitle":25975,"status":103,"phases":25976,"primaryCompletion":3320,"completion":3320,"start":3133,"enrollment":2733,"conditions":25977,"interventions":25978},"NCT00370292","Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[86],[1694],[25965,25979],"Pemetrexed - After Protocol Amendment",{"trials":25981,"activeCount":97},[],{"trials":25983,"activeCount":97},[],{"trials":25985,"activeCount":97},[],{"intervention":25979,"totalTrials":314,"cells":25987},{"EARLY_PHASE1":25988,"PHASE1":25990,"PHASE2":25992,"PHASE3":25998,"PHASE4":26000,"NA":26002},{"trials":25989,"activeCount":97},[],{"trials":25991,"activeCount":97},[],{"trials":25993,"activeCount":97},[25994],{"nctId":25974,"briefTitle":25975,"status":103,"phases":25995,"primaryCompletion":3320,"completion":3320,"start":3133,"enrollment":2733,"conditions":25996,"interventions":25997},[86],[1694],[25965,25979],{"trials":25999,"activeCount":97},[],{"trials":26001,"activeCount":97},[],{"trials":26003,"activeCount":97},[],{"intervention":26005,"totalTrials":314,"cells":26006},"LY041001",{"EARLY_PHASE1":26007,"PHASE1":26009,"PHASE2":26011,"PHASE3":26019,"PHASE4":26021,"NA":26023},{"trials":26008,"activeCount":97},[],{"trials":26010,"activeCount":97},[],{"trials":26012,"activeCount":97},[26013],{"nctId":26014,"briefTitle":26015,"status":103,"phases":26016,"completion":2833,"start":3646,"enrollment":6509,"conditions":26017,"interventions":26018},"NCT00099515","Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)",[86],[18],[26005,26005],{"trials":26020,"activeCount":97},[],{"trials":26022,"activeCount":97},[],{"trials":26024,"activeCount":97},[],{"intervention":26026,"totalTrials":314,"cells":26027},"LY6249492",{"EARLY_PHASE1":26028,"PHASE1":26030,"PHASE2":26032,"PHASE3":26041,"PHASE4":26043,"NA":26045},{"trials":26029,"activeCount":97},[],{"trials":26031,"activeCount":97},[],{"trials":26033,"activeCount":97},[26034],{"nctId":26035,"briefTitle":26036,"status":999,"phases":26037,"primaryCompletion":26038,"completion":26038,"start":2138,"enrollment":314,"conditions":26039,"interventions":26040},"NCT07030868","A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes",[86],"2025-07-29",[24,27,30],[26026],{"trials":26042,"activeCount":97},[],{"trials":26044,"activeCount":97},[],{"trials":26046,"activeCount":97},[],{"intervention":14159,"totalTrials":314,"cells":26048},{"EARLY_PHASE1":26049,"PHASE1":26051,"PHASE2":26053,"PHASE3":26059,"PHASE4":26061,"NA":26063},{"trials":26050,"activeCount":97},[],{"trials":26052,"activeCount":97},[],{"trials":26054,"activeCount":97},[26055],{"nctId":14151,"briefTitle":14152,"status":103,"phases":26056,"completion":5953,"start":4634,"enrollment":658,"conditions":26057,"interventions":26058},[86],[14155,14156],[14142,14158,14159,14160],{"trials":26060,"activeCount":97},[],{"trials":26062,"activeCount":97},[],{"trials":26064,"activeCount":97},[],{"intervention":14160,"totalTrials":314,"cells":26066},{"EARLY_PHASE1":26067,"PHASE1":26069,"PHASE2":26071,"PHASE3":26077,"PHASE4":26079,"NA":26081},{"trials":26068,"activeCount":97},[],{"trials":26070,"activeCount":97},[],{"trials":26072,"activeCount":97},[26073],{"nctId":14151,"briefTitle":14152,"status":103,"phases":26074,"completion":5953,"start":4634,"enrollment":658,"conditions":26075,"interventions":26076},[86],[14155,14156],[14142,14158,14159,14160],{"trials":26078,"activeCount":97},[],{"trials":26080,"activeCount":97},[],{"trials":26082,"activeCount":97},[],{"intervention":26084,"totalTrials":314,"cells":26085},"Volenrelaxin",{"EARLY_PHASE1":26086,"PHASE1":26088,"PHASE2":26090,"PHASE3":26099,"PHASE4":26101,"NA":26103},{"trials":26087,"activeCount":97},[],{"trials":26089,"activeCount":97},[],{"trials":26091,"activeCount":97},[26092],{"nctId":26093,"briefTitle":26094,"status":384,"phases":26095,"primaryCompletion":26096,"completion":26096,"start":521,"enrollment":97,"conditions":26097,"interventions":26098},"NCT06598631","Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease",[86],"2024-12-30",[412],[26084],{"trials":26100,"activeCount":97},[],{"trials":26102,"activeCount":97},[],{"trials":26104,"activeCount":97},[],{"intervention":26106,"totalTrials":314,"cells":26107},"sPLA2 Inhibitor",{"EARLY_PHASE1":26108,"PHASE1":26110,"PHASE2":26112,"PHASE3":26120,"PHASE4":26122,"NA":26124},{"trials":26109,"activeCount":97},[],{"trials":26111,"activeCount":97},[],{"trials":26113,"activeCount":97},[26114],{"nctId":26115,"briefTitle":26116,"status":103,"phases":26117,"completion":3236,"start":6075,"enrollment":2236,"conditions":26118,"interventions":26119},"NCT00034476","A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis",[85,86],[14074],[26106],{"trials":26121,"activeCount":97},[],{"trials":26123,"activeCount":97},[],{"trials":26125,"activeCount":97},[],{"intervention":6544,"totalTrials":314,"cells":26127},{"EARLY_PHASE1":26128,"PHASE1":26130,"PHASE2":26132,"PHASE3":26138,"PHASE4":26140,"NA":26142},{"trials":26129,"activeCount":97},[],{"trials":26131,"activeCount":97},[],{"trials":26133,"activeCount":97},[26134],{"nctId":6536,"briefTitle":6537,"status":103,"phases":26135,"primaryCompletion":3049,"completion":3049,"start":3012,"enrollment":6539,"conditions":26136,"interventions":26137},[86],[1504,6541],[61,6543,6544],{"trials":26139,"activeCount":97},[],{"trials":26141,"activeCount":97},[],{"trials":26143,"activeCount":97},[],{"intervention":26145,"totalTrials":314,"cells":26146},"LY2422347",{"EARLY_PHASE1":26147,"PHASE1":26149,"PHASE2":26151,"PHASE3":26160,"PHASE4":26162,"NA":26164},{"trials":26148,"activeCount":97},[],{"trials":26150,"activeCount":97},[],{"trials":26152,"activeCount":97},[26153],{"nctId":26154,"briefTitle":26155,"status":103,"phases":26156,"completion":2930,"start":3228,"enrollment":4775,"conditions":26157,"interventions":26159},"NCT00259311","Efficacy Study of LY2422347 to Treat Insomnia",[86],[26158],"Sleep Initiation and Maintenance Disorders",[26145],{"trials":26161,"activeCount":97},[],{"trials":26163,"activeCount":97},[],{"trials":26165,"activeCount":97},[],{"intervention":20034,"totalTrials":314,"cells":26167},{"EARLY_PHASE1":26168,"PHASE1":26170,"PHASE2":26172,"PHASE3":26178,"PHASE4":26180,"NA":26182},{"trials":26169,"activeCount":97},[],{"trials":26171,"activeCount":97},[],{"trials":26173,"activeCount":97},[26174],{"nctId":20028,"briefTitle":20029,"status":103,"phases":26175,"primaryCompletion":5860,"completion":3251,"start":2974,"enrollment":20031,"conditions":26176,"interventions":26177},[86],[15444],[20034,19673],{"trials":26179,"activeCount":97},[],{"trials":26181,"activeCount":97},[],{"trials":26183,"activeCount":97},[],{"intervention":23415,"totalTrials":314,"cells":26185},{"EARLY_PHASE1":26186,"PHASE1":26188,"PHASE2":26190,"PHASE3":26196,"PHASE4":26198,"NA":26200},{"trials":26187,"activeCount":97},[],{"trials":26189,"activeCount":97},[],{"trials":26191,"activeCount":97},[26192],{"nctId":23410,"briefTitle":23411,"status":103,"phases":26193,"primaryCompletion":3545,"completion":3545,"start":6883,"enrollment":2867,"conditions":26194,"interventions":26195},[86],[3244],[23381,23415],{"trials":26197,"activeCount":97},[],{"trials":26199,"activeCount":97},[],{"trials":26201,"activeCount":97},[],{"intervention":26203,"totalTrials":314,"cells":26204},"LY2525623 Intravenous",{"EARLY_PHASE1":26205,"PHASE1":26207,"PHASE2":26209,"PHASE3":26218,"PHASE4":26220,"NA":26222},{"trials":26206,"activeCount":97},[],{"trials":26208,"activeCount":97},[],{"trials":26210,"activeCount":97},[26211],{"nctId":26212,"briefTitle":26213,"status":999,"phases":26214,"primaryCompletion":2956,"completion":3012,"start":6883,"enrollment":4323,"conditions":26215,"interventions":26216},"NCT01018810","A Study for Adults With Plaque Psoriasis",[86],[447],[26203,26217],"LY2525623 Subcutaneous",{"trials":26219,"activeCount":97},[],{"trials":26221,"activeCount":97},[],{"trials":26223,"activeCount":97},[],{"intervention":26217,"totalTrials":314,"cells":26225},{"EARLY_PHASE1":26226,"PHASE1":26228,"PHASE2":26230,"PHASE3":26236,"PHASE4":26238,"NA":26240},{"trials":26227,"activeCount":97},[],{"trials":26229,"activeCount":97},[],{"trials":26231,"activeCount":97},[26232],{"nctId":26212,"briefTitle":26213,"status":999,"phases":26233,"primaryCompletion":2956,"completion":3012,"start":6883,"enrollment":4323,"conditions":26234,"interventions":26235},[86],[447],[26203,26217],{"trials":26237,"activeCount":97},[],{"trials":26239,"activeCount":97},[],{"trials":26241,"activeCount":97},[],{"intervention":7703,"totalTrials":314,"cells":26243},{"EARLY_PHASE1":26244,"PHASE1":26246,"PHASE2":26248,"PHASE3":26254,"PHASE4":26256,"NA":26258},{"trials":26245,"activeCount":97},[],{"trials":26247,"activeCount":97},[],{"trials":26249,"activeCount":97},[26250],{"nctId":7696,"briefTitle":7697,"status":103,"phases":26251,"primaryCompletion":4955,"completion":4955,"start":3266,"enrollment":7699,"conditions":26252,"interventions":26253},[86],[7701],[2979,2560,7703,7704],{"trials":26255,"activeCount":97},[],{"trials":26257,"activeCount":97},[],{"trials":26259,"activeCount":97},[],{"intervention":7704,"totalTrials":314,"cells":26261},{"EARLY_PHASE1":26262,"PHASE1":26264,"PHASE2":26266,"PHASE3":26272,"PHASE4":26274,"NA":26276},{"trials":26263,"activeCount":97},[],{"trials":26265,"activeCount":97},[],{"trials":26267,"activeCount":97},[26268],{"nctId":7696,"briefTitle":7697,"status":103,"phases":26269,"primaryCompletion":4955,"completion":4955,"start":3266,"enrollment":7699,"conditions":26270,"interventions":26271},[86],[7701],[2979,2560,7703,7704],{"trials":26273,"activeCount":97},[],{"trials":26275,"activeCount":97},[],{"trials":26277,"activeCount":97},[],{"intervention":17922,"totalTrials":314,"cells":26279},{"EARLY_PHASE1":26280,"PHASE1":26282,"PHASE2":26284,"PHASE3":26290,"PHASE4":26292,"NA":26294},{"trials":26281,"activeCount":97},[],{"trials":26283,"activeCount":97},[],{"trials":26285,"activeCount":97},[26286],{"nctId":17917,"briefTitle":17918,"status":103,"phases":26287,"primaryCompletion":2928,"completion":2928,"start":3185,"enrollment":11714,"conditions":26288,"interventions":26289},[86],[17540,17470],[17922,17422,17923,17924,17925],{"trials":26291,"activeCount":97},[],{"trials":26293,"activeCount":97},[],{"trials":26295,"activeCount":97},[],{"intervention":17923,"totalTrials":314,"cells":26297},{"EARLY_PHASE1":26298,"PHASE1":26300,"PHASE2":26302,"PHASE3":26308,"PHASE4":26310,"NA":26312},{"trials":26299,"activeCount":97},[],{"trials":26301,"activeCount":97},[],{"trials":26303,"activeCount":97},[26304],{"nctId":17917,"briefTitle":17918,"status":103,"phases":26305,"primaryCompletion":2928,"completion":2928,"start":3185,"enrollment":11714,"conditions":26306,"interventions":26307},[86],[17540,17470],[17922,17422,17923,17924,17925],{"trials":26309,"activeCount":97},[],{"trials":26311,"activeCount":97},[],{"trials":26313,"activeCount":97},[],{"intervention":17924,"totalTrials":314,"cells":26315},{"EARLY_PHASE1":26316,"PHASE1":26318,"PHASE2":26320,"PHASE3":26326,"PHASE4":26328,"NA":26330},{"trials":26317,"activeCount":97},[],{"trials":26319,"activeCount":97},[],{"trials":26321,"activeCount":97},[26322],{"nctId":17917,"briefTitle":17918,"status":103,"phases":26323,"primaryCompletion":2928,"completion":2928,"start":3185,"enrollment":11714,"conditions":26324,"interventions":26325},[86],[17540,17470],[17922,17422,17923,17924,17925],{"trials":26327,"activeCount":97},[],{"trials":26329,"activeCount":97},[],{"trials":26331,"activeCount":97},[],{"intervention":17925,"totalTrials":314,"cells":26333},{"EARLY_PHASE1":26334,"PHASE1":26336,"PHASE2":26338,"PHASE3":26344,"PHASE4":26346,"NA":26348},{"trials":26335,"activeCount":97},[],{"trials":26337,"activeCount":97},[],{"trials":26339,"activeCount":97},[26340],{"nctId":17917,"briefTitle":17918,"status":103,"phases":26341,"primaryCompletion":2928,"completion":2928,"start":3185,"enrollment":11714,"conditions":26342,"interventions":26343},[86],[17540,17470],[17922,17422,17923,17924,17925],{"trials":26345,"activeCount":97},[],{"trials":26347,"activeCount":97},[],{"trials":26349,"activeCount":97},[],{"intervention":3603,"totalTrials":314,"cells":26351},{"EARLY_PHASE1":26352,"PHASE1":26354,"PHASE2":26356,"PHASE3":26362,"PHASE4":26364,"NA":26366},{"trials":26353,"activeCount":97},[],{"trials":26355,"activeCount":97},[],{"trials":26357,"activeCount":97},[26358],{"nctId":3597,"briefTitle":3598,"status":103,"phases":26359,"primaryCompletion":3524,"completion":3524,"start":2834,"enrollment":3041,"conditions":26360,"interventions":26361},[86],[2584,3601,3548],[3603,1669,1512],{"trials":26363,"activeCount":97},[],{"trials":26365,"activeCount":97},[],{"trials":26367,"activeCount":97},[],{"intervention":9121,"totalTrials":314,"cells":26369},{"EARLY_PHASE1":26370,"PHASE1":26372,"PHASE2":26374,"PHASE3":26380,"PHASE4":26382,"NA":26384},{"trials":26371,"activeCount":97},[],{"trials":26373,"activeCount":97},[],{"trials":26375,"activeCount":97},[26376],{"nctId":9115,"briefTitle":9116,"status":103,"phases":26377,"primaryCompletion":1474,"completion":2754,"start":3069,"enrollment":9118,"conditions":26378,"interventions":26379},[85,86],[1850],[4101,9121,1746],{"trials":26381,"activeCount":97},[],{"trials":26383,"activeCount":97},[],{"trials":26385,"activeCount":97},[],{"intervention":26387,"totalTrials":314,"cells":26388},"Testosterone Solution 2%",{"EARLY_PHASE1":26389,"PHASE1":26391,"PHASE2":26393,"PHASE3":26402,"PHASE4":26404,"NA":26406},{"trials":26390,"activeCount":97},[],{"trials":26392,"activeCount":97},[],{"trials":26394,"activeCount":97},[26395],{"nctId":26396,"briefTitle":26397,"status":103,"phases":26398,"primaryCompletion":3049,"completion":3049,"start":8217,"enrollment":3284,"conditions":26399,"interventions":26401},"NCT01419236","A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels",[86],[26400,16086],"Ejaculatory Dysfunction",[26387],{"trials":26403,"activeCount":97},[],{"trials":26405,"activeCount":97},[],{"trials":26407,"activeCount":97},[],{"intervention":23422,"totalTrials":314,"cells":26409},{"EARLY_PHASE1":26410,"PHASE1":26412,"PHASE2":26414,"PHASE3":26420,"PHASE4":26422,"NA":26424},{"trials":26411,"activeCount":97},[],{"trials":26413,"activeCount":97},[],{"trials":26415,"activeCount":97},[26416],{"nctId":23417,"briefTitle":23418,"status":103,"phases":26417,"primaryCompletion":2966,"completion":5022,"start":8217,"enrollment":3041,"conditions":26418,"interventions":26419},[86],[1571],[23381,23422,23393,23423],{"trials":26421,"activeCount":97},[],{"trials":26423,"activeCount":97},[],{"trials":26425,"activeCount":97},[],{"intervention":23423,"totalTrials":314,"cells":26427},{"EARLY_PHASE1":26428,"PHASE1":26430,"PHASE2":26432,"PHASE3":26438,"PHASE4":26440,"NA":26442},{"trials":26429,"activeCount":97},[],{"trials":26431,"activeCount":97},[],{"trials":26433,"activeCount":97},[26434],{"nctId":23417,"briefTitle":23418,"status":103,"phases":26435,"primaryCompletion":2966,"completion":5022,"start":8217,"enrollment":3041,"conditions":26436,"interventions":26437},[86],[1571],[23381,23422,23393,23423],{"trials":26439,"activeCount":97},[],{"trials":26441,"activeCount":97},[],{"trials":26443,"activeCount":97},[],{"intervention":26445,"totalTrials":314,"cells":26446},"Nasal Glucagon 1 mg",{"EARLY_PHASE1":26447,"PHASE1":26449,"PHASE2":26451,"PHASE3":26462,"PHASE4":26464,"NA":26466},{"trials":26448,"activeCount":97},[],{"trials":26450,"activeCount":97},[],{"trials":26452,"activeCount":97},[26453],{"nctId":26454,"briefTitle":26455,"status":103,"phases":26456,"primaryCompletion":3545,"completion":3545,"start":3886,"enrollment":12,"conditions":26457,"interventions":26458},"NCT01556594","Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia",[86],[139],[26445,26459,26460,26461],"Nasal Glucagon 2 mg","SC Glucagon","Nasal Glucagon 3 mg",{"trials":26463,"activeCount":97},[],{"trials":26465,"activeCount":97},[],{"trials":26467,"activeCount":97},[],{"intervention":26459,"totalTrials":314,"cells":26469},{"EARLY_PHASE1":26470,"PHASE1":26472,"PHASE2":26474,"PHASE3":26480,"PHASE4":26482,"NA":26484},{"trials":26471,"activeCount":97},[],{"trials":26473,"activeCount":97},[],{"trials":26475,"activeCount":97},[26476],{"nctId":26454,"briefTitle":26455,"status":103,"phases":26477,"primaryCompletion":3545,"completion":3545,"start":3886,"enrollment":12,"conditions":26478,"interventions":26479},[86],[139],[26445,26459,26460,26461],{"trials":26481,"activeCount":97},[],{"trials":26483,"activeCount":97},[],{"trials":26485,"activeCount":97},[],{"intervention":26460,"totalTrials":314,"cells":26487},{"EARLY_PHASE1":26488,"PHASE1":26490,"PHASE2":26492,"PHASE3":26498,"PHASE4":26500,"NA":26502},{"trials":26489,"activeCount":97},[],{"trials":26491,"activeCount":97},[],{"trials":26493,"activeCount":97},[26494],{"nctId":26454,"briefTitle":26455,"status":103,"phases":26495,"primaryCompletion":3545,"completion":3545,"start":3886,"enrollment":12,"conditions":26496,"interventions":26497},[86],[139],[26445,26459,26460,26461],{"trials":26499,"activeCount":97},[],{"trials":26501,"activeCount":97},[],{"trials":26503,"activeCount":97},[],{"intervention":26461,"totalTrials":314,"cells":26505},{"EARLY_PHASE1":26506,"PHASE1":26508,"PHASE2":26510,"PHASE3":26516,"PHASE4":26518,"NA":26520},{"trials":26507,"activeCount":97},[],{"trials":26509,"activeCount":97},[],{"trials":26511,"activeCount":97},[26512],{"nctId":26454,"briefTitle":26455,"status":103,"phases":26513,"primaryCompletion":3545,"completion":3545,"start":3886,"enrollment":12,"conditions":26514,"interventions":26515},[86],[139],[26445,26459,26460,26461],{"trials":26517,"activeCount":97},[],{"trials":26519,"activeCount":97},[],{"trials":26521,"activeCount":97},[],{"intervention":26523,"totalTrials":314,"cells":26524},"SIG-001",{"EARLY_PHASE1":26525,"PHASE1":26527,"PHASE2":26529,"PHASE3":26540,"PHASE4":26542,"NA":26544},{"trials":26526,"activeCount":97},[],{"trials":26528,"activeCount":97},[],{"trials":26530,"activeCount":97},[26531],{"nctId":26532,"briefTitle":26533,"status":999,"phases":26534,"primaryCompletion":26535,"completion":2023,"start":26536,"enrollment":1232,"conditions":26537,"interventions":26539},"NCT04541628","Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A",[85,86],"2022-10-28","2020-09-28",[26538],"Hemophilia A",[26523],{"trials":26541,"activeCount":97},[],{"trials":26543,"activeCount":97},[],{"trials":26545,"activeCount":97},[],{"intervention":8280,"totalTrials":314,"cells":26547},{"EARLY_PHASE1":26548,"PHASE1":26550,"PHASE2":26552,"PHASE3":26558,"PHASE4":26560,"NA":26562},{"trials":26549,"activeCount":97},[],{"trials":26551,"activeCount":97},[],{"trials":26553,"activeCount":97},[26554],{"nctId":8275,"briefTitle":8276,"status":103,"phases":26555,"primaryCompletion":7316,"completion":7316,"start":3545,"enrollment":5248,"conditions":26556,"interventions":26557},[86],[1114],[3034,8280,8259],{"trials":26559,"activeCount":97},[],{"trials":26561,"activeCount":97},[],{"trials":26563,"activeCount":97},[],{"intervention":15154,"totalTrials":314,"cells":26565},{"EARLY_PHASE1":26566,"PHASE1":26568,"PHASE2":26570,"PHASE3":26576,"PHASE4":26578,"NA":26580},{"trials":26567,"activeCount":97},[],{"trials":26569,"activeCount":97},[],{"trials":26571,"activeCount":97},[26572],{"nctId":15148,"briefTitle":15149,"status":999,"phases":26573,"primaryCompletion":2918,"completion":2918,"start":3050,"enrollment":15151,"conditions":26574,"interventions":26575},[86],[24],[15154,15139,2334],{"trials":26577,"activeCount":97},[],{"trials":26579,"activeCount":97},[],{"trials":26581,"activeCount":97},[],{"intervention":3033,"totalTrials":314,"cells":26583},{"EARLY_PHASE1":26584,"PHASE1":26586,"PHASE2":26588,"PHASE3":26594,"PHASE4":26596,"NA":26598},{"trials":26585,"activeCount":97},[],{"trials":26587,"activeCount":97},[],{"trials":26589,"activeCount":97},[26590],{"nctId":3024,"briefTitle":3025,"status":103,"phases":26591,"primaryCompletion":3027,"completion":3028,"start":3029,"enrollment":2733,"conditions":26592,"interventions":26593},[86],[1694],[1612,1510,3032,3033,3034],{"trials":26595,"activeCount":97},[],{"trials":26597,"activeCount":97},[],{"trials":26599,"activeCount":97},[],{"intervention":26601,"totalTrials":314,"cells":26602},"LY2196044",{"EARLY_PHASE1":26603,"PHASE1":26605,"PHASE2":26607,"PHASE3":26616,"PHASE4":26618,"NA":26620},{"trials":26604,"activeCount":97},[],{"trials":26606,"activeCount":97},[],{"trials":26608,"activeCount":97},[26609],{"nctId":26610,"briefTitle":26611,"status":103,"phases":26612,"primaryCompletion":3087,"completion":3087,"start":2974,"enrollment":26613,"conditions":26614,"interventions":26615},"NCT00804570","A Study for the Treatment of Alcohol Dependence",[86],375,[25367],[26601],{"trials":26617,"activeCount":97},[],{"trials":26619,"activeCount":97},[],{"trials":26621,"activeCount":97},[],{"intervention":26623,"totalTrials":314,"cells":26624},"Pemetrexed - Phase 1",{"EARLY_PHASE1":26625,"PHASE1":26627,"PHASE2":26629,"PHASE3":26640,"PHASE4":26642,"NA":26644},{"trials":26626,"activeCount":97},[],{"trials":26628,"activeCount":97},[],{"trials":26630,"activeCount":97},[26631],{"nctId":26632,"briefTitle":26633,"status":103,"phases":26634,"primaryCompletion":3087,"completion":3087,"start":2947,"enrollment":1302,"conditions":26635,"interventions":26636},"NCT00489359","Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer",[85,86],[2584,3621],[26623,26637,26638,26639],"Carboplatin - Phase 1","Pemetrexed - Phase 2","Carboplatin - Phase 2",{"trials":26641,"activeCount":97},[],{"trials":26643,"activeCount":97},[],{"trials":26645,"activeCount":97},[],{"intervention":26637,"totalTrials":314,"cells":26647},{"EARLY_PHASE1":26648,"PHASE1":26650,"PHASE2":26652,"PHASE3":26658,"PHASE4":26660,"NA":26662},{"trials":26649,"activeCount":97},[],{"trials":26651,"activeCount":97},[],{"trials":26653,"activeCount":97},[26654],{"nctId":26632,"briefTitle":26633,"status":103,"phases":26655,"primaryCompletion":3087,"completion":3087,"start":2947,"enrollment":1302,"conditions":26656,"interventions":26657},[85,86],[2584,3621],[26623,26637,26638,26639],{"trials":26659,"activeCount":97},[],{"trials":26661,"activeCount":97},[],{"trials":26663,"activeCount":97},[],{"intervention":26638,"totalTrials":314,"cells":26665},{"EARLY_PHASE1":26666,"PHASE1":26668,"PHASE2":26670,"PHASE3":26676,"PHASE4":26678,"NA":26680},{"trials":26667,"activeCount":97},[],{"trials":26669,"activeCount":97},[],{"trials":26671,"activeCount":97},[26672],{"nctId":26632,"briefTitle":26633,"status":103,"phases":26673,"primaryCompletion":3087,"completion":3087,"start":2947,"enrollment":1302,"conditions":26674,"interventions":26675},[85,86],[2584,3621],[26623,26637,26638,26639],{"trials":26677,"activeCount":97},[],{"trials":26679,"activeCount":97},[],{"trials":26681,"activeCount":97},[],{"intervention":26639,"totalTrials":314,"cells":26683},{"EARLY_PHASE1":26684,"PHASE1":26686,"PHASE2":26688,"PHASE3":26694,"PHASE4":26696,"NA":26698},{"trials":26685,"activeCount":97},[],{"trials":26687,"activeCount":97},[],{"trials":26689,"activeCount":97},[26690],{"nctId":26632,"briefTitle":26633,"status":103,"phases":26691,"primaryCompletion":3087,"completion":3087,"start":2947,"enrollment":1302,"conditions":26692,"interventions":26693},[85,86],[2584,3621],[26623,26637,26638,26639],{"trials":26695,"activeCount":97},[],{"trials":26697,"activeCount":97},[],{"trials":26699,"activeCount":97},[],{"intervention":26701,"totalTrials":314,"cells":26702},"LY3972406",{"EARLY_PHASE1":26703,"PHASE1":26705,"PHASE2":26707,"PHASE3":26718,"PHASE4":26720,"NA":26722},{"trials":26704,"activeCount":97},[],{"trials":26706,"activeCount":97},[],{"trials":26708,"activeCount":97},[26709],{"nctId":26710,"briefTitle":26711,"status":103,"phases":26712,"primaryCompletion":26713,"completion":26714,"start":26715,"enrollment":5015,"conditions":26716,"interventions":26717},"NCT06176768","A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis",[86],"2025-04-01","2025-05-06","2023-12-06",[926],[26701],{"trials":26719,"activeCount":97},[],{"trials":26721,"activeCount":97},[],{"trials":26723,"activeCount":97},[],{"intervention":1781,"totalTrials":314,"cells":26725},{"EARLY_PHASE1":26726,"PHASE1":26728,"PHASE2":26730,"PHASE3":26736,"PHASE4":26738,"NA":26740},{"trials":26727,"activeCount":97},[],{"trials":26729,"activeCount":97},[],{"trials":26731,"activeCount":97},[26732],{"nctId":1771,"briefTitle":1772,"status":103,"phases":26733,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":128,"conditions":26734,"interventions":26735},[85,86],[1778,1779],[48,1745,1746,1781,1782],{"trials":26737,"activeCount":97},[],{"trials":26739,"activeCount":97},[],{"trials":26741,"activeCount":97},[],{"intervention":1782,"totalTrials":314,"cells":26743},{"EARLY_PHASE1":26744,"PHASE1":26746,"PHASE2":26748,"PHASE3":26754,"PHASE4":26756,"NA":26758},{"trials":26745,"activeCount":97},[],{"trials":26747,"activeCount":97},[],{"trials":26749,"activeCount":97},[26750],{"nctId":1771,"briefTitle":1772,"status":103,"phases":26751,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":128,"conditions":26752,"interventions":26753},[85,86],[1778,1779],[48,1745,1746,1781,1782],{"trials":26755,"activeCount":97},[],{"trials":26757,"activeCount":97},[],{"trials":26759,"activeCount":97},[],{"intervention":1795,"totalTrials":314,"cells":26761},{"EARLY_PHASE1":26762,"PHASE1":26764,"PHASE2":26766,"PHASE3":26772,"PHASE4":26774,"NA":26776},{"trials":26763,"activeCount":97},[],{"trials":26765,"activeCount":97},[],{"trials":26767,"activeCount":97},[26768],{"nctId":1784,"briefTitle":1785,"status":103,"phases":26769,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1790,"conditions":26770,"interventions":26771},[86],[1792,1793],[48,1577,1468,1795],{"trials":26773,"activeCount":97},[],{"trials":26775,"activeCount":97},[],{"trials":26777,"activeCount":97},[],{"intervention":14668,"totalTrials":314,"cells":26779},{"EARLY_PHASE1":26780,"PHASE1":26782,"PHASE2":26784,"PHASE3":26790,"PHASE4":26792,"NA":26794},{"trials":26781,"activeCount":97},[],{"trials":26783,"activeCount":97},[],{"trials":26785,"activeCount":97},[26786],{"nctId":14661,"briefTitle":14662,"status":103,"phases":26787,"primaryCompletion":2956,"completion":2918,"start":2974,"enrollment":14664,"conditions":26788,"interventions":26789},[86],[14666],[14652,14668,14669,14670],{"trials":26791,"activeCount":97},[],{"trials":26793,"activeCount":97},[],{"trials":26795,"activeCount":97},[],{"intervention":26797,"totalTrials":314,"cells":26798},"Cetuximab + platinum + gemcitabine",{"EARLY_PHASE1":26799,"PHASE1":26801,"PHASE2":26803,"PHASE3":26812,"PHASE4":26814,"NA":26816},{"trials":26800,"activeCount":97},[],{"trials":26802,"activeCount":97},[],{"trials":26804,"activeCount":97},[26805],{"nctId":26806,"briefTitle":26807,"status":103,"phases":26808,"primaryCompletion":3060,"completion":3060,"start":4538,"enrollment":2080,"conditions":26809,"interventions":26810},"NCT00112346","Study of Gemcitabine\u002FPlatinum +\u002F- Cetuximab as First-Line Treatment for Patients With Advanced\u002FMetastatic Non-Small Cell Lung Cancer",[86],[2903],[26797,26811],"Platinum + Gemcitabine",{"trials":26813,"activeCount":97},[],{"trials":26815,"activeCount":97},[],{"trials":26817,"activeCount":97},[],{"intervention":26811,"totalTrials":314,"cells":26819},{"EARLY_PHASE1":26820,"PHASE1":26822,"PHASE2":26824,"PHASE3":26830,"PHASE4":26832,"NA":26834},{"trials":26821,"activeCount":97},[],{"trials":26823,"activeCount":97},[],{"trials":26825,"activeCount":97},[26826],{"nctId":26806,"briefTitle":26807,"status":103,"phases":26827,"primaryCompletion":3060,"completion":3060,"start":4538,"enrollment":2080,"conditions":26828,"interventions":26829},[86],[2903],[26797,26811],{"trials":26831,"activeCount":97},[],{"trials":26833,"activeCount":97},[],{"trials":26835,"activeCount":97},[],{"intervention":26837,"totalTrials":314,"cells":26838},"Erbitux",{"EARLY_PHASE1":26839,"PHASE1":26841,"PHASE2":26843,"PHASE3":26851,"PHASE4":26853,"NA":26855},{"trials":26840,"activeCount":97},[],{"trials":26842,"activeCount":97},[],{"trials":26844,"activeCount":97},[26845],{"nctId":26846,"briefTitle":26847,"status":103,"phases":26848,"primaryCompletion":3176,"completion":3176,"start":14199,"enrollment":445,"conditions":26849,"interventions":26850},"NCT00044863","Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma",[86],[2557,5763],[26837],{"trials":26852,"activeCount":97},[],{"trials":26854,"activeCount":97},[],{"trials":26856,"activeCount":97},[],{"intervention":26858,"totalTrials":314,"cells":26859},"Sivelestat",{"EARLY_PHASE1":26860,"PHASE1":26862,"PHASE2":26864,"PHASE3":26874,"PHASE4":26876,"NA":26878},{"trials":26861,"activeCount":97},[],{"trials":26863,"activeCount":97},[],{"trials":26865,"activeCount":97},[26866],{"nctId":26867,"briefTitle":26868,"status":103,"phases":26869,"completion":3161,"start":14413,"enrollment":2122,"conditions":26870,"interventions":26873},"NCT00036062","A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury",[85,86],[26871,26872],"Respiratory Distress Syndrome, Adult","Acute Lung Injury",[26858],{"trials":26875,"activeCount":97},[],{"trials":26877,"activeCount":97},[],{"trials":26879,"activeCount":97},[],{"intervention":22637,"totalTrials":314,"cells":26881},{"EARLY_PHASE1":26882,"PHASE1":26884,"PHASE2":26886,"PHASE3":26892,"PHASE4":26894,"NA":26896},{"trials":26883,"activeCount":97},[],{"trials":26885,"activeCount":97},[],{"trials":26887,"activeCount":97},[26888],{"nctId":22632,"briefTitle":22633,"status":103,"phases":26889,"primaryCompletion":2798,"completion":4098,"start":2929,"enrollment":128,"conditions":26890,"interventions":26891},[86],[2608],[2870,22637,6527],{"trials":26893,"activeCount":97},[],{"trials":26895,"activeCount":97},[],{"trials":26897,"activeCount":97},[],{"intervention":24455,"totalTrials":314,"cells":26899},{"EARLY_PHASE1":26900,"PHASE1":26902,"PHASE2":26904,"PHASE3":26910,"PHASE4":26912,"NA":26914},{"trials":26901,"activeCount":97},[],{"trials":26903,"activeCount":97},[],{"trials":26905,"activeCount":97},[26906],{"nctId":24448,"briefTitle":24449,"status":103,"phases":26907,"primaryCompletion":3087,"completion":3087,"start":3132,"enrollment":2406,"conditions":26908,"interventions":26909},[86],[24452,24453],[24426,24426,24455],{"trials":26911,"activeCount":97},[],{"trials":26913,"activeCount":97},[],{"trials":26915,"activeCount":97},[],{"intervention":25233,"totalTrials":314,"cells":26917},{"EARLY_PHASE1":26918,"PHASE1":26920,"PHASE2":26922,"PHASE3":26928,"PHASE4":26930,"NA":26932},{"trials":26919,"activeCount":97},[],{"trials":26921,"activeCount":97},[],{"trials":26923,"activeCount":97},[26924],{"nctId":25228,"briefTitle":25229,"status":999,"phases":26925,"primaryCompletion":2918,"completion":2918,"start":3087,"enrollment":280,"conditions":26926,"interventions":26927},[86],[18],[25213,25233],{"trials":26929,"activeCount":97},[],{"trials":26931,"activeCount":97},[],{"trials":26933,"activeCount":97},[],{"intervention":5851,"totalTrials":314,"cells":26935},{"EARLY_PHASE1":26936,"PHASE1":26938,"PHASE2":26940,"PHASE3":26946,"PHASE4":26948,"NA":26950},{"trials":26937,"activeCount":97},[],{"trials":26939,"activeCount":97},[],{"trials":26941,"activeCount":97},[26942],{"nctId":5846,"briefTitle":5847,"status":103,"phases":26943,"primaryCompletion":3152,"completion":3152,"start":3308,"enrollment":1839,"conditions":26944,"interventions":26945},[86],[1694],[2838,5851],{"trials":26947,"activeCount":97},[],{"trials":26949,"activeCount":97},[],{"trials":26951,"activeCount":97},[],{"intervention":24355,"totalTrials":314,"cells":26953},{"EARLY_PHASE1":26954,"PHASE1":26956,"PHASE2":26958,"PHASE3":26964,"PHASE4":26966,"NA":26968},{"trials":26955,"activeCount":97},[],{"trials":26957,"activeCount":97},[],{"trials":26959,"activeCount":97},[26960],{"nctId":24350,"briefTitle":24351,"status":999,"phases":26961,"primaryCompletion":2929,"completion":2929,"start":2974,"enrollment":2080,"conditions":26962,"interventions":26963},[86],[7495],[24355,17113],{"trials":26965,"activeCount":97},[],{"trials":26967,"activeCount":97},[],{"trials":26969,"activeCount":97},[],{"intervention":26971,"totalTrials":314,"cells":26972},"LY450139 dihydrate",{"EARLY_PHASE1":26973,"PHASE1":26975,"PHASE2":26977,"PHASE3":26985,"PHASE4":26987,"NA":26989},{"trials":26974,"activeCount":97},[],{"trials":26976,"activeCount":97},[],{"trials":26978,"activeCount":97},[26979],{"nctId":26980,"briefTitle":26981,"status":103,"phases":26982,"completion":3060,"start":2856,"enrollment":34,"conditions":26983,"interventions":26984},"NCT00244322","Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease",[86],[4040],[26971],{"trials":26986,"activeCount":97},[],{"trials":26988,"activeCount":97},[],{"trials":26990,"activeCount":97},[],{"intervention":23712,"totalTrials":314,"cells":26992},{"EARLY_PHASE1":26993,"PHASE1":26995,"PHASE2":26997,"PHASE3":27003,"PHASE4":27005,"NA":27007},{"trials":26994,"activeCount":97},[],{"trials":26996,"activeCount":97},[],{"trials":26998,"activeCount":97},[26999],{"nctId":23707,"briefTitle":23708,"status":103,"phases":27000,"primaryCompletion":3318,"completion":22720,"start":4160,"enrollment":174,"conditions":27001,"interventions":27002},[86],[1653],[23672,23712],{"trials":27004,"activeCount":97},[],{"trials":27006,"activeCount":97},[],{"trials":27008,"activeCount":97},[],{"intervention":27010,"totalTrials":314,"cells":27011},"LY2828360",{"EARLY_PHASE1":27012,"PHASE1":27014,"PHASE2":27016,"PHASE3":27024,"PHASE4":27026,"NA":27028},{"trials":27013,"activeCount":97},[],{"trials":27015,"activeCount":97},[],{"trials":27017,"activeCount":97},[27018],{"nctId":27019,"briefTitle":27020,"status":103,"phases":27021,"primaryCompletion":3494,"completion":3494,"start":3837,"enrollment":3041,"conditions":27022,"interventions":27023},"NCT01319929","A Study of LY2828360 in Patients With Osteoarthritic Knee Pain",[86],[2424],[27010],{"trials":27025,"activeCount":97},[],{"trials":27027,"activeCount":97},[],{"trials":27029,"activeCount":97},[],{"intervention":24701,"totalTrials":314,"cells":27031},{"EARLY_PHASE1":27032,"PHASE1":27034,"PHASE2":27036,"PHASE3":27042,"PHASE4":27044,"NA":27046},{"trials":27033,"activeCount":97},[],{"trials":27035,"activeCount":97},[],{"trials":27037,"activeCount":97},[27038],{"nctId":24695,"briefTitle":24696,"status":103,"phases":27039,"completion":2930,"start":3133,"enrollment":3546,"conditions":27040,"interventions":27041},[86],[24699],[18111,24701],{"trials":27043,"activeCount":97},[],{"trials":27045,"activeCount":97},[],{"trials":27047,"activeCount":97},[],{"intervention":27049,"totalTrials":314,"cells":27050},"olanzapine-RAIM",{"EARLY_PHASE1":27051,"PHASE1":27053,"PHASE2":27055,"PHASE3":27063,"PHASE4":27065,"NA":27067},{"trials":27052,"activeCount":97},[],{"trials":27054,"activeCount":97},[],{"trials":27056,"activeCount":97},[27057],{"nctId":27058,"briefTitle":27059,"status":103,"phases":27060,"completion":3005,"start":4266,"enrollment":5729,"conditions":27061,"interventions":27062},"NCT00316238","A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia",[86],[4897],[27049],{"trials":27064,"activeCount":97},[],{"trials":27066,"activeCount":97},[],{"trials":27068,"activeCount":97},[],{"intervention":27070,"totalTrials":314,"cells":27071},"Tadalafil- Tablet or Oral suspension",{"EARLY_PHASE1":27072,"PHASE1":27074,"PHASE2":27076,"PHASE3":27086,"PHASE4":27088,"NA":27090},{"trials":27073,"activeCount":97},[],{"trials":27075,"activeCount":97},[],{"trials":27077,"activeCount":97},[27078],{"nctId":27079,"briefTitle":27080,"status":103,"phases":27081,"primaryCompletion":6697,"completion":8755,"start":27082,"enrollment":1082,"conditions":27083,"interventions":27085},"NCT01484431","A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension",[85,86],"2012-07-17",[27084],"Pulmonary Arterial Hypertension",[27070],{"trials":27087,"activeCount":97},[],{"trials":27089,"activeCount":97},[],{"trials":27091,"activeCount":97},[],{"intervention":4489,"totalTrials":314,"cells":27093},{"EARLY_PHASE1":27094,"PHASE1":27096,"PHASE2":27098,"PHASE3":27104,"PHASE4":27106,"NA":27108},{"trials":27095,"activeCount":97},[],{"trials":27097,"activeCount":97},[],{"trials":27099,"activeCount":97},[27100],{"nctId":4484,"briefTitle":4485,"status":103,"phases":27101,"completion":3645,"start":4459,"enrollment":963,"conditions":27102,"interventions":27103},[86],[4224],[1511,4489],{"trials":27105,"activeCount":97},[],{"trials":27107,"activeCount":97},[],{"trials":27109,"activeCount":97},[],{"intervention":25204,"totalTrials":314,"cells":27111},{"EARLY_PHASE1":27112,"PHASE1":27114,"PHASE2":27116,"PHASE3":27122,"PHASE4":27124,"NA":27126},{"trials":27113,"activeCount":97},[],{"trials":27115,"activeCount":97},[],{"trials":27117,"activeCount":97},[27118],{"nctId":25199,"briefTitle":25200,"status":103,"phases":27119,"primaryCompletion":3685,"completion":3685,"start":3338,"enrollment":290,"conditions":27120,"interventions":27121},[86],[23247],[8220,25204,25205],{"trials":27123,"activeCount":97},[],{"trials":27125,"activeCount":97},[],{"trials":27127,"activeCount":97},[],{"intervention":25205,"totalTrials":314,"cells":27129},{"EARLY_PHASE1":27130,"PHASE1":27132,"PHASE2":27134,"PHASE3":27140,"PHASE4":27142,"NA":27144},{"trials":27131,"activeCount":97},[],{"trials":27133,"activeCount":97},[],{"trials":27135,"activeCount":97},[27136],{"nctId":25199,"briefTitle":25200,"status":103,"phases":27137,"primaryCompletion":3685,"completion":3685,"start":3338,"enrollment":290,"conditions":27138,"interventions":27139},[86],[23247],[8220,25204,25205],{"trials":27141,"activeCount":97},[],{"trials":27143,"activeCount":97},[],{"trials":27145,"activeCount":97},[],{"intervention":24522,"totalTrials":314,"cells":27147},{"EARLY_PHASE1":27148,"PHASE1":27150,"PHASE2":27152,"PHASE3":27158,"PHASE4":27160,"NA":27162},{"trials":27149,"activeCount":97},[],{"trials":27151,"activeCount":97},[],{"trials":27153,"activeCount":97},[27154],{"nctId":24517,"briefTitle":24518,"status":103,"phases":27155,"primaryCompletion":6093,"completion":2799,"start":3103,"enrollment":4222,"conditions":27156,"interventions":27157},[86],[2901,7754],[3072,24522],{"trials":27159,"activeCount":97},[],{"trials":27161,"activeCount":97},[],{"trials":27163,"activeCount":97},[],{"intervention":27165,"totalTrials":314,"cells":27166},"LY2189265 and Lifestyle Measures",{"EARLY_PHASE1":27167,"PHASE1":27169,"PHASE2":27171,"PHASE3":27179,"PHASE4":27181,"NA":27183},{"trials":27168,"activeCount":97},[],{"trials":27170,"activeCount":97},[],{"trials":27172,"activeCount":97},[27173],{"nctId":27174,"briefTitle":27175,"status":103,"phases":27176,"primaryCompletion":3685,"completion":3685,"start":2928,"enrollment":2778,"conditions":27177,"interventions":27178},"NCT00791479","Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes",[86],[18],[27165],{"trials":27180,"activeCount":97},[],{"trials":27182,"activeCount":97},[],{"trials":27184,"activeCount":97},[],{"intervention":9645,"totalTrials":314,"cells":27186},{"EARLY_PHASE1":27187,"PHASE1":27189,"PHASE2":27191,"PHASE3":27197,"PHASE4":27199,"NA":27201},{"trials":27188,"activeCount":97},[],{"trials":27190,"activeCount":97},[],{"trials":27192,"activeCount":97},[27193],{"nctId":9637,"briefTitle":9638,"status":999,"phases":27194,"primaryCompletion":1618,"completion":1618,"start":1475,"enrollment":9640,"conditions":27195,"interventions":27196},[86],[18],[9643,9644,1631,9645],{"trials":27198,"activeCount":97},[],{"trials":27200,"activeCount":97},[],{"trials":27202,"activeCount":97},[],{"intervention":3721,"totalTrials":314,"cells":27204},{"EARLY_PHASE1":27205,"PHASE1":27207,"PHASE2":27209,"PHASE3":27215,"PHASE4":27217,"NA":27219},{"trials":27206,"activeCount":97},[],{"trials":27208,"activeCount":97},[],{"trials":27210,"activeCount":97},[27211],{"nctId":3714,"briefTitle":3715,"status":103,"phases":27212,"primaryCompletion":3717,"completion":3250,"start":2918,"enrollment":3718,"conditions":27213,"interventions":27214},[86],[1503],[1541,1512,3721],{"trials":27216,"activeCount":97},[],{"trials":27218,"activeCount":97},[],{"trials":27220,"activeCount":97},[],{"intervention":3254,"totalTrials":314,"cells":27222},{"EARLY_PHASE1":27223,"PHASE1":27225,"PHASE2":27227,"PHASE3":27233,"PHASE4":27235,"NA":27237},{"trials":27224,"activeCount":97},[],{"trials":27226,"activeCount":97},[],{"trials":27228,"activeCount":97},[27229],{"nctId":3247,"briefTitle":3248,"status":103,"phases":27230,"primaryCompletion":3250,"completion":2799,"start":3251,"enrollment":128,"conditions":27231,"interventions":27232},[86],[1503],[1541,1510,3254],{"trials":27234,"activeCount":97},[],{"trials":27236,"activeCount":97},[],{"trials":27238,"activeCount":97},[],{"intervention":9653,"totalTrials":314,"cells":27240},{"EARLY_PHASE1":27241,"PHASE1":27243,"PHASE2":27245,"PHASE3":27251,"PHASE4":27253,"NA":27255},{"trials":27242,"activeCount":97},[],{"trials":27244,"activeCount":97},[],{"trials":27246,"activeCount":97},[27247],{"nctId":9647,"briefTitle":9648,"status":999,"phases":27248,"primaryCompletion":1473,"completion":1473,"start":3049,"enrollment":874,"conditions":27249,"interventions":27250},[85,86],[120],[9652,9653,1631],{"trials":27252,"activeCount":97},[],{"trials":27254,"activeCount":97},[],{"trials":27256,"activeCount":97},[],{"intervention":27258,"totalTrials":314,"cells":27259},"Enzastaurin 500 milligram",{"EARLY_PHASE1":27260,"PHASE1":27262,"PHASE2":27264,"PHASE3":27273,"PHASE4":27275,"NA":27277},{"trials":27261,"activeCount":97},[],{"trials":27263,"activeCount":97},[],{"trials":27265,"activeCount":97},[27266],{"nctId":27267,"briefTitle":27268,"status":103,"phases":27269,"primaryCompletion":3087,"completion":7775,"start":3235,"enrollment":874,"conditions":27270,"interventions":27271},"NCT00509821","Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma",[86],[9128],[27258,27272],"Enzastaurin 250 mg Twice Daily",{"trials":27274,"activeCount":97},[],{"trials":27276,"activeCount":97},[],{"trials":27278,"activeCount":97},[],{"intervention":27272,"totalTrials":314,"cells":27280},{"EARLY_PHASE1":27281,"PHASE1":27283,"PHASE2":27285,"PHASE3":27291,"PHASE4":27293,"NA":27295},{"trials":27282,"activeCount":97},[],{"trials":27284,"activeCount":97},[],{"trials":27286,"activeCount":97},[27287],{"nctId":27267,"briefTitle":27268,"status":103,"phases":27288,"primaryCompletion":3087,"completion":7775,"start":3235,"enrollment":874,"conditions":27289,"interventions":27290},[86],[9128],[27258,27272],{"trials":27292,"activeCount":97},[],{"trials":27294,"activeCount":97},[],{"trials":27296,"activeCount":97},[],{"intervention":27298,"totalTrials":314,"cells":27299},"Gemzar and Alimta",{"EARLY_PHASE1":27300,"PHASE1":27302,"PHASE2":27304,"PHASE3":27312,"PHASE4":27314,"NA":27316},{"trials":27301,"activeCount":97},[],{"trials":27303,"activeCount":97},[],{"trials":27305,"activeCount":97},[27306],{"nctId":27307,"briefTitle":27308,"status":999,"phases":27309,"conditions":27310,"interventions":27311},"NCT00055432","Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer",[86],[2584,5631],[27298],{"trials":27313,"activeCount":97},[],{"trials":27315,"activeCount":97},[],{"trials":27317,"activeCount":97},[],{"intervention":27319,"totalTrials":314,"cells":27320},"Pemetrexed Phase 1",{"EARLY_PHASE1":27321,"PHASE1":27323,"PHASE2":27325,"PHASE3":27336,"PHASE4":27338,"NA":27340},{"trials":27322,"activeCount":97},[],{"trials":27324,"activeCount":97},[],{"trials":27326,"activeCount":97},[27327],{"nctId":27328,"briefTitle":27329,"status":103,"phases":27330,"primaryCompletion":3012,"completion":2898,"start":3176,"enrollment":3309,"conditions":27331,"interventions":27332},"NCT00529100","Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA\u002FB Non Small Cell Lung Cancer",[85,86],[1718],[27319,27333,27334,27335],"Cisplatin Phase 1","Pemetrexed Phase 2","Cisplatin Phase 2",{"trials":27337,"activeCount":97},[],{"trials":27339,"activeCount":97},[],{"trials":27341,"activeCount":97},[],{"intervention":27333,"totalTrials":314,"cells":27343},{"EARLY_PHASE1":27344,"PHASE1":27346,"PHASE2":27348,"PHASE3":27354,"PHASE4":27356,"NA":27358},{"trials":27345,"activeCount":97},[],{"trials":27347,"activeCount":97},[],{"trials":27349,"activeCount":97},[27350],{"nctId":27328,"briefTitle":27329,"status":103,"phases":27351,"primaryCompletion":3012,"completion":2898,"start":3176,"enrollment":3309,"conditions":27352,"interventions":27353},[85,86],[1718],[27319,27333,27334,27335],{"trials":27355,"activeCount":97},[],{"trials":27357,"activeCount":97},[],{"trials":27359,"activeCount":97},[],{"intervention":27334,"totalTrials":314,"cells":27361},{"EARLY_PHASE1":27362,"PHASE1":27364,"PHASE2":27366,"PHASE3":27372,"PHASE4":27374,"NA":27376},{"trials":27363,"activeCount":97},[],{"trials":27365,"activeCount":97},[],{"trials":27367,"activeCount":97},[27368],{"nctId":27328,"briefTitle":27329,"status":103,"phases":27369,"primaryCompletion":3012,"completion":2898,"start":3176,"enrollment":3309,"conditions":27370,"interventions":27371},[85,86],[1718],[27319,27333,27334,27335],{"trials":27373,"activeCount":97},[],{"trials":27375,"activeCount":97},[],{"trials":27377,"activeCount":97},[],{"intervention":27335,"totalTrials":314,"cells":27379},{"EARLY_PHASE1":27380,"PHASE1":27382,"PHASE2":27384,"PHASE3":27390,"PHASE4":27392,"NA":27394},{"trials":27381,"activeCount":97},[],{"trials":27383,"activeCount":97},[],{"trials":27385,"activeCount":97},[27386],{"nctId":27328,"briefTitle":27329,"status":103,"phases":27387,"primaryCompletion":3012,"completion":2898,"start":3176,"enrollment":3309,"conditions":27388,"interventions":27389},[85,86],[1718],[27319,27333,27334,27335],{"trials":27391,"activeCount":97},[],{"trials":27393,"activeCount":97},[],{"trials":27395,"activeCount":97},[],{"intervention":5085,"totalTrials":314,"cells":27397},{"EARLY_PHASE1":27398,"PHASE1":27400,"PHASE2":27402,"PHASE3":27408,"PHASE4":27410,"NA":27412},{"trials":27399,"activeCount":97},[],{"trials":27401,"activeCount":97},[],{"trials":27403,"activeCount":97},[27404],{"nctId":5078,"briefTitle":5079,"status":103,"phases":27405,"primaryCompletion":5081,"completion":5082,"start":1547,"enrollment":19,"conditions":27406,"interventions":27407},[86],[1271],[4944,5085],{"trials":27409,"activeCount":97},[],{"trials":27411,"activeCount":97},[],{"trials":27413,"activeCount":97},[],{"intervention":27415,"totalTrials":314,"cells":27416},"ALIMTA plus Epirubicin",{"EARLY_PHASE1":27417,"PHASE1":27419,"PHASE2":27421,"PHASE3":27429,"PHASE4":27431,"NA":27433},{"trials":27418,"activeCount":97},[],{"trials":27420,"activeCount":97},[],{"trials":27422,"activeCount":97},[27423],{"nctId":27424,"briefTitle":27425,"status":103,"phases":27426,"conditions":27427,"interventions":27428},"NCT00097383","Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer",[85,86],[36],[27415],{"trials":27430,"activeCount":97},[],{"trials":27432,"activeCount":97},[],{"trials":27434,"activeCount":97},[],{"intervention":22895,"totalTrials":314,"cells":27436},{"EARLY_PHASE1":27437,"PHASE1":27439,"PHASE2":27441,"PHASE3":27447,"PHASE4":27449,"NA":27451},{"trials":27438,"activeCount":97},[],{"trials":27440,"activeCount":97},[],{"trials":27442,"activeCount":97},[27443],{"nctId":22889,"briefTitle":22890,"status":103,"phases":27444,"primaryCompletion":2844,"completion":2844,"start":3266,"enrollment":1839,"conditions":27445,"interventions":27446},[86],[22893],[3117,22895],{"trials":27448,"activeCount":97},[],{"trials":27450,"activeCount":97},[],{"trials":27452,"activeCount":97},[],{"intervention":27454,"totalTrials":314,"cells":27455},"LY2300559",{"EARLY_PHASE1":27456,"PHASE1":27458,"PHASE2":27460,"PHASE3":27468,"PHASE4":27470,"NA":27472},{"trials":27457,"activeCount":97},[],{"trials":27459,"activeCount":97},[],{"trials":27461,"activeCount":97},[27462],{"nctId":27463,"briefTitle":27464,"status":999,"phases":27465,"primaryCompletion":2864,"completion":2864,"start":4258,"enrollment":8967,"conditions":27466,"interventions":27467},"NCT01184508","A Study in Migraine Prevention",[86],[7495],[27454],{"trials":27469,"activeCount":97},[],{"trials":27471,"activeCount":97},[],{"trials":27473,"activeCount":97},[],{"intervention":6627,"totalTrials":314,"cells":27475},{"EARLY_PHASE1":27476,"PHASE1":27478,"PHASE2":27480,"PHASE3":27486,"PHASE4":27488,"NA":27490},{"trials":27477,"activeCount":97},[],{"trials":27479,"activeCount":97},[],{"trials":27481,"activeCount":97},[27482],{"nctId":6621,"briefTitle":6622,"status":103,"phases":27483,"primaryCompletion":5022,"completion":5354,"start":5090,"enrollment":6624,"conditions":27484,"interventions":27485},[86],[36],[61,6627],{"trials":27487,"activeCount":97},[],{"trials":27489,"activeCount":97},[],{"trials":27491,"activeCount":97},[],{"intervention":25633,"totalTrials":314,"cells":27493},{"EARLY_PHASE1":27494,"PHASE1":27496,"PHASE2":27498,"PHASE3":27504,"PHASE4":27506,"NA":27508},{"trials":27495,"activeCount":97},[],{"trials":27497,"activeCount":97},[],{"trials":27499,"activeCount":97},[27500],{"nctId":25626,"briefTitle":25627,"status":103,"phases":27501,"completion":3153,"start":4459,"enrollment":19669,"conditions":27502,"interventions":27503},[86],[25630,25631],[25633,25634],{"trials":27505,"activeCount":97},[],{"trials":27507,"activeCount":97},[],{"trials":27509,"activeCount":97},[],{"intervention":27511,"totalTrials":314,"cells":27512},"Subcutaneous Teriparatide",{"EARLY_PHASE1":27513,"PHASE1":27515,"PHASE2":27517,"PHASE3":27526,"PHASE4":27528,"NA":27530},{"trials":27514,"activeCount":97},[],{"trials":27516,"activeCount":97},[],{"trials":27518,"activeCount":97},[27519],{"nctId":27520,"briefTitle":27521,"status":103,"phases":27522,"primaryCompletion":3494,"completion":3494,"start":3217,"enrollment":1409,"conditions":27523,"interventions":27524},"NCT01011556","A Study for the Transdermal Application of Teriparatide",[86],[14617],[27511,27525],"Transdermal Teriparatide",{"trials":27527,"activeCount":97},[],{"trials":27529,"activeCount":97},[],{"trials":27531,"activeCount":97},[],{"intervention":27525,"totalTrials":314,"cells":27533},{"EARLY_PHASE1":27534,"PHASE1":27536,"PHASE2":27538,"PHASE3":27544,"PHASE4":27546,"NA":27548},{"trials":27535,"activeCount":97},[],{"trials":27537,"activeCount":97},[],{"trials":27539,"activeCount":97},[27540],{"nctId":27520,"briefTitle":27521,"status":103,"phases":27541,"primaryCompletion":3494,"completion":3494,"start":3217,"enrollment":1409,"conditions":27542,"interventions":27543},[86],[14617],[27511,27525],{"trials":27545,"activeCount":97},[],{"trials":27547,"activeCount":97},[],{"trials":27549,"activeCount":97},[],{"intervention":27551,"totalTrials":314,"cells":27552},"LY3295668",{"EARLY_PHASE1":27553,"PHASE1":27555,"PHASE2":27557,"PHASE3":27567,"PHASE4":27569,"NA":27571},{"trials":27554,"activeCount":97},[],{"trials":27556,"activeCount":97},[],{"trials":27558,"activeCount":97},[27559],{"nctId":27560,"briefTitle":27561,"status":103,"phases":27562,"primaryCompletion":25257,"completion":25257,"start":27563,"enrollment":1199,"conditions":27564,"interventions":27566},"NCT03092934","A Study of AK-01 (LY3295668) in Solid Tumors",[85,86],"2017-05-29",[1870,1478,2555,2792,1893,27565,2504],"Solid Tumor, Adult",[27551],{"trials":27568,"activeCount":97},[],{"trials":27570,"activeCount":97},[],{"trials":27572,"activeCount":97},[],{"intervention":27574,"totalTrials":314,"cells":27575},"LY2541546",{"EARLY_PHASE1":27576,"PHASE1":27578,"PHASE2":27580,"PHASE3":27588,"PHASE4":27590,"NA":27592},{"trials":27577,"activeCount":97},[],{"trials":27579,"activeCount":97},[],{"trials":27581,"activeCount":97},[27582],{"nctId":27583,"briefTitle":27584,"status":103,"phases":27585,"primaryCompletion":2865,"completion":4420,"start":3012,"enrollment":7145,"conditions":27586,"interventions":27587},"NCT01144377","A Study of LY2541546 in Women With Low Bone Mineral Density",[86],[14617],[27574],{"trials":27589,"activeCount":97},[],{"trials":27591,"activeCount":97},[],{"trials":27593,"activeCount":97},[],{"intervention":27595,"totalTrials":314,"cells":27596},"LY500307",{"EARLY_PHASE1":27597,"PHASE1":27599,"PHASE2":27601,"PHASE3":27609,"PHASE4":27611,"NA":27613},{"trials":27598,"activeCount":97},[],{"trials":27600,"activeCount":97},[],{"trials":27602,"activeCount":97},[27603],{"nctId":27604,"briefTitle":27605,"status":999,"phases":27606,"primaryCompletion":3004,"completion":3004,"start":3251,"enrollment":357,"conditions":27607,"interventions":27608},"NCT01097707","A Study in Men With Benign Prostatic Hyperplasia",[86],[15444],[27595],{"trials":27610,"activeCount":97},[],{"trials":27612,"activeCount":97},[],{"trials":27614,"activeCount":97},[],{"intervention":3749,"totalTrials":314,"cells":27616},{"EARLY_PHASE1":27617,"PHASE1":27619,"PHASE2":27621,"PHASE3":27627,"PHASE4":27629,"NA":27631},{"trials":27618,"activeCount":97},[],{"trials":27620,"activeCount":97},[],{"trials":27622,"activeCount":97},[27623],{"nctId":3743,"briefTitle":3744,"status":103,"phases":27624,"primaryCompletion":3132,"completion":3132,"start":3746,"enrollment":658,"conditions":27625,"interventions":27626},[86],[36],[1511,1512,3749],{"trials":27628,"activeCount":97},[],{"trials":27630,"activeCount":97},[],{"trials":27632,"activeCount":97},[],{"intervention":13330,"totalTrials":314,"cells":27634},{"EARLY_PHASE1":27635,"PHASE1":27637,"PHASE2":27639,"PHASE3":27645,"PHASE4":27647,"NA":27649},{"trials":27636,"activeCount":97},[],{"trials":27638,"activeCount":97},[],{"trials":27640,"activeCount":97},[27641],{"nctId":13321,"briefTitle":13322,"status":103,"phases":27642,"primaryCompletion":13324,"completion":13325,"start":13326,"enrollment":299,"conditions":27643,"interventions":27644},[86],[13328],[1513,13330],{"trials":27646,"activeCount":97},[],{"trials":27648,"activeCount":97},[],{"trials":27650,"activeCount":97},[],{"intervention":1538,"totalTrials":1082,"cells":27652},{"EARLY_PHASE1":27653,"PHASE1":27655,"PHASE2":27745,"PHASE3":27747,"PHASE4":27749,"NA":27751},{"trials":27654,"activeCount":97},[],{"trials":27656,"activeCount":97},[27657,27661,27669,27673,27677,27681,27685,27689,27693,27701,27705,27709,27713,27717,27721,27725,27729,27733,27737,27741],{"nctId":22181,"briefTitle":22182,"status":103,"phases":27658,"primaryCompletion":22184,"completion":22184,"start":13467,"enrollment":310,"conditions":27659,"interventions":27660},[85],[15],[1538,7043,22187],{"nctId":27662,"briefTitle":27663,"status":103,"phases":27664,"primaryCompletion":288,"completion":288,"start":27665,"enrollment":156,"conditions":27666,"interventions":27667},"NCT04559568","A Study of LY3522348 in Healthy Participants",[85],"2020-10-15",[15],[27668,1538],"LY3522348",{"nctId":9231,"briefTitle":9232,"status":103,"phases":27670,"primaryCompletion":9234,"completion":9234,"start":6465,"enrollment":4475,"conditions":27671,"interventions":27672},[85],[18],[402,9237,1538],{"nctId":10907,"briefTitle":10908,"status":999,"phases":27674,"primaryCompletion":10910,"completion":10910,"start":1156,"enrollment":10911,"conditions":27675,"interventions":27676},[85],[15],[10914,2562,1538],{"nctId":1527,"briefTitle":1528,"status":103,"phases":27678,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":27679,"interventions":27680},[85],[1466,1534,1535,1490],[1537,1538,48,1539,1511,1540,1541],{"nctId":5458,"briefTitle":5459,"status":103,"phases":27682,"primaryCompletion":819,"completion":819,"start":5461,"enrollment":1082,"conditions":27683,"interventions":27684},[85],[15],[1538,1667],{"nctId":9472,"briefTitle":9473,"status":103,"phases":27686,"primaryCompletion":9475,"completion":9475,"start":9476,"enrollment":9477,"conditions":27687,"interventions":27688},[85],[15],[945,1538,1538],{"nctId":1600,"briefTitle":1601,"status":103,"phases":27690,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":27691,"interventions":27692},[85],[1466,1560,1608,1571,1609,1610],[1513,1538,1468,1612,1510,48,1613],{"nctId":27694,"briefTitle":27695,"status":103,"phases":27696,"primaryCompletion":23561,"completion":23561,"start":27697,"enrollment":410,"conditions":27698,"interventions":27699},"NCT06153355","A First-In-Human Study of LY3839840 in Healthy Participants",[85],"2023-12-04",[15],[27700,1538],"LY3839840",{"nctId":6147,"briefTitle":6148,"status":103,"phases":27702,"primaryCompletion":4420,"completion":6150,"start":6151,"enrollment":2939,"conditions":27703,"interventions":27704},[85],[1466],[3623,1538,1761],{"nctId":6239,"briefTitle":6240,"status":103,"phases":27706,"primaryCompletion":364,"completion":6242,"start":6243,"enrollment":1071,"conditions":27707,"interventions":27708},[85],[15],[1538,2685],{"nctId":11662,"briefTitle":11663,"status":103,"phases":27710,"primaryCompletion":11665,"completion":11665,"start":11666,"enrollment":425,"conditions":27711,"interventions":27712},[85],[1571],[8162,3871,1538],{"nctId":10939,"briefTitle":10940,"status":103,"phases":27714,"primaryCompletion":1462,"completion":1462,"start":10942,"enrollment":2720,"conditions":27715,"interventions":27716},[85],[15],[1574,1171,2562,2065,1538],{"nctId":7841,"briefTitle":7842,"status":103,"phases":27718,"primaryCompletion":7844,"completion":7844,"start":7845,"enrollment":1548,"conditions":27719,"interventions":27720},[85],[15],[2655,1093,2093,1538,1538],{"nctId":18082,"briefTitle":18083,"status":103,"phases":27722,"primaryCompletion":18085,"completion":18085,"start":18086,"enrollment":2931,"conditions":27723,"interventions":27724},[85],[15],[7043,9237,2092,1538],{"nctId":2067,"briefTitle":2068,"status":103,"phases":27726,"primaryCompletion":1300,"completion":1300,"start":2070,"enrollment":2071,"conditions":27727,"interventions":27728},[85],[15],[2043,1538,2074],{"nctId":2084,"briefTitle":2085,"status":103,"phases":27730,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":27731,"interventions":27732},[85],[15,2090,27],[2043,2092,1093,2093,217,1538,2094],{"nctId":22533,"briefTitle":22534,"status":103,"phases":27734,"primaryCompletion":10145,"completion":10145,"start":7021,"enrollment":310,"conditions":27735,"interventions":27736},[85],[24],[6982,1538,1172,1170],{"nctId":18838,"briefTitle":18839,"status":103,"phases":27738,"primaryCompletion":18841,"completion":18841,"start":5476,"enrollment":3041,"conditions":27739,"interventions":27740},[85],[15],[18844,5095,1172,5480,1538,1102],{"nctId":24254,"briefTitle":24255,"status":999,"phases":27742,"primaryCompletion":4258,"completion":4258,"start":3114,"enrollment":205,"conditions":27743,"interventions":27744},[85],[1466],[24240,1538],{"trials":27746,"activeCount":97},[],{"trials":27748,"activeCount":97},[],{"trials":27750,"activeCount":97},[],{"trials":27752,"activeCount":97},[],{"intervention":1172,"totalTrials":3293,"cells":27754},{"EARLY_PHASE1":27755,"PHASE1":27757,"PHASE2":27798,"PHASE3":27800,"PHASE4":27802,"NA":27804},{"trials":27756,"activeCount":97},[],{"trials":27758,"activeCount":97},[27759,27763,27767,27771,27775,27782,27786,27790,27794],{"nctId":17270,"briefTitle":17271,"status":103,"phases":27760,"primaryCompletion":2964,"completion":2964,"start":3348,"enrollment":1237,"conditions":27761,"interventions":27762},[85],[21],[17257,1172],{"nctId":6931,"briefTitle":6932,"status":103,"phases":27764,"primaryCompletion":4160,"completion":4160,"start":3494,"enrollment":165,"conditions":27765,"interventions":27766},[85],[18],[6936,1172],{"nctId":16527,"briefTitle":16528,"status":103,"phases":27768,"primaryCompletion":2798,"completion":4122,"start":8217,"enrollment":1199,"conditions":27769,"interventions":27770},[85],[1503,16531],[16533,2979],{"nctId":17320,"briefTitle":17321,"status":103,"phases":27772,"primaryCompletion":2845,"completion":2845,"start":5354,"enrollment":290,"conditions":27773,"interventions":27774},[85],[21],[17257,1172],{"nctId":27776,"briefTitle":27777,"status":103,"phases":27778,"primaryCompletion":3235,"completion":3235,"start":4566,"enrollment":874,"conditions":27779,"interventions":27781},"NCT00533026","Duloxetine - Warfarin Pharmacodynamic Study",[85],[27780],"Anticoagulant Effect of Warfarin When Taken With Duloxetine.",[14492,1172],{"nctId":1164,"briefTitle":1165,"status":103,"phases":27783,"primaryCompletion":1167,"completion":1167,"start":872,"enrollment":1071,"conditions":27784,"interventions":27785},[85],[15],[1170,1171,1172,1070],{"nctId":16946,"briefTitle":16947,"status":103,"phases":27787,"primaryCompletion":3283,"completion":3283,"start":3152,"enrollment":12,"conditions":27788,"interventions":27789},[85],[13955],[1172,13957],{"nctId":22533,"briefTitle":22534,"status":103,"phases":27791,"primaryCompletion":10145,"completion":10145,"start":7021,"enrollment":310,"conditions":27792,"interventions":27793},[85],[24],[6982,1538,1172,1170],{"nctId":18838,"briefTitle":18839,"status":103,"phases":27795,"primaryCompletion":18841,"completion":18841,"start":5476,"enrollment":3041,"conditions":27796,"interventions":27797},[85],[15],[18844,5095,1172,5480,1538,1102],{"trials":27799,"activeCount":97},[],{"trials":27801,"activeCount":97},[],{"trials":27803,"activeCount":97},[],{"trials":27805,"activeCount":97},[],{"intervention":1093,"totalTrials":4323,"cells":27807},{"EARLY_PHASE1":27808,"PHASE1":27810,"PHASE2":27844,"PHASE3":27846,"PHASE4":27848,"NA":27850},{"trials":27809,"activeCount":97},[],{"trials":27811,"activeCount":97},[27812,27816,27820,27824,27828,27832,27836,27840],{"nctId":1086,"briefTitle":1087,"status":103,"phases":27813,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1071,"conditions":27814,"interventions":27815},[85],[15],[1070,1093],{"nctId":16898,"briefTitle":16899,"status":103,"phases":27817,"primaryCompletion":3283,"completion":3283,"start":3152,"enrollment":1620,"conditions":27818,"interventions":27819},[85],[13955],[13957,1093],{"nctId":7841,"briefTitle":7842,"status":103,"phases":27821,"primaryCompletion":7844,"completion":7844,"start":7845,"enrollment":1548,"conditions":27822,"interventions":27823},[85],[15],[2655,1093,2093,1538,1538],{"nctId":6998,"briefTitle":6999,"status":103,"phases":27825,"primaryCompletion":5090,"completion":5090,"start":3494,"enrollment":290,"conditions":27826,"interventions":27827},[85],[18],[1093,303],{"nctId":5006,"briefTitle":5007,"status":103,"phases":27829,"primaryCompletion":2917,"completion":2917,"start":3282,"enrollment":165,"conditions":27830,"interventions":27831},[85],[21],[4944,1093],{"nctId":5473,"briefTitle":5474,"status":103,"phases":27833,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":27834,"interventions":27835},[85],[15],[1667,1102,1171,5480,2074,2093,1093],{"nctId":17338,"briefTitle":17339,"status":103,"phases":27837,"primaryCompletion":5022,"completion":5022,"start":3027,"enrollment":1071,"conditions":27838,"interventions":27839},[85],[21],[17257,1093],{"nctId":2084,"briefTitle":2085,"status":103,"phases":27841,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":27842,"interventions":27843},[85],[15,2090,27],[2043,2092,1093,2093,217,1538,2094],{"trials":27845,"activeCount":97},[],{"trials":27847,"activeCount":97},[],{"trials":27849,"activeCount":97},[],{"trials":27851,"activeCount":97},[],{"intervention":1171,"totalTrials":1054,"cells":27853},{"EARLY_PHASE1":27854,"PHASE1":27856,"PHASE2":27886,"PHASE3":27888,"PHASE4":27890,"NA":27892},{"trials":27855,"activeCount":97},[],{"trials":27857,"activeCount":97},[27858,27862,27866,27870,27874,27878,27882],{"nctId":17295,"briefTitle":17296,"status":103,"phases":27859,"primaryCompletion":3697,"completion":3697,"start":5030,"enrollment":3718,"conditions":27860,"interventions":27861},[85],[15],[17257,1171],{"nctId":6231,"briefTitle":6232,"status":103,"phases":27863,"primaryCompletion":6234,"completion":6234,"start":6235,"enrollment":1082,"conditions":27864,"interventions":27865},[85],[15],[2685,1171],{"nctId":10939,"briefTitle":10940,"status":103,"phases":27867,"primaryCompletion":1462,"completion":1462,"start":10942,"enrollment":2720,"conditions":27868,"interventions":27869},[85],[15],[1574,1171,2562,2065,1538],{"nctId":6247,"briefTitle":6248,"status":103,"phases":27871,"primaryCompletion":1557,"completion":1557,"start":5346,"enrollment":1082,"conditions":27872,"interventions":27873},[85],[15],[2685,6252,1171],{"nctId":5473,"briefTitle":5474,"status":103,"phases":27875,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":27876,"interventions":27877},[85],[15],[1667,1102,1171,5480,2074,2093,1093],{"nctId":1164,"briefTitle":1165,"status":103,"phases":27879,"primaryCompletion":1167,"completion":1167,"start":872,"enrollment":1071,"conditions":27880,"interventions":27881},[85],[15],[1170,1171,1172,1070],{"nctId":5035,"briefTitle":5036,"status":103,"phases":27883,"primaryCompletion":4980,"completion":4980,"start":4955,"enrollment":1620,"conditions":27884,"interventions":27885},[85],[21],[4944,1171],{"trials":27887,"activeCount":97},[],{"trials":27889,"activeCount":97},[],{"trials":27891,"activeCount":97},[],{"trials":27893,"activeCount":97},[],{"intervention":27895,"totalTrials":1677,"cells":27896},"LY3074828",{"EARLY_PHASE1":27897,"PHASE1":27899,"PHASE2":27942,"PHASE3":27944,"PHASE4":27946,"NA":27948},{"trials":27898,"activeCount":97},[],{"trials":27900,"activeCount":97},[27901,27908,27914,27921,27927,27935],{"nctId":27902,"briefTitle":27903,"status":103,"phases":27904,"primaryCompletion":27905,"completion":27905,"start":11312,"enrollment":1587,"conditions":27906,"interventions":27907},"NCT03662100","A Study of Two Formulations of LY3074828 in Healthy Participants",[85],"2019-01-25",[15],[27895,27895],{"nctId":27909,"briefTitle":27910,"status":103,"phases":27911,"primaryCompletion":6224,"completion":6224,"start":13271,"enrollment":1587,"conditions":27912,"interventions":27913},"NCT03886948","A Study of Injections of LY3074828 in Healthy Participants",[85],[15],[27895],{"nctId":27915,"briefTitle":27916,"status":103,"phases":27917,"primaryCompletion":19939,"completion":19939,"start":8754,"enrollment":874,"conditions":27918,"interventions":27919},"NCT03748940","Study of LY3074828 in Healthy Participants",[85],[15],[27895,27920],"LY900021",{"nctId":27922,"briefTitle":27923,"status":103,"phases":27924,"primaryCompletion":5110,"completion":5110,"start":19103,"enrollment":31,"conditions":27925,"interventions":27926},"NCT03188510","A Study of Two Different Formulations of LY3074828 in Healthy Participants",[85],[15],[27895],{"nctId":27928,"briefTitle":27929,"status":103,"phases":27930,"primaryCompletion":27931,"completion":27931,"start":27932,"enrollment":1767,"conditions":27933,"interventions":27934},"NCT03456713","A Study of LY3074828 in Healthy Participants",[85],"2018-08-13","2018-03-06",[15],[27895],{"nctId":27936,"briefTitle":27937,"status":103,"phases":27938,"primaryCompletion":27939,"completion":27939,"start":11313,"enrollment":1767,"conditions":27940,"interventions":27941},"NCT03220126","A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants",[85],"2018-02-23",[15],[27895,27920],{"trials":27943,"activeCount":97},[],{"trials":27945,"activeCount":97},[],{"trials":27947,"activeCount":97},[],{"trials":27949,"activeCount":97},[],{"intervention":27951,"totalTrials":425,"cells":27952},"Cephalexin",{"EARLY_PHASE1":27953,"PHASE1":27955,"PHASE2":27987,"PHASE3":27989,"PHASE4":27991,"NA":27993},{"trials":27954,"activeCount":97},[],{"trials":27956,"activeCount":97},[27957,27963,27969,27975,27981],{"nctId":27958,"briefTitle":27959,"status":103,"phases":27960,"primaryCompletion":4098,"completion":4098,"start":4098,"enrollment":165,"conditions":27961,"interventions":27962},"NCT02123459","A Study of Cephalexin Suspension in Healthy Participants",[85],[21],[27951],{"nctId":27964,"briefTitle":27965,"status":103,"phases":27966,"primaryCompletion":4098,"completion":4098,"start":1475,"enrollment":165,"conditions":27967,"interventions":27968},"NCT02123446","A Study of Cephalexin Capsules in Healthy Participants",[85],[21],[27951],{"nctId":27970,"briefTitle":27971,"status":103,"phases":27972,"primaryCompletion":4097,"completion":4097,"start":4097,"enrollment":165,"conditions":27973,"interventions":27974},"NCT02490670","A Study of Cephalexin Liquid in Healthy Participants",[85],[15],[27951],{"nctId":27976,"briefTitle":27977,"status":103,"phases":27978,"primaryCompletion":4098,"completion":4098,"start":1475,"enrollment":165,"conditions":27979,"interventions":27980},"NCT02100826","A Study of Cephalexin in Healthy Participants",[85],[21],[27951],{"nctId":27982,"briefTitle":27983,"status":103,"phases":27984,"primaryCompletion":4098,"completion":4098,"start":4098,"enrollment":165,"conditions":27985,"interventions":27986},"NCT02123472","A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants",[85],[21],[27951],{"trials":27988,"activeCount":97},[],{"trials":27990,"activeCount":97},[],{"trials":27992,"activeCount":97},[],{"trials":27994,"activeCount":97},[],{"intervention":1632,"totalTrials":425,"cells":27996},{"EARLY_PHASE1":27997,"PHASE1":27999,"PHASE2":28026,"PHASE3":28028,"PHASE4":28030,"NA":28032},{"trials":27998,"activeCount":97},[],{"trials":28000,"activeCount":97},[28001,28005,28014,28018,28022],{"nctId":9603,"briefTitle":9604,"status":384,"phases":28002,"primaryCompletion":9606,"completion":9606,"start":9607,"enrollment":97,"conditions":28003,"interventions":28004},[85],[15],[9610,1632,2092,1631],{"nctId":28006,"briefTitle":28007,"status":384,"phases":28008,"primaryCompletion":28009,"completion":28009,"start":28010,"enrollment":97,"conditions":28011,"interventions":28012},"NCT03545087","A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants",[85],"2019-01","2018-06",[147],[28013,1632],"Lanabecestat",{"nctId":9612,"briefTitle":9613,"status":103,"phases":28015,"primaryCompletion":9615,"completion":9615,"start":7463,"enrollment":3718,"conditions":28016,"interventions":28017},[85],[15],[9618,1632,1631],{"nctId":1624,"briefTitle":1625,"status":103,"phases":28019,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":233,"conditions":28020,"interventions":28021},[85],[15],[48,1631,1632],{"nctId":9624,"briefTitle":9625,"status":103,"phases":28023,"primaryCompletion":629,"completion":629,"start":9627,"enrollment":12,"conditions":28024,"interventions":28025},[85],[15],[9618,1631,1632],{"trials":28027,"activeCount":97},[],{"trials":28029,"activeCount":97},[],{"trials":28031,"activeCount":97},[],{"trials":28033,"activeCount":97},[],{"intervention":6946,"totalTrials":1400,"cells":28035},{"EARLY_PHASE1":28036,"PHASE1":28038,"PHASE2":28066,"PHASE3":28068,"PHASE4":28070,"NA":28072},{"trials":28037,"activeCount":97},[],{"trials":28039,"activeCount":97},[28040,28046,28050,28058],{"nctId":28041,"briefTitle":28042,"status":103,"phases":28043,"primaryCompletion":6978,"completion":6978,"start":1157,"enrollment":233,"conditions":28044,"interventions":28045},"NCT04498390","A Safety Study of LY3493269 in Healthy Participants",[85],[15],[6946],{"nctId":6938,"briefTitle":6939,"status":103,"phases":28047,"primaryCompletion":6941,"completion":6941,"start":6942,"enrollment":6943,"conditions":28048,"interventions":28049},[85],[18],[6946,303],{"nctId":28051,"briefTitle":28052,"status":103,"phases":28053,"primaryCompletion":9398,"completion":9398,"start":28054,"enrollment":233,"conditions":28055,"interventions":28056},"NCT04682106","A Study of LY3493269 in Healthy Participants",[85],"2021-05-03",[15],[6946,28057],"Salcaprozate Sodium",{"nctId":28059,"briefTitle":28060,"status":999,"phases":28061,"primaryCompletion":28062,"completion":28062,"start":2014,"enrollment":137,"conditions":28063,"interventions":28064},"NCT05794243","A Multiple-Dose Study of LY3493269 in Healthy Participants",[85],"2023-06-20",[15],[6946,28065,28057],"Sodium Caprate",{"trials":28067,"activeCount":97},[],{"trials":28069,"activeCount":97},[],{"trials":28071,"activeCount":97},[],{"trials":28073,"activeCount":97},[],{"intervention":1480,"totalTrials":1400,"cells":28075},{"EARLY_PHASE1":28076,"PHASE1":28078,"PHASE2":28096,"PHASE3":28098,"PHASE4":28100,"NA":28102},{"trials":28077,"activeCount":97},[],{"trials":28079,"activeCount":97},[28080,28084,28088,28092],{"nctId":22308,"briefTitle":22309,"status":103,"phases":28081,"primaryCompletion":4980,"completion":4980,"start":3282,"enrollment":1620,"conditions":28082,"interventions":28083},[85],[21],[9643,17281,4983,1480],{"nctId":1470,"briefTitle":1471,"status":103,"phases":28085,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":893,"conditions":28086,"interventions":28087},[85],[1477,1478],[48,1480],{"nctId":22233,"briefTitle":22234,"status":103,"phases":28089,"primaryCompletion":22236,"completion":22236,"start":766,"enrollment":893,"conditions":28090,"interventions":28091},[85],[15],[7043,1480],{"nctId":16933,"briefTitle":16934,"status":103,"phases":28093,"primaryCompletion":4160,"completion":4160,"start":3004,"enrollment":1062,"conditions":28094,"interventions":28095},[85],[4937],[13957,1480],{"trials":28097,"activeCount":97},[],{"trials":28099,"activeCount":97},[],{"trials":28101,"activeCount":97},[],{"trials":28103,"activeCount":97},[],{"intervention":1102,"totalTrials":1400,"cells":28105},{"EARLY_PHASE1":28106,"PHASE1":28108,"PHASE2":28126,"PHASE3":28128,"PHASE4":28130,"NA":28132},{"trials":28107,"activeCount":97},[],{"trials":28109,"activeCount":97},[28110,28114,28118,28122],{"nctId":6204,"briefTitle":6205,"status":103,"phases":28111,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":1071,"conditions":28112,"interventions":28113},[85],[15],[1102,2685],{"nctId":1095,"briefTitle":1096,"status":103,"phases":28115,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1071,"conditions":28116,"interventions":28117},[85],[15],[1102,1070],{"nctId":5473,"briefTitle":5474,"status":103,"phases":28119,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":28120,"interventions":28121},[85],[15],[1667,1102,1171,5480,2074,2093,1093],{"nctId":18838,"briefTitle":18839,"status":103,"phases":28123,"primaryCompletion":18841,"completion":18841,"start":5476,"enrollment":3041,"conditions":28124,"interventions":28125},[85],[15],[18844,5095,1172,5480,1538,1102],{"trials":28127,"activeCount":97},[],{"trials":28129,"activeCount":97},[],{"trials":28131,"activeCount":97},[],{"trials":28133,"activeCount":97},[],{"intervention":4983,"totalTrials":1232,"cells":28135},{"EARLY_PHASE1":28136,"PHASE1":28138,"PHASE2":28152,"PHASE3":28154,"PHASE4":28156,"NA":28158},{"trials":28137,"activeCount":97},[],{"trials":28139,"activeCount":97},[28140,28144,28148],{"nctId":22308,"briefTitle":22309,"status":103,"phases":28141,"primaryCompletion":4980,"completion":4980,"start":3282,"enrollment":1620,"conditions":28142,"interventions":28143},[85],[21],[9643,17281,4983,1480],{"nctId":23927,"briefTitle":23928,"status":103,"phases":28145,"primaryCompletion":3086,"completion":3086,"start":3004,"enrollment":2720,"conditions":28146,"interventions":28147},[85],[4997],[18097,4983],{"nctId":4977,"briefTitle":4978,"status":103,"phases":28149,"primaryCompletion":4980,"completion":4980,"start":2917,"enrollment":214,"conditions":28150,"interventions":28151},[85],[21],[4944,4983,4984],{"trials":28153,"activeCount":97},[],{"trials":28155,"activeCount":97},[],{"trials":28157,"activeCount":97},[],{"trials":28159,"activeCount":97},[],{"intervention":6219,"totalTrials":1232,"cells":28161},{"EARLY_PHASE1":28162,"PHASE1":28164,"PHASE2":28178,"PHASE3":28180,"PHASE4":28182,"NA":28184},{"trials":28163,"activeCount":97},[],{"trials":28165,"activeCount":97},[28166,28170,28174],{"nctId":17264,"briefTitle":17265,"status":103,"phases":28167,"primaryCompletion":5022,"completion":5022,"start":3027,"enrollment":893,"conditions":28168,"interventions":28169},[85],[21],[17257,6219],{"nctId":6212,"briefTitle":6213,"status":103,"phases":28171,"primaryCompletion":6215,"completion":6216,"start":3617,"enrollment":290,"conditions":28172,"interventions":28173},[85],[15],[2685,2562,6219],{"nctId":11550,"briefTitle":11535,"status":103,"phases":28175,"primaryCompletion":3319,"completion":3319,"start":3318,"enrollment":290,"conditions":28176,"interventions":28177},[85],[21],[3870,6219],{"trials":28179,"activeCount":97},[],{"trials":28181,"activeCount":97},[],{"trials":28183,"activeCount":97},[],{"trials":28185,"activeCount":97},[],{"intervention":7756,"totalTrials":1232,"cells":28187},{"EARLY_PHASE1":28188,"PHASE1":28190,"PHASE2":28208,"PHASE3":28210,"PHASE4":28212,"NA":28214},{"trials":28189,"activeCount":97},[],{"trials":28191,"activeCount":97},[28192,28196,28202],{"nctId":7750,"briefTitle":7751,"status":999,"phases":28193,"primaryCompletion":3020,"completion":3020,"start":3419,"enrollment":864,"conditions":28194,"interventions":28195},[85],[5763,1706,2585,7754],[7756,1721,1575],{"nctId":28197,"briefTitle":28198,"status":103,"phases":28199,"primaryCompletion":5090,"completion":5090,"start":3029,"enrollment":3293,"conditions":28200,"interventions":28201},"NCT01241461","A Study of LY2584702 in Solid Tumors",[85],[2824],[7756],{"nctId":28203,"briefTitle":28204,"status":999,"phases":28205,"primaryCompletion":3069,"completion":3069,"start":2974,"enrollment":3718,"conditions":28206,"interventions":28207},"NCT01394003","A Study of LY2584702 in Participants With Advanced Cancer",[85],[1466],[7756],{"trials":28209,"activeCount":97},[],{"trials":28211,"activeCount":97},[],{"trials":28213,"activeCount":97},[],{"trials":28215,"activeCount":97},[],{"intervention":28217,"totalTrials":1232,"cells":28218},"Mirikizumab - SC",{"EARLY_PHASE1":28219,"PHASE1":28221,"PHASE2":28246,"PHASE3":28248,"PHASE4":28250,"NA":28252},{"trials":28220,"activeCount":97},[],{"trials":28222,"activeCount":97},[28223,28230,28239],{"nctId":28224,"briefTitle":28225,"status":103,"phases":28226,"primaryCompletion":694,"completion":694,"start":707,"enrollment":874,"conditions":28227,"interventions":28228},"NCT04137380","A Study of Mirikizumab in Healthy Chinese Participants",[85],[15],[28229,28217],"Mirikizumab - IV",{"nctId":28231,"briefTitle":28232,"status":103,"phases":28233,"primaryCompletion":28234,"completion":28235,"start":28236,"enrollment":4945,"conditions":28237,"interventions":28238},"NCT02568423","A Study of Mirikizumab (LY3074828) in Healthy Participants",[85],"2018-07-16","2018-10-24","2015-12-02",[15],[28229,28217],{"nctId":28240,"briefTitle":28241,"status":103,"phases":28242,"primaryCompletion":1473,"completion":1473,"start":4955,"enrollment":34,"conditions":28243,"interventions":28244},"NCT01947933","A Safety Study of Mirikizumab (LY3074828)",[85],[447],[28245,28217],"Mirikizumab- IV",{"trials":28247,"activeCount":97},[],{"trials":28249,"activeCount":97},[],{"trials":28251,"activeCount":97},[],{"trials":28253,"activeCount":97},[],{"intervention":867,"totalTrials":1232,"cells":28255},{"EARLY_PHASE1":28256,"PHASE1":28258,"PHASE2":28272,"PHASE3":28274,"PHASE4":28276,"NA":28278},{"trials":28257,"activeCount":97},[],{"trials":28259,"activeCount":97},[28260,28264,28268],{"nctId":7204,"briefTitle":7205,"status":103,"phases":28261,"primaryCompletion":7207,"completion":7207,"start":7208,"enrollment":165,"conditions":28262,"interventions":28263},[85],[447],[867,449],{"nctId":859,"briefTitle":860,"status":103,"phases":28265,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":28266,"interventions":28267},[85],[447],[867,588],{"nctId":1634,"briefTitle":1635,"status":103,"phases":28269,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":118,"conditions":28270,"interventions":28271},[85],[1478],[867,48],{"trials":28273,"activeCount":97},[],{"trials":28275,"activeCount":97},[],{"trials":28277,"activeCount":97},[],{"trials":28279,"activeCount":97},[],{"intervention":4984,"totalTrials":1232,"cells":28281},{"EARLY_PHASE1":28282,"PHASE1":28284,"PHASE2":28298,"PHASE3":28300,"PHASE4":28302,"NA":28304},{"trials":28283,"activeCount":97},[],{"trials":28285,"activeCount":97},[28286,28290,28294],{"nctId":4977,"briefTitle":4978,"status":103,"phases":28287,"primaryCompletion":4980,"completion":4980,"start":2917,"enrollment":214,"conditions":28288,"interventions":28289},[85],[21],[4944,4983,4984],{"nctId":22984,"briefTitle":22985,"status":103,"phases":28291,"primaryCompletion":22987,"completion":22987,"start":6280,"enrollment":214,"conditions":28292,"interventions":28293},[85],[15],[10978,10978,4984],{"nctId":8326,"briefTitle":8327,"status":103,"phases":28295,"primaryCompletion":8329,"completion":8329,"start":8330,"enrollment":1158,"conditions":28296,"interventions":28297},[85],[15],[2695,4984],{"trials":28299,"activeCount":97},[],{"trials":28301,"activeCount":97},[],{"trials":28303,"activeCount":97},[],{"trials":28305,"activeCount":97},[],{"intervention":2074,"totalTrials":1232,"cells":28307},{"EARLY_PHASE1":28308,"PHASE1":28310,"PHASE2":28324,"PHASE3":28326,"PHASE4":28328,"NA":28330},{"trials":28309,"activeCount":97},[],{"trials":28311,"activeCount":97},[28312,28316,28320],{"nctId":5473,"briefTitle":5474,"status":103,"phases":28313,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":28314,"interventions":28315},[85],[15],[1667,1102,1171,5480,2074,2093,1093],{"nctId":2067,"briefTitle":2068,"status":103,"phases":28317,"primaryCompletion":1300,"completion":1300,"start":2070,"enrollment":2071,"conditions":28318,"interventions":28319},[85],[15],[2043,1538,2074],{"nctId":16965,"briefTitle":16966,"status":103,"phases":28321,"primaryCompletion":2966,"completion":2966,"start":3004,"enrollment":12,"conditions":28322,"interventions":28323},[85],[4937],[13957,2074],{"trials":28325,"activeCount":97},[],{"trials":28327,"activeCount":97},[],{"trials":28329,"activeCount":97},[],{"trials":28331,"activeCount":97},[],{"intervention":17603,"totalTrials":1232,"cells":28333},{"EARLY_PHASE1":28334,"PHASE1":28336,"PHASE2":28350,"PHASE3":28352,"PHASE4":28354,"NA":28356},{"trials":28335,"activeCount":97},[],{"trials":28337,"activeCount":97},[28338,28342,28346],{"nctId":18313,"briefTitle":18314,"status":103,"phases":28339,"primaryCompletion":3004,"completion":5090,"start":3004,"enrollment":1071,"conditions":28340,"interventions":28341},[85],[15],[18296,17603],{"nctId":22344,"briefTitle":22345,"status":103,"phases":28343,"primaryCompletion":2898,"completion":2898,"start":3545,"enrollment":1082,"conditions":28344,"interventions":28345},[85],[33],[9643,17603],{"nctId":17596,"briefTitle":17597,"status":103,"phases":28347,"primaryCompletion":8217,"completion":8217,"start":3283,"enrollment":310,"conditions":28348,"interventions":28349},[85],[18],[9681,17601,17602,17603],{"trials":28351,"activeCount":97},[],{"trials":28353,"activeCount":97},[],{"trials":28355,"activeCount":97},[],{"trials":28357,"activeCount":97},[],{"intervention":19049,"totalTrials":1232,"cells":28359},{"EARLY_PHASE1":28360,"PHASE1":28362,"PHASE2":28380,"PHASE3":28382,"PHASE4":28384,"NA":28386},{"trials":28361,"activeCount":97},[],{"trials":28363,"activeCount":97},[28364,28370,28376],{"nctId":28365,"briefTitle":28366,"status":103,"phases":28367,"primaryCompletion":2844,"completion":2844,"start":3029,"enrollment":9038,"conditions":28368,"interventions":28369},"NCT01248052","A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers",[85],[4919],[19049],{"nctId":28371,"briefTitle":28372,"status":103,"phases":28373,"primaryCompletion":3838,"completion":3838,"start":6093,"enrollment":9083,"conditions":28374,"interventions":28375},"NCT01383967","A Study of LY2979165 in Healthy Subjects",[85],[4919],[19049],{"nctId":19044,"briefTitle":19045,"status":103,"phases":28377,"primaryCompletion":3027,"completion":3027,"start":2864,"enrollment":251,"conditions":28378,"interventions":28379},[85],[21],[19049,14381],{"trials":28381,"activeCount":97},[],{"trials":28383,"activeCount":97},[],{"trials":28385,"activeCount":97},[],{"trials":28387,"activeCount":97},[],{"intervention":22668,"totalTrials":947,"cells":28389},{"EARLY_PHASE1":28390,"PHASE1":28392,"PHASE2":28402,"PHASE3":28404,"PHASE4":28406,"NA":28408},{"trials":28391,"activeCount":97},[],{"trials":28393,"activeCount":97},[28394,28398],{"nctId":22663,"briefTitle":22664,"status":999,"phases":28395,"primaryCompletion":3348,"completion":3348,"start":3838,"enrollment":3041,"conditions":28396,"interventions":28397},[85],[21],[22668,22669,2092],{"nctId":22920,"briefTitle":22921,"status":103,"phases":28399,"primaryCompletion":22923,"completion":22923,"start":22924,"enrollment":864,"conditions":28400,"interventions":28401},[85],[21],[22668,22669],{"trials":28403,"activeCount":97},[],{"trials":28405,"activeCount":97},[],{"trials":28407,"activeCount":97},[],{"trials":28409,"activeCount":97},[],{"intervention":28411,"totalTrials":947,"cells":28412},"Mirikizumab Prefilled Syringe",{"EARLY_PHASE1":28413,"PHASE1":28415,"PHASE2":28432,"PHASE3":28434,"PHASE4":28436,"NA":28438},{"trials":28414,"activeCount":97},[],{"trials":28416,"activeCount":97},[28417,28425],{"nctId":28418,"briefTitle":28419,"status":103,"phases":28420,"primaryCompletion":1291,"completion":1291,"start":28421,"enrollment":1790,"conditions":28422,"interventions":28423},"NCT05069896","A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants",[85],"2021-10-05",[15],[28411,28424],"Mirikizumab Autoinjector",{"nctId":28426,"briefTitle":28427,"status":103,"phases":28428,"primaryCompletion":28429,"completion":28429,"start":18085,"enrollment":2502,"conditions":28430,"interventions":28431},"NCT04607733","A Study of Mirikizumab in Healthy Participants",[85],"2021-05-17",[15],[28411,28424],{"trials":28433,"activeCount":97},[],{"trials":28435,"activeCount":97},[],{"trials":28437,"activeCount":97},[],{"trials":28439,"activeCount":97},[],{"intervention":28424,"totalTrials":947,"cells":28441},{"EARLY_PHASE1":28442,"PHASE1":28444,"PHASE2":28454,"PHASE3":28456,"PHASE4":28458,"NA":28460},{"trials":28443,"activeCount":97},[],{"trials":28445,"activeCount":97},[28446,28450],{"nctId":28418,"briefTitle":28419,"status":103,"phases":28447,"primaryCompletion":1291,"completion":1291,"start":28421,"enrollment":1790,"conditions":28448,"interventions":28449},[85],[15],[28411,28424],{"nctId":28426,"briefTitle":28427,"status":103,"phases":28451,"primaryCompletion":28429,"completion":28429,"start":18085,"enrollment":2502,"conditions":28452,"interventions":28453},[85],[15],[28411,28424],{"trials":28455,"activeCount":97},[],{"trials":28457,"activeCount":97},[],{"trials":28459,"activeCount":97},[],{"trials":28461,"activeCount":97},[],{"intervention":28463,"totalTrials":947,"cells":28464},"Blosozumab",{"EARLY_PHASE1":28465,"PHASE1":28467,"PHASE2":28481,"PHASE3":28483,"PHASE4":28485,"NA":28487},{"trials":28466,"activeCount":97},[],{"trials":28468,"activeCount":97},[28469,28475],{"nctId":28470,"briefTitle":28471,"status":999,"phases":28472,"primaryCompletion":1596,"completion":1596,"start":5030,"enrollment":165,"conditions":28473,"interventions":28474},"NCT02337387","A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women",[85],[14168],[28463],{"nctId":28476,"briefTitle":28477,"status":103,"phases":28478,"primaryCompletion":7316,"completion":7316,"start":1475,"enrollment":1158,"conditions":28479,"interventions":28480},"NCT02109042","A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants",[85],[14168],[28463],{"trials":28482,"activeCount":97},[],{"trials":28484,"activeCount":97},[],{"trials":28486,"activeCount":97},[],{"trials":28488,"activeCount":97},[],{"intervention":28490,"totalTrials":947,"cells":28491},"LY2541546 - IV",{"EARLY_PHASE1":28492,"PHASE1":28494,"PHASE2":28509,"PHASE3":28511,"PHASE4":28513,"NA":28515},{"trials":28493,"activeCount":97},[],{"trials":28495,"activeCount":97},[28496,28503],{"nctId":28497,"briefTitle":28498,"status":103,"phases":28499,"primaryCompletion":2918,"completion":2918,"start":3575,"enrollment":874,"conditions":28500,"interventions":28501},"NCT01742078","A Study of LY2541546 in Healthy Postmenopausal Women",[85],[15],[28490,28502],"LY2541546 - SC",{"nctId":28504,"briefTitle":28505,"status":103,"phases":28506,"primaryCompletion":3419,"completion":3419,"start":14517,"enrollment":2996,"conditions":28507,"interventions":28508},"NCT01742091","A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women",[85],[15],[28502,28490],{"trials":28510,"activeCount":97},[],{"trials":28512,"activeCount":97},[],{"trials":28514,"activeCount":97},[],{"trials":28516,"activeCount":97},[],{"intervention":28502,"totalTrials":947,"cells":28518},{"EARLY_PHASE1":28519,"PHASE1":28521,"PHASE2":28531,"PHASE3":28533,"PHASE4":28535,"NA":28537},{"trials":28520,"activeCount":97},[],{"trials":28522,"activeCount":97},[28523,28527],{"nctId":28497,"briefTitle":28498,"status":103,"phases":28524,"primaryCompletion":2918,"completion":2918,"start":3575,"enrollment":874,"conditions":28525,"interventions":28526},[85],[15],[28490,28502],{"nctId":28504,"briefTitle":28505,"status":103,"phases":28528,"primaryCompletion":3419,"completion":3419,"start":14517,"enrollment":2996,"conditions":28529,"interventions":28530},[85],[15],[28502,28490],{"trials":28532,"activeCount":97},[],{"trials":28534,"activeCount":97},[],{"trials":28536,"activeCount":97},[],{"trials":28538,"activeCount":97},[],{"intervention":8760,"totalTrials":947,"cells":28540},{"EARLY_PHASE1":28541,"PHASE1":28543,"PHASE2":28553,"PHASE3":28555,"PHASE4":28557,"NA":28559},{"trials":28542,"activeCount":97},[],{"trials":28544,"activeCount":97},[28545,28549],{"nctId":8751,"briefTitle":8752,"status":103,"phases":28546,"primaryCompletion":8754,"completion":8755,"start":8756,"enrollment":4353,"conditions":28547,"interventions":28548},[85],[1478],[2545,5985,8759,1745,8760],{"nctId":18165,"briefTitle":18166,"status":103,"phases":28550,"primaryCompletion":18168,"completion":18169,"start":13481,"enrollment":290,"conditions":28551,"interventions":28552},[85],[1506],[2545,5985,8760,18172],{"trials":28554,"activeCount":97},[],{"trials":28556,"activeCount":97},[],{"trials":28558,"activeCount":97},[],{"trials":28560,"activeCount":97},[],{"intervention":17281,"totalTrials":947,"cells":28562},{"EARLY_PHASE1":28563,"PHASE1":28565,"PHASE2":28575,"PHASE3":28577,"PHASE4":28579,"NA":28581},{"trials":28564,"activeCount":97},[],{"trials":28566,"activeCount":97},[28567,28571],{"nctId":22308,"briefTitle":22309,"status":103,"phases":28568,"primaryCompletion":4980,"completion":4980,"start":3282,"enrollment":1620,"conditions":28569,"interventions":28570},[85],[21],[9643,17281,4983,1480],{"nctId":17276,"briefTitle":17277,"status":103,"phases":28572,"primaryCompletion":4420,"completion":4420,"start":4122,"enrollment":290,"conditions":28573,"interventions":28574},[85],[21],[17257,17281],{"trials":28576,"activeCount":97},[],{"trials":28578,"activeCount":97},[],{"trials":28580,"activeCount":97},[],{"trials":28582,"activeCount":97},[],{"intervention":17060,"totalTrials":947,"cells":28584},{"EARLY_PHASE1":28585,"PHASE1":28587,"PHASE2":28597,"PHASE3":28599,"PHASE4":28601,"NA":28603},{"trials":28586,"activeCount":97},[],{"trials":28588,"activeCount":97},[28589,28593],{"nctId":17053,"briefTitle":17054,"status":103,"phases":28590,"primaryCompletion":17056,"completion":17056,"start":17057,"enrollment":963,"conditions":28591,"interventions":28592},[85],[7486],[17046,17060],{"nctId":17163,"briefTitle":17164,"status":103,"phases":28594,"primaryCompletion":17166,"completion":17166,"start":56,"enrollment":107,"conditions":28595,"interventions":28596},[85],[17168,17169],[17046,17060],{"trials":28598,"activeCount":97},[],{"trials":28600,"activeCount":97},[],{"trials":28602,"activeCount":97},[],{"trials":28604,"activeCount":97},[],{"intervention":28606,"totalTrials":947,"cells":28607},"LY2928057",{"EARLY_PHASE1":28608,"PHASE1":28610,"PHASE2":28625,"PHASE3":28627,"PHASE4":28629,"NA":28631},{"trials":28609,"activeCount":97},[],{"trials":28611,"activeCount":97},[28612,28619],{"nctId":28613,"briefTitle":28614,"status":103,"phases":28615,"primaryCompletion":3250,"completion":3250,"start":3049,"enrollment":165,"conditions":28616,"interventions":28618},"NCT01991483","A Study of LY2928057 in Hemodialysis Participants",[85],[22360,28617],"Kidney Disease, Chronic",[28606],{"nctId":28620,"briefTitle":28621,"status":103,"phases":28622,"primaryCompletion":3494,"completion":3494,"start":3837,"enrollment":310,"conditions":28623,"interventions":28624},"NCT01330953","A First Human Study of a Ferroportin Antibody",[85],[21],[28606],{"trials":28626,"activeCount":97},[],{"trials":28628,"activeCount":97},[],{"trials":28630,"activeCount":97},[],{"trials":28632,"activeCount":97},[],{"intervention":6966,"totalTrials":947,"cells":28634},{"EARLY_PHASE1":28635,"PHASE1":28637,"PHASE2":28647,"PHASE3":28649,"PHASE4":28651,"NA":28653},{"trials":28636,"activeCount":97},[],{"trials":28638,"activeCount":97},[28639,28643],{"nctId":17283,"briefTitle":17284,"status":103,"phases":28640,"primaryCompletion":3282,"completion":3282,"start":4122,"enrollment":1488,"conditions":28641,"interventions":28642},[85],[21],[6966,17257],{"nctId":6961,"briefTitle":6962,"status":103,"phases":28644,"primaryCompletion":3086,"completion":3086,"start":3004,"enrollment":6633,"conditions":28645,"interventions":28646},[85],[18],[6966,303],{"trials":28648,"activeCount":97},[],{"trials":28650,"activeCount":97},[],{"trials":28652,"activeCount":97},[],{"trials":28654,"activeCount":97},[],{"intervention":28656,"totalTrials":947,"cells":28657},"LY3050258",{"EARLY_PHASE1":28658,"PHASE1":28660,"PHASE2":28673,"PHASE3":28675,"PHASE4":28677,"NA":28679},{"trials":28659,"activeCount":97},[],{"trials":28661,"activeCount":97},[28662,28668],{"nctId":28663,"briefTitle":28664,"status":103,"phases":28665,"primaryCompletion":3049,"completion":3049,"start":2917,"enrollment":280,"conditions":28666,"interventions":28667},"NCT01929707","A Study of LY3050258 in Healthy Participants",[85],[4997],[28656],{"nctId":28669,"briefTitle":28664,"status":103,"phases":28670,"primaryCompletion":3776,"completion":3776,"start":5354,"enrollment":9415,"conditions":28671,"interventions":28672},"NCT02121834",[85],[21],[28656],{"trials":28674,"activeCount":97},[],{"trials":28676,"activeCount":97},[],{"trials":28678,"activeCount":97},[],{"trials":28680,"activeCount":97},[],{"intervention":11075,"totalTrials":947,"cells":28682},{"EARLY_PHASE1":28683,"PHASE1":28685,"PHASE2":28695,"PHASE3":28697,"PHASE4":28699,"NA":28701},{"trials":28684,"activeCount":97},[],{"trials":28686,"activeCount":97},[28687,28691],{"nctId":22204,"briefTitle":22205,"status":103,"phases":28688,"primaryCompletion":22207,"completion":22207,"start":1397,"enrollment":893,"conditions":28689,"interventions":28690},[85],[15],[7043,11075],{"nctId":11069,"briefTitle":11070,"status":103,"phases":28692,"primaryCompletion":1346,"completion":1346,"start":11072,"enrollment":874,"conditions":28693,"interventions":28694},[85],[15],[2768,11075],{"trials":28696,"activeCount":97},[],{"trials":28698,"activeCount":97},[],{"trials":28700,"activeCount":97},[],{"trials":28702,"activeCount":97},[],{"intervention":1509,"totalTrials":947,"cells":28704},{"EARLY_PHASE1":28705,"PHASE1":28707,"PHASE2":28719,"PHASE3":28721,"PHASE4":28723,"NA":28725},{"trials":28706,"activeCount":97},[],{"trials":28708,"activeCount":97},[28709,28713],{"nctId":1495,"briefTitle":1496,"status":999,"phases":28710,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":28711,"interventions":28712},[85],[1503,36,1504,1505,1506],[1508,1509,48,1510,1511,1512,1513],{"nctId":28714,"briefTitle":28715,"status":103,"phases":28716,"primaryCompletion":5030,"completion":7324,"start":3114,"enrollment":25,"conditions":28717,"interventions":28718},"NCT01226485","A Study in Advanced Cancer",[85],[1466],[1509],{"trials":28720,"activeCount":97},[],{"trials":28722,"activeCount":97},[],{"trials":28724,"activeCount":97},[],{"trials":28726,"activeCount":97},[],{"intervention":28728,"totalTrials":947,"cells":28729},"LY3866288",{"EARLY_PHASE1":28730,"PHASE1":28732,"PHASE2":28750,"PHASE3":28752,"PHASE4":28754,"NA":28756},{"trials":28731,"activeCount":97},[],{"trials":28733,"activeCount":97},[28734,28741],{"nctId":28735,"briefTitle":28736,"status":103,"phases":28737,"primaryCompletion":28738,"completion":28738,"start":23838,"enrollment":1158,"conditions":28739,"interventions":28740},"NCT06641037","A Study of LY3866288 in Healthy Participants",[85],"2024-12-02",[15],[28728],{"nctId":28742,"briefTitle":28743,"status":103,"phases":28744,"primaryCompletion":28745,"completion":28745,"start":28746,"enrollment":1158,"conditions":28747,"interventions":28748},"NCT06644378","A Study of [14C]-LY3866288 in Healthy Participants",[85],"2025-01-03","2024-10-28",[15],[28749,28728,28749],"[14C]-LY3866288",{"trials":28751,"activeCount":97},[],{"trials":28753,"activeCount":97},[],{"trials":28755,"activeCount":97},[],{"trials":28757,"activeCount":97},[],{"intervention":28229,"totalTrials":947,"cells":28759},{"EARLY_PHASE1":28760,"PHASE1":28762,"PHASE2":28772,"PHASE3":28774,"PHASE4":28776,"NA":28778},{"trials":28761,"activeCount":97},[],{"trials":28763,"activeCount":97},[28764,28768],{"nctId":28224,"briefTitle":28225,"status":103,"phases":28765,"primaryCompletion":694,"completion":694,"start":707,"enrollment":874,"conditions":28766,"interventions":28767},[85],[15],[28229,28217],{"nctId":28231,"briefTitle":28232,"status":103,"phases":28769,"primaryCompletion":28234,"completion":28235,"start":28236,"enrollment":4945,"conditions":28770,"interventions":28771},[85],[15],[28229,28217],{"trials":28773,"activeCount":97},[],{"trials":28775,"activeCount":97},[],{"trials":28777,"activeCount":97},[],{"trials":28779,"activeCount":97},[],{"intervention":28781,"totalTrials":947,"cells":28782},"LY3185643",{"EARLY_PHASE1":28783,"PHASE1":28785,"PHASE2":28803,"PHASE3":28805,"PHASE4":28807,"NA":28809},{"trials":28784,"activeCount":97},[],{"trials":28786,"activeCount":97},[28787,28795],{"nctId":28788,"briefTitle":28789,"status":103,"phases":28790,"primaryCompletion":6390,"completion":6390,"start":5030,"enrollment":4353,"conditions":28791,"interventions":28792},"NCT02342314","A Study of LY3143753 and LY3185643 in Healthy Participants",[85],[15],[28793,28781,28794],"LY3143753","rGlucagon",{"nctId":28796,"briefTitle":28797,"status":103,"phases":28798,"primaryCompletion":28799,"completion":18671,"start":28800,"enrollment":1488,"conditions":28801,"interventions":28802},"NCT02951780","A Study of LY3185643 and rGlucagon in Healthy Participants",[85],"2017-01-24","2016-11-01",[15],[28781,28794],{"trials":28804,"activeCount":97},[],{"trials":28806,"activeCount":97},[],{"trials":28808,"activeCount":97},[],{"trials":28810,"activeCount":97},[],{"intervention":28794,"totalTrials":947,"cells":28812},{"EARLY_PHASE1":28813,"PHASE1":28815,"PHASE2":28825,"PHASE3":28827,"PHASE4":28829,"NA":28831},{"trials":28814,"activeCount":97},[],{"trials":28816,"activeCount":97},[28817,28821],{"nctId":28788,"briefTitle":28789,"status":103,"phases":28818,"primaryCompletion":6390,"completion":6390,"start":5030,"enrollment":4353,"conditions":28819,"interventions":28820},[85],[15],[28793,28781,28794],{"nctId":28796,"briefTitle":28797,"status":103,"phases":28822,"primaryCompletion":28799,"completion":18671,"start":28800,"enrollment":1488,"conditions":28823,"interventions":28824},[85],[15],[28781,28794],{"trials":28826,"activeCount":97},[],{"trials":28828,"activeCount":97},[],{"trials":28830,"activeCount":97},[],{"trials":28832,"activeCount":97},[],{"intervention":10914,"totalTrials":947,"cells":28834},{"EARLY_PHASE1":28835,"PHASE1":28837,"PHASE2":28851,"PHASE3":28853,"PHASE4":28855,"NA":28857},{"trials":28836,"activeCount":97},[],{"trials":28838,"activeCount":97},[28839,28843],{"nctId":10907,"briefTitle":10908,"status":999,"phases":28840,"primaryCompletion":10910,"completion":10910,"start":1156,"enrollment":10911,"conditions":28841,"interventions":28842},[85],[15],[10914,2562,1538],{"nctId":28844,"briefTitle":28845,"status":999,"phases":28846,"primaryCompletion":23165,"completion":23165,"start":7463,"enrollment":1620,"conditions":28847,"interventions":28848},"NCT04152382","A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis",[85],[447],[28849,28850,10914],"LY3462817 - IV","LY3462817 - SC",{"trials":28852,"activeCount":97},[],{"trials":28854,"activeCount":97},[],{"trials":28856,"activeCount":97},[],{"trials":28858,"activeCount":97},[],{"intervention":1537,"totalTrials":947,"cells":28860},{"EARLY_PHASE1":28861,"PHASE1":28863,"PHASE2":28877,"PHASE3":28879,"PHASE4":28881,"NA":28883},{"trials":28862,"activeCount":97},[],{"trials":28864,"activeCount":97},[28865,28869],{"nctId":1527,"briefTitle":1528,"status":103,"phases":28866,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":28867,"interventions":28868},[85],[1466,1534,1535,1490],[1537,1538,48,1539,1511,1540,1541],{"nctId":28870,"briefTitle":28871,"status":103,"phases":28872,"primaryCompletion":5201,"completion":5201,"start":28873,"enrollment":1677,"conditions":28874,"interventions":28875},"NCT04033341","A Study of LY3214996 in Healthy Participants",[85],"2019-08-01",[15],[1537,28876],"[14C]-LY3214996",{"trials":28878,"activeCount":97},[],{"trials":28880,"activeCount":97},[],{"trials":28882,"activeCount":97},[],{"trials":28884,"activeCount":97},[],{"intervention":22855,"totalTrials":947,"cells":28886},{"EARLY_PHASE1":28887,"PHASE1":28889,"PHASE2":28899,"PHASE3":28901,"PHASE4":28903,"NA":28905},{"trials":28888,"activeCount":97},[],{"trials":28890,"activeCount":97},[28891,28895],{"nctId":22850,"briefTitle":22851,"status":103,"phases":28892,"primaryCompletion":3662,"completion":3662,"start":3160,"enrollment":9038,"conditions":28893,"interventions":28894},[85],[2824],[3117,22855,22855,22855,22855],{"nctId":22863,"briefTitle":22864,"status":103,"phases":28896,"primaryCompletion":5860,"completion":5860,"start":4538,"enrollment":5922,"conditions":28897,"interventions":28898},[85],[2802],[3117,22855,22855,22855,22855,22855,22855],{"trials":28900,"activeCount":97},[],{"trials":28902,"activeCount":97},[],{"trials":28904,"activeCount":97},[],{"trials":28906,"activeCount":97},[],{"intervention":14247,"totalTrials":947,"cells":28908},{"EARLY_PHASE1":28909,"PHASE1":28911,"PHASE2":28923,"PHASE3":28925,"PHASE4":28927,"NA":28929},{"trials":28910,"activeCount":97},[],{"trials":28912,"activeCount":97},[28913,28919],{"nctId":28914,"briefTitle":28915,"status":103,"phases":28916,"primaryCompletion":2865,"completion":2865,"start":3086,"enrollment":2542,"conditions":28917,"interventions":28918},"NCT01528124","A Study of LY3025876 in Healthy Volunteers",[85],[21],[14247],{"nctId":14242,"briefTitle":14243,"status":103,"phases":28920,"primaryCompletion":3776,"completion":3776,"start":2964,"enrollment":1767,"conditions":28921,"interventions":28922},[85],[120],[14247,188],{"trials":28924,"activeCount":97},[],{"trials":28926,"activeCount":97},[],{"trials":28928,"activeCount":97},[],{"trials":28930,"activeCount":97},[],{"intervention":28932,"totalTrials":947,"cells":28933},"LY2784544",{"EARLY_PHASE1":28934,"PHASE1":28936,"PHASE2":28960,"PHASE3":28962,"PHASE4":28964,"NA":28966},{"trials":28935,"activeCount":97},[],{"trials":28937,"activeCount":97},[28938,28950],{"nctId":28939,"briefTitle":28940,"status":103,"phases":28941,"primaryCompletion":28942,"completion":28943,"start":28944,"enrollment":1692,"conditions":28945,"interventions":28949},"NCT01520220","Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms",[85],"2015-06-26","2017-02-24","2012-06-11",[28946,28947,23248,28948],"Myeloproliferative Neoplasms of","Polycythemia Vera","Myelofibrosis",[28932],{"nctId":28951,"briefTitle":28952,"status":103,"phases":28953,"primaryCompletion":1475,"completion":28954,"start":3251,"enrollment":4475,"conditions":28955,"interventions":28959},"NCT01134120","A Study in Myeloproliferative Disorders",[85],"2018-02-22",[28956,28957,28947,28958],"Myeloproliferative Disorders","Thrombocythemia, Essential","Primary Myelofibrosis",[28932],{"trials":28961,"activeCount":97},[],{"trials":28963,"activeCount":97},[],{"trials":28965,"activeCount":97},[],{"trials":28967,"activeCount":97},[],{"intervention":12912,"totalTrials":947,"cells":28969},{"EARLY_PHASE1":28970,"PHASE1":28972,"PHASE2":28988,"PHASE3":28990,"PHASE4":28992,"NA":28994},{"trials":28971,"activeCount":97},[],{"trials":28973,"activeCount":97},[28974,28978],{"nctId":12907,"briefTitle":12908,"status":103,"phases":28975,"primaryCompletion":1546,"completion":1546,"start":2799,"enrollment":1488,"conditions":28976,"interventions":28977},[85],[15],[12912,9698,438],{"nctId":28979,"briefTitle":28980,"status":103,"phases":28981,"primaryCompletion":7603,"completion":7603,"start":28982,"enrollment":233,"conditions":28983,"interventions":28984},"NCT05067270","A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus",[85],"2021-10-22",[9437],[28985,12912,28986,28987],"Sodium Citrate","Humalog diluent","Magnesium Chloride",{"trials":28989,"activeCount":97},[],{"trials":28991,"activeCount":97},[],{"trials":28993,"activeCount":97},[],{"trials":28995,"activeCount":97},[],{"intervention":2826,"totalTrials":947,"cells":28997},{"EARLY_PHASE1":28998,"PHASE1":29000,"PHASE2":29012,"PHASE3":29014,"PHASE4":29016,"NA":29018},{"trials":28999,"activeCount":97},[],{"trials":29001,"activeCount":97},[29002,29008],{"nctId":29003,"briefTitle":29004,"status":103,"phases":29005,"primaryCompletion":3717,"completion":3717,"start":1473,"enrollment":1488,"conditions":29006,"interventions":29007},"NCT02370485","A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children",[85],[15],[2826],{"nctId":2817,"briefTitle":2818,"status":103,"phases":29009,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":377,"conditions":29010,"interventions":29011},[85],[2824],[2826,1541,1510,1511,61],{"trials":29013,"activeCount":97},[],{"trials":29015,"activeCount":97},[],{"trials":29017,"activeCount":97},[],{"trials":29019,"activeCount":97},[],{"intervention":7954,"totalTrials":947,"cells":29021},{"EARLY_PHASE1":29022,"PHASE1":29024,"PHASE2":29038,"PHASE3":29040,"PHASE4":29042,"NA":29044},{"trials":29023,"activeCount":97},[],{"trials":29025,"activeCount":97},[29026,29030],{"nctId":7947,"briefTitle":7948,"status":103,"phases":29027,"primaryCompletion":7950,"completion":7950,"start":7951,"enrollment":1767,"conditions":29028,"interventions":29029},[85],[1503],[7954,2696,7955],{"nctId":29031,"briefTitle":29032,"status":103,"phases":29033,"primaryCompletion":29034,"completion":29034,"start":29035,"enrollment":3718,"conditions":29036,"interventions":29037},"NCT02265536","A Study of LY3022855 In Participants With Breast or Prostate Cancer",[85],"2017-11-03","2015-05-01",[1870,1478],[7954],{"trials":29039,"activeCount":97},[],{"trials":29041,"activeCount":97},[],{"trials":29043,"activeCount":97},[],{"trials":29045,"activeCount":97},[],{"intervention":28013,"totalTrials":947,"cells":29047},{"EARLY_PHASE1":29048,"PHASE1":29050,"PHASE2":29064,"PHASE3":29066,"PHASE4":29068,"NA":29070},{"trials":29049,"activeCount":97},[],{"trials":29051,"activeCount":97},[29052,29056],{"nctId":28006,"briefTitle":28007,"status":384,"phases":29053,"primaryCompletion":28009,"completion":28009,"start":28010,"enrollment":97,"conditions":29054,"interventions":29055},[85],[147],[28013,1632],{"nctId":29057,"briefTitle":29058,"status":384,"phases":29059,"primaryCompletion":29060,"completion":29060,"start":28010,"enrollment":97,"conditions":29061,"interventions":29062},"NCT03506399","A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive",[85],"2018-10",[15],[28013,29063],"Oral Contraceptive",{"trials":29065,"activeCount":97},[],{"trials":29067,"activeCount":97},[],{"trials":29069,"activeCount":97},[],{"trials":29071,"activeCount":97},[],{"intervention":27920,"totalTrials":947,"cells":29073},{"EARLY_PHASE1":29074,"PHASE1":29076,"PHASE2":29086,"PHASE3":29088,"PHASE4":29090,"NA":29092},{"trials":29075,"activeCount":97},[],{"trials":29077,"activeCount":97},[29078,29082],{"nctId":27915,"briefTitle":27916,"status":103,"phases":29079,"primaryCompletion":19939,"completion":19939,"start":8754,"enrollment":874,"conditions":29080,"interventions":29081},[85],[15],[27895,27920],{"nctId":27936,"briefTitle":27937,"status":103,"phases":29083,"primaryCompletion":27939,"completion":27939,"start":11313,"enrollment":1767,"conditions":29084,"interventions":29085},[85],[15],[27895,27920],{"trials":29087,"activeCount":97},[],{"trials":29089,"activeCount":97},[],{"trials":29091,"activeCount":97},[],{"trials":29093,"activeCount":97},[],{"intervention":29095,"totalTrials":947,"cells":29096},"LY2405319",{"EARLY_PHASE1":29097,"PHASE1":29099,"PHASE2":29113,"PHASE3":29115,"PHASE4":29117,"NA":29119},{"trials":29098,"activeCount":97},[],{"trials":29100,"activeCount":97},[29101,29107],{"nctId":29102,"briefTitle":29103,"status":103,"phases":29104,"primaryCompletion":5860,"completion":6883,"start":2846,"enrollment":128,"conditions":29105,"interventions":29106},"NCT01869959","A Study of LY2405319 in Participants With Type 2 Diabetes",[85],[18],[29095],{"nctId":29108,"briefTitle":29109,"status":103,"phases":29110,"completion":2928,"start":3216,"enrollment":5922,"conditions":29111,"interventions":29112},"NCT00481117","Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes",[85],[30],[29095],{"trials":29114,"activeCount":97},[],{"trials":29116,"activeCount":97},[],{"trials":29118,"activeCount":97},[],{"trials":29120,"activeCount":97},[],{"intervention":29122,"totalTrials":947,"cells":29123},"LY2922470",{"EARLY_PHASE1":29124,"PHASE1":29126,"PHASE2":29140,"PHASE3":29142,"PHASE4":29144,"NA":29146},{"trials":29125,"activeCount":97},[],{"trials":29127,"activeCount":97},[29128,29134],{"nctId":29129,"briefTitle":29130,"status":103,"phases":29131,"primaryCompletion":3112,"completion":3112,"start":2964,"enrollment":1587,"conditions":29132,"interventions":29133},"NCT01867216","A Study of Multiple Doses of LY2922470 in Participants With Diabetes",[85],[18],[29122],{"nctId":29135,"briefTitle":29136,"status":103,"phases":29137,"primaryCompletion":3124,"completion":3124,"start":4122,"enrollment":893,"conditions":29138,"interventions":29139},"NCT01746017","A Study of LY2922470 in Healthy Participants and Participants With Diabetes",[85],[18],[29122],{"trials":29141,"activeCount":97},[],{"trials":29143,"activeCount":97},[],{"trials":29145,"activeCount":97},[],{"trials":29147,"activeCount":97},[],{"intervention":28057,"totalTrials":947,"cells":29149},{"EARLY_PHASE1":29150,"PHASE1":29152,"PHASE2":29162,"PHASE3":29164,"PHASE4":29166,"NA":29168},{"trials":29151,"activeCount":97},[],{"trials":29153,"activeCount":97},[29154,29158],{"nctId":28051,"briefTitle":28052,"status":103,"phases":29155,"primaryCompletion":9398,"completion":9398,"start":28054,"enrollment":233,"conditions":29156,"interventions":29157},[85],[15],[6946,28057],{"nctId":28059,"briefTitle":28060,"status":999,"phases":29159,"primaryCompletion":28062,"completion":28062,"start":2014,"enrollment":137,"conditions":29160,"interventions":29161},[85],[15],[6946,28065,28057],{"trials":29163,"activeCount":97},[],{"trials":29165,"activeCount":97},[],{"trials":29167,"activeCount":97},[],{"trials":29169,"activeCount":97},[],{"intervention":25578,"totalTrials":947,"cells":29171},{"EARLY_PHASE1":29172,"PHASE1":29174,"PHASE2":29186,"PHASE3":29188,"PHASE4":29190,"NA":29192},{"trials":29173,"activeCount":97},[],{"trials":29175,"activeCount":97},[29176,29180],{"nctId":25573,"briefTitle":25574,"status":103,"phases":29177,"primaryCompletion":5022,"completion":5022,"start":3282,"enrollment":290,"conditions":29178,"interventions":29179},[85],[21],[25578,23609],{"nctId":29181,"briefTitle":29182,"status":103,"phases":29183,"primaryCompletion":3027,"completion":3027,"start":3068,"enrollment":2071,"conditions":29184,"interventions":29185},"NCT01750853","A Study of LY3045697 in Healthy Participants",[85],[21],[25578],{"trials":29187,"activeCount":97},[],{"trials":29189,"activeCount":97},[],{"trials":29191,"activeCount":97},[],{"trials":29193,"activeCount":97},[],{"intervention":5480,"totalTrials":947,"cells":29195},{"EARLY_PHASE1":29196,"PHASE1":29198,"PHASE2":29208,"PHASE3":29210,"PHASE4":29212,"NA":29214},{"trials":29197,"activeCount":97},[],{"trials":29199,"activeCount":97},[29200,29204],{"nctId":5473,"briefTitle":5474,"status":103,"phases":29201,"primaryCompletion":5476,"completion":5476,"start":5477,"enrollment":2847,"conditions":29202,"interventions":29203},[85],[15],[1667,1102,1171,5480,2074,2093,1093],{"nctId":18838,"briefTitle":18839,"status":103,"phases":29205,"primaryCompletion":18841,"completion":18841,"start":5476,"enrollment":3041,"conditions":29206,"interventions":29207},[85],[15],[18844,5095,1172,5480,1538,1102],{"trials":29209,"activeCount":97},[],{"trials":29211,"activeCount":97},[],{"trials":29213,"activeCount":97},[],{"trials":29215,"activeCount":97},[],{"intervention":2804,"totalTrials":947,"cells":29217},{"EARLY_PHASE1":29218,"PHASE1":29220,"PHASE2":29230,"PHASE3":29232,"PHASE4":29234,"NA":29236},{"trials":29219,"activeCount":97},[],{"trials":29221,"activeCount":97},[29222,29226],{"nctId":2795,"briefTitle":2796,"status":999,"phases":29223,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":1808,"conditions":29224,"interventions":29225},[85],[2802],[1511,1722,1746,1510,1721,2804],{"nctId":5590,"briefTitle":5591,"status":103,"phases":29227,"primaryCompletion":4160,"completion":4160,"start":3094,"enrollment":3041,"conditions":29228,"interventions":29229},[85],[2589],[2804,1612],{"trials":29231,"activeCount":97},[],{"trials":29233,"activeCount":97},[],{"trials":29235,"activeCount":97},[],{"trials":29237,"activeCount":97},[],{"intervention":29239,"totalTrials":947,"cells":29240},"LY2624803 -",{"EARLY_PHASE1":29241,"PHASE1":29243,"PHASE2":29260,"PHASE3":29262,"PHASE4":29264,"NA":29266},{"trials":29242,"activeCount":97},[],{"trials":29244,"activeCount":97},[29245,29253],{"nctId":29246,"briefTitle":29247,"status":103,"phases":29248,"primaryCompletion":2974,"completion":2974,"start":3292,"enrollment":310,"conditions":29249,"interventions":29251},"NCT01779830","A Study of LY2624803 in Participants With Transient Insomnia",[85],[29250],"Transient Insomnia",[29239,29252],"Zolpidem -",{"nctId":29254,"briefTitle":29255,"status":103,"phases":29256,"primaryCompletion":3419,"completion":3419,"start":14517,"enrollment":290,"conditions":29257,"interventions":29258},"NCT01784614","A Study of LY2624803 in Japanese Participants With Transient Insomnia",[85],[26158],[29259,29239],"LY2624803 - Solution",{"trials":29261,"activeCount":97},[],{"trials":29263,"activeCount":97},[],{"trials":29265,"activeCount":97},[],{"trials":29267,"activeCount":97},[],{"intervention":29269,"totalTrials":947,"cells":29270},"LY3113593",{"EARLY_PHASE1":29271,"PHASE1":29273,"PHASE2":29289,"PHASE3":29291,"PHASE4":29293,"NA":29295},{"trials":29272,"activeCount":97},[],{"trials":29274,"activeCount":97},[29275,29283],{"nctId":29276,"briefTitle":29277,"status":103,"phases":29278,"primaryCompletion":29279,"completion":29279,"start":29280,"enrollment":1054,"conditions":29281,"interventions":29282},"NCT02604160","A Study of LY3113593 in Participants With Chronic Kidney Disease",[85],"2016-06-22","2015-11-17",[412],[29269],{"nctId":29284,"briefTitle":29285,"status":103,"phases":29286,"primaryCompletion":1474,"completion":1474,"start":5354,"enrollment":2867,"conditions":29287,"interventions":29288},"NCT02144285","A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis",[85],[8857],[29269,29269],{"trials":29290,"activeCount":97},[],{"trials":29292,"activeCount":97},[],{"trials":29294,"activeCount":97},[],{"trials":29296,"activeCount":97},[],{"intervention":217,"totalTrials":947,"cells":29298},{"EARLY_PHASE1":29299,"PHASE1":29301,"PHASE2":29311,"PHASE3":29313,"PHASE4":29315,"NA":29317},{"trials":29300,"activeCount":97},[],{"trials":29302,"activeCount":97},[29303,29307],{"nctId":209,"briefTitle":210,"status":103,"phases":29304,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":29305,"interventions":29306},[85],[27,24,18],[92,217],{"nctId":2084,"briefTitle":2085,"status":103,"phases":29308,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":29309,"interventions":29310},[85],[15,2090,27],[2043,2092,1093,2093,217,1538,2094],{"trials":29312,"activeCount":97},[],{"trials":29314,"activeCount":97},[],{"trials":29316,"activeCount":97},[],{"trials":29318,"activeCount":97},[],{"intervention":1657,"totalTrials":947,"cells":29320},{"EARLY_PHASE1":29321,"PHASE1":29323,"PHASE2":29333,"PHASE3":29335,"PHASE4":29337,"NA":29339},{"trials":29322,"activeCount":97},[],{"trials":29324,"activeCount":97},[29325,29329],{"nctId":11587,"briefTitle":11588,"status":103,"phases":29326,"primaryCompletion":1567,"completion":11590,"start":11591,"enrollment":11592,"conditions":29327,"interventions":29328},[85],[1503],[1657,1656],{"nctId":1643,"briefTitle":1644,"status":103,"phases":29330,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":1649,"conditions":29331,"interventions":29332},[85],[1503,1651,1652,1653,1654],[1656,61,48,1493,1657],{"trials":29334,"activeCount":97},[],{"trials":29336,"activeCount":97},[],{"trials":29338,"activeCount":97},[],{"trials":29340,"activeCount":97},[],{"intervention":11800,"totalTrials":947,"cells":29342},{"EARLY_PHASE1":29343,"PHASE1":29345,"PHASE2":29361,"PHASE3":29363,"PHASE4":29365,"NA":29367},{"trials":29344,"activeCount":97},[],{"trials":29346,"activeCount":97},[29347,29351],{"nctId":11795,"briefTitle":11796,"status":103,"phases":29348,"primaryCompletion":6592,"completion":6592,"start":47,"enrollment":6633,"conditions":29349,"interventions":29350},[85],[3980],[11800,11801,11780],{"nctId":29352,"briefTitle":29353,"status":103,"phases":29354,"primaryCompletion":29355,"completion":29355,"start":29356,"enrollment":1767,"conditions":29357,"interventions":29358},"NCT02754830","A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)",[85],"2018-07-10","2016-04-25",[4040],[11800,29359,29360],"Saline Solution - IV","LY3303560 - SC",{"trials":29362,"activeCount":97},[],{"trials":29364,"activeCount":97},[],{"trials":29366,"activeCount":97},[],{"trials":29368,"activeCount":97},[],{"intervention":1170,"totalTrials":947,"cells":29370},{"EARLY_PHASE1":29371,"PHASE1":29373,"PHASE2":29383,"PHASE3":29385,"PHASE4":29387,"NA":29389},{"trials":29372,"activeCount":97},[],{"trials":29374,"activeCount":97},[29375,29379],{"nctId":1164,"briefTitle":1165,"status":103,"phases":29376,"primaryCompletion":1167,"completion":1167,"start":872,"enrollment":1071,"conditions":29377,"interventions":29378},[85],[15],[1170,1171,1172,1070],{"nctId":22533,"briefTitle":22534,"status":103,"phases":29380,"primaryCompletion":10145,"completion":10145,"start":7021,"enrollment":310,"conditions":29381,"interventions":29382},[85],[24],[6982,1538,1172,1170],{"trials":29384,"activeCount":97},[],{"trials":29386,"activeCount":97},[],{"trials":29388,"activeCount":97},[],{"trials":29390,"activeCount":97},[],{"intervention":29392,"totalTrials":947,"cells":29393},"LY3090106",{"EARLY_PHASE1":29394,"PHASE1":29396,"PHASE2":29413,"PHASE3":29415,"PHASE4":29417,"NA":29419},{"trials":29395,"activeCount":97},[],{"trials":29397,"activeCount":97},[29398,29406],{"nctId":29399,"briefTitle":29400,"status":103,"phases":29401,"primaryCompletion":16651,"completion":16651,"start":29402,"enrollment":310,"conditions":29403,"interventions":29405},"NCT02614716","A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)",[85],"2015-12-10",[29404],"Sjögren's Syndrome",[29392],{"nctId":29407,"briefTitle":29408,"status":103,"phases":29409,"primaryCompletion":9693,"completion":9693,"start":29410,"enrollment":1620,"conditions":29411,"interventions":29412},"NCT03736772","A Study of LY3090106 in Japanese and Caucasian Healthy Participants",[85],"2018-11-19",[15],[29392],{"trials":29414,"activeCount":97},[],{"trials":29416,"activeCount":97},[],{"trials":29418,"activeCount":97},[],{"trials":29420,"activeCount":97},[],{"intervention":2094,"totalTrials":947,"cells":29422},{"EARLY_PHASE1":29423,"PHASE1":29425,"PHASE2":29435,"PHASE3":29437,"PHASE4":29439,"NA":29441},{"trials":29424,"activeCount":97},[],{"trials":29426,"activeCount":97},[29427,29431],{"nctId":2084,"briefTitle":2085,"status":103,"phases":29428,"primaryCompletion":2087,"completion":2087,"start":1899,"enrollment":2088,"conditions":29429,"interventions":29430},[85],[15,2090,27],[2043,2092,1093,2093,217,1538,2094],{"nctId":19035,"briefTitle":19036,"status":103,"phases":29432,"primaryCompletion":3004,"completion":3004,"start":3494,"enrollment":1620,"conditions":29433,"interventions":29434},[85],[19039],[14381,19041,19042],{"trials":29436,"activeCount":97},[],{"trials":29438,"activeCount":97},[],{"trials":29440,"activeCount":97},[],{"trials":29442,"activeCount":97},[],{"intervention":29444,"totalTrials":314,"cells":29445},"LY110140",{"EARLY_PHASE1":29446,"PHASE1":29448,"PHASE2":29456,"PHASE3":29458,"PHASE4":29460,"NA":29462},{"trials":29447,"activeCount":97},[],{"trials":29449,"activeCount":97},[29450],{"nctId":29451,"briefTitle":29452,"status":103,"phases":29453,"primaryCompletion":2898,"completion":2898,"start":2864,"enrollment":6943,"conditions":29454,"interventions":29455},"NCT01569126","A Study of LY110140 in Healthy Japanese Male Participants",[85],[23499],[29444],{"trials":29457,"activeCount":97},[],{"trials":29459,"activeCount":97},[],{"trials":29461,"activeCount":97},[],{"trials":29463,"activeCount":97},[],{"intervention":29465,"totalTrials":314,"cells":29466},"LY2334737",{"EARLY_PHASE1":29467,"PHASE1":29469,"PHASE2":29478,"PHASE3":29480,"PHASE4":29482,"NA":29484},{"trials":29468,"activeCount":97},[],{"trials":29470,"activeCount":97},[29471],{"nctId":29472,"briefTitle":29473,"status":103,"phases":29474,"primaryCompletion":3048,"completion":3048,"start":3320,"enrollment":93,"conditions":29475,"interventions":29477},"NCT01648764","A Study of LY2334737 in Participants With Cancer That is Advanced and\u002For Has Spread",[85],[2968,1503,29476],"Metastatic Tumor",[29465],{"trials":29479,"activeCount":97},[],{"trials":29481,"activeCount":97},[],{"trials":29483,"activeCount":97},[],{"trials":29485,"activeCount":97},[],{"intervention":11539,"totalTrials":314,"cells":29487},{"EARLY_PHASE1":29488,"PHASE1":29490,"PHASE2":29496,"PHASE3":29498,"PHASE4":29500,"NA":29502},{"trials":29489,"activeCount":97},[],{"trials":29491,"activeCount":97},[29492],{"nctId":11534,"briefTitle":11535,"status":103,"phases":29493,"primaryCompletion":1473,"completion":1473,"start":5030,"enrollment":205,"conditions":29494,"interventions":29495},[85],[21],[3870,11539],{"trials":29497,"activeCount":97},[],{"trials":29499,"activeCount":97},[],{"trials":29501,"activeCount":97},[],{"trials":29503,"activeCount":97},[],{"intervention":29505,"totalTrials":314,"cells":29506},"LY3006072",{"EARLY_PHASE1":29507,"PHASE1":29509,"PHASE2":29519,"PHASE3":29521,"PHASE4":29523,"NA":29525},{"trials":29508,"activeCount":97},[],{"trials":29510,"activeCount":97},[29511],{"nctId":29512,"briefTitle":29513,"status":999,"phases":29514,"primaryCompletion":29515,"completion":29515,"start":29516,"enrollment":12,"conditions":29517,"interventions":29518},"NCT01640249","A Study of LY3006072 in Healthy Participants",[85],"2012-11-26","2012-07-24",[21],[29505],{"trials":29520,"activeCount":97},[],{"trials":29522,"activeCount":97},[],{"trials":29524,"activeCount":97},[],{"trials":29526,"activeCount":97},[],{"intervention":22187,"totalTrials":314,"cells":29528},{"EARLY_PHASE1":29529,"PHASE1":29531,"PHASE2":29537,"PHASE3":29539,"PHASE4":29541,"NA":29543},{"trials":29530,"activeCount":97},[],{"trials":29532,"activeCount":97},[29533],{"nctId":22181,"briefTitle":22182,"status":103,"phases":29534,"primaryCompletion":22184,"completion":22184,"start":13467,"enrollment":310,"conditions":29535,"interventions":29536},[85],[15],[1538,7043,22187],{"trials":29538,"activeCount":97},[],{"trials":29540,"activeCount":97},[],{"trials":29542,"activeCount":97},[],{"trials":29544,"activeCount":97},[],{"intervention":29546,"totalTrials":314,"cells":29547},"LY3002813-IV",{"EARLY_PHASE1":29548,"PHASE1":29550,"PHASE2":29561,"PHASE3":29563,"PHASE4":29565,"NA":29567},{"trials":29549,"activeCount":97},[],{"trials":29551,"activeCount":97},[29552],{"nctId":29553,"briefTitle":29554,"status":103,"phases":29555,"primaryCompletion":29556,"completion":29556,"start":29557,"enrollment":9415,"conditions":29558,"interventions":29559},"NCT01837641","A Study of LY3002813 in Participants With Alzheimer's Disease",[85],"2016-08-24","2013-05-03",[3980],[29546,29560],"LY3002813-SC",{"trials":29562,"activeCount":97},[],{"trials":29564,"activeCount":97},[],{"trials":29566,"activeCount":97},[],{"trials":29568,"activeCount":97},[],{"intervention":29560,"totalTrials":314,"cells":29570},{"EARLY_PHASE1":29571,"PHASE1":29573,"PHASE2":29579,"PHASE3":29581,"PHASE4":29583,"NA":29585},{"trials":29572,"activeCount":97},[],{"trials":29574,"activeCount":97},[29575],{"nctId":29553,"briefTitle":29554,"status":103,"phases":29576,"primaryCompletion":29556,"completion":29556,"start":29557,"enrollment":9415,"conditions":29577,"interventions":29578},[85],[3980],[29546,29560],{"trials":29580,"activeCount":97},[],{"trials":29582,"activeCount":97},[],{"trials":29584,"activeCount":97},[],{"trials":29586,"activeCount":97},[],{"intervention":29588,"totalTrials":314,"cells":29589},"gp75 DNA vaccine",{"EARLY_PHASE1":29590,"PHASE1":29592,"PHASE2":29601,"PHASE3":29603,"PHASE4":29605,"NA":29607},{"trials":29591,"activeCount":97},[],{"trials":29593,"activeCount":97},[29594],{"nctId":29595,"briefTitle":29596,"status":103,"phases":29597,"primaryCompletion":3039,"completion":3039,"start":4366,"enrollment":1178,"conditions":29598,"interventions":29600},"NCT00034554","Study of gp75 Vaccine in Patients With Stage III and IV Melanoma",[85],[29599],"Malignant Melanoma",[29588],{"trials":29602,"activeCount":97},[],{"trials":29604,"activeCount":97},[],{"trials":29606,"activeCount":97},[],{"trials":29608,"activeCount":97},[],{"intervention":29610,"totalTrials":314,"cells":29611},"LY3405105",{"EARLY_PHASE1":29612,"PHASE1":29614,"PHASE2":29624,"PHASE3":29626,"PHASE4":29628,"NA":29630},{"trials":29613,"activeCount":97},[],{"trials":29615,"activeCount":97},[29616],{"nctId":29617,"briefTitle":29618,"status":999,"phases":29619,"primaryCompletion":29620,"completion":29620,"start":29621,"enrollment":31,"conditions":29622,"interventions":29623},"NCT03770494","A Study of LY3405105 in Participants With Advanced Cancer",[85],"2021-02-04","2019-01-31",[1503],[29610],{"trials":29625,"activeCount":97},[],{"trials":29627,"activeCount":97},[],{"trials":29629,"activeCount":97},[],{"trials":29631,"activeCount":97},[],{"intervention":6381,"totalTrials":314,"cells":29633},{"EARLY_PHASE1":29634,"PHASE1":29636,"PHASE2":29642,"PHASE3":29644,"PHASE4":29646,"NA":29648},{"trials":29635,"activeCount":97},[],{"trials":29637,"activeCount":97},[29638],{"nctId":6374,"briefTitle":6375,"status":103,"phases":29639,"primaryCompletion":6377,"completion":562,"start":6378,"enrollment":22,"conditions":29640,"interventions":29641},[85],[3062,3399,1718,2608],[61,6381],{"trials":29643,"activeCount":97},[],{"trials":29645,"activeCount":97},[],{"trials":29647,"activeCount":97},[],{"trials":29649,"activeCount":97},[],{"intervention":29651,"totalTrials":314,"cells":29652},"LY2881835",{"EARLY_PHASE1":29653,"PHASE1":29655,"PHASE2":29665,"PHASE3":29667,"PHASE4":29669,"NA":29671},{"trials":29654,"activeCount":97},[],{"trials":29656,"activeCount":97},[29657],{"nctId":29658,"briefTitle":29659,"status":103,"phases":29660,"primaryCompletion":29661,"completion":29661,"start":29662,"enrollment":12,"conditions":29663,"interventions":29664},"NCT01358981","A Study of LY2881835 in Healthy People and People With Diabetes",[85],"2011-08-17","2011-05-24",[18],[29651],{"trials":29666,"activeCount":97},[],{"trials":29668,"activeCount":97},[],{"trials":29670,"activeCount":97},[],{"trials":29672,"activeCount":97},[],{"intervention":22974,"totalTrials":314,"cells":29674},{"EARLY_PHASE1":29675,"PHASE1":29677,"PHASE2":29683,"PHASE3":29685,"PHASE4":29687,"NA":29689},{"trials":29676,"activeCount":97},[],{"trials":29678,"activeCount":97},[29679],{"nctId":22969,"briefTitle":22970,"status":103,"phases":29680,"primaryCompletion":7775,"completion":7775,"start":4383,"enrollment":1071,"conditions":29681,"interventions":29682},[85],[15],[10978,22974],{"trials":29684,"activeCount":97},[],{"trials":29686,"activeCount":97},[],{"trials":29688,"activeCount":97},[],{"trials":29690,"activeCount":97},[],{"intervention":24220,"totalTrials":314,"cells":29692},{"EARLY_PHASE1":29693,"PHASE1":29695,"PHASE2":29701,"PHASE3":29703,"PHASE4":29705,"NA":29707},{"trials":29694,"activeCount":97},[],{"trials":29696,"activeCount":97},[29697],{"nctId":24215,"briefTitle":24216,"status":103,"phases":29698,"primaryCompletion":2875,"completion":2875,"start":3646,"enrollment":874,"conditions":29699,"interventions":29700},[85],[2589],[10770,10770,10770,24220,10770,10770,10770,10770,10770,10770,10770,10770],{"trials":29702,"activeCount":97},[],{"trials":29704,"activeCount":97},[],{"trials":29706,"activeCount":97},[],{"trials":29708,"activeCount":97},[],{"intervention":29710,"totalTrials":314,"cells":29711},"LY3374849 - SC",{"EARLY_PHASE1":29712,"PHASE1":29714,"PHASE2":29726,"PHASE3":29728,"PHASE4":29730,"NA":29732},{"trials":29713,"activeCount":97},[],{"trials":29715,"activeCount":97},[29716],{"nctId":29717,"briefTitle":29718,"status":103,"phases":29719,"primaryCompletion":29720,"completion":29720,"start":502,"enrollment":2939,"conditions":29721,"interventions":29722},"NCT03726125","A Study of LY3374849 in Healthy Participants",[85],"2019-09-27",[15],[29710,29723,29724,29725],"Insulin Degludec - SC","LY3374849 - IV","Insulin Degludec - IV",{"trials":29727,"activeCount":97},[],{"trials":29729,"activeCount":97},[],{"trials":29731,"activeCount":97},[],{"trials":29733,"activeCount":97},[],{"intervention":29723,"totalTrials":314,"cells":29735},{"EARLY_PHASE1":29736,"PHASE1":29738,"PHASE2":29744,"PHASE3":29746,"PHASE4":29748,"NA":29750},{"trials":29737,"activeCount":97},[],{"trials":29739,"activeCount":97},[29740],{"nctId":29717,"briefTitle":29718,"status":103,"phases":29741,"primaryCompletion":29720,"completion":29720,"start":502,"enrollment":2939,"conditions":29742,"interventions":29743},[85],[15],[29710,29723,29724,29725],{"trials":29745,"activeCount":97},[],{"trials":29747,"activeCount":97},[],{"trials":29749,"activeCount":97},[],{"trials":29751,"activeCount":97},[],{"intervention":29724,"totalTrials":314,"cells":29753},{"EARLY_PHASE1":29754,"PHASE1":29756,"PHASE2":29762,"PHASE3":29764,"PHASE4":29766,"NA":29768},{"trials":29755,"activeCount":97},[],{"trials":29757,"activeCount":97},[29758],{"nctId":29717,"briefTitle":29718,"status":103,"phases":29759,"primaryCompletion":29720,"completion":29720,"start":502,"enrollment":2939,"conditions":29760,"interventions":29761},[85],[15],[29710,29723,29724,29725],{"trials":29763,"activeCount":97},[],{"trials":29765,"activeCount":97},[],{"trials":29767,"activeCount":97},[],{"trials":29769,"activeCount":97},[],{"intervention":29725,"totalTrials":314,"cells":29771},{"EARLY_PHASE1":29772,"PHASE1":29774,"PHASE2":29780,"PHASE3":29782,"PHASE4":29784,"NA":29786},{"trials":29773,"activeCount":97},[],{"trials":29775,"activeCount":97},[29776],{"nctId":29717,"briefTitle":29718,"status":103,"phases":29777,"primaryCompletion":29720,"completion":29720,"start":502,"enrollment":2939,"conditions":29778,"interventions":29779},[85],[15],[29710,29723,29724,29725],{"trials":29781,"activeCount":97},[],{"trials":29783,"activeCount":97},[],{"trials":29785,"activeCount":97},[],{"trials":29787,"activeCount":97},[],{"intervention":24252,"totalTrials":314,"cells":29789},{"EARLY_PHASE1":29790,"PHASE1":29792,"PHASE2":29798,"PHASE3":29800,"PHASE4":29802,"NA":29804},{"trials":29791,"activeCount":97},[],{"trials":29793,"activeCount":97},[29794],{"nctId":24247,"briefTitle":24248,"status":999,"phases":29795,"primaryCompletion":3152,"completion":3152,"start":2899,"enrollment":1400,"conditions":29796,"interventions":29797},[85],[7766,1466],[24252,24240],{"trials":29799,"activeCount":97},[],{"trials":29801,"activeCount":97},[],{"trials":29803,"activeCount":97},[],{"trials":29805,"activeCount":97},[],{"intervention":29807,"totalTrials":314,"cells":29808},"IMC-CS4",{"EARLY_PHASE1":29809,"PHASE1":29811,"PHASE2":29820,"PHASE3":29822,"PHASE4":29824,"NA":29826},{"trials":29810,"activeCount":97},[],{"trials":29812,"activeCount":97},[29813],{"nctId":29814,"briefTitle":29815,"status":103,"phases":29816,"primaryCompletion":6235,"completion":6235,"start":29817,"enrollment":251,"conditions":29818,"interventions":29819},"NCT01346358","A Study of IMC-CS4 in Subjects With Advanced Solid Tumors",[85],"2011-06-15",[1870],[29807],{"trials":29821,"activeCount":97},[],{"trials":29823,"activeCount":97},[],{"trials":29825,"activeCount":97},[],{"trials":29827,"activeCount":97},[],{"intervention":29829,"totalTrials":314,"cells":29830},"LY3985863",{"EARLY_PHASE1":29831,"PHASE1":29833,"PHASE2":29842,"PHASE3":29844,"PHASE4":29846,"NA":29848},{"trials":29832,"activeCount":97},[],{"trials":29834,"activeCount":97},[29835],{"nctId":29836,"briefTitle":29837,"status":103,"phases":29838,"primaryCompletion":8853,"completion":8853,"start":29839,"enrollment":290,"conditions":29840,"interventions":29841},"NCT07030127","A Study of LY3985863 in Healthy Participants",[85],"2025-08-11",[15],[29829],{"trials":29843,"activeCount":97},[],{"trials":29845,"activeCount":97},[],{"trials":29847,"activeCount":97},[],{"trials":29849,"activeCount":97},[],{"intervention":29851,"totalTrials":314,"cells":29852},"LY3007113",{"EARLY_PHASE1":29853,"PHASE1":29855,"PHASE2":29863,"PHASE3":29865,"PHASE4":29867,"NA":29869},{"trials":29854,"activeCount":97},[],{"trials":29856,"activeCount":97},[29857],{"nctId":29858,"briefTitle":29859,"status":103,"phases":29860,"primaryCompletion":3049,"completion":3049,"start":4160,"enrollment":2071,"conditions":29861,"interventions":29862},"NCT01463631","A Study of LY3007113 in Participants With Advanced Cancer",[85],[1560],[29851],{"trials":29864,"activeCount":97},[],{"trials":29866,"activeCount":97},[],{"trials":29868,"activeCount":97},[],{"trials":29870,"activeCount":97},[],{"intervention":11001,"totalTrials":314,"cells":29872},{"EARLY_PHASE1":29873,"PHASE1":29875,"PHASE2":29881,"PHASE3":29883,"PHASE4":29885,"NA":29887},{"trials":29874,"activeCount":97},[],{"trials":29876,"activeCount":97},[29877],{"nctId":10994,"briefTitle":10995,"status":103,"phases":29878,"primaryCompletion":10997,"completion":10997,"start":10998,"enrollment":1071,"conditions":29879,"interventions":29880},[85],[15],[11001,1574,11001],{"trials":29882,"activeCount":97},[],{"trials":29884,"activeCount":97},[],{"trials":29886,"activeCount":97},[],{"trials":29888,"activeCount":97},[],{"intervention":29890,"totalTrials":314,"cells":29891},"LY3314814",{"EARLY_PHASE1":29892,"PHASE1":29894,"PHASE2":29903,"PHASE3":29905,"PHASE4":29907,"NA":29909},{"trials":29893,"activeCount":97},[],{"trials":29895,"activeCount":97},[29896],{"nctId":29897,"briefTitle":29898,"status":384,"phases":29899,"primaryCompletion":29900,"completion":29900,"start":28010,"enrollment":97,"conditions":29901,"interventions":29902},"NCT03499041","A Study of LY3314814 in Participants With Liver Impairment",[85],"2018-12",[6228],[29890],{"trials":29904,"activeCount":97},[],{"trials":29906,"activeCount":97},[],{"trials":29908,"activeCount":97},[],{"trials":29910,"activeCount":97},[],{"intervention":29912,"totalTrials":314,"cells":29913},"LY3002815",{"EARLY_PHASE1":29914,"PHASE1":29916,"PHASE2":29925,"PHASE3":29927,"PHASE4":29929,"NA":29931},{"trials":29915,"activeCount":97},[],{"trials":29917,"activeCount":97},[29918],{"nctId":29919,"briefTitle":29920,"status":999,"phases":29921,"primaryCompletion":29922,"completion":13324,"start":365,"enrollment":34,"conditions":29923,"interventions":29924},"NCT03148431","A Study of LY3002815 in Healthy Participants",[85],"2017-12-15",[15],[29912],{"trials":29926,"activeCount":97},[],{"trials":29928,"activeCount":97},[],{"trials":29930,"activeCount":97},[],{"trials":29932,"activeCount":97},[],{"intervention":29934,"totalTrials":314,"cells":29935},"Ramucirumab - IV",{"EARLY_PHASE1":29936,"PHASE1":29938,"PHASE2":29949,"PHASE3":29951,"PHASE4":29953,"NA":29955},{"trials":29937,"activeCount":97},[],{"trials":29939,"activeCount":97},[29940],{"nctId":29941,"briefTitle":29942,"status":103,"phases":29943,"primaryCompletion":29944,"completion":29944,"start":29945,"enrollment":2088,"conditions":29946,"interventions":29947},"NCT04495478","A Study of Ramucirumab (LY3009806) in Healthy Participants",[85],"2021-05-09","2020-07-30",[15],[29934,29948],"Ramucirumab - SC",{"trials":29950,"activeCount":97},[],{"trials":29952,"activeCount":97},[],{"trials":29954,"activeCount":97},[],{"trials":29956,"activeCount":97},[],{"intervention":29948,"totalTrials":314,"cells":29958},{"EARLY_PHASE1":29959,"PHASE1":29961,"PHASE2":29967,"PHASE3":29969,"PHASE4":29971,"NA":29973},{"trials":29960,"activeCount":97},[],{"trials":29962,"activeCount":97},[29963],{"nctId":29941,"briefTitle":29942,"status":103,"phases":29964,"primaryCompletion":29944,"completion":29944,"start":29945,"enrollment":2088,"conditions":29965,"interventions":29966},[85],[15],[29934,29948],{"trials":29968,"activeCount":97},[],{"trials":29970,"activeCount":97},[],{"trials":29972,"activeCount":97},[],{"trials":29974,"activeCount":97},[],{"intervention":7201,"totalTrials":314,"cells":29976},{"EARLY_PHASE1":29977,"PHASE1":29979,"PHASE2":29985,"PHASE3":29987,"PHASE4":29989,"NA":29991},{"trials":29978,"activeCount":97},[],{"trials":29980,"activeCount":97},[29981],{"nctId":7196,"briefTitle":7197,"status":103,"phases":29982,"primaryCompletion":4383,"completion":3123,"start":1618,"enrollment":25,"conditions":29983,"interventions":29984},[85],[15],[449,7201,7202],{"trials":29986,"activeCount":97},[],{"trials":29988,"activeCount":97},[],{"trials":29990,"activeCount":97},[],{"trials":29992,"activeCount":97},[],{"intervention":7202,"totalTrials":314,"cells":29994},{"EARLY_PHASE1":29995,"PHASE1":29997,"PHASE2":30003,"PHASE3":30005,"PHASE4":30007,"NA":30009},{"trials":29996,"activeCount":97},[],{"trials":29998,"activeCount":97},[29999],{"nctId":7196,"briefTitle":7197,"status":103,"phases":30000,"primaryCompletion":4383,"completion":3123,"start":1618,"enrollment":25,"conditions":30001,"interventions":30002},[85],[15],[449,7201,7202],{"trials":30004,"activeCount":97},[],{"trials":30006,"activeCount":97},[],{"trials":30008,"activeCount":97},[],{"trials":30010,"activeCount":97},[],{"intervention":30012,"totalTrials":314,"cells":30013},"[¹⁴C]-LY3502970",{"EARLY_PHASE1":30014,"PHASE1":30016,"PHASE2":30025,"PHASE3":30027,"PHASE4":30029,"NA":30031},{"trials":30015,"activeCount":97},[],{"trials":30017,"activeCount":97},[30018],{"nctId":30019,"briefTitle":30020,"status":103,"phases":30021,"primaryCompletion":30022,"completion":30022,"start":573,"enrollment":1677,"conditions":30023,"interventions":30024},"NCT04680767","A Study of LY3502970 in Healthy Male Participants",[85],"2021-07-03",[15],[30012],{"trials":30026,"activeCount":97},[],{"trials":30028,"activeCount":97},[],{"trials":30030,"activeCount":97},[],{"trials":30032,"activeCount":97},[],{"intervention":24799,"totalTrials":314,"cells":30034},{"EARLY_PHASE1":30035,"PHASE1":30037,"PHASE2":30043,"PHASE3":30045,"PHASE4":30047,"NA":30049},{"trials":30036,"activeCount":97},[],{"trials":30038,"activeCount":97},[30039],{"nctId":24794,"briefTitle":24795,"status":103,"phases":30040,"primaryCompletion":2956,"completion":2956,"start":3103,"enrollment":23787,"conditions":30041,"interventions":30042},[85],[18],[24787,24799],{"trials":30044,"activeCount":97},[],{"trials":30046,"activeCount":97},[],{"trials":30048,"activeCount":97},[],{"trials":30050,"activeCount":97},[],{"intervention":30052,"totalTrials":314,"cells":30053},"Glucagon Nasal Powder [Baqsimi]",{"EARLY_PHASE1":30054,"PHASE1":30056,"PHASE2":30066,"PHASE3":30068,"PHASE4":30070,"NA":30072},{"trials":30055,"activeCount":97},[],{"trials":30057,"activeCount":97},[30058],{"nctId":30059,"briefTitle":30060,"status":103,"phases":30061,"primaryCompletion":30062,"completion":30062,"start":30063,"enrollment":1054,"conditions":30064,"interventions":30065},"NCT04992312","A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes",[85],"2023-11-05","2022-03-24",[466],[30052],{"trials":30067,"activeCount":97},[],{"trials":30069,"activeCount":97},[],{"trials":30071,"activeCount":97},[],{"trials":30073,"activeCount":97},[],{"intervention":8260,"totalTrials":314,"cells":30075},{"EARLY_PHASE1":30076,"PHASE1":30078,"PHASE2":30084,"PHASE3":30086,"PHASE4":30088,"NA":30090},{"trials":30077,"activeCount":97},[],{"trials":30079,"activeCount":97},[30080],{"nctId":8254,"briefTitle":8255,"status":103,"phases":30081,"primaryCompletion":1473,"completion":1474,"start":3545,"enrollment":1071,"conditions":30082,"interventions":30083},[85],[1114],[8259,8260,8261,3034],{"trials":30085,"activeCount":97},[],{"trials":30087,"activeCount":97},[],{"trials":30089,"activeCount":97},[],{"trials":30091,"activeCount":97},[],{"intervention":8261,"totalTrials":314,"cells":30093},{"EARLY_PHASE1":30094,"PHASE1":30096,"PHASE2":30102,"PHASE3":30104,"PHASE4":30106,"NA":30108},{"trials":30095,"activeCount":97},[],{"trials":30097,"activeCount":97},[30098],{"nctId":8254,"briefTitle":8255,"status":103,"phases":30099,"primaryCompletion":1473,"completion":1474,"start":3545,"enrollment":1071,"conditions":30100,"interventions":30101},[85],[1114],[8259,8260,8261,3034],{"trials":30103,"activeCount":97},[],{"trials":30105,"activeCount":97},[],{"trials":30107,"activeCount":97},[],{"trials":30109,"activeCount":97},[],{"intervention":27668,"totalTrials":314,"cells":30111},{"EARLY_PHASE1":30112,"PHASE1":30114,"PHASE2":30120,"PHASE3":30122,"PHASE4":30124,"NA":30126},{"trials":30113,"activeCount":97},[],{"trials":30115,"activeCount":97},[30116],{"nctId":27662,"briefTitle":27663,"status":103,"phases":30117,"primaryCompletion":288,"completion":288,"start":27665,"enrollment":156,"conditions":30118,"interventions":30119},[85],[15],[27668,1538],{"trials":30121,"activeCount":97},[],{"trials":30123,"activeCount":97},[],{"trials":30125,"activeCount":97},[],{"trials":30127,"activeCount":97},[],{"intervention":7831,"totalTrials":314,"cells":30129},{"EARLY_PHASE1":30130,"PHASE1":30132,"PHASE2":30138,"PHASE3":30140,"PHASE4":30142,"NA":30144},{"trials":30131,"activeCount":97},[],{"trials":30133,"activeCount":97},[30134],{"nctId":7825,"briefTitle":7826,"status":103,"phases":30135,"primaryCompletion":7828,"completion":7828,"start":2181,"enrollment":1071,"conditions":30136,"interventions":30137},[85],[15],[2655,7831,7831],{"trials":30139,"activeCount":97},[],{"trials":30141,"activeCount":97},[],{"trials":30143,"activeCount":97},[],{"trials":30145,"activeCount":97},[],{"intervention":4958,"totalTrials":314,"cells":30147},{"EARLY_PHASE1":30148,"PHASE1":30150,"PHASE2":30156,"PHASE3":30158,"PHASE4":30160,"NA":30162},{"trials":30149,"activeCount":97},[],{"trials":30151,"activeCount":97},[30152],{"nctId":4952,"briefTitle":4953,"status":103,"phases":30153,"primaryCompletion":4955,"completion":4955,"start":2917,"enrollment":12,"conditions":30154,"interventions":30155},[85],[21],[4944,4958],{"trials":30157,"activeCount":97},[],{"trials":30159,"activeCount":97},[],{"trials":30161,"activeCount":97},[],{"trials":30163,"activeCount":97},[],{"intervention":30165,"totalTrials":314,"cells":30166},"LY2484595 Reference Formulation",{"EARLY_PHASE1":30167,"PHASE1":30169,"PHASE2":30178,"PHASE3":30180,"PHASE4":30182,"NA":30184},{"trials":30168,"activeCount":97},[],{"trials":30170,"activeCount":97},[30171],{"nctId":30172,"briefTitle":30173,"status":103,"phases":30174,"primaryCompletion":4160,"completion":4160,"start":3004,"enrollment":3041,"conditions":30175,"interventions":30176},"NCT01450098","A Study of LY2484595 in Healthy Subjects",[85],[21],[30165,30177],"LY2484595 spray-dried solid dispersion-propyl gallate",{"trials":30179,"activeCount":97},[],{"trials":30181,"activeCount":97},[],{"trials":30183,"activeCount":97},[],{"trials":30185,"activeCount":97},[],{"intervention":30177,"totalTrials":314,"cells":30187},{"EARLY_PHASE1":30188,"PHASE1":30190,"PHASE2":30196,"PHASE3":30198,"PHASE4":30200,"NA":30202},{"trials":30189,"activeCount":97},[],{"trials":30191,"activeCount":97},[30192],{"nctId":30172,"briefTitle":30173,"status":103,"phases":30193,"primaryCompletion":4160,"completion":4160,"start":3004,"enrollment":3041,"conditions":30194,"interventions":30195},[85],[21],[30165,30177],{"trials":30197,"activeCount":97},[],{"trials":30199,"activeCount":97},[],{"trials":30201,"activeCount":97},[],{"trials":30203,"activeCount":97},[],{"intervention":16889,"totalTrials":314,"cells":30205},{"EARLY_PHASE1":30206,"PHASE1":30208,"PHASE2":30214,"PHASE3":30216,"PHASE4":30218,"NA":30220},{"trials":30207,"activeCount":97},[],{"trials":30209,"activeCount":97},[30210],{"nctId":16884,"briefTitle":16885,"status":103,"phases":30211,"primaryCompletion":3494,"completion":3494,"start":6093,"enrollment":6633,"conditions":30212,"interventions":30213},[85],[4937],[13957,16889],{"trials":30215,"activeCount":97},[],{"trials":30217,"activeCount":97},[],{"trials":30219,"activeCount":97},[],{"trials":30221,"activeCount":97},[],{"intervention":2496,"totalTrials":314,"cells":30223},{"EARLY_PHASE1":30224,"PHASE1":30226,"PHASE2":30232,"PHASE3":30234,"PHASE4":30236,"NA":30238},{"trials":30225,"activeCount":97},[],{"trials":30227,"activeCount":97},[30228],{"nctId":2489,"briefTitle":2490,"status":103,"phases":30229,"primaryCompletion":2492,"completion":2493,"start":971,"enrollment":251,"conditions":30230,"interventions":30231},[85],[1466],[2496,1696],{"trials":30233,"activeCount":97},[],{"trials":30235,"activeCount":97},[],{"trials":30237,"activeCount":97},[],{"trials":30239,"activeCount":97},[],{"intervention":30241,"totalTrials":314,"cells":30242},"[14C]-LY3871801",{"EARLY_PHASE1":30243,"PHASE1":30245,"PHASE2":30255,"PHASE3":30257,"PHASE4":30259,"NA":30261},{"trials":30244,"activeCount":97},[],{"trials":30246,"activeCount":97},[30247],{"nctId":30248,"briefTitle":30249,"status":103,"phases":30250,"primaryCompletion":30251,"completion":30251,"start":30252,"enrollment":4323,"conditions":30253,"interventions":30254},"NCT06049108","A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants",[85],"2023-11-03","2023-09-15",[15],[30241],{"trials":30256,"activeCount":97},[],{"trials":30258,"activeCount":97},[],{"trials":30260,"activeCount":97},[],{"trials":30262,"activeCount":97},[],{"intervention":30264,"totalTrials":314,"cells":30265},"LY333334",{"EARLY_PHASE1":30266,"PHASE1":30268,"PHASE2":30277,"PHASE3":30279,"PHASE4":30281,"NA":30283},{"trials":30267,"activeCount":97},[],{"trials":30269,"activeCount":97},[30270],{"nctId":30271,"briefTitle":30272,"status":103,"phases":30273,"primaryCompletion":2844,"completion":2844,"start":3029,"enrollment":30274,"conditions":30275,"interventions":30276},"NCT01250145","A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women",[85],251,[14168],[30264],{"trials":30278,"activeCount":97},[],{"trials":30280,"activeCount":97},[],{"trials":30282,"activeCount":97},[],{"trials":30284,"activeCount":97},[],{"intervention":18054,"totalTrials":314,"cells":30286},{"EARLY_PHASE1":30287,"PHASE1":30289,"PHASE2":30295,"PHASE3":30297,"PHASE4":30299,"NA":30301},{"trials":30288,"activeCount":97},[],{"trials":30290,"activeCount":97},[30291],{"nctId":18047,"briefTitle":18048,"status":103,"phases":30292,"primaryCompletion":18050,"completion":18050,"start":7775,"enrollment":874,"conditions":30293,"interventions":30294},[85],[18052],[18054,9237,2092],{"trials":30296,"activeCount":97},[],{"trials":30298,"activeCount":97},[],{"trials":30300,"activeCount":97},[],{"trials":30302,"activeCount":97},[],{"intervention":11585,"totalTrials":314,"cells":30304},{"EARLY_PHASE1":30305,"PHASE1":30307,"PHASE2":30313,"PHASE3":30315,"PHASE4":30317,"NA":30319},{"trials":30306,"activeCount":97},[],{"trials":30308,"activeCount":97},[30309],{"nctId":11578,"briefTitle":11579,"status":999,"phases":30310,"primaryCompletion":11581,"completion":11582,"start":3684,"enrollment":874,"conditions":30311,"interventions":30312},[85],[1503,1694,2585,2506],[11585,1656],{"trials":30314,"activeCount":97},[],{"trials":30316,"activeCount":97},[],{"trials":30318,"activeCount":97},[],{"trials":30320,"activeCount":97},[],{"intervention":10905,"totalTrials":314,"cells":30322},{"EARLY_PHASE1":30323,"PHASE1":30325,"PHASE2":30331,"PHASE3":30333,"PHASE4":30335,"NA":30337},{"trials":30324,"activeCount":97},[],{"trials":30326,"activeCount":97},[30327],{"nctId":10898,"briefTitle":10899,"status":103,"phases":30328,"primaryCompletion":3697,"completion":3697,"start":3319,"enrollment":118,"conditions":30329,"interventions":30330},[85],[21],[10903,2562,2092,10904,10905],{"trials":30332,"activeCount":97},[],{"trials":30334,"activeCount":97},[],{"trials":30336,"activeCount":97},[],{"trials":30338,"activeCount":97},[],{"intervention":6394,"totalTrials":314,"cells":30340},{"EARLY_PHASE1":30341,"PHASE1":30343,"PHASE2":30349,"PHASE3":30351,"PHASE4":30353,"NA":30355},{"trials":30342,"activeCount":97},[],{"trials":30344,"activeCount":97},[30345],{"nctId":6387,"briefTitle":6388,"status":103,"phases":30346,"primaryCompletion":6390,"completion":6390,"start":1475,"enrollment":4323,"conditions":30347,"interventions":30348},[85],[6392],[61,6394],{"trials":30350,"activeCount":97},[],{"trials":30352,"activeCount":97},[],{"trials":30354,"activeCount":97},[],{"trials":30356,"activeCount":97},[],{"intervention":30358,"totalTrials":314,"cells":30359},"Cetuximab + Gefitinib",{"EARLY_PHASE1":30360,"PHASE1":30362,"PHASE2":30370,"PHASE3":30372,"PHASE4":30374,"NA":30376},{"trials":30361,"activeCount":97},[],{"trials":30363,"activeCount":97},[30364],{"nctId":30365,"briefTitle":30366,"status":103,"phases":30367,"primaryCompletion":4266,"completion":4266,"start":3218,"enrollment":1620,"conditions":30368,"interventions":30369},"NCT00162318","A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced\u002FMetastatic Non-Small Cell Lung Cancer",[85],[2903],[30358],{"trials":30371,"activeCount":97},[],{"trials":30373,"activeCount":97},[],{"trials":30375,"activeCount":97},[],{"trials":30377,"activeCount":97},[],{"intervention":30379,"totalTrials":314,"cells":30380},"LY3316531",{"EARLY_PHASE1":30381,"PHASE1":30383,"PHASE2":30393,"PHASE3":30395,"PHASE4":30397,"NA":30399},{"trials":30382,"activeCount":97},[],{"trials":30384,"activeCount":97},[30385],{"nctId":30386,"briefTitle":30387,"status":103,"phases":30388,"primaryCompletion":30389,"completion":30389,"start":30390,"enrollment":1071,"conditions":30391,"interventions":30392},"NCT03611608","A Study of LY3316531 in Healthy Participants",[85],"2019-03-15","2018-08-30",[15],[30379],{"trials":30394,"activeCount":97},[],{"trials":30396,"activeCount":97},[],{"trials":30398,"activeCount":97},[],{"trials":30400,"activeCount":97},[],{"intervention":16896,"totalTrials":314,"cells":30402},{"EARLY_PHASE1":30403,"PHASE1":30405,"PHASE2":30411,"PHASE3":30413,"PHASE4":30415,"NA":30417},{"trials":30404,"activeCount":97},[],{"trials":30406,"activeCount":97},[30407],{"nctId":16891,"briefTitle":16892,"status":103,"phases":30408,"primaryCompletion":3494,"completion":3494,"start":3020,"enrollment":165,"conditions":30409,"interventions":30410},[85],[13955],[13957,16896],{"trials":30412,"activeCount":97},[],{"trials":30414,"activeCount":97},[],{"trials":30416,"activeCount":97},[],{"trials":30418,"activeCount":97},[],{"intervention":18230,"totalTrials":314,"cells":30420},{"EARLY_PHASE1":30421,"PHASE1":30423,"PHASE2":30429,"PHASE3":30431,"PHASE4":30433,"NA":30435},{"trials":30422,"activeCount":97},[],{"trials":30424,"activeCount":97},[30425],{"nctId":18225,"briefTitle":18226,"status":103,"phases":30426,"primaryCompletion":4420,"completion":4420,"start":2898,"enrollment":4279,"conditions":30427,"interventions":30428},[85],[15],[13099,18230],{"trials":30430,"activeCount":97},[],{"trials":30432,"activeCount":97},[],{"trials":30434,"activeCount":97},[],{"trials":30436,"activeCount":97},[],{"intervention":28793,"totalTrials":314,"cells":30438},{"EARLY_PHASE1":30439,"PHASE1":30441,"PHASE2":30447,"PHASE3":30449,"PHASE4":30451,"NA":30453},{"trials":30440,"activeCount":97},[],{"trials":30442,"activeCount":97},[30443],{"nctId":28788,"briefTitle":28789,"status":103,"phases":30444,"primaryCompletion":6390,"completion":6390,"start":5030,"enrollment":4353,"conditions":30445,"interventions":30446},[85],[15],[28793,28781,28794],{"trials":30448,"activeCount":97},[],{"trials":30450,"activeCount":97},[],{"trials":30452,"activeCount":97},[],{"trials":30454,"activeCount":97},[],{"intervention":30456,"totalTrials":314,"cells":30457},"IMC-TR1",{"EARLY_PHASE1":30458,"PHASE1":30460,"PHASE2":30469,"PHASE3":30471,"PHASE4":30473,"NA":30475},{"trials":30459,"activeCount":97},[],{"trials":30461,"activeCount":97},[30462],{"nctId":30463,"briefTitle":30464,"status":103,"phases":30465,"primaryCompletion":3318,"completion":3318,"start":3545,"enrollment":1062,"conditions":30466,"interventions":30468},"NCT01646203","A Study of IMC-TR1 in Participants With Advanced Solid Tumors",[85],[1870,30467],"Tumor",[30456],{"trials":30470,"activeCount":97},[],{"trials":30472,"activeCount":97},[],{"trials":30474,"activeCount":97},[],{"trials":30476,"activeCount":97},[],{"intervention":30478,"totalTrials":314,"cells":30479},"LY2608204 Reference",{"EARLY_PHASE1":30480,"PHASE1":30482,"PHASE2":30491,"PHASE3":30493,"PHASE4":30495,"NA":30497},{"trials":30481,"activeCount":97},[],{"trials":30483,"activeCount":97},[30484],{"nctId":30485,"briefTitle":30486,"status":103,"phases":30487,"primaryCompletion":3069,"completion":3069,"start":3837,"enrollment":1071,"conditions":30488,"interventions":30489},"NCT01313286","A Study to Compare Two Forms of LY2608204 in Healthy People",[85],[21],[30478,30490],"LY2608204 Test",{"trials":30492,"activeCount":97},[],{"trials":30494,"activeCount":97},[],{"trials":30496,"activeCount":97},[],{"trials":30498,"activeCount":97},[],{"intervention":30490,"totalTrials":314,"cells":30500},{"EARLY_PHASE1":30501,"PHASE1":30503,"PHASE2":30509,"PHASE3":30511,"PHASE4":30513,"NA":30515},{"trials":30502,"activeCount":97},[],{"trials":30504,"activeCount":97},[30505],{"nctId":30485,"briefTitle":30486,"status":103,"phases":30506,"primaryCompletion":3069,"completion":3069,"start":3837,"enrollment":1071,"conditions":30507,"interventions":30508},[85],[21],[30478,30490],{"trials":30510,"activeCount":97},[],{"trials":30512,"activeCount":97},[],{"trials":30514,"activeCount":97},[],{"trials":30516,"activeCount":97},[],{"intervention":1524,"totalTrials":314,"cells":30518},{"EARLY_PHASE1":30519,"PHASE1":30521,"PHASE2":30527,"PHASE3":30529,"PHASE4":30531,"NA":30533},{"trials":30520,"activeCount":97},[],{"trials":30522,"activeCount":97},[30523],{"nctId":1515,"briefTitle":1516,"status":103,"phases":30524,"primaryCompletion":1518,"completion":1519,"start":1520,"enrollment":757,"conditions":30525,"interventions":30526},[85],[1522],[48,1524,1525],{"trials":30528,"activeCount":97},[],{"trials":30530,"activeCount":97},[],{"trials":30532,"activeCount":97},[],{"trials":30534,"activeCount":97},[],{"intervention":1525,"totalTrials":314,"cells":30536},{"EARLY_PHASE1":30537,"PHASE1":30539,"PHASE2":30545,"PHASE3":30547,"PHASE4":30549,"NA":30551},{"trials":30538,"activeCount":97},[],{"trials":30540,"activeCount":97},[30541],{"nctId":1515,"briefTitle":1516,"status":103,"phases":30542,"primaryCompletion":1518,"completion":1519,"start":1520,"enrollment":757,"conditions":30543,"interventions":30544},[85],[1522],[48,1524,1525],{"trials":30546,"activeCount":97},[],{"trials":30548,"activeCount":97},[],{"trials":30550,"activeCount":97},[],{"trials":30552,"activeCount":97},[],{"intervention":30554,"totalTrials":314,"cells":30555},"LY3009385",{"EARLY_PHASE1":30556,"PHASE1":30558,"PHASE2":30566,"PHASE3":30568,"PHASE4":30570,"NA":30572},{"trials":30557,"activeCount":97},[],{"trials":30559,"activeCount":97},[30560],{"nctId":30561,"briefTitle":30562,"status":103,"phases":30563,"primaryCompletion":3886,"completion":3886,"start":5090,"enrollment":233,"conditions":30564,"interventions":30565},"NCT01477567","A First-in-Human Study of LY3009385 in Healthy Participants",[85],[18],[30554],{"trials":30567,"activeCount":97},[],{"trials":30569,"activeCount":97},[],{"trials":30571,"activeCount":97},[],{"trials":30573,"activeCount":97},[],{"intervention":1540,"totalTrials":314,"cells":30575},{"EARLY_PHASE1":30576,"PHASE1":30578,"PHASE2":30584,"PHASE3":30586,"PHASE4":30588,"NA":30590},{"trials":30577,"activeCount":97},[],{"trials":30579,"activeCount":97},[30580],{"nctId":1527,"briefTitle":1528,"status":103,"phases":30581,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":631,"conditions":30582,"interventions":30583},[85],[1466,1534,1535,1490],[1537,1538,48,1539,1511,1540,1541],{"trials":30585,"activeCount":97},[],{"trials":30587,"activeCount":97},[],{"trials":30589,"activeCount":97},[],{"trials":30591,"activeCount":97},[],{"intervention":22736,"totalTrials":314,"cells":30593},{"EARLY_PHASE1":30594,"PHASE1":30596,"PHASE2":30602,"PHASE3":30604,"PHASE4":30606,"NA":30608},{"trials":30595,"activeCount":97},[],{"trials":30597,"activeCount":97},[30598],{"nctId":22728,"briefTitle":22729,"status":103,"phases":30599,"primaryCompletion":22731,"completion":22731,"start":22732,"enrollment":3293,"conditions":30600,"interventions":30601},[85],[1466,1560,1490,1610],[22735,22736],{"trials":30603,"activeCount":97},[],{"trials":30605,"activeCount":97},[],{"trials":30607,"activeCount":97},[],{"trials":30609,"activeCount":97},[],{"intervention":5568,"totalTrials":314,"cells":30611},{"EARLY_PHASE1":30612,"PHASE1":30614,"PHASE2":30620,"PHASE3":30622,"PHASE4":30624,"NA":30626},{"trials":30613,"activeCount":97},[],{"trials":30615,"activeCount":97},[30616],{"nctId":5563,"briefTitle":5564,"status":103,"phases":30617,"primaryCompletion":3419,"completion":2899,"start":3337,"enrollment":1178,"conditions":30618,"interventions":30619},[85],[2824],[5568,5568,5568,5568,5568,2838,2838],{"trials":30621,"activeCount":97},[],{"trials":30623,"activeCount":97},[],{"trials":30625,"activeCount":97},[],{"trials":30627,"activeCount":97},[],{"intervention":30629,"totalTrials":314,"cells":30630},"LY2969822",{"EARLY_PHASE1":30631,"PHASE1":30633,"PHASE2":30641,"PHASE3":30643,"PHASE4":30645,"NA":30647},{"trials":30632,"activeCount":97},[],{"trials":30634,"activeCount":97},[30635],{"nctId":30636,"briefTitle":30637,"status":103,"phases":30638,"primaryCompletion":1473,"completion":1473,"start":3049,"enrollment":4083,"conditions":30639,"interventions":30640},"NCT02018887","A Study of LY2969822 in Healthy Participants",[85],[21],[30629],{"trials":30642,"activeCount":97},[],{"trials":30644,"activeCount":97},[],{"trials":30646,"activeCount":97},[],{"trials":30648,"activeCount":97},[],{"intervention":30650,"totalTrials":314,"cells":30651},"LY3844583",{"EARLY_PHASE1":30652,"PHASE1":30654,"PHASE2":30663,"PHASE3":30665,"PHASE4":30667,"NA":30669},{"trials":30653,"activeCount":97},[],{"trials":30655,"activeCount":97},[30656],{"nctId":30657,"briefTitle":30658,"status":999,"phases":30659,"primaryCompletion":30660,"completion":30660,"start":13081,"enrollment":9083,"conditions":30661,"interventions":30662},"NCT05486208","A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis",[85],"2024-01-20",[15,1368],[30650],{"trials":30664,"activeCount":97},[],{"trials":30666,"activeCount":97},[],{"trials":30668,"activeCount":97},[],{"trials":30670,"activeCount":97},[],{"intervention":30672,"totalTrials":314,"cells":30673},"LY3462817 IV",{"EARLY_PHASE1":30674,"PHASE1":30676,"PHASE2":30686,"PHASE3":30688,"PHASE4":30690,"NA":30692},{"trials":30675,"activeCount":97},[],{"trials":30677,"activeCount":97},[30678],{"nctId":30679,"briefTitle":30680,"status":103,"phases":30681,"primaryCompletion":30682,"completion":30682,"start":18765,"enrollment":2867,"conditions":30683,"interventions":30684},"NCT03715192","A Safety Study of LY3462817 in Healthy Participants",[85],"2019-12-11",[15],[30672,30685],"LY3462817 SC",{"trials":30687,"activeCount":97},[],{"trials":30689,"activeCount":97},[],{"trials":30691,"activeCount":97},[],{"trials":30693,"activeCount":97},[],{"intervention":30685,"totalTrials":314,"cells":30695},{"EARLY_PHASE1":30696,"PHASE1":30698,"PHASE2":30704,"PHASE3":30706,"PHASE4":30708,"NA":30710},{"trials":30697,"activeCount":97},[],{"trials":30699,"activeCount":97},[30700],{"nctId":30679,"briefTitle":30680,"status":103,"phases":30701,"primaryCompletion":30682,"completion":30682,"start":18765,"enrollment":2867,"conditions":30702,"interventions":30703},[85],[15],[30672,30685],{"trials":30705,"activeCount":97},[],{"trials":30707,"activeCount":97},[],{"trials":30709,"activeCount":97},[],{"trials":30711,"activeCount":97},[],{"intervention":4968,"totalTrials":314,"cells":30713},{"EARLY_PHASE1":30714,"PHASE1":30716,"PHASE2":30722,"PHASE3":30724,"PHASE4":30726,"NA":30728},{"trials":30715,"activeCount":97},[],{"trials":30717,"activeCount":97},[30718],{"nctId":4960,"briefTitle":4961,"status":103,"phases":30719,"primaryCompletion":4963,"completion":4964,"start":4965,"enrollment":137,"conditions":30720,"interventions":30721},[85],[15],[4968,4944],{"trials":30723,"activeCount":97},[],{"trials":30725,"activeCount":97},[],{"trials":30727,"activeCount":97},[],{"trials":30729,"activeCount":97},[],{"intervention":30731,"totalTrials":314,"cells":30732},"14C Tirzepatide",{"EARLY_PHASE1":30733,"PHASE1":30735,"PHASE2":30743,"PHASE3":30745,"PHASE4":30747,"NA":30749},{"trials":30734,"activeCount":97},[],{"trials":30736,"activeCount":97},[30737],{"nctId":30738,"briefTitle":30739,"status":103,"phases":30740,"primaryCompletion":19594,"completion":19594,"start":4392,"enrollment":1677,"conditions":30741,"interventions":30742},"NCT04311424","Study of Tirzepatide in Healthy Participants",[85],[15],[30731],{"trials":30744,"activeCount":97},[],{"trials":30746,"activeCount":97},[],{"trials":30748,"activeCount":97},[],{"trials":30750,"activeCount":97},[],{"intervention":18514,"totalTrials":314,"cells":30752},{"EARLY_PHASE1":30753,"PHASE1":30755,"PHASE2":30761,"PHASE3":30763,"PHASE4":30765,"NA":30767},{"trials":30754,"activeCount":97},[],{"trials":30756,"activeCount":97},[30757],{"nctId":18509,"briefTitle":18510,"status":103,"phases":30758,"primaryCompletion":1596,"completion":1596,"start":1475,"enrollment":290,"conditions":30759,"interventions":30760},[85],[33],[12954,18514],{"trials":30762,"activeCount":97},[],{"trials":30764,"activeCount":97},[],{"trials":30766,"activeCount":97},[],{"trials":30768,"activeCount":97},[],{"intervention":30770,"totalTrials":314,"cells":30771},"LY3108743 -",{"EARLY_PHASE1":30772,"PHASE1":30774,"PHASE2":30783,"PHASE3":30785,"PHASE4":30787,"NA":30789},{"trials":30773,"activeCount":97},[],{"trials":30775,"activeCount":97},[30776],{"nctId":30777,"briefTitle":30778,"status":103,"phases":30779,"primaryCompletion":1475,"completion":1475,"start":3049,"enrollment":37,"conditions":30780,"interventions":30781},"NCT01995656","A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes",[85],[18],[30770,30782],"LY3108743 - Solution",{"trials":30784,"activeCount":97},[],{"trials":30786,"activeCount":97},[],{"trials":30788,"activeCount":97},[],{"trials":30790,"activeCount":97},[],{"intervention":30782,"totalTrials":314,"cells":30792},{"EARLY_PHASE1":30793,"PHASE1":30795,"PHASE2":30801,"PHASE3":30803,"PHASE4":30805,"NA":30807},{"trials":30794,"activeCount":97},[],{"trials":30796,"activeCount":97},[30797],{"nctId":30777,"briefTitle":30778,"status":103,"phases":30798,"primaryCompletion":1475,"completion":1475,"start":3049,"enrollment":37,"conditions":30799,"interventions":30800},[85],[18],[30770,30782],{"trials":30802,"activeCount":97},[],{"trials":30804,"activeCount":97},[],{"trials":30806,"activeCount":97},[],{"trials":30808,"activeCount":97},[],{"intervention":30810,"totalTrials":314,"cells":30811},"Citrate-Free Mirikizumab",{"EARLY_PHASE1":30812,"PHASE1":30814,"PHASE2":30824,"PHASE3":30826,"PHASE4":30828,"NA":30830},{"trials":30813,"activeCount":97},[],{"trials":30815,"activeCount":97},[30816],{"nctId":30817,"briefTitle":30818,"status":103,"phases":30819,"primaryCompletion":30820,"completion":30820,"start":1985,"enrollment":30821,"conditions":30822,"interventions":30823},"NCT06475729","A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants",[85],"2024-12-27",498,[15],[30810],{"trials":30825,"activeCount":97},[],{"trials":30827,"activeCount":97},[],{"trials":30829,"activeCount":97},[],{"trials":30831,"activeCount":97},[],{"intervention":30833,"totalTrials":314,"cells":30834},"LY3079514",{"EARLY_PHASE1":30835,"PHASE1":30837,"PHASE2":30845,"PHASE3":30847,"PHASE4":30849,"NA":30851},{"trials":30836,"activeCount":97},[],{"trials":30838,"activeCount":97},[30839],{"nctId":30840,"briefTitle":30841,"status":103,"phases":30842,"primaryCompletion":1619,"completion":1619,"start":3318,"enrollment":118,"conditions":30843,"interventions":30844},"NCT02242903","A Study of LY3079514 in Healthy Participants",[85],[21],[30833,30833],{"trials":30846,"activeCount":97},[],{"trials":30848,"activeCount":97},[],{"trials":30850,"activeCount":97},[],{"trials":30852,"activeCount":97},[],{"intervention":30854,"totalTrials":314,"cells":30855},"LY3876602",{"EARLY_PHASE1":30856,"PHASE1":30858,"PHASE2":30867,"PHASE3":30869,"PHASE4":30871,"NA":30873},{"trials":30857,"activeCount":97},[],{"trials":30859,"activeCount":97},[30860],{"nctId":30861,"briefTitle":30862,"status":103,"phases":30863,"primaryCompletion":30864,"completion":30864,"start":1043,"enrollment":14469,"conditions":30865,"interventions":30866},"NCT06007638","A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants",[85],"2025-09-20",[15],[30854],{"trials":30868,"activeCount":97},[],{"trials":30870,"activeCount":97},[],{"trials":30872,"activeCount":97},[],{"trials":30874,"activeCount":97},[],{"intervention":30876,"totalTrials":314,"cells":30877},"LY2775240",{"EARLY_PHASE1":30878,"PHASE1":30880,"PHASE2":30890,"PHASE3":30892,"PHASE4":30894,"NA":30896},{"trials":30879,"activeCount":97},[],{"trials":30881,"activeCount":97},[30882],{"nctId":30883,"briefTitle":30884,"status":103,"phases":30885,"primaryCompletion":30886,"completion":30886,"start":1627,"enrollment":1548,"conditions":30887,"interventions":30888},"NCT02963779","A Study of LY2775240 in Healthy Participants",[85],"2017-10-05",[15],[30876,30889],"Apremilast",{"trials":30891,"activeCount":97},[],{"trials":30893,"activeCount":97},[],{"trials":30895,"activeCount":97},[],{"trials":30897,"activeCount":97},[],{"intervention":30889,"totalTrials":314,"cells":30899},{"EARLY_PHASE1":30900,"PHASE1":30902,"PHASE2":30908,"PHASE3":30910,"PHASE4":30912,"NA":30914},{"trials":30901,"activeCount":97},[],{"trials":30903,"activeCount":97},[30904],{"nctId":30883,"briefTitle":30884,"status":103,"phases":30905,"primaryCompletion":30886,"completion":30886,"start":1627,"enrollment":1548,"conditions":30906,"interventions":30907},[85],[15],[30876,30889],{"trials":30909,"activeCount":97},[],{"trials":30911,"activeCount":97},[],{"trials":30913,"activeCount":97},[],{"trials":30915,"activeCount":97},[],{"intervention":30917,"totalTrials":314,"cells":30918},"LY3002813",{"EARLY_PHASE1":30919,"PHASE1":30921,"PHASE2":30930,"PHASE3":30932,"PHASE4":30934,"NA":30936},{"trials":30920,"activeCount":97},[],{"trials":30922,"activeCount":97},[30923],{"nctId":30924,"briefTitle":30925,"status":103,"phases":30926,"primaryCompletion":18656,"completion":18656,"start":30927,"enrollment":3125,"conditions":30928,"interventions":30929},"NCT02624778","A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD",[85],"2015-12-22",[3980],[30917],{"trials":30931,"activeCount":97},[],{"trials":30933,"activeCount":97},[],{"trials":30935,"activeCount":97},[],{"trials":30937,"activeCount":97},[],{"intervention":12899,"totalTrials":314,"cells":30939},{"EARLY_PHASE1":30940,"PHASE1":30942,"PHASE2":30948,"PHASE3":30950,"PHASE4":30952,"NA":30954},{"trials":30941,"activeCount":97},[],{"trials":30943,"activeCount":97},[30944],{"nctId":12892,"briefTitle":12893,"status":103,"phases":30945,"primaryCompletion":12895,"completion":12895,"start":12896,"enrollment":1082,"conditions":30946,"interventions":30947},[85],[33],[12899,438],{"trials":30949,"activeCount":97},[],{"trials":30951,"activeCount":97},[],{"trials":30953,"activeCount":97},[],{"trials":30955,"activeCount":97},[],{"intervention":30957,"totalTrials":314,"cells":30958},"LY3461767",{"EARLY_PHASE1":30959,"PHASE1":30961,"PHASE2":30972,"PHASE3":30974,"PHASE4":30976,"NA":30978},{"trials":30960,"activeCount":97},[],{"trials":30962,"activeCount":97},[30963],{"nctId":30964,"briefTitle":30965,"status":103,"phases":30966,"primaryCompletion":30967,"completion":30967,"start":30968,"enrollment":37,"conditions":30969,"interventions":30971},"NCT04840914","A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction",[85],"2024-05-09","2021-06-01",[30970],"Chronic Heart Failure With Reduced Ejection Fraction",[30957],{"trials":30973,"activeCount":97},[],{"trials":30975,"activeCount":97},[],{"trials":30977,"activeCount":97},[],{"trials":30979,"activeCount":97},[],{"intervention":16909,"totalTrials":314,"cells":30981},{"EARLY_PHASE1":30982,"PHASE1":30984,"PHASE2":30990,"PHASE3":30992,"PHASE4":30994,"NA":30996},{"trials":30983,"activeCount":97},[],{"trials":30985,"activeCount":97},[30986],{"nctId":16904,"briefTitle":16905,"status":103,"phases":30987,"primaryCompletion":4258,"completion":4258,"start":3152,"enrollment":11639,"conditions":30988,"interventions":30989},[85],[13955],[13957,16909],{"trials":30991,"activeCount":97},[],{"trials":30993,"activeCount":97},[],{"trials":30995,"activeCount":97},[],{"trials":30997,"activeCount":97},[],{"intervention":30999,"totalTrials":314,"cells":31000},"LY2922083",{"EARLY_PHASE1":31001,"PHASE1":31003,"PHASE2":31011,"PHASE3":31013,"PHASE4":31015,"NA":31017},{"trials":31002,"activeCount":97},[],{"trials":31004,"activeCount":97},[31005],{"nctId":31006,"briefTitle":31007,"status":103,"phases":31008,"primaryCompletion":2917,"completion":2917,"start":4122,"enrollment":214,"conditions":31009,"interventions":31010},"NCT01748552","A Study of LY2922083 in Healthy Participants and Participants With Diabetes",[85],[18],[30999],{"trials":31012,"activeCount":97},[],{"trials":31014,"activeCount":97},[],{"trials":31016,"activeCount":97},[],{"trials":31018,"activeCount":97},[],{"intervention":178,"totalTrials":314,"cells":31020},{"EARLY_PHASE1":31021,"PHASE1":31023,"PHASE2":31029,"PHASE3":31031,"PHASE4":31033,"NA":31035},{"trials":31022,"activeCount":97},[],{"trials":31024,"activeCount":97},[31025],{"nctId":169,"briefTitle":170,"status":103,"phases":31026,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":31027,"interventions":31028},[85],[15],[177,92,178],{"trials":31030,"activeCount":97},[],{"trials":31032,"activeCount":97},[],{"trials":31034,"activeCount":97},[],{"trials":31036,"activeCount":97},[],{"intervention":31038,"totalTrials":314,"cells":31039},"LY900009 - Dose Escalation Phase",{"EARLY_PHASE1":31040,"PHASE1":31042,"PHASE2":31051,"PHASE3":31053,"PHASE4":31055,"NA":31057},{"trials":31041,"activeCount":97},[],{"trials":31043,"activeCount":97},[31044],{"nctId":31045,"briefTitle":31046,"status":103,"phases":31047,"primaryCompletion":2966,"completion":2966,"start":2899,"enrollment":1548,"conditions":31048,"interventions":31049},"NCT01158404","Notch Inhibitor in Advanced Cancer",[85],[1466],[31038,31050],"LY900009 - Dose Confirmation Phase",{"trials":31052,"activeCount":97},[],{"trials":31054,"activeCount":97},[],{"trials":31056,"activeCount":97},[],{"trials":31058,"activeCount":97},[],{"intervention":31050,"totalTrials":314,"cells":31060},{"EARLY_PHASE1":31061,"PHASE1":31063,"PHASE2":31069,"PHASE3":31071,"PHASE4":31073,"NA":31075},{"trials":31062,"activeCount":97},[],{"trials":31064,"activeCount":97},[31065],{"nctId":31045,"briefTitle":31046,"status":103,"phases":31066,"primaryCompletion":2966,"completion":2966,"start":2899,"enrollment":1548,"conditions":31067,"interventions":31068},[85],[1466],[31038,31050],{"trials":31070,"activeCount":97},[],{"trials":31072,"activeCount":97},[],{"trials":31074,"activeCount":97},[],{"trials":31076,"activeCount":97},[],{"intervention":31078,"totalTrials":314,"cells":31079},"Mirikizumab Test",{"EARLY_PHASE1":31080,"PHASE1":31082,"PHASE2":31092,"PHASE3":31094,"PHASE4":31096,"NA":31098},{"trials":31081,"activeCount":97},[],{"trials":31083,"activeCount":97},[31084],{"nctId":31085,"briefTitle":31086,"status":103,"phases":31087,"primaryCompletion":12869,"completion":12869,"start":31088,"enrollment":6927,"conditions":31089,"interventions":31090},"NCT03053622","A Study of Mirikizumab (LY3074828) Injection in Healthy Participants",[85],"2017-04-24",[15],[31078,31078,31091],"Mirikizumab Reference",{"trials":31093,"activeCount":97},[],{"trials":31095,"activeCount":97},[],{"trials":31097,"activeCount":97},[],{"trials":31099,"activeCount":97},[],{"intervention":31091,"totalTrials":314,"cells":31101},{"EARLY_PHASE1":31102,"PHASE1":31104,"PHASE2":31110,"PHASE3":31112,"PHASE4":31114,"NA":31116},{"trials":31103,"activeCount":97},[],{"trials":31105,"activeCount":97},[31106],{"nctId":31085,"briefTitle":31086,"status":103,"phases":31107,"primaryCompletion":12869,"completion":12869,"start":31088,"enrollment":6927,"conditions":31108,"interventions":31109},[85],[15],[31078,31078,31091],{"trials":31111,"activeCount":97},[],{"trials":31113,"activeCount":97},[],{"trials":31115,"activeCount":97},[],{"trials":31117,"activeCount":97},[],{"intervention":4991,"totalTrials":314,"cells":31119},{"EARLY_PHASE1":31120,"PHASE1":31122,"PHASE2":31128,"PHASE3":31130,"PHASE4":31132,"NA":31134},{"trials":31121,"activeCount":97},[],{"trials":31123,"activeCount":97},[31124],{"nctId":4986,"briefTitle":4987,"status":103,"phases":31125,"primaryCompletion":3049,"completion":3049,"start":4955,"enrollment":12,"conditions":31126,"interventions":31127},[85],[21],[4944,4991],{"trials":31129,"activeCount":97},[],{"trials":31131,"activeCount":97},[],{"trials":31133,"activeCount":97},[],{"trials":31135,"activeCount":97},[],{"intervention":23737,"totalTrials":314,"cells":31137},{"EARLY_PHASE1":31138,"PHASE1":31140,"PHASE2":31146,"PHASE3":31148,"PHASE4":31150,"NA":31152},{"trials":31139,"activeCount":97},[],{"trials":31141,"activeCount":97},[31142],{"nctId":23732,"briefTitle":23733,"status":103,"phases":31143,"primaryCompletion":4122,"completion":4122,"start":2898,"enrollment":1620,"conditions":31144,"interventions":31145},[85],[4997],[3561,3561,23737],{"trials":31147,"activeCount":97},[],{"trials":31149,"activeCount":97},[],{"trials":31151,"activeCount":97},[],{"trials":31153,"activeCount":97},[],{"intervention":4752,"totalTrials":314,"cells":31155},{"EARLY_PHASE1":31156,"PHASE1":31158,"PHASE2":31164,"PHASE3":31166,"PHASE4":31168,"NA":31170},{"trials":31157,"activeCount":97},[],{"trials":31159,"activeCount":97},[31160],{"nctId":4744,"briefTitle":4745,"status":103,"phases":31161,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":4749,"conditions":31162,"interventions":31163},[85],[27,24],[4752,4737],{"trials":31165,"activeCount":97},[],{"trials":31167,"activeCount":97},[],{"trials":31169,"activeCount":97},[],{"trials":31171,"activeCount":97},[],{"intervention":28876,"totalTrials":314,"cells":31173},{"EARLY_PHASE1":31174,"PHASE1":31176,"PHASE2":31182,"PHASE3":31184,"PHASE4":31186,"NA":31188},{"trials":31175,"activeCount":97},[],{"trials":31177,"activeCount":97},[31178],{"nctId":28870,"briefTitle":28871,"status":103,"phases":31179,"primaryCompletion":5201,"completion":5201,"start":28873,"enrollment":1677,"conditions":31180,"interventions":31181},[85],[15],[1537,28876],{"trials":31183,"activeCount":97},[],{"trials":31185,"activeCount":97},[],{"trials":31187,"activeCount":97},[],{"trials":31189,"activeCount":97},[],{"intervention":16916,"totalTrials":314,"cells":31191},{"EARLY_PHASE1":31192,"PHASE1":31194,"PHASE2":31200,"PHASE3":31202,"PHASE4":31204,"NA":31206},{"trials":31193,"activeCount":97},[],{"trials":31195,"activeCount":97},[31196],{"nctId":16911,"briefTitle":16912,"status":103,"phases":31197,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":118,"conditions":31198,"interventions":31199},[85],[13955],[13957,16916,16917],{"trials":31201,"activeCount":97},[],{"trials":31203,"activeCount":97},[],{"trials":31205,"activeCount":97},[],{"trials":31207,"activeCount":97},[],{"intervention":4125,"totalTrials":314,"cells":31209},{"EARLY_PHASE1":31210,"PHASE1":31212,"PHASE2":31218,"PHASE3":31220,"PHASE4":31222,"NA":31224},{"trials":31211,"activeCount":97},[],{"trials":31213,"activeCount":97},[31214],{"nctId":4119,"briefTitle":4120,"status":103,"phases":31215,"primaryCompletion":2864,"completion":4122,"start":3020,"enrollment":1082,"conditions":31216,"interventions":31217},[85],[2824],[3287,4125,1612,1511],{"trials":31219,"activeCount":97},[],{"trials":31221,"activeCount":97},[],{"trials":31223,"activeCount":97},[],{"trials":31225,"activeCount":97},[],{"intervention":31227,"totalTrials":314,"cells":31228},"[¹⁴C]-LY3023414",{"EARLY_PHASE1":31229,"PHASE1":31231,"PHASE2":31239,"PHASE3":31241,"PHASE4":31243,"NA":31245},{"trials":31230,"activeCount":97},[],{"trials":31232,"activeCount":97},[31233],{"nctId":31234,"briefTitle":31235,"status":103,"phases":31236,"primaryCompletion":4383,"completion":4383,"start":3250,"enrollment":4323,"conditions":31237,"interventions":31238},"NCT02575703","A Study of [¹⁴C]-LY3023414 in Healthy Participants",[85],[15],[31227],{"trials":31240,"activeCount":97},[],{"trials":31242,"activeCount":97},[],{"trials":31244,"activeCount":97},[],{"trials":31246,"activeCount":97},[],{"intervention":31248,"totalTrials":314,"cells":31249},"IMC-EB10",{"EARLY_PHASE1":31250,"PHASE1":31252,"PHASE2":31261,"PHASE3":31263,"PHASE4":31265,"NA":31267},{"trials":31251,"activeCount":97},[],{"trials":31253,"activeCount":97},[31254],{"nctId":31255,"briefTitle":31256,"status":999,"phases":31257,"primaryCompletion":3012,"completion":3012,"start":5860,"enrollment":9038,"conditions":31258,"interventions":31260},"NCT00887926","Study of IMC-EB10 in Participant With Leukemia",[85],[31259],"Myeloid Leukemia",[31248],{"trials":31262,"activeCount":97},[],{"trials":31264,"activeCount":97},[],{"trials":31266,"activeCount":97},[],{"trials":31268,"activeCount":97},[],{"intervention":31270,"totalTrials":314,"cells":31271},"LY3114062 SC",{"EARLY_PHASE1":31272,"PHASE1":31274,"PHASE2":31284,"PHASE3":31286,"PHASE4":31288,"NA":31290},{"trials":31273,"activeCount":97},[],{"trials":31275,"activeCount":97},[31276],{"nctId":31277,"briefTitle":31278,"status":103,"phases":31279,"primaryCompletion":3717,"completion":1619,"start":5354,"enrollment":2542,"conditions":31280,"interventions":31282},"NCT02144272","Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis",[85],[31281],"Inflammatory Arthritis",[31270,31283],"LY3114062 IV",{"trials":31285,"activeCount":97},[],{"trials":31287,"activeCount":97},[],{"trials":31289,"activeCount":97},[],{"trials":31291,"activeCount":97},[],{"intervention":31283,"totalTrials":314,"cells":31293},{"EARLY_PHASE1":31294,"PHASE1":31296,"PHASE2":31302,"PHASE3":31304,"PHASE4":31306,"NA":31308},{"trials":31295,"activeCount":97},[],{"trials":31297,"activeCount":97},[31298],{"nctId":31277,"briefTitle":31278,"status":103,"phases":31299,"primaryCompletion":3717,"completion":1619,"start":5354,"enrollment":2542,"conditions":31300,"interventions":31301},[85],[31281],[31270,31283],{"trials":31303,"activeCount":97},[],{"trials":31305,"activeCount":97},[],{"trials":31307,"activeCount":97},[],{"trials":31309,"activeCount":97},[],{"intervention":6405,"totalTrials":314,"cells":31311},{"EARLY_PHASE1":31312,"PHASE1":31314,"PHASE2":31320,"PHASE3":31322,"PHASE4":31324,"NA":31326},{"trials":31313,"activeCount":97},[],{"trials":31315,"activeCount":97},[31316],{"nctId":6400,"briefTitle":6401,"status":103,"phases":31317,"primaryCompletion":3086,"completion":3886,"start":3283,"enrollment":1677,"conditions":31318,"interventions":31319},[85],[2586],[61,1745,6405,2923],{"trials":31321,"activeCount":97},[],{"trials":31323,"activeCount":97},[],{"trials":31325,"activeCount":97},[],{"trials":31327,"activeCount":97},[],{"intervention":28849,"totalTrials":314,"cells":31329},{"EARLY_PHASE1":31330,"PHASE1":31332,"PHASE2":31338,"PHASE3":31340,"PHASE4":31342,"NA":31344},{"trials":31331,"activeCount":97},[],{"trials":31333,"activeCount":97},[31334],{"nctId":28844,"briefTitle":28845,"status":999,"phases":31335,"primaryCompletion":23165,"completion":23165,"start":7463,"enrollment":1620,"conditions":31336,"interventions":31337},[85],[447],[28849,28850,10914],{"trials":31339,"activeCount":97},[],{"trials":31341,"activeCount":97},[],{"trials":31343,"activeCount":97},[],{"trials":31345,"activeCount":97},[],{"intervention":28850,"totalTrials":314,"cells":31347},{"EARLY_PHASE1":31348,"PHASE1":31350,"PHASE2":31356,"PHASE3":31358,"PHASE4":31360,"NA":31362},{"trials":31349,"activeCount":97},[],{"trials":31351,"activeCount":97},[31352],{"nctId":28844,"briefTitle":28845,"status":999,"phases":31353,"primaryCompletion":23165,"completion":23165,"start":7463,"enrollment":1620,"conditions":31354,"interventions":31355},[85],[447],[28849,28850,10914],{"trials":31357,"activeCount":97},[],{"trials":31359,"activeCount":97},[],{"trials":31361,"activeCount":97},[],{"trials":31363,"activeCount":97},[],{"intervention":31365,"totalTrials":314,"cells":31366},"Prasugrel ODT1 -",{"EARLY_PHASE1":31367,"PHASE1":31369,"PHASE2":31379,"PHASE3":31381,"PHASE4":31383,"NA":31385},{"trials":31368,"activeCount":97},[],{"trials":31370,"activeCount":97},[31371],{"nctId":31372,"briefTitle":31373,"status":103,"phases":31374,"primaryCompletion":2966,"completion":2966,"start":3545,"enrollment":1082,"conditions":31375,"interventions":31376},"NCT01648790","A Study of Prasugrel in Healthy Participants",[85],[21],[31365,31377,31378],"Prasugrel ODT2 -","Prasugrel ODT2 - Suspension",{"trials":31380,"activeCount":97},[],{"trials":31382,"activeCount":97},[],{"trials":31384,"activeCount":97},[],{"trials":31386,"activeCount":97},[],{"intervention":31377,"totalTrials":314,"cells":31388},{"EARLY_PHASE1":31389,"PHASE1":31391,"PHASE2":31397,"PHASE3":31399,"PHASE4":31401,"NA":31403},{"trials":31390,"activeCount":97},[],{"trials":31392,"activeCount":97},[31393],{"nctId":31372,"briefTitle":31373,"status":103,"phases":31394,"primaryCompletion":2966,"completion":2966,"start":3545,"enrollment":1082,"conditions":31395,"interventions":31396},[85],[21],[31365,31377,31378],{"trials":31398,"activeCount":97},[],{"trials":31400,"activeCount":97},[],{"trials":31402,"activeCount":97},[],{"trials":31404,"activeCount":97},[],{"intervention":31378,"totalTrials":314,"cells":31406},{"EARLY_PHASE1":31407,"PHASE1":31409,"PHASE2":31415,"PHASE3":31417,"PHASE4":31419,"NA":31421},{"trials":31408,"activeCount":97},[],{"trials":31410,"activeCount":97},[31411],{"nctId":31372,"briefTitle":31373,"status":103,"phases":31412,"primaryCompletion":2966,"completion":2966,"start":3545,"enrollment":1082,"conditions":31413,"interventions":31414},[85],[21],[31365,31377,31378],{"trials":31416,"activeCount":97},[],{"trials":31418,"activeCount":97},[],{"trials":31420,"activeCount":97},[],{"trials":31422,"activeCount":97},[],{"intervention":7955,"totalTrials":314,"cells":31424},{"EARLY_PHASE1":31425,"PHASE1":31427,"PHASE2":31433,"PHASE3":31435,"PHASE4":31437,"NA":31439},{"trials":31426,"activeCount":97},[],{"trials":31428,"activeCount":97},[31429],{"nctId":7947,"briefTitle":7948,"status":103,"phases":31430,"primaryCompletion":7950,"completion":7950,"start":7951,"enrollment":1767,"conditions":31431,"interventions":31432},[85],[1503],[7954,2696,7955],{"trials":31434,"activeCount":97},[],{"trials":31436,"activeCount":97},[],{"trials":31438,"activeCount":97},[],{"trials":31440,"activeCount":97},[],{"intervention":31442,"totalTrials":314,"cells":31443},"[^14C]-LY2157299",{"EARLY_PHASE1":31444,"PHASE1":31446,"PHASE2":31454,"PHASE3":31456,"PHASE4":31458,"NA":31460},{"trials":31445,"activeCount":97},[],{"trials":31447,"activeCount":97},[31448],{"nctId":31449,"briefTitle":31450,"status":103,"phases":31451,"primaryCompletion":4420,"completion":4420,"start":3068,"enrollment":4323,"conditions":31452,"interventions":31453},"NCT01746004","A Study of LY2157299 Monohydrate in Healthy Volunteers",[85],[21],[31442],{"trials":31455,"activeCount":97},[],{"trials":31457,"activeCount":97},[],{"trials":31459,"activeCount":97},[],{"trials":31461,"activeCount":97},[],{"intervention":27700,"totalTrials":314,"cells":31463},{"EARLY_PHASE1":31464,"PHASE1":31466,"PHASE2":31472,"PHASE3":31474,"PHASE4":31476,"NA":31478},{"trials":31465,"activeCount":97},[],{"trials":31467,"activeCount":97},[31468],{"nctId":27694,"briefTitle":27695,"status":103,"phases":31469,"primaryCompletion":23561,"completion":23561,"start":27697,"enrollment":410,"conditions":31470,"interventions":31471},[85],[15],[27700,1538],{"trials":31473,"activeCount":97},[],{"trials":31475,"activeCount":97},[],{"trials":31477,"activeCount":97},[],{"trials":31479,"activeCount":97},[],{"intervention":31481,"totalTrials":314,"cells":31482},"LY3015014 IV",{"EARLY_PHASE1":31483,"PHASE1":31485,"PHASE2":31494,"PHASE3":31496,"PHASE4":31498,"NA":31500},{"trials":31484,"activeCount":97},[],{"trials":31486,"activeCount":97},[31487],{"nctId":31488,"briefTitle":31489,"status":103,"phases":31490,"primaryCompletion":2964,"completion":2964,"start":3494,"enrollment":3013,"conditions":31491,"interventions":31492},"NCT01426412","A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol",[85],[17394],[31481,31493],"LY3015014 SC",{"trials":31495,"activeCount":97},[],{"trials":31497,"activeCount":97},[],{"trials":31499,"activeCount":97},[],{"trials":31501,"activeCount":97},[],{"intervention":31493,"totalTrials":314,"cells":31503},{"EARLY_PHASE1":31504,"PHASE1":31506,"PHASE2":31512,"PHASE3":31514,"PHASE4":31516,"NA":31518},{"trials":31505,"activeCount":97},[],{"trials":31507,"activeCount":97},[31508],{"nctId":31488,"briefTitle":31489,"status":103,"phases":31509,"primaryCompletion":2964,"completion":2964,"start":3494,"enrollment":3013,"conditions":31510,"interventions":31511},[85],[17394],[31481,31493],{"trials":31513,"activeCount":97},[],{"trials":31515,"activeCount":97},[],{"trials":31517,"activeCount":97},[],{"trials":31519,"activeCount":97},[],{"intervention":23312,"totalTrials":314,"cells":31521},{"EARLY_PHASE1":31522,"PHASE1":31524,"PHASE2":31530,"PHASE3":31532,"PHASE4":31534,"NA":31536},{"trials":31523,"activeCount":97},[],{"trials":31525,"activeCount":97},[31526],{"nctId":23305,"briefTitle":23306,"status":103,"phases":31527,"primaryCompletion":23308,"completion":23308,"start":23309,"enrollment":2477,"conditions":31528,"interventions":31529},[85],[15],[1508,23312],{"trials":31531,"activeCount":97},[],{"trials":31533,"activeCount":97},[],{"trials":31535,"activeCount":97},[],{"trials":31537,"activeCount":97},[],{"intervention":31539,"totalTrials":314,"cells":31540},"LY3463251",{"EARLY_PHASE1":31541,"PHASE1":31543,"PHASE2":31551,"PHASE3":31553,"PHASE4":31555,"NA":31557},{"trials":31542,"activeCount":97},[],{"trials":31544,"activeCount":97},[31545],{"nctId":31546,"briefTitle":31547,"status":999,"phases":31548,"primaryCompletion":7080,"completion":7080,"start":5227,"enrollment":3618,"conditions":31549,"interventions":31550},"NCT03764774","A Study of LY3463251 in Healthy Participants",[85],[15],[31539],{"trials":31552,"activeCount":97},[],{"trials":31554,"activeCount":97},[],{"trials":31556,"activeCount":97},[],{"trials":31558,"activeCount":97},[],{"intervention":22996,"totalTrials":314,"cells":31560},{"EARLY_PHASE1":31561,"PHASE1":31563,"PHASE2":31569,"PHASE3":31571,"PHASE4":31573,"NA":31575},{"trials":31562,"activeCount":97},[],{"trials":31564,"activeCount":97},[31565],{"nctId":22991,"briefTitle":22992,"status":103,"phases":31566,"primaryCompletion":1485,"completion":1485,"start":1498,"enrollment":4323,"conditions":31567,"interventions":31568},[85],[15],[10978,22996],{"trials":31570,"activeCount":97},[],{"trials":31572,"activeCount":97},[],{"trials":31574,"activeCount":97},[],{"trials":31576,"activeCount":97},[],{"intervention":31578,"totalTrials":314,"cells":31579},"LY3009120",{"EARLY_PHASE1":31580,"PHASE1":31582,"PHASE2":31592,"PHASE3":31594,"PHASE4":31596,"NA":31598},{"trials":31581,"activeCount":97},[],{"trials":31583,"activeCount":97},[31584],{"nctId":31585,"briefTitle":31586,"status":999,"phases":31587,"primaryCompletion":31588,"completion":7591,"start":31589,"enrollment":4945,"conditions":31590,"interventions":31591},"NCT02014116","A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body",[85],"2017-04-07","2013-11-26",[1870,1478,1732,1589,2557],[31578],{"trials":31593,"activeCount":97},[],{"trials":31595,"activeCount":97},[],{"trials":31597,"activeCount":97},[],{"trials":31599,"activeCount":97},[],{"intervention":2592,"totalTrials":314,"cells":31601},{"EARLY_PHASE1":31602,"PHASE1":31604,"PHASE2":31610,"PHASE3":31612,"PHASE4":31614,"NA":31616},{"trials":31603,"activeCount":97},[],{"trials":31605,"activeCount":97},[31606],{"nctId":2576,"briefTitle":2577,"status":103,"phases":31607,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":31608,"interventions":31609},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":31611,"activeCount":97},[],{"trials":31613,"activeCount":97},[],{"trials":31615,"activeCount":97},[],{"trials":31617,"activeCount":97},[],{"intervention":2594,"totalTrials":314,"cells":31619},{"EARLY_PHASE1":31620,"PHASE1":31622,"PHASE2":31628,"PHASE3":31630,"PHASE4":31632,"NA":31634},{"trials":31621,"activeCount":97},[],{"trials":31623,"activeCount":97},[31624],{"nctId":2576,"briefTitle":2577,"status":103,"phases":31625,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":31626,"interventions":31627},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":31629,"activeCount":97},[],{"trials":31631,"activeCount":97},[],{"trials":31633,"activeCount":97},[],{"trials":31635,"activeCount":97},[],{"intervention":2595,"totalTrials":314,"cells":31637},{"EARLY_PHASE1":31638,"PHASE1":31640,"PHASE2":31646,"PHASE3":31648,"PHASE4":31650,"NA":31652},{"trials":31639,"activeCount":97},[],{"trials":31641,"activeCount":97},[31642],{"nctId":2576,"briefTitle":2577,"status":103,"phases":31643,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":31644,"interventions":31645},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":31647,"activeCount":97},[],{"trials":31649,"activeCount":97},[],{"trials":31651,"activeCount":97},[],{"trials":31653,"activeCount":97},[],{"intervention":2597,"totalTrials":314,"cells":31655},{"EARLY_PHASE1":31656,"PHASE1":31658,"PHASE2":31664,"PHASE3":31666,"PHASE4":31668,"NA":31670},{"trials":31657,"activeCount":97},[],{"trials":31659,"activeCount":97},[31660],{"nctId":2576,"briefTitle":2577,"status":103,"phases":31661,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":31662,"interventions":31663},[85],[1732,1903,2584,2585,2586,2587,2588,2589,36],[2591,2592,2593,2594,1843,2595,1696,1669,2596,2597],{"trials":31665,"activeCount":97},[],{"trials":31667,"activeCount":97},[],{"trials":31669,"activeCount":97},[],{"trials":31671,"activeCount":97},[],{"intervention":24631,"totalTrials":314,"cells":31673},{"EARLY_PHASE1":31674,"PHASE1":31676,"PHASE2":31682,"PHASE3":31684,"PHASE4":31686,"NA":31688},{"trials":31675,"activeCount":97},[],{"trials":31677,"activeCount":97},[31678],{"nctId":24625,"briefTitle":24626,"status":103,"phases":31679,"primaryCompletion":3086,"completion":3086,"start":2800,"enrollment":11639,"conditions":31680,"interventions":31681},[85],[24629],[24631,16655],{"trials":31683,"activeCount":97},[],{"trials":31685,"activeCount":97},[],{"trials":31687,"activeCount":97},[],{"trials":31689,"activeCount":97},[],{"intervention":11625,"totalTrials":314,"cells":31691},{"EARLY_PHASE1":31692,"PHASE1":31694,"PHASE2":31700,"PHASE3":31702,"PHASE4":31704,"NA":31706},{"trials":31693,"activeCount":97},[],{"trials":31695,"activeCount":97},[31696],{"nctId":11618,"briefTitle":11619,"status":103,"phases":31697,"primaryCompletion":11621,"completion":11622,"start":9559,"enrollment":1071,"conditions":31698,"interventions":31699},[85],[15],[11625,1666,11625],{"trials":31701,"activeCount":97},[],{"trials":31703,"activeCount":97},[],{"trials":31705,"activeCount":97},[],{"trials":31707,"activeCount":97},[],{"intervention":2782,"totalTrials":314,"cells":31709},{"EARLY_PHASE1":31710,"PHASE1":31712,"PHASE2":31718,"PHASE3":31720,"PHASE4":31722,"NA":31724},{"trials":31711,"activeCount":97},[],{"trials":31713,"activeCount":97},[31714],{"nctId":2774,"briefTitle":2775,"status":103,"phases":31715,"primaryCompletion":1499,"completion":1499,"start":2777,"enrollment":2778,"conditions":31716,"interventions":31717},[85],[1478,2557,36],[2781,1510,1541,2782,1612,2783,1513,2521],{"trials":31719,"activeCount":97},[],{"trials":31721,"activeCount":97},[],{"trials":31723,"activeCount":97},[],{"trials":31725,"activeCount":97},[],{"intervention":18062,"totalTrials":314,"cells":31727},{"EARLY_PHASE1":31728,"PHASE1":31730,"PHASE2":31736,"PHASE3":31738,"PHASE4":31740,"NA":31742},{"trials":31729,"activeCount":97},[],{"trials":31731,"activeCount":97},[31732],{"nctId":18056,"briefTitle":18057,"status":103,"phases":31733,"primaryCompletion":11256,"completion":11256,"start":18059,"enrollment":310,"conditions":31734,"interventions":31735},[85],[15],[18062,18063,9237,18064],{"trials":31737,"activeCount":97},[],{"trials":31739,"activeCount":97},[],{"trials":31741,"activeCount":97},[],{"trials":31743,"activeCount":97},[],{"intervention":18063,"totalTrials":314,"cells":31745},{"EARLY_PHASE1":31746,"PHASE1":31748,"PHASE2":31754,"PHASE3":31756,"PHASE4":31758,"NA":31760},{"trials":31747,"activeCount":97},[],{"trials":31749,"activeCount":97},[31750],{"nctId":18056,"briefTitle":18057,"status":103,"phases":31751,"primaryCompletion":11256,"completion":11256,"start":18059,"enrollment":310,"conditions":31752,"interventions":31753},[85],[15],[18062,18063,9237,18064],{"trials":31755,"activeCount":97},[],{"trials":31757,"activeCount":97},[],{"trials":31759,"activeCount":97},[],{"trials":31761,"activeCount":97},[],{"intervention":18064,"totalTrials":314,"cells":31763},{"EARLY_PHASE1":31764,"PHASE1":31766,"PHASE2":31772,"PHASE3":31774,"PHASE4":31776,"NA":31778},{"trials":31765,"activeCount":97},[],{"trials":31767,"activeCount":97},[31768],{"nctId":18056,"briefTitle":18057,"status":103,"phases":31769,"primaryCompletion":11256,"completion":11256,"start":18059,"enrollment":310,"conditions":31770,"interventions":31771},[85],[15],[18062,18063,9237,18064],{"trials":31773,"activeCount":97},[],{"trials":31775,"activeCount":97},[],{"trials":31777,"activeCount":97},[],{"trials":31779,"activeCount":97},[],{"intervention":31781,"totalTrials":314,"cells":31782},"LY3461767 - SC",{"EARLY_PHASE1":31783,"PHASE1":31785,"PHASE2":31794,"PHASE3":31796,"PHASE4":31798,"NA":31800},{"trials":31784,"activeCount":97},[],{"trials":31786,"activeCount":97},[31787],{"nctId":31788,"briefTitle":31789,"status":103,"phases":31790,"primaryCompletion":562,"completion":562,"start":1379,"enrollment":118,"conditions":31791,"interventions":31792},"NCT04352114","A Study of LY3461767 in Healthy Participants",[85],[15],[31781,31793],"LY3461767 - IV",{"trials":31795,"activeCount":97},[],{"trials":31797,"activeCount":97},[],{"trials":31799,"activeCount":97},[],{"trials":31801,"activeCount":97},[],{"intervention":31793,"totalTrials":314,"cells":31803},{"EARLY_PHASE1":31804,"PHASE1":31806,"PHASE2":31812,"PHASE3":31814,"PHASE4":31816,"NA":31818},{"trials":31805,"activeCount":97},[],{"trials":31807,"activeCount":97},[31808],{"nctId":31788,"briefTitle":31789,"status":103,"phases":31809,"primaryCompletion":562,"completion":562,"start":1379,"enrollment":118,"conditions":31810,"interventions":31811},[85],[15],[31781,31793],{"trials":31813,"activeCount":97},[],{"trials":31815,"activeCount":97},[],{"trials":31817,"activeCount":97},[],{"trials":31819,"activeCount":97},[],{"intervention":18072,"totalTrials":314,"cells":31821},{"EARLY_PHASE1":31822,"PHASE1":31824,"PHASE2":31830,"PHASE3":31832,"PHASE4":31834,"NA":31836},{"trials":31823,"activeCount":97},[],{"trials":31825,"activeCount":97},[31826],{"nctId":18066,"briefTitle":18067,"status":103,"phases":31827,"primaryCompletion":18069,"completion":18069,"start":1969,"enrollment":1767,"conditions":31828,"interventions":31829},[85],[15],[18072,9237],{"trials":31831,"activeCount":97},[],{"trials":31833,"activeCount":97},[],{"trials":31835,"activeCount":97},[],{"trials":31837,"activeCount":97},[],{"intervention":10937,"totalTrials":314,"cells":31839},{"EARLY_PHASE1":31840,"PHASE1":31842,"PHASE2":31848,"PHASE3":31850,"PHASE4":31852,"NA":31854},{"trials":31841,"activeCount":97},[],{"trials":31843,"activeCount":97},[31844],{"nctId":10931,"briefTitle":10932,"status":103,"phases":31845,"primaryCompletion":2820,"completion":2820,"start":10934,"enrollment":137,"conditions":31846,"interventions":31847},[85],[15],[10937,2562],{"trials":31849,"activeCount":97},[],{"trials":31851,"activeCount":97},[],{"trials":31853,"activeCount":97},[],{"trials":31855,"activeCount":97},[],{"intervention":31857,"totalTrials":314,"cells":31858},"[^14C]-LY2940680",{"EARLY_PHASE1":31859,"PHASE1":31861,"PHASE2":31868,"PHASE3":31870,"PHASE4":31872,"NA":31874},{"trials":31860,"activeCount":97},[],{"trials":31862,"activeCount":97},[31863],{"nctId":31864,"briefTitle":23733,"status":103,"phases":31865,"primaryCompletion":3124,"completion":3124,"start":3068,"enrollment":1677,"conditions":31866,"interventions":31867},"NCT01746745",[85],[21],[31857],{"trials":31869,"activeCount":97},[],{"trials":31871,"activeCount":97},[],{"trials":31873,"activeCount":97},[],{"trials":31875,"activeCount":97},[],{"intervention":31877,"totalTrials":314,"cells":31878},"LY3039478 Capsule Formulation",{"EARLY_PHASE1":31879,"PHASE1":31881,"PHASE2":31891,"PHASE3":31893,"PHASE4":31895,"NA":31897},{"trials":31880,"activeCount":97},[],{"trials":31882,"activeCount":97},[31883],{"nctId":31884,"briefTitle":31885,"status":103,"phases":31886,"primaryCompletion":2965,"completion":2965,"start":22720,"enrollment":864,"conditions":31887,"interventions":31888},"NCT02659865","A Study of LY3039478 in Healthy Participants",[85],[15],[31877,31889,31890],"LY3039478 Drug-in","LY3039478 Formulated",{"trials":31892,"activeCount":97},[],{"trials":31894,"activeCount":97},[],{"trials":31896,"activeCount":97},[],{"trials":31898,"activeCount":97},[],{"intervention":31889,"totalTrials":314,"cells":31900},{"EARLY_PHASE1":31901,"PHASE1":31903,"PHASE2":31909,"PHASE3":31911,"PHASE4":31913,"NA":31915},{"trials":31902,"activeCount":97},[],{"trials":31904,"activeCount":97},[31905],{"nctId":31884,"briefTitle":31885,"status":103,"phases":31906,"primaryCompletion":2965,"completion":2965,"start":22720,"enrollment":864,"conditions":31907,"interventions":31908},[85],[15],[31877,31889,31890],{"trials":31910,"activeCount":97},[],{"trials":31912,"activeCount":97},[],{"trials":31914,"activeCount":97},[],{"trials":31916,"activeCount":97},[],{"intervention":31890,"totalTrials":314,"cells":31918},{"EARLY_PHASE1":31919,"PHASE1":31921,"PHASE2":31927,"PHASE3":31929,"PHASE4":31931,"NA":31933},{"trials":31920,"activeCount":97},[],{"trials":31922,"activeCount":97},[31923],{"nctId":31884,"briefTitle":31885,"status":103,"phases":31924,"primaryCompletion":2965,"completion":2965,"start":22720,"enrollment":864,"conditions":31925,"interventions":31926},[85],[15],[31877,31889,31890],{"trials":31928,"activeCount":97},[],{"trials":31930,"activeCount":97},[],{"trials":31932,"activeCount":97},[],{"trials":31934,"activeCount":97},[],{"intervention":31936,"totalTrials":314,"cells":31937},"LY3016859 intravenous",{"EARLY_PHASE1":31938,"PHASE1":31940,"PHASE2":31949,"PHASE3":31951,"PHASE4":31953,"NA":31955},{"trials":31939,"activeCount":97},[],{"trials":31941,"activeCount":97},[31942],{"nctId":31943,"briefTitle":31944,"status":103,"phases":31945,"primaryCompletion":2898,"completion":2898,"start":2864,"enrollment":6943,"conditions":31946,"interventions":31947},"NCT01545583","A Study of LY3016859 in Healthy Volunteers",[85],[21],[31936,31948],"LY3016859 subcutaneous",{"trials":31950,"activeCount":97},[],{"trials":31952,"activeCount":97},[],{"trials":31954,"activeCount":97},[],{"trials":31956,"activeCount":97},[],{"intervention":31948,"totalTrials":314,"cells":31958},{"EARLY_PHASE1":31959,"PHASE1":31961,"PHASE2":31967,"PHASE3":31969,"PHASE4":31971,"NA":31973},{"trials":31960,"activeCount":97},[],{"trials":31962,"activeCount":97},[31963],{"nctId":31943,"briefTitle":31944,"status":103,"phases":31964,"primaryCompletion":2898,"completion":2898,"start":2864,"enrollment":6943,"conditions":31965,"interventions":31966},[85],[21],[31936,31948],{"trials":31968,"activeCount":97},[],{"trials":31970,"activeCount":97},[],{"trials":31972,"activeCount":97},[],{"trials":31974,"activeCount":97},[],{"intervention":6252,"totalTrials":314,"cells":31976},{"EARLY_PHASE1":31977,"PHASE1":31979,"PHASE2":31985,"PHASE3":31987,"PHASE4":31989,"NA":31991},{"trials":31978,"activeCount":97},[],{"trials":31980,"activeCount":97},[31981],{"nctId":6247,"briefTitle":6248,"status":103,"phases":31982,"primaryCompletion":1557,"completion":1557,"start":5346,"enrollment":1082,"conditions":31983,"interventions":31984},[85],[15],[2685,6252,1171],{"trials":31986,"activeCount":97},[],{"trials":31988,"activeCount":97},[],{"trials":31990,"activeCount":97},[],{"trials":31992,"activeCount":97},[],{"intervention":31994,"totalTrials":314,"cells":31995},"LY2886721 in a",{"EARLY_PHASE1":31996,"PHASE1":31998,"PHASE2":32007,"PHASE3":32009,"PHASE4":32011,"NA":32013},{"trials":31997,"activeCount":97},[],{"trials":31999,"activeCount":97},[32000],{"nctId":32001,"briefTitle":32002,"status":103,"phases":32003,"primaryCompletion":3282,"completion":3282,"start":4420,"enrollment":893,"conditions":32004,"interventions":32005},"NCT01775904","A Study of Two Dosage Forms of LY2886721 in Healthy Participants",[85],[21],[31994,32006],"LY2886721 in an orally disintegrating",{"trials":32008,"activeCount":97},[],{"trials":32010,"activeCount":97},[],{"trials":32012,"activeCount":97},[],{"trials":32014,"activeCount":97},[],{"intervention":32006,"totalTrials":314,"cells":32016},{"EARLY_PHASE1":32017,"PHASE1":32019,"PHASE2":32025,"PHASE3":32027,"PHASE4":32029,"NA":32031},{"trials":32018,"activeCount":97},[],{"trials":32020,"activeCount":97},[32021],{"nctId":32001,"briefTitle":32002,"status":103,"phases":32022,"primaryCompletion":3282,"completion":3282,"start":4420,"enrollment":893,"conditions":32023,"interventions":32024},[85],[21],[31994,32006],{"trials":32026,"activeCount":97},[],{"trials":32028,"activeCount":97},[],{"trials":32030,"activeCount":97},[],{"trials":32032,"activeCount":97},[],{"intervention":32034,"totalTrials":314,"cells":32035},"LY2624587",{"EARLY_PHASE1":32036,"PHASE1":32038,"PHASE2":32046,"PHASE3":32048,"PHASE4":32050,"NA":32052},{"trials":32037,"activeCount":97},[],{"trials":32039,"activeCount":97},[32040],{"nctId":32041,"briefTitle":32042,"status":103,"phases":32043,"primaryCompletion":5090,"completion":5090,"start":2918,"enrollment":6943,"conditions":32044,"interventions":32045},"NCT01139788","A Study of LY2624587 in Patients With Advanced Cancer",[85],[1560],[32034],{"trials":32047,"activeCount":97},[],{"trials":32049,"activeCount":97},[],{"trials":32051,"activeCount":97},[],{"trials":32053,"activeCount":97},[],{"intervention":32055,"totalTrials":314,"cells":32056},"Cetuximab + Erlotinib",{"EARLY_PHASE1":32057,"PHASE1":32059,"PHASE2":32067,"PHASE3":32069,"PHASE4":32071,"NA":32073},{"trials":32058,"activeCount":97},[],{"trials":32060,"activeCount":97},[32061],{"nctId":32062,"briefTitle":32063,"status":103,"phases":32064,"primaryCompletion":3005,"completion":3005,"start":14103,"enrollment":5015,"conditions":32065,"interventions":32066},"NCT00207077","Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors",[85],[1870],[32055],{"trials":32068,"activeCount":97},[],{"trials":32070,"activeCount":97},[],{"trials":32072,"activeCount":97},[],{"trials":32074,"activeCount":97},[],{"intervention":32076,"totalTrials":314,"cells":32077},"LY3164530",{"EARLY_PHASE1":32078,"PHASE1":32080,"PHASE2":32089,"PHASE3":32091,"PHASE4":32093,"NA":32095},{"trials":32079,"activeCount":97},[],{"trials":32081,"activeCount":97},[32082],{"nctId":32083,"briefTitle":32084,"status":103,"phases":32085,"primaryCompletion":32086,"completion":32086,"start":3122,"enrollment":864,"conditions":32087,"interventions":32088},"NCT02221882","A Study of LY3164530 in Participants With Cancer",[85],"2017-03-07",[1870,1478],[32076],{"trials":32090,"activeCount":97},[],{"trials":32092,"activeCount":97},[],{"trials":32094,"activeCount":97},[],{"trials":32096,"activeCount":97},[],{"intervention":2612,"totalTrials":314,"cells":32098},{"EARLY_PHASE1":32099,"PHASE1":32101,"PHASE2":32107,"PHASE3":32109,"PHASE4":32111,"NA":32113},{"trials":32100,"activeCount":97},[],{"trials":32102,"activeCount":97},[32103],{"nctId":2599,"briefTitle":2600,"status":999,"phases":32104,"primaryCompletion":989,"completion":989,"start":862,"enrollment":947,"conditions":32105,"interventions":32106},[85],[1503,2603,2604,2605,2606,2607,2608,2609,2610],[2612,1696],{"trials":32108,"activeCount":97},[],{"trials":32110,"activeCount":97},[],{"trials":32112,"activeCount":97},[],{"trials":32114,"activeCount":97},[],{"intervention":28749,"totalTrials":314,"cells":32116},{"EARLY_PHASE1":32117,"PHASE1":32119,"PHASE2":32125,"PHASE3":32127,"PHASE4":32129,"NA":32131},{"trials":32118,"activeCount":97},[],{"trials":32120,"activeCount":97},[32121],{"nctId":28742,"briefTitle":28743,"status":103,"phases":32122,"primaryCompletion":28745,"completion":28745,"start":28746,"enrollment":1158,"conditions":32123,"interventions":32124},[85],[15],[28749,28728,28749],{"trials":32126,"activeCount":97},[],{"trials":32128,"activeCount":97},[],{"trials":32130,"activeCount":97},[],{"trials":32132,"activeCount":97},[],{"intervention":6268,"totalTrials":314,"cells":32134},{"EARLY_PHASE1":32135,"PHASE1":32137,"PHASE2":32143,"PHASE3":32145,"PHASE4":32147,"NA":32149},{"trials":32136,"activeCount":97},[],{"trials":32138,"activeCount":97},[32139],{"nctId":6263,"briefTitle":6264,"status":103,"phases":32140,"primaryCompletion":5120,"completion":5120,"start":364,"enrollment":2477,"conditions":32141,"interventions":32142},[85],[15],[6268,2685,6268],{"trials":32144,"activeCount":97},[],{"trials":32146,"activeCount":97},[],{"trials":32148,"activeCount":97},[],{"trials":32150,"activeCount":97},[],{"intervention":32152,"totalTrials":314,"cells":32153},"LY4060874",{"EARLY_PHASE1":32154,"PHASE1":32156,"PHASE2":32164,"PHASE3":32166,"PHASE4":32168,"NA":32170},{"trials":32155,"activeCount":97},[],{"trials":32157,"activeCount":97},[32158],{"nctId":32159,"briefTitle":32160,"status":103,"phases":32161,"primaryCompletion":2381,"completion":2381,"start":28738,"enrollment":3487,"conditions":32162,"interventions":32163},"NCT06709820","A Study of LY4060874 in Healthy Participants",[85],[4997],[32152,32152],{"trials":32165,"activeCount":97},[],{"trials":32167,"activeCount":97},[],{"trials":32169,"activeCount":97},[],{"trials":32171,"activeCount":97},[],{"intervention":32173,"totalTrials":314,"cells":32174},"LY3875383",{"EARLY_PHASE1":32175,"PHASE1":32177,"PHASE2":32186,"PHASE3":32188,"PHASE4":32190,"NA":32192},{"trials":32176,"activeCount":97},[],{"trials":32178,"activeCount":97},[32179],{"nctId":32180,"briefTitle":32181,"status":999,"phases":32182,"primaryCompletion":375,"completion":375,"start":23786,"enrollment":2542,"conditions":32183,"interventions":32185},"NCT05609825","A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia",[85],[32184],"Hypertriglyceridemia",[32173],{"trials":32187,"activeCount":97},[],{"trials":32189,"activeCount":97},[],{"trials":32191,"activeCount":97},[],{"trials":32193,"activeCount":97},[],{"intervention":25526,"totalTrials":314,"cells":32195},{"EARLY_PHASE1":32196,"PHASE1":32198,"PHASE2":32204,"PHASE3":32206,"PHASE4":32208,"NA":32210},{"trials":32197,"activeCount":97},[],{"trials":32199,"activeCount":97},[32200],{"nctId":25520,"briefTitle":25521,"status":103,"phases":32201,"primaryCompletion":3821,"completion":3821,"start":25523,"enrollment":3293,"conditions":32202,"interventions":32203},[85],[15],[25526,25513,25526],{"trials":32205,"activeCount":97},[],{"trials":32207,"activeCount":97},[],{"trials":32209,"activeCount":97},[],{"trials":32211,"activeCount":97},[],{"intervention":32213,"totalTrials":314,"cells":32214},"[^14C]-LY3023703",{"EARLY_PHASE1":32215,"PHASE1":32217,"PHASE2":32225,"PHASE3":32227,"PHASE4":32229,"NA":32231},{"trials":32216,"activeCount":97},[],{"trials":32218,"activeCount":97},[32219],{"nctId":32220,"briefTitle":32221,"status":999,"phases":32222,"primaryCompletion":4955,"completion":4955,"start":4955,"enrollment":12,"conditions":32223,"interventions":32224},"NCT01965782","A Study of [14C]-LY3023703 in Healthy Participants",[85],[21],[32213],{"trials":32226,"activeCount":97},[],{"trials":32228,"activeCount":97},[],{"trials":32230,"activeCount":97},[],{"trials":32232,"activeCount":97},[],{"intervention":17581,"totalTrials":314,"cells":32234},{"EARLY_PHASE1":32235,"PHASE1":32237,"PHASE2":32243,"PHASE3":32245,"PHASE4":32247,"NA":32249},{"trials":32236,"activeCount":97},[],{"trials":32238,"activeCount":97},[32239],{"nctId":17576,"briefTitle":17577,"status":103,"phases":32240,"primaryCompletion":8217,"completion":8217,"start":3837,"enrollment":4945,"conditions":32241,"interventions":32242},[85],[18],[9681,2334,17581],{"trials":32244,"activeCount":97},[],{"trials":32246,"activeCount":97},[],{"trials":32248,"activeCount":97},[],{"trials":32250,"activeCount":97},[],{"intervention":32252,"totalTrials":314,"cells":32253},"IMC-RON8",{"EARLY_PHASE1":32254,"PHASE1":32256,"PHASE2":32264,"PHASE3":32266,"PHASE4":32268,"NA":32270},{"trials":32255,"activeCount":97},[],{"trials":32257,"activeCount":97},[32258],{"nctId":32259,"briefTitle":32260,"status":103,"phases":32261,"primaryCompletion":4980,"completion":4980,"start":2956,"enrollment":3041,"conditions":32262,"interventions":32263},"NCT01119456","A Study of IMC-RON8 in Advanced Solid Tumors",[85],[2824],[32252,32252,32252,32252,32252,32252,32252,32252],{"trials":32265,"activeCount":97},[],{"trials":32267,"activeCount":97},[],{"trials":32269,"activeCount":97},[],{"trials":32271,"activeCount":97},[],{"intervention":28065,"totalTrials":314,"cells":32273},{"EARLY_PHASE1":32274,"PHASE1":32276,"PHASE2":32282,"PHASE3":32284,"PHASE4":32286,"NA":32288},{"trials":32275,"activeCount":97},[],{"trials":32277,"activeCount":97},[32278],{"nctId":28059,"briefTitle":28060,"status":999,"phases":32279,"primaryCompletion":28062,"completion":28062,"start":2014,"enrollment":137,"conditions":32280,"interventions":32281},[85],[15],[6946,28065,28057],{"trials":32283,"activeCount":97},[],{"trials":32285,"activeCount":97},[],{"trials":32287,"activeCount":97},[],{"trials":32289,"activeCount":97},[],{"intervention":32291,"totalTrials":314,"cells":32292},"LY3493269 - SC",{"EARLY_PHASE1":32293,"PHASE1":32295,"PHASE2":32306,"PHASE3":32308,"PHASE4":32310,"NA":32312},{"trials":32294,"activeCount":97},[],{"trials":32296,"activeCount":97},[32297],{"nctId":32298,"briefTitle":32299,"status":103,"phases":32300,"primaryCompletion":32301,"completion":32301,"start":32302,"enrollment":5015,"conditions":32303,"interventions":32304},"NCT04178733","A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants",[85],"2020-05-11","2020-01-10",[15],[32291,32305],"LY3493269 - IV",{"trials":32307,"activeCount":97},[],{"trials":32309,"activeCount":97},[],{"trials":32311,"activeCount":97},[],{"trials":32313,"activeCount":97},[],{"intervention":32305,"totalTrials":314,"cells":32315},{"EARLY_PHASE1":32316,"PHASE1":32318,"PHASE2":32324,"PHASE3":32326,"PHASE4":32328,"NA":32330},{"trials":32317,"activeCount":97},[],{"trials":32319,"activeCount":97},[32320],{"nctId":32298,"briefTitle":32299,"status":103,"phases":32321,"primaryCompletion":32301,"completion":32301,"start":32302,"enrollment":5015,"conditions":32322,"interventions":32323},[85],[15],[32291,32305],{"trials":32325,"activeCount":97},[],{"trials":32327,"activeCount":97},[],{"trials":32329,"activeCount":97},[],{"trials":32331,"activeCount":97},[],{"intervention":10961,"totalTrials":314,"cells":32333},{"EARLY_PHASE1":32334,"PHASE1":32336,"PHASE2":32342,"PHASE3":32344,"PHASE4":32346,"NA":32348},{"trials":32335,"activeCount":97},[],{"trials":32337,"activeCount":97},[32338],{"nctId":10954,"briefTitle":10955,"status":999,"phases":32339,"primaryCompletion":10957,"completion":10957,"start":10958,"enrollment":214,"conditions":32340,"interventions":32341},[85],[15],[10961,2562,10961],{"trials":32343,"activeCount":97},[],{"trials":32345,"activeCount":97},[],{"trials":32347,"activeCount":97},[],{"trials":32349,"activeCount":97},[],{"intervention":32351,"totalTrials":314,"cells":32352},"[¹⁴C]-LY3202626",{"EARLY_PHASE1":32353,"PHASE1":32355,"PHASE2":32363,"PHASE3":32365,"PHASE4":32367,"NA":32369},{"trials":32354,"activeCount":97},[],{"trials":32356,"activeCount":97},[32357],{"nctId":32358,"briefTitle":32359,"status":103,"phases":32360,"primaryCompletion":4383,"completion":4383,"start":1618,"enrollment":1677,"conditions":32361,"interventions":32362},"NCT02555449","A Study of [¹⁴C]-LY3202626 in Healthy Male Participants",[85],[15],[32351],{"trials":32364,"activeCount":97},[],{"trials":32366,"activeCount":97},[],{"trials":32368,"activeCount":97},[],{"trials":32370,"activeCount":97},[],{"intervention":32372,"totalTrials":314,"cells":32373},"[¹⁴C]-LY3372689",{"EARLY_PHASE1":32374,"PHASE1":32376,"PHASE2":32385,"PHASE3":32387,"PHASE4":32389,"NA":32391},{"trials":32375,"activeCount":97},[],{"trials":32377,"activeCount":97},[32378],{"nctId":32379,"briefTitle":32380,"status":103,"phases":32381,"primaryCompletion":32382,"completion":32382,"start":10145,"enrollment":4323,"conditions":32383,"interventions":32384},"NCT05749848","A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants",[85],"2023-04-18",[15],[32372],{"trials":32386,"activeCount":97},[],{"trials":32388,"activeCount":97},[],{"trials":32390,"activeCount":97},[],{"trials":32392,"activeCount":97},[],{"intervention":32394,"totalTrials":314,"cells":32395},"[^14C]-LY2801653",{"EARLY_PHASE1":32396,"PHASE1":32398,"PHASE2":32406,"PHASE3":32408,"PHASE4":32410,"NA":32412},{"trials":32397,"activeCount":97},[],{"trials":32399,"activeCount":97},[32400],{"nctId":32401,"briefTitle":32402,"status":103,"phases":32403,"primaryCompletion":3049,"completion":3049,"start":4980,"enrollment":1677,"conditions":32404,"interventions":32405},"NCT01981408","A Study of LY2801653 in Healthy Participants",[85],[21],[32394],{"trials":32407,"activeCount":97},[],{"trials":32409,"activeCount":97},[],{"trials":32411,"activeCount":97},[],{"trials":32413,"activeCount":97},[],{"intervention":24118,"totalTrials":314,"cells":32415},{"EARLY_PHASE1":32416,"PHASE1":32418,"PHASE2":32424,"PHASE3":32426,"PHASE4":32428,"NA":32430},{"trials":32417,"activeCount":97},[],{"trials":32419,"activeCount":97},[32420],{"nctId":24110,"briefTitle":24111,"status":103,"phases":32421,"primaryCompletion":24113,"completion":24114,"start":24115,"enrollment":195,"conditions":32422,"interventions":32423},[85],[1466],[7768,24118,24119,24120],{"trials":32425,"activeCount":97},[],{"trials":32427,"activeCount":97},[],{"trials":32429,"activeCount":97},[],{"trials":32431,"activeCount":97},[],{"intervention":24119,"totalTrials":314,"cells":32433},{"EARLY_PHASE1":32434,"PHASE1":32436,"PHASE2":32442,"PHASE3":32444,"PHASE4":32446,"NA":32448},{"trials":32435,"activeCount":97},[],{"trials":32437,"activeCount":97},[32438],{"nctId":24110,"briefTitle":24111,"status":103,"phases":32439,"primaryCompletion":24113,"completion":24114,"start":24115,"enrollment":195,"conditions":32440,"interventions":32441},[85],[1466],[7768,24118,24119,24120],{"trials":32443,"activeCount":97},[],{"trials":32445,"activeCount":97},[],{"trials":32447,"activeCount":97},[],{"trials":32449,"activeCount":97},[],{"intervention":24120,"totalTrials":314,"cells":32451},{"EARLY_PHASE1":32452,"PHASE1":32454,"PHASE2":32460,"PHASE3":32462,"PHASE4":32464,"NA":32466},{"trials":32453,"activeCount":97},[],{"trials":32455,"activeCount":97},[32456],{"nctId":24110,"briefTitle":24111,"status":103,"phases":32457,"primaryCompletion":24113,"completion":24114,"start":24115,"enrollment":195,"conditions":32458,"interventions":32459},[85],[1466],[7768,24118,24119,24120],{"trials":32461,"activeCount":97},[],{"trials":32463,"activeCount":97},[],{"trials":32465,"activeCount":97},[],{"trials":32467,"activeCount":97},[],{"intervention":32469,"totalTrials":314,"cells":32470},"[¹⁴C]-LY3337641",{"EARLY_PHASE1":32471,"PHASE1":32473,"PHASE2":32481,"PHASE3":32483,"PHASE4":32485,"NA":32487},{"trials":32472,"activeCount":97},[],{"trials":32474,"activeCount":97},[32475],{"nctId":32476,"briefTitle":32477,"status":103,"phases":32478,"primaryCompletion":2754,"completion":2754,"start":6390,"enrollment":1677,"conditions":32479,"interventions":32480},"NCT02914379","A Study of LY3337641 in Healthy Male Participants",[85],[15],[32469],{"trials":32482,"activeCount":97},[],{"trials":32484,"activeCount":97},[],{"trials":32486,"activeCount":97},[],{"trials":32488,"activeCount":97},[],{"intervention":32490,"totalTrials":314,"cells":32491},"LY3434172",{"EARLY_PHASE1":32492,"PHASE1":32494,"PHASE2":32504,"PHASE3":32506,"PHASE4":32508,"NA":32510},{"trials":32493,"activeCount":97},[],{"trials":32495,"activeCount":97},[32496],{"nctId":32497,"briefTitle":32498,"status":999,"phases":32499,"primaryCompletion":32500,"completion":32501,"start":5159,"enrollment":757,"conditions":32502,"interventions":32503},"NCT03936959","A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",[85],"2020-03-30","2021-04-29",[1466],[32490],{"trials":32505,"activeCount":97},[],{"trials":32507,"activeCount":97},[],{"trials":32509,"activeCount":97},[],{"trials":32511,"activeCount":97},[],{"intervention":32513,"totalTrials":314,"cells":32514},"LY3873862",{"EARLY_PHASE1":32515,"PHASE1":32517,"PHASE2":32526,"PHASE3":32528,"PHASE4":32530,"NA":32532},{"trials":32516,"activeCount":97},[],{"trials":32518,"activeCount":97},[32519],{"nctId":32520,"briefTitle":32521,"status":103,"phases":32522,"primaryCompletion":32523,"completion":32523,"start":13081,"enrollment":25,"conditions":32524,"interventions":32525},"NCT05492201","A Study of LY3873862 in Healthy Participants",[85],"2025-04-29",[15],[32513],{"trials":32527,"activeCount":97},[],{"trials":32529,"activeCount":97},[],{"trials":32531,"activeCount":97},[],{"trials":32533,"activeCount":97},[],{"intervention":11642,"totalTrials":314,"cells":32535},{"EARLY_PHASE1":32536,"PHASE1":32538,"PHASE2":32544,"PHASE3":32546,"PHASE4":32548,"NA":32550},{"trials":32537,"activeCount":97},[],{"trials":32539,"activeCount":97},[32540],{"nctId":11634,"briefTitle":11635,"status":103,"phases":32541,"primaryCompletion":11637,"completion":11637,"start":11638,"enrollment":11639,"conditions":32542,"interventions":32543},[85],[15],[1666,11642],{"trials":32545,"activeCount":97},[],{"trials":32547,"activeCount":97},[],{"trials":32549,"activeCount":97},[],{"trials":32551,"activeCount":97},[],{"intervention":22257,"totalTrials":314,"cells":32553},{"EARLY_PHASE1":32554,"PHASE1":32556,"PHASE2":32562,"PHASE3":32564,"PHASE4":32566,"NA":32568},{"trials":32555,"activeCount":97},[],{"trials":32557,"activeCount":97},[32558],{"nctId":22250,"briefTitle":22251,"status":103,"phases":32559,"primaryCompletion":22253,"completion":22253,"start":22254,"enrollment":757,"conditions":32560,"interventions":32561},[85],[15],[7043,22257],{"trials":32563,"activeCount":97},[],{"trials":32565,"activeCount":97},[],{"trials":32567,"activeCount":97},[],{"trials":32569,"activeCount":97},[],{"intervention":32571,"totalTrials":314,"cells":32572},"[14C]-lasmiditan",{"EARLY_PHASE1":32573,"PHASE1":32575,"PHASE2":32585,"PHASE3":32587,"PHASE4":32589,"NA":32591},{"trials":32574,"activeCount":97},[],{"trials":32576,"activeCount":97},[32577],{"nctId":32578,"briefTitle":32579,"status":103,"phases":32580,"primaryCompletion":32581,"completion":32581,"start":32582,"enrollment":4323,"conditions":32583,"interventions":32584},"NCT03040362","Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration",[85],"2017-05-06","2017-04-20",[15],[32571],{"trials":32586,"activeCount":97},[],{"trials":32588,"activeCount":97},[],{"trials":32590,"activeCount":97},[],{"trials":32592,"activeCount":97},[],{"intervention":29252,"totalTrials":314,"cells":32594},{"EARLY_PHASE1":32595,"PHASE1":32597,"PHASE2":32603,"PHASE3":32605,"PHASE4":32607,"NA":32609},{"trials":32596,"activeCount":97},[],{"trials":32598,"activeCount":97},[32599],{"nctId":29246,"briefTitle":29247,"status":103,"phases":32600,"primaryCompletion":2974,"completion":2974,"start":3292,"enrollment":310,"conditions":32601,"interventions":32602},[85],[29250],[29239,29252],{"trials":32604,"activeCount":97},[],{"trials":32606,"activeCount":97},[],{"trials":32608,"activeCount":97},[],{"trials":32610,"activeCount":97},[],{"intervention":32612,"totalTrials":314,"cells":32613},"LY3985297",{"EARLY_PHASE1":32614,"PHASE1":32616,"PHASE2":32625,"PHASE3":32627,"PHASE4":32629,"NA":32631},{"trials":32615,"activeCount":97},[],{"trials":32617,"activeCount":97},[32618],{"nctId":32619,"briefTitle":32620,"status":103,"phases":32621,"primaryCompletion":12687,"completion":12687,"start":32622,"enrollment":410,"conditions":32623,"interventions":32624},"NCT06395012","A First-In-Human Study of LY3985297 in Healthy Participants",[85],"2024-06-07",[15],[32612],{"trials":32626,"activeCount":97},[],{"trials":32628,"activeCount":97},[],{"trials":32630,"activeCount":97},[],{"trials":32632,"activeCount":97},[],{"intervention":32634,"totalTrials":314,"cells":32635},"LY3885125",{"EARLY_PHASE1":32636,"PHASE1":32638,"PHASE2":32648,"PHASE3":32650,"PHASE4":32652,"NA":32654},{"trials":32637,"activeCount":97},[],{"trials":32639,"activeCount":97},[32640],{"nctId":32641,"briefTitle":32642,"status":999,"phases":32643,"primaryCompletion":32644,"completion":32644,"start":7828,"enrollment":3309,"conditions":32645,"interventions":32647},"NCT06007651","A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)",[85],"2025-02-12",[18052,32646],"Non-Alcoholic Fatty Liver Disease",[32634],{"trials":32649,"activeCount":97},[],{"trials":32651,"activeCount":97},[],{"trials":32653,"activeCount":97},[],{"trials":32655,"activeCount":97},[],{"intervention":32657,"totalTrials":314,"cells":32658},"LY3084077",{"EARLY_PHASE1":32659,"PHASE1":32661,"PHASE2":32669,"PHASE3":32671,"PHASE4":32673,"NA":32675},{"trials":32660,"activeCount":97},[],{"trials":32662,"activeCount":97},[32663],{"nctId":32664,"briefTitle":32665,"status":103,"phases":32666,"primaryCompletion":3049,"completion":3049,"start":3282,"enrollment":4222,"conditions":32667,"interventions":32668},"NCT01846702","A Study of LY3084077 in Healthy Participants",[85],[21],[32657],{"trials":32670,"activeCount":97},[],{"trials":32672,"activeCount":97},[],{"trials":32674,"activeCount":97},[],{"trials":32676,"activeCount":97},[],{"intervention":32678,"totalTrials":314,"cells":32679},"IMC-20D7S",{"EARLY_PHASE1":32680,"PHASE1":32682,"PHASE2":32690,"PHASE3":32692,"PHASE4":32694,"NA":32696},{"trials":32681,"activeCount":97},[],{"trials":32683,"activeCount":97},[32684],{"nctId":32685,"briefTitle":32686,"status":103,"phases":32687,"primaryCompletion":2966,"completion":2966,"start":2918,"enrollment":2071,"conditions":32688,"interventions":32689},"NCT01137006","An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma",[85],[29599],[32678,32678,32678,32678,32678,32678,32678],{"trials":32691,"activeCount":97},[],{"trials":32693,"activeCount":97},[],{"trials":32695,"activeCount":97},[],{"trials":32697,"activeCount":97},[],{"intervention":24949,"totalTrials":314,"cells":32699},{"EARLY_PHASE1":32700,"PHASE1":32702,"PHASE2":32708,"PHASE3":32710,"PHASE4":32712,"NA":32714},{"trials":32701,"activeCount":97},[],{"trials":32703,"activeCount":97},[32704],{"nctId":24942,"briefTitle":24943,"status":103,"phases":32705,"primaryCompletion":7565,"completion":7565,"start":24945,"enrollment":24946,"conditions":32706,"interventions":32707},[85],[15],[24935,24949],{"trials":32709,"activeCount":97},[],{"trials":32711,"activeCount":97},[],{"trials":32713,"activeCount":97},[],{"trials":32715,"activeCount":97},[],{"intervention":32717,"totalTrials":314,"cells":32718},"Axiron",{"EARLY_PHASE1":32719,"PHASE1":32721,"PHASE2":32729,"PHASE3":32731,"PHASE4":32733,"NA":32735},{"trials":32720,"activeCount":97},[],{"trials":32722,"activeCount":97},[32723],{"nctId":32724,"briefTitle":32725,"status":103,"phases":32726,"primaryCompletion":3049,"completion":3049,"start":3049,"enrollment":2477,"conditions":32727,"interventions":32728},"NCT02004132","A Study of Axiron® in Healthy Participants",[85],[21],[32717],{"trials":32730,"activeCount":97},[],{"trials":32732,"activeCount":97},[],{"trials":32734,"activeCount":97},[],{"trials":32736,"activeCount":97},[],{"intervention":17152,"totalTrials":314,"cells":32738},{"EARLY_PHASE1":32739,"PHASE1":32741,"PHASE2":32747,"PHASE3":32749,"PHASE4":32751,"NA":32753},{"trials":32740,"activeCount":97},[],{"trials":32742,"activeCount":97},[32743],{"nctId":17146,"briefTitle":17147,"status":103,"phases":32744,"primaryCompletion":17149,"completion":17149,"start":676,"enrollment":6509,"conditions":32745,"interventions":32746},[85],[15],[17046,17152,2093],{"trials":32748,"activeCount":97},[],{"trials":32750,"activeCount":97},[],{"trials":32752,"activeCount":97},[],{"trials":32754,"activeCount":97},[],{"intervention":18692,"totalTrials":314,"cells":32756},{"EARLY_PHASE1":32757,"PHASE1":32759,"PHASE2":32765,"PHASE3":32767,"PHASE4":32769,"NA":32771},{"trials":32758,"activeCount":97},[],{"trials":32760,"activeCount":97},[32761],{"nctId":18686,"briefTitle":18687,"status":103,"phases":32762,"conditions":32763,"interventions":32764},[85],[8969,2824],[2893,18691,18692],{"trials":32766,"activeCount":97},[],{"trials":32768,"activeCount":97},[],{"trials":32770,"activeCount":97},[],{"trials":32772,"activeCount":97},[],{"intervention":17161,"totalTrials":314,"cells":32774},{"EARLY_PHASE1":32775,"PHASE1":32777,"PHASE2":32783,"PHASE3":32785,"PHASE4":32787,"NA":32789},{"trials":32776,"activeCount":97},[],{"trials":32778,"activeCount":97},[32779],{"nctId":17154,"briefTitle":17155,"status":103,"phases":32780,"primaryCompletion":17157,"completion":17157,"start":17158,"enrollment":2790,"conditions":32781,"interventions":32782},[85],[15],[17161,17046],{"trials":32784,"activeCount":97},[],{"trials":32786,"activeCount":97},[],{"trials":32788,"activeCount":97},[],{"trials":32790,"activeCount":97},[],{"intervention":32792,"totalTrials":314,"cells":32793},"LY3361237 - SC",{"EARLY_PHASE1":32794,"PHASE1":32796,"PHASE2":32806,"PHASE3":32808,"PHASE4":32810,"NA":32812},{"trials":32795,"activeCount":97},[],{"trials":32797,"activeCount":97},[32798],{"nctId":32799,"briefTitle":32800,"status":103,"phases":32801,"primaryCompletion":1703,"completion":1703,"start":32802,"enrollment":2867,"conditions":32803,"interventions":32804},"NCT03695198","A Study of LY3361237 in Healthy Participants",[85],"2018-10-26",[15],[32792,32805],"LY3361237 - IV",{"trials":32807,"activeCount":97},[],{"trials":32809,"activeCount":97},[],{"trials":32811,"activeCount":97},[],{"trials":32813,"activeCount":97},[],{"intervention":32805,"totalTrials":314,"cells":32815},{"EARLY_PHASE1":32816,"PHASE1":32818,"PHASE2":32824,"PHASE3":32826,"PHASE4":32828,"NA":32830},{"trials":32817,"activeCount":97},[],{"trials":32819,"activeCount":97},[32820],{"nctId":32799,"briefTitle":32800,"status":103,"phases":32821,"primaryCompletion":1703,"completion":1703,"start":32802,"enrollment":2867,"conditions":32822,"interventions":32823},[85],[15],[32792,32805],{"trials":32825,"activeCount":97},[],{"trials":32827,"activeCount":97},[],{"trials":32829,"activeCount":97},[],{"trials":32831,"activeCount":97},[],{"intervention":236,"totalTrials":314,"cells":32833},{"EARLY_PHASE1":32834,"PHASE1":32836,"PHASE2":32842,"PHASE3":32844,"PHASE4":32846,"NA":32848},{"trials":32835,"activeCount":97},[],{"trials":32837,"activeCount":97},[32838],{"nctId":228,"briefTitle":229,"status":103,"phases":32839,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":32840,"interventions":32841},[85],[15],[92,236],{"trials":32843,"activeCount":97},[],{"trials":32845,"activeCount":97},[],{"trials":32847,"activeCount":97},[],{"trials":32849,"activeCount":97},[],{"intervention":22933,"totalTrials":314,"cells":32851},{"EARLY_PHASE1":32852,"PHASE1":32854,"PHASE2":32860,"PHASE3":32862,"PHASE4":32864,"NA":32866},{"trials":32853,"activeCount":97},[],{"trials":32855,"activeCount":97},[32856],{"nctId":22928,"briefTitle":22929,"status":103,"phases":32857,"primaryCompletion":1475,"completion":1475,"start":4955,"enrollment":4475,"conditions":32858,"interventions":32859},[85],[21],[22933,22669],{"trials":32861,"activeCount":97},[],{"trials":32863,"activeCount":97},[],{"trials":32865,"activeCount":97},[],{"trials":32867,"activeCount":97},[],{"intervention":32869,"totalTrials":314,"cells":32870},"Insulin lispro A",{"EARLY_PHASE1":32871,"PHASE1":32873,"PHASE2":32882,"PHASE3":32884,"PHASE4":32886,"NA":32888},{"trials":32872,"activeCount":97},[],{"trials":32874,"activeCount":97},[32875],{"nctId":32876,"briefTitle":32877,"status":103,"phases":32878,"primaryCompletion":3012,"completion":3012,"start":2956,"enrollment":2542,"conditions":32879,"interventions":32880},"NCT01133392","Bioequivalence of Two Lispro Formulations",[85],[21],[32869,32881],"Insulin lispro B",{"trials":32883,"activeCount":97},[],{"trials":32885,"activeCount":97},[],{"trials":32887,"activeCount":97},[],{"trials":32889,"activeCount":97},[],{"intervention":32881,"totalTrials":314,"cells":32891},{"EARLY_PHASE1":32892,"PHASE1":32894,"PHASE2":32900,"PHASE3":32902,"PHASE4":32904,"NA":32906},{"trials":32893,"activeCount":97},[],{"trials":32895,"activeCount":97},[32896],{"nctId":32876,"briefTitle":32877,"status":103,"phases":32897,"primaryCompletion":3012,"completion":3012,"start":2956,"enrollment":2542,"conditions":32898,"interventions":32899},[85],[21],[32869,32881],{"trials":32901,"activeCount":97},[],{"trials":32903,"activeCount":97},[],{"trials":32905,"activeCount":97},[],{"trials":32907,"activeCount":97},[],{"intervention":5025,"totalTrials":314,"cells":32909},{"EARLY_PHASE1":32910,"PHASE1":32912,"PHASE2":32918,"PHASE3":32920,"PHASE4":32922,"NA":32924},{"trials":32911,"activeCount":97},[],{"trials":32913,"activeCount":97},[32914],{"nctId":5019,"briefTitle":5020,"status":103,"phases":32915,"primaryCompletion":4980,"completion":4980,"start":5022,"enrollment":12,"conditions":32916,"interventions":32917},[85],[21],[4944,5025],{"trials":32919,"activeCount":97},[],{"trials":32921,"activeCount":97},[],{"trials":32923,"activeCount":97},[],{"trials":32925,"activeCount":97},[],{"intervention":32927,"totalTrials":314,"cells":32928},"LY3541105",{"EARLY_PHASE1":32929,"PHASE1":32931,"PHASE2":32941,"PHASE3":32943,"PHASE4":32945,"NA":32947},{"trials":32930,"activeCount":97},[],{"trials":32932,"activeCount":97},[32933],{"nctId":32934,"briefTitle":32935,"status":103,"phases":32936,"primaryCompletion":32937,"completion":32937,"start":32938,"enrollment":523,"conditions":32939,"interventions":32940},"NCT05380323","A Study of LY3541105 in Healthy and Overweight Participants",[85],"2024-08-27","2022-05-10",[27,15],[32927],{"trials":32942,"activeCount":97},[],{"trials":32944,"activeCount":97},[],{"trials":32946,"activeCount":97},[],{"trials":32948,"activeCount":97},[],{"intervention":32950,"totalTrials":314,"cells":32951},"[14C]-LY3556050",{"EARLY_PHASE1":32952,"PHASE1":32954,"PHASE2":32963,"PHASE3":32965,"PHASE4":32967,"NA":32969},{"trials":32953,"activeCount":97},[],{"trials":32955,"activeCount":97},[32956],{"nctId":32957,"briefTitle":32958,"status":103,"phases":32959,"primaryCompletion":32960,"completion":32960,"start":492,"enrollment":1054,"conditions":32961,"interventions":32962},"NCT06052462","A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants",[85],"2023-11-04",[15],[32950],{"trials":32964,"activeCount":97},[],{"trials":32966,"activeCount":97},[],{"trials":32968,"activeCount":97},[],{"trials":32970,"activeCount":97},[],{"intervention":11801,"totalTrials":314,"cells":32972},{"EARLY_PHASE1":32973,"PHASE1":32975,"PHASE2":32981,"PHASE3":32983,"PHASE4":32985,"NA":32987},{"trials":32974,"activeCount":97},[],{"trials":32976,"activeCount":97},[32977],{"nctId":11795,"briefTitle":11796,"status":103,"phases":32978,"primaryCompletion":6592,"completion":6592,"start":47,"enrollment":6633,"conditions":32979,"interventions":32980},[85],[3980],[11800,11801,11780],{"trials":32982,"activeCount":97},[],{"trials":32984,"activeCount":97},[],{"trials":32986,"activeCount":97},[],{"trials":32988,"activeCount":97},[],{"intervention":32990,"totalTrials":314,"cells":32991},"LY3200327",{"EARLY_PHASE1":32992,"PHASE1":32994,"PHASE2":33002,"PHASE3":33004,"PHASE4":33006,"NA":33008},{"trials":32993,"activeCount":97},[],{"trials":32995,"activeCount":97},[32996],{"nctId":32997,"briefTitle":32998,"status":103,"phases":32999,"primaryCompletion":1628,"completion":1628,"start":4383,"enrollment":251,"conditions":33000,"interventions":33001},"NCT02595736","A Study of LY3200327 in Healthy Participants",[85],[15],[32990,32990],{"trials":33003,"activeCount":97},[],{"trials":33005,"activeCount":97},[],{"trials":33007,"activeCount":97},[],{"trials":33009,"activeCount":97},[],{"intervention":272,"totalTrials":314,"cells":33011},{"EARLY_PHASE1":33012,"PHASE1":33014,"PHASE2":33020,"PHASE3":33022,"PHASE4":33024,"NA":33026},{"trials":33013,"activeCount":97},[],{"trials":33015,"activeCount":97},[33016],{"nctId":264,"briefTitle":265,"status":103,"phases":33017,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":33018,"interventions":33019},[85],[24,27],[110,272,92,273],{"trials":33021,"activeCount":97},[],{"trials":33023,"activeCount":97},[],{"trials":33025,"activeCount":97},[],{"trials":33027,"activeCount":97},[],{"intervention":1161,"totalTrials":314,"cells":33029},{"EARLY_PHASE1":33030,"PHASE1":33032,"PHASE2":33038,"PHASE3":33040,"PHASE4":33042,"NA":33044},{"trials":33031,"activeCount":97},[],{"trials":33033,"activeCount":97},[33034],{"nctId":1153,"briefTitle":1154,"status":103,"phases":33035,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":33036,"interventions":33037},[85],[15],[1161,1162,1070],{"trials":33039,"activeCount":97},[],{"trials":33041,"activeCount":97},[],{"trials":33043,"activeCount":97},[],{"trials":33045,"activeCount":97},[],{"intervention":1162,"totalTrials":314,"cells":33047},{"EARLY_PHASE1":33048,"PHASE1":33050,"PHASE2":33056,"PHASE3":33058,"PHASE4":33060,"NA":33062},{"trials":33049,"activeCount":97},[],{"trials":33051,"activeCount":97},[33052],{"nctId":1153,"briefTitle":1154,"status":103,"phases":33053,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":33054,"interventions":33055},[85],[15],[1161,1162,1070],{"trials":33057,"activeCount":97},[],{"trials":33059,"activeCount":97},[],{"trials":33061,"activeCount":97},[],{"trials":33063,"activeCount":97},[],{"intervention":5033,"totalTrials":314,"cells":33065},{"EARLY_PHASE1":33066,"PHASE1":33068,"PHASE2":33074,"PHASE3":33076,"PHASE4":33078,"NA":33080},{"trials":33067,"activeCount":97},[],{"trials":33069,"activeCount":97},[33070],{"nctId":5027,"briefTitle":5028,"status":103,"phases":33071,"primaryCompletion":1473,"completion":1473,"start":5030,"enrollment":4323,"conditions":33072,"interventions":33073},[85],[21],[4944,5033],{"trials":33075,"activeCount":97},[],{"trials":33077,"activeCount":97},[],{"trials":33079,"activeCount":97},[],{"trials":33081,"activeCount":97},[],{"intervention":14236,"totalTrials":314,"cells":33083},{"EARLY_PHASE1":33084,"PHASE1":33086,"PHASE2":33092,"PHASE3":33094,"PHASE4":33096,"NA":33098},{"trials":33085,"activeCount":97},[],{"trials":33087,"activeCount":97},[33088],{"nctId":14230,"briefTitle":14231,"status":103,"phases":33089,"primaryCompletion":7124,"completion":7124,"start":14233,"enrollment":4475,"conditions":33090,"interventions":33091},[85],[18],[14236,188,9644],{"trials":33093,"activeCount":97},[],{"trials":33095,"activeCount":97},[],{"trials":33097,"activeCount":97},[],{"trials":33099,"activeCount":97},[],{"intervention":33101,"totalTrials":314,"cells":33102},"Lyumjev with 50% basal rate reduction",{"EARLY_PHASE1":33103,"PHASE1":33105,"PHASE2":33118,"PHASE3":33120,"PHASE4":33122,"NA":33124},{"trials":33104,"activeCount":97},[],{"trials":33106,"activeCount":97},[33107],{"nctId":33108,"briefTitle":33109,"status":103,"phases":33110,"primaryCompletion":33111,"completion":33111,"start":33112,"enrollment":9038,"conditions":33113,"interventions":33114},"NCT05262387","A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes",[85],"2023-03-07","2022-02-14",[33],[33101,33115,33116,33117],"Humalog with 50% basal rate reduction","Humalog with 100% basal rate reduction","Lyumjev with 100% basal rate reduction",{"trials":33119,"activeCount":97},[],{"trials":33121,"activeCount":97},[],{"trials":33123,"activeCount":97},[],{"trials":33125,"activeCount":97},[],{"intervention":33115,"totalTrials":314,"cells":33127},{"EARLY_PHASE1":33128,"PHASE1":33130,"PHASE2":33136,"PHASE3":33138,"PHASE4":33140,"NA":33142},{"trials":33129,"activeCount":97},[],{"trials":33131,"activeCount":97},[33132],{"nctId":33108,"briefTitle":33109,"status":103,"phases":33133,"primaryCompletion":33111,"completion":33111,"start":33112,"enrollment":9038,"conditions":33134,"interventions":33135},[85],[33],[33101,33115,33116,33117],{"trials":33137,"activeCount":97},[],{"trials":33139,"activeCount":97},[],{"trials":33141,"activeCount":97},[],{"trials":33143,"activeCount":97},[],{"intervention":33116,"totalTrials":314,"cells":33145},{"EARLY_PHASE1":33146,"PHASE1":33148,"PHASE2":33154,"PHASE3":33156,"PHASE4":33158,"NA":33160},{"trials":33147,"activeCount":97},[],{"trials":33149,"activeCount":97},[33150],{"nctId":33108,"briefTitle":33109,"status":103,"phases":33151,"primaryCompletion":33111,"completion":33111,"start":33112,"enrollment":9038,"conditions":33152,"interventions":33153},[85],[33],[33101,33115,33116,33117],{"trials":33155,"activeCount":97},[],{"trials":33157,"activeCount":97},[],{"trials":33159,"activeCount":97},[],{"trials":33161,"activeCount":97},[],{"intervention":33117,"totalTrials":314,"cells":33163},{"EARLY_PHASE1":33164,"PHASE1":33166,"PHASE2":33172,"PHASE3":33174,"PHASE4":33176,"NA":33178},{"trials":33165,"activeCount":97},[],{"trials":33167,"activeCount":97},[33168],{"nctId":33108,"briefTitle":33109,"status":103,"phases":33169,"primaryCompletion":33111,"completion":33111,"start":33112,"enrollment":9038,"conditions":33170,"interventions":33171},[85],[33],[33101,33115,33116,33117],{"trials":33173,"activeCount":97},[],{"trials":33175,"activeCount":97},[],{"trials":33177,"activeCount":97},[],{"trials":33179,"activeCount":97},[],{"intervention":33181,"totalTrials":314,"cells":33182},"IMC-3G3",{"EARLY_PHASE1":33183,"PHASE1":33185,"PHASE2":33193,"PHASE3":33195,"PHASE4":33197,"NA":33199},{"trials":33184,"activeCount":97},[],{"trials":33186,"activeCount":97},[33187],{"nctId":33188,"briefTitle":33189,"status":103,"phases":33190,"primaryCompletion":2866,"completion":3685,"start":3060,"enrollment":1082,"conditions":33191,"interventions":33192},"NCT00768391","Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available",[85],[2589],[33181],{"trials":33194,"activeCount":97},[],{"trials":33196,"activeCount":97},[],{"trials":33198,"activeCount":97},[],{"trials":33200,"activeCount":97},[],{"intervention":33202,"totalTrials":314,"cells":33203},"LY3322207",{"EARLY_PHASE1":33204,"PHASE1":33206,"PHASE2":33216,"PHASE3":33218,"PHASE4":33220,"NA":33222},{"trials":33205,"activeCount":97},[],{"trials":33207,"activeCount":97},[33208],{"nctId":33209,"briefTitle":33210,"status":999,"phases":33211,"primaryCompletion":33212,"completion":33212,"start":33213,"enrollment":28,"conditions":33214,"interventions":33215},"NCT03590860","A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)",[85],"2019-01-17","2018-07-13",[2156],[33202],{"trials":33217,"activeCount":97},[],{"trials":33219,"activeCount":97},[],{"trials":33221,"activeCount":97},[],{"trials":33223,"activeCount":97},[],{"intervention":33225,"totalTrials":314,"cells":33226},"[¹⁴C]-LY3437943",{"EARLY_PHASE1":33227,"PHASE1":33229,"PHASE2":33238,"PHASE3":33240,"PHASE4":33242,"NA":33244},{"trials":33228,"activeCount":97},[],{"trials":33230,"activeCount":97},[33231],{"nctId":33232,"briefTitle":33233,"status":103,"phases":33234,"primaryCompletion":33235,"completion":33235,"start":23651,"enrollment":1054,"conditions":33236,"interventions":33237},"NCT05757531","A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants",[85],"2023-06-23",[15],[33225],{"trials":33239,"activeCount":97},[],{"trials":33241,"activeCount":97},[],{"trials":33243,"activeCount":97},[],{"trials":33245,"activeCount":97},[],{"intervention":16944,"totalTrials":314,"cells":33247},{"EARLY_PHASE1":33248,"PHASE1":33250,"PHASE2":33256,"PHASE3":33258,"PHASE4":33260,"NA":33262},{"trials":33249,"activeCount":97},[],{"trials":33251,"activeCount":97},[33252],{"nctId":16939,"briefTitle":16940,"status":103,"phases":33253,"primaryCompletion":4160,"completion":4160,"start":3020,"enrollment":1082,"conditions":33254,"interventions":33255},[85],[4937],[13957,16944],{"trials":33257,"activeCount":97},[],{"trials":33259,"activeCount":97},[],{"trials":33261,"activeCount":97},[],{"trials":33263,"activeCount":97},[],{"intervention":23637,"totalTrials":314,"cells":33265},{"EARLY_PHASE1":33266,"PHASE1":33268,"PHASE2":33274,"PHASE3":33276,"PHASE4":33278,"NA":33280},{"trials":33267,"activeCount":97},[],{"trials":33269,"activeCount":97},[33270],{"nctId":23631,"briefTitle":23632,"status":103,"phases":33271,"primaryCompletion":23634,"completion":23634,"start":8621,"enrollment":1071,"conditions":33272,"interventions":33273},[85],[15],[23637,23637,23617],{"trials":33275,"activeCount":97},[],{"trials":33277,"activeCount":97},[],{"trials":33279,"activeCount":97},[],{"trials":33281,"activeCount":97},[],{"intervention":33283,"totalTrials":314,"cells":33284},"LY2409021 Reference Form",{"EARLY_PHASE1":33285,"PHASE1":33287,"PHASE2":33298,"PHASE3":33300,"PHASE4":33302,"NA":33304},{"trials":33286,"activeCount":97},[],{"trials":33288,"activeCount":97},[33289],{"nctId":33290,"briefTitle":33291,"status":103,"phases":33292,"primaryCompletion":3004,"completion":3004,"start":3069,"enrollment":1548,"conditions":33293,"interventions":33294},"NCT01354496","A Study of LY2409021 Formulations and the Effect of Food",[85],[21],[33283,33295,33296,33297],"LY2409021 Test-Med Formulation","LY2409021 Test-High Formulation","LY2409021 Test-Low Formulation",{"trials":33299,"activeCount":97},[],{"trials":33301,"activeCount":97},[],{"trials":33303,"activeCount":97},[],{"trials":33305,"activeCount":97},[],{"intervention":33295,"totalTrials":314,"cells":33307},{"EARLY_PHASE1":33308,"PHASE1":33310,"PHASE2":33316,"PHASE3":33318,"PHASE4":33320,"NA":33322},{"trials":33309,"activeCount":97},[],{"trials":33311,"activeCount":97},[33312],{"nctId":33290,"briefTitle":33291,"status":103,"phases":33313,"primaryCompletion":3004,"completion":3004,"start":3069,"enrollment":1548,"conditions":33314,"interventions":33315},[85],[21],[33283,33295,33296,33297],{"trials":33317,"activeCount":97},[],{"trials":33319,"activeCount":97},[],{"trials":33321,"activeCount":97},[],{"trials":33323,"activeCount":97},[],{"intervention":33296,"totalTrials":314,"cells":33325},{"EARLY_PHASE1":33326,"PHASE1":33328,"PHASE2":33334,"PHASE3":33336,"PHASE4":33338,"NA":33340},{"trials":33327,"activeCount":97},[],{"trials":33329,"activeCount":97},[33330],{"nctId":33290,"briefTitle":33291,"status":103,"phases":33331,"primaryCompletion":3004,"completion":3004,"start":3069,"enrollment":1548,"conditions":33332,"interventions":33333},[85],[21],[33283,33295,33296,33297],{"trials":33335,"activeCount":97},[],{"trials":33337,"activeCount":97},[],{"trials":33339,"activeCount":97},[],{"trials":33341,"activeCount":97},[],{"intervention":33297,"totalTrials":314,"cells":33343},{"EARLY_PHASE1":33344,"PHASE1":33346,"PHASE2":33352,"PHASE3":33354,"PHASE4":33356,"NA":33358},{"trials":33345,"activeCount":97},[],{"trials":33347,"activeCount":97},[33348],{"nctId":33290,"briefTitle":33291,"status":103,"phases":33349,"primaryCompletion":3004,"completion":3004,"start":3069,"enrollment":1548,"conditions":33350,"interventions":33351},[85],[21],[33283,33295,33296,33297],{"trials":33353,"activeCount":97},[],{"trials":33355,"activeCount":97},[],{"trials":33357,"activeCount":97},[],{"trials":33359,"activeCount":97},[],{"intervention":33361,"totalTrials":314,"cells":33362},"IMC-3C5",{"EARLY_PHASE1":33363,"PHASE1":33365,"PHASE2":33373,"PHASE3":33375,"PHASE4":33377,"NA":33379},{"trials":33364,"activeCount":97},[],{"trials":33366,"activeCount":97},[33367],{"nctId":33368,"briefTitle":33369,"status":103,"phases":33370,"primaryCompletion":7316,"completion":7316,"start":3837,"enrollment":37,"conditions":33371,"interventions":33372},"NCT01288989","A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors",[85],[1870],[33361],{"trials":33374,"activeCount":97},[],{"trials":33376,"activeCount":97},[],{"trials":33378,"activeCount":97},[],{"trials":33380,"activeCount":97},[],{"intervention":28985,"totalTrials":314,"cells":33382},{"EARLY_PHASE1":33383,"PHASE1":33385,"PHASE2":33391,"PHASE3":33393,"PHASE4":33395,"NA":33397},{"trials":33384,"activeCount":97},[],{"trials":33386,"activeCount":97},[33387],{"nctId":28979,"briefTitle":28980,"status":103,"phases":33388,"primaryCompletion":7603,"completion":7603,"start":28982,"enrollment":233,"conditions":33389,"interventions":33390},[85],[9437],[28985,12912,28986,28987],{"trials":33392,"activeCount":97},[],{"trials":33394,"activeCount":97},[],{"trials":33396,"activeCount":97},[],{"trials":33398,"activeCount":97},[],{"intervention":28986,"totalTrials":314,"cells":33400},{"EARLY_PHASE1":33401,"PHASE1":33403,"PHASE2":33409,"PHASE3":33411,"PHASE4":33413,"NA":33415},{"trials":33402,"activeCount":97},[],{"trials":33404,"activeCount":97},[33405],{"nctId":28979,"briefTitle":28980,"status":103,"phases":33406,"primaryCompletion":7603,"completion":7603,"start":28982,"enrollment":233,"conditions":33407,"interventions":33408},[85],[9437],[28985,12912,28986,28987],{"trials":33410,"activeCount":97},[],{"trials":33412,"activeCount":97},[],{"trials":33414,"activeCount":97},[],{"trials":33416,"activeCount":97},[],{"intervention":28987,"totalTrials":314,"cells":33418},{"EARLY_PHASE1":33419,"PHASE1":33421,"PHASE2":33427,"PHASE3":33429,"PHASE4":33431,"NA":33433},{"trials":33420,"activeCount":97},[],{"trials":33422,"activeCount":97},[33423],{"nctId":28979,"briefTitle":28980,"status":103,"phases":33424,"primaryCompletion":7603,"completion":7603,"start":28982,"enrollment":233,"conditions":33425,"interventions":33426},[85],[9437],[28985,12912,28986,28987],{"trials":33428,"activeCount":97},[],{"trials":33430,"activeCount":97},[],{"trials":33432,"activeCount":97},[],{"trials":33434,"activeCount":97},[],{"intervention":29063,"totalTrials":314,"cells":33436},{"EARLY_PHASE1":33437,"PHASE1":33439,"PHASE2":33445,"PHASE3":33447,"PHASE4":33449,"NA":33451},{"trials":33438,"activeCount":97},[],{"trials":33440,"activeCount":97},[33441],{"nctId":29057,"briefTitle":29058,"status":384,"phases":33442,"primaryCompletion":29060,"completion":29060,"start":28010,"enrollment":97,"conditions":33443,"interventions":33444},[85],[15],[28013,29063],{"trials":33446,"activeCount":97},[],{"trials":33448,"activeCount":97},[],{"trials":33450,"activeCount":97},[],{"trials":33452,"activeCount":97},[],{"intervention":33454,"totalTrials":314,"cells":33455},"LY4064809 Test Formulation",{"EARLY_PHASE1":33456,"PHASE1":33458,"PHASE2":33468,"PHASE3":33470,"PHASE4":33472,"NA":33474},{"trials":33457,"activeCount":97},[],{"trials":33459,"activeCount":97},[33460],{"nctId":33461,"briefTitle":33462,"status":103,"phases":33463,"primaryCompletion":33464,"completion":33464,"start":5265,"enrollment":290,"conditions":33465,"interventions":33466},"NCT07339735","A Study of LY4064809 in Healthy Adult Participants",[85],"2026-03-19",[4997],[33454,33467],"LY4064809 Reference Formulation",{"trials":33469,"activeCount":97},[],{"trials":33471,"activeCount":97},[],{"trials":33473,"activeCount":97},[],{"trials":33475,"activeCount":97},[],{"intervention":33467,"totalTrials":314,"cells":33477},{"EARLY_PHASE1":33478,"PHASE1":33480,"PHASE2":33486,"PHASE3":33488,"PHASE4":33490,"NA":33492},{"trials":33479,"activeCount":97},[],{"trials":33481,"activeCount":97},[33482],{"nctId":33461,"briefTitle":33462,"status":103,"phases":33483,"primaryCompletion":33464,"completion":33464,"start":5265,"enrollment":290,"conditions":33484,"interventions":33485},[85],[4997],[33454,33467],{"trials":33487,"activeCount":97},[],{"trials":33489,"activeCount":97},[],{"trials":33491,"activeCount":97},[],{"trials":33493,"activeCount":97},[],{"intervention":33495,"totalTrials":314,"cells":33496},"LY3415244",{"EARLY_PHASE1":33497,"PHASE1":33499,"PHASE2":33509,"PHASE3":33511,"PHASE4":33513,"NA":33515},{"trials":33498,"activeCount":97},[],{"trials":33500,"activeCount":97},[33501],{"nctId":33502,"briefTitle":33503,"status":999,"phases":33504,"primaryCompletion":33505,"completion":33505,"start":33506,"enrollment":2477,"conditions":33507,"interventions":33508},"NCT03752177","A Study of LY3415244 in Participants With Advanced Solid Tumors",[85],"2019-10-09","2018-11-22",[1503],[33495],{"trials":33510,"activeCount":97},[],{"trials":33512,"activeCount":97},[],{"trials":33514,"activeCount":97},[],{"trials":33516,"activeCount":97},[],{"intervention":33518,"totalTrials":314,"cells":33519},"LY900014 U-200",{"EARLY_PHASE1":33520,"PHASE1":33522,"PHASE2":33531,"PHASE3":33533,"PHASE4":33535,"NA":33537},{"trials":33521,"activeCount":97},[],{"trials":33523,"activeCount":97},[33524],{"nctId":33525,"briefTitle":33526,"status":103,"phases":33527,"primaryCompletion":8456,"completion":8456,"start":9950,"enrollment":3013,"conditions":33528,"interventions":33529},"NCT03616977","Study to Compare 2 Formulations of LY900014 in Healthy Participants",[85],[15],[33518,33530],"LY900014 U-100",{"trials":33532,"activeCount":97},[],{"trials":33534,"activeCount":97},[],{"trials":33536,"activeCount":97},[],{"trials":33538,"activeCount":97},[],{"intervention":33530,"totalTrials":314,"cells":33540},{"EARLY_PHASE1":33541,"PHASE1":33543,"PHASE2":33549,"PHASE3":33551,"PHASE4":33553,"NA":33555},{"trials":33542,"activeCount":97},[],{"trials":33544,"activeCount":97},[33545],{"nctId":33525,"briefTitle":33526,"status":103,"phases":33546,"primaryCompletion":8456,"completion":8456,"start":9950,"enrollment":3013,"conditions":33547,"interventions":33548},[85],[15],[33518,33530],{"trials":33550,"activeCount":97},[],{"trials":33552,"activeCount":97},[],{"trials":33554,"activeCount":97},[],{"trials":33556,"activeCount":97},[],{"intervention":33558,"totalTrials":314,"cells":33559},"LY3090106 - SQ",{"EARLY_PHASE1":33560,"PHASE1":33562,"PHASE2":33571,"PHASE3":33573,"PHASE4":33575,"NA":33577},{"trials":33561,"activeCount":97},[],{"trials":33563,"activeCount":97},[33564],{"nctId":33565,"briefTitle":33566,"status":103,"phases":33567,"primaryCompletion":5030,"completion":1618,"start":2917,"enrollment":4222,"conditions":33568,"interventions":33569},"NCT01925157","A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)",[85],[5218],[33558,33570],"LY3090106 - IV",{"trials":33572,"activeCount":97},[],{"trials":33574,"activeCount":97},[],{"trials":33576,"activeCount":97},[],{"trials":33578,"activeCount":97},[],{"intervention":33570,"totalTrials":314,"cells":33580},{"EARLY_PHASE1":33581,"PHASE1":33583,"PHASE2":33589,"PHASE3":33591,"PHASE4":33593,"NA":33595},{"trials":33582,"activeCount":97},[],{"trials":33584,"activeCount":97},[33585],{"nctId":33565,"briefTitle":33566,"status":103,"phases":33586,"primaryCompletion":5030,"completion":1618,"start":2917,"enrollment":4222,"conditions":33587,"interventions":33588},[85],[5218],[33558,33570],{"trials":33590,"activeCount":97},[],{"trials":33592,"activeCount":97},[],{"trials":33594,"activeCount":97},[],{"trials":33596,"activeCount":97},[],{"intervention":17179,"totalTrials":314,"cells":33598},{"EARLY_PHASE1":33599,"PHASE1":33601,"PHASE2":33607,"PHASE3":33609,"PHASE4":33611,"NA":33613},{"trials":33600,"activeCount":97},[],{"trials":33602,"activeCount":97},[33603],{"nctId":17172,"briefTitle":17173,"status":103,"phases":33604,"primaryCompletion":17175,"completion":17175,"start":17176,"enrollment":1620,"conditions":33605,"interventions":33606},[85],[15],[17046,17179],{"trials":33608,"activeCount":97},[],{"trials":33610,"activeCount":97},[],{"trials":33612,"activeCount":97},[],{"trials":33614,"activeCount":97},[],{"intervention":33616,"totalTrials":314,"cells":33617},"IM Glucagon",{"EARLY_PHASE1":33618,"PHASE1":33620,"PHASE2":33629,"PHASE3":33631,"PHASE4":33633,"NA":33635},{"trials":33619,"activeCount":97},[],{"trials":33621,"activeCount":97},[33622],{"nctId":33623,"briefTitle":33624,"status":103,"phases":33625,"primaryCompletion":33626,"completion":33626,"start":29410,"enrollment":4083,"conditions":33627,"interventions":33628},"NCT03765502","A Study Comparing User Experience of Different Delivery Devices for Glucagon",[85],"2019-01-03",[15],[33616],{"trials":33630,"activeCount":97},[],{"trials":33632,"activeCount":97},[],{"trials":33634,"activeCount":97},[],{"trials":33636,"activeCount":97},[],{"intervention":33638,"totalTrials":314,"cells":33639},"LY2780301",{"EARLY_PHASE1":33640,"PHASE1":33642,"PHASE2":33650,"PHASE3":33652,"PHASE4":33654,"NA":33656},{"trials":33641,"activeCount":97},[],{"trials":33643,"activeCount":97},[33644],{"nctId":33645,"briefTitle":33646,"status":103,"phases":33647,"primaryCompletion":3545,"completion":3545,"start":3419,"enrollment":4475,"conditions":33648,"interventions":33649},"NCT01115751","A Study in Patients With Advanced or Metastatic Cancer",[85],[5763],[33638],{"trials":33651,"activeCount":97},[],{"trials":33653,"activeCount":97},[],{"trials":33655,"activeCount":97},[],{"trials":33657,"activeCount":97},[],{"intervention":33659,"totalTrials":314,"cells":33660},"LY3000328",{"EARLY_PHASE1":33661,"PHASE1":33663,"PHASE2":33671,"PHASE3":33673,"PHASE4":33675,"NA":33677},{"trials":33662,"activeCount":97},[],{"trials":33664,"activeCount":97},[33665],{"nctId":33666,"briefTitle":33667,"status":103,"phases":33668,"primaryCompletion":2865,"completion":2865,"start":3086,"enrollment":12,"conditions":33669,"interventions":33670},"NCT01515358","A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants",[85],[21],[33659],{"trials":33672,"activeCount":97},[],{"trials":33674,"activeCount":97},[],{"trials":33676,"activeCount":97},[],{"trials":33678,"activeCount":97},[],{"intervention":33680,"totalTrials":314,"cells":33681},"Cetuximab + Irinotecan",{"EARLY_PHASE1":33682,"PHASE1":33684,"PHASE2":33692,"PHASE3":33694,"PHASE4":33696,"NA":33698},{"trials":33683,"activeCount":97},[],{"trials":33685,"activeCount":97},[33686],{"nctId":33687,"briefTitle":33688,"status":103,"phases":33689,"primaryCompletion":3338,"completion":3338,"start":14103,"enrollment":118,"conditions":33690,"interventions":33691},"NCT00110357","Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors",[85],[2824,1779],[33680,33680],{"trials":33693,"activeCount":97},[],{"trials":33695,"activeCount":97},[],{"trials":33697,"activeCount":97},[],{"trials":33699,"activeCount":97},[],{"intervention":33701,"totalTrials":314,"cells":33702},"FGF Receptor",{"EARLY_PHASE1":33703,"PHASE1":33705,"PHASE2":33714,"PHASE3":33716,"PHASE4":33718,"NA":33720},{"trials":33704,"activeCount":97},[],{"trials":33706,"activeCount":97},[33707],{"nctId":33708,"briefTitle":33709,"status":103,"phases":33710,"primaryCompletion":3122,"completion":1473,"start":3152,"enrollment":1501,"conditions":33711,"interventions":33712},"NCT01212107","A Phase 1 Study of LY2874455 in Participants With Advanced Cancer",[85],[1466],[33701,33713],"Phosphate Binders",{"trials":33715,"activeCount":97},[],{"trials":33717,"activeCount":97},[],{"trials":33719,"activeCount":97},[],{"trials":33721,"activeCount":97},[],{"intervention":33713,"totalTrials":314,"cells":33723},{"EARLY_PHASE1":33724,"PHASE1":33726,"PHASE2":33732,"PHASE3":33734,"PHASE4":33736,"NA":33738},{"trials":33725,"activeCount":97},[],{"trials":33727,"activeCount":97},[33728],{"nctId":33708,"briefTitle":33709,"status":103,"phases":33729,"primaryCompletion":3122,"completion":1473,"start":3152,"enrollment":1501,"conditions":33730,"interventions":33731},[85],[1466],[33701,33713],{"trials":33733,"activeCount":97},[],{"trials":33735,"activeCount":97},[],{"trials":33737,"activeCount":97},[],{"trials":33739,"activeCount":97},[],{"intervention":29359,"totalTrials":314,"cells":33741},{"EARLY_PHASE1":33742,"PHASE1":33744,"PHASE2":33750,"PHASE3":33752,"PHASE4":33754,"NA":33756},{"trials":33743,"activeCount":97},[],{"trials":33745,"activeCount":97},[33746],{"nctId":29352,"briefTitle":29353,"status":103,"phases":33747,"primaryCompletion":29355,"completion":29355,"start":29356,"enrollment":1767,"conditions":33748,"interventions":33749},[85],[4040],[11800,29359,29360],{"trials":33751,"activeCount":97},[],{"trials":33753,"activeCount":97},[],{"trials":33755,"activeCount":97},[],{"trials":33757,"activeCount":97},[],{"intervention":29360,"totalTrials":314,"cells":33759},{"EARLY_PHASE1":33760,"PHASE1":33762,"PHASE2":33768,"PHASE3":33770,"PHASE4":33772,"NA":33774},{"trials":33761,"activeCount":97},[],{"trials":33763,"activeCount":97},[33764],{"nctId":29352,"briefTitle":29353,"status":103,"phases":33765,"primaryCompletion":29355,"completion":29355,"start":29356,"enrollment":1767,"conditions":33766,"interventions":33767},[85],[4040],[11800,29359,29360],{"trials":33769,"activeCount":97},[],{"trials":33771,"activeCount":97},[],{"trials":33773,"activeCount":97},[],{"trials":33775,"activeCount":97},[],{"intervention":33777,"totalTrials":314,"cells":33778},"LY3023414 Reference Fasted",{"EARLY_PHASE1":33779,"PHASE1":33781,"PHASE2":33791,"PHASE3":33793,"PHASE4":33795,"NA":33797},{"trials":33780,"activeCount":97},[],{"trials":33782,"activeCount":97},[33783],{"nctId":33784,"briefTitle":33785,"status":103,"phases":33786,"primaryCompletion":1685,"completion":1685,"start":1546,"enrollment":1620,"conditions":33787,"interventions":33788},"NCT02818335","A Study of LY3023414 Formulations and the Effect of Food",[85],[15],[33777,33789,33790],"LY3023414 Test Fasted","LY3023414 Test Fed",{"trials":33792,"activeCount":97},[],{"trials":33794,"activeCount":97},[],{"trials":33796,"activeCount":97},[],{"trials":33798,"activeCount":97},[],{"intervention":33789,"totalTrials":314,"cells":33800},{"EARLY_PHASE1":33801,"PHASE1":33803,"PHASE2":33809,"PHASE3":33811,"PHASE4":33813,"NA":33815},{"trials":33802,"activeCount":97},[],{"trials":33804,"activeCount":97},[33805],{"nctId":33784,"briefTitle":33785,"status":103,"phases":33806,"primaryCompletion":1685,"completion":1685,"start":1546,"enrollment":1620,"conditions":33807,"interventions":33808},[85],[15],[33777,33789,33790],{"trials":33810,"activeCount":97},[],{"trials":33812,"activeCount":97},[],{"trials":33814,"activeCount":97},[],{"trials":33816,"activeCount":97},[],{"intervention":33790,"totalTrials":314,"cells":33818},{"EARLY_PHASE1":33819,"PHASE1":33821,"PHASE2":33827,"PHASE3":33829,"PHASE4":33831,"NA":33833},{"trials":33820,"activeCount":97},[],{"trials":33822,"activeCount":97},[33823],{"nctId":33784,"briefTitle":33785,"status":103,"phases":33824,"primaryCompletion":1685,"completion":1685,"start":1546,"enrollment":1620,"conditions":33825,"interventions":33826},[85],[15],[33777,33789,33790],{"trials":33828,"activeCount":97},[],{"trials":33830,"activeCount":97},[],{"trials":33832,"activeCount":97},[],{"trials":33834,"activeCount":97},[],{"intervention":33836,"totalTrials":314,"cells":33837},"Sodium chloride",{"EARLY_PHASE1":33838,"PHASE1":33840,"PHASE2":33851,"PHASE3":33853,"PHASE4":33855,"NA":33857},{"trials":33839,"activeCount":97},[],{"trials":33841,"activeCount":97},[33842],{"nctId":33843,"briefTitle":33844,"status":103,"phases":33845,"primaryCompletion":33846,"completion":33846,"start":594,"enrollment":37,"conditions":33847,"interventions":33848},"NCT05154968","A Study of Two Formulations (Both Refrigerated and Room Temperature) Using an Autoinjector Device in Healthy Participants",[85],"2021-12-14",[4997],[33836,33849,33850],"Citrate buffer","Mannitol",{"trials":33852,"activeCount":97},[],{"trials":33854,"activeCount":97},[],{"trials":33856,"activeCount":97},[],{"trials":33858,"activeCount":97},[],{"intervention":33849,"totalTrials":314,"cells":33860},{"EARLY_PHASE1":33861,"PHASE1":33863,"PHASE2":33869,"PHASE3":33871,"PHASE4":33873,"NA":33875},{"trials":33862,"activeCount":97},[],{"trials":33864,"activeCount":97},[33865],{"nctId":33843,"briefTitle":33844,"status":103,"phases":33866,"primaryCompletion":33846,"completion":33846,"start":594,"enrollment":37,"conditions":33867,"interventions":33868},[85],[4997],[33836,33849,33850],{"trials":33870,"activeCount":97},[],{"trials":33872,"activeCount":97},[],{"trials":33874,"activeCount":97},[],{"trials":33876,"activeCount":97},[],{"intervention":33850,"totalTrials":314,"cells":33878},{"EARLY_PHASE1":33879,"PHASE1":33881,"PHASE2":33887,"PHASE3":33889,"PHASE4":33891,"NA":33893},{"trials":33880,"activeCount":97},[],{"trials":33882,"activeCount":97},[33883],{"nctId":33843,"briefTitle":33844,"status":103,"phases":33884,"primaryCompletion":33846,"completion":33846,"start":594,"enrollment":37,"conditions":33885,"interventions":33886},[85],[4997],[33836,33849,33850],{"trials":33888,"activeCount":97},[],{"trials":33890,"activeCount":97},[],{"trials":33892,"activeCount":97},[],{"trials":33894,"activeCount":97},[],{"intervention":17355,"totalTrials":314,"cells":33896},{"EARLY_PHASE1":33897,"PHASE1":33899,"PHASE2":33905,"PHASE3":33907,"PHASE4":33909,"NA":33911},{"trials":33898,"activeCount":97},[],{"trials":33900,"activeCount":97},[33901],{"nctId":17350,"briefTitle":17351,"status":103,"phases":33902,"primaryCompletion":3112,"completion":3112,"start":4955,"enrollment":290,"conditions":33903,"interventions":33904},[85],[21],[17257,17355],{"trials":33906,"activeCount":97},[],{"trials":33908,"activeCount":97},[],{"trials":33910,"activeCount":97},[],{"trials":33912,"activeCount":97},[],{"intervention":22761,"totalTrials":314,"cells":33914},{"EARLY_PHASE1":33915,"PHASE1":33917,"PHASE2":33923,"PHASE3":33925,"PHASE4":33927,"NA":33929},{"trials":33916,"activeCount":97},[],{"trials":33918,"activeCount":97},[33919],{"nctId":22753,"briefTitle":22754,"status":103,"phases":33920,"primaryCompletion":22756,"completion":22757,"start":22758,"enrollment":1677,"conditions":33921,"interventions":33922},[85],[1466],[22761,2781],{"trials":33924,"activeCount":97},[],{"trials":33926,"activeCount":97},[],{"trials":33928,"activeCount":97},[],{"trials":33930,"activeCount":97},[],{"intervention":33932,"totalTrials":314,"cells":33933},"Testosterone",{"EARLY_PHASE1":33934,"PHASE1":33936,"PHASE2":33944,"PHASE3":33946,"PHASE4":33948,"NA":33950},{"trials":33935,"activeCount":97},[],{"trials":33937,"activeCount":97},[33938],{"nctId":33939,"briefTitle":33940,"status":103,"phases":33941,"primaryCompletion":3068,"completion":3068,"start":3048,"enrollment":1620,"conditions":33942,"interventions":33943},"NCT01725451","A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants",[85],[4997],[33932],{"trials":33945,"activeCount":97},[],{"trials":33947,"activeCount":97},[],{"trials":33949,"activeCount":97},[],{"trials":33951,"activeCount":97},[],{"intervention":33953,"totalTrials":314,"cells":33954},"[^14C]-LY2835219",{"EARLY_PHASE1":33955,"PHASE1":33957,"PHASE2":33965,"PHASE3":33967,"PHASE4":33969,"NA":33971},{"trials":33956,"activeCount":97},[],{"trials":33958,"activeCount":97},[33959],{"nctId":33960,"briefTitle":33961,"status":103,"phases":33962,"primaryCompletion":4955,"completion":4955,"start":2917,"enrollment":1677,"conditions":33963,"interventions":33964},"NCT01913314","A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants",[85],[21],[33953],{"trials":33966,"activeCount":97},[],{"trials":33968,"activeCount":97},[],{"trials":33970,"activeCount":97},[],{"trials":33972,"activeCount":97},[],{"intervention":19041,"totalTrials":314,"cells":33974},{"EARLY_PHASE1":33975,"PHASE1":33977,"PHASE2":33983,"PHASE3":33985,"PHASE4":33987,"NA":33989},{"trials":33976,"activeCount":97},[],{"trials":33978,"activeCount":97},[33979],{"nctId":19035,"briefTitle":19036,"status":103,"phases":33980,"primaryCompletion":3004,"completion":3004,"start":3494,"enrollment":1620,"conditions":33981,"interventions":33982},[85],[19039],[14381,19041,19042],{"trials":33984,"activeCount":97},[],{"trials":33986,"activeCount":97},[],{"trials":33988,"activeCount":97},[],{"trials":33990,"activeCount":97},[],{"intervention":17362,"totalTrials":314,"cells":33992},{"EARLY_PHASE1":33993,"PHASE1":33995,"PHASE2":34001,"PHASE3":34003,"PHASE4":34005,"NA":34007},{"trials":33994,"activeCount":97},[],{"trials":33996,"activeCount":97},[33997],{"nctId":17357,"briefTitle":17358,"status":103,"phases":33998,"primaryCompletion":3319,"completion":3319,"start":3318,"enrollment":4323,"conditions":33999,"interventions":34000},[85],[21],[17257,17362],{"trials":34002,"activeCount":97},[],{"trials":34004,"activeCount":97},[],{"trials":34006,"activeCount":97},[],{"trials":34008,"activeCount":97},[],{"intervention":18172,"totalTrials":314,"cells":34010},{"EARLY_PHASE1":34011,"PHASE1":34013,"PHASE2":34019,"PHASE3":34021,"PHASE4":34023,"NA":34025},{"trials":34012,"activeCount":97},[],{"trials":34014,"activeCount":97},[34015],{"nctId":18165,"briefTitle":18166,"status":103,"phases":34016,"primaryCompletion":18168,"completion":18169,"start":13481,"enrollment":290,"conditions":34017,"interventions":34018},[85],[1506],[2545,5985,8760,18172],{"trials":34020,"activeCount":97},[],{"trials":34022,"activeCount":97},[],{"trials":34024,"activeCount":97},[],{"trials":34026,"activeCount":97},[],{"intervention":34028,"totalTrials":314,"cells":34029},"LY3478006 - IV",{"EARLY_PHASE1":34030,"PHASE1":34032,"PHASE2":34041,"PHASE3":34043,"PHASE4":34045,"NA":34047},{"trials":34031,"activeCount":97},[],{"trials":34033,"activeCount":97},[34034],{"nctId":34035,"briefTitle":34036,"status":999,"phases":34037,"primaryCompletion":7390,"completion":7390,"start":2681,"enrollment":1400,"conditions":34038,"interventions":34039},"NCT04230122","A Study of LY3478006 in Healthy Participants",[85],[15],[34028,34040],"LY3478006 - SC",{"trials":34042,"activeCount":97},[],{"trials":34044,"activeCount":97},[],{"trials":34046,"activeCount":97},[],{"trials":34048,"activeCount":97},[],{"intervention":34040,"totalTrials":314,"cells":34050},{"EARLY_PHASE1":34051,"PHASE1":34053,"PHASE2":34059,"PHASE3":34061,"PHASE4":34063,"NA":34065},{"trials":34052,"activeCount":97},[],{"trials":34054,"activeCount":97},[34055],{"nctId":34035,"briefTitle":34036,"status":999,"phases":34056,"primaryCompletion":7390,"completion":7390,"start":2681,"enrollment":1400,"conditions":34057,"interventions":34058},[85],[15],[34028,34040],{"trials":34060,"activeCount":97},[],{"trials":34062,"activeCount":97},[],{"trials":34064,"activeCount":97},[],{"trials":34066,"activeCount":97},[],{"intervention":34068,"totalTrials":314,"cells":34069},"LY2811376",{"EARLY_PHASE1":34070,"PHASE1":34072,"PHASE2":34080,"PHASE3":34082,"PHASE4":34084,"NA":34086},{"trials":34071,"activeCount":97},[],{"trials":34073,"activeCount":97},[34074],{"nctId":34075,"briefTitle":34076,"status":103,"phases":34077,"primaryCompletion":5860,"completion":5860,"start":2928,"enrollment":3125,"conditions":34078,"interventions":34079},"NCT00838084","A Safety Study of LY2811376 Single Doses in Healthy Subjects",[85],[4040],[34068],{"trials":34081,"activeCount":97},[],{"trials":34083,"activeCount":97},[],{"trials":34085,"activeCount":97},[],{"trials":34087,"activeCount":97},[],{"intervention":34089,"totalTrials":314,"cells":34090},"LY2584702 Reference Formulation",{"EARLY_PHASE1":34091,"PHASE1":34093,"PHASE2":34102,"PHASE3":34104,"PHASE4":34106,"NA":34108},{"trials":34092,"activeCount":97},[],{"trials":34094,"activeCount":97},[34095],{"nctId":34096,"briefTitle":34097,"status":103,"phases":34098,"primaryCompletion":3494,"completion":3494,"start":3020,"enrollment":864,"conditions":34099,"interventions":34100},"NCT01372085","Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702",[85],[4997],[34089,34101],"LY2584702 Test Formulation",{"trials":34103,"activeCount":97},[],{"trials":34105,"activeCount":97},[],{"trials":34107,"activeCount":97},[],{"trials":34109,"activeCount":97},[],{"intervention":34101,"totalTrials":314,"cells":34111},{"EARLY_PHASE1":34112,"PHASE1":34114,"PHASE2":34120,"PHASE3":34122,"PHASE4":34124,"NA":34126},{"trials":34113,"activeCount":97},[],{"trials":34115,"activeCount":97},[34116],{"nctId":34096,"briefTitle":34097,"status":103,"phases":34117,"primaryCompletion":3494,"completion":3494,"start":3020,"enrollment":864,"conditions":34118,"interventions":34119},[85],[4997],[34089,34101],{"trials":34121,"activeCount":97},[],{"trials":34123,"activeCount":97},[],{"trials":34125,"activeCount":97},[],{"trials":34127,"activeCount":97},[],{"intervention":1681,"totalTrials":314,"cells":34129},{"EARLY_PHASE1":34130,"PHASE1":34132,"PHASE2":34138,"PHASE3":34140,"PHASE4":34142,"NA":34144},{"trials":34131,"activeCount":97},[],{"trials":34133,"activeCount":97},[34134],{"nctId":1671,"briefTitle":1672,"status":103,"phases":34135,"primaryCompletion":1674,"completion":1675,"start":1676,"enrollment":1677,"conditions":34136,"interventions":34137},[85],[1466],[48,1680,1681],{"trials":34139,"activeCount":97},[],{"trials":34141,"activeCount":97},[],{"trials":34143,"activeCount":97},[],{"trials":34145,"activeCount":97},[],{"intervention":34147,"totalTrials":314,"cells":34148},"LY3475766 - IV",{"EARLY_PHASE1":34149,"PHASE1":34151,"PHASE2":34160,"PHASE3":34162,"PHASE4":34164,"NA":34166},{"trials":34150,"activeCount":97},[],{"trials":34152,"activeCount":97},[34153],{"nctId":34154,"briefTitle":34155,"status":103,"phases":34156,"primaryCompletion":666,"completion":666,"start":1557,"enrollment":118,"conditions":34157,"interventions":34158},"NCT04052594","A Study of LY3475766 in Healthy Participants",[85],[18052],[34147,34159],"LY3475766 - SC",{"trials":34161,"activeCount":97},[],{"trials":34163,"activeCount":97},[],{"trials":34165,"activeCount":97},[],{"trials":34167,"activeCount":97},[],{"intervention":34159,"totalTrials":314,"cells":34169},{"EARLY_PHASE1":34170,"PHASE1":34172,"PHASE2":34178,"PHASE3":34180,"PHASE4":34182,"NA":34184},{"trials":34171,"activeCount":97},[],{"trials":34173,"activeCount":97},[34174],{"nctId":34154,"briefTitle":34155,"status":103,"phases":34175,"primaryCompletion":666,"completion":666,"start":1557,"enrollment":118,"conditions":34176,"interventions":34177},[85],[18052],[34147,34159],{"trials":34179,"activeCount":97},[],{"trials":34181,"activeCount":97},[],{"trials":34183,"activeCount":97},[],{"trials":34185,"activeCount":97},[],{"intervention":17602,"totalTrials":314,"cells":34187},{"EARLY_PHASE1":34188,"PHASE1":34190,"PHASE2":34196,"PHASE3":34198,"PHASE4":34200,"NA":34202},{"trials":34189,"activeCount":97},[],{"trials":34191,"activeCount":97},[34192],{"nctId":17596,"briefTitle":17597,"status":103,"phases":34193,"primaryCompletion":8217,"completion":8217,"start":3283,"enrollment":310,"conditions":34194,"interventions":34195},[85],[18],[9681,17601,17602,17603],{"trials":34197,"activeCount":97},[],{"trials":34199,"activeCount":97},[],{"trials":34201,"activeCount":97},[],{"trials":34203,"activeCount":97},[],{"intervention":24481,"totalTrials":314,"cells":34205},{"EARLY_PHASE1":34206,"PHASE1":34208,"PHASE2":34214,"PHASE3":34216,"PHASE4":34218,"NA":34220},{"trials":34207,"activeCount":97},[],{"trials":34209,"activeCount":97},[34210],{"nctId":24476,"briefTitle":24477,"status":103,"phases":34211,"primaryCompletion":3494,"completion":3494,"start":6093,"enrollment":290,"conditions":34212,"interventions":34213},[85],[14741],[24463,10904,24481],{"trials":34215,"activeCount":97},[],{"trials":34217,"activeCount":97},[],{"trials":34219,"activeCount":97},[],{"trials":34221,"activeCount":97},[],{"intervention":24668,"totalTrials":314,"cells":34223},{"EARLY_PHASE1":34224,"PHASE1":34226,"PHASE2":34232,"PHASE3":34234,"PHASE4":34236,"NA":34238},{"trials":34225,"activeCount":97},[],{"trials":34227,"activeCount":97},[34228],{"nctId":24663,"briefTitle":24664,"status":103,"phases":34229,"primaryCompletion":14233,"completion":14233,"start":24000,"enrollment":864,"conditions":34230,"interventions":34231},[85],[15],[24668,24649,24649],{"trials":34233,"activeCount":97},[],{"trials":34235,"activeCount":97},[],{"trials":34237,"activeCount":97},[],{"trials":34239,"activeCount":97},[],{"intervention":13497,"totalTrials":314,"cells":34241},{"EARLY_PHASE1":34242,"PHASE1":34244,"PHASE2":34250,"PHASE3":34252,"PHASE4":34254,"NA":34256},{"trials":34243,"activeCount":97},[],{"trials":34245,"activeCount":97},[34246],{"nctId":13490,"briefTitle":13491,"status":103,"phases":34247,"primaryCompletion":13493,"completion":13493,"start":13494,"enrollment":3654,"conditions":34248,"interventions":34249},[85],[15],[13497,13498,506],{"trials":34251,"activeCount":97},[],{"trials":34253,"activeCount":97},[],{"trials":34255,"activeCount":97},[],{"trials":34257,"activeCount":97},[],{"intervention":13498,"totalTrials":314,"cells":34259},{"EARLY_PHASE1":34260,"PHASE1":34262,"PHASE2":34268,"PHASE3":34270,"PHASE4":34272,"NA":34274},{"trials":34261,"activeCount":97},[],{"trials":34263,"activeCount":97},[34264],{"nctId":13490,"briefTitle":13491,"status":103,"phases":34265,"primaryCompletion":13493,"completion":13493,"start":13494,"enrollment":3654,"conditions":34266,"interventions":34267},[85],[15],[13497,13498,506],{"trials":34269,"activeCount":97},[],{"trials":34271,"activeCount":97},[],{"trials":34273,"activeCount":97},[],{"trials":34275,"activeCount":97},[],{"intervention":16963,"totalTrials":314,"cells":34277},{"EARLY_PHASE1":34278,"PHASE1":34280,"PHASE2":34286,"PHASE3":34288,"PHASE4":34290,"NA":34292},{"trials":34279,"activeCount":97},[],{"trials":34281,"activeCount":97},[34282],{"nctId":16958,"briefTitle":16959,"status":103,"phases":34283,"primaryCompletion":3283,"completion":3283,"start":3152,"enrollment":165,"conditions":34284,"interventions":34285},[85],[13955],[13957,16963],{"trials":34287,"activeCount":97},[],{"trials":34289,"activeCount":97},[],{"trials":34291,"activeCount":97},[],{"trials":34293,"activeCount":97},[],{"intervention":34295,"totalTrials":314,"cells":34296},"U-500R",{"EARLY_PHASE1":34297,"PHASE1":34299,"PHASE2":34308,"PHASE3":34310,"PHASE4":34312,"NA":34314},{"trials":34298,"activeCount":97},[],{"trials":34300,"activeCount":97},[34301],{"nctId":34302,"briefTitle":34303,"status":999,"phases":34304,"primaryCompletion":3616,"completion":3616,"start":34305,"enrollment":205,"conditions":34306,"interventions":34307},"NCT02588950","A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes",[85],"2016-01-12",[18],[34295],{"trials":34309,"activeCount":97},[],{"trials":34311,"activeCount":97},[],{"trials":34313,"activeCount":97},[],{"trials":34315,"activeCount":97},[],{"intervention":18566,"totalTrials":314,"cells":34317},{"EARLY_PHASE1":34318,"PHASE1":34320,"PHASE2":34326,"PHASE3":34328,"PHASE4":34330,"NA":34332},{"trials":34319,"activeCount":97},[],{"trials":34321,"activeCount":97},[34322],{"nctId":18561,"briefTitle":18562,"status":999,"phases":34323,"primaryCompletion":1627,"completion":1627,"start":3123,"enrollment":2088,"conditions":34324,"interventions":34325},[85],[15,4040,13418],[18566,18554],{"trials":34327,"activeCount":97},[],{"trials":34329,"activeCount":97},[],{"trials":34331,"activeCount":97},[],{"trials":34333,"activeCount":97},[],{"intervention":34335,"totalTrials":314,"cells":34336},"LY3375880 IV",{"EARLY_PHASE1":34337,"PHASE1":34339,"PHASE2":34348,"PHASE3":34350,"PHASE4":34352,"NA":34354},{"trials":34338,"activeCount":97},[],{"trials":34340,"activeCount":97},[34341],{"nctId":34342,"briefTitle":34343,"status":103,"phases":34344,"primaryCompletion":5130,"completion":5130,"start":3684,"enrollment":4475,"conditions":34345,"interventions":34346},"NCT03343587","A Study of LY3375880 in Healthy Participants",[85],[15],[34335,34347],"LY3375880 SC",{"trials":34349,"activeCount":97},[],{"trials":34351,"activeCount":97},[],{"trials":34353,"activeCount":97},[],{"trials":34355,"activeCount":97},[],{"intervention":34347,"totalTrials":314,"cells":34357},{"EARLY_PHASE1":34358,"PHASE1":34360,"PHASE2":34366,"PHASE3":34368,"PHASE4":34370,"NA":34372},{"trials":34359,"activeCount":97},[],{"trials":34361,"activeCount":97},[34362],{"nctId":34342,"briefTitle":34343,"status":103,"phases":34363,"primaryCompletion":5130,"completion":5130,"start":3684,"enrollment":4475,"conditions":34364,"interventions":34365},[85],[15],[34335,34347],{"trials":34367,"activeCount":97},[],{"trials":34369,"activeCount":97},[],{"trials":34371,"activeCount":97},[],{"trials":34373,"activeCount":97},[],{"intervention":34375,"totalTrials":314,"cells":34376},"LY2787106",{"EARLY_PHASE1":34377,"PHASE1":34379,"PHASE2":34388,"PHASE3":34390,"PHASE4":34392,"NA":34394},{"trials":34378,"activeCount":97},[],{"trials":34380,"activeCount":97},[34381],{"nctId":34382,"briefTitle":34383,"status":103,"phases":34384,"primaryCompletion":3776,"completion":3776,"start":3685,"enrollment":5015,"conditions":34385,"interventions":34387},"NCT01340976","A Phase 1 Study of LY2787106 in Cancer and Anemia",[85],[34386],"Anemia",[34375],{"trials":34389,"activeCount":97},[],{"trials":34391,"activeCount":97},[],{"trials":34393,"activeCount":97},[],{"trials":34395,"activeCount":97},[],{"intervention":28245,"totalTrials":314,"cells":34397},{"EARLY_PHASE1":34398,"PHASE1":34400,"PHASE2":34406,"PHASE3":34408,"PHASE4":34410,"NA":34412},{"trials":34399,"activeCount":97},[],{"trials":34401,"activeCount":97},[34402],{"nctId":28240,"briefTitle":28241,"status":103,"phases":34403,"primaryCompletion":1473,"completion":1473,"start":4955,"enrollment":34,"conditions":34404,"interventions":34405},[85],[447],[28245,28217],{"trials":34407,"activeCount":97},[],{"trials":34409,"activeCount":97},[],{"trials":34411,"activeCount":97},[],{"trials":34413,"activeCount":97},[],{"intervention":34415,"totalTrials":314,"cells":34416},"LY2393910",{"EARLY_PHASE1":34417,"PHASE1":34419,"PHASE2":34427,"PHASE3":34429,"PHASE4":34431,"NA":34433},{"trials":34418,"activeCount":97},[],{"trials":34420,"activeCount":97},[34421],{"nctId":34422,"briefTitle":34423,"status":103,"phases":34424,"primaryCompletion":2844,"completion":2844,"start":3419,"enrollment":280,"conditions":34425,"interventions":34426},"NCT01253278","A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients",[85],[18],[34415],{"trials":34428,"activeCount":97},[],{"trials":34430,"activeCount":97},[],{"trials":34432,"activeCount":97},[],{"trials":34434,"activeCount":97},[],{"intervention":34436,"totalTrials":314,"cells":34437},"LY3076226",{"EARLY_PHASE1":34438,"PHASE1":34440,"PHASE2":34448,"PHASE3":34450,"PHASE4":34452,"NA":34454},{"trials":34439,"activeCount":97},[],{"trials":34441,"activeCount":97},[34442],{"nctId":34443,"briefTitle":34444,"status":103,"phases":34445,"primaryCompletion":5193,"completion":5193,"start":1618,"enrollment":9038,"conditions":34446,"interventions":34447},"NCT02529553","A Study of LY3076226 in Participants With Advanced or Metastatic Cancer",[85],[1466,1560],[34436],{"trials":34449,"activeCount":97},[],{"trials":34451,"activeCount":97},[],{"trials":34453,"activeCount":97},[],{"trials":34455,"activeCount":97},[],{"intervention":34457,"totalTrials":314,"cells":34458},"LY900014-U200",{"EARLY_PHASE1":34459,"PHASE1":34461,"PHASE2":34471,"PHASE3":34473,"PHASE4":34475,"NA":34477},{"trials":34460,"activeCount":97},[],{"trials":34462,"activeCount":97},[34463],{"nctId":34464,"briefTitle":34465,"status":103,"phases":34466,"primaryCompletion":6651,"completion":6651,"start":34467,"enrollment":3309,"conditions":34468,"interventions":34469},"NCT03334448","A Study to Compare 2 Formulations of LY900014 in Healthy Participants",[85],"2017-12-04",[15],[34457,34470],"LY900014-U100",{"trials":34472,"activeCount":97},[],{"trials":34474,"activeCount":97},[],{"trials":34476,"activeCount":97},[],{"trials":34478,"activeCount":97},[],{"intervention":34470,"totalTrials":314,"cells":34480},{"EARLY_PHASE1":34481,"PHASE1":34483,"PHASE2":34489,"PHASE3":34491,"PHASE4":34493,"NA":34495},{"trials":34482,"activeCount":97},[],{"trials":34484,"activeCount":97},[34485],{"nctId":34464,"briefTitle":34465,"status":103,"phases":34486,"primaryCompletion":6651,"completion":6651,"start":34467,"enrollment":3309,"conditions":34487,"interventions":34488},[85],[15],[34457,34470],{"trials":34490,"activeCount":97},[],{"trials":34492,"activeCount":97},[],{"trials":34494,"activeCount":97},[],{"trials":34496,"activeCount":97},[],{"intervention":8195,"totalTrials":314,"cells":34498},{"EARLY_PHASE1":34499,"PHASE1":34501,"PHASE2":34507,"PHASE3":34509,"PHASE4":34511,"NA":34513},{"trials":34500,"activeCount":97},[],{"trials":34502,"activeCount":97},[34503],{"nctId":8188,"briefTitle":8189,"status":999,"phases":34504,"primaryCompletion":8191,"completion":8191,"start":8192,"enrollment":12,"conditions":34505,"interventions":34506},[85],[15,1271],[8195,1906],{"trials":34508,"activeCount":97},[],{"trials":34510,"activeCount":97},[],{"trials":34512,"activeCount":97},[],{"trials":34514,"activeCount":97},[],{"intervention":19873,"totalTrials":314,"cells":34516},{"EARLY_PHASE1":34517,"PHASE1":34519,"PHASE2":34525,"PHASE3":34527,"PHASE4":34529,"NA":34531},{"trials":34518,"activeCount":97},[],{"trials":34520,"activeCount":97},[34521],{"nctId":19865,"briefTitle":19866,"status":103,"phases":34522,"primaryCompletion":19868,"completion":19868,"start":19869,"enrollment":1741,"conditions":34523,"interventions":34524},[85],[27],[6982,19872,19873],{"trials":34526,"activeCount":97},[],{"trials":34528,"activeCount":97},[],{"trials":34530,"activeCount":97},[],{"trials":34532,"activeCount":97},[],{"intervention":18337,"totalTrials":314,"cells":34534},{"EARLY_PHASE1":34535,"PHASE1":34537,"PHASE2":34543,"PHASE3":34545,"PHASE4":34547,"NA":34549},{"trials":34536,"activeCount":97},[],{"trials":34538,"activeCount":97},[34539],{"nctId":18331,"briefTitle":18332,"status":103,"phases":34540,"primaryCompletion":3348,"completion":3348,"start":3124,"enrollment":214,"conditions":34541,"interventions":34542},[85],[18335],[18296,18337],{"trials":34544,"activeCount":97},[],{"trials":34546,"activeCount":97},[],{"trials":34548,"activeCount":97},[],{"trials":34550,"activeCount":97},[],{"intervention":9275,"totalTrials":314,"cells":34552},{"EARLY_PHASE1":34553,"PHASE1":34555,"PHASE2":34561,"PHASE3":34563,"PHASE4":34565,"NA":34567},{"trials":34554,"activeCount":97},[],{"trials":34556,"activeCount":97},[34557],{"nctId":9268,"briefTitle":9269,"status":103,"phases":34558,"primaryCompletion":1932,"completion":1932,"start":9271,"enrollment":12,"conditions":34559,"interventions":34560},[85],[9273],[9275,402,9275],{"trials":34562,"activeCount":97},[],{"trials":34564,"activeCount":97},[],{"trials":34566,"activeCount":97},[],{"trials":34568,"activeCount":97},[],{"intervention":34570,"totalTrials":314,"cells":34571},"LY3316531 - IV",{"EARLY_PHASE1":34572,"PHASE1":34574,"PHASE2":34584,"PHASE3":34586,"PHASE4":34588,"NA":34590},{"trials":34573,"activeCount":97},[],{"trials":34575,"activeCount":97},[34576],{"nctId":34577,"briefTitle":34578,"status":103,"phases":34579,"primaryCompletion":34580,"completion":1766,"start":1268,"enrollment":9415,"conditions":34581,"interventions":34582},"NCT03418493","A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis",[85],"2018-12-24",[447],[34570,34583],"LY3316531 - SC",{"trials":34585,"activeCount":97},[],{"trials":34587,"activeCount":97},[],{"trials":34589,"activeCount":97},[],{"trials":34591,"activeCount":97},[],{"intervention":34583,"totalTrials":314,"cells":34593},{"EARLY_PHASE1":34594,"PHASE1":34596,"PHASE2":34602,"PHASE3":34604,"PHASE4":34606,"NA":34608},{"trials":34595,"activeCount":97},[],{"trials":34597,"activeCount":97},[34598],{"nctId":34577,"briefTitle":34578,"status":103,"phases":34599,"primaryCompletion":34580,"completion":1766,"start":1268,"enrollment":9415,"conditions":34600,"interventions":34601},[85],[447],[34570,34583],{"trials":34603,"activeCount":97},[],{"trials":34605,"activeCount":97},[],{"trials":34607,"activeCount":97},[],{"trials":34609,"activeCount":97},[],{"intervention":29259,"totalTrials":314,"cells":34611},{"EARLY_PHASE1":34612,"PHASE1":34614,"PHASE2":34620,"PHASE3":34622,"PHASE4":34624,"NA":34626},{"trials":34613,"activeCount":97},[],{"trials":34615,"activeCount":97},[34616],{"nctId":29254,"briefTitle":29255,"status":103,"phases":34617,"primaryCompletion":3419,"completion":3419,"start":14517,"enrollment":290,"conditions":34618,"interventions":34619},[85],[26158],[29259,29239],{"trials":34621,"activeCount":97},[],{"trials":34623,"activeCount":97},[],{"trials":34625,"activeCount":97},[],{"trials":34627,"activeCount":97},[],{"intervention":5046,"totalTrials":314,"cells":34629},{"EARLY_PHASE1":34630,"PHASE1":34632,"PHASE2":34638,"PHASE3":34640,"PHASE4":34642,"NA":34644},{"trials":34631,"activeCount":97},[],{"trials":34633,"activeCount":97},[34634],{"nctId":5041,"briefTitle":5042,"status":103,"phases":34635,"primaryCompletion":4955,"completion":4955,"start":3027,"enrollment":1082,"conditions":34636,"interventions":34637},[85],[21],[4944,5046],{"trials":34639,"activeCount":97},[],{"trials":34641,"activeCount":97},[],{"trials":34643,"activeCount":97},[],{"trials":34645,"activeCount":97},[],{"intervention":34647,"totalTrials":314,"cells":34648},"opioid receptor kappa antagonist",{"EARLY_PHASE1":34649,"PHASE1":34651,"PHASE2":34659,"PHASE3":34661,"PHASE4":34663,"NA":34665},{"trials":34650,"activeCount":97},[],{"trials":34652,"activeCount":97},[34653],{"nctId":34654,"briefTitle":34655,"status":103,"phases":34656,"primaryCompletion":3069,"completion":3069,"start":3152,"enrollment":1199,"conditions":34657,"interventions":34658},"NCT01232439","A Study of Brain Receptor Occupancy in Healthy Subjects",[85],[25367],[34647],{"trials":34660,"activeCount":97},[],{"trials":34662,"activeCount":97},[],{"trials":34664,"activeCount":97},[],{"trials":34666,"activeCount":97},[],{"intervention":34668,"totalTrials":314,"cells":34669},"Capsaicin",{"EARLY_PHASE1":34670,"PHASE1":34680,"PHASE2":34682,"PHASE3":34684,"PHASE4":34686,"NA":34688},{"trials":34671,"activeCount":97},[34672],{"nctId":34673,"briefTitle":34674,"status":103,"phases":34675,"primaryCompletion":34676,"completion":34676,"start":34677,"enrollment":5922,"conditions":34678,"interventions":34679},"NCT02766517","Biomarker Study in Participants With Migraine",[84],"2017-01-01","2016-09-28",[17067],[34668],{"trials":34681,"activeCount":97},[],{"trials":34683,"activeCount":97},[],{"trials":34685,"activeCount":97},[],{"trials":34687,"activeCount":97},[],{"trials":34689,"activeCount":97},[],{"intervention":14492,"totalTrials":2867,"cells":34691},{"EARLY_PHASE1":34692,"PHASE1":34694,"PHASE2":34704,"PHASE3":34733,"PHASE4":35005,"NA":35084},{"trials":34693,"activeCount":97},[],{"trials":34695,"activeCount":97},[34696,34700],{"nctId":14487,"briefTitle":14488,"status":103,"phases":34697,"completion":3005,"start":2930,"enrollment":1548,"conditions":34698,"interventions":34699},[85],[13955],[14492,14480],{"nctId":27776,"briefTitle":27777,"status":103,"phases":34701,"primaryCompletion":3235,"completion":3235,"start":4566,"enrollment":874,"conditions":34702,"interventions":34703},[85],[27780],[14492,1172],{"trials":34705,"activeCount":97},[34706,34714,34721,34727],{"nctId":34707,"briefTitle":34708,"status":103,"phases":34709,"completion":4266,"start":34710,"enrollment":776,"conditions":34711,"interventions":34713},"NCT00190606","Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence",[86],"2002-01",[34712],"Urinary Stress Incontinence",[14492],{"nctId":34715,"briefTitle":34716,"status":103,"phases":34717,"completion":3218,"start":3274,"enrollment":542,"conditions":34718,"interventions":34720},"NCT00475696","Urge Incontinence Bladder Overactivity Study",[86],[34719],"Urinary Incontinence",[14492],{"nctId":34722,"briefTitle":34723,"status":103,"phases":34724,"primaryCompletion":3320,"completion":3320,"start":3813,"enrollment":1767,"conditions":34725,"interventions":34726},"NCT00529789","Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder",[86],[13955],[14004],{"nctId":34728,"briefTitle":34729,"status":103,"phases":34730,"completion":4266,"start":6075,"enrollment":2088,"conditions":34731,"interventions":34732},"NCT00190567","Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence",[86],[34712],[14004],{"trials":34734,"activeCount":97},[34735,34739,34746,34752,34759,34768,34772,34778,34785,34791,34797,34803,34810,34817,34824,34830,34836,34843,34850,34856,34862,34870,34877,34884,34890,34896,34900,34907,34911,34918,34924,34930,34936,34940,34947,34953,34959,34965,34972,34978,34982,34989,34995,35001],{"nctId":14674,"briefTitle":14675,"status":103,"phases":34736,"primaryCompletion":5090,"completion":5090,"start":3419,"enrollment":14677,"conditions":34737,"interventions":34738},[87],[14666],[14492,14652],{"nctId":34740,"briefTitle":34741,"status":103,"phases":34742,"primaryCompletion":3235,"completion":3235,"start":2930,"enrollment":34743,"conditions":34744,"interventions":34745},"NCT00408421","Duloxetine Versus Placebo for Osteoarthritis Knee Pain",[87],231,[25392],[14492],{"nctId":34747,"briefTitle":34748,"status":103,"phases":34749,"completion":3133,"start":4538,"enrollment":3887,"conditions":34750,"interventions":34751},"NCT00190853","Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence",[87],[34712],[14492],{"nctId":34753,"briefTitle":34754,"status":103,"phases":34755,"primaryCompletion":3685,"completion":3685,"start":2928,"enrollment":631,"conditions":34756,"interventions":34758},"NCT00803361","Duloxetine for the Treatment of Generalized Anxiety Disorder",[87],[34757],"Generalized Anxiety Disorder",[14492],{"nctId":34760,"briefTitle":34761,"status":103,"phases":34762,"primaryCompletion":4420,"completion":2964,"start":3020,"enrollment":7024,"conditions":34763,"interventions":34767},"NCT01226511","A Study in Pediatric Participants With Generalized Anxiety Disorder",[87],[34764,34765,34766],"Anxiety Neuroses","Anxiety States, Neurotic","Neuroses, Anxiety",[14492],{"nctId":14851,"briefTitle":14852,"status":103,"phases":34769,"completion":3168,"start":4448,"enrollment":14854,"conditions":34770,"interventions":34771},[87],[13955],[14492,14857],{"nctId":34773,"briefTitle":34774,"status":103,"phases":34775,"completion":4459,"start":3161,"conditions":34776,"interventions":34777},"NCT00042562","Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression",[87],[13955],[14004],{"nctId":34779,"briefTitle":34780,"status":103,"phases":34781,"primaryCompletion":7775,"completion":7775,"start":5030,"enrollment":3887,"conditions":34782,"interventions":34784},"NCT02335346","An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)",[87],[34783],"Osteoarthritis of the Knee",[14492],{"nctId":34786,"briefTitle":34787,"status":103,"phases":34788,"primaryCompletion":2917,"completion":2917,"start":3069,"enrollment":23180,"conditions":34789,"interventions":34790},"NCT01179672","A Study in Participants With Diabetic Peripheral Neuropathic Pain in China",[87],[14666],[14492],{"nctId":34792,"briefTitle":34793,"status":103,"phases":34794,"primaryCompletion":3069,"completion":3069,"start":3217,"enrollment":21126,"conditions":34795,"interventions":34796},"NCT01018680","A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis",[87],[25392],[14492],{"nctId":34798,"briefTitle":34799,"status":103,"phases":34800,"completion":4474,"start":3168,"enrollment":631,"conditions":34801,"interventions":34802},"NCT00190866","Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome",[87],[20920],[14492],{"nctId":34804,"briefTitle":34805,"status":103,"phases":34806,"completion":4459,"start":3274,"enrollment":34807,"conditions":34808,"interventions":34809},"NCT00489073","Duloxetine Versus Placebo for Fibromyalgia",[87],345,[20920],[14004],{"nctId":34811,"briefTitle":34812,"status":103,"phases":34813,"completion":3259,"start":3186,"enrollment":20820,"conditions":34814,"interventions":34816},"NCT00191204","Open Label Phase III Duloxetine Study for Stress Urinary Incontinence",[87],[34815],"Urinary Incontinence Stress",[14492],{"nctId":34818,"briefTitle":34819,"status":103,"phases":34820,"primaryCompletion":3227,"completion":3132,"start":3337,"enrollment":3349,"conditions":34821,"interventions":34823},"NCT00424593","Duloxetine Versus Placebo in Chronic Low Back Pain",[87],[34822],"Back Pain Without Radiation",[14492],{"nctId":34825,"briefTitle":34819,"status":103,"phases":34826,"primaryCompletion":3266,"completion":3266,"start":3060,"enrollment":34827,"conditions":34828,"interventions":34829},"NCT00408876",[87],404,[34822],[14492],{"nctId":34831,"briefTitle":34832,"status":103,"phases":34833,"primaryCompletion":9748,"completion":9748,"start":3838,"enrollment":7363,"conditions":34834,"interventions":34835},"NCT01621191","An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)",[87],[20920],[14492],{"nctId":34837,"briefTitle":34838,"status":103,"phases":34839,"completion":2948,"start":4459,"enrollment":2080,"conditions":34840,"interventions":34842},"NCT00475397","Duloxetine Stress Urinary Incontinence Efficacy and Safety Study",[87],[34841],"Urinary Incontinence, Stress",[14492],{"nctId":34844,"briefTitle":34845,"status":103,"phases":34846,"primaryCompletion":14233,"completion":34847,"start":3837,"enrollment":4315,"conditions":34848,"interventions":34849},"NCT01237587","A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome",[87],"2017-11-28",[20920],[14492],{"nctId":34851,"briefTitle":34852,"status":103,"phases":34853,"completion":5690,"start":3195,"enrollment":2080,"conditions":34854,"interventions":34855},"NCT00475358","Efficacy and Safety Stress Urinary Incontinence Study",[87],[34841],[14492],{"nctId":34857,"briefTitle":34858,"status":103,"phases":34859,"primaryCompletion":3292,"completion":3292,"start":2875,"enrollment":3365,"conditions":34860,"interventions":34861},"NCT00433290","Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain",[87],[25392],[14492],{"nctId":34863,"briefTitle":34864,"status":103,"phases":34865,"primaryCompletion":3059,"completion":3059,"start":3320,"enrollment":34866,"conditions":34867,"interventions":34869},"NCT00767806","A Study for Patient With Chronic Low Back Pain",[87],401,[34868],"Chronic Low Back Pain",[14492],{"nctId":34871,"briefTitle":34872,"status":103,"phases":34873,"completion":4266,"start":34874,"enrollment":2122,"conditions":34875,"interventions":34876},"NCT00190632","To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence",[87],"2001-03",[16512],[14492],{"nctId":34878,"briefTitle":34879,"status":103,"phases":34880,"primaryCompletion":3308,"completion":3308,"start":3218,"enrollment":34881,"conditions":34882,"interventions":34883},"NCT00105989","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",[87],514,[4937],[14492],{"nctId":34885,"briefTitle":34886,"status":103,"phases":34887,"completion":2833,"start":5953,"enrollment":776,"conditions":34888,"interventions":34889},"NCT00191685","Duloxetine in the Treatment of Melancholic Depression",[87],[4937],[14004],{"nctId":34891,"briefTitle":34892,"status":103,"phases":34893,"completion":14199,"start":3635,"enrollment":2080,"conditions":34894,"interventions":34895},"NCT00042575","Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",[87],[13955],[14492],{"nctId":20167,"briefTitle":20168,"status":103,"phases":34897,"completion":3337,"start":3566,"enrollment":14922,"conditions":34898,"interventions":34899},[87],[20171],[14492,20156],{"nctId":34901,"briefTitle":34902,"status":103,"phases":34903,"completion":3339,"start":3040,"enrollment":7514,"conditions":34904,"interventions":34906},"NCT00062673","Study of Duloxetine in Elderly Patients With Major Depressive Disorder",[87],[14033,34905],"Cognition",[14492],{"nctId":20174,"briefTitle":20168,"status":103,"phases":34908,"completion":3228,"start":2948,"enrollment":14854,"conditions":34909,"interventions":34910},[87],[20177],[14492,20156],{"nctId":34912,"briefTitle":34913,"status":103,"phases":34914,"primaryCompletion":3776,"completion":3776,"start":5022,"enrollment":13828,"conditions":34915,"interventions":34917},"NCT01914666","An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain",[87],[34916],"Back Pain Lower Back Chronic",[14492],{"nctId":34919,"briefTitle":34920,"status":103,"phases":34921,"completion":3259,"start":2834,"enrollment":1568,"conditions":34922,"interventions":34923},"NCT00190827","Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)",[87],[34841],[14004],{"nctId":34925,"briefTitle":34926,"status":103,"phases":34927,"completion":3259,"start":21049,"enrollment":2122,"conditions":34928,"interventions":34929},"NCT00190645","To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence",[87],[16512],[14492],{"nctId":34931,"briefTitle":34932,"status":103,"phases":34933,"primaryCompletion":1596,"completion":1619,"start":5022,"enrollment":14693,"conditions":34934,"interventions":34935},"NCT01931475","A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China",[87],[2191],[14492],{"nctId":14504,"briefTitle":14505,"status":103,"phases":34937,"completion":3153,"start":3078,"enrollment":14507,"conditions":34938,"interventions":34939},[87],[14033],[14004,14510],{"nctId":34941,"briefTitle":34942,"status":103,"phases":34943,"completion":3259,"start":34944,"enrollment":1692,"conditions":34945,"interventions":34946},"NCT00190619","Efficacy and Safety of Duloxetine",[87],"2001-05",[34712],[14492],{"nctId":34948,"briefTitle":34949,"status":103,"phases":34950,"completion":4474,"start":2833,"enrollment":2413,"conditions":34951,"interventions":34952},"NCT00233025","Duloxetine Versus Placebo in the Treatment of FMS",[87],[20920],[14492],{"nctId":34954,"briefTitle":34955,"status":103,"phases":34956,"primaryCompletion":1619,"completion":1619,"start":3318,"enrollment":11330,"conditions":34957,"interventions":34958},"NCT02248480","A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan",[87],[34783],[14492],{"nctId":34960,"briefTitle":34961,"status":103,"phases":34962,"completion":3259,"start":2834,"enrollment":2122,"conditions":34963,"interventions":34964},"NCT00190814","Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.",[87],[34841],[14004],{"nctId":34966,"briefTitle":34967,"status":103,"phases":34968,"completion":3259,"start":15163,"enrollment":34969,"conditions":34970,"interventions":34971},"NCT00191087","Duloxetine in the Treatment of Stress Urinary Incontinence.",[87],458,[34841],[14492],{"nctId":34973,"briefTitle":34974,"status":103,"phases":34975,"completion":4642,"start":2947,"enrollment":2413,"conditions":34976,"interventions":34977},"NCT00125892","A Study of Duloxetine in the Treatment of Fibromyalgia",[87],[20920],[14004],{"nctId":13998,"briefTitle":13999,"status":103,"phases":34979,"primaryCompletion":3283,"completion":3494,"start":2866,"enrollment":1995,"conditions":34980,"interventions":34981},[87],[13955],[14003,14004,14004],{"nctId":34983,"briefTitle":34984,"status":103,"phases":34985,"completion":3168,"start":3077,"enrollment":23562,"conditions":34986,"interventions":34988},"NCT00475969","Duloxetine vs Placebo in the Treatment of General Anxiety",[87],[34987],"Anxiety",[14004],{"nctId":34990,"briefTitle":34991,"status":103,"phases":34992,"primaryCompletion":2956,"completion":2956,"start":3059,"enrollment":1358,"conditions":34993,"interventions":34994},"NCT00945945","A Study of Duloxetine in Patients With Osteoarthritis Knee Pain",[87],[25392],[14492],{"nctId":34996,"briefTitle":34997,"status":103,"phases":34998,"primaryCompletion":7316,"completion":7316,"start":3282,"enrollment":34969,"conditions":34999,"interventions":35000},"NCT01855919","A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain",[87],[34916],[14492],{"nctId":14006,"briefTitle":13999,"status":103,"phases":35002,"primaryCompletion":3837,"completion":3004,"start":2866,"enrollment":14008,"conditions":35003,"interventions":35004},[87],[13955],[14004,14003],{"trials":35006,"activeCount":97},[35007,35011,35018,35024,35028,35034,35043,35049,35056,35062,35068,35074,35080],{"nctId":14514,"briefTitle":14515,"status":103,"phases":35008,"primaryCompletion":3152,"completion":3152,"start":14517,"enrollment":14518,"conditions":35009,"interventions":35010},[88],[13955],[14492,14480],{"nctId":35012,"briefTitle":35013,"status":103,"phases":35014,"primaryCompletion":8233,"completion":8233,"start":3217,"enrollment":35015,"conditions":35016,"interventions":35017},"NCT01000805","A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms",[88],528,[13955],[14492],{"nctId":35019,"briefTitle":35020,"status":103,"phases":35021,"primaryCompletion":3124,"completion":3124,"start":3685,"enrollment":874,"conditions":35022,"interventions":35023},"NCT01051466","A Study of the Neurobiology of Depression",[88],[13955,4997],[14492],{"nctId":14683,"briefTitle":14684,"status":103,"phases":35025,"primaryCompletion":14686,"completion":14686,"start":3697,"enrollment":13712,"conditions":35026,"interventions":35027},[88],[9378],[14492,14652],{"nctId":35029,"briefTitle":35030,"status":103,"phases":35031,"primaryCompletion":3059,"completion":3059,"start":3575,"enrollment":1249,"conditions":35032,"interventions":35033},"NCT00696774","Switching to Duloxetine in Patients With Depression",[88],[4937],[14492],{"nctId":35035,"briefTitle":35036,"status":103,"phases":35037,"primaryCompletion":3029,"completion":3029,"start":14517,"enrollment":35038,"conditions":35039,"interventions":35042},"NCT00965081","A Study for Adult Patients With Fibromyalgia",[88],308,[35040,35041],"Fibromyalgia, Primary","Fibromyalgia, Secondary",[14492],{"nctId":35044,"briefTitle":35045,"status":103,"phases":35046,"primaryCompletion":3545,"completion":3545,"start":8233,"enrollment":7081,"conditions":35047,"interventions":35048},"NCT01118780","A Study of Duloxetine in Elderly Generalized Anxiety Disorder",[88],[34757],[14492],{"nctId":35050,"briefTitle":35051,"status":103,"phases":35052,"completion":3168,"start":4221,"enrollment":35053,"conditions":35054,"interventions":35055},"NCT00494377","Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression",[88],940,[14033],[14004],{"nctId":35057,"briefTitle":35058,"status":384,"phases":35059,"primaryCompletion":3012,"completion":3012,"start":3419,"enrollment":97,"conditions":35060,"interventions":35061},"NCT01089621","A Study for Adolescents With Fibromyalgia Syndrome",[88],[20920],[14492],{"nctId":35063,"briefTitle":35064,"status":103,"phases":35065,"completion":3592,"start":3077,"enrollment":14826,"conditions":35066,"interventions":35067},"NCT00191932","Switching to Duloxetine From Other Antidepressants",[88],[13955],[14492],{"nctId":35069,"briefTitle":35070,"status":103,"phases":35071,"primaryCompletion":3837,"completion":3837,"start":3419,"enrollment":5355,"conditions":35072,"interventions":35073},"NCT01070329","A Study in Depression and Associated Painful Physical Symptoms",[88],[13955],[14492],{"nctId":35075,"briefTitle":35076,"status":103,"phases":35077,"primaryCompletion":3235,"completion":3235,"start":4266,"enrollment":12221,"conditions":35078,"interventions":35079},"NCT00322621","Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)",[88],[20294],[14492],{"nctId":14029,"briefTitle":14030,"status":103,"phases":35081,"primaryCompletion":3103,"completion":2866,"start":3292,"enrollment":2514,"conditions":35082,"interventions":35083},[88],[14033],[14004,14003,14035,14036,14037],{"trials":35085,"activeCount":97},[35086],{"nctId":35087,"briefTitle":35088,"status":103,"phases":35089,"primaryCompletion":35090,"completion":35090,"start":3059,"enrollment":9477,"conditions":35091,"interventions":35093},"NCT01074151","The Cymbalta Pregnancy Registry",[],"2021-07-26",[35092],"Pregnancy",[14004],{"intervention":14720,"totalTrials":1741,"cells":35095},{"EARLY_PHASE1":35096,"PHASE1":35098,"PHASE2":35114,"PHASE3":35156,"PHASE4":35293,"NA":35367},{"trials":35097,"activeCount":97},[],{"trials":35099,"activeCount":97},[35100,35104,35110],{"nctId":10898,"briefTitle":10899,"status":103,"phases":35101,"primaryCompletion":3697,"completion":3697,"start":3319,"enrollment":118,"conditions":35102,"interventions":35103},[85],[21],[10903,2562,2092,10904,10905],{"nctId":35105,"briefTitle":35106,"status":103,"phases":35107,"primaryCompletion":3069,"completion":3069,"start":2899,"enrollment":290,"conditions":35108,"interventions":35109},"NCT01183650","A Study of Tadalafil in Benign Prostatic Hyperplasia",[85],[15444],[10904],{"nctId":24476,"briefTitle":24477,"status":103,"phases":35111,"primaryCompletion":3494,"completion":3494,"start":6093,"enrollment":290,"conditions":35112,"interventions":35113},[85],[14741],[24463,10904,24481],{"trials":35115,"activeCount":97},[35116,35120,35124,35130,35136,35145,35152],{"nctId":19651,"briefTitle":19652,"status":103,"phases":35117,"primaryCompletion":3575,"completion":3575,"start":3235,"enrollment":13828,"conditions":35118,"interventions":35119},[86],[15444],[10904,19642],{"nctId":24485,"briefTitle":24486,"status":103,"phases":35121,"primaryCompletion":5090,"completion":5090,"start":8233,"enrollment":24488,"conditions":35122,"interventions":35123},[86],[14741],[24463,14720],{"nctId":35125,"briefTitle":35126,"status":103,"phases":35127,"primaryCompletion":3292,"completion":3292,"start":2876,"enrollment":776,"conditions":35128,"interventions":35129},"NCT00386009","Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",[86],[15444],[10904],{"nctId":35131,"briefTitle":35132,"status":103,"phases":35133,"completion":3524,"start":2833,"enrollment":9828,"conditions":35134,"interventions":35135},"NCT00157326","Tadalafil in Subjects With Mild to Moderate Hypertension",[86],[2156],[14720],{"nctId":35137,"briefTitle":35138,"status":103,"phases":35139,"completion":2947,"start":2948,"enrollment":35140,"conditions":35141,"interventions":35144},"NCT00547625","Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ\u002FUrinary Tract Problems",[86],275,[35142,35143],"Prostatic Hyperplasia","Prostate",[14720],{"nctId":35146,"briefTitle":35147,"status":103,"phases":35148,"completion":2834,"start":3140,"enrollment":947,"conditions":35149,"interventions":35151},"NCT00050609","Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying",[86],[35150],"Gastroparesis",[14720,14720],{"nctId":23603,"briefTitle":23604,"status":103,"phases":35153,"primaryCompletion":1596,"completion":1596,"start":3122,"enrollment":13712,"conditions":35154,"interventions":35155},[86],[23607],[10903,10904,23609],{"trials":35157,"activeCount":97},[35158,35165,35169,35177,35181,35187,35193,35200,35207,35213,35220,35224,35230,35236,35242,35246,35253,35260,35266,35272,35278,35286],{"nctId":35159,"briefTitle":35160,"status":103,"phases":35161,"primaryCompletion":2798,"completion":2798,"start":4160,"enrollment":35162,"conditions":35163,"interventions":35164},"NCT01460342","Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)",[87],610,[15444],[10904],{"nctId":20500,"briefTitle":20501,"status":103,"phases":35166,"primaryCompletion":20503,"completion":665,"start":20504,"enrollment":1548,"conditions":35167,"interventions":35168},[87],[20506],[10904,20489],{"nctId":35170,"briefTitle":35171,"status":103,"phases":35172,"primaryCompletion":3813,"completion":3813,"start":14103,"enrollment":35173,"conditions":35174,"interventions":35176},"NCT00125918","PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension",[87],406,[35175],"Pulmonary Hypertension",[14720,14720,14720,14720],{"nctId":14713,"briefTitle":14714,"status":103,"phases":35178,"completion":5953,"start":3274,"enrollment":14716,"conditions":35179,"interventions":35180},[87],[14718],[14720,14702],{"nctId":35182,"briefTitle":35183,"status":103,"phases":35184,"primaryCompletion":3235,"completion":3132,"start":2855,"enrollment":1022,"conditions":35185,"interventions":35186},"NCT00384930","Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",[86,87],[15444],[14720,14720,14720,14720],{"nctId":35188,"briefTitle":35189,"status":103,"phases":35190,"completion":3646,"start":2938,"enrollment":15151,"conditions":35191,"interventions":35192},"NCT00547495","Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection",[87],[14718],[14720,14720,14720],{"nctId":35194,"briefTitle":35195,"status":103,"phases":35196,"completion":3153,"start":2948,"enrollment":35197,"conditions":35198,"interventions":35199},"NCT00547183","Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection",[87],298,[14718],[14720,14720],{"nctId":35201,"briefTitle":35202,"status":103,"phases":35203,"completion":2834,"start":3236,"enrollment":35204,"conditions":35205,"interventions":35206},"NCT00547508","To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking",[87],485,[14718],[14720,14720,14720,14720],{"nctId":35208,"briefTitle":35209,"status":103,"phases":35210,"primaryCompletion":2899,"completion":2899,"start":2866,"enrollment":5347,"conditions":35211,"interventions":35212},"NCT00855582","A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia",[87],[14741,15444],[10904],{"nctId":35214,"briefTitle":35215,"status":103,"phases":35216,"completion":3168,"start":3039,"enrollment":9828,"conditions":35217,"interventions":35219},"NCT00421083","Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury",[87],[14741,35218],"Spinal Cord Injuries",[14720],{"nctId":21282,"briefTitle":21283,"status":103,"phases":35221,"primaryCompletion":3086,"completion":2865,"start":3114,"enrollment":21285,"conditions":35222,"interventions":35223},[87],[15444,21287],[10904,21271],{"nctId":35225,"briefTitle":35226,"status":103,"phases":35227,"primaryCompletion":3545,"completion":3545,"start":3114,"enrollment":6509,"conditions":35228,"interventions":35229},"NCT01152190","A Study in Benign Prostatic Hyperplasia",[87],[15444],[10904],{"nctId":35231,"briefTitle":35232,"status":103,"phases":35233,"completion":4459,"start":3195,"enrollment":1328,"conditions":35234,"interventions":35235},"NCT00547573","Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection",[87],[14718],[14720,14720],{"nctId":35237,"briefTitle":35238,"status":103,"phases":35239,"primaryCompletion":3217,"completion":3217,"start":3662,"enrollment":15032,"conditions":35240,"interventions":35241},"NCT00827242","Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily",[87],[15444],[14720],{"nctId":19659,"briefTitle":19660,"status":103,"phases":35243,"primaryCompletion":2918,"completion":2918,"start":2866,"enrollment":19662,"conditions":35244,"interventions":35245},[87],[15444],[10904,19642],{"nctId":35247,"briefTitle":35248,"status":103,"phases":35249,"completion":2938,"start":3567,"enrollment":35250,"conditions":35251,"interventions":35252},"NCT00547417","To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections",[87],1933,[14718],[14720],{"nctId":35254,"briefTitle":35255,"status":103,"phases":35256,"primaryCompletion":3685,"completion":3685,"start":3662,"enrollment":35257,"conditions":35258,"interventions":35259},"NCT00836693","Effect of Tadalafil Once a Day in Men With Erectile Dysfunction",[87],217,[14741],[14720],{"nctId":35261,"briefTitle":35262,"status":103,"phases":35263,"completion":3524,"start":5623,"enrollment":1269,"conditions":35264,"interventions":35265},"NCT00381732","A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction",[87],[14741],[14720],{"nctId":35267,"briefTitle":35268,"status":103,"phases":35269,"primaryCompletion":3308,"completion":3308,"start":2930,"enrollment":4711,"conditions":35270,"interventions":35271},"NCT00422734","Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life",[87],[14718],[14720],{"nctId":35273,"briefTitle":35274,"status":103,"phases":35275,"primaryCompletion":6883,"completion":6883,"start":2866,"enrollment":366,"conditions":35276,"interventions":35277},"NCT00848081","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers",[87],[15444],[10904],{"nctId":35279,"briefTitle":35280,"status":999,"phases":35281,"primaryCompletion":3123,"completion":7775,"start":5022,"enrollment":35282,"conditions":35283,"interventions":35285},"NCT01865084","A Study of Tadalafil for Duchenne Muscular Dystrophy",[87],331,[35284],"Muscular Dystrophy, Duchenne",[10904],{"nctId":35287,"briefTitle":35288,"status":103,"phases":35289,"primaryCompletion":3086,"completion":3086,"start":3176,"enrollment":35290,"conditions":35291,"interventions":35292},"NCT00549302","Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs",[87],357,[20506],[14720,14720],{"trials":35294,"activeCount":97},[35295,35299,35303,35307,35314,35318,35325,35332,35338,35344,35348,35355,35361],{"nctId":14724,"briefTitle":14725,"status":103,"phases":35296,"completion":3168,"start":3194,"enrollment":5729,"conditions":35297,"interventions":35298},[88],[14718],[14720,14702],{"nctId":15439,"briefTitle":15440,"status":103,"phases":35300,"primaryCompletion":1547,"completion":1547,"start":3697,"enrollment":15442,"conditions":35301,"interventions":35302},[88],[15444],[10904,15426],{"nctId":15642,"briefTitle":15643,"status":103,"phases":35304,"primaryCompletion":3020,"completion":3020,"start":2956,"enrollment":15645,"conditions":35305,"interventions":35306},[88],[14741],[10904,15629],{"nctId":35308,"briefTitle":35309,"status":103,"phases":35310,"primaryCompletion":3661,"completion":3661,"start":3012,"enrollment":35311,"conditions":35312,"interventions":35313},"NCT01130532","A Study in Erectile Dysfunction",[88],623,[14741],[10904],{"nctId":14730,"briefTitle":14731,"status":103,"phases":35315,"completion":3646,"start":5623,"enrollment":14733,"conditions":35316,"interventions":35317},[88],[14718],[14720,14702],{"nctId":35319,"briefTitle":35320,"status":103,"phases":35321,"primaryCompletion":2799,"completion":5370,"start":3318,"enrollment":35322,"conditions":35323,"interventions":35324},"NCT02224846","A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction",[88],635,[14741],[10904],{"nctId":35326,"briefTitle":35327,"status":103,"phases":35328,"primaryCompletion":2798,"completion":2798,"start":3217,"enrollment":35329,"conditions":35330,"interventions":35331},"NCT01026818","A Study of Tadalafil After Radical Prostatectomy",[88],583,[14741],[10904],{"nctId":35333,"briefTitle":35309,"status":103,"phases":35334,"primaryCompletion":5860,"completion":5860,"start":3103,"enrollment":35335,"conditions":35336,"interventions":35337},"NCT00833638",[88],372,[14741],[10904],{"nctId":35339,"briefTitle":35340,"status":103,"phases":35341,"completion":2855,"start":3168,"enrollment":3867,"conditions":35342,"interventions":35343},"NCT00333281","A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months",[88],[14741],[14720],{"nctId":14737,"briefTitle":14738,"status":103,"phases":35345,"primaryCompletion":3838,"completion":3545,"start":3020,"enrollment":7040,"conditions":35346,"interventions":35347},[88],[14741],[10904,14743],{"nctId":35349,"briefTitle":35350,"status":103,"phases":35351,"completion":4448,"start":3195,"enrollment":35352,"conditions":35353,"interventions":35354},"NCT00547599","Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects",[88],659,[14718],[14720],{"nctId":35356,"briefTitle":35357,"status":103,"phases":35358,"completion":2833,"start":2948,"enrollment":776,"conditions":35359,"interventions":35360},"NCT00422578","Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction",[88],[14718,14741],[14720],{"nctId":35362,"briefTitle":35363,"status":103,"phases":35364,"completion":3176,"start":3078,"enrollment":820,"conditions":35365,"interventions":35366},"NCT00382135","A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg",[88],[14741],[14720],{"trials":35368,"activeCount":97},[35369],{"nctId":35370,"briefTitle":35371,"status":103,"phases":35372,"primaryCompletion":3122,"completion":3122,"start":3685,"enrollment":35373,"conditions":35374,"interventions":35375},"NCT01066845","Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension",[],1809,[27084],[14720],{"intervention":13976,"totalTrials":5922,"cells":35377},{"EARLY_PHASE1":35378,"PHASE1":35380,"PHASE2":35382,"PHASE3":35395,"PHASE4":35470,"NA":35564},{"trials":35379,"activeCount":97},[],{"trials":35381,"activeCount":97},[],{"trials":35383,"activeCount":97},[35384,35388],{"nctId":19053,"briefTitle":19054,"status":103,"phases":35385,"primaryCompletion":3132,"completion":3132,"start":2975,"enrollment":19056,"conditions":35386,"interventions":35387},[86],[4897],[14381,14381,14381,14381,13976],{"nctId":35389,"briefTitle":35390,"status":103,"phases":35391,"conditions":35392,"interventions":35393},"NCT00089869","A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia",[85,86],[4897],[9670,35394],"atomoxetine",{"trials":35396,"activeCount":97},[35397,35401,35407,35411,35418,35424,35428,35432,35436,35443,35447,35451,35457,35464],{"nctId":9663,"briefTitle":9664,"status":103,"phases":35398,"primaryCompletion":3320,"completion":3320,"start":2930,"enrollment":9666,"conditions":35399,"interventions":35400},[87],[4897,9668],[9670,9671,9672,9673],{"nctId":35402,"briefTitle":35403,"status":103,"phases":35404,"completion":3592,"start":3168,"enrollment":1692,"conditions":35405,"interventions":35406},"NCT00113594","Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder",[87],[4897,4919],[13976],{"nctId":13970,"briefTitle":13971,"status":999,"phases":35408,"primaryCompletion":4383,"completion":4383,"start":2898,"enrollment":12091,"conditions":35409,"interventions":35410},[87],[13974],[13976,13944],{"nctId":35412,"briefTitle":35413,"status":103,"phases":35414,"primaryCompletion":3292,"completion":3292,"start":3228,"enrollment":6624,"conditions":35415,"interventions":35417},"NCT00259272","Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine",[87],[35416],"Bipolar Disorder I or II",[9670],{"nctId":35419,"briefTitle":35420,"status":103,"phases":35421,"primaryCompletion":3419,"completion":2899,"start":3813,"enrollment":34881,"conditions":35422,"interventions":35423},"NCT00510146","Olanzapine Treatment of Patients With Bipolar I Disorder",[87],[14018],[13976],{"nctId":21123,"briefTitle":21124,"status":103,"phases":35425,"primaryCompletion":14517,"completion":14517,"start":4266,"enrollment":21126,"conditions":35426,"interventions":35427},[87],[4897],[9670,21112],{"nctId":14346,"briefTitle":14347,"status":103,"phases":35429,"primaryCompletion":2929,"completion":2929,"start":3228,"enrollment":11714,"conditions":35430,"interventions":35431},[87],[14350],[9670,14352,14353,14354],{"nctId":14385,"briefTitle":14386,"status":999,"phases":35433,"primaryCompletion":2798,"completion":2798,"start":2918,"enrollment":14388,"conditions":35434,"interventions":35435},[86,87],[4897],[14381,13976,14391,14380,14392],{"nctId":35437,"briefTitle":35438,"status":103,"phases":35439,"completion":3228,"start":2938,"enrollment":542,"conditions":35440,"interventions":35442},"NCT00091650","Olanzapine in Patients With Borderline Personality Disorder",[87],[35441],"Borderline Personality Disorder",[13976],{"nctId":13992,"briefTitle":13993,"status":103,"phases":35444,"completion":2947,"start":3677,"enrollment":2122,"conditions":35445,"interventions":35446},[87],[13955],[13976,13944],{"nctId":14808,"briefTitle":14809,"status":103,"phases":35448,"primaryCompletion":3662,"completion":3662,"start":2947,"enrollment":1827,"conditions":35449,"interventions":35450},[87],[4919],[9670,14793],{"nctId":35452,"briefTitle":35453,"status":103,"phases":35454,"primaryCompletion":3114,"completion":3114,"start":3094,"enrollment":2670,"conditions":35455,"interventions":35456},"NCT00618748","Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed",[87],[16359],[13976],{"nctId":35458,"briefTitle":35459,"status":103,"phases":35460,"completion":3566,"start":3274,"enrollment":35461,"conditions":35462,"interventions":35463},"NCT00051298","Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia",[87],107,[4897],[13976],{"nctId":35465,"briefTitle":35466,"status":103,"phases":35467,"completion":13847,"start":4221,"enrollment":855,"conditions":35468,"interventions":35469},"NCT00088036","Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder",[87],[35441],[13976],{"trials":35471,"activeCount":97},[35472,35476,35482,35488,35492,35496,35502,35506,35512,35518,35522,35526,35530,35534,35538,35542,35546,35550,35554,35560],{"nctId":15001,"briefTitle":15002,"status":103,"phases":35473,"completion":3592,"start":3339,"enrollment":2630,"conditions":35474,"interventions":35475},[88],[4897,14400],[13976,14392],{"nctId":35477,"briefTitle":35478,"status":103,"phases":35479,"completion":3228,"start":2834,"enrollment":2122,"conditions":35480,"interventions":35481},"NCT00100776","Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder",[88],[4897,14400],[13976],{"nctId":35483,"briefTitle":35484,"status":103,"phases":35485,"completion":3153,"start":3274,"enrollment":2206,"conditions":35486,"interventions":35487},"NCT00050206","Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder",[88],[4919],[13976],{"nctId":15502,"briefTitle":15503,"status":103,"phases":35489,"completion":3040,"start":3186,"enrollment":15505,"conditions":35490,"interventions":35491},[88],[14033,4897,14400],[9670,15489],{"nctId":14396,"briefTitle":14397,"status":103,"phases":35493,"primaryCompletion":3575,"completion":3575,"start":5623,"enrollment":2206,"conditions":35494,"interventions":35495},[88],[4897,14400],[9670,14366],{"nctId":35497,"briefTitle":35498,"status":103,"phases":35499,"completion":14103,"start":3040,"enrollment":874,"conditions":35500,"interventions":35501},"NCT00191828","A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme",[88],[544],[9670],{"nctId":14913,"briefTitle":14914,"status":103,"phases":35503,"completion":2855,"start":3339,"enrollment":2122,"conditions":35504,"interventions":35505},[88],[4897],[13976,14391],{"nctId":35507,"briefTitle":35508,"status":103,"phases":35509,"completion":3592,"start":2948,"enrollment":9828,"conditions":35510,"interventions":35511},"NCT00191997","Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode",[88],[4919],[13976],{"nctId":35513,"briefTitle":35514,"status":103,"phases":35515,"primaryCompletion":3282,"completion":3282,"start":14517,"enrollment":15483,"conditions":35516,"interventions":35517},"NCT00982020","Study in Adolescents With Schizophrenia or Bipolar Disorder",[88],[16359,4897],[13976],{"nctId":14403,"briefTitle":14404,"status":103,"phases":35519,"primaryCompletion":3227,"completion":3227,"start":3259,"enrollment":11322,"conditions":35520,"interventions":35521},[88],[4897,14400,14407],[9670,14366,14366],{"nctId":14410,"briefTitle":14411,"status":103,"phases":35523,"completion":14199,"start":14413,"enrollment":14414,"conditions":35524,"interventions":35525},[88],[4919],[9670,14366],{"nctId":14816,"briefTitle":14817,"status":999,"phases":35527,"primaryCompletion":3566,"completion":3566,"start":2948,"enrollment":205,"conditions":35528,"interventions":35529},[88],[4919],[9670,14793,14821],{"nctId":14014,"briefTitle":14015,"status":103,"phases":35531,"completion":3592,"start":5953,"enrollment":658,"conditions":35532,"interventions":35533},[88],[14018],[13976,13944],{"nctId":14919,"briefTitle":14920,"status":103,"phases":35535,"completion":4566,"start":5623,"enrollment":14922,"conditions":35536,"interventions":35537},[88],[4897],[13976,14391],{"nctId":14823,"briefTitle":14824,"status":103,"phases":35539,"completion":3259,"start":13765,"enrollment":14826,"conditions":35540,"interventions":35541},[88],[4897],[9670,14793],{"nctId":14021,"briefTitle":14022,"status":103,"phases":35543,"completion":4538,"start":3078,"enrollment":14024,"conditions":35544,"interventions":35545},[88],[4919],[13976,13944,14027],{"nctId":14358,"briefTitle":14359,"status":103,"phases":35547,"completion":3524,"start":3039,"enrollment":2080,"conditions":35548,"interventions":35549},[88],[4919],[9670,14354],{"nctId":16216,"briefTitle":16217,"status":103,"phases":35551,"completion":3060,"start":2948,"enrollment":1568,"conditions":35552,"interventions":35553},[88],[4919],[9670,16203],{"nctId":35555,"briefTitle":35556,"status":103,"phases":35557,"completion":3209,"start":14413,"enrollment":972,"conditions":35558,"interventions":35559},"NCT00036088","Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia",[88],[4897],[13976],{"nctId":16354,"briefTitle":16355,"status":103,"phases":35561,"primaryCompletion":3094,"completion":3094,"start":3060,"enrollment":16357,"conditions":35562,"interventions":35563},[88],[16359],[9670,16341],{"trials":35565,"activeCount":97},[35566],{"nctId":35567,"briefTitle":35568,"status":103,"phases":35569,"completion":2929,"start":3645,"enrollment":35570,"conditions":35571,"interventions":35572},"NCT00510211","An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.",[],1131,[4897,4919],[9670],{"intervention":14202,"totalTrials":1178,"cells":35574},{"EARLY_PHASE1":35575,"PHASE1":35577,"PHASE2":35579,"PHASE3":35594,"PHASE4":35670,"NA":35730},{"trials":35576,"activeCount":97},[],{"trials":35578,"activeCount":97},[],{"trials":35580,"activeCount":97},[35581,35587],{"nctId":35582,"briefTitle":35583,"status":103,"phases":35584,"completion":3592,"start":5690,"enrollment":5729,"conditions":35585,"interventions":35586},"NCT00191867","Clinical Trial of Teriparatide in Japan",[86],[14617],[14202],{"nctId":35588,"briefTitle":35589,"status":103,"phases":35590,"completion":4474,"start":2909,"enrollment":1868,"conditions":35591,"interventions":35593},"NCT00190944","Effects of Teriparatide on Distal Radius Fracture Healing",[86],[35592],"Colles' Fracture",[14202],{"trials":35595,"activeCount":97},[35596,35602,35608,35614,35620,35624,35628,35632,35638,35645,35652,35656,35660,35666],{"nctId":35597,"briefTitle":35598,"status":103,"phases":35599,"completion":2909,"start":3078,"enrollment":2088,"conditions":35600,"interventions":35601},"NCT00532207","Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis",[87],[14193],[14170],{"nctId":35603,"briefTitle":35604,"status":103,"phases":35605,"completion":3176,"start":3339,"enrollment":874,"conditions":35606,"interventions":35607},"NCT00191321","Teriparatide Use in Hip Replaced Subjects",[87],[14617],[14202],{"nctId":35609,"briefTitle":35610,"status":103,"phases":35611,"completion":2856,"start":2834,"enrollment":2080,"conditions":35612,"interventions":35613},"NCT00191802","Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients",[87],[14617],[14170],{"nctId":35615,"briefTitle":35616,"status":103,"phases":35617,"primaryCompletion":3292,"completion":2928,"start":3308,"enrollment":776,"conditions":35618,"interventions":35619},"NCT00577863","Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy",[87],[14617],[14170],{"nctId":14758,"briefTitle":14759,"status":103,"phases":35621,"primaryCompletion":5860,"completion":2918,"start":3524,"enrollment":14761,"conditions":35622,"interventions":35623},[87],[14168,14763,14764],[14170,14766],{"nctId":20876,"briefTitle":20877,"status":103,"phases":35625,"primaryCompletion":3185,"completion":3308,"start":3274,"enrollment":20879,"conditions":35626,"interventions":35627},[87],[14617],[14202,20865],{"nctId":14164,"briefTitle":14165,"status":103,"phases":35629,"conditions":35630,"interventions":35631},[87],[14168],[14170,14171],{"nctId":35633,"briefTitle":35634,"status":103,"phases":35635,"completion":2930,"start":2834,"enrollment":1587,"conditions":35636,"interventions":35637},"NCT00191893","Bone Effects of Teriparatide Following Alendronate",[87],[14617],[14170],{"nctId":35639,"briefTitle":35640,"status":103,"phases":35641,"primaryCompletion":3320,"completion":14517,"start":3337,"enrollment":35642,"conditions":35643,"interventions":35644},"NCT00433160","Phase 3 Clinical Trial of Teriparatide in Japan",[87],207,[14617],[14202],{"nctId":35646,"briefTitle":35647,"status":103,"phases":35648,"primaryCompletion":3049,"completion":3049,"start":3086,"enrollment":3267,"conditions":35649,"interventions":35651},"NCT01473589","Effect of Teriparatide on Hip Fracture Healing",[87],[35650],"Femur Neck Fracture",[14202],{"nctId":14768,"briefTitle":14769,"status":103,"phases":35653,"primaryCompletion":8233,"completion":8233,"start":4566,"enrollment":5645,"conditions":35654,"interventions":35655},[87],[14617],[14202,14747],{"nctId":15252,"briefTitle":15253,"status":103,"phases":35657,"primaryCompletion":15255,"completion":15255,"start":15256,"enrollment":15257,"conditions":35658,"interventions":35659},[87],[14168],[14170,14170,15241,15260],{"nctId":35661,"briefTitle":35662,"status":103,"phases":35663,"primaryCompletion":4980,"completion":4980,"start":3661,"enrollment":3041,"conditions":35664,"interventions":35665},"NCT01473602","Second Study of the Effect of Teriparatide on Hip Fracture Healing",[87],[35650],[14202],{"nctId":22030,"briefTitle":22031,"status":103,"phases":35667,"primaryCompletion":2800,"completion":2800,"start":3060,"enrollment":22033,"conditions":35668,"interventions":35669},[87],[14617],[14202,22019],{"trials":35671,"activeCount":97},[35672,35676,35680,35684,35690,35694,35698,35704,35708,35714,35718,35722,35726],{"nctId":15084,"briefTitle":15085,"status":103,"phases":35673,"completion":2947,"start":6075,"enrollment":13807,"conditions":35674,"interventions":35675},[88],[14168],[14170,15061],{"nctId":15480,"briefTitle":15481,"status":103,"phases":35677,"primaryCompletion":3536,"completion":3536,"start":15163,"enrollment":15483,"conditions":35678,"interventions":35679},[88],[14617],[14202,15467],{"nctId":14196,"briefTitle":14197,"status":103,"phases":35681,"completion":3228,"start":14199,"enrollment":9707,"conditions":35682,"interventions":35683},[88],[14168],[14202,14142],{"nctId":35685,"briefTitle":35686,"status":103,"phases":35687,"primaryCompletion":8233,"completion":2844,"start":3266,"enrollment":1548,"conditions":35688,"interventions":35689},"NCT00557310","A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide",[88],[14168],[14170],{"nctId":15779,"briefTitle":15780,"status":103,"phases":35691,"completion":3337,"start":2833,"enrollment":93,"conditions":35692,"interventions":35693},[88],[14214],[14202,15766],{"nctId":15948,"briefTitle":15949,"status":103,"phases":35695,"primaryCompletion":8233,"completion":2864,"start":3059,"enrollment":3013,"conditions":35696,"interventions":35697},[88],[15952],[14202,15935],{"nctId":35699,"briefTitle":35700,"status":103,"phases":35701,"completion":3746,"start":3195,"enrollment":34,"conditions":35702,"interventions":35703},"NCT00532545","Bone Marker Changes With Teriparatide\u002FPostmenopausal Osteoporosis",[88],[14193],[14202],{"nctId":16104,"briefTitle":16105,"status":103,"phases":35705,"primaryCompletion":4160,"completion":4160,"start":8217,"enrollment":1620,"conditions":35706,"interventions":35707},[88],[14617],[14202,16091,16109],{"nctId":35709,"briefTitle":35710,"status":103,"phases":35711,"primaryCompletion":3059,"completion":3059,"start":3228,"enrollment":2477,"conditions":35712,"interventions":35713},"NCT00259298","Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis",[88],[14617],[14170],{"nctId":14210,"briefTitle":14211,"status":103,"phases":35715,"completion":3005,"start":3646,"enrollment":776,"conditions":35716,"interventions":35717},[88],[14214],[14170,14216,14171],{"nctId":14776,"briefTitle":14777,"status":103,"phases":35719,"primaryCompletion":1546,"completion":1546,"start":2798,"enrollment":14779,"conditions":35720,"interventions":35721},[88],[14214],[14202,14747,14782,14783],{"nctId":14785,"briefTitle":14786,"status":103,"phases":35723,"primaryCompletion":1474,"completion":1474,"start":2846,"enrollment":1827,"conditions":35724,"interventions":35725},[88],[14617],[14202,14747],{"nctId":15264,"briefTitle":15265,"status":103,"phases":35727,"primaryCompletion":5354,"completion":5354,"start":3068,"enrollment":3013,"conditions":35728,"interventions":35729},[88],[14617],[14202,15269,15270,15271,15241,14783],{"trials":35731,"activeCount":97},[35732,35740],{"nctId":35733,"briefTitle":35734,"status":103,"phases":35735,"primaryCompletion":3152,"completion":3152,"start":3094,"enrollment":35736,"conditions":35737,"interventions":35738},"NCT00761332","Back Pain in Patients With Severe Osteoporosis",[],650,[14617],[14170,35739],"antiresorptives",{"nctId":35741,"briefTitle":35742,"status":103,"phases":35743,"primaryCompletion":3069,"completion":3069,"start":3575,"enrollment":35744,"conditions":35745,"interventions":35746},"NCT00696644","A Study for Teriparatide in Severe Osteoporosis",[],794,[14168,14617],[14202],{"intervention":15345,"totalTrials":1620,"cells":35748},{"EARLY_PHASE1":35749,"PHASE1":35751,"PHASE2":35759,"PHASE3":35777,"PHASE4":35847,"NA":35933},{"trials":35750,"activeCount":97},[],{"trials":35752,"activeCount":97},[35753],{"nctId":35754,"briefTitle":35755,"status":103,"phases":35756,"primaryCompletion":8233,"completion":8233,"start":3012,"enrollment":137,"conditions":35757,"interventions":35758},"NCT01177943","A Bioequivalence (BE) Study in Healthy Subjects",[85],[13785],[15345],{"trials":35760,"activeCount":97},[35761,35767,35773],{"nctId":35762,"briefTitle":35763,"status":103,"phases":35764,"primaryCompletion":2995,"completion":2995,"start":2975,"enrollment":34,"conditions":35765,"interventions":35766},"NCT00530335","Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit\u002FHyperactivity Disorder (ADHD)",[86],[13785],[15345],{"nctId":35768,"briefTitle":35769,"status":103,"phases":35770,"primaryCompletion":3320,"completion":3132,"start":3338,"enrollment":34,"conditions":35771,"interventions":35772},"NCT00636818","Atomoxetine Asian Study in Adult Subjects With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[86],[13785],[15345],{"nctId":35389,"briefTitle":35390,"status":103,"phases":35774,"conditions":35775,"interventions":35776},[85,86],[4897],[9670,35394],{"trials":35778,"activeCount":97},[35779,35786,35794,35800,35806,35812,35818,35825,35831,35837,35841],{"nctId":35780,"briefTitle":35781,"status":103,"phases":35782,"primaryCompletion":3283,"completion":3283,"start":2955,"enrollment":35783,"conditions":35784,"interventions":35785},"NCT00962104","Atomoxetine to Treat Asian Adult Patients With Attention-Deficit\u002FHyperactivity Disorder",[87],391,[13785],[15345],{"nctId":35787,"briefTitle":35788,"status":103,"phases":35789,"primaryCompletion":3050,"completion":3050,"start":35790,"enrollment":35791,"conditions":35792,"interventions":35793},"NCT00190684","Long-Term, Open Label Atomoxetine Study",[87],"2000-08",1553,[13785],[35394],{"nctId":35795,"briefTitle":35796,"status":103,"phases":35797,"completion":2855,"start":3218,"enrollment":1692,"conditions":35798,"interventions":35799},"NCT00191542","Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents",[87],[13785],[15345],{"nctId":35801,"briefTitle":35802,"status":103,"phases":35803,"completion":5690,"start":3339,"enrollment":1868,"conditions":35804,"interventions":35805},"NCT00386581","Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit\u002FHyperactivity Disorder",[87],[13919],[35394],{"nctId":35807,"briefTitle":35808,"status":103,"phases":35809,"completion":3160,"start":2948,"enrollment":3219,"conditions":35810,"interventions":35811},"NCT00191737","An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit\u002FHyperactivity Disorder",[87],[13785],[15345],{"nctId":35813,"briefTitle":35814,"status":103,"phases":35815,"completion":3160,"start":2948,"enrollment":617,"conditions":35816,"interventions":35817},"NCT00191516","An Open-Label Study of Atomoxetine in Children With Attention-Deficit\u002FHyperactivity Disorder",[87],[13785],[15345],{"nctId":35819,"briefTitle":35820,"status":103,"phases":35821,"primaryCompletion":3132,"completion":3132,"start":4266,"enrollment":35822,"conditions":35823,"interventions":35824},"NCT00320528","Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[87],269,[13919],[35394],{"nctId":35826,"briefTitle":35827,"status":103,"phases":35828,"completion":3133,"start":5690,"enrollment":2502,"conditions":35829,"interventions":35830},"NCT00191295","Atomoxetine Versus Placebo in Children With Attention Deficit\u002FHyperactivity Disorder (ADHD)",[86,87],[13785],[15345],{"nctId":35832,"briefTitle":35833,"status":103,"phases":35834,"completion":3524,"start":5953,"enrollment":1692,"conditions":35835,"interventions":35836},"NCT00191880","Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit\u002FHyperactivity Disorder",[87],[13785],[35394],{"nctId":21555,"briefTitle":21556,"status":103,"phases":35838,"primaryCompletion":2866,"completion":3059,"start":4642,"enrollment":6654,"conditions":35839,"interventions":35840},[87],[13785],[15345,21544],{"nctId":35842,"briefTitle":35843,"status":103,"phases":35844,"primaryCompletion":3661,"completion":3661,"start":3217,"enrollment":6086,"conditions":35845,"interventions":35846},"NCT00969618","A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder",[87],[13785],[15345],{"trials":35848,"activeCount":97},[35849,35856,35862,35866,35873,35880,35887,35894,35901,35908,35914,35920,35927],{"nctId":35850,"briefTitle":35851,"status":103,"phases":35852,"completion":13847,"start":3077,"enrollment":410,"conditions":35853,"interventions":35855},"NCT00190957","Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse",[88],[13912,35854],"Comorbid Alcohol Abuse",[15345],{"nctId":35857,"briefTitle":35858,"status":103,"phases":35859,"primaryCompletion":2974,"completion":2974,"start":3645,"enrollment":8,"conditions":35860,"interventions":35861},"NCT00471354","A Study for Patients With Attention-Deficit\u002FHyperactivity Disorder Treated With Atomoxetine",[88],[13785],[15345],{"nctId":15340,"briefTitle":15341,"status":999,"phases":35863,"primaryCompletion":2844,"completion":2844,"start":2918,"enrollment":1488,"conditions":35864,"interventions":35865},[88],[13785],[15345,15327],{"nctId":35867,"briefTitle":35868,"status":103,"phases":35869,"primaryCompletion":3662,"completion":3662,"start":2930,"enrollment":35870,"conditions":35871,"interventions":35872},"NCT00406354","Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany",[88],181,[13785,13863],[15345],{"nctId":35874,"briefTitle":35875,"status":999,"phases":35876,"primaryCompletion":5860,"completion":5860,"start":3320,"enrollment":1054,"conditions":35877,"interventions":35879},"NCT00687609","Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE",[88],[13785,35878],"Cannabis Abuse",[15345],{"nctId":35881,"briefTitle":35882,"status":103,"phases":35883,"primaryCompletion":3292,"completion":3132,"start":2876,"enrollment":6509,"conditions":35884,"interventions":35886},"NCT00380692","Atomoxetine Versus Placebo for Symptoms of Attention-Deficit\u002FHyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder",[88],[35885,13919],"Autistic Disorder",[15345],{"nctId":35888,"briefTitle":35889,"status":103,"phases":35890,"completion":3524,"start":3566,"enrollment":776,"conditions":35891,"interventions":35893},"NCT00191633","Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes",[88],[35892],"Attention-Deficit\u002FHyperactivity Disorder",[15345],{"nctId":35895,"briefTitle":35896,"status":103,"phases":35897,"primaryCompletion":1546,"completion":1546,"start":3320,"enrollment":8918,"conditions":35898,"interventions":35900},"NCT00716274","Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia",[88],[13785,35899],"Dyslexia",[15345],{"nctId":35902,"briefTitle":35903,"status":103,"phases":35904,"primaryCompletion":3012,"completion":3114,"start":3320,"enrollment":35905,"conditions":35906,"interventions":35907},"NCT00760747","Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit\u002FHyperactivity Disorder(ADHD)",[88],112,[13785],[15345],{"nctId":35909,"briefTitle":35910,"status":103,"phases":35911,"primaryCompletion":3029,"completion":3283,"start":3338,"enrollment":11592,"conditions":35912,"interventions":35913},"NCT00607919","Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia",[88],[13785,35899],[15345],{"nctId":35915,"briefTitle":35916,"status":103,"phases":35917,"completion":2930,"start":2938,"enrollment":7531,"conditions":35918,"interventions":35919},"NCT00191035","Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD",[88],[35892],[15345],{"nctId":35921,"briefTitle":35922,"status":103,"phases":35923,"completion":3592,"start":5623,"enrollment":1868,"conditions":35924,"interventions":35926},"NCT00191048","Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD",[88],[35892,35925],"Comorbid Dyslexia",[15345],{"nctId":35928,"briefTitle":35929,"status":103,"phases":35930,"primaryCompletion":2929,"completion":2929,"start":3235,"enrollment":174,"conditions":35931,"interventions":35932},"NCT00546910","Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[88],[13785],[15345],{"trials":35934,"activeCount":97},[35935,35945],{"nctId":35936,"briefTitle":35937,"status":103,"phases":35938,"primaryCompletion":3320,"completion":3320,"start":3308,"enrollment":35939,"conditions":35940,"interventions":35943},"NCT00634439","Safety Study of Atomoxetine and Cerebrovascular Outcomes",[],72000,[35941,35942,13912],"Cerebrovascular Accident","Transient Ischemic Attack",[35394,35944],"Stimulants",{"nctId":35946,"briefTitle":35947,"status":103,"phases":35948,"completion":5860,"start":3266,"enrollment":35949,"conditions":35950,"interventions":35951},"NCT00540826","Treatment Compliance in Children and Adolescents on ADHD Medication",[],518,[13912],[15345,35952],"stimulants",{"intervention":14528,"totalTrials":893,"cells":35954},{"EARLY_PHASE1":35955,"PHASE1":35957,"PHASE2":35959,"PHASE3":35961,"PHASE4":36036,"NA":36118},{"trials":35956,"activeCount":97},[],{"trials":35958,"activeCount":97},[],{"trials":35960,"activeCount":97},[],{"trials":35962,"activeCount":97},[35963,35970,35977,35984,35991,35998,36004,36011,36017,36023,36029],{"nctId":35964,"briefTitle":35965,"status":103,"phases":35966,"completion":3524,"start":3169,"enrollment":35967,"conditions":35968,"interventions":35969},"NCT00190996","Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence",[87],2765,[34841],[14528],{"nctId":35971,"briefTitle":35972,"status":103,"phases":35973,"completion":4642,"start":4538,"enrollment":35974,"conditions":35975,"interventions":35976},"NCT00122863","Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder",[87],380,[20177],[14528],{"nctId":35978,"briefTitle":35979,"status":103,"phases":35980,"completion":3169,"start":4366,"enrollment":16,"conditions":35981,"interventions":35983},"NCT00036335","Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain",[87],[14033,35982],"Pain",[14528],{"nctId":35985,"briefTitle":35986,"status":103,"phases":35987,"completion":3218,"start":3236,"enrollment":5230,"conditions":35988,"interventions":35989},"NCT00058968","A Study for the Treatment of Painful Diabetic Neuropathy",[87],[14666],[35990],"Duloxetine hydrochloride",{"nctId":35992,"briefTitle":35993,"status":103,"phases":35994,"primaryCompletion":3419,"completion":3419,"start":3338,"enrollment":35995,"conditions":35996,"interventions":35997},"NCT00641719","A Long-term Study for the Treatment of Painful Diabetic Neuropathy",[87],258,[20294],[35990,35990],{"nctId":35999,"briefTitle":36000,"status":103,"phases":36001,"completion":2855,"start":3218,"enrollment":1868,"conditions":36002,"interventions":36003},"NCT00191594","Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials",[87],[13955],[14528],{"nctId":36005,"briefTitle":36006,"status":103,"phases":36007,"primaryCompletion":3012,"completion":3029,"start":3132,"enrollment":36008,"conditions":36009,"interventions":36010},"NCT00755807","Duloxetine for Multiple Sclerosis Pain",[87],239,[9417],[14528],{"nctId":36012,"briefTitle":36013,"status":103,"phases":36014,"completion":2833,"start":3194,"enrollment":14854,"conditions":36015,"interventions":36016},"NCT00122824","Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder",[87],[20177],[14696],{"nctId":36018,"briefTitle":36019,"status":103,"phases":36020,"primaryCompletion":3094,"completion":3094,"start":3060,"enrollment":12828,"conditions":36021,"interventions":36022},"NCT00408993","Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China",[87],[20294],[14528],{"nctId":36024,"briefTitle":36025,"status":103,"phases":36026,"completion":3259,"start":3153,"enrollment":1282,"conditions":36027,"interventions":36028},"NCT00191919","A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain",[87],[4937],[14528],{"nctId":36030,"briefTitle":36031,"status":103,"phases":36032,"completion":3567,"start":3356,"conditions":36033,"interventions":36035},"NCT00036309","Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder",[87],[36034],"Depressive Disorder",[14528],{"trials":36037,"activeCount":97},[36038,36044,36050,36056,36062,36069,36076,36080,36084,36088,36095,36101,36107,36114],{"nctId":36039,"briefTitle":36040,"status":103,"phases":36041,"primaryCompletion":2846,"completion":3059,"start":3575,"enrollment":972,"conditions":36042,"interventions":36043},"NCT00673452","A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia",[88],[20920],[14696],{"nctId":36045,"briefTitle":36046,"status":103,"phases":36047,"primaryCompletion":3283,"completion":3069,"start":2955,"enrollment":933,"conditions":36048,"interventions":36049},"NCT00960986","A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder",[88],[17004],[35990],{"nctId":36051,"briefTitle":36052,"status":103,"phases":36053,"completion":3645,"start":3176,"enrollment":924,"conditions":36054,"interventions":36055},"NCT00266643","Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain",[88],[14666],[14696],{"nctId":36057,"briefTitle":36058,"status":103,"phases":36059,"completion":4538,"start":3077,"enrollment":4865,"conditions":36060,"interventions":36061},"NCT00479726","Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)",[88],[13955],[14696],{"nctId":36063,"briefTitle":36064,"status":103,"phases":36065,"completion":3337,"start":2856,"enrollment":36066,"conditions":36067,"interventions":36068},"NCT00244296","To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms",[88],276,[34841],[35990],{"nctId":36070,"briefTitle":36071,"status":103,"phases":36072,"primaryCompletion":3292,"completion":2928,"start":2975,"enrollment":36073,"conditions":36074,"interventions":36075},"NCT00536471","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",[88],776,[13955],[35990],{"nctId":14522,"briefTitle":14523,"status":103,"phases":36077,"primaryCompletion":3087,"completion":3419,"start":2974,"enrollment":14525,"conditions":36078,"interventions":36079},[88],[13955],[14528,14480],{"nctId":15205,"briefTitle":15206,"status":103,"phases":36081,"completion":2938,"start":3195,"enrollment":14854,"conditions":36082,"interventions":36083},[88],[14033],[14528,15192],{"nctId":14690,"briefTitle":14691,"status":103,"phases":36085,"primaryCompletion":2955,"completion":3217,"start":3133,"enrollment":14693,"conditions":36086,"interventions":36087},[88],[14666],[14696,14697,14698],{"nctId":36089,"briefTitle":36090,"status":103,"phases":36091,"primaryCompletion":3059,"completion":3059,"start":4642,"enrollment":13828,"conditions":36092,"interventions":36094},"NCT00437125","Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease",[88],[13955,36093],"Idiopathic Parkinson Disease",[35990],{"nctId":36096,"briefTitle":36097,"status":103,"phases":36098,"primaryCompletion":3059,"completion":3217,"start":2930,"enrollment":20363,"conditions":36099,"interventions":36100},"NCT00406848","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",[88],[13955],[14696],{"nctId":36102,"briefTitle":36103,"status":103,"phases":36104,"primaryCompletion":3216,"completion":3216,"start":2875,"enrollment":13650,"conditions":36105,"interventions":36106},"NCT00422162","A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression",[88],[13955],[35990],{"nctId":36108,"briefTitle":36109,"status":103,"phases":36110,"completion":13847,"start":2948,"enrollment":36111,"conditions":36112,"interventions":36113},"NCT00191061","A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder",[88],640,[36034],[14696],{"nctId":15211,"briefTitle":15212,"status":103,"phases":36115,"completion":5953,"start":3567,"enrollment":2413,"conditions":36116,"interventions":36117},[88],[14033],[14528,15192],{"trials":36119,"activeCount":97},[36120],{"nctId":36121,"briefTitle":36122,"status":2032,"phases":36123,"conditions":36124,"interventions":36125},"NCT00071708","Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial",[],[13955,20920,9378,34757],[14528],{"intervention":2545,"totalTrials":1071,"cells":36127},{"EARLY_PHASE1":36128,"PHASE1":36130,"PHASE2":36164,"PHASE3":36197,"PHASE4":36203,"NA":36205},{"trials":36129,"activeCount":97},[],{"trials":36131,"activeCount":97},[36132,36136,36144,36148,36152,36156,36160],{"nctId":8751,"briefTitle":8752,"status":103,"phases":36133,"primaryCompletion":8754,"completion":8755,"start":8756,"enrollment":4353,"conditions":36134,"interventions":36135},[85],[1478],[2545,5985,8759,1745,8760],{"nctId":36137,"briefTitle":36138,"status":103,"phases":36139,"primaryCompletion":3661,"completion":3661,"start":3114,"enrollment":1071,"conditions":36140,"interventions":36143},"NCT01199822","Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors",[85],[36141,36142],"Malignancy","Metastasis",[2545],{"nctId":18138,"briefTitle":18139,"status":103,"phases":36145,"primaryCompletion":18141,"completion":18141,"start":18142,"enrollment":4945,"conditions":36146,"interventions":36147},[85],[1506],[2545,5985],{"nctId":2536,"briefTitle":2537,"status":103,"phases":36149,"primaryCompletion":2539,"completion":2540,"start":2541,"enrollment":2542,"conditions":36150,"interventions":36151},[85],[1506],[2545,1696],{"nctId":18146,"briefTitle":18147,"status":103,"phases":36153,"primaryCompletion":18149,"completion":18150,"start":18151,"enrollment":9038,"conditions":36154,"interventions":36155},[85],[1477],[2545,5985],{"nctId":18155,"briefTitle":18156,"status":103,"phases":36157,"primaryCompletion":18158,"completion":18159,"start":18160,"enrollment":3309,"conditions":36158,"interventions":36159},[85],[18162],[2545,5985],{"nctId":18165,"briefTitle":18166,"status":103,"phases":36161,"primaryCompletion":18168,"completion":18169,"start":13481,"enrollment":290,"conditions":36162,"interventions":36163},[85],[1506],[2545,5985,8760,18172],{"trials":36165,"activeCount":97},[36166,36170,36174,36178,36182,36186,36193],{"nctId":19446,"briefTitle":19447,"status":103,"phases":36167,"primaryCompletion":3004,"completion":9748,"start":5860,"enrollment":174,"conditions":36168,"interventions":36169},[86],[2553],[2545,4610],{"nctId":18180,"briefTitle":18181,"status":103,"phases":36171,"primaryCompletion":3122,"completion":3028,"start":8233,"enrollment":4005,"conditions":36172,"interventions":36173},[85,86],[18162],[2545,3143],{"nctId":4309,"briefTitle":4310,"status":103,"phases":36175,"primaryCompletion":4312,"completion":4313,"start":4314,"enrollment":4315,"conditions":36176,"interventions":36177},[85,86],[4317],[2545,1539,1511],{"nctId":4389,"briefTitle":4390,"status":103,"phases":36179,"primaryCompletion":4392,"completion":4393,"start":4394,"enrollment":1282,"conditions":36180,"interventions":36181},[85,86],[1506],[2545,1511,1722],{"nctId":3681,"briefTitle":3682,"status":103,"phases":36183,"primaryCompletion":2917,"completion":3684,"start":3685,"enrollment":3686,"conditions":36184,"interventions":36185},[86],[1718],[2545,1669,1512],{"nctId":36187,"briefTitle":36188,"status":999,"phases":36189,"primaryCompletion":2865,"completion":3048,"start":8217,"enrollment":11639,"conditions":36190,"interventions":36192},"NCT01316263","A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and\u002For Metastatic Gastrointestinal Stromal Tumors",[86],[36191],"Gastrointestinal Stromal Tumor (GIST)",[2545],{"nctId":8230,"briefTitle":8231,"status":103,"phases":36194,"primaryCompletion":2898,"completion":4955,"start":8233,"enrollment":8234,"conditions":36195,"interventions":36196},[86],[1903],[2545,8228,1906],{"trials":36198,"activeCount":97},[36199],{"nctId":18200,"briefTitle":18201,"status":103,"phases":36200,"primaryCompletion":18203,"completion":1647,"start":7343,"enrollment":18204,"conditions":36201,"interventions":36202},[87],[1506],[2545,5985],{"trials":36204,"activeCount":97},[],{"trials":36206,"activeCount":97},[36207],{"nctId":36208,"briefTitle":36209,"status":2032,"phases":36210,"conditions":36211,"interventions":36212},"NCT03994627","Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma",[],[1506],[2545],{"intervention":19885,"totalTrials":757,"cells":36214},{"EARLY_PHASE1":36215,"PHASE1":36217,"PHASE2":36219,"PHASE3":36221,"PHASE4":36267,"NA":36278},{"trials":36216,"activeCount":97},[],{"trials":36218,"activeCount":97},[],{"trials":36220,"activeCount":97},[],{"trials":36222,"activeCount":97},[36223,36227,36236,36243,36249,36256,36263],{"nctId":19879,"briefTitle":19880,"status":103,"phases":36224,"primaryCompletion":3227,"completion":3227,"start":19882,"enrollment":7145,"conditions":36225,"interventions":36226},[87],[15689],[19885,19858,19886],{"nctId":36228,"briefTitle":36229,"status":103,"phases":36230,"completion":36231,"start":36232,"enrollment":35905,"conditions":36233,"interventions":36235},"NCT00570011","Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients",[87],"1998-12","1997-06",[36234],"Growth Hormone Deficiency",[19885,19885],{"nctId":36237,"briefTitle":36238,"status":103,"phases":36239,"completion":13765,"start":36240,"enrollment":1692,"conditions":36241,"interventions":36242},"NCT00406926","The Effect of Growth Hormone in Very Young Girls With Turner Syndrome",[87],"1999-08",[15689],[19885],{"nctId":36244,"briefTitle":36245,"status":103,"phases":36246,"primaryCompletion":2995,"completion":2995,"start":2938,"enrollment":2071,"conditions":36247,"interventions":36248},"NCT00191165","Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency",[87],[36234],[19885,19885],{"nctId":36250,"briefTitle":36251,"status":103,"phases":36252,"completion":3259,"start":3169,"enrollment":4353,"conditions":36253,"interventions":36255},"NCT00191360","Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency",[87],[36254],"Adult Growth Hormone Deficiency",[19885],{"nctId":36257,"briefTitle":36258,"status":103,"phases":36259,"completion":4474,"start":3161,"enrollment":776,"conditions":36260,"interventions":36262},"NCT00191529","Growth Hormone Treatment in Short Children Born Small for Gestational Age",[87],[36261],"Infant, Small for Gestational Age",[21947],{"nctId":21941,"briefTitle":21942,"status":103,"phases":36264,"primaryCompletion":4097,"completion":4097,"start":3524,"enrollment":4279,"conditions":36265,"interventions":36266},[87],[21945],[21947,21930],{"trials":36268,"activeCount":97},[36269],{"nctId":36270,"briefTitle":36271,"status":103,"phases":36272,"completion":36273,"start":36274,"enrollment":19000,"conditions":36275,"interventions":36277},"NCT00490191","Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency",[88],"2001-07","1999-01",[36276],"Hypopituitarism",[19885],{"trials":36279,"activeCount":97},[36280,36291],{"nctId":36281,"briefTitle":36282,"status":103,"phases":36283,"primaryCompletion":1618,"completion":1618,"start":15255,"enrollment":36284,"conditions":36285,"interventions":36290},"NCT01088412","Observational Study of Somatropin Treatment in Children",[],22845,[36286,36287,36288,36289],"Growth Hormone (GH) Deficiency","Short Stature Homeobox Containing Gene (SHOX) Deficiency","SHOX Deficiency-related Disorder","Non-GH-deficient Growth Disorders",[19885],{"nctId":36292,"briefTitle":36293,"status":103,"phases":36294,"primaryCompletion":4122,"completion":4122,"start":14136,"enrollment":36295,"conditions":36296,"interventions":36299},"NCT01088399","A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults",[],10673,[36276,36297,36298],"Pituitary Insufficiency","Growth Hormone Deficiency, Adult",[19885],{"intervention":19837,"totalTrials":1400,"cells":36301},{"EARLY_PHASE1":36302,"PHASE1":36304,"PHASE2":36306,"PHASE3":36319,"PHASE4":36325,"NA":36327},{"trials":36303,"activeCount":97},[],{"trials":36305,"activeCount":97},[],{"trials":36307,"activeCount":97},[36308,36312],{"nctId":19829,"briefTitle":19830,"status":103,"phases":36309,"primaryCompletion":7530,"completion":19832,"start":19833,"enrollment":19834,"conditions":36310,"interventions":36311},[86],[5284],[19837,19820,19838,19839],{"nctId":36313,"briefTitle":36314,"status":103,"phases":36315,"primaryCompletion":36316,"completion":36316,"start":1133,"enrollment":3051,"conditions":36317,"interventions":36318},"NCT04701658","A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)",[86],"2021-06-22",[5284],[19837],{"trials":36320,"activeCount":97},[36321],{"nctId":19843,"briefTitle":19844,"status":103,"phases":36322,"primaryCompletion":19846,"completion":19847,"start":19848,"enrollment":19849,"conditions":36323,"interventions":36324},[87],[5284,19851],[19837,19820],{"trials":36326,"activeCount":97},[],{"trials":36328,"activeCount":97},[36329],{"nctId":36330,"briefTitle":36331,"status":13373,"phases":36332,"conditions":36333,"interventions":36334},"NCT04603651","Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19",[],[5284],[19837],{"intervention":17122,"totalTrials":1400,"cells":36336},{"EARLY_PHASE1":36337,"PHASE1":36339,"PHASE2":36349,"PHASE3":36351,"PHASE4":36353,"NA":36355},{"trials":36338,"activeCount":97},[],{"trials":36340,"activeCount":97},[36341,36345],{"nctId":16911,"briefTitle":16912,"status":103,"phases":36342,"primaryCompletion":3837,"completion":3837,"start":3152,"enrollment":118,"conditions":36343,"interventions":36344},[85],[13955],[13957,16916,16917],{"nctId":17115,"briefTitle":17116,"status":103,"phases":36346,"primaryCompletion":17118,"completion":17118,"start":17119,"enrollment":37,"conditions":36347,"interventions":36348},[85],[15],[17046,17122],{"trials":36350,"activeCount":97},[],{"trials":36352,"activeCount":97},[],{"trials":36354,"activeCount":97},[],{"trials":36356,"activeCount":97},[36357,36365],{"nctId":36358,"briefTitle":36359,"status":103,"phases":36360,"primaryCompletion":5306,"completion":5306,"start":36361,"enrollment":290,"conditions":36362,"interventions":36363},"NCT05692869","A Study of Continuous Blood Pressure Monitoring in Healthy Participants",[89],"2023-01-31",[15],[17122,36364],"Pseudoephedrine",{"nctId":36366,"briefTitle":36367,"status":103,"phases":36368,"primaryCompletion":6302,"completion":6302,"start":36369,"enrollment":11639,"conditions":36370,"interventions":36371},"NCT04682184","A Study of Continuous Heart Rate Monitoring in Healthy Participants",[89],"2021-01-27",[15],[17122,36364],{"intervention":36364,"totalTrials":947,"cells":36373},{"EARLY_PHASE1":36374,"PHASE1":36376,"PHASE2":36378,"PHASE3":36380,"PHASE4":36382,"NA":36384},{"trials":36375,"activeCount":97},[],{"trials":36377,"activeCount":97},[],{"trials":36379,"activeCount":97},[],{"trials":36381,"activeCount":97},[],{"trials":36383,"activeCount":97},[],{"trials":36385,"activeCount":97},[36386,36390],{"nctId":36358,"briefTitle":36359,"status":103,"phases":36387,"primaryCompletion":5306,"completion":5306,"start":36361,"enrollment":290,"conditions":36388,"interventions":36389},[89],[15],[17122,36364],{"nctId":36366,"briefTitle":36367,"status":103,"phases":36391,"primaryCompletion":6302,"completion":6302,"start":36369,"enrollment":11639,"conditions":36392,"interventions":36393},[89],[15],[17122,36364],{"intervention":35944,"totalTrials":947,"cells":36395},{"EARLY_PHASE1":36396,"PHASE1":36398,"PHASE2":36400,"PHASE3":36402,"PHASE4":36404,"NA":36406},{"trials":36397,"activeCount":97},[],{"trials":36399,"activeCount":97},[],{"trials":36401,"activeCount":97},[],{"trials":36403,"activeCount":97},[],{"trials":36405,"activeCount":97},[],{"trials":36407,"activeCount":97},[36408,36412],{"nctId":35936,"briefTitle":35937,"status":103,"phases":36409,"primaryCompletion":3320,"completion":3320,"start":3308,"enrollment":35939,"conditions":36410,"interventions":36411},[],[35941,35942,13912],[35394,35944],{"nctId":35946,"briefTitle":35947,"status":103,"phases":36413,"completion":5860,"start":3266,"enrollment":35949,"conditions":36414,"interventions":36415},[],[13912],[15345,35952],{"intervention":36417,"totalTrials":314,"cells":36418},"Analog or Human Insulin",{"EARLY_PHASE1":36419,"PHASE1":36421,"PHASE2":36423,"PHASE3":36425,"PHASE4":36427,"NA":36429},{"trials":36420,"activeCount":97},[],{"trials":36422,"activeCount":97},[],{"trials":36424,"activeCount":97},[],{"trials":36426,"activeCount":97},[],{"trials":36428,"activeCount":97},[],{"trials":36430,"activeCount":97},[36431],{"nctId":36432,"briefTitle":36433,"status":103,"phases":36434,"primaryCompletion":3087,"completion":3087,"start":2975,"enrollment":36435,"conditions":36436,"interventions":36437},"NCT00549887","An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin",[],2459,[18],[36417],{"intervention":36439,"totalTrials":314,"cells":36440},"Insulins",{"EARLY_PHASE1":36441,"PHASE1":36443,"PHASE2":36445,"PHASE3":36447,"PHASE4":36449,"NA":36451},{"trials":36442,"activeCount":97},[],{"trials":36444,"activeCount":97},[],{"trials":36446,"activeCount":97},[],{"trials":36448,"activeCount":97},[],{"trials":36450,"activeCount":97},[],{"trials":36452,"activeCount":97},[36453],{"nctId":36454,"briefTitle":36455,"status":103,"phases":36456,"primaryCompletion":3029,"completion":3029,"start":3685,"enrollment":36457,"conditions":36458,"interventions":36459},"NCT01055808","Observational Study in Japanese Type 2 Diabetes Patients",[],677,[18],[36439],{"intervention":36461,"totalTrials":314,"cells":36462},"AM0010",{"EARLY_PHASE1":36463,"PHASE1":36465,"PHASE2":36467,"PHASE3":36469,"PHASE4":36471,"NA":36473},{"trials":36464,"activeCount":97},[],{"trials":36466,"activeCount":97},[],{"trials":36468,"activeCount":97},[],{"trials":36470,"activeCount":97},[],{"trials":36472,"activeCount":97},[],{"trials":36474,"activeCount":97},[36475],{"nctId":36476,"briefTitle":36477,"status":13373,"phases":36478,"conditions":36479,"interventions":36480},"NCT03554434","An Expanded Access Program for AM0010 (Pegilodecakin)",[],[1732,1903,2584,2585,2586,2587,2588,2589,36],[36461],{"intervention":36482,"totalTrials":314,"cells":36483},"SSRIs",{"EARLY_PHASE1":36484,"PHASE1":36486,"PHASE2":36488,"PHASE3":36490,"PHASE4":36492,"NA":36494},{"trials":36485,"activeCount":97},[],{"trials":36487,"activeCount":97},[],{"trials":36489,"activeCount":97},[],{"trials":36491,"activeCount":97},[],{"trials":36493,"activeCount":97},[],{"trials":36495,"activeCount":97},[36496],{"nctId":36497,"briefTitle":36498,"status":103,"phases":36499,"completion":5860,"start":3266,"enrollment":36500,"conditions":36501,"interventions":36502},"NCT00561509","Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months",[],1626,[13955],[36482,36503],"Dual antidepressants",{"intervention":36503,"totalTrials":314,"cells":36505},{"EARLY_PHASE1":36506,"PHASE1":36508,"PHASE2":36510,"PHASE3":36512,"PHASE4":36514,"NA":36516},{"trials":36507,"activeCount":97},[],{"trials":36509,"activeCount":97},[],{"trials":36511,"activeCount":97},[],{"trials":36513,"activeCount":97},[],{"trials":36515,"activeCount":97},[],{"trials":36517,"activeCount":97},[36518],{"nctId":36497,"briefTitle":36498,"status":103,"phases":36519,"completion":5860,"start":3266,"enrollment":36500,"conditions":36520,"interventions":36521},[],[13955],[36482,36503],{"intervention":13344,"totalTrials":314,"cells":36523},{"EARLY_PHASE1":36524,"PHASE1":36526,"PHASE2":36528,"PHASE3":36530,"PHASE4":36532,"NA":36534},{"trials":36525,"activeCount":97},[],{"trials":36527,"activeCount":97},[],{"trials":36529,"activeCount":97},[],{"trials":36531,"activeCount":97},[],{"trials":36533,"activeCount":97},[],{"trials":36535,"activeCount":97},[36536],{"nctId":13338,"briefTitle":13339,"status":13340,"phases":36537,"conditions":36538,"interventions":36539},[],[2824],[13344,1513,13345,13346],{"intervention":13345,"totalTrials":314,"cells":36541},{"EARLY_PHASE1":36542,"PHASE1":36544,"PHASE2":36546,"PHASE3":36548,"PHASE4":36550,"NA":36552},{"trials":36543,"activeCount":97},[],{"trials":36545,"activeCount":97},[],{"trials":36547,"activeCount":97},[],{"trials":36549,"activeCount":97},[],{"trials":36551,"activeCount":97},[],{"trials":36553,"activeCount":97},[36554],{"nctId":13338,"briefTitle":13339,"status":13340,"phases":36555,"conditions":36556,"interventions":36557},[],[2824],[13344,1513,13345,13346],{"intervention":13346,"totalTrials":314,"cells":36559},{"EARLY_PHASE1":36560,"PHASE1":36562,"PHASE2":36564,"PHASE3":36566,"PHASE4":36568,"NA":36570},{"trials":36561,"activeCount":97},[],{"trials":36563,"activeCount":97},[],{"trials":36565,"activeCount":97},[],{"trials":36567,"activeCount":97},[],{"trials":36569,"activeCount":97},[],{"trials":36571,"activeCount":97},[36572],{"nctId":13338,"briefTitle":13339,"status":13340,"phases":36573,"conditions":36574,"interventions":36575},[],[2824],[13344,1513,13345,13346],{"intervention":36577,"totalTrials":314,"cells":36578},"ADP receptor inhibitors",{"EARLY_PHASE1":36579,"PHASE1":36581,"PHASE2":36583,"PHASE3":36585,"PHASE4":36587,"NA":36589},{"trials":36580,"activeCount":97},[],{"trials":36582,"activeCount":97},[],{"trials":36584,"activeCount":97},[],{"trials":36586,"activeCount":97},[],{"trials":36588,"activeCount":97},[],{"trials":36590,"activeCount":97},[36591],{"nctId":36592,"briefTitle":36593,"status":103,"phases":36594,"primaryCompletion":3112,"completion":3112,"start":3419,"enrollment":36595,"conditions":36596,"interventions":36597},"NCT01088503","Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome",[],12227,[17470],[36577],{"intervention":36599,"totalTrials":314,"cells":36600},"Insulin Lispro and\u002For Insulin Glargine",{"EARLY_PHASE1":36601,"PHASE1":36603,"PHASE2":36605,"PHASE3":36607,"PHASE4":36609,"NA":36611},{"trials":36602,"activeCount":97},[],{"trials":36604,"activeCount":97},[],{"trials":36606,"activeCount":97},[],{"trials":36608,"activeCount":97},[],{"trials":36610,"activeCount":97},[],{"trials":36612,"activeCount":97},[36613],{"nctId":36614,"briefTitle":36615,"status":103,"phases":36616,"primaryCompletion":561,"completion":561,"start":12895,"enrollment":6927,"conditions":36617,"interventions":36618},"NCT04484779","A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes",[89],[466,30],[36599],{"intervention":36620,"totalTrials":314,"cells":36621},"FORTEO",{"EARLY_PHASE1":36622,"PHASE1":36624,"PHASE2":36626,"PHASE3":36628,"PHASE4":36630,"NA":36632},{"trials":36623,"activeCount":97},[],{"trials":36625,"activeCount":97},[],{"trials":36627,"activeCount":97},[],{"trials":36629,"activeCount":97},[],{"trials":36631,"activeCount":97},[],{"trials":36633,"activeCount":97},[36634],{"nctId":36635,"briefTitle":36636,"status":103,"phases":36637,"primaryCompletion":3283,"completion":3283,"start":13765,"enrollment":36638,"conditions":36639,"interventions":36640},"NCT01078805","Study of FORTEO Use in Subjects in the Community Setting",[],4167,[14617],[36620],{"intervention":36642,"totalTrials":314,"cells":36643},"PDE5 Inhibitors",{"EARLY_PHASE1":36644,"PHASE1":36646,"PHASE2":36648,"PHASE3":36650,"PHASE4":36652,"NA":36654},{"trials":36645,"activeCount":97},[],{"trials":36647,"activeCount":97},[],{"trials":36649,"activeCount":97},[],{"trials":36651,"activeCount":97},[],{"trials":36653,"activeCount":97},[],{"trials":36655,"activeCount":97},[36656],{"nctId":36657,"briefTitle":36658,"status":103,"phases":36659,"primaryCompletion":3123,"completion":3123,"start":2956,"enrollment":34807,"conditions":36660,"interventions":36662},"NCT01131104","A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors",[],[36661],"Nonarteritic Anterior Ischemic Optic Neuropathy",[36642],{"intervention":36664,"totalTrials":314,"cells":36665},"Treatment for Fibromyalgia",{"EARLY_PHASE1":36666,"PHASE1":36668,"PHASE2":36670,"PHASE3":36672,"PHASE4":36674,"NA":36676},{"trials":36667,"activeCount":97},[],{"trials":36669,"activeCount":97},[],{"trials":36671,"activeCount":97},[],{"trials":36673,"activeCount":97},[],{"trials":36675,"activeCount":97},[],{"trials":36677,"activeCount":97},[36678],{"nctId":36679,"briefTitle":36680,"status":103,"phases":36681,"primaryCompletion":3069,"completion":3069,"start":3575,"enrollment":36682,"conditions":36683,"interventions":36684},"NCT00725101","Fibromyalgia Health Outcome Study on Cost of Treatments",[],1700,[20920],[36664],{"intervention":35739,"totalTrials":314,"cells":36686},{"EARLY_PHASE1":36687,"PHASE1":36689,"PHASE2":36691,"PHASE3":36693,"PHASE4":36695,"NA":36697},{"trials":36688,"activeCount":97},[],{"trials":36690,"activeCount":97},[],{"trials":36692,"activeCount":97},[],{"trials":36694,"activeCount":97},[],{"trials":36696,"activeCount":97},[],{"trials":36698,"activeCount":97},[36699],{"nctId":35733,"briefTitle":35734,"status":103,"phases":36700,"primaryCompletion":3152,"completion":3152,"start":3094,"enrollment":35736,"conditions":36701,"interventions":36702},[],[14617],[14170,35739],{"intervention":36704,"totalTrials":314,"cells":36705},"Any platinum-based doublet chemotherapy",{"EARLY_PHASE1":36706,"PHASE1":36708,"PHASE2":36710,"PHASE3":36712,"PHASE4":36714,"NA":36716},{"trials":36707,"activeCount":97},[],{"trials":36709,"activeCount":97},[],{"trials":36711,"activeCount":97},[],{"trials":36713,"activeCount":97},[],{"trials":36715,"activeCount":97},[],{"trials":36717,"activeCount":97},[36718],{"nctId":36719,"briefTitle":36720,"status":103,"phases":36721,"primaryCompletion":3545,"completion":3545,"start":2846,"enrollment":36722,"conditions":36723,"interventions":36724},"NCT01067794","Chemotherapy in Treating Patients With Lung Cancer",[],1610,[1694],[36704]]